FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Habarta, N Wang, GS Mulatu, MS Larish, N AF Habarta, Nancy Wang, Guoshen Mulatu, Mesfin S. Larish, Nili TI HIV Testing by Transgender Status at Centers for Disease Control and Prevention-Funded Sites in the United States, Puerto Rico, and US Virgin Islands, 2009-2011 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SAN-FRANCISCO; RISK BEHAVIORS; MENTAL-HEALTH; NONTRANSGENDER MEN; WOMEN; CARE; PREVALENCE; SEX; DISCRIMINATION AB Objectives. We examined HIV testing services, seropositivity, and the characteristics associated with newly identified, confirmed HIV-positive tests among transgender individuals. Methods. We analyzed data (2009-2011) using bivariate and multivariable logistic regression to examine the relationships between HIV positivity and sociodemographic and risk characteristics among male-to-female transgender individuals. Results. Most of the testing was conducted in females (51.1%), followed by males (48.7%) and transgender individuals (0.17%). Tests in male-to-female transgender individuals had the highest, newly identified confirmed HIV positivity (2.7%), followed by males (0.9%), female-to-male transgender individuals (0.5%), and females (0.2%). The associated characteristics with an HIV-positive test among male-to-female transgender individuals included ages 20 to 29 and 40 to 49 years (adjusted odds ratio [AOR] = 2.8; 95% confidence interval [CI] = 1.4, 5.6 and AOR = 2.8; 95% CI = 1.3, 5.9, respectively), African American (AOR = 4.6; 95% CI = 2.7, 7.9) or Hispanic/Latino (AOR = 2.6; 95% CI = 1.5, 4.5) race/ethnicity, and reporting sex without condom within the past year (AOR = 1.9; 95% CI = 1.3, 2.6), sex with an HIV-positive person (AOR = 1.5; 95% CI = 1.1, 2.0), or injection drug use (AOR = 2.0; 95% CI = 1.3, 3.0). Conclusions. High levels of HIV positivity among transgender individuals, particularly male-to-female transgender individuals, underscore the necessity for targeted HIV prevention services that are responsive to the needs of this population. C1 [Habarta, Nancy; Larish, Nili] Ctr Dis Control & Prevent, Prevent Commun Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA USA. RP Habarta, N (reprint author), 1600 Clifton Rd NE,Mail Stop E-49, Atlanta, GA 30333 USA. EM nhabarta@cdc.gov NR 56 TC 4 Z9 4 U1 3 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2015 VL 105 IS 9 BP 1917 EP 1925 DI 10.2105/AJPH.2015.302659 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV5PG UT WOS:000364322600050 PM 26180964 ER PT J AU Warner, L Cox, S Whiteman, M Jamieson, DJ Macaluso, M Bansil, P Kuklina, E Kourtis, AP Posner, S Barfield, WD AF Warner, Lee Cox, Shanna Whiteman, Maura Jamieson, Denise J. Macaluso, Maurizio Bansil, Pooja Kuklina, Elena Kourtis, Athena P. Posner, Samuel Barfield, Wanda D. TI Impact of Health Insurance Type on Trends in Newborn Circumcision, United States, 2000 to 2010 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POLICY STATEMENT; BENEFITS; OUTCOMES; HIV AB Objectives. We explored how changes in insurance coverage contributed to recent nationwide decreases in newborn circumcision. Methods. Hospital discharge data from the 2000-2010 Nationwide Inpatient Sample were analyzed to assess trends in circumcision incidence among male newborn birth hospitalizations covered by private insurance or Medicaid. We examined the impact of insurance coverage on circumcision incidence. Results. Overall, circumcision incidence decreased significantly from 61.3% in 2000 to 56.9% in 2010 in unadjusted analyses (P for trend = .008), but not in analyses adjusted for insurance status (P for trend = .46) and other predictors (P for trend = .55). Significant decreases were observed only in the South, where adjusted analyses revealed decreases in circumcision overall (P for trend = .007) and among hospitalizations with Medicaid (P for trend = .005) but not those with private insurance (P for trend = .13). Newborn male birth hospitalizations covered by Medicaid increased from 36.0% (2000) to 50.1% (2010; P for trend < .001), suggesting 390 000 additional circumcisions might have occurred nationwide had insurance coverage remained constant. Conclusions. Shifts in insurance coverage, particularly toward Medicaid, likely contributed to decreases in newborn circumcision nationwide and in the South. Barriers to the availability of circumcision should be revisited, particularly for families who desire but have less financial access to the procedure. C1 [Warner, Lee; Cox, Shanna; Whiteman, Maura; Jamieson, Denise J.; Macaluso, Maurizio; Bansil, Pooja; Kuklina, Elena; Kourtis, Athena P.; Posner, Samuel; Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Warner, L (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,MS F-74, Atlanta, GA 30341 USA. EM dlw7@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 31 TC 2 Z9 2 U1 0 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2015 VL 105 IS 9 BP 1943 EP 1949 DI 10.2105/AJPH.2015.302629 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV5PG UT WOS:000364322600053 PM 26180994 ER PT J AU Davidow, AL Katz, D Ghosh, S Blumberg, H Tamhane, A Sevilla, A Reves, R AF Davidow, Amy L. Katz, Dolly Ghosh, Smita Blumberg, Henry Tamhane, Ashutosh Sevilla, Anna Reves, Randall CA TB Epidemiologic Studies TI Preventing Infectious Pulmonary Tuberculosis Among Foreign-Born Residents of the United States SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; IMMIGRATION; IMPLEMENTATION; REACTIVATION AB Objectives. We described risk factors associated with infectious tuberculosis (TB) and missed TB-prevention opportunities in foreign-born US residents, who account for almost two thirds of the nation's TB patients. Methods. In a cross-sectional study at 20 US sites of foreign-born persons diagnosed with TB in 2005 through 2006, we collected results of sputum smear microscopy for acid-fast bacilli (a marker for infectiousness) and data on visa status, sociodemographics, TB-related care seeking, and latent TB infection (LTBI) diagnosis opportunities. Results. Among 980 persons with pulmonary TB who reported their visa status, 601 (61%) were legal permanent residents, 131 (13.4%) had temporary visas, and 248 (25.3%) were undocumented. Undocumented persons were more likely than permanent residents to have acid-fast bacilli-positive smears at diagnosis (risk ratio = 1.3; 95% confidence interval = 1.2, 1.4). Of those diagnosed 1 year or more after arrival, 57.3% reported LTBI screening opportunities; fewer than 25% actually were. Undocumented persons reported fewer LTBI screening opportunities and were less likely to be tested. Conclusions. Progress toward TB elimination in the United States depends upon expanding opportunities for regular medical care and promotion of LTBI screening and treatment among foreign-born persons. C1 [Davidow, Amy L.] Univ Med & Dent New Jersey, New Jersey Med Sch, Rutgers Biomed & Hlth Sci, Dept Prevent Med & Community Hlth, Newark, NJ 07103 USA. [Katz, Dolly; Ghosh, Smita] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Blumberg, Henry] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Tamhane, Ashutosh] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Sevilla, Anna] Rutgers Biol & Hlth Sci, Global TB Inst, Denver, CO USA. [Reves, Randall] Denver Hlth & Hosp Author, Denver, CO USA. RP Davidow, AL (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Rutgers Biomed & Hlth Sci, Dept Prevent Med & Community Hlth, 185 S Orange Ave, Newark, NJ 07103 USA. EM davidoal@njms.rutgers.edu OI Tamhane, Ashutosh/0000-0002-4475-2760 FU Centers for Disease Control and Prevention through the Tuberculosis Epidemiologic Studies Consortium FX This study was funded by the Centers for Disease Control and Prevention through the Tuberculosis Epidemiologic Studies Consortium. NR 28 TC 5 Z9 5 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2015 VL 105 IS 9 BP E81 EP E88 DI 10.2105/AJPH.2015.302662 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV5PG UT WOS:000364322600019 PM 26180947 ER PT J AU Willby, M Sikes, RD Malik, S Metchock, B Posey, JE AF Willby, Mebsa Sikes, R. David Malik, Seidu Metchock, Beverly Posey, James E. TI Correlation between GyrA Substitutions and Ofloxacin, Levofloxacin, and Moxifloxacin Cross-Resistance in Mycobacterium tuberculosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID FLUOROQUINOLONE RESISTANCE; MOLECULAR CHARACTERIZATION; PULMONARY TUBERCULOSIS; BACTERICIDAL ACTIVITY; DRUG-RESISTANCE; MUTATIONS; QUINOLONE; STRAINS; SUSCEPTIBILITY; PHARMACOKINETICS AB The newer fluoroquinolones moxifloxacin (MXF) and levofloxacin (LVX) are becoming more common components of tuberculosis (TB) treatment regimens. However, the critical concentrations for testing susceptibility of Mycobacterium tuberculosis to MXF and LVX are not yet well established. Additionally, the degree of cross-resistance between ofloxacin (OFX) and these newer fluoroquinolones has not been thoroughly investigated. In this study, the MICs for MXF and LVX and susceptibility to the critical concentration of OFX were determined using the agar proportion method for 133 isolates of M. tuberculosis. Most isolates resistant to OFX had LVX MICs of > 1 mu g/ml and MXF MICs of > 0.5 mu g/ml. The presence of mutations within the gyrA quinolone resistance-determining regions (QRDR) correlated well with increased MICs, and the level of LVX and MXF resistance was dependent on the specific gyrA mutation present. Substitutions Ala90Val, Asp94Ala, and Asp94Tyr resulted in low-level MXF resistance (MICs were > 0.5 but <= 2 mu g/ml), while other mutations led to MXF MICs of > 2 mu g/ml. Based on these results, a critical concentration of 1 mu g/ml is suggested for LVX and 0.5 mu g/ml for MXF drug susceptibility testing by agar proportion with reflex testing for MXF at 2 mu g/ml. C1 [Willby, Mebsa; Sikes, R. David; Malik, Seidu; Metchock, Beverly; Posey, James E.] Ctr Dis Control & Prevent, Branch Lab, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Posey, JE (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jposey@cdc.gov NR 45 TC 10 Z9 11 U1 4 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2015 VL 59 IS 9 BP 5427 EP 5434 DI 10.1128/AAC.00662-15 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CV5XD UT WOS:000364343900042 PM 26100699 ER PT J AU Plucinski, MM Talundzic, E Morton, L Dimbu, PR Macaia, AP Fortes, F Goldman, I Lucchi, N Stennies, G MacArthur, JR Udhayakumar, V AF Plucinski, Mateusz M. Talundzic, Eldin Morton, Lindsay Dimbu, Pedro Rafael Macaia, Aleixo Panzo Fortes, Filomeno Goldman, Ira Lucchi, Naomi Stennies, Gail MacArthur, John R. Udhayakumar, Venkatachalam TI Reply to "No Robust Evidence of Lumefantrine Resistance" SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Letter ID PLASMODIUM-FALCIPARUM MALARIA; ARTEMETHER-LUMEFANTRINE; TRIALS; EFFICACY; CHILDREN C1 [Plucinski, Mateusz M.; Talundzic, Eldin; Morton, Lindsay; Goldman, Ira; Lucchi, Naomi; Stennies, Gail; MacArthur, John R.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Ctr Global Hlth, Atlanta, GA 30333 USA. [Plucinski, Mateusz M.; Talundzic, Eldin; Morton, Lindsay; Goldman, Ira; Lucchi, Naomi; Stennies, Gail; MacArthur, John R.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Presidents Malaria Initiat, Div Parasitic & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Dimbu, Pedro Rafael; Fortes, Filomeno] Minist Hlth, Natl Malaria Control Program, Luanda, Angola. [Macaia, Aleixo Panzo] Minist Hlth, Field Epidemol & Lab Training Program, Luanda, Angola. RP Plucinski, MM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Ctr Global Hlth, Atlanta, GA 30333 USA. EM mplucinski@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2015 VL 59 IS 9 BP 5867 EP 5868 DI 10.1128/AAC.01355-15 PG 2 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CV5XD UT WOS:000364343900105 PM 26276896 ER PT J AU Ing, SW Orchard, TS Lu, B LaMonte, MJ Barbour, KE Cauley, JA Jackson, RD AF Ing, Steven W. Orchard, Tonya S. Lu, Bo LaMonte, Michael J. Barbour, Kamil E. Cauley, Jane A. Jackson, Rebecca D. TI TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID NECROSIS-FACTOR-ALPHA; INFLAMMATORY MARKERS; WOMEN; OLDER; MEN; DESIGN; OMEGA-3-FATTY-ACIDS; OSTEOPOROSIS; ACTIVATION; BURDEN AB Context: Chronic inflammation may increase the risk of fracture, and omega-3 polyunsaturated fatty acids (PUFAs) may reduce fracture risk via down-regulation of inflammatory cytokine gene expression and other mechanisms. Objective: We investigated associations between baseline samples of inflammatory markers, TNF alpha soluble receptors 1 and 2 (TNF alpha-sR1 and -sR2), and incident hip fracture. These associations were then tested for effect modification by dietary PUFA intake estimated by a baseline food frequency questionnaire. Design and Setting: A nested case-control study was conducted among participants of the Women's Health Initiative Observational Study (ages, 50-79 y). Multivariable conditional logistic regression models were constructed to account for the paired design. Participants: This study sampled 400 pairs of hip fracture cases and controls without incident hip fracture, matched on age, year of enrollment, and menopausal hormone use. Main Outcome Measures: Odds ratio of hip fracture by quartile of TNF soluble receptors. Results: The odds ratio of hip fracture comparing the highest to lowest quartiles was 2.24 (95% confidence interval, 1.05-4.79; P for linear trend,.048) for TNF alpha-sR1 and 2.83 (95% confidence interval, 1.34-5.99; P for linear trend,.011) for TNF alpha-sR2, adjusted for FRAX hip fracture score, nutritional variables, and selected factors impacting inflammation; there was a gradient of risk by increasing quartile in TNF alpha-sR1. PUFA intake did not modify these associations. Conclusions: Women with the highest levels of TNF alpha-sR1 and TNF alpha-sR2 had a greater than 2-fold increased hip fracture risk, independent of other fracture risk factors. These associations did not differ by high vs low PUFA intake. C1 [Ing, Steven W.; Jackson, Rebecca D.] Ohio State Univ, Div Endocrinol Diabet & Metab, Dept Human Sci, Columbus, OH 43210 USA. [Orchard, Tonya S.] Ohio State Univ, Human Nutr Program, Columbus, OH 43210 USA. [Lu, Bo] Ohio State Univ, Div Biostat, Columbus, OH 43210 USA. [LaMonte, Michael J.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA. [Barbour, Kamil E.] Ctr Dis Control & Prevent, Arthrit Program, Div Populat Hlth, Atlanta, GA 30431 USA. [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Jackson, RD (reprint author), Ohio State Univ, Med Ctr, Div Endocrinol Diabet & Metab, 376 W 10th Ave,Suite 205, Columbus, OH 43210 USA. EM Rebecca.Jackson@osumc.edu RI Cauley, Jane/N-4836-2015; Ing, Steven/E-3287-2011 OI Cauley, Jane/0000-0003-0752-4408; FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN-268201100004C, HHSN271201100004C] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN-268201100004C, and HHSN271201100004C. NR 33 TC 2 Z9 2 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2015 VL 100 IS 9 BP 3380 EP 3387 DI 10.1210/JC.2015-1662 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CW3BV UT WOS:000364867800044 PM 26161450 ER PT J AU Griffing, SM Tauil, PL Udhayakumar, V Silva-Flannery, L AF Griffing, Sean Michael Tauil, Pedro Luiz Udhayakumar, Venkatachalam Silva-Flannery, Luciana TI A historical perspective on malaria control in Brazil SO MEMORIAS DO INSTITUTO OSWALDO CRUZ LA English DT Review DE Brazil; malaria; Plasmodium; vivax; falciparum; drug resistance; control; history ID FALCIPARUM DRUG-RESISTANCE; WESTERN AMAZON REGION; PLASMODIUM-FALCIPARUM; CHLOROQUINE-RESISTANCE; DIHYDROFOLATE-REDUCTASE; ANOPHELES-GAMBIAE; ENDEMIC AREAS; SOUTH-AMERICA; TRANSMISSION; STATE AB Malaria has always been an important public health problem in Brazil. The early history of Brazilian malaria and its control was powered by colonisation by Europeans and the forced relocation of Africans as slaves. Internal migration brought malaria to many regions in Brazil where, given suitable Anopheles mosquito vectors, it thrived. Almost from the start, officials recognised the problem malaria presented to economic development, but early control efforts were hampered by still developing public health control and ignorance of the underlying biology and ecology of malaria. Multiple regional and national malaria control efforts have been attempted with varying success. At present, the Amazon Basin accounts for 99% of Brazil's reported malaria cases with regional increases in incidence often associated with large scale public works or migration. Here, we provide an exhaustive summary of primary literature in English, Spanish and Portuguese regarding Brazilian malaria control. Our goal was not to interpret the history of Brazilian malaria control from a particular political or theoretical perspective, but rather to provide a straightforward, chronological narrative of the events that have transpired in Brazil over the past 200 years and identify common themes. C1 [Griffing, Sean Michael; Udhayakumar, Venkatachalam; Silva-Flannery, Luciana] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Griffing, Sean Michael; Udhayakumar, Venkatachalam; Silva-Flannery, Luciana] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Tauil, Pedro Luiz] Univ Brasilia, Ctr Med Trop, Brasilia, DF, Brazil. RP Griffing, SM (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. EM sean.griffing@gmail.com FU NSF-GRFP FX FSMG was supported by the NSF-GRFP NR 109 TC 3 Z9 3 U1 1 U2 10 PU FUNDACO OSWALDO CRUZ PI RIO DE JANEIRO, RJ PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL SN 0074-0276 EI 1678-8060 J9 MEM I OSWALDO CRUZ JI Mem. Inst. Oswaldo Cruz PD SEP PY 2015 VL 110 IS 6 BP 701 EP 718 DI 10.1590/0074-02760150041 PG 18 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA CV7BW UT WOS:000364428100001 PM 26517649 ER PT J AU Barrera, R AF Barrera, Roberto TI Dengue and Chikungunya vector control: Is it necessary to re-examine present strategies? SO BIOMEDICA LA Spanish DT Editorial Material ID AEDES-AEGYPTI DIPTERA; INSECTICIDE; MEXICO; SURVEILLANCE; CULICIDAE; TRINIDAD; OVITRAPS C1 Ctr Dis Control & Prevent CDC, Dengue Branch, San Juan, PR 00937 USA. RP Barrera, R (reprint author), Ctr Dis Control & Prevent CDC, Dengue Branch, San Juan, PR 00937 USA. FU Intramural CDC HHS [CC999999] NR 29 TC 0 Z9 0 U1 0 U2 3 PU INST NACIONAL SALUD PI BOGOTA D C PA AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C, 00000, COLOMBIA SN 0120-4157 J9 BIOMEDICA JI Biomedica PD SEP PY 2015 VL 35 IS 3 BP 297 EP 299 PG 3 WC Tropical Medicine SC Tropical Medicine GA CV4TX UT WOS:000364260500001 PM 26849689 ER PT J AU Henley, SJ Weir, HK Jim, MA Watson, M Richardson, LC AF Henley, S. Jane Weir, Hannah K. Jim, Melissa A. Watson, Meg Richardson, Lisa C. TI Gallbladder Cancer Incidence and Mortality, United States 1999-2011 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID AMERICAN-INDIANS; ALASKA-NATIVES; BILIARY-TRACT; DISEASE; EPIDEMIOLOGY; PREVALENCE; RATES; RISK; AGE; US AB Background: Gallbladder cancer is a rare cancer with unusual distribution, and few population-based estimates for the United States have been published. Methods: Using population-based cancer incidence and mortality data, we examined U.S. gallbladder cancer incidence and death rates for 2007-2011 and trends for 1999-2011. Results: During 2007 to 2011, approximately 3,700 persons were diagnosed with primary gallbladder cancer (rate = 1.13 cases per 100,000) and 2,000 died from the disease (rate = 0.62 deaths per 100,000) each year in the United States. Two thirds of gallbladder cancer cases and deaths occurred among women. Gallbladder cancer incidence and death rates were three times higher among American Indian and Alaska Native persons than non-Hispanic white persons. By state, gallbladder cancer incidence and death rates ranged by about 2-fold. During 1999 to 2011, gallbladder cancer incidence rates decreased amongwomen but remained level among men; death rates declined among women but stabilized among men after declining from 1999 to 2006. Gallbladder cancer incidence rates increased in some subgroups, notably among black persons, those aged <45 years, and for endocrine tumors. Conclusions: Data from U.S. population-based cancer registries confirm that gallbladder cancer incidence and death rates are higher among women than men, highest among American Indian and Alaska Native persons, and differ by region. While overall incidence and death rates decreased during 1999 to 2011, incidence rates increased among some small subgroups. Impact: Surveillance of gallbladder cancer incidence and mortality, particularly to monitor increases in subgroups, may provide clues to etiology and stimulate further research. (C) 2015 AACR. C1 [Henley, S. Jane; Weir, Hannah K.; Jim, Melissa A.; Watson, Meg; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Henley, SJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,Bldg 107,Mail Stop F-76, Atlanta, GA 30341 USA. EM shenley@cdc.gov FU Division of Cancer Prevention and Control at the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention FX This work was supported by the Division of Cancer Prevention and Control at the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (all authors). NR 29 TC 7 Z9 7 U1 3 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD SEP PY 2015 VL 24 IS 9 BP 1319 EP 1326 DI 10.1158/1055-9965.EPI-15-0199 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CU3CK UT WOS:000363401000005 PM 26070529 ER PT J AU Bruce, MG Bruden, D Morris, J Sacco, F Hurlburt, D McMahon, B AF Bruce, M. G. Bruden, D. Morris, J. Sacco, F. Hurlburt, D. McMahon, B. TI REINFECTION TWELVE YEARS AFTER SUCCESSFUL ERADICATION OF HELICOBACTER PYLORI IN ALASKA SO HELICOBACTER LA English DT Meeting Abstract CT European-Helicobacter-Study-Group 28th International Workshop on Helicobacter and Microbiota in Inflammation and Cancer CY SEP 24-26, 2015 CL Nicosia, CYPRUS SP European Helicobacter Study Grp C1 [Bruce, M. G.; Bruden, D.; Morris, J.; Hurlburt, D.; McMahon, B.] Ctr Dis Control & Prevent, Anchorage, AK USA. [Sacco, F.] Alaska Native Med Ctr, Anchorage, AK USA. [McMahon, B.] Div Community Hlth Serv, Liver Dis & Hepatitis Program, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1083-4389 EI 1523-5378 J9 HELICOBACTER JI Helicobacter PD SEP PY 2015 VL 20 SU 1 SI SI MA W4.2 BP 80 EP 80 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA CT8KE UT WOS:000363064400032 ER PT J AU Lee, EK Yuan, F Pietz, FH Benecke, BA Burel, G AF Lee, Eva K. Yuan, Fan Pietz, Ferdinand H. Benecke, Bernard A. Burel, Greg TI Vaccine Prioritization for Effective Pandemic Response SO INTERFACES LA English DT Article DE ordinary differential equations; queueing; optimization; public health policy making; pandemic containment; vaccine prioritization; disease propagation; decision support; agent-based simulation; epidemiology ID INFLUENZA VACCINATION; MATHEMATICAL-MODELS; UNITED-STATES; ALLOCATION; BENEFITS; H1N1; RISK AB Public health experts agree that the best strategy to contain a pandemic, where vaccination is the prophylactic treatment but vaccine supply is limited, is to give higher priority to higher-risk populations. We derive a mathematical decision framework to track the effectiveness of prioritized vaccination through the course of a pandemic. Our approach couples a disease-propagation model with a vaccine queueing model and an optimization engine to determine optimal prioritized coverage in a mixed-vaccination strategy. This demonstrably minimizes infection and mortality. Given estimated outbreak characteristics, vaccine inventory levels, and individual risk factors, the study reveals an optimal coverage for the high-risk group that results in the lowest overall attack and mortality rates. This knowledge is critical to public health policy makers for determining the best strategies for population protection. This becomes particularly important in determining when to switch from a prioritized strategy emphasizing high-risk groups to a nonprioritized strategy in which the vaccine becomes available publicly. Our analysis highlights the importance of uninterrupted vaccine supply. Although the 2009 H1N1 supply, received in interrupted batches, eventually covered over 30 percent of the population, the resulting attack and mortality rates are significantly inferior to those in a scenario where only 20 percent of the population is covered with an uninterrupted supply. We also learned that early vaccination is important. Contrasting the 2009 H1N1 supply to a 10 percent uninterrupted supply, a three-week delay in vaccination reduces the 9.9 percent infection reduction of the former to a mere 0.9 percent. The optimal trigger for switching from prioritized to nonprioritized vaccination is sensitive to infectivity and vulnerability of the high-risk groups. Our study further underscores the importance of throughput efficiency in dispensing and its effects on the overall attack and mortality rates. The more transmissible the virus is, the lower the threshold for switching to nonprioritized vaccination. Our model, which can be generalized, allows the incorporation of seasonality and virus mutation of the biological agents. The system empowers policy makers to make the right decisions at the appropriate time to save more lives, better utilize limited resources, and reduce the health-service burden during a pandemic event. C1 [Lee, Eva K.; Yuan, Fan] Ctr Operat Res Med & HealthCare, Atlanta, GA 30332 USA. [Lee, Eva K.; Yuan, Fan] NSF I UCRC Ctr Hlth Org Transformat Ind & Syst En, Atlanta, GA 30332 USA. [Pietz, Ferdinand H.; Burel, Greg] Ctr Dis Control & Prevent, Strateg Natl Stockpile, Atlanta, GA 30322 USA. [Benecke, Bernard A.] Ctr Dis Control & Prevent, Global Dis Detect & Emergency Response, Atlanta, GA 30322 USA. RP Lee, EK (reprint author), Ctr Operat Res Med & HealthCare, Atlanta, GA 30332 USA. EM eva.lee@gatech.edu; fanyuan@gatech.edu FU Centers for Disease Control and Prevention; National Science Foundation [IIP-1516074] FX The authors thank James Lawler of Naval Medical Research Center's Biological Defense Research Directorate Frederick Laboratory, Carter Mecher of the U.S. Department of Veterans Affairs, and Duane Caneva of the Department of Homeland Security for their insightful discussion regarding vaccine dispensing strategies in the United States. The work is partially supported by a grant from the Centers for Disease Control and Prevention, and from the National Science Foundation [IIP-1516074]. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 30 TC 0 Z9 0 U1 5 U2 8 PU INFORMS PI CATONSVILLE PA 5521 RESEARCH PARK DR, SUITE 200, CATONSVILLE, MD 21228 USA SN 0092-2102 EI 1526-551X J9 INTERFACES JI Interfaces PD SEP-OCT PY 2015 VL 45 IS 5 BP 425 EP 443 DI 10.1287/inte.2015.0814 PG 19 WC Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA CU1GR UT WOS:000363269000005 ER PT J AU Fresquez, MR Gonzalez-Jimenez, N Gray, N Watson, CH Pappas, RS AF Fresquez, Mark R. Gonzalez-Jimenez, Nathalie Gray, Naudia Watson, Clifford H. Pappas, R. Steven TI High-Throughput Determination of Mercury in Tobacco and Mainstream Smoke from Little Cigars SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID PLASMA-MASS SPECTROMETRY; CIGARETTES; CADMIUM; BLOOD; EXPOSURE; ASTHMA; URINE; LEAD AB A method was developed that utilizes a platinum trap for mercury from mainstream tobacco smoke, which represents an improvement over traditional approaches that require impingers and long sample preparation procedures. In this approach, the trapped mercury is directly released for analysis by heating the trap in a direct mercury analyzer. The method was applied to the analysis of mercury in the mainstream smoke of little cigars. The mercury levels in little cigar smoke obtained under Health Canada Intense smoking machine conditions ranged from 7.1 x 10(-3) to 1.2 x 10(-2) mg/m(3). These air mercury levels exceed the chronic inhalation minimal risk level corrected for intermittent exposure to metallic mercury (e.g., 1 or 2 h per day, 5 days per week) determined by the Agency for Toxic Substances and Disease Registry. Multivariate statistical analysis was used to assess associations between mercury levels and little cigar physical design properties. Filter ventilation was identified as the principal physical parameter influencing mercury concentrations in mainstream little cigar smoke generated under ISO machine smoking conditions. With filter ventilation blocked under Health Canada Intense smoking conditions, mercury concentrations in tobacco and puff number (smoke volume) were the primary physical parameters that influenced mainstream smoke mercury concentrations. C1 [Fresquez, Mark R.] Battelle Atlanta Analyt Serv, Atlanta, GA 30329 USA. [Gonzalez-Jimenez, Nathalie; Gray, Naudia; Watson, Clifford H.; Pappas, R. Steven] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Atlanta, GA 30341 USA. [Gonzalez-Jimenez, Nathalie] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA. RP Pappas, RS (reprint author), Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, 4770 Buford Highway,MS F-44, Atlanta, GA 30341 USA. EM rpappas@cdc.gov FU U.S. Food and Drug Administration Center for Tobacco Products FX This study was funded by an interagency agreement by the U.S. Food and Drug Administration Center for Tobacco Products. NR 33 TC 0 Z9 0 U1 2 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-4760 EI 1945-2403 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD SEP PY 2015 VL 39 IS 7 BP 545 EP 550 DI 10.1093/jat/bkv069 PG 6 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA CU1AL UT WOS:000363251300007 PM 26051388 ER PT J AU Tsai, YP AF Tsai, Yuping TI Social security income and the utilization of home care: Evidence from the social security notch SO JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Social Security; Retirement income; Long-term care; Formal home care; Informal home care ID INFORMAL CARE; LIVING ARRANGEMENTS; ACCUMULATION; SUBSTITUTE; INFERENCE; BENEFIT AB This paper exploits Social Security law changes to identify the effect of Social Security income on the use of formal and informal home care by the elderly. Results from an instrumental variables estimation strategy show that as retirement income increases, elderly individuals increase their use of formal home care and become less likely to rely on informal home care provided to them by their children. This negative effect on informal home care is most likely driven by male children withdrawing from their caregiving roles. The empirical results also suggest that higher Social Security benefits would encourage the use of formal home care by those who would not have otherwise used any type of home care and would also encourage the use of both types of home care services among elderly individuals. Published by Elsevier B.V. C1 [Tsai, Yuping] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Tsai, YP (reprint author), Ctr Dis Control & Prevent, NCIRD, 1600 Clifton Rd NE,MS A19, Atlanta, GA 30329 USA. EM ytsai@cdc.gov NR 23 TC 1 Z9 1 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6296 EI 1879-1646 J9 J HEALTH ECON JI J. Health Econ. PD SEP PY 2015 VL 43 BP 45 EP 55 DI 10.1016/j.jhealeco.2014.10.001 PG 11 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CT8PN UT WOS:000363078600004 PM 26184382 ER PT J AU Zhang, L Vickerman, K Malarcher, A Carpenter, K AF Zhang, Lei Vickerman, Katrina Malarcher, Ann Carpenter, Kelly TI Changes in Quitline Caller Characteristics During a National Tobacco Education Campaign SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID MASS-MEDIA CAMPAIGN; TELEVISION ADVERTISEMENTS; SMOKERS; SMOKING; IMPACT AB Introduction: The Centers for Disease Control and Prevention launched the first federally-funded national tobacco education campaign, "Tips From Former Smokers" (Tips), in 2012. This study examined changes in quitline caller characteristics, including demographics and smoking-related behaviors before and during the Tips campaign. Methods: Using quitline data from 20 U.S. states and the District of Columbia, we examined characteristics of 76,933 callers during the Tips campaign (March 19, 2012 to June 10, 2012) compared to 44,710 callers from a similar time period in 2011 (March 21, 2011 to June 12, 2011). We also examined whether characteristics differed by self-reported awareness of Tips during the campaign in 13 quitlines that added a Tips awareness question. Group differences were assessed using chi-square and t tests, adjusted for clustering by state. Results: Overall, few meaningful differences in caller characteristic existed, indicating broad reach of the Tips campaign across demographic groups. Compared with 2011, the number of callers during Tips increased by 72% and callers were twice as likely to hear about the quitline through television media. The proportion of uninsured callers was slightly higher during the Tips campaign than in 2011. Persons aware of the campaign were slightly more likely to be non-Hispanic Blacks, younger than age 55 years, and uninsured than those unaware of the campaign. Conclusions: The Tips campaign increased the reach of quitline services to the general population of smokers, with increases across all demographic and tobacco use groups, but particularly among those who were uninsured. Such campaigns have the potential to increase access to cessation services for the uninsured. C1 [Zhang, Lei; Malarcher, Ann] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Vickerman, Katrina; Carpenter, Kelly] Alere Wellbeing, Res Training & Evaluat Serv, Seattle, WA USA. RP Zhang, L (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE Mailstop F79, Atlanta, GA 30341 USA. EM lzhang2@cdc.gov FU Centers for Disease Control and Prevention [200-2012-M-51442] FX This work was funded by the Centers for Disease Control and Prevention (Contract #200-2012-M-51442). NR 19 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD SEP PY 2015 VL 17 IS 9 BP 1161 EP 1166 DI 10.1093/ntr/ntu271 PG 6 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CT9ZB UT WOS:000363174000015 PM 25561612 ER PT J AU Debarba, JA Monteiro, KM Moura, H Barr, JR Ferreira, HB Zaha, A AF Debarba, Joao Antonio Monteiro, Karina Mariante Moura, Hercules Barr, John R. Ferreira, Henrique Bunselmeyer Zaha, Arnaldo TI Identification of Newly Synthesized Proteins by Echinococcus granulosus Protoscoleces upon Induction of Strobilation SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID STATISTICAL-MODEL; MASS-SPECTROMETRY; MAMMALIAN-CELLS; SMALL RNAS; BIOCHEMISTRY; PATHWAYS; BIOLOGY; TRICKS; GENOME; HOST AB Background The proteins responsible for the key molecular events leading to the structural changes between the developmental stages of Echinococcus granulosus remain unknown. In this work, azidohomoalanine (AHA)-specific labeling was used to identify proteins expressed by E. granulosus protoscoleces (PSCs) upon the induction of strobilar development. Methodology/Principal Findings The in vitro incorporation of AHA with different tags into newly synthesized proteins (NSPs) by PSCs was analyzed using SDS-PAGE and confocal microscopy. The LC-MS/MS analysis of AHA-labeled NSPs by PSCs undergoing strobilation allowed for the identification of 365 proteins, of which 75 were differentially expressed in comparison between the presence or absence of strobilation stimuli and 51 were expressed exclusively in either condition. These proteins were mainly involved in metabolic, regulatory and signaling processes. Conclusions/Significance After the controlled-labeling of proteins during the induction of strobilar development, we identified modifications in protein expression. The changes in the metabolism and the activation of control and signaling pathways may be important for the correct parasite development and be target for further studies. C1 [Debarba, Joao Antonio; Monteiro, Karina Mariante; Ferreira, Henrique Bunselmeyer; Zaha, Arnaldo] Univ Fed Rio Grande do Sul, Ctr Biotechnol, Programa Posgrad Biol Celular & Mol, Porto Alegre, RS, Brazil. [Debarba, Joao Antonio; Monteiro, Karina Mariante; Ferreira, Henrique Bunselmeyer; Zaha, Arnaldo] Univ Fed Rio Grande do Sul, Ctr Biotechnol, Lab Biol Mol Cestodeos, Porto Alegre, RS, Brazil. [Debarba, Joao Antonio; Monteiro, Karina Mariante; Ferreira, Henrique Bunselmeyer; Zaha, Arnaldo] Univ Fed Rio Grande do Sul, Ctr Biotechnol, Lab Genom Estrutural & Func, Porto Alegre, RS, Brazil. [Monteiro, Karina Mariante; Ferreira, Henrique Bunselmeyer; Zaha, Arnaldo] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biol Mol & Biotecnol, BR-90049 Porto Alegre, RS, Brazil. [Moura, Hercules; Barr, John R.] Ctr Dis Control & Prevent, Biol Mass Spectrometry Lab, Clin Chem Branch, Div Lab Sci,Natl Ctr Environm Hlth, Atlanta, GA USA. RP Debarba, JA (reprint author), Univ Fed Rio Grande do Sul, Ctr Biotechnol, Programa Posgrad Biol Celular & Mol, Porto Alegre, RS, Brazil. EM zaha@cbiot.ufrgs.br RI Monteiro, Karina/D-5379-2013 FU CNPq; CAPES; FAPERGS FX This work was supported by CNPq (www.cnpq.br), CAPES (www.capes.gov.br) and FAPERGS (www.fapergs.rs.gov.br) grants. JAD is a recipient of a CNPq fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 2 Z9 2 U1 3 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2015 VL 9 IS 9 AR e0004085 DI 10.1371/journal.pntd.0004085 PG 18 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CT7YI UT WOS:000363031200059 PM 26393918 ER PT J AU George, L Lenhart, A Toledo, J Lazaro, A Han, WW Velayudhan, R Ranzinger, SR Horstick, O AF George, Leyanna Lenhart, Audrey Toledo, Joao Lazaro, Adhara Han, Wai Wai Velayudhan, Raman Ranzinger, Silvia Runge Horstick, Olaf TI Community-Effectiveness of Temephos for Dengue Vector Control: A Systematic Literature Review SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Review ID AEDES-AEGYPTI; INTEGRATED CONTROL; ABATE LARVICIDE; FIELD; ALBOPICTUS; THAILAND; POPULATION; ARGENTINA; MALATHION; VILLAGES AB The application of the organophosphate larvicide temephos to water storage containers is one of the most commonly employed dengue vector control methods. This systematic literature review is to the knowledge of the authors the first that aims to assess the community-effectiveness of temephos in controlling both vectors and dengue transmission when delivered either as a single intervention or in combination with other interventions. A comprehensive literature search of 6 databases was performed (PubMed, WHOLIS, GIFT, CDSR, EMBASE, Wiley), grey literature and cross references were also screened for relevant studies. Data were extracted and methodological quality of the studies was assessed independently by two reviewers. 27 studies were included in this systematic review (11 single intervention studies and 16 combined intervention studies). All 11 single intervention studies showed consistently that using temephos led to a reduction in entomological indices. Although 11 of the 16 combined intervention studies showed that temephos application together with other chemical vector control methods also reduced entomological indices, this was either not sustained over time or-as in the five remaining studies-failed to reduce the immature stages. The community-effectiveness of temephos was found to be dependent on factors such as quality of delivery, water turnover rate, type of water, and environmental factors such as organic debris, temperature and exposure to sunlight. Timing of temephos deployment and its need for reapplication, along with behavioural factors such as the reluctance of its application to drinking water, and operational aspects such as cost, supplies, time and labour were further limitations identified in this review. In conclusion, when applied as a single intervention, temephos was found to be effective at suppressing entomological indices, however, the same effect has not been observed when temephos was applied in combination with other interventions. There is no evidence to suggest that temephos use is associated with reductions in dengue transmission. C1 [George, Leyanna] Amrita Inst Med Sci, Dept Community Med, Kochi, Kerala, India. [Lenhart, Audrey] US Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Toledo, Joao] Minist Hlth, Brasilia, DF, Brazil. [Han, Wai Wai] Minist Hlth, Yangon, Myanmar. [Velayudhan, Raman] WHO, Dept Control Neglected Trop Dis, CH-1211 Geneva, Switzerland. [Ranzinger, Silvia Runge] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland. [Horstick, Olaf] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany. RP George, L (reprint author), Amrita Inst Med Sci, Dept Community Med, Kochi, Kerala, India. EM Olaf.Horstick@uni-heidelberg.de FU Deutsche Forschungsgemeinschaft; Ruprecht-Karls-Universitat Heidelberg FX We acknowledge the financial support of the Deutsche Forschungsgemeinschaft and Ruprecht-Karls-Universitat Heidelberg within the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 8 Z9 8 U1 2 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2015 VL 9 IS 9 AR e0004006 DI 10.1371/journal.pntd.0004006 PG 22 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CT7YI UT WOS:000363031200016 PM 26371470 ER PT J AU Lewis, T Schwebel, DC Elliott, MN Visser, SN Toomey, SL McLaughlin, KA Cuccaro, P Emery, ST Banspach, SW Schuster, MA AF Lewis, Terri Schwebel, David C. Elliott, Marc N. Visser, Susanna N. Toomey, Sara L. McLaughlin, Katie A. Cuccaro, Paula Emery, Susan Tortolero Banspach, Stephen W. Schuster, Mark A. TI The Association Between Youth Violence Exposure and Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in a Sample of Fifth-Graders SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE violence exposure; ADHD; gender; victimization; witnessing violence; school-age children ID POSTTRAUMATIC-STRESS-DISORDER; DEFICIT HYPERACTIVITY DISORDER; OF-THE-LITERATURE; NATIONAL SAMPLE; CHILD MALTREATMENT; COMMUNITY VIOLENCE; POLY-VICTIMIZATION; DOMESTIC VIOLENCE; BEHAVIOR PROBLEMS; MENTAL-HEALTH AB The purpose of the current study was to examine the association between violence exposures (no exposure, witness or victim only, and both witness and victim) and attention-deficit/hyperactivity disorder (ADHD) symptoms, as well as the potential moderating role of gender. Data from 4,745 5th graders and their primary caregivers were drawn from the Healthy Passages study of adolescent health. Parent respondents completed the DISC Predictive Scales for ADHD, and youth provided information about exposure to violence. Results indicated that youth who reported both witnessing and victimization had more parent-reported ADHD symptoms and were more likely to meet predictive criteria for ADHD. Among those with both exposures, girls exhibited a steeper increase in ADHD symptoms and higher probability of meeting predictive criteria than did boys. Findings indicate that being both victim-of and witness-to violence is significantly associated with ADHD symptoms particularly among girls. C1 [Lewis, Terri] Univ Colorado, Sch Med, Dept Pediat, Kempe Ctr Prevent & Treatment Child Abuse & Negle, Boulder, CO 80309 USA. [Schwebel, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL USA. [Elliott, Marc N.] RAND Hlth, Santa Monica, CA USA. [Visser, Susanna N.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Disabil, Atlanta, GA USA. [Toomey, Sara L.; McLaughlin, Katie A.; Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA. [Toomey, Sara L.; McLaughlin, Katie A.; Schuster, Mark A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [McLaughlin, Katie A.] Univ Washington, Seattle, WA 98195 USA. [Cuccaro, Paula; Emery, Susan Tortolero] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA. [Banspach, Stephen W.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Lewis, T (reprint author), Univ Colorado Denver, Dept Pediat, 13123 E 16th Ave,B390, Aurora, CO 80045 USA. EM Terri.Lewis@Childrenscolorado.org FU Centers for Disease Control and Prevention [CCU409679, CCU609653, CCU915773] FX Funded by the Centers for Disease Control and Prevention (Cooperative Agreements CCU409679, CCU609653, CCU915773). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 58 TC 0 Z9 0 U1 3 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PD SEP PY 2015 VL 85 IS 5 BP 504 EP 513 DI 10.1037/ort0000081 PG 10 WC Psychiatry; Social Work SC Psychiatry; Social Work GA CT5LQ UT WOS:000362852300010 PM 26460708 ER PT J AU Basavaraju, SV Kuehnert, MJ AF Basavaraju, Sridhar V. Kuehnert, Matthew J. TI Custodes invicem custodiunt (the watchmen can watch each other) SO TRANSFUSION LA English DT Letter C1 [Basavaraju, Sridhar V.; Kuehnert, Matthew J.] Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30329 USA. RP Basavaraju, SV (reprint author), Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30329 USA. EM mgk8@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2015 VL 55 IS 9 BP 2293 EP 2294 DI 10.1111/trf.13194 PG 3 WC Hematology SC Hematology GA CT6HO UT WOS:000362914300031 PM 26372918 ER PT J AU Lee, JY Park, J Park, H Coca, A Kim, JH Taylor, NAS Son, SY Tochihara, Y AF Lee, Joo-Young Park, Joonhee Park, Huiju Coca, Aitor Kim, Jung-Hyun Taylor, Nigel A. S. Son, Su-Young Tochihara, Yutaka TI What do firefighters desire from the next generation of personal protective equipment? Outcomes from an international survey SO INDUSTRIAL HEALTH LA English DT Article DE Auxiliary cooling; Firefighter; Location monitoring; Personal protective equipment (PPE); Wireless communication ID LOAD CARRIAGE; ENERGY COST; TEMPERATURES; PERFORMANCE; EXPENDITURE; INJURIES; WORK AB The purpose of this study was to investigate smart features required for the next generation of personal protective equipment (PPE) for firefighters in Australia, Korea, Japan, and the USA. Questionnaire responses were obtained from 167 Australian, 351 Japanese, 413 Korean, and 763 U.S. firefighters (1,611 males and 61 females). Preferences concerning smart features varied among countries, with 27% of Korean and 30% of U.S. firefighters identifying 'a location monitoring system' as the most important element. On the other hand, 43% of Japanese firefighters preferred 'an automatic body cooling system' while 21% of the Australian firefighters selected equally 'an automatic body cooling system' and 'a wireless communication system'. When asked to rank these elements in descending priority, responses across these countries were very similar with the following items ranked highest: 'a location monitoring system', 'an automatic body cooling system', 'a wireless communication system', and 'a vision support system'. The least preferred elements were 'an automatic body warming system' and 'a voice recording system'. No preferential relationship was apparent for age, work experience, gender or anthropometric characteristics. These results have implications for the development of the next generation of PPE along with the international standardisation of the smart PPE. C1 [Lee, Joo-Young; Park, Joonhee] Seoul Natl Univ, Dept Text Merchandising & Fash Design, Seoul 151, South Korea. [Park, Huiju] Cornell Univ, Dept Fiber Sci & Apparel Design, Ithaca, NY 14853 USA. [Coca, Aitor; Kim, Jung-Hyun] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Natl Personal Protect Technol Lab, Atlanta, GA USA. [Taylor, Nigel A. S.] Univ Wollongong, Sch Med, Ctr Human & Appl Physiol, Wollongong, NSW 2522, Australia. [Son, Su-Young] NIOSH, Human Engn & Risk Management Res Grp, Tokyo, Japan. [Tochihara, Yutaka] Kyushu Univ, Fukuoka 812, Japan. RP Lee, JY (reprint author), Seoul Natl Univ, Dept Text Merchandising & Fash Design, Seoul 151, South Korea. EM leex3140@snu.ac.kr FU National Emergency Management Agency in Korea [2013-NEMA15-009-01010000-2013] FX We sincerely thank Yoon-Jeong Baek and Hyo-Hyun Lee for their constructive comments. We also express our thanks to Siyeon Kim, Young-loon Jong, Jeong-Yoon Ha, Sung-Jin Park, Hae-Eun Lee and Eric A. Stone for their assistance and Jim Brinkley (Director of Occupational Health and Safety, IAFF) for his support for the survey administration in the U.S. This study was supported by the National Emergency Management Agency in Korea (2013-NEMA15-009-01010000-2013). NR 36 TC 2 Z9 2 U1 3 U2 7 PU NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN PI KAWASAKI KANAGAWA PA 21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN SN 0019-8366 EI 1880-8026 J9 IND HEALTH JI Ind. Health PD SEP PY 2015 VL 53 IS 5 BP 434 EP 444 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CT2HX UT WOS:000362623700007 PM 26027710 ER PT J AU O'Leary, ST Barnard, J Lockhart, S Kolasa, M Shmueli, D Dickinson, LM Kile, D Dibert, E Kempe, A AF O'Leary, Sean T. Barnard, Juliana Lockhart, Steven Kolasa, Maureen Shmueli, Doron Dickinson, L. Miriam Kile, Deidre Dibert, Eva Kempe, Allison TI Urban and Rural Differences in Parental Attitudes About Influenza Vaccination and Vaccine Delivery Models SO JOURNAL OF RURAL HEALTH LA English DT Article DE health services research; influenza; rural; utilization of health services; vaccine ID SCHOOL-AGED CHILDREN; UNITED-STATES; HEALTH-CARE; COMMUNITY VACCINATORS; YOUNG-CHILDREN; IMMUNIZATION; PHYSICIANS; TRENDS; RECOMMENDATIONS; PERSPECTIVES AB ObjectivesTo assess and compare among parents of healthy children in urban and rural areas: (1) reported influenza vaccination status; (2) attitudes regarding influenza vaccination; and (3) attitudes about collaborative models for influenza vaccination delivery involving practices and public health departments. MethodsA mail survey to random samples of parents from 2 urban and 2 rural private practices in Colorado from April 2012 to June 2012. ResultsThe response rate was 58% (288/500). In the prior season, 63% of urban and 41% of rural parents reported their child received influenza vaccination (P < .001). No differences in attitudes about influenza infection or vaccination between urban and rural parents were found, with 75% of urban and 73% of rural parents agreeing their child should receive an influenza vaccine every year (P = .71). High proportions reported willingness to participate in a collaborative clinic in a community setting (59% urban, 70% rural, P = .05) or at their child's provider (73% urban, 73% rural, P = .99) with public health department assisting. Fewer (36% urban, 53% rural, P < .01) were likely to go to the public health department if referred by their provider. Rural parents were more willing for their child to receive vaccination outside of their provider's office (70% vs. 55%, P = .01). ConclusionsWhile attitudes regarding influenza vaccination were similar, rural children were much less likely to have received vaccination. Most parents were amenable to collaborative models of influenza vaccination delivery, but rural parents were more comfortable with influenza vaccination outside their provider's office, suggesting that other venues for influenza vaccination in rural settings should be promoted. C1 [O'Leary, Sean T.; Kempe, Allison] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA. [O'Leary, Sean T.; Barnard, Juliana; Lockhart, Steven; Shmueli, Doron; Dickinson, L. Miriam; Kile, Deidre; Dibert, Eva; Kempe, Allison] Childrens Hosp Colorado, Childrens Outcomes Res Program, Aurora, CO USA. [Kolasa, Maureen] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Dickinson, L. Miriam; Kempe, Allison] Univ Colorado, Colorado Hlth Outcomes Res, Aurora, CO 80045 USA. RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM sean.o'leary@childrenscolorado.org FU Centers for Disease Control and Prevention [U01IP000320] FX This investigation was funded by a grant from the Centers for Disease Control and Prevention (U01IP000320). NR 42 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD FAL PY 2015 VL 31 IS 4 BP 421 EP 430 DI 10.1111/jrh.12119 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS9RW UT WOS:000362430200010 PM 25951772 ER PT J AU Kalb, SR Boyer, AE Barr, JR AF Kalb, Suzanne R. Boyer, Anne E. Barr, John R. TI Mass Spectrometric Detection of Bacterial Protein Toxins and Their Enzymatic Activity SO TOXINS LA English DT Article DE anthrax; anthrax lethal factor; botulinum neurotoxin; botulism; mass spectrometry ID BOTULINUM NEUROTOXIN SEROTYPE; LASER-DESORPTION IONIZATION; ANTHRAX LETHAL FACTOR; ENDOPEP-MS ASSAY; PROTECTIVE ANTIGEN; INHALATION ANTHRAX; PEPTIDE SUBSTRATE; IDENTIFICATION; SNAP-25; PROTEOLYSIS AB Mass spectrometry has recently become a powerful technique for bacterial identification. Mass spectrometry approaches generally rely upon introduction of the bacteria into a matrix-assisted laser-desorption time-of-flight (MALDI-TOF) mass spectrometer with mass spectrometric recognition of proteins specific to that organism that form a reliable fingerprint. With some bacteria, such as Bacillus anthracis and Clostridium botulinum, the health threat posed by these organisms is not the organism itself, but rather the protein toxins produced by the organisms. One such example is botulinum neurotoxin (BoNT), a potent neurotoxin produced by C. botulinum. There are seven known serotypes of BoNT, A-G, and many of the serotypes can be further differentiated into toxin variants, which are up to 99.9% identical in some cases. Mass spectrometric proteomic techniques have been established to differentiate the serotype or toxin variant of BoNT produced by varied strains of C. botulinum. Detection of potent biological toxins requires high analytical sensitivity and mass spectrometry based methods have been developed to determine the enzymatic activity of BoNT and the anthrax lethal toxins produced by B. anthracis. This enzymatic activity, unique for each toxin, is assessed with detection of the toxin-induced cleavage of strategically designed peptide substrates by MALDI-TOF mass spectrometry offering unparalleled specificity. Furthermore, activity assays allow for the assessment of the biological activity of a toxin and its potential health risk. Such methods have become important diagnostics for botulism and anthrax. Here, we review mass spectrometry based methods for the enzymatic activity of BoNT and the anthrax lethal factor toxin. C1 [Kalb, Suzanne R.; Boyer, Anne E.; Barr, John R.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM skalb@cdc.gov; aboyer@cdc.gov; jbarr@cdc.gov NR 50 TC 3 Z9 3 U1 3 U2 14 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6651 J9 TOXINS JI Toxins PD SEP PY 2015 VL 7 IS 9 BP 3497 EP 3511 DI 10.3390/toxins7093497 PG 15 WC Toxicology SC Toxicology GA CS0OU UT WOS:000361762200009 PM 26404376 ER PT J AU Wendelboe, AM Campbell, J McCumber, M Bratzler, D Ding, K Beckman, M Reyes, N Raskob, G AF Wendelboe, Aaron M. Campbell, Janis McCumber, Micah Bratzler, Dale Ding, Kai Beckman, Michele Reyes, Nimia Raskob, Gary TI The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods SO AMERICAN HEART JOURNAL LA English DT Article ID UNITED-STATES; RIVAROXABAN AB Estimates of venous thromboembolism (VTE) incidence in the United States are limited by lack of a national surveillance system. We implemented a population-based surveillance system in Oklahoma County, OK, for April 1, 2012 to March 31, 2014, to estimate the incidences of first-time and recurrent VTE events, VTE-related mortality, and the proportion of case patients with provoked versus unprovoked VTE. The Commissioner of Health made VTE a reportable condition and delegated surveillancerelated responsibilities to the University of Oklahoma, College of Public Health. The surveillance system included active and passive methods. Active surveillance involved reviewing imaging studies (such as chest computed tomography and compression ultrasounds) from all inpatient and outpatient facilities. Interrater agreement between surveillance officers collecting data was assessed using.. Passive surveillance used International Classification of Disease, Ninth Revision (ICD-9) codes from hospital discharge data to identify cases. The sensitivity and specificity of various ICD-9-based case definitions will be assessed by comparison with cases identified through active surveillance. As of February 1, 2015, we screened 54,494 (99.5%) of the imaging studies and identified 2,725 case patients, of which 91.6% were from inpatient facilities, and 8.4% were from outpatient facilities. Agreement between surveillance officers was high (kappa >= 0.61 for 93.2% of variables). Agreement for the diagnosis of pulmonary embolism and diagnosis of deep vein thrombosis was kappa = 0.92 (95% CI 0.74-1.00) and kappa = 0.89 (95% CI 0.71-1.00), respectively. This surveillance system will provide data on the accuracy of ICD-9-based case definitions for surveillance of VTE events and help the Centers for Disease Control and Prevention develop a national VTE surveillance system. C1 [Wendelboe, Aaron M.; Campbell, Janis; McCumber, Micah; Bratzler, Dale; Ding, Kai; Raskob, Gary] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK USA. [Beckman, Michele; Reyes, Nimia] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. RP Wendelboe, AM (reprint author), 801 NE 13th St,CHB 323, Oklahoma City, OK 73104 USA. EM aaron-wendelboe@ouhsc.edu OI Wendelboe, Aaron/0000-0002-8670-7730 FU CDC [DD14-1407] FX This surveillance system was funded by a cooperative agreement with the CDC DD14-1407. We are also deeply grateful for the work of the surveillance officer, Natalie Feland, Aubrey Balch, Jannate Ahmed, Evaren Page, and Ashley Sword-Buster, for their tireless dedication in collecting the data. We are also grateful for Pravina Kota for her information technology support, including the development of the database. NR 18 TC 1 Z9 1 U1 3 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD SEP PY 2015 VL 170 IS 3 BP 447 EP + DI 10.1016/j.ahj.2015.06.004 PG 26 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR8BC UT WOS:000361575100004 PM 26385027 ER PT J AU Isenberg, SL Carter, MD Graham, LA Mathews, TP Johnson, D Thomas, JD Pirkle, JL Johnson, RC AF Isenberg, Samantha L. Carter, Melissa D. Graham, Leigh Ann Mathews, Thomas P. Johnson, Darryl Thomas, Jerry D. Pirkle, James L. Johnson, Rudolph C. TI Quantification of Metabolites for Assessing Human Exposure to Soapberry Toxins Hypoglycin A and Methylenecyclopropylglycine SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Article ID ACKEE BLIGHIA-SAPIDA; BIOLOGICALLY-ACTIVE POLYPEPTIDES; JAMAICAN VOMITING SICKNESS; ENOYL-COA HYDRATASE; ACUTE ENCEPHALITIS; ACYL-COA; FRUIT; (METHYLENECYCLOPROPYL)FORMYL-COA; INACTIVATION; MECHANISM AB Ingestion of soapberry fruit toxins hypoglycin A and methylenecyclopropylglycine has been linked to public health challenges worldwide. In 1976, over 100 years after Jamaican vomiting sickness (JVS) was first reported, the cause of JVS was linked to the ingestion of the toxin hypoglycin A produced by ackee fruit. A structural analogue of hypoglycin A, methylenecyclopropylglycine (MCPG), was implicated as the cause of an acute encephalitis syndrome (AES). Much of the evidence linking hypoglycin A and MCPG to these diseases has been largely circumstantial due to the lack of an analytical method for specific metabolites. This study presents an analytical approach to identify and quantify specific urine metabolites for exposure to hypoglycin A and MCPG. The metabolites are excreted in urine as glycine adducts methylenecyclopropylacetyl-glycine (MCPA-Gly) and methylenecyclopropylformyl-glycine (MCPF-Gly). These metabolites were processed by isotope dilution, separated by reverse-phase liquid chromatography, and monitored by electrospray ionization tandem mass spectrometry. The analytical response ratio was linearly proportional to the concentration of MCPF-Gly and MCPA-Gly in urine from 0.10 to 20 mu g/mL with a correlation coefficient of r > 0.99. The assay demonstrated accuracy >= 80% and precision <= 20% RSD across the calibration range. This method has been applied to assess exposure to hypoglycin A and MCPG as part of a larger public health initiative and was used to provide the first reported identification of MCPF-Gly and MCPA-Gly in human urine. C1 [Isenberg, Samantha L.; Graham, Leigh Ann; Mathews, Thomas P.; Johnson, Darryl] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Carter, Melissa D.; Thomas, Jerry D.; Pirkle, James L.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Carter, MD (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM vsm8@cdc.gov FU Centers for Disease Control and Prevention; Oak Ridge Institute for Science and Education FX This work was supported by the Centers for Disease Control and Prevention and the Oak Ridge Institute for Science and Education. NR 43 TC 4 Z9 4 U1 2 U2 14 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0893-228X EI 1520-5010 J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD SEP PY 2015 VL 28 IS 9 BP 1753 EP 1759 DI 10.1021/acs.chemrestox.5b00205 PG 7 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA CS1YR UT WOS:000361865300012 PM 26328472 ER PT J AU Reis, GF Ritter, JM Bellini, WJ Rota, PA Bollen, AW AF Reis, Gerald F. Ritter, Jana M. Bellini, William J. Rota, Paul A. Bollen, Andrew W. TI A 29-year-old pregnant woman with worsening left hemiparesis, encephalopathy, and hemodynamic instability: a case report of subacute sclerosing panencephalitis SO CLINICAL NEUROPATHOLOGY LA English DT Article DE measles; subacute sclerosing panencephalitis; electron microscopy; central nervous system; pregnancy; vaccination; N450 sequence analysis ID MEASLES-VIRUS; EPIDEMIOLOGY; SSPE; ENGLAND; NEURONS; DISEASE; INDIA AB A 29-year-old pregnant woman developed progressively worsening encephalopathy, left hemiparesis, and hemodynamic instability over a 6-week period. Initial brain MRI and work-up for infectious and autoimmune causes were normal, although elevated IgG and oligoclonal bands were seen on analysis of the cerebrospinal fluid (CSF). After uncomplicated spontaneous delivery of a preterm healthy infant, her condition worsened. Repeat brain MRI demonstrated generalized volume loss and evidence of corticospinal tract degeneration. She underwent a brain biopsy, which showed characteristic viral inclusions of the type seen in subacute sclerosing panencephalitis (SSPE). The diagnosis was confirmed by immunohistochemistry and electron microscopy, and additional CSF analysis also showed markedly elevated IgG titer for measles. Sequence analysis of the nucleoprotein gene N-450 demonstrated a close relationship to the sequences of viruses in genotype D7. This case documents an similar to 6-month progression to death of SSPE in a pregnant woman. C1 [Reis, Gerald F.; Bollen, Andrew W.] Univ Calif San Francisco, Sch Med, Div Neuropathol, Dept Anat Pathol, San Francisco, CA USA. [Ritter, Jana M.] Natl Ctr Emerging & Zoonot Infect Dis, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesviruses Lab Branch, Div Viral Dis, Nation Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Bollen, AW (reprint author), UCSF Sch Med, Dept Pathol, Div Neuropathol, 505 Parnassus Ave,M-580, San Francisco, CA 94143 USA. EM andrew.bollen@ucsf.edu FU Intramural CDC HHS [CC999999] NR 26 TC 1 Z9 1 U1 0 U2 0 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0722-5091 J9 CLIN NEUROPATHOL JI Clin. Neuropathol. PD SEP-OCT PY 2015 VL 34 IS 5 BP 258 EP 266 DI 10.5414/NP300843 PG 9 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA CS1VC UT WOS:000361855600003 PM 25943270 ER PT J AU Olano, VA Matiz, MI Lenhart, A Cabezas, L Vargas, SL Jaramillo, JF Sarmiento, D Alexander, N Stenstrom, TA Overgaard, HJ AF Alberto Olano, Victor Ines Matiz, Maria Lenhart, Audrey Cabezas, Laura Lucia Vargas, Sandra Felipe Jaramillo, Juan Sarmiento, Diana Alexander, Neal Stenstroem, Thor Axel Overgaard, Hans J. TI SCHOOLS AS POTENTIAL RISK SITES FOR VECTOR-BORNE DISEASE TRANSMISSION: MOSQUITO VECTORS IN RURAL SCHOOLS IN TWO MUNICIPALITIES IN COLOMBIA SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Aedes; dengue; mosquitoes; malaria; primary schools ID VENEZUELAN EQUINE ENCEPHALITIS; DENGUE VIRUS-INFECTION; AEDES-AEGYPTI DIPTERA; WEST-NILE-VIRUS; THAI VILLAGES; CULICIDAE; ARGENTINA; CHILDREN; FOCI AB Dengue and other vector-borne diseases are of great public health importance in Colombia. Vector surveillance and control activities are often focused at the household level. Little is known about the importance of nonhousehold sites, including schools, in maintaining vector-borne disease transmission. The objectives of this paper were to determine the mosquito species composition in rural schools in 2 municipalities in Colombia and to assess the potential risk of vector-borne disease transmission in school settings. Entomological surveys were carried out in rural schools during the dry and rainy seasons of 2011. A total of 12 mosquito species were found: Aedes aegypti, Anopheles pseudopunctipennis, Culex coronator, Cx. quinquefasciatus, and Limatus durhamii in both immature and adult forms; Ae. fluviatilis, Cx. nigripalpus, Cx. corniger, and Psorophora ferox in immature forms only; and Ae. angustivittatus, Haemagogus equinus, and Trichoprosopon lampropus in adult forms only. The most common mosquito species was Cx. quinquefasciatus. Classrooms contained the greatest abundance of adult female Ae. aegypti and Cx. quinquefasciatus. The most common Ae. aegypti breeding sites were containers classified as "others'' (e.g., cans), followed by containers used for water storage. A high level of Ae. aegypti infestation was found during the wet season. Our results suggest that rural schools are potentially important foci for the transmission of dengue and other mosquito-borne diseases. We propose that public health programs should be implemented in rural schools to prevent vector-borne diseases. C1 [Alberto Olano, Victor; Ines Matiz, Maria; Cabezas, Laura; Lucia Vargas, Sandra; Felipe Jaramillo, Juan; Sarmiento, Diana] Univ Bosque, Inst Salud & Ambiente, Bogota 11021, Colombia. [Lenhart, Audrey] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Lenhart, Audrey] US Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Alexander, Neal] Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England. [Stenstroem, Thor Axel] Durban Univ Technol, Inst Water & Waste Water Technol, ZA-4000 Durban, South Africa. [Overgaard, Hans J.] Norwegian Univ Life Sci, Dept Math & Technol Sci, N-1432 As, Norway. [Overgaard, Hans J.] Kasetsart Univ, Dept Entomol, Bangkok 10900, Thailand. [Overgaard, Hans J.] MIVEGEC, Inst Rech Dev, F-34934 Montpellier 5, France. RP Overgaard, HJ (reprint author), Norwegian Univ Life Sci, Dept Math & Technol Sci, N-1432 As, Norway. FU Research Council of Norway [201349]; Lazos de Calandaima Foundation; Universidad El Bosque, Colombia FX We thank the mayors' offices, health departments, and education departments of both Anapoima and La Mesa municipalities and the personnel of the rural schools in these municipalities for their collaboration during the undertaking of this project, as well as the fieldworkers: Humberto Mosquera, Nancy Herrera, Rosa Silva, Laura Hernandez, and Ana Cuellar. We thank Edgar Ibanez from Universidad El Bosque for statistical support. This project was funded by the Research Council of Norway as part of the HEALTH-PLATFORM study (Project no. 201349), the Lazos de Calandaima Foundation, and Universidad El Bosque, Colombia. NR 58 TC 7 Z9 7 U1 0 U2 6 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X EI 1943-6270 J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2015 VL 31 IS 3 BP 212 EP 222 PG 11 WC Entomology SC Entomology GA CR7VZ UT WOS:000361561200002 PM 26375902 ER PT J AU Harwood, JF Arimoto, H Nunn, P Richardson, AG Obenauer, PJ AF Harwood, James F. Arimoto, Hanayo Nunn, Peter Richardson, Alec G. Obenauer, Peter J. TI ASSESSING CARBON DIOXIDE AND SYNTHETIC LURE-BAITED TRAPS FOR DENGUE AND CHIKUNGUNYA VECTOR SURVEILLANCE SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Aedes aegypti; Aedes albopictus; Centers for Disease Control and Prevention light trap; BG-Sentinel 2; BG-Mosquitito Trap; Zumba Trap ID ALBOPICTUS DIPTERA-CULICIDAE; AEDES-ALBOPICTUS; ANOPHELES-GAMBIAE; FLORIDA; YEAST; SUBURBAN AB The Aedes mosquito vectors of dengue virus (DENV) and chikungunya virus (CHIKV) are attracted to specific host cues that are not generated by traditional light traps. For this reason multiple companies have designed traps to specifically target those species. Recently the standard trap for DENV and CHIKV vectors, the BG-Sentinel (BGS) trap, has been remodeled to be more durable and better suited for use in harsh field conditions, common during military operations, and relabeled the BG-Sentinel 2 (BGS2). This new trap was evaluated against the standard Centers for Disease Control and Prevention (CDC) light trap, Zumba Trap, and BG-Mosquitito Trap to determine relative effectiveness in collecting adult Aedes aegypti and Ae. albopictus. Evaluations were conducted under semifield and field conditions in suburban areas in northeastern Florida from May to August 2014. The BGS2 trap collected more DENV and CHIKV vectors than the standard CDC light trap, Zumba Trap, and BG-Mosquitito Trap, but attracted fewer species, while the BG-Mosquitito Trap attracted the greatest number of mosquito species. C1 [Harwood, James F.; Arimoto, Hanayo; Nunn, Peter; Richardson, Alec G.] Navy Entomol Ctr Excellence, Naval Air Stn, Jacksonville, FL 32212 USA. [Obenauer, Peter J.] Ctr Dis Control & Prevent, Atlanta, GA 30324 USA. RP Harwood, JF (reprint author), Navy Entomol Ctr Excellence, Naval Air Stn, Bldg 937, Jacksonville, FL 32212 USA. FU Deployed War Fighter Protection Research Program FX Title 17 U.S.C. 105 provides that "Copyright protection under this title is not available for any work of the United States Government." Title 17 U.S.C. 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties. We thank M. McDonough, J. Knapp, B. Turnwall, D. Spatola, K. Justice, and W. Adamec for assisting in collecting and identifying specimens. This project was supported through funding from the Deployed War Fighter Protection Research Program. NR 20 TC 2 Z9 2 U1 0 U2 6 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X EI 1943-6270 J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2015 VL 31 IS 3 BP 242 EP 247 PG 6 WC Entomology SC Entomology GA CR7VZ UT WOS:000361561200005 PM 26375905 ER PT J AU Hoel, DF Dunford, JC Kline, DL Irish, SR Weber, M Richardson, AG Doud, CW Wirtz, RA AF Hoel, David F. Dunford, James C. Kline, Daniel L. Irish, Seth R. Weber, Michael Richardson, Alec G. Doud, Carl W. Wirtz, Robert A. TI A COMPARISON OF CARBON DIOXIDE SOURCES FOR MOSQUITO CAPTURE IN CENTERS FOR DISEASE CONTROL AND PREVENTION LIGHT TRAPS ON THE FLORIDA GULF COAST SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Carbon dioxide; generator; dry ice; citric acid; sodium bicarbonate; yeast ID L-LACTIC ACID; ANOPHELES-GAMBIAE; AEDES-AEGYPTI; BITING FLIES; 1-OCTEN-3-OL; ATTRACTANTS; YEAST; CULICIDAE; DIPTERA; BLENDS AB Traditional sources of carbon dioxide (CO2), dry ice, and compressed gas, were tested against 3 combinations of food-grade reagents known to generate CO2 using a compact, lightweight generator delivery system with Centers for Disease Control and Prevention light traps. Three 6 3 6 Latin square trials were completed near the Florida Gulf Coast in the Lower Suwannee Wildlife Refuge during the summer of 2013, collecting a total of 31,632 female mosquitoes. Treatments included dry ice, compressed CO2 gas, a control trap (no CO2), citric acid + sodium bicarbonate, vinegar + sodium bicarbonate, and yeast +/- sugar. Decreasing order of trap collections (treatment mean number of mosquitoes per trap night 6 standard error) were dry ice 773.5 (+/- 110.1). compressed gas 440.7 (+/- 42.3) > citric acid + sodium bicarbonate 197.6 (+/- 30.4), yeast + sugar 153.6 (+/- 27.4) > vinegar + sodium bicarbonate 109.6 (+/- 16.2) > control 82.4 (+/- 14.0). A 2-way Kruskal-Wallis analysis by treatment, site, and treatment 3 site interaction identified significant differences between all treatments. Although dry ice and compressed CO2 gas collected significantly more mosquitoes than other combinations (P < 0.05), use of citric acid and sodium bicarbonate or yeast and sugar greatly outperformed unbaited traps and offer a good alternative to dry ice and compressed gas in areas where these agents are not readily available or are difficult to obtain due to logistical constraints. An inexpensive, portable CO2 generator for use with food-grade reagents is described. C1 [Hoel, David F.] Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Detachment, Atlanta, GA 30329 USA. [Hoel, David F.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Dunford, James C.] US Navy Environm & Prevent Med, Norfolk, VA 23511 USA. [Kline, Daniel L.] USDA ARS, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA. [Irish, Seth R.; Wirtz, Robert A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Weber, Michael] OnVector Technol, Sunnyvale, CA 94087 USA. [Richardson, Alec G.; Doud, Carl W.] Navy Entomol Ctr Excellence, Naval Air Stn Jacksonville, Jacksonville, FL 32212 USA. RP Hoel, DF (reprint author), Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Detachment, 1600 Clifton Rd, Atlanta, GA 30329 USA. NR 31 TC 1 Z9 1 U1 0 U2 6 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X EI 1943-6270 J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2015 VL 31 IS 3 BP 248 EP 257 PG 10 WC Entomology SC Entomology GA CR7VZ UT WOS:000361561200006 PM 26375906 ER PT J AU Kroelinger, CD Waddell, LF Goodman, DA Pliska, E Rudolph, C Ahmed, E Addison, D AF Kroelinger, Charlan D. Waddell, Lisa F. Goodman, David A. Pliska, Ellen Rudolph, Claire Ahmed, Einas Addison, Donna TI Working with State Health Departments on Emerging Issues in Maternal and Child Health: Immediate Postpartum Long-Acting Reversible Contraceptives SO JOURNAL OF WOMENS HEALTH LA English DT Article ID VISIT; POPULATION; PREVENTION; PREDICTORS; PREGNANCY; CARE AB Background: Immediate postpartum long-acting reversible contraceptives (LARC) are highly effective in preventing unintended pregnancy. State health departments are in the process of implementing a systems change approach to better apply policies supporting the use of immediate postpartum LARC. Methods: Beginning in 2014, a group of national organizations, federal agencies, and six states have convened a LARC Learning Community to share strategies and best practices in immediate postpartum LARC policy development and implementation. Community activities consist of in-person meetings and a webinar series as forums to discuss systems change. Results: The Learning Community identified eight domains for discussion and development of resources: training, pay streams, stocking and supply, consent, outreach, stakeholder partnerships, service location, and data and surveillance. The community is currently developing resource materials and guidance for use by other state health departments. Conclusions: To effectively implement policies on immediate postpartum LARC, states must engage a number of stakeholders in the process, raise awareness of the challenges to implementation, and communicate strategies across agencies during policy development. C1 [Kroelinger, Charlan D.; Goodman, David A.; Addison, Donna] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Waddell, Lisa F.; Pliska, Ellen; Rudolph, Claire; Ahmed, Einas] Assoc State & Terr Hlth Officials, Arlington, VA USA. RP Kroelinger, CD (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Northeast MS K-22, Atlanta, GA 30341 USA. EM ckroelinger@cdc.gov FU [CDC-RFA-0173-1302] FX Partial funding of this activity was provided by CDC-RFA-0173-1302. No other competing financial interests exist. NR 30 TC 3 Z9 3 U1 0 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD SEP 1 PY 2015 VL 24 IS 9 BP 693 EP 701 DI 10.1089/jwh.2015.5401 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CR6RT UT WOS:000361475700002 PM 26390378 ER PT J AU Mizuno, Y Frazier, EL Huang, P Skarbinski, J AF Mizuno, Yuko Frazier, Emma L. Huang, Ping Skarbinski, Jacek TI Characteristics of Transgender Women Living with HIV Receiving Medical Care in the United States SO LGBT HEALTH LA English DT Article DE HIV; Medical Monitoring Project (MMP); transgender women ID HEALTH OUTCOMES; RETENTION AB Purpose: Little has been reported from population-based surveys on the characteristics of transgender persons living with HIV. Using Medical Monitoring Project (MMP) data, we describe the characteristics of HIV-infected transgender women and examine their care and treatment needs. Methods: We used combined data from the 2009 to 2011 cycles of MMP, an HIV surveillance system designed to produce nationally representative estimates of the characteristics of HIV-infected adults receiving medical care in the United States, to compare demographic, behavioral, and clinical characteristics, and met and unmet needs for supportive services of transgender women with those of non-transgender persons using Rao-Scott chi-square tests. Results: An estimated 1.3% of HIV-infected persons receiving care in the United States self-identified as transgender women. Transgender women were socioeconomically more marginalized than non-transgender men and women. We found no differences between transgender women and non-transgender men and women in the percentages prescribed antiretroviral therapy (ART). However, a significantly lower percentage of transgender women compared to non-transgender men had 100% ART dose adherence (78.4% vs. 87.4%) and durable viral suppression (50.8% vs. 61.4%). Higher percentages of transgender women needed supportive services. No differences were observed in receipt of most of supportive services, but transgender women had higher unmet needs than non-transgender men for basic services such as food and housing. Conclusion: We found little difference between transgender women and non-transgender persons in regards to receipt of care, treatment, and most of supportive services. However, the noted disparities in durable viral suppression and unmet needs for basic services should be explored further. C1 [Mizuno, Yuko; Frazier, Emma L.; Huang, Ping; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP Mizuno, Y (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30329 USA. EM ybm2@cdc.gov FU Centers for Disease Control and Prevention [PS09-937] FX All the authors declare no conflict of interest. Funding for the Medical Monitoring Project is provided by a cooperative agreement (PS09-937) from the Centers for Disease Control and Prevention. NR 13 TC 3 Z9 3 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD SEP PY 2015 VL 2 IS 3 BP 228 EP 234 DI 10.1089/lgbt.2014.0099 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR9RH UT WOS:000361693800005 PM 26788671 ER PT J AU Lesesne, CA Rasberry, CN Kroupa, E Topete, P Carver, LH Morris, E Robin, L AF Lesesne, Catherine A. Rasberry, Catherine N. Kroupa, Elizabeth Topete, Pablo Carver, Lisa H. Morris, Elana Robin, Leah TI Communicating with School Staff About Sexual Identity, Health and Safety: An Exploratory Study of the Experiences and Preferences of Black and Latino Teen Young Men Who Have Sex with Men SO LGBT HEALTH LA English DT Article DE adolescent; communication; lesbian; gay; bisexual; and transgender (LGBT); safety; school health; young men who have sex with men (YMSM) ID ADOLESCENT HOMOSEXUALS; GAY; VICTIMIZATION; YOUTH; ENVIRONMENT; ORIENTATION; ADJUSTMENT; STUDENTS AB Purpose: This exploratory study examined the experiences of black and Latino teen young men who have sex with men (YMSM) and their preferences for communication with school staff about matters related to sexual orientation. Methods: Participants for this study were recruited in three urban centers in the United States and by multiple community-based organizations serving black and Latino YMSM. Eligible youth were male, black and Latino, ages 13-19, enrolled in 90 days of school in the previous 18 months, and reported attraction to or sexual behavior with other males, or identified as gay or bisexual. Participants completed web-based questionnaires (n = 415) and/ or in-depth interviews (n = 32). Results: Questionnaire participants reported willingness to talk to at least one school staff member about: safety, dating and relationships, and feeling attracted to other guys (63.4%, 58.4%, and 55.9%, respectively). About one-third of the sample reported they would not talk with any school staff about these topics. Exploratory analyses revealed youth who experienced feeling unsafe at school and who had higher levels of trust in the information provided by school staff were more likely to be willing to talk with school staff about safety issues, dating, or same sex attraction (adjusted odds ratio [AOR] = 2.80 and AOR = 4.85, respectively). Interview participants reported being most willing to talk to staff who were able and willing to help them, who would keep discussions confidential, and who expressed genuine care. Preferences for confiding in school staff perceived to be lesbian, gay, bisexual, and transgender (LGBT) and having similar racial/ethnic background were also noted. Conclusion: Findings suggest school staff can serve as points of contact for reaching YMSM and professional development and interventions can be tailored to reach YMSM and connect them to services they need. Additional research is needed to understand how to increase YMSM comfort talking with school staff about sexual health or sexual identity concerns. C1 [Lesesne, Catherine A.; Topete, Pablo; Carver, Lisa H.] ICF Int, Div Publ Hlth & Survey Res, Atlanta, GA 30329 USA. [Rasberry, Catherine N.; Morris, Elana; Robin, Leah] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Kroupa, Elizabeth] ICF Int, Div Publ Hlth & Survey Res, Seattle, WA USA. RP Lesesne, CA (reprint author), ICF Int, Div Publ Hlth & Survey Res, 3 Corp Sq,Suite 370, Atlanta, GA 30329 USA. EM Catherine.Lesesne@icfi.com RI Rasberry, Catherine/P-1984-2016 OI Rasberry, Catherine/0000-0001-8256-6961 FU Centers for Disease Control and Prevention, Division of Adolescent and School Health [200-2009-30503] FX This formative evaluation was supported by contract 200-2009-30503 from the Centers for Disease Control and Prevention, Division of Adolescent and School Health. The authors would like to acknowledge the important contribution of other team members and partners. We thank Andrew Hebert, Ye Xu, and William Moore for data management, analysis, and reporting support. We thank LaSamuel Stallworth for coordination of data collection efforts. Lastly, we thank the following community-based organizations for assisting with evaluation recruitment: Attic Youth Center; COLOURS Organization, Inc.; Dimensions Clinic; Gay and Lesbian Latino AIDS Education Initiative (GALAEI); Gay Men of African Descent; Gay Men's Health Crisis; Harlem United; Health Initiatives for Youth (HIFY); Hetrick-Martin Institute; Larkin Street Youth Services; Lavender Youth Recreation and Information Center (LYRIC); Mazzoni Center; and the San Francisco Department of Public Health. The findings and conclusions in the manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 21 TC 1 Z9 1 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD SEP PY 2015 VL 2 IS 3 BP 258 EP 264 DI 10.1089/lgbt.2014.0087 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR9RH UT WOS:000361693800009 PM 26436114 ER PT J AU Murphy, WJ Fackler, CJ Berger, EH Shaw, PB Stergar, M AF Murphy, William J. Fackler, Cameron J. Berger, Elliott H. Shaw, Peter B. Stergar, Mike TI Measurement of impulse peak insertion loss from two acoustic test fixtures and four hearing protector conditions with an acoustic shock tube SO NOISE & HEALTH LA English DT Article DE Acoustic test fixture; American National Standards Institute (ANSI) S12; 42-2010; hearing protection; impulse noise ID NOISE EXPOSURE; ATTENUATION AB Impulse peak insertion loss (IPIL) was studied with two acoustic test fixtures and four hearing protector conditions at the E-A-RCAL Laboratory. IPIL is the difference between the maximum estimated pressure for the open-ear condition and the maximum pressure measured when a hearing protector is placed on an acoustic test fixture (ATF). Two models of an ATF manufactured by the French-German Research Institute of Saint-Louis (ISL) were evaluated with high-level acoustic impulses created by an acoustic shock tube at levels of 134 decibels (dB), 150 dB, and 168 dB. The fixtures were identical except that the E-A-RCAL ISL fixture had ear canals that were 3 mm longer than the National Institute for Occupational Safety and Health (NIOSH) ISL fixture. Four hearing protection conditions were tested: Combat Arms earplug with the valve open, ETYPlugs ((R)) earplug, TacticalPro headset, and a dual-protector ETYPlugs earplug with TacticalPro earmuff. The IPILs measured for the E-A-RCAL fixture were 1.4 dB greater than the National Institute for Occupational Safety and Health (NIOSH) ISL ATF. For the E-A-RCAL ISL ATF, the left ear IPIL was 2.0 dB greater than the right ear IPIL. For the NIOSH ATF, the right ear IPIL was 0.3 dB greater than the left ear IPIL. C1 [Murphy, William J.; Fackler, Cameron J.; Shaw, Peter B.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Fackler, Cameron J.; Berger, Elliott H.; Stergar, Mike] 3M E A RCAL Lab, Indianapolis, IN USA. RP Murphy, WJ (reprint author), NIOSH, Hearing Loss Prevent Team, 1090 Tusculum Ave MS C-27, Cincinnati, OH 45226 USA. EM wjm4@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 1 Z9 1 U1 3 U2 5 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1463-1741 EI 1998-4030 J9 NOISE HEALTH JI Noise Health PD SEP-OCT PY 2015 VL 17 IS 78 BP 364 EP 373 PG 10 WC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health SC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health GA CR8JD UT WOS:000361596400016 PM 26356380 ER PT J AU Kading, RC Kityo, R Nakayiki, T Ledermann, J Crabtree, MB Lutwama, J Miller, BR AF Kading, Rebekah C. Kityo, Robert Nakayiki, Teddie Ledermann, Jeremy Crabtree, Mary B. Lutwama, Julius Miller, Barry R. TI Detection of Entebbe Bat Virus after 54 Years SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID YELLOW-FEVER VIRUS; MOLECULAR CHARACTERIZATION; DENGUE VIRUS; PHYLOGENY; UGANDA; INHIBITION; FLAVIVIRUS; GENUS AB Entebbe bat virus (ENTV; Flaviviridae: Flavivirus), closely related to yellow fever virus, was first isolated from a little free-tailed bat (Chaerephon pumilus) in Uganda in 1957, but was not detected after that initial isolation. In 2011, we isolated ENTV from a little free-tailed bat captured from the attic of a house near where it had originally been found. Infectious virus was recovered from the spleen and lung, and the viral RNA was sequenced and compared with that of the original isolate. Across the polypeptide sequence, there were 76 amino acid substitutions, resulting in 97.8% identity at the amino acid level between the 1957 and 2011 isolates. Further study of this virus would provide valuable insights into the ecological and genetic factors governing the evolution and transmission of bat- and mosquitoborne flaviviruses. C1 US Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Kityo, Robert] Makerere Univ, Dept Biol Sci, Kampala, Uganda. [Nakayiki, Teddie; Lutwama, Julius] Uganda Virus Res Inst, Dept Arbovirol, Entebbe, Uganda. [Kading, Rebekah C.] Genesis Labs Inc, Wellington, CO 80549 USA. [Ledermann, Jeremy; Crabtree, Mary B.; Miller, Barry R.] CDC, Div Vector Borne Dis, Ft Collins, CO USA. RP Kading, RC (reprint author), Genesis Labs Inc, POB 1195, Wellington, CO 80549 USA. EM rcmosquito@gmail.com; kityrob@gmail.com; nakayikiteddie@yahoo.com; bpj7@cdc.gov; meb3@cdc.gov; jjlutwama03@yahoo.com; brm4@cdc.gov RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU Centers for Disease Control; United States Agency for International Development FX This work was funded by an interagency agreement between the Centers for Disease Control and the United States Agency for International Development. NR 26 TC 0 Z9 1 U1 1 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2015 VL 93 IS 3 BP 475 EP 477 DI 10.4269/ajtmh.15-0065 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CR3TB UT WOS:000361254900009 PM 26101270 ER PT J AU Heitzinger, K Rocha, CA Quick, RE Montano, SM Tilley, DH Mock, CN Carrasco, AJ Cabrera, RM Hawes, SE AF Heitzinger, Kristen Rocha, Claudio A. Quick, Robert E. Montano, Silvia M. Tilley, Drake H., Jr. Mock, Charles N. Jannet Carrasco, A. Cabrera, Ricardo M. Hawes, Stephen E. TI "Improved" but Not Necessarily Safe: An Assessment of Fecal Contamination of Household Drinking Water in Rural Peru SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID NORTHERN COASTAL ECUADOR; MICROBIOLOGICAL EFFECTIVENESS; DEVELOPING-COUNTRIES; ESCHERICHIA-COLI; DISINFECTING WATER; DIARRHEAL DISEASE; QUALITY; RISK; CAMBODIA; ACCESS AB The indicator used to measure progress toward the Millennium Development Goal (MDG) for water is access to an improved water supply. However, improved supplies are frequently fecally contaminated in developing countries. We examined factors associated with Escherichia colt contamination of improved water supplies in rural Pisco province, Peru. A random sample of 207 households with at least one child less than 5 years old was surveyed, and water samples from the source and storage container were tested for E. colt contamination. Although over 90% of households used an improved water source, 47% of source and 43% of stored water samples were contaminated with E. colt. Pouring or using a spigot to obtain water from the storage container instead of dipping a hand or object was associated with decreased risk of contamination of stored water (adjusted prevalence ratio [aPR] = 0.58, 95% confidence interval [CI] = 0.42, 0.80). Container cleanliness (aPR = 0.67, 95% CI = 0.45, 1.00) and correct handwashing technique (aPR = 0.62, 95% CI = 0.42, 0.90) were also associated with decreased contamination risk. These findings highlighted the limitations of improved water supplies as an indicator of safe water access. To ensure water safety in the home, household water treatment and improved hygiene, water handling, and storage practices should be promoted. C1 [Heitzinger, Kristen; Mock, Charles N.; Hawes, Stephen E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Rocha, Claudio A.; Montano, Silvia M.] US Naval Med Res Unit 6, Dept Bacteriol, Callao, Peru. [Quick, Robert E.] US Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA USA. Ica Reg Minist Hlth, Hosp San Juan de Dios, Dept Environm Hlth, Pisco, Peru. [Tilley, Drake H., Jr.] Naval Med Ctr, Div Infect Dis, San Diego, CA USA. [Jannet Carrasco, A.; Cabrera, Ricardo M.] Hosp San Juan Dios, Dept Environm Hlth, Pisco, Peru. RP Heitzinger, K (reprint author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. EM heitzk@uw.edu; claudio.rocha@med.navy.mil; rxql@cdc.gov; silvia.montano@med.navy.mil; drake.tilley@med.navy.mil; cmock@uw.edu; jannet09@hotmail.com; rcabrerac@hotmail.com; hawes@uw.edu FU Department of Defense; NIH by the Fogarty International Center [R25 TW009345] FX This research was supported by the Department of Defense Humanitarian Assistance Program and by NIH research training grant no. R25 TW009345 awarded to the Northern Pacific Global Health Fellows Program by the Fogarty International Center. NR 50 TC 3 Z9 3 U1 2 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2015 VL 93 IS 3 BP 501 EP 508 DI 10.4269/ajtmh.14-0802 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CR3TB UT WOS:000361254900014 PM 26195455 ER PT J AU Menon, MP Yoon, SS AF Menon, Manoj P. Yoon, Steven S. CA Uganda Malaria Indicator Survey Te TI Prevalence and Factors Associated with Anemia among Children under 5 Years of Age-Uganda, 2009 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID IRON-DEFICIENCY ANEMIA; PLASMODIUM-FALCIPARUM MALARIA; PLACEBO-CONTROLLED TRIAL; MIDDLE-INCOME COUNTRIES; YOUNG-CHILDREN; SYSTEMATIC ANALYSIS; PRESCHOOL-CHILDREN; RISK-FACTORS; SUPPLEMENTATION; BURDEN AB Anemia in children under 5 years of age, defined by the World Health Organization as a hemoglobin concentration < 11 g/dL, is a global public health problem. According to the 2006 Demographic Health Survey, the prevalence of anemia among children under five in Uganda was 72% in 2006. The 2009 Uganda Malaria Indicator Survey was conducted in late 2009 and revealed that over 60% of children less than 5 years of age were anemic and that over half of children tested positive for malaria via a rapid diagnostic test. Children with concomitant malaria infection, and in households without any type of mosquito net were more likely to be anemic, confirming that children under 5 years, are vulnerable to both the threat of malaria and anemia and the beneficial effect of malaria prevention tools. However, prevention and treatment of other factors associated with the etiology of anemia (e.g., iron deficiency) are likely necessary to combat the toll of anemia in Uganda. C1 [Menon, Manoj P.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. Univ Washington, Seattle, WA 98195 USA. RP Menon, MP (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA. EM mmenon@fhcrc.org FU United States Agency for International Development (USAID); U.S. President's Malaria Initiative (PMI); Career Development in Clinical Hematology award [5 K12 HL 087165] FX Funding for the UMIS was provided by the United States Agency for International Development (USAID) and the U.S. President's Malaria Initiative (PMI). Support for Manoj P. Menon was also provided via Career Development in Clinical Hematology award (5 K12 HL 087165). NR 54 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2015 VL 93 IS 3 BP 521 EP 526 DI 10.4269/ajtmh.15-0102 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CR3TB UT WOS:000361254900017 PM 26055748 ER PT J AU Bwire, G Malimbo, M Kagirita, A Makumbi, I Mintz, E Mengel, MA Orach, CG AF Bwire, Godfrey Malimbo, Mugagga Kagirita, Atek Makumbi, Issa Mintz, Eric Mengel, Martin A. Orach, Christopher Garimoi TI Nosocomial Cholera Outbreak in a Mental Hospital: Challenges and Lessons Learnt from Butabika National Referral Mental Hospital, Uganda SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID AFRICA; TRANSMISSION; EPIDEMIC; 1ST AB During the last four decades, Uganda has experienced repeated cholera outbreaks in communities; no cholera outbreaks have been reported in Ugandan health facilities. In October 2008, a unique cholera outbreak was confirmed in Butabika National Mental Referral Hospital (BNMRH), Uganda. This article describes actions taken to control the outbreak, challenges, and lessons learnt. We reviewed patient and hospital reports for clinical symptoms and signs, treatment and outcome, patient mental diagnosis, and challenges noted during management of patients and contacts. Out of 114 BNMRH patients on two affected wards, 18 cholera cases and five deaths were documented for an attack rate of 15.8% and a case fatality rate of 28%. Wards and surroundings were intensively disinfected and 96 contacts (psychiatric patients) in the affected wards received chemoprophylaxis with oral ciprofioxacin 500 mg twice daily until November 5, 2008. We documented a nosocomial cholera outbreak in BNMRH with a high case fatality of 28% compared with the national average of 2.4% for cholera outbreaks in communities. To avoid cholera outbreaks and potentially high mortality among patients in mental institutions, procedures for prompt diagnosis, treatment, disinfection, and prophylaxis are needed and preemptive use of oral cholera vaccines should be considered. C1 Minist Hlth, Control Diarrheal Dis Sect, Kampala, Uganda. Minist Hlth, Epidemiol Surveillance Div, Kampala, Uganda. US Ctr Dis Control & Prevent, Atlanta, GA USA. Cent Publ Hlth Lab, Kampala, Uganda. Agence Med Prevent, Paris, France. Makerere Univ, Sch Publ Hlth, Kampala, Uganda. RP Mintz, E (reprint author), Ctr Dis Control & Prevent, Mailstop C-09, Atlanta, GA 30333 USA. EM emintz@cdc.gov NR 26 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2015 VL 93 IS 3 BP 534 EP 538 DI 10.4269/ajtmh.14-0730 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CR3TB UT WOS:000361254900019 PM 26195468 ER PT J AU Drexler, NA Traeger, MS McQuiston, JH Williams, V Hamilton, C Regan, JJ AF Drexler, Naomi A. Traeger, Marc S. McQuiston, Jennifer H. Williams, Velda Hamilton, Charlene Regan, Joanna J. TI Medical and Indirect Costs Associated with a Rocky Mountain Spotted Fever Epidemic in Arizona, 2002-2011 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ENDEMIC AREA-ARIZONA; UNITED-STATES; DISEASE AB Rocky Mountain spotted fever (RMSF) is an emerging public health issue on some American Indian reservations in Arizona. RMSF causes an acute febrile illness that, if untreated, can cause severe illness, permanent sequelae requiring lifelong medical support, and death. We describe costs associated with medical care, loss of productivity, and death among cases of RMSF on two American Indian reservations (estimated population 20,000) between 2002 and 2011. Acute medical costs totaled more than $1.3 million. This study further estimated $181,100 in acute productivity lost due to illness, and $11.6 million in lifetime productivity lost from premature death. Aggregate costs of RMSF cases in Arizona 2002-2011 amounted. to $13.2 million. We believe this to be a significant underestimate of the cost of the epidemic, but it underlines the severity of the disease and need for a more comprehensive study. C1 Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. Whiteriver Indian Hlth Serv Hosp, Whiteriver, AZ USA. [Williams, Velda] Dept Hlth Serv, Tribe A, Phoenix, AZ USA. [Hamilton, Charlene] Dept Hlth Serv, Tribe B, Phoenix, AZ USA. [Drexler, Naomi A.; McQuiston, Jennifer H.; Regan, Joanna J.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Traeger, Marc S.] Whiteriver Indian Hlth Serv Hosp, Indian Hlth Serv, Whiteriver, AZ USA. RP Drexler, NA (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,Mailstop A-30, Atlanta, GA 30333 USA. EM isj3@cdc.gov; marc.traeger@ihs.gov; fzh7@cdc.gov; velda.williams@scat-nsn.gov; charlenehamilton123@yahoo.com; dlo8@cdc.gov OI Regan, Joanna/0000-0002-9179-6694 NR 13 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2015 VL 93 IS 3 BP 549 EP 551 DI 10.4269/ajtmh.15-0104 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CR3TB UT WOS:000361254900023 PM 26033020 ER PT J AU Varan, AK Bruniera-Oliveira, R Peter, CR Fonseca-Ford, M Waterman, SH AF Varan, Aiden K. Bruniera-Oliveira, Robson Peter, Christopher R. Fonseca-Ford, Maureen Waterman, Stephen H. TI Multinational Disease Surveillance Programs: Promoting Global Information Exchange for Infectious Diseases SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article AB Cross-border surveillance for emerging diseases such as Ebola and other infectious diseases requires effective international collaboration. We surveyed representatives from 12 multinational disease surveillance programs between January 2013 and April 2014. Our survey identified programmatic similarities despite variation in health priorities, geography, and socioeconomic context, providing a contemporary perspective on infectious disease surveillance networks. C1 Council State & Terr Epidemiologists, CDC CSTE Appl Epidemiol Fellowship, Atlanta, GA USA. Cty San Diego Hlth & Human Serv Agcy, San Diego, CA USA. [Varan, Aiden K.; Fonseca-Ford, Maureen; Waterman, Stephen H.] Ctr Dis Control & Prevent, San Diego, CA 92110 USA. [Bruniera-Oliveira, Robson] Natl Sch Publ Hlth, Rio De Janeiro, Brazil. RP Waterman, SH (reprint author), Ctr Dis Control & Prevent, 3851 Rosecrans St,Suite 715, San Diego, CA 92110 USA. EM vv15@cdc.gov; robson.bruniera@gmail.com; ausgermph@gmail.com; mrf5@cdc.gov; shw2@cdc.gov FU Centers for Disease Control and Prevention (CDC) [1U380T000143-01] FX This study/report was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number 1U380T000143-01. NR 21 TC 0 Z9 0 U1 2 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2015 VL 93 IS 3 BP 668 EP 671 DI 10.4269/ajtmh.15-0097 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CR3TB UT WOS:000361254900043 PM 26033019 ER PT J AU Simeone, RM Oster, ME Hobbs, CA Robbins, JM Collins, RT Honein, MA AF Simeone, Regina M. Oster, Matthew E. Hobbs, Charlotte A. Robbins, James M. Collins, R. Thomas Honein, Margaret A. TI Population-based study of hospital costs for hospitalizations of infants, children, and adults with a congenital heart defect, Arkansas 2006 to 2011 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE arkansas; congenital heart defects; hospital costs; state inpatient database; healthcare cost and utilization project ID GENERAL-POPULATION; UNITED-STATES; DISEASE; PREVALENCE; ASCERTAINMENT; ADMISSIONS; TRENDS AB BackgroundCongenital heart defects (CHDs) are common birth defects and are associated with high hospital costs. The objectives of this study were to assess hospitalization costs, across the lifespan, of patients with CHDs in Arkansas. MethodsData from the 2006 to 2011 Healthcare Cost and Utilization Project Arkansas State Inpatient Databases were used. We included hospitalizations of patients whose admission occurred between January 1, 2006, and December 31, 2011, and included a principal or secondary CHD ICD-9-CM diagnosis code (745.0-747.49, except 747.0 and 745.5 for preterm infants). Hospitalizations were excluded if they involved out-of-state residents, normal newborn births, or if missing data included age at admission, state of residence, or hospital charges. Children were defined as those<18 years-old at time of admission. ResultsBetween 2006 and 2011, there were 2,242,484 inpatient hospitalizations in Arkansas. There were 9071 (0.4%) hospitalizations with a CHD, including 5,158 hospitalizations of children (2.2% of hospitalizations among children) and 3,913 hospitalizations of adults (0.2% of hospitalizations of adults). Hospital costs for these CHD hospitalizations totaled $355,543,696. The average annual cost of CHD hospitalizations in Arkansas was $59,257,283 during this time period. Infants accounted for 72% of all CHD-related hospital costs; total costs of CHD hospitalizations for children were almost five times those of hospitalization costs for adults with CHD. ConclusionHospitalizations with CHDs account for a disproportionate share of hospital costs in Arkansas. Hospitalizations of children with CHD accounted for a higher proportion of total hospitalizations than did hospitalizations of adults with CHD. Birth Defects Research (Part A) 103:814-820, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Simeone, Regina M.; Oster, Matthew E.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Oster, Matthew E.] Childrens Healthcare Atlanta, Sibley Heart Ctr, Atlanta, GA USA. [Hobbs, Charlotte A.; Robbins, James M.; Collins, R. Thomas] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. RP Simeone, RM (reprint author), Ctr Dis Control & Prevent & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM rsimeone@cdc.gov OI Robbins, James/0000-0003-2200-1947 FU Intramural CDC HHS [CC999999] NR 30 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD SEP PY 2015 VL 103 IS 9 BP 814 EP 820 DI 10.1002/bdra.23379 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CR3PQ UT WOS:000361245800010 PM 26069215 ER PT J AU Traina, MI Sanchez, DR Hernandez, S Bradfield, JS Labedi, MR Ngab, TA Steurer, F Montgomery, SP Meymandi, SK AF Traina, Mahmoud I. Sanchez, Daniel R. Hernandez, Salvador Bradfield, Jason S. Labedi, Mohamed R. Ngab, Tarik A. Steurer, Frank Montgomery, Susan P. Meymandi, Sheba K. TI Prevalence and Impact of Chagas Disease Among Latin American Immigrants With Nonischemic Cardiomyopathy in Los Angeles, California SO CIRCULATION-HEART FAILURE LA English DT Article DE cardiomyopathies; Chagas cardiomyopathy; heart failure; mortality; prognosis ID HEART-DISEASE; DILATED CARDIOMYOPATHY; TRYPANOSOMA-CRUZI; UNITED-STATES; GENETIC-VARIABILITY; TRANSPLANTATION; AMIODARONE; PATHOGENESIS; ASSOCIATION; ARRHYTHMIAS AB Background Chagas disease is a well-known cause of cardiomyopathy in Latin America; however, 300 000 individuals are estimated to have Chagas disease in the United States. This study examined the prevalence and impact of Chagas cardiomyopathy (CCM) in a US population. We hypothesized that patients with CCM would have increased morbidity and mortality when compared with patients with non-CCM. Methods and Results This is a single-center, prospective cohort study. Enrollment criteria were new diagnosis of nonischemic cardiomyopathy (left ventricular ejection fraction 40%) and previous residence in Latin America for at least 12 months. Serological testing for Trypanosoma cruzi was performed at enrollment. The primary end point was all-cause mortality or heart transplantation. The secondary end point was heart failure-related hospitalization. A total of 135 patients were enrolled, with a median of 43 months of follow-up. Chagas disease was diagnosed in 25 (19%) patients. The primary end point occurred in 9 patients (36%) in the CCM group and in 11 patients (10%) in the non-CCM group (hazard ratio [HR], 4.46; 95% confidence interval, 1.8-10.8; P=0.001). The secondary end point occurred in 13 patients (52%) in the CCM group and in 35 patients (32%) in the non-CCM group (HR, 2.22; 95% confidence interval, 1.2-4.2; P=0.01). Conclusions There is a high prevalence of Chagas disease among Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles. Advanced CCM portends a poor prognosis and is associated with increased all-cause mortality/heart transplantation and heart failure-related hospitalization. C1 [Traina, Mahmoud I.; Sanchez, Daniel R.; Hernandez, Salvador; Bradfield, Jason S.; Labedi, Mohamed R.; Ngab, Tarik A.; Meymandi, Sheba K.] Olive View UCLA Med Ctr, Ctr Excellence Chagas Dis, Sylmar, CA 91342 USA. [Bradfield, Jason S.] Ronald Reagan UCLA Med Ctr, UCLA Cardiac Arrhythmia Ctr, Los Angeles, CA USA. [Steurer, Frank; Montgomery, Susan P.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Traina, MI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Olive View UCLA Med Ctr, Ctr Excellence Treatment Chagas Dis, 14445 Olive View Dr,Room 2C-121, Sylmar, CA 91342 USA. EM mtraina@dhs.lacounty.gov NR 34 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD SEP PY 2015 VL 8 IS 5 BP 938 EP 943 DI 10.1161/CIRCHEARTFAILURE.115.002229 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR2UL UT WOS:000361186000014 PM 26206855 ER PT J AU Wack, EE Ampel, NM Sunenshine, RH Galgiani, JN AF Wack, Elizabeth E. Ampel, Neil M. Sunenshine, Rebecca H. Galgiani, John N. TI The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE coccidioidomycosis; delayed type hypersensitivity; skin test; cellular immunity; diagnostic test ID CHEMICALLY-DEFINED MEDIUM; DERMAL SENSITIVITY; WASHINGTON-STATE; IMMUNE-RESPONSE; IMMITIS; SPHERULIN; PNEUMONIA; OUTBREAK; ARIZONA; USA AB A skin test that detects dermal hypersensitivity in persons with past infection with Coccidioides species is again available for clinical use. Nearly all of the clinical studies with similar materials were published prior to the 1990s, and as a result, many practicing physicians will be unfamiliar with how skin testing for coccidioidomycosis might be useful in patient management or as a research tool. We review clinical and epidemiological studies with past skin test antigens, the composition of past and current skin test preparations with particular attention to differences in the preservatives, and how the current preparation could be used today. C1 [Wack, Elizabeth E.; Galgiani, John N.] Valley Fever Ctr Excellence, Tucson, AZ USA. [Ampel, Neil M.; Galgiani, John N.] Univ Arizona, Coll Med, Tucson, AZ 85724 USA. [Ampel, Neil M.] Southern Arizona Vet Affairs Hlth Care Syst, Tucson, AZ USA. [Sunenshine, Rebecca H.] Maricopa Cty Dept Hlth, Phoenix, AZ USA. [Sunenshine, Rebecca H.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Galgiani, JN (reprint author), Univ Arizona, Coll Med, 1656 E Mabel St,Rm 119,POB 245215, Tucson, AZ 85724 USA. EM spherule@u.arizona.edu FU Nielsen Biosciences FX J. N. G.'s institution, the Valley Fever Center for Excellence, has received an unrestricted educational grant from Nielsen Biosciences. N. M. A. has received research support from Nielsen Biosciences. All other authors report no potential conflicts. NR 39 TC 5 Z9 5 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2015 VL 61 IS 5 BP 787 EP 791 DI 10.1093/cid/civ388 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR6PD UT WOS:000361468700017 PM 25979308 ER PT J AU Minguez-Alarcon, L Gaskins, AJ Chiu, YH Williams, PL Ehrlich, S Chavarro, JE Petrozza, JC Ford, JB Calafat, AM Hauser, R AF Minguez-Alarcon, Lidia Gaskins, Audrey J. Chiu, Yu-Han Williams, Paige L. Ehrlich, Shelley Chavarro, Jorge E. Petrozza, John C. Ford, Jennifer B. Calafat, Antonia M. Hauser, Russ CA EARTH Study Team TI Urinary bisphenol A concentrations and association with in vitro fertilization outcomes among women from a fertility clinic SO HUMAN REPRODUCTION LA English DT Article DE bisphenol A; IVF outcomes; epidemiology; reproductive health; endocrine disruptor ID ESTROGEN-RECEPTOR-ALPHA; INTRAUTERINE IMPLANTATION; LACTATIONAL EXPOSURE; NEONATAL EXPOSURE; ETHINYL ESTRADIOL; DIETARY EXPOSURE; SEMEN QUALITY; MICE; VARIABILITY; CELLS AB Are urinary BPA concentrations associated with in vitro fertilization (IVF) outcomes among women attending an academic fertility center? Urinary BPA concentrations were not associated with adverse reproductive and pregnancy outcomes among women from a fertility clinic. Bisphenol A (BPA), an endocrine disruptor, is detected in the urine of most Americans. Although animal studies have demonstrated that BPA reduces female fertility through effects on the ovarian follicle and uterus, data from human populations are scarce and equivocal. This prospective cohort study between 2004 and 2012 at the Massachusetts General Hospital Fertility Center included 256 women (n = 375 IVF cycles) who provided up to two urine samples prior to oocyte retrieval (total N = 673). Study participants were women enrolled in the Environment and Reproductive Health (EARTH) Study. Intermediate and clinical end-points of IVF treatments were abstracted from electronic medical records. We used generalized linear mixed models with random intercepts to evaluate the association between urinary BPA concentrations and IVF outcomes adjusted by age, race, body mass index, smoking status and infertility diagnosis. The specific gravity-adjusted geometric mean of BPA was 1.87 A mu g/l, which is comparable to that for female participants in the National Health and Nutrition Examination Survey, 2011-2012. Urinary BPA concentrations were not associated with endometrial wall thickness, peak estradiol levels, proportion of high quality embryos or fertilization rates. Furthermore, there were no associations between urinary BPA concentrations and implantation, clinical pregnancy or live birth rates per initiated cycle or per embryo transfer. Although we did not find any associations between urinary BPA concentrations and IVF outcomes, the relation between BPA and endometrial wall thickness was modified by age. Younger women (< 37 years old) had thicker endometrial thickness across increasing quartiles of urinary BPA concentrations, while older women (a parts per thousand yen37 years old) had thinner endometrial thickness across increasing quartiles of urinary BPA concentrations. Limitations to this study include a possible misclassification of BPA exposure and difficulties in extrapolating the findings to the general population. Data on the relation between urinary BPA concentrations and reproductive outcomes remain scarce and additional research is needed to clarify its role in human reproduction. C1 [Minguez-Alarcon, Lidia; Ford, Jennifer B.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Gaskins, Audrey J.; Chiu, Yu-Han; Chavarro, Jorge E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Gaskins, Audrey J.; Williams, Paige L.; Chavarro, Jorge E.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Ehrlich, Shelley] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Environm Hlth, Div Biostat & Epidemiol, Cincinnati, OH USA. [Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Chavarro, Jorge E.; Petrozza, John C.; Hauser, Russ] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Petrozza, John C.] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Minguez-Alarcon, L (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM lminguez@hsph.harvard.edu RI Ehrlich , Shelley/L-6991-2015 FU NIH from National Institute of Environmental Health Sciences (NIEHS) [R01ES022955, R01ES009718, R01ES000002]; National Institute of Child Health and Human Development (NICHD) [T32DK00770316] FX This work was supported by NIH grants R01ES022955, R01ES009718, and R01ES000002 from the National Institute of Environmental Health Sciences (NIEHS) and grant T32DK00770316 from the National Institute of Child Health and Human Development (NICHD). NR 52 TC 8 Z9 8 U1 3 U2 21 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD SEP PY 2015 VL 30 IS 9 BP 2120 EP 2128 DI 10.1093/humrep/dev183 PG 9 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CR3FV UT WOS:000361217300018 PM 26209788 ER PT J AU Koslap-Petraco, MB AF Koslap-Petraco, Mary Beth TI SHOULD VACCINATION BE MANDATORY FOR PRESCHOOL ATTENDANCE? SO JNP-JOURNAL FOR NURSE PRACTITIONERS LA English DT Editorial Material C1 [Koslap-Petraco, Mary Beth] Long Isl Univ Post, Greenvale, NY 11548 USA. [Koslap-Petraco, Mary Beth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Koslap-Petraco, Mary Beth] Immunizat Act Coalit, Advisory Board, St Paul, MN USA. [Koslap-Petraco, Mary Beth] Natl Vaccine Advisory Comm, Washington, DC USA. RP Koslap-Petraco, MB (reprint author), Long Isl Univ Post, Greenvale, NY 11548 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1555-4155 EI 1878-058X J9 JNP-J NURSE PRACT JI JNP-J. Nurse Pract. PD SEP PY 2015 VL 11 IS 8 BP 764 EP 764 PG 1 WC Nursing SC Nursing GA CR7BW UT WOS:000361503900006 ER PT J AU Eke, PI AF Eke, Paul I. TI Self-reported Current or Prior Periodontal Disease Performs Moderately Well in Characterizing Periodontitis Status in Postmenopausal Women Who Receive Regular Dental Checkups SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE LA English DT Editorial Material C1 Ctr Dis Control & Prevent CDC, Div Populat Hlth, Atlanta, GA 30329 USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent CDC, Div Populat Hlth, Atlanta, GA 30329 USA. EM peke@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-3382 EI 1532-3390 J9 J EVID-BASED DENT PR JI J. Evid.-Based Dent. Pract. PD SEP PY 2015 VL 15 IS 3 BP 121 EP 123 DI 10.1016/j.jebdp.2015.07.005 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CR5VR UT WOS:000361413000008 PM 26337583 ER PT J AU Judd, MC Emukule, GO Njuguna, H McMorrow, ML Arunga, GO Katz, MA Montgomery, JM Wong, JM Breiman, RF Mott, JA AF Judd, Michael C. Emukule, Gideon O. Njuguna, Henry McMorrow, Meredith L. Arunga, Geoffrey O. Katz, Mark A. Montgomery, Joel M. Wong, Joshua M. Breiman, Robert F. Mott, Joshua A. TI The Role of HIV in the Household Introduction and Transmission of Influenza in an Urban Slum, Nairobi, Kenya, 2008-2011 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza transmission; influenza-like illness; HIV; Kenya; Kibera; slum; informal settlement ID HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; INFECTION; OUTBREAK; EPIDEMIOLOGY; DISEASE AB Background. Little is known about how human immunodeficiency virus (HIV) infection affects influenza transmission within homes in sub-Saharan Africa. Methods. We used respiratory illness surveillance and HIV testing data gathered in Kibera, an urban slum in Nairobi, Kenya, to examine the impact of HIV status on (1) introducing influenza to the home and (2) transmitting influenza to household contacts. Results. While HIV status did not affect the likelihood of being an influenza index case, household contacts of HIV-infected influenza index cases had twice the risk of developing secondary influenza-like illness than contacts of HIV-negative index cases. Conclusions. HIV-infected influenza index cases may facilitate transmission of influenza within the home. C1 [Judd, Michael C.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [McMorrow, Meredith L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Emukule, Gideon O.; Njuguna, Henry; Katz, Mark A.; Montgomery, Joel M.; Wong, Joshua M.; Breiman, Robert F.; Mott, Joshua A.] Ctr Dis Control & Prevent, Int Emerging Infect Program, Nairobi 00621, Kenya. [Arunga, Geoffrey O.] Kenya Govt Med Res Ctr, Nairobi, Kenya. RP Mott, JA (reprint author), Ctr Dis Control & Prevent, POB 606, Nairobi 00621, Kenya. EM jmott@cdc.gov FU Kenya Medical Research Institute/CDC Research and Public Health Collaboration, Kenya [GH10-003: GH00048-05] FX This work was supported by a cooperative agreement between the Kenya Medical Research Institute/CDC Research and Public Health Collaboration, Kenya (award GH10-003: GH00048-05). NR 15 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2015 VL 212 IS 5 BP 740 EP 744 DI 10.1093/infdis/jiv106 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR4EO UT WOS:000361284800009 PM 25722293 ER PT J AU Wong, JM Cosmas, L Nyachieo, D Williamson, JM Olack, B Okoth, G Njuguna, H Feikin, DR Burke, H Montgomery, JM Breiman, RF AF Wong, Joshua M. Cosmas, Leonard Nyachieo, Dhillon Williamson, John M. Olack, Beatrice Okoth, George Njuguna, Henry Feikin, Daniel R. Burke, Heather Montgomery, Joel M. Breiman, Robert F. TI Increased Rates of Respiratory and Diarrheal Illnesses in HIV-Negative Persons Living With HIV-Infected Individuals in a Densely Populated Urban Slum in Kenya SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; surveillance; home-based counseling and testing; household transmission; Africa; Kibera; nonspecific febrile illness; respiratory infection; pneumonia; influenzalike illness; ILI; acute lower respiratory infection; ALRI; diarrhea; nonspecific febrile illness; incidence rates; urban slum ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; WESTERN KENYA; RISK-FACTORS; INFLUENZA; HEALTH; CRYPTOSPORIDIOSIS; HIV/AIDS; AFRICA; EPIDEMIOLOGY AB Background. Prolonged pathogen shedding and increased duration of illness associated with infections in immunosuppressed individuals put close human immunodeficiency virus (HIV)-negative contacts of HIV-infected persons at increased risk of exposure to infectious pathogens. Methods. We calculated incidence and longitudinal prevalence (number of days per year) of influenzalike illness (ILI), diarrhea, and nonspecific febrile illness during 2008 from a population-based surveillance program in the urban slum of Kibera (Kenya) that included 1830 HIV-negative household contacts of HIV-infected individuals and 13 677 individuals living in exclusively HIV-negative households. Results. For individuals >= 5 years old, incidence was significantly increased for ILI (risk ratio [RR], 1.47; P<.05) and diarrhea (RR, 1.41; P<.05) in HIV-negative household contacts of HIV-infected individuals compared with exclusively HIV-negative households. The risk of illness among HIV-negative persons was directly proportional to the number of HIV-infected persons living in the home for ILI (RR, 1.39; P<.05) and diarrhea (RR, 1.36; P<.01). We found no increased rates of illness in children <5 years old who lived with HIV-infected individuals. Conclusions. Living with HIV-infected individuals is associated with modestly increased rates of respiratory and diarrheal infections in HIV-negative individuals >5 years old. Targeted interventions are needed, including ensuring that HIV-infected persons are receiving appropriate care and treatment. C1 [Wong, Joshua M.; Cosmas, Leonard; Njuguna, Henry; Montgomery, Joel M.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Nyachieo, Dhillon; Olack, Beatrice; Okoth, George] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Williamson, John M.; Feikin, Daniel R.; Burke, Heather] Ctr Dis Control & Prevent, Atlanta, GA USA. [Breiman, Robert F.] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA. RP Breiman, RF (reprint author), Emory Univ, Emory Global Hlth Inst, 1599 Clifton Rd, Atlanta, GA 30322 USA. EM rfbreiman@emory.edu FU CDC; Kenya Medical Research Institute FX All funding was provided by the CDC and Kenya Medical Research Institute. NR 36 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2015 VL 212 IS 5 BP 745 EP 753 DI 10.1093/infdis/jiv107 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR4EO UT WOS:000361284800010 PM 25722292 ER PT J AU An, YM McCullers, JA Alymova, I Parsons, LM Cipollo, JF AF An, Yanming McCullers, Jonathan A. Alymova, Irina Parsons, Lisa M. Cipollo, John F. TI Glycosylation Analysis of Engineered H3N2 Influenza A Virus Hemagglutinins with Sequentially Added Historically Relevant Glycosylation Sites SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE influenza; hemagglutinin; glycoprotein; glycan; mass spectrometry; glycopeptide; LC-MS; SP-D; antigenic site; H3N2 ID BIOLOGICAL-ACTIVITIES; RECEPTOR-BINDING; RECOGNITION; PREDICTION; INFECTION; ANTIBODY; GLYCANS; MICE AB The influenza virus surface glycoprotein hemagglutinin (HA) is the major target of host neutralizing antibodies. The oligosaccharides of HA can contribute to HA's antigenic characteristics. After a leap to humans from a zoonotic host, influenza can gain N-glycosylation sequons over time as part of its fitness strategy. This glycosylation expansion has not been studied at the structural level. Here we examine HA N-glycosylation of H3N2 virus strains that we have engineered to closely mimic glycosylation sites gained between 1968 through 2002 starting with pandemic A/Hong Kong/1/68 (H3N2: HK68). HAs studied include HK68 and engineered forms with 1, 2, and 4 added sites. We have used: nano-LC-MSE for glycopeptide composition, sequence and site occupancy analysis, and MALDI-TOF MS permethylation profiling for characterization of released glycans. Our study reveals that 1) the majority of N-sequons are occupied at >90%, 2) the class and complexity of the glycans varies by region over the landscape of the proteins, 3) Asn 165 and Asn 246, which are associated with interactions between HA and SP-D lung collectin, are exclusively high mannose type. Based on this study and previous reports we provide structural insight as to how the immune system responses may differ depending on HA glycosylation. C1 [An, Yanming; Parsons, Lisa M.; Cipollo, John F.] Food & Drug Adm, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA. [McCullers, Jonathan A.; Alymova, Irina] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [McCullers, Jonathan A.] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA. [Alymova, Irina] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Cipollo, JF (reprint author), Food & Drug Adm, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA. EM john.cipollo@fda.hhs.gov FU ALSAC; CBER Pandemic Flu and Medical Counter Measures targeted internal funds FX This study was funded by ALSAC to J.A.M. and the CBER Pandemic Flu and Medical Counter Measures targeted internal funds to J.F.C. We would like to acknowledge Drs. Ian York and Terry Tumpey of the Influenza Division of the CDC for helpful discussions, and Shane Gansebom of the Infectious Disease Department of St. Jude Children's Research Hospital for technical assistance. NR 41 TC 10 Z9 11 U1 2 U2 14 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 EI 1535-3907 J9 J PROTEOME RES JI J. Proteome Res. PD SEP PY 2015 VL 14 IS 9 BP 3957 EP 3969 DI 10.1021/acs.jproteome.5b00416 PG 13 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA CR1LU UT WOS:000361087100049 PM 26202417 ER PT J AU Chang, MH Molla, MT Truman, BI Athar, H Moonesinghe, R Yoon, PW AF Chang, Man-Huei Molla, Michael T. Truman, Benedict I. Athar, Heba Moonesinghe, Ramal Yoon, Paula W. TI Differences in healthy life expectancy for the US population by sex, race/ethnicity and geographic region: 2008 SO JOURNAL OF PUBLIC HEALTH LA English DT Article DE ethnicity; life expectancy; morbidity; mortality; race; region; sex ID SELF-RATED HEALTH; UNITED-STATES; EDUCATIONAL-DIFFERENCES; MORTALITY ADVANTAGE; COUNTRIES; DISEASE; CARE AB Background Healthy life expectancy (HLE) varies among demographic segments of the US population and by geography. To quantify that variation, we estimated the national and regional HLE for the US population by sex, race/ethnicity and geographic region in 2008. Methods National HLEs were calculated using the published 2008 life table and the self-reported health status data from the National Health Interview Survey (NHIS). Regional HLEs were calculated using the combined 2007-09 mortality, population and NHIS health status data. Results In 2008, HLE in the USA varied significantly by sex, race/ethnicity and geographical regions. At 25 years of age, HLE for females was 47.3 years and similar to 2.9 years greater than that for males at 44.4 years. HLE for non-Hispanic white adults was 2.6 years greater than that for Hispanic adults and 7.8 years greater than that for non-Hispanic black adults. By region, the Northeast had the longest HLE and the South had the shortest. Conclusions The HLE estimates in this report can be used to monitor trends in the health of populations, compare estimates across populations and identify health inequalities that require attention. C1 [Chang, Man-Huei; Truman, Benedict I.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Molla, Michael T.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Athar, Heba; Yoon, Paula W.] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Moonesinghe, Ramal] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Equ, Atlanta, GA 30333 USA. RP Chang, MH (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM mchang@cdc.gov NR 45 TC 1 Z9 1 U1 7 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-3842 EI 1741-3850 J9 J PUBLIC HEALTH-UK JI J. Public Health PD SEP PY 2015 VL 37 IS 3 BP 470 EP 479 DI 10.1093/pubmed/fdu059 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR4PC UT WOS:000361316900014 PM 25174043 ER PT J AU Scott, SM Wallander, JL Depaoli, S Elliott, MN Grunbaum, JA Tortolero, SR Cuccaro, PM Schuster, MA AF Scott, Sarah M. Wallander, Jan L. Depaoli, Sarah Elliott, Marc N. Grunbaum, Jo Anne Tortolero, Susan R. Cuccaro, Paula M. Schuster, Mark A. TI Gender role orientation is associated with health-related quality of life differently among African-American, Hispanic, and White youth SO QUALITY OF LIFE RESEARCH LA English DT Article DE Gender role orientation; Early adolescence; Health; Quality of life; Race; Ethnicity ID GENERIC CORE SCALES; MEASUREMENT INVARIANCE; SOCIOECONOMIC-STATUS; ANXIETY SYMPTOMS; MASCULINE NORMS; FIT INDEXES; ADOLESCENTS; SEX; RACE; PEDSQL(TM)-4.0 AB Purpose This study examined the association between gender role orientation (GRO) and health-related quality of life (HRQOL) in youth, and how this relationship may differ between males and females as well as among African-American, White, and Hispanic individuals. GRO has been reported to influence serious health outcomes including cancer, heart disease, mental illness, and mortality rates. However, few studies have examined the link between GRO and health outcomes for children, even though gender identity is formed in childhood. Methods Data were examined from 4824 participants in the Healthy Passages (TM) project, a population-based survey of fifth-grade children in three US metropolitan areas. Children reported their own HRQOL using the PedsQL and degree of female, male, and androgynous GRO using the Children's Sex Role Inventory. Results Based on structural equations analysis, male GRO was positively associated with HRQOL for all racial/ethnic groups, regardless of sex, whereas female GRO was associated with better HRQOL for Hispanic and White females and poorer HRQOL for Hispanic males. Androgynous GRO was associated with better HRQOL among Hispanic and White females, but not males nor African-Americans of either sex. Conclusions Racial/ethnic differences emerged for female and androgynous, but not male, GROs. Hispanic males are the only group for which GRO (female) was associated with poorer HRQOL. Future research should find ways to help youth overcome negative effects on health from gender beliefs and behavior patterns with sensitivity to racial/ethnic membership. C1 [Scott, Sarah M.; Wallander, Jan L.; Depaoli, Sarah] Univ Calif Merced, SSHA, Psychol Sci & Hlth Sci Res Inst, Merced, CA 95343 USA. [Elliott, Marc N.; Schuster, Mark A.] RAND Corp, Santa Monica, CA USA. [Grunbaum, Jo Anne] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Tortolero, Susan R.; Cuccaro, Paula M.] Univ Texas Houston, Sch Publ Hlth, Prevent Res Ctr, Houston, TX USA. [Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA. [Schuster, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Wallander, JL (reprint author), Univ Calif Merced, SSHA, Psychol Sci & Hlth Sci Res Inst, 5200 N Lake Rd, Merced, CA 95343 USA. EM jwallander@ucmerced.edu OI Cuccaro, Paula/0000-0002-9551-4789 FU Centers for Disease Control and Prevention, Prevention Research Centers [CCU409679, CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056, U19DP002663, U19DP002664, U19DP002665] FX The Healthy Passages (TM) study was funded by the Centers for Disease Control and Prevention, Prevention Research Centers (Cooperative Agreements CCU409679, CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056, U19DP002663, U19DP002664, and U19DP002665). The contributions made to this research by study participants in the Birmingham, Houston, and Los Angeles areas, other Healthy Passages (TM) investigators, field teams at each site, and the CDC Division of Adolescent and School Health are gratefully acknowledged. NR 53 TC 1 Z9 1 U1 4 U2 14 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD SEP PY 2015 VL 24 IS 9 BP 2139 EP 2149 DI 10.1007/s11136-015-0951-5 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CR0LS UT WOS:000361010800009 PM 25703499 ER PT J AU Marshall, NB Lukomska, E Long, CM Kashon, ML Sharpnack, DD Nayak, AP Anderson, KL Meade, BJ Anderson, SE AF Marshall, Nikki B. Lukomska, Ewa Long, Carrie M. Kashon, Michael L. Sharpnack, Douglas D. Nayak, Ajay P. Anderson, Katie L. Meade, B. Jean Anderson, Stacey E. TI Triclosan Induces Thymic Stromal Lymphopoietin in Skin Promoting Th2 Allergic Responses SO TOXICOLOGICAL SCIENCES LA English DT Article DE triclosan; allergy; TSLP; OVA; Th2 ID AGGRAVATES EXPERIMENTAL ASTHMA; HAND DISINFECTION; ATOPIC-DERMATITIS; DENDRITIC CELLS; TSLP EXPRESSION; OX40 LIGAND; INFLAMMATION; SENSITIZATION; EXPOSURE; CHILDREN AB Triclosan is an antimicrobial chemical incorporated into many personal, medical and household products. Approximately, 75% of the U.S. population has detectable levels of triclosan in their urine, and although it is not typically considered a contact sensitizer, recent studies have begun to link triclosan exposure with augmented allergic disease. We examined the effects of dermal triclosan exposure on the skin and lymph nodes of mice and in a human skin model to identify mechanisms for augmenting allergic responses. Triclosan (0%-3%) was applied topically at 24-h intervals to the ear pinnae of OVA-sensitized BALB/c mice. Skin and draining lymph nodes were evaluated for cellular responses and cytokine expression over time. The effects of triclosan (0%-0.75%) on cytokine expression in a human skin tissue model were also examined. Exposure to triclosan increased the expression of TSLP, IL-1 beta, and TNF-alpha in the skin with concomitant decreases in IL-25, IL-33, and IL-1 alpha. Similar changes in TSLP, IL1B, and IL33 expression occurred in human skin. Topical application of triclosan also increased draining lymph node cellularity consisting of activated CD86(+)GL-7(+) B cells, CD80(+)CD86(+) dendritic cells, GATA-3(+)OX-40(+)IL-4(+)IL-13(+) Th2 cells and IL-17 A(+) CD4 T cells. In vivo antibody blockade of TSLP reduced skin irritation, IL-1 beta expression, lymph node cellularity, and Th2 responses augmented by triclosan. Repeated dermal exposure to triclosan induces TSLP expression in skin tissue as a potential mechanism for augmenting allergic responses. C1 [Marshall, Nikki B.; Lukomska, Ewa; Long, Carrie M.; Nayak, Ajay P.; Anderson, Katie L.; Meade, B. Jean; Anderson, Stacey E.] NIOSH, CDC, Allergy & Clin Immunol Branch, Morgantown, WV 26505 USA. [Kashon, Michael L.] NIOSH, CDC, Biostat & Epidemiol Branch, Morgantown, WV 26505 USA. [Sharpnack, Douglas D.] Vet Path Serv Inc, Mason, OH 45040 USA. RP Marshall, NB (reprint author), NIOSH, CDC, Allergy & Clin Immunol Branch, 1095 Willowdale Rd,M-S 4020, Morgantown, WV 26505 USA. EM nmarshall@cdc.gov FU National Institute for Occupational Safety and Health (CAN) [927ZLCU] FX This work was supported by National Institute for Occupational Safety and Health intramural funding (CAN number 927ZLCU). NR 39 TC 2 Z9 2 U1 5 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 EI 1096-0929 J9 TOXICOL SCI JI Toxicol. Sci. PD SEP PY 2015 VL 147 IS 1 BP 127 EP 139 DI 10.1093/toxsci/kfv113 PG 13 WC Toxicology SC Toxicology GA CR4QQ UT WOS:000361322000012 PM 26048654 ER PT J AU Wat'senga, F Manzambi, E Ilombe, G Mulumbu, R Fasine, S Binene, G Losimba, J Irish, S Dotson, E AF Wat'senga, F. Manzambi, E. Ilombe, G. Mulumbu, R. Fasine, S. Binene, G. Losimba, J. Irish, S. Dotson, E. TI Insecticide susceptibility of Anopheles gambiae s.l. in sentinel sites in the Democratic Republic of Congo SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Wat'senga, F.; Manzambi, E.; Ilombe, G.; Mulumbu, R.; Fasine, S.; Binene, G.] Inst Natl Rech Biomed, Entomol, Atlanta, GA USA. [Losimba, J.] Congolese Natl Malaria Control Progam, Kinshasa, DEM REP CONGO. [Irish, S.; Dotson, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI BP 20 EP 20 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758800047 ER PT J AU Monroe, BP Mccollum, A Doty, J Osadebee, L Nolen, L Kabamba, J Okitolonga, E Reynolds, M AF Monroe, B. P. Mccollum, A. Doty, J. Osadebee, L. Nolen, L. Kabamba, J. Okitolonga, E. Reynolds, M. TI A fine-scale geospatial analysis of factors associated with monkeypox transmission, Tshuapa District, Democratic Republic of the Congo, 2013 SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Monroe, B. P.; Mccollum, A.; Doty, J.; Osadebee, L.; Reynolds, M.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. [Nolen, L.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA USA. [Kabamba, J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Okitolonga, E.] Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI BP 39 EP 39 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758800094 ER PT J AU Meurs, L Brienen, E Mbow, M Ochola, EA Mboup, S Karanja, DMS Secor, WE Polman, K van Lieshout, L AF Meurs, L. Brienen, E. Mbow, M. Ochola, E. A. Mboup, S. Karanja, D. M. S. Secor, W. E. Polman, K. van Lieshout, L. TI Is PCR the next gold standard for the diagnosis of Schistosoma in stool? A comparison with microscopy in Senegal and Kenya SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Meurs, L.; Brienen, E.; van Lieshout, L.] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands. [Meurs, L.; Polman, K.] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium. [Mbow, M.; Mboup, S.] Aristide Le Dantec Teaching Hosp, Lab Bacteriol & Virol, Dakar, Senegal. [Ochola, E. A.; Karanja, D. M. S.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Secor, W. E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI BP 47 EP 47 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758800115 ER PT J AU Kaur, H Green, MD Fernandez, FM AF Kaur, H. Green, M. D. Fernandez, F. M. TI Systematic sampling approach reveals fewer falsified first line antimalarials than previously reported SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Kaur, H.] London Sch Hyg & Trop Med, London WC1, England. [Green, M. D.] Georgia Inst Technol, US Ctr Dis Control & Prevent, Atlanta, GA 30332 USA. [Fernandez, F. M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI BP 137 EP 137 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758800335 ER PT J AU Senga, M Pringle, K Brett-Major, D Fowler, RA French, I Vandi, M Ramsay, A Sellu, J Pratt, C Sidu, J Jacquerioz, F Shindo, N AF Senga, M. Pringle, K. Brett-Major, D. Fowler, R. A. French, I. Vandi, M. Ramsay, A. Sellu, J. Pratt, C. Sidu, J. Jacquerioz, F. Shindo, N. CA Sierra Leone Kenema Dist Kenema Govt Hosp TI Factors associated with mortality of health workers with Ebola virus disease in Kenema district, Sierra Leone SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Senga, M.; Brett-Major, D.; Ramsay, A.; Jacquerioz, F.; Shindo, N.] World Hlth Org, Geneva, Switzerland. [Pringle, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fowler, R. A.] Univ Toronto, Toronto, ON, Canada. [French, I.; Vandi, M.; Sellu, J.; Pratt, C.; Sidu, J.] Kenema Govt Hosp, Kenema, Sierra Leone. NR 0 TC 0 Z9 0 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI MA PS1.077 BP 200 EP 201 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758801077 ER PT J AU Hsu, CH Champaloux, SW Bilivogui, P Knust, B Mccollum, AM AF Hsu, C. H. Champaloux, S. W. Bilivogui, P. Knust, B. Mccollum, A. M. TI An analysis of suspect case definitions utilized in Guinea during the 2014 Ebola epidemic SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Hsu, C. H.; Champaloux, S. W.; Knust, B.; Mccollum, A. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bilivogui, P.] Minist Hlth, Natl Ebola Coordinat Cell, Conakry, Guinea. [Bilivogui, P.] Sect Chief Surveillance, Conakry, Guinea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI MA PS1.078 BP 201 EP 201 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758801078 ER PT J AU Briet, OJT Huho, BJ Gimnig, JE Bayoh, N Seyoum, A Sikaala, CH Govella, N Diallo, DA Abdullah, S Smith, TA Killeen, GF AF Briet, O. J. T. Huho, B. J. Gimnig, J. E. Bayoh, N. Seyoum, A. Sikaala, C. H. Govella, N. Diallo, D. A. Abdullah, S. Smith, T. A. Killeen, G. F. TI Applications and limitations of Centers for Disease Control and Prevention miniature light traps for measuring biting densities of African malaria vector populations: a pooled analysis of 13 comparisons with human landing catches SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Briet, O. J. T.; Huho, B. J.; Smith, T. A.] Swiss TPH, EPH, Basel, Switzerland. [Briet, O. J. T.; Huho, B. J.; Smith, T. A.] Univ Basel, Basel, Switzerland. [Huho, B. J.; Govella, N.; Abdullah, S.; Killeen, G. F.] Ifakara Hlth Inst, Ifakara, Tanzania. [Gimnig, J. E.; Bayoh, N.] Ctr Global Hlth Res, Kisumu, Kenya. [Gimnig, J. E.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Bayoh, N.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Seyoum, A.; Sikaala, C. H.; Killeen, G. F.] Univ Liverpool, Liverpool Sch Trop Med, Vector Biol Dept, Liverpool L3 5QA, Merseyside, England. [Sikaala, C. H.] Natl Malaria Control Ctr, Lusaka, Zambia. [Diallo, D. A.] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI MA PS2.255 BP 398 EP 399 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758802235 ER PT J AU Elbadry, MA De Rochars, MB Rashid, M Louis, YJF Imponivil, D Boncy, J Morris, JG Okech, BA AF Elbadry, M. A. De Rochars, M. Beau Rashid, M. Louis, Y. J. F. Imponivil, D. Boncy, J. Morris, J. G. Okech, B. A. TI Chikungunya virus infection in wild caught Aedes aegypti mosquitoes in Haiti SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Elbadry, M. A.; De Rochars, M. Beau; Rashid, M.; Okech, B. A.] Emerging Pathogen Inst, Gainesville, FL USA. [Elbadry, M. A.; Okech, B. A.] Environm & Global Hlth, Gainesville, FL USA. [De Rochars, M. Beau] Univ Florida, Hlth Serv Res Management & Policy, Gainesville, FL USA. [Louis, Y. J. F.] US Ctr Dis Control & Prevent, Port Au Prince, Haiti. [Imponivil, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Boncy, J.] Minist Publ Hlth & Populat, Natl Publ Hlth Lab, Port Au Prince, Haiti. [Morris, J. G.] Univ Florida, Emerging Pathogen Inst, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 SU 1 SI SI MA PS2.273 BP 406 EP 406 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CQ7BW UT WOS:000360758802253 ER PT J AU Barker, LE Shaw, KM AF Barker, Lawrence E. Shaw, Kate M. TI Best (but oft-forgotten) practices: checking assumptions concerning regression residuals SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE assumptions; regression; statistics; residuals; variance; normality ID NORMALITY; TRANSFORMATIONS; SAMPLES; FAT AB The residuals of a least squares regression model are defined as the observations minus the modeled values. For least squares regression to produce valid CIs and P values, the residuals must be independent, be normally distributed, and have a constant variance. If these assumptions are not satisfied, estimates can be biased and power can be reduced. However, there are ways to assess these assumptions and steps one can take if the assumptions are violated. Here, we discuss both assessment and appropriate responses to violation of assumptions. C1 [Barker, Lawrence E.; Shaw, Kate M.] Ctr Dis Control & Prevent, Chamblee, GA 30345 USA. RP Barker, LE (reprint author), Ctr Dis Control & Prevent, Chamblee, GA 30345 USA. EM lsb8@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 2 Z9 2 U1 0 U2 5 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2015 VL 102 IS 3 BP 533 EP 539 DI 10.3945/ajcn.115.113498 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CR2II UT WOS:000361150900003 PM 26201816 ER PT J AU Bailey, RL Looker, AC Lu, ZH Fan, RZ Eicher-Miller, HA Fakhouri, TH Gahche, JJ Weaver, CM Mills, JL AF Bailey, Regan L. Looker, Anne C. Lu, Zhaohui Fan, Ruzong Eicher-Miller, Heather A. Fakhouri, Tala H. Gahche, Jaime J. Weaver, Connie M. Mills, James L. TI B-vitamin status and bone mineral density and risk of lumbar osteoporosis in older females in the United States SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE DXA; NHANES; bone turnover markers; homocysteine; osteoporosis ID RANDOMIZED CONTROLLED-TRIAL; METHYLMALONIC ACID CONCENTRATIONS; NUTRITION EXAMINATION SURVEYS; FOLIC-ACID; POSTMENOPAUSAL WOMEN; TURNOVER MARKERS; TOTAL HOMOCYSTEINE; NATIONAL-HEALTH; FRACTURE RISK; COBALAMIN DEFICIENCY AB Background: Previous data suggest that elevated serum total homocysteine (tHcy) may be a risk factor for bone fracture and osteoporosis. Nutritional causes of elevated tHcy are suboptimal B-vitamin status. To our knowledge, this is the first nationally representative report on the relation of B vitamins and bone health from a population with folic acid fortification. Objective: The purpose of this analysis was to examine the relation between B-vitamin status biomarkers and bone mineral density (BMD), risk of osteoporosis, and biomarkers of bone turnover. Design: We examined the relation of tHcy, methylmalonic acid (MMA), and serum/red blood cell folate and total-body and lumbar spine BMD in women aged >= 50 y participating in the NHANES 1999-2004 (n = 2806), a nationally representative cross-sectional survey. These are the only years with concurrent measurement of tHcy and whole-body dual-energy X-ray absorptiometry. We also examined B-vitamin biomarkers relative to bone turnover markers, bone alkaline phosphatase, and urinary N-terminal cross-linked telopeptide of type I collagen in a 1999-2002 subset with available data (n = 1813). Results: In comparison with optimal concentrations, women with elevated tHcy were older with lower serum vitamin B-12, red blood cell folate, and dietary micronutrient intakes and had significantly higher mean +/- SE markers of bone turnover (bone alkaline phosphatase: 15.8 +/- 0.59 compared with 14.0 +/- 0.25 mu g/L; urinary N-terminal crosslinked telopeptide of type I collagen: 48.2 +/- 2.9 compared with 38.9 +/- 0.90 nmol bone collagen equivalents per mmol creatinine/L). Elevated MMA (OR: 1.88; 95% CI: 1.10, 3.18) and tHcy (OR: 2.17; 95% CI: 1.14, 4.15) were related to increased risk of lumbar osteoporosis. When examined as a continuous variable, tHcy was negatively associated, serum folates were positively associated, and MMA and vitamin B-12 were not significantly associated with lumbar and total-body BMD. Conclusion: In this nationally representative population of older US women with high exposure to B vitamins through food fortification and dietary supplements, only elevated tHcy and MMA were independently associated with risk of lumbar spine osteoporosis. C1 [Bailey, Regan L.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Lu, Zhaohui; Fan, Ruzong; Mills, James L.] NIH, Eunice Kennedy Shriver Natl Inst Child & Human De, Bethesda, MD 20892 USA. [Looker, Anne C.; Gahche, Jaime J.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Bailey, Regan L.; Eicher-Miller, Heather A.; Weaver, Connie M.] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA. [Fakhouri, Tala H.] ICF Int, Rockville, MD USA. RP Bailey, RL (reprint author), NIH, Off Dietary Supplements, Bldg 10, Bethesda, MD 20892 USA. EM baileyr@mail.nih.gov FU Intramural Research Program, Eunice Kennedy Shriver National Institute of Child and Human Development; Office of Dietary Supplements, NIH FX Supported in part by the Intramural Research Program, Eunice Kennedy Shriver National Institute of Child and Human Development and the Office of Dietary Supplements, NIH. NR 80 TC 3 Z9 3 U1 5 U2 10 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2015 VL 102 IS 3 BP 687 EP 694 DI 10.3945/ajcn.115.108787 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CR2II UT WOS:000361150900021 PM 26224297 ER PT J AU Sircar, K Clower, J Shin, MK Bailey, C King, M Yip, F AF Sircar, Kanta Clower, Jacquelyn Shin, Mi Kyong Bailey, Cathy King, Michael Yip, Fuyuen TI Carbon monoxide poisoning deaths in the United States, 1999 to 2012 SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID ICE STORM; EXPOSURES; PREVENTION; AWARENESS; INJURIES AB Background: Unintentional, non-fire related (UNFR) carbon monoxide (CO) poisoning deaths are preventable. Surveillance of the populations most at-risk for unintentional, non-fire related (UNFR) carbon monoxide (CO) poisoning is crucial for targeting prevention efforts. Objective: This study provides estimates on UNFR CO poisoning mortality in the United States and characterizes the at-risk populations. Methods: We used 1999 to 2012 data to calculate death rates. We used underlying and multiple conditions variables from death records to identify UNFR CO poisoning cases. Results: For this study, we identified 6136 CO poisoning fatalities during 1999 to 2012 resulting in an average of 438 deaths annually. The annual average age-adjusted death rate was 1.48 deaths permillion. Fifty four percent of the deaths occurred in a home. Age-adjusted death rates were highest for males (2.21 deaths per million) and non-Hispanic blacks (1.74 deaths per million). The age-specific death rate was highest for those aged >= 85 years (6.00 deaths per million). The annual rate of UNFR CO poisoning deaths did not change substantially during the study period, but we observed a decrease in the rate of suicide and unintentional fire related cases. Conclusion: CO poisoning was the second most common non-medicinal poisonings death. Developing and enhancing current public health interventions could reduce ongoing exposures to CO from common sources, such as those in the residential setting. Published by Elsevier Inc. C1 [Sircar, Kanta; Bailey, Cathy; Yip, Fuyuen] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Shin, Mi Kyong] Ctr Dis Control & Prevent, Environm Publ Hlth Tracking, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [King, Michael] Ctr Dis Control & Prevent, Epidemiol Workforce Branch, Div Sci Educ & Profess Dev, Ctr Surveillance,Epidemiol & Lab Serv, Chamblee, GA 30341 USA. RP Sircar, K (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Chamblee, GA 30341 USA. EM ddq0@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 10 Z9 10 U1 1 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD SEP PY 2015 VL 33 IS 9 BP 1140 EP 1145 DI 10.1016/j.ajem.2015.05.002 PG 6 WC Emergency Medicine SC Emergency Medicine GA CQ9GG UT WOS:000360920700005 PM 26032660 ER PT J AU Correa, JE Meneses-Echavez, JF Barengo, NC Tovar, G Ruiz-Castellanos, E Lobelo, F Ramirez-Velez, R AF Correa, Jorge E. Meneses-Echavez, Jose F. Barengo, Noel C. Tovar, Gustavo Ruiz-Castellanos, Erika Lobelo, Felipe Ramirez-Velez, Robinson TI School initiatives and sports leads from the International Federation of Football Association (FIFA): systematic review SO GLOBAL HEALTH PROMOTION LA Spanish DT Article DE conducta saludable; deporte; factores positivos; FIFA; futbol; educacion fisica; ninez; ocio; programacion ID RANDOMIZED CONTROLLED-TRIAL; INJURY PREVENTION PROGRAM; AMATEUR SOCCER PLAYERS; WARM-UP PROGRAM; PHYSICAL-ACTIVITY; HEALTH-PROMOTION; CHILDHOOD OBESITY; PERFORMANCE RESPONSES; YOUTH FOOTBALL; ALL-CAUSE AB Introduccion: Los programas iniciados por la Federation Internationale de Football Association (FIFA) consisten en la difusion de mensajes relacionados con el cuidado de la salud y como estrategia de prevencion de lesiones deportivas entre los ninos y jovenes. El objetivo de esta revision sistematica fue resumir los resultados de la implementacion de los programas FIFA 11 para la salud y FIFA 11+. Metodos: Se realizo una busqueda sistematica en las bases de datos electronicos de MEDLINE, EMBASE y Scopus, identificando los estudios que evaluaran la implementacion de los programas FIFA 11 para la salud y FIFA 11+, durante los ultimos 10 anos (1 enero 2003 a 1 diciembre 2013). Resultados: Incluimos 17 estudios. Dos estudios evaluaron la implementacion del programa FIFA 11 para la salud y encontraron un aumento significativo en el conocimiento de los mensajes de promocion de la salud; 15 estudios evaluaron los efectos del programa FIFA 11+, reportando una reduccion en el riesgo de lesiones deportivas y mejorias en el rendimiento deportivo. Discusion: Los programas FIFA 11 para la salud y FIFA 11+ han demostrado resultados positivos para la salud, en el ambito escolar y deportivo. Conclusiones: Dichos programas del FIFA representan una oportunidad para crear habitos protectores y fomentar modos de vida saludables en ninos y jovenes. C1 [Correa, Jorge E.; Meneses-Echavez, Jose F.; Barengo, Noel C.; Ruiz-Castellanos, Erika; Ramirez-Velez, Robinson] Univ Rosario, Ctr Estudios Med Actividad Fis CEMA, Escuela Med & Ciencias Salud, Bogota, Colombia. [Barengo, Noel C.] Univ Helsinki, Hjelt Inst, Helsinki, Finland. [Tovar, Gustavo] Minist Salud & Protecc Social, Subdirecc Enfermedades Transmisibles, Bogota, Colombia. [Lobelo, Felipe] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Global Hlth Promot, Atlanta, GA 30333 USA. [Ramirez-Velez, Robinson] Univ Santo Tomas, Grp Invest Ciencias Aplicadas Ejercicio Fis Depor, Bogota, Colombia. RP Correa, JE (reprint author), Univ Rosario, Ctr Estudios Med Actividad Fis CEMA, Escuela Med & Ciencias Salud, Bogota, Colombia. EM jorge.correa@urosario.edu.co RI Correa-Bautista, Jorge Enrique/N-2741-2015; Ramirez-Velez, Robinson/D-5311-2016 OI Correa-Bautista, Jorge Enrique/0000-0002-0646-2316; Ramirez-Velez, Robinson/0000-0003-3075-6960 NR 47 TC 0 Z9 0 U1 25 U2 52 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1757-9759 EI 1757-9767 J9 GLOB HEALTH PROMOT JI Glob. Health Promot. PD SEP PY 2015 VL 22 IS 3 BP 67 EP 76 DI 10.1177/1757975914543575 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ8EI UT WOS:000360838900008 PM 25193653 ER PT J AU Sehulster, LM AF Sehulster, Lynne M. TI Healthcare Laundry and Textiles in the United States: Review and Commentary on Contemporary Infection Prevention Issues SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Review ID RESISTANT STAPHYLOCOCCUS-AUREUS; HOSPITAL LAUNDRY; BACILLUS-CEREUS; LAUNDERED FABRICS; ANTIMICROBIAL PROPERTIES; MICROBIAL-CONTAMINATION; NOSOCOMIAL INFECTIONS; ISOLATION PRECAUTIONS; SODIUM-HYPOCHLORITE; BACTERIAL SURVIVAL AB Healthcare professionals have questions about the infection prevention effectiveness of contemporary laundry processes for healthcare textiles (HCTs). Current industrial laundry processes achieve microbial reductions via physical, chemical, and thermal actions, all of which result in producing hygienically clean HCTs. European researchers have demonstrated that oxidative laundry additives have sufficient potency to meet US Environmental Protection Agency benchmarks for sanitizers and disinfectants. Outbreaks of infectious diseases associated with laundered HCTs are extremely rare; only 12 such outbreaks have been reported worldwide in the past 43 years. Root cause analyses have identified inadvertent exposure of clean HCTs to environmental contamination (including but not limited to exposure to dust in storage areas) or a process failure during laundering. To date, patient-to-patient transmission of infection has not been associated with hygienically clean HCTs laundered in accordance with industry process standards. Occupationally acquired infection involved mishandling of soiled HCTs and failure to use personal protective equipment properly. Laboratory studies of antimicrobial treatments for HCTs demonstrate a wide range of activity from 1 to 7 log(10) reduction of pathogens under various experimental conditions. Clinical studies are needed to evaluate potential use of these treatments for infection prevention. Microbiological testing of clean HCTs for certification purposes is now available in the United States. Key features (eg, microbial sampling strategy, numbers of textiles sampled) and justification of the testing are discussed. C1 [Sehulster, Lynne M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. RP Sehulster, LM (reprint author), Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop A-35, Atlanta, GA 30329 USA. EM lynne.sehulster@cdc.hhs.gov NR 116 TC 2 Z9 3 U1 5 U2 10 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2015 VL 36 IS 9 BP 1073 EP 1088 DI 10.1017/ice.2015.135 PG 16 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CQ9FD UT WOS:000360917200012 PM 26082994 ER PT J AU Davila, EP Suleiman, Z Mghamba, J Rolle, I Ahluwalia, I Mmbuji, P de Courten, M Bader, A Zahniser, SC Krag, M Jarrar, B AF Davila, Evelyn P. Suleiman, Zubeda Mghamba, Janneth Rolle, Italia Ahluwalia, Indu Mmbuji, Peter de Courten, Maximilian Bader, Andrea Zahniser, S. Christine Krag, Marlene Jarrar, Bassam TI Non-communicable disease training for public health workers in low- and middle-income countries: lessons learned from a pilot training in Tanzania SO INTERNATIONAL HEALTH LA English DT Article DE Chronic disease; Developing nations; Non-communicable disease; Public health worker; Training ID RESPONSE-SHIFT BIAS; APPLIED EPIDEMIOLOGY; CAPACITY; SERVICE AB Non-communicable diseases (NCDs) are increasing worldwide. A lack of training and experience in NCDs among public health workers is evident in low- and middle- income countries. We describe the design and outcomes of applied training in NCD epidemiology and control piloted in Tanzania that included a 2-week interactive course and a 6-month NCD field project. Trainees (n=14 initiated; n=13 completed) were epidemiology-trained Ministry of Health or hospital staff. We evaluated the training using Kirkpatrick's evaluation model for measuring reactions, learning, behavior and results using pre- and post-tests and closed-ended and open-ended questions. Significant improvements in knowledge and self-reported competencies were observed. Trainees reported applying competencies at work and supervisors reported improvements in trainees' performance. Six field projects were completed; one led to staffing changes and education materials for patients with diabetes and another to the initiation of an injury surveillance system. Workplace support and mentoring were factors that facilitated the completion of projects. Follow-up of participants was difficult, limiting our evaluation of the training's outcomes. The applied NCD epidemiology and control training piloted in Tanzania was well received and showed improvements in knowledge, skill and self-efficacy and changes in workplace behavior and institutional and organizational changes. Further evaluations are needed to better understand the impact of similar NCD trainings and future trainers should ensure that trainees have mentoring and workplace support prior to participating in an applied NCD training. C1 [Davila, Evelyn P.; Jarrar, Bassam] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Div Publ Hlth Syst & Workforce Dev, Atlanta, GA 30329 USA. [Suleiman, Zubeda; Mghamba, Janneth; Mmbuji, Peter] Minist Hlth & Social Welf, Field Epidemiol Lab Training Program Tanzania, Dar Es Salaam, Tanzania. [Rolle, Italia] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Ahluwalia, Indu] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [de Courten, Maximilian] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, DK-1168 Copenhagen, Denmark. [de Courten, Maximilian; Krag, Marlene] Univ Copenhagen, Copenhagen Sch Global Hlth, DK-1168 Copenhagen, Denmark. [Bader, Andrea] Deloitte Consulting, Atlanta, GA USA. [Zahniser, S. Christine] GEARS Inc, Atlanta, GA USA. [Zahniser, S. Christine] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Davila, EP (reprint author), Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Div Publ Hlth Syst & Workforce Dev, Atlanta, GA 30329 USA. EM evelyn.p.davila@gmail.com RI de Courten, Maximilian/B-3300-2012 OI de Courten, Maximilian/0000-0001-9997-9359 FU CDC FX This training was funded in part by the CDC. NR 32 TC 1 Z9 1 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1876-3413 EI 1876-3405 J9 INT HEALTH JI Int. Health PD SEP PY 2015 VL 7 IS 5 SI SI BP 339 EP 347 DI 10.1093/inthealth/ihu090 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR3GT UT WOS:000361220200008 PM 25526907 ER PT J AU Fujishiro, K Lawson, CC Hibert, EL Chavarro, JE Rich-Edwards, JW AF Fujishiro, K. Lawson, C. C. Hibert, E. L. Chavarro, J. E. Rich-Edwards, J. W. TI Job strain and changes in the body mass index among working women: a prospective study SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID ADVERSE HEALTH BEHAVIORS; WHITEHALL-II; WEIGHT-LOSS; PHYSICAL-ACTIVITY; LIFE-STYLE; STRESS; OBESITY; ASSOCIATION; CORTISOL; BMI AB OBJECTIVE: The relationship between job strain and weight gain has been unclear, especially for women. Using data from over 52 000 working women, we compare the association between change in job strain and change in body mass index (BMI) across different levels of baseline BMI. SUBJECTS/METHODS: We used data from participants in the Nurses' Health Study II (n = 52 656, mean age = 38.4 years), an ongoing prospective cohort study. Using linear regression, we modeled the change in BMI over 4 years as a function of the change in job strain, baseline BMI and the interaction between the two. Change in job strain was characterized in four categories combining baseline and follow-up levels as follows: consistently low strain (low at both points), decreased strain (high strain at baseline only), increased strain (high strain at follow-up only) and consistently high strain (high at both points). Age, race/ethnicity, pregnancy history, job types and health behaviors at baseline were controlled for in the model. RESULTS: In adjusted models, women who reported high job strain at least once during the 4-year period had a greater increase in BMI (Delta BMI = 0.06-0.12, P<0.05) compared with those who never reported high job strain. The association between the change in job strain exposure and the change in BMI depended on the baseline BMI level (P = 0.015 for the interaction): the greater the baseline BMI, the greater the BMI gain associated with consistently high job strain. The BMI gain associated with increased or decreased job strain was uniform across the range of baseline BMI. CONCLUSIONS: Women with higher BMI may be more vulnerable to BMI gain when exposed to constant work stress. Future research focusing on mediating mechanisms between job strain and BMI change should explore the possibility of differential responses to job strain by initial BMI. C1 [Fujishiro, K.; Lawson, C. C.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Hibert, E. L.; Chavarro, J. E.] Brigham & Womens Hosp, Dept Med, Div Network Med, Boston, MA 02115 USA. [Hibert, E. L.; Chavarro, J. E.] Harvard Univ, Sch Med, Boston, MA USA. [Chavarro, J. E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Chavarro, J. E.; Rich-Edwards, J. W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Rich-Edwards, J. W.] Harvard Univ, Sch Publ Hlth, Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA. RP Fujishiro, K (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent CDC, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA. EM Kfujishiro@cdc.gov FU National Institutes of Health [UM1 CA176726]; NIH [P30 DK046200]; National Institute for Occupational Safety and Health intramural grant [NORA-FY13-927ZKWG] FX The collection of the Nurses' Health Study II data were supported by the National Institutes of Health (UM1 CA176726). The analysis for this paper was supported by NIH grant P30 DK046200 and the National Institute for Occupational Safety and Health intramural grant (NORA-FY13-927ZKWG). NR 35 TC 2 Z9 2 U1 3 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD SEP PY 2015 VL 39 IS 9 BP 1395 EP 1400 DI 10.1038/ijo.2015.91 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CR0BY UT WOS:000360984400010 PM 25986779 ER PT J AU Guy, GP Watson, M Haileyesus, T AF Guy, Gery P., Jr. Watson, Meg Haileyesus, Tadesse TI Problems Assessing Indoor Tanning-Related Injuries Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Guy, Gery P., Jr.; Watson, Meg; Haileyesus, Tadesse] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,Mail Stop K-76, Atlanta, GA 30341 USA. EM irm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2015 VL 175 IS 9 BP 1584 EP 1584 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CR1CH UT WOS:000361059900056 PM 26348521 ER PT J AU Calderon, EJ Cushion, MT Xiao, LH Lorenzo-Morales, J Matos, O Kaneshiro, ES Weiss, LM AF Calderon, Enrique J. Cushion, Melanie T. Xiao, Lihua Lorenzo-Morales, Jacob Matos, Olga Kaneshiro, Edna S. Weiss, Louis M. TI The 13th International Workshops on Opportunistic Protists (IWOP13) SO JOURNAL OF EUKARYOTIC MICROBIOLOGY LA English DT Article DE Acanthamoeba; Blastocystis; Cryptosporidium; Giardia; Microsporidia; Pneumocystis; Toxoplasma AB The 13th International Workshops on Opportunistic Protists (IWOP-13) was held November 13-15, 2014 in Seville, Spain. The objectives of the IWOP meetings are to: (1) serve as a forum for exchange of new information among active researchers concerning the basic biology, molecular genetics, immunology, biochemistry, pathogenesis, drug development, therapy, and epidemiology of these immunodeficiency- associated pathogenic eukaryotic microorganisms that are seen in patients with AIDS and; (2) to foster the entry of new and young investigators into these underserved research areas. The IWOP meeting focuses on opportunistic protists; e.g. the free-living amoebae, Pneumocystis, Cryptosporidium, Toxoplasma, the Microsporidia, and kinetoplastid flagellates. This conference represents the major conference which brings together research groups working on these opportunistic pathogens. Progress has been achieved on understanding the biology of these pathogenic organisms, their involvement in disease causation in both immune deficient and immune competent hosts and is providing important insights into these emerging and reemerging pathogens. A continuing concern of the participants is the ongoing loss of scientific expertise and diversity in this research community. This decline is due to the small size of these research communities and an ongoing lack of understanding by the broader scientific community of the challenges and limitations faced by researchers working on these organisms, which makes these research communities very sensitive to declines in research funding. C1 [Calderon, Enrique J.] Virgen Rocio Univ, Dept Internal Med, Seville, Spain. [Calderon, Enrique J.] Virgen Rocio Univ, Ctr Biomed Res Network Epidemiol & Publ Hlth, Seville, Spain. [Cushion, Melanie T.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Cushion, Melanie T.] Univ Cincinnati, Coll Med, Vet Adm Med Ctr, Cincinnati, OH USA. [Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Lorenzo-Morales, Jacob] Univ La Laguna, Inst Trop Dis & Publ Hlth Canary Isl, Dept Parasitol Ecol & Genet, Canary Isl, Spain. [Matos, Olga] Univ Nova Lisboa, Inst Hyg & Trop Med, CMDT, Dept Med Parasitol, Lisbon, Portugal. [Kaneshiro, Edna S.] Univ Cincinnati, Dept Biol Sci, Cincinnati, OH USA. [Weiss, Louis M.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA. [Weiss, Louis M.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA. RP Weiss, LM (reprint author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave,Room 504 Forchheimer Bldg, Bronx, NY 10461 USA. EM louis.weiss@einstein.yu.edu RI Xiao, Lihua/B-1704-2013; IBIS, EPIDEMIOLOGIA/O-8791-2015; OI Xiao, Lihua/0000-0001-8532-2727; MATOS, OLGA/0000-0001-5793-7716; Lorenzo-Morales, Jacob/0000-0002-7683-2888 FU Programa Ibero-americano de Ciencia y Tecnologia para el Desarrolla (CY-TED); Universidad de Sevilla; Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocio de Sevilla; CIBER de Epidemiologica y Salud Publica FX IWOP13 was supported by grants from the Programa Ibero-americano de Ciencia y Tecnologia para el Desarrolla (CY-TED), Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio de Sevilla, CIBER de Epidemiologica y Salud Publica, The Company of Biologists Ltd. (www.biologists.com). We thank members of our laboratory groups for reading this manuscript. NR 6 TC 0 Z9 1 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5234 EI 1550-7408 J9 J EUKARYOT MICROBIOL JI J. Eukaryot. Microbiol. PD SEP-OCT PY 2015 VL 62 IS 5 BP 701 EP 709 DI 10.1111/jeu.12221 PG 9 WC Microbiology SC Microbiology GA CQ9XT UT WOS:000360970100016 PM 25923469 ER PT J AU Lyons, JI Kerr, GR Mueller, PW AF Lyons, Justine I. Kerr, Gregory R. Mueller, Patricia W. TI Fragile X Syndrome Scientific Background and Screening Technologies SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID MENTAL-RETARDATION PROTEIN; POLYMERASE-CHAIN-REACTION; FMR1 GENE; HIPPOCAMPAL-NEURONS; EXPANDED ALLELES; CGG EXPANSIONS; DNA; IDENTIFICATION; METHYLATION; PREVALENCE AB Fragile X is the most common inherited cause of mental retardation with a prevalence of 1 in 4000 for males and 1 in 5000 to 8000 for females. The American College of Medical Genetics and Genomics has recommended diagnostic testing for fragile X in symptomatic persons, women with ovarian dysfunction, and persons with tremor/ataxia syndrome. Although medical and scientific professionals do not currently recommend screening nonsymptomatic populations, improvements in current treatment approaches and ongoing clinical trials have generated growing interest in screening for fragile X. Here, we briefly review the relevant molecular basis of fragile X and fragile X testing and compare three different molecular technologies available for fragile X screening in both males and females. These technologic approaches include destabilizing the CGG-repeat region with betaine and using chimeric CGG-targeted PCR primers, using heat pulses to destabilize C-G bonds in the PCR extension step, and using melting curve analysis to differentiate expanded CGG repeats from normals. The first two-step method performed with high sensitivity and specificity. The second method provided agarose gel images that allow identification of males with expanded CGG repeats and females with expanded CGG-repeat bands which are sometimes faint. The third melting curve analysis method would require controls in each run to correct for shifting optimal cutoff values. C1 [Lyons, Justine I.; Kerr, Gregory R.; Mueller, Patricia W.] Ctr Dis Control & Prevent, Mol Risk Assessment Lab, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. RP Mueller, PW (reprint author), Ctr Dis Control & Prevent, Mailstop F24,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM pwm2@cdc.gov FU Centers for Disease Control and Prevention, U.S. Department of Health and Human Services FX Supported by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. NR 32 TC 2 Z9 2 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD SEP PY 2015 VL 17 IS 5 BP 463 EP 471 DI 10.1016/j.jmoldx.2015.04.006 PG 9 WC Pathology SC Pathology GA CQ7JB UT WOS:000360777700001 PM 26162330 ER PT J AU Ramirez, JC Cura, CI Moreira, OD Lages-Silva, E Juiz, N Velazquez, E Ramirez, JD Alberti, A Pavia, P Flores-Chavez, MD Munoz-Calderon, A Perez-Morales, D Santalla, J Guedes, PMD Peneau, J Marcet, P Padilla, C Cruz-Robles, D Valencia, E Crisante, GE Greif, G Zulantay, I Costales, JA Alvarez-Martinez, M Martinez, NE Villarroel, R Villarroel, S Sanchez, Z Bisio, M Parrado, R Galvao, LMD da Camara, ACJ Espinoza, B de Noya, BA Puerta, C Riarte, A Diosque, P Sosa-Estani, S Guhl, F Ribeiro, I Aznar, C Britto, C Yadon, ZE Schijman, AG AF Carlos Ramirez, Juan Ines Cura, Carolina da Cruz Moreira, Otacilio Lages-Silva, Eliane Juiz, Natalia Velazquez, Elsa David Ramirez, Juan Alberti, Anahi Pavia, Paula Delmans Flores-Chavez, Maria Munoz-Calderon, Arturo Perez-Morales, Deyanira Santalla, Jose da Matta Guedes, Paulo Marcos Peneau, Julie Marcet, Paula Padilla, Carlos Cruz-Robles, David Valencia, Edward Elena Crisante, Gladys Greif, Gonzalo Zulantay, Ines Alfredo Costales, Jaime Alvarez-Martinez, Miriam Edith Martinez, Norma Villarroel, Rodrigo Villarroel, Sandro Sanchez, Zunilda Bisio, Margarita Parrado, Rudy da Cunha Galvao, Lucia Maria Jacome da Camara, Antonia Claudia Espinoza, Bertha Alarcon de Noya, Belkisyole Puerta, Concepcion Riarte, Adelina Diosque, Patricio Sosa-Estani, Sergio Guhl, Felipe Ribeiro, Isabela Aznar, Christine Britto, Constanca Estela Yadon, Zaida Schijman, Alejandro G. TI Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID PARASITEMIA; CONSENSUS; LINEAGES; REGIONS; ASSAYS; TRIAL AB An international study was performed by 26 experienced PCR laboratories from 14 countries to assess the performance of duplex quantitative real-time PCR (qPCR) strategies on the basis of TaqMan probes for detection and quantification of parasitic Loads in peripheral blood samples from Chagas disease patients. Two methods were studied: Satellite DNA (SatDNA) qPCR and kinetoplastid DNA (kDNA) qPCR. Both methods included an internal amplification control. Reportable range, analytical sensitivity, limits of detection and quantification, and precision were estimated according to international guidelines. In addition, inclusivity and exclusivity were estimated with DNA from stocks representing the different Trypanosoma cruzi discrete typing units and Tlypanosoma rangeli and Leishmania spp. Both methods were challenged against 156 blood samples provided by the participant laboratories, including samples from acute and chronic patients with varied clinical findings, infected by oral route or vectorial transmission. kDNA qPCR showed better analytical sensitivity than SatDNA qPCR with Limits of detection of 0.23 and 0.70 parasite equivalents/mL, respectively. Analyses of clinical samples revealed a high concordance in terms of sensitivity and parasitic loads determined by both SatDNA and kDNA qPCRs. This effort is a major step toward international validation of qPCR methods for the quantification of T. auzi DNA in human blood samples, aiming to provide an accurate surrogate biomarker for diagnosis and treatment monitoring for patients with Chagas disease. C1 [Carlos Ramirez, Juan; Ines Cura, Carolina; Juiz, Natalia; Bisio, Margarita; Schijman, Alejandro G.] Inst Invest Ingn Genet & Biol & Mol INGEBI CONICE, Lab Mol Biol Chagas Dis LaBMECh, Buenos Aires, DF, Argentina. [da Cruz Moreira, Otacilio; Britto, Constanca] Fiocruz MS, Lab Mol Biol Endem Dis, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil. [Lages-Silva, Eliane] Univ Fed Triangulo Mineiro, Lab Discipline Parasitol, Uberaba, Brazil. [Lages-Silva, Eliane] Natl Inst Parasitol Dr Mario Fatala Chaben, Buenos Aires, DF, Argentina. [David Ramirez, Juan; Guhl, Felipe] Univ Los Andes, Ctr Res Trop Microbiol & Parasitol, Bogota, Colombia. [Alberti, Anahi; Diosque, Patricio] Univ Nacl Salta, Inst Expt Pathol, CONICET, Salta, Argentina. [Pavia, Paula; Puerta, Concepcion] Pontificia Univ Javeriana, Lab Mol Parasitol, Bogota, Colombia. [Delmans Flores-Chavez, Maria] Inst Salud Carlos III, Natl Ctr Microbiol, Madrid, Spain. [Munoz-Calderon, Arturo] Cent Univ Venezuela, Inst Trop Med, Caracas, Venezuela. [Perez-Morales, Deyanira; Espinoza, Bertha] Univ Nacl Autonoma Mexico, Biomed Res Inst, Mexico City 04510, DF, Mexico. [Santalla, Jose] Inst Nacl Lab Salud, Lab Parasitol & Mol Biol, La Paz, Bolivia. [da Matta Guedes, Paulo Marcos; da Cunha Galvao, Lucia Maria; Jacome da Camara, Antonia Claudia] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil. [Peneau, Julie; Aznar, Christine] Hosp & Univ Lab CH Andree Rosemon, Cayenne, French Guiana. [Marcet, Paula] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Padilla, Carlos] Inst Nacl Salud, Natl Ctr Publ Hlth, Lima, Peru. [Cruz-Robles, David] Inst Nacl Cardiol Ignacio Chavez, Lab Genom, Mexico City, DF, Mexico. [Valencia, Edward] Univ Peruana Cayetano Heredia, Lab Res Infect Dis, Lima, Peru. [Elena Crisante, Gladys] Univ Los Andes, Dept Biol, Merida, Venezuela. [Greif, Gonzalo] Inst Pasteur Montevideo, Mol Biol Unit, Montevideo, Uruguay. [Zulantay, Ines] Univ Chile, Basic Clin Parasitol Lab, Santiago, Chile. [Alfredo Costales, Jaime] Pontificia Univ Catolica Ecuador, Res Ctr Infect Dis, Quito, Ecuador. [Alvarez-Martinez, Miriam] Hosp Clin Barcelona, Dept Microbiol, Barcelona, Spain. [Alvarez-Martinez, Miriam] Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain. [Edith Martinez, Norma] State Lab Publ Hlth, Acapulco, Mexico. [Villarroel, Rodrigo] Inst Salud Publ Chile, Biomed Dept, Santiago, Chile. [Parrado, Rudy] Univ Mayor San Simon, Lab Mol Biol, Cochabamba, Bolivia. [Sanchez, Zunilda] Univ Nacl Asuncion, Res Inst Hlth Sci, Asuncion, Paraguay. [Ribeiro, Isabela] DNDi, Geneva, Switzerland. [Estela Yadon, Zaida] PAHO WHO, Communicable Dis & Hlth Anal Dept, Rio De Janeiro, Brazil. RP Schijman, AG (reprint author), Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina. EM schijman@dna.uba.ar RI Ramirez, Juan David/F-3524-2016; OI Ramirez, Juan David/0000-0002-1344-9312; Marcet, Paula/0000-0002-0676-3020; Cruz-Robles, David/0000-0003-4234-9561; Puerta Bula, Concepcion Judith/0000-0002-3449-3961 FU CDR/Small Grant Programme PAHO/WHO; CONICET [PIP 112-200801-02915]; National Agency of Science and Technology grant [PICT 33955] FX Supported by CDR/Small Grant Programme PAHO/WHO (A.G.S.) and partially by CONICET grant PIP 112-200801-02915 and the National Agency of Science and Technology grant PICT 33955. NR 34 TC 12 Z9 13 U1 0 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD SEP PY 2015 VL 17 IS 5 BP 605 EP 615 DI 10.1016/j.jmoldx.2015.04.010 PG 11 WC Pathology SC Pathology GA CQ7JB UT WOS:000360777700017 PM 26320872 ER PT J AU Vishwanathan, SA Burgener, A Bosinger, SE Tharp, GK Guenthner, PC Patel, NB Birse, K Hanson, DL Westmacott, GR Henning, TR Radzio, J Garcia-Lerma, JG Ball, TB McNicholl, JM Kersh, EN AF Vishwanathan, S. A. Burgener, A. Bosinger, S. E. Tharp, G. K. Guenthner, P. C. Patel, N. B. Birse, K. Hanson, D. L. Westmacott, G. R. Henning, T. R. Radzio, J. Garcia-Lerma, J. G. Ball, T. B. McNicholl, J. M. Kersh, E. N. TI Cataloguing of Potential HIV Susceptibility Factors during the Menstrual Cycle of Pig-Tailed Macaques by Using a Systems Biology Approach SO JOURNAL OF VIROLOGY LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; IMMUNODEFICIENCY-VIRUS TYPE-1; PIGTAIL MACAQUES; CYSTATIN ANTIPROTEASES; RHESUS MACAQUES; INNATE IMMUNITY; CATHEPSIN-G; TRANSMISSION; REPLICATION; EXPRESSION AB Our earlier studies with pig-tailed macaques demonstrated various simian-human immunodeficiency virus (SHIV) susceptibilities during the menstrual cycle, likely caused by cyclic variations in immune responses in the female genital tract. There is concern that high-dose, long-lasting, injectable progestin-based contraception could mimic the high-progesterone luteal phase and predispose women to human immunodeficiency type 1 (HIV-1) acquisition and transmission. In this study, we adopted a systems biology approach employing proteomics (tandem mass spectrometry), transcriptomics (RNA microarray hybridization), and other specific protein assays (enzyme-linked immunosorbent assays and multiplex chemokine and cytokine measurements) to characterize the effects of hormonal changes on the expression of innate factors and secreted proteins in the macaque vagina. Several antiviral factors and pathways (including acute-phase response signaling and complement system) were overexpressed in the follicular phase. Conversely, during the luteal phase there were factors overexpressed (including moesins, syndecans, and integrins, among others) that could play direct or indirect roles in enhancing HIV-1 infection. Thus, our study showed that specific pathways and proteins or genes might work in tandem to regulate innate immunity, thus fostering further investigation and future design of approaches to help counter HIV-1 acquisition in the female genital tract. IMPORTANCE HIV infection in women is poorly understood. High levels of the hormone progesterone may make women more vulnerable to infection. This could be the case during the menstrual cycle, when using hormone-based birth control, or during pregnancy. The biological basis for increased HIV vulnerability is not known. We used an animal model with high risk for infection during periods of high progesterone. Genital secretions and tissues during the menstrual cycle were studied. Our goal was to identify biological factors upregulated at high progesterone levels, and we indeed show an upregulation of genes and proteins which enhance the ability of HIV to infect when progesterone is high. In contrast, during low-progesterone periods, we found more HIV inhibitory factors. This study contributes to our understanding of mechanisms that may regulate HIV infection in females under hormonal influences. Such knowledge is needed for the development of novel prevention strategies. C1 [Vishwanathan, S. A.; Guenthner, P. C.; Hanson, D. L.; Henning, T. R.; Radzio, J.; Garcia-Lerma, J. G.; McNicholl, J. M.; Kersh, E. N.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Burgener, A.; Birse, K.; Ball, T. B.] Univ Manitoba, Dept Med Microbiol & Immunol, Winnipeg, MB, Canada. [Westmacott, G. R.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. [Burgener, A.; Ball, T. B.] JC Wilt Infect Dis Res Ctr, Natl Lab HIV Immunol, Winnipeg, MB, Canada. [Tharp, G. K.; Patel, N. B.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Burgener, A.] Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Unit Infect Dis,Dept Med Solna, Stockholm, Sweden. [Bosinger, S. E.] Emory Univ, Yerkes Natl Primate Res Ctr, Nonhuman Primate Genom Core Lab, Atlanta, GA 30322 USA. [Bosinger, S. E.] Emory Univ, Div Microbiol & Immunol, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. RP Vishwanathan, SA (reprint author), CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM ile0@cdc.gov FU CDC [Y1-AI-0681-02]; NIH [Y1-AI-0681-02] FX This work was supported by the CDC and by an Interagency Agreement (Y1-AI-0681-02) between the CDC and NIH. NR 54 TC 3 Z9 3 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD SEP PY 2015 VL 89 IS 18 BP 9167 EP 9177 DI 10.1128/JVI.00263-15 PG 11 WC Virology SC Virology GA CQ6HE UT WOS:000360704400004 PM 26109722 ER PT J AU Fowlkes, A Steffens, A Temte, J Di Lonardo, S McHugh, L Martin, K Rubino, H Feist, M Davis, C Selzer, C Lojo, J Oni, O Kurkjian, K Thomas, A Boulton, R Bryan, N Lynfield, R Biggerstaff, M Finelli, L AF Fowlkes, Ashley Steffens, Andrea Temte, Jon Di Lonardo, Steve McHugh, Lisa Martin, Karen Rubino, Heather Feist, Michelle Davis, Carol Selzer, Christine Lojo, Jose Oni, Oluwakemi Kurkjian, Katie Thomas, Ann Boulton, Rachelle Bryan, Nicole Lynfield, Ruth Biggerstaff, Matthew Finelli, Lyn CA Influenza Incidence Surveillance P TI Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13 SO LANCET RESPIRATORY MEDICINE LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; HEALTH-CARE; ILLNESS; MORTALITY; BURDEN; COMMUNITY; CHILDREN; VACCINE; DISEASE AB Background Since the introduction of pandemic influenza A (H1N1) to the USA in 2009, the Influenza Incidence Surveillance Project has monitored the burden of influenza in the outpatient setting through population-based surveillance. Methods From Oct 1, 2009, to July 31, 2013, outpatient clinics representing 13 health jurisdictions in the USA reported counts of influenza-like illness (fever including cough or sore throat) and all patient visits by age. During four years, staff at 104 unique clinics (range 35-64 per year) with a combined median population of 368 559 (IQR 352 595-428 286) attended 35 663 patients with influenza-like illness and collected 13 925 respiratory specimens. Clinical data and a respiratory specimen for influenza testing by RT-PCR were collected from the first ten patients presenting with infl uenza-like illness each week. We calculated the incidence of visits for infl uenza-like illness using the size of the patient population, and the incidence attributable to influenza was extrapolated from the proportion of patients with positive tests each week. Findings The site-median peak percentage of specimens positive for influenza ranged from 58.3% to 77.8%. Children aged 2 to 17 years had the highest incidence of infl uenza-associated visits (range 4.2-28.0 per 1000 people by year), and adults older than 65 years had the lowest (range 0.5-3.5 per 1000 population). Influenza A H3N2, pandemic H1N1, and influenza B equally co-circulated in the first post-pandemic season, whereas H3N2 predominated for the next two seasons. Of patients for whom data was available, influenza vaccination was reported in 3289 (28.7%) of 11 459 patients with infl uenza-like illness, and antivirals were prescribed to 1644 (13.8%) of 11 953 patients. Interpretation Influenza incidence varied with age groups and by season after the pandemic of 2009 influenza A H1N1. High levels of influenza virus circulation, especially in young children, emphasise the need for additional efforts to increase the uptake of influenza vaccines and antivirals. C1 [Fowlkes, Ashley; Steffens, Andrea; Biggerstaff, Matthew; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Temte, Jon] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Di Lonardo, Steve] Gotham Ctr, New York City Dept Hlth & Mental Hyg, Div Prevent & Primary Care, Long Isl City, NY USA. [McHugh, Lisa] New Jersey Dept Hlth, Communicable Dis Serv Infect & Zoonot Dis, Trenton, NJ USA. [Martin, Karen; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Rubino, Heather] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. [Feist, Michelle] North Dakota Dept Hlth, Div Dis Control, Bismarck, ND USA. [Davis, Carol] Texas Dept Hlth, Publ Hlth Preparedness & Epidemiol Program, Temple, TX USA. [Selzer, Christine] Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control Program, Los Angeles, CA USA. [Lojo, Jose] Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. [Oni, Oluwakemi] Iowa Dept Publ Hlth, Ctr Acute Dis Epidemiol, Des Moines, IA 50319 USA. [Kurkjian, Katie] Virginia Dept Hlth, Div Surveillance & Invest, Richmond, VA USA. [Thomas, Ann] Oregon Publ Hlth Div, Acute & Communicable Dis Program, Portland, OR USA. [Boulton, Rachelle] Utah Dept Hlth, Div Dis Control & Prevent, Salt Lake City, UT 84116 USA. [Bryan, Nicole] Council State & Terr Epidemiologists, Atlanta, GA USA. RP Fowlkes, A (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM afowlkes@cdc.gov NR 31 TC 6 Z9 6 U1 2 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD SEP PY 2015 VL 3 IS 9 BP 709 EP 718 DI 10.1016/S2213-2600(15)00278-7 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CR0AX UT WOS:000360981500028 PM 26300111 ER PT J AU Koszowski, B Viray, LC Stanfill, SB Lisko, JG Rosenberry, ZR Potts, JL Pickworth, WB AF Koszowski, Bartosz Viray, Lauren C. Stanfill, Stephen B. Lisko, Joseph G. Rosenberry, Zach R. Potts, Jennifer L. Pickworth, Wallace B. TI Nicotine delivery and pharmacologic response from Verve, an oral nicotine delivery product SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE Oral nicotine delivery product (ONDP); Verve; Nicotine pharmacokinetics; Tobacco ID SMOKELESS TOBACCO PRODUCTS; CHEWING GUM; MOIST SNUFF; CIGARETTE; SMOKING; PHARMACOKINETICS; HUMANS AB Verve, an oral nicotine delivery product (ONDP), was introduced by Nu Mark (Altria Client Group, Richmond VA) for smokers to use in places where smoking is prohibited. This study assessed the effect of this ONDP on plasma nicotine levels, heart rate, product satisfaction, and ability to suppress smoking urge and cigarette cravings. Thirteen daily cigarette smokers 18 men and 5 women; average age 33.4 years] attended two laboratory sessions, one occurred after overnight tobacco abstinence. Plasma samples were collected before and after ONDP use and measured for nicotine. In non-abstinent smokers, mean plasma nicotine levels increased from 18.3 to 21.0 ng/mL. In abstinent smokers, average nicotine levels increased from 3.1 to 4.5 ng/mL. After overnight tobacco abstinence, ONDP use significantly (p < 0.01) increased heart rate from 69 beats per minute (bpm) to 75 bpm; while urge to smoke decreased significantly (p < 0.01) from a score of 8.6 to 4.9. Participants indicated moderate product satisfaction that was not changed by tobacco abstinence. Analysis of unused ONDP revealed total nicotine levels of 1.68 +/- 0.09 mg/disc. Spent ONDP discs were also analyzed to determine % nicotine liberated during chewing; results were 80% in the non-abstinent and 82% in the abstinent conditions (ns). Our study results indicate that ONDP use can increase plasma nicotine levels and heart rate and reduce cigarette cravings in abstinent smokers. (C) 2015 Elsevier Inc. All rights reserved. C1 [Koszowski, Bartosz; Viray, Lauren C.; Rosenberry, Zach R.; Potts, Jennifer L.; Pickworth, Wallace B.] Battelle Publ Hlth Ctr Tobacco Res, Baltimore, MD 21209 USA. [Stanfill, Stephen B.; Lisko, Joseph G.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Pickworth, WB (reprint author), Battelle Publ Hlth Ctr Tobacco Res, 6115 Falls Rd,Suite 200, Baltimore, MD 21209 USA. EM pickworthw@battelle.org OI Koszowski, Bartosz/0000-0002-7929-7040 FU Battelle Internal resources FX We gratefully acknowledge the assistance of Dr. Lacy Fabian and Natalia Ceaicovscaia for the proof reading and editorial assistance. Funding for this study was provided by Battelle Internal resources. NR 31 TC 0 Z9 0 U1 4 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD SEP PY 2015 VL 136 BP 1 EP 6 DI 10.1016/j.pbb.2015.06.010 PG 6 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA CQ9PX UT WOS:000360948300001 PM 26096037 ER PT J AU Kruger, J Jama, A Homa, DM Babb, SD King, BA AF Kruger, Judy Jama, Amal Homa, David M. Babb, Stephen D. King, Brian A. TI Smoke-free home and vehicle rules by tobacco use status among US adults SO PREVENTIVE MEDICINE LA English DT Article DE Smoke-free transactions; Nonsmoking homes; Vehicles; Public places ID UNITED-STATES; ASSOCIATION; LAWS AB Objective. To assess the prevalence and characteristics of smoke-free home and vehicle rules by tobacco use. Methods. Data came from the 2012-2013 National Adult Tobacco Survey, a telephone survey of adults aged >= 18. Respondents who reported smoking is 'never allowed' inside their home or any family vehicle were considered to have smoke-free home and vehicle rules, respectively. Prevalence and characteristics of smoke-free rules were assessed overall and by current tobacco use (combustible only, noncombustible only, combustible and noncombustible, no current tobacco use). Assessed characteristics included: sex, age, race/ethnicity, education, marital status, income, region, and sexual orientation. Results. Nationally, 83.7% of adults (n = 48,871) had smoke-free home rules and 78.1% (n = 46,183) had smoke-free vehicle rules. By tobacco use, prevalence was highest among nonusers of tobacco (homes: 90.8%; vehicles: 88.9%) and lowest among combustible-only users (homes: 53.7%; vehicles: 34.2%). Prevalence of smoke-free home and vehicle rules was higher among males, adults with a graduate degree, and adults living in the West. Conclusions. Most adults have smoke-free home and vehicle rules, but differences exist by tobacco use. Opportunities exist to educate adults about the dangers of secondhand smoke and the benefits of smoke-free environments, particularly among combustible tobacco users. Published by Elsevier Inc. C1 [Kruger, Judy; Homa, David M.; Babb, Stephen D.; King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Jama, Amal] DB Consulting Grp, Atlanta, GA 30341 USA. RP Kruger, J (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway NE,F-79, Atlanta, GA 30341 USA. EM ezk0@cdc.gov FU Intramural CDC HHS [CC999999] NR 18 TC 2 Z9 2 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD SEP PY 2015 VL 78 BP 9 EP 13 DI 10.1016/j.ypmed.2015.06.004 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CQ7IQ UT WOS:000360776600002 PM 26092055 ER PT J AU Jones, SA Moore, LV Moore, K Zagorski, M Brines, SJ Roux, AVD Evenson, KR AF Jones, Sydney A. Moore, Latetia V. Moore, Kari Zagorski, Melissa Brines, Shannon J. Roux, Ana V. Diez Evenson, Kelly R. TI Disparities in physical activity resource availability in six US regions SO PREVENTIVE MEDICINE LA English DT Article DE Parks and recreation; Physical activity; Geographic information systems (GIS); Policy; Environment ID SOCIOECONOMIC-STATUS; PUBLIC PARKS; OLDER-ADULTS; NEIGHBORHOOD ENVIRONMENT; NATURAL EXPERIMENT; BUILT ENVIRONMENT; ATHEROSCLEROSIS; FACILITIES; RECREATION; HEALTH AB Objective. We conducted an ecological study to determine physical activity resource availability overall and by sociodemographic groups in parts of six states (CA, IL, MD, MN, NC, NY). Methods. Data on parks and recreational facilities were collected from 3 sources in 2009-2012. Three measures characterized park and recreational facility availability at the census tract level: presence of resource, number of resources, and >= 1 resource kernel density. Associations between resource availability and census tract characteristics (predominant racial/ethnic group, median income, and proportion of children and older adults) were estimated using linear, binomial, and zero-inflated negative binomial regression in 2014. Pooled and stratified analyses were conducted. Results. The study included 7139 census tracts, comprising 9.5% of the 2010 US population. Overall the availability of parks and recreational facilities was lower in predominantly minority relative to non-Hispanic white census tracts. Low-income census tracts and those with a higher proportion of children had an equal or greater availability of park resources but fewer recreational facilities. Stratification revealed substantial variation in resource availability by site. Conclusion. The availability of physical activity resources varied by sociodemographic characteristics and across regions. Improved knowledge of resource distribution can inform strategies to provide equitable access to parks and recreational facilities. (C) 2015 Elsevier Inc. All rights reserved. C1 [Jones, Sydney A.; Evenson, Kelly R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27514 USA. [Moore, Latetia V.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Moore, Kari; Roux, Ana V. Diez] Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Zagorski, Melissa] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Brines, Shannon J.] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA. RP Jones, SA (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, 137 East Franklin St,Suite 306, Chapel Hill, NC 27514 USA. EM SydneyJones@unc.edu FU National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [2R01 HL071759]; NIH/NHLBI [N01-HC-95159, N01-HC-95165, N01-HC-95169]; NHLBI [NRSA: T32-HL007055-38]; University of North Carolina Royster Society of Fellows FX We thank the other investigators, staff, and participants of the Multi-Ethnic Study of Atherosclerosis for their valuable contributions. We acknowledge Dr. Jana Hirsch for her advice on kernel density analyses. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the NIH or the CDC. This work was supported by grant 2R01 HL071759 from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). The Center for Health Promotion and Disease Prevention at the University of North Carolina, a member of the Prevention Research Centers' Program of the Centers for Disease Control and Prevention (CDC) managed the subcontract to KRE (cooperative agreement #U48-DP000059). The Multi-Ethnic Study of Atherosclerosis was supported by the NIH/NHLBI (contracts N01-HC-95159 through N01-HC-95165 through N01-HC-95169). SAJ was supported by the NHLBI (NRSA: T32-HL007055-38) and the University of North Carolina Royster Society of Fellows. This research was previously presented at the Active Living Research Conference in San Diego, CA in February, 2015. No financial disclosures were reported by the authors of this paper. NR 59 TC 5 Z9 5 U1 3 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD SEP PY 2015 VL 78 BP 17 EP 22 DI 10.1016/j.ypmed.2015.05.028 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CQ7IQ UT WOS:000360776600004 PM 26067479 ER PT J AU Cooper, CP Saraiya, M AF Cooper, Crystale Purvis Saraiya, Mona TI Perceived effectiveness of HPV test as a primary screening modality among US providers SO PREVENTIVE MEDICINE LA English DT Article DE Cervical cancer; Screening; Human papillomavirus DNA test; Health care providers AB Background. The human papillomavirus (HPV) test, administered alone without the Papanicolaou (Pap) test, was recently recognized as a cervical cancer screening option in the United States by the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology, and the Food and Drug Administration has approved an HPV test for primary screening. Methods. Surveys of US internists, family practitioners, nurse practitioners, and obstetrician-gynecologists were conducted in 2009 and 2012 to investigate providers' perceptions of the effectiveness of the HPV test administered alone as a population-based screening modality (2009: N = 1040, 141-494 per provider group; 2012: N = 1039, 155-435 per provider group). Results. The majority in each provider group agreed that the HPV test administered alone is an effective screening modality in 2009 (753%-86.1%) and 2012 (79.5%-91.8%), and agreement rose significantly during this time period among family practitioners (chi(2) = 15.26, df = 1, p < 0.001) and nurse practitioners (chi(2) = 4.53, df = 1,p = 0.033). Conclusions. Agreement that the HPV test administered alone is an effective cervical cancer screening modality was widespread among providers in both 2009 and 2012, however implementation of guidelines for screening with the HPV test may be influenced by many other factors including reimbursement and patient preferences. Published by Elsevier Inc. C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ 85704 USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Cooper, CP (reprint author), Soltera Ctr Canc Prevent & Control, 9566 N Placita Roca de Bronce, Tucson, AZ 85704 USA. EM aystale_cooper@comcast.net; yzs2@cdc.gov FU CDC's Inside Knowledge: Get the Facts about Gynecologic Cancer campaign FX The authors have no conflicts of interest to declare. This study was funded by CDC's Inside Knowledge: Get the Facts about Gynecologic Cancer campaign. However, the findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD SEP PY 2015 VL 78 BP 33 EP 37 DI 10.1016/j.ypmed.2015.06.007 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CQ7IQ UT WOS:000360776600007 PM 26116889 ER PT J AU Han, XS Yabroff, KR Guy, GP Zheng, ZY Jemal, A AF Han, Xuesong Yabroff, K. Robin Guy, Gery P., Jr. Zheng, Zhiyuan Jemal, Ahrnedin TI Has recommended preventive service use increased after elimination of cost-sharing as part of the Affordable Care Act in the United States? SO PREVENTIVE MEDICINE LA English DT Article DE Affordable Care Act; Preventive services; Cancer screening; Cost-sharing; Insurance ID SOCIOECONOMIC-STATUS; CERVICAL-CANCER; HEALTH REFORM; COVERAGE; ADULTS; DISPARITIES; GUIDELINES; BENEFITS; ACCESS AB Background. An early provision of the Affordable Care Act (ACA) eliminated cost-sharing for a range of recommended preventive services. This provision took effect in September 2010, but little is known about its effect on preventive service use. Methods. We evaluated changes in the use of recommended preventive services from 2009 (before the implementation of ACA cost-sharing provision) to 2011/2012 (after the implementation) in the Medical Expenditure Panel Survey, a nationally representative household interview survey in the US. Specifically, we examined: blood pressure check, cholesterol check, flu vaccination, and cervical, breast, and colorectal cancer screening, controlling for demographic characteristics and stratifying by insurance type. Results. There were 64,280 (21,310 before and 42,970 after the implementation of ACA cost-sharing provision) adults included in the analyses. Receipt of recent blood pressure check, cholesterol check and flu vaccination increased significantly from 2009 to 2011/2012, primarily in the privately insured population aged 18-64 years, with adjusted prevalence ratios (95% confidence intervals) 1.03 (1.01-1.05) for blood pressure check, 1.13 (1.09-1.18) for cholesterol check and 1.04 (1.00-1.08) for flu vaccination (all p-values < 0.05). However, few changes were observed for cancer screening. We observed little change in the uninsured population. Conclusions. These early observations suggest positive benefits from the ACA policy of eliminating cost-sharing for some preventive services. Future research is warranted to monitor and evaluate longer term effects of the ACA on access to care and health outcomes. (C) 2015 Elsevier Inc All rights reserved. C1 [Han, Xuesong; Zheng, Zhiyuan; Jemal, Ahrnedin] Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA 30303 USA. [Yabroff, K. Robin] NCI, Hlth Serv & Econ Branch, Rockville, MD USA. [Guy, Gery P., Jr.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Han, XS (reprint author), Amer Canc Soc, 250 Williams St NW, Atlanta, GA 30303 USA. EM xuesong.han@cancer.org FU Intramural CDC HHS [CC999999] NR 35 TC 9 Z9 9 U1 3 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD SEP PY 2015 VL 78 BP 85 EP 91 DI 10.1016/j.ypmed.2015.07.012 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CQ7IQ UT WOS:000360776600015 PM 26209914 ER PT J AU Kapaya, M Tong, V Ding, H AF Kapaya, Martha Tong, Van Ding, Helen TI Nicotine replacement therapy and other interventions for pregnant smokers: Pregnancy Risk Assessment Monitoring System, 2009-2010 SO PREVENTIVE MEDICINE LA English DT Article DE Nicotine replacement therapy; Smoking; Prenatal care counseling; Smoking cessation; Tobacco use cessation products; Maternal smoking ID SMOKING-CESSATION; PRENATAL-CARE; UNITED-STATES; GYNECOLOGISTS; DISPARITIES; CIGARETTES; PROVIDERS; ADULTS; WOMEN AB Background. Current U.S. guidelines recommend consideration of nicotine replacement therapy (NRT) for pregnant smokers if behavioral therapies fail, only under close supervision of a provider, and after discussion of known risks of continued smoking and possible risks of NRT. The percentage of pregnant smokers offered NRT by their prenatal care providers is unknown. Purpose. The study aims to calculate the percentage of pregnant smokers offered cessation intervention and NRT and assess independent associations between selected maternal characteristics and being offered NRT. Methods. Data were analyzed from the 2009-2010 Pregnancy Risk Assessment Monitoring System from four states that asked about provider practices for prenatal smoking cessation. Adjusted prevalence ratios were calculated to examine associations between being offered NRT, selected maternal characteristics, and smoking level. Variables used in adjusted models were based on factors associated with smoking cessation during pregnancy from prior literature and included race, age, education, insurance type, and stress. Results. Of 3559 women who smoked 3 months before pregnancy, 77.4% (95% CI: 74.2, 80.3) of 3rd trimester smokers and 42% (95% CI: 38.5, 46.4) of women who quit smoking during pregnancy were offered at least one cessation method. Among smokers, 19.1% (95% CI: 165, 22.1) were offered NRT and of these, almost all (94%) were offered another cessation method. Conclusions. One in five pregnant smokers was offered NRT. About a quarter of pregnant smokers did not receive any interventions to stop smoking. There may still be reluctance to provide NRT to pregnant women, despite known harms of continued smoking during pregnancy. (C) 2015 Elsevier Inc. All rights reserved. C1 [Kapaya, Martha; Ding, Helen] DB Consulting Grp Inc, Silver Spring, MD USA. [Tong, Van] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kapaya, M (reprint author), 4770 Buford Hwy NE,MS F74, Atlanta, GA 30341 USA. EM MKapaya@cdc.gov FU Intramural CDC HHS [CC999999] NR 36 TC 3 Z9 3 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD SEP PY 2015 VL 78 BP 92 EP 100 DI 10.1016/j.ypmed.2015.07.008 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CQ7IQ UT WOS:000360776600016 PM 26190366 ER PT J AU Porter, KA Kirk, C Fearey, D Castrodale, LJ Verbrugge, D McLaughlin, J AF Porter, Kimberly A. Kirk, Cassandra Fearey, Donna Castrodale, Louisa J. Verbrugge, David McLaughlin, Joseph TI Elevated Blood Lead Levels Among Fire Assay Workers and Their Children in Alaska, 2010-2011 SO PUBLIC HEALTH REPORTS LA English DT Article ID US ADULTS; MORTALITY; EXPOSURE AB In October 2010, an employee at Facility A in Alaska that performs fire assay analysis, an industrial technique that uses lead-containing flux to obtain metals from pulverized rocks, was reported to the Alaska Section of Epidemiology (wSOE) with an elevated blood lead level (BLL) >= 10 micrograms per deciliter (mu g/dL). The SOE initiated an investigation; investigators interviewed employees, offered blood lead screening to employees and their families, and observed a visit to the industrial facility by the Alaska Occupational Safety and Health Section (AKOSH). Among the 15 employees with known work responsibilities, 12 had an elevated BLL at least once from October 2010 through February 2011. Of these 12 employees, 10 reported working in the fire assay room. Four children of employees had BLLs >= 5 mu g/dL. Employees working in Facility A's fire assay room were likely exposed to lead at work and could have brought lead home. AKOSH inspectors reported that they could not share their consultative report with SOE investigators because of the confidentiality requirements of a federal regulation, which hampered Alaska SOE investigators from fully characterizing the lead exposure standards. C1 [Porter, Kimberly A.; Kirk, Cassandra; Fearey, Donna; Castrodale, Louisa J.; McLaughlin, Joseph] Alaska Dept Hlth & Social Serv, Div Publ Hlth, Epidemiol Sect, Anchorage, AK USA. [Verbrugge, David] Alaska Dept Hlth & Social Serv, Div Publ Hlth, Alaska State Publ Hlth Lab, Anchorage, AK USA. RP Porter, KA (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM kaporter@cdc.gov NR 21 TC 0 Z9 0 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2015 VL 130 IS 5 BP 440 EP 446 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR1KX UT WOS:000361084800006 PM 26327721 ER PT J AU An, Q Song, RG Hernandez, A Hall, HI AF An, Qian Song, Ruiguang Hernandez, Angela Hall, H. Irene TI Trends and Differences Among Three New Indicators of HIV Infection Progression SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; DRUG-USE; CARE; DIAGNOSIS; ADHERENCE; SURVIVAL; IMPACT; AIDS AB Objective. This study proposes three indicators of, and assesses the disparities and trends in, the risk of HIV infection progression among people living with diagnosed HIV infection in the United States. Methods. Using data reported to national HIV surveillance through June 2012, we calculated the AIDS diagnosis hazard, HIV (including AIDS) death hazard, and AIDS death hazard for people living with diagnosed HIV infection for each calendar year from 1997 to 2010. We also calculated a stratified hazard in 2010 by age, race/ethnicity, mode of transmission, region of residence at diagnosis, and year of diagnosis. Results. The risk of HIV infection progression among people living with diagnosed HIV infection decreased significantly from 1997 to 2010. The risks of progression to AIDS and death in 2010 were higher among African Americans and people of multiple races, males exposed through injection drug use (IDU) or heterosexual contact, females exposed through IDU, people residing in the South at diagnosis, and people diagnosed in 2009 compared with white individuals, men who have sex with men, females with infection attributed to heterosexual contact, those residing in the Northeast, and those diagnosed in previous years, respectively. People aged 15-29 years had the highest AIDS diagnosis hazard in 2010. Conclusion. Continued efforts are needed to ensure early HIV diagnosis as well as initial linkage to and continued engagement in HIV medical care among all people living with HIV. Targeted interventions are needed to improve healthcare and supportive services for those with worse health outcomes. C1 [An, Qian; Hernandez, Angela; Hall, H. Irene] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, HIV Incidence & Case Surveillance Branch, Atlanta, GA 30329 USA. [Song, Ruiguang] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Quantitat Sci & Data Management Branch, Atlanta, GA 30329 USA. RP An, Q (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30329 USA. EM fei8@cdc.gov NR 29 TC 3 Z9 3 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2015 VL 130 IS 5 BP 468 EP 474 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR1KX UT WOS:000361084800010 PM 26327725 ER PT J AU Aiona, K Lowenthal, P Painter, JA Reves, R Flood, J Parker, M Fu, YX Wall, K Walter, ND AF Aiona, Kaylynn Lowenthal, Phillip Painter, John A. Reves, Randall Flood, Jennifer Parker, Matthew Fu, Yunxin Wall, Kirsten Walter, Nicholas D. TI Transnational Record Linkage for Tuberculosis Surveillance and Program Evaluation SO PUBLIC HEALTH REPORTS LA English DT Article ID FOREIGN-BORN PERSONS; COST-EFFECTIVENESS ANALYSIS; GAMMA RELEASE ASSAYS; UNITED-STATES; LATENT TUBERCULOSIS; IMMIGRANTS; INFECTION; IMPLEMENTATION; CHILDHOOD; REFUGEES AB Objective. Pre-immigration tuberculosis (TB) screening, followed by post-arrival rescreening during the first year, is critical to reducing TB among foreign-born people in the United States. However, existing U.S. public health surveillance is inadequate to monitor TB among immigrants during subsequent years. We developed and tested a novel method for ascertaining post-U.S.-arrival TB outcomes among high-TB-risk immigrant cohorts to improve surveillance. Methods. We used a probabilistic record linkage program to link pre-immigration screening records from U.S.-bound immigrants from the Philippines (n=422,593) and Vietnam (n=214,401) with the California TB registry during 2000-2010. We estimated sensitivity using Monte Carlo simulations to account for uncertainty in key inputs. Specificity was evaluated by using a time-stratified approach, which defined false-positives as TB records linked to pre-immigration screening records dated after the person had arrived in the United States. Results. TB was reported in 4,382 and 2,830 people born in the Philippines and Vietnam, respectively, in California during the study period. Of these TB cases, records for 973 and 452 cases of people born in the Philippines and Vietnam, respectively, were linked to pre-immigration screening records. Sensitivity and specificity of linkage were 89% (90% credible interval [Crl] 83, 97) and 100%, respectively, for the Philippines, and 90% (90% Crl 83, 98) and 99.9%, respectively, for Vietnam. Conclusion. Electronic linkage of pre-immigration screening records to a domestic TB registry was feasible, sensitive, and highly specific in two high-priority immigrant cohorts. Transnational record linkage can be used for program evaluation and routine monitoring of post-U.S.-arrival TB risk among immigrants, but requires interagency data sharing and collaboration. C1 [Aiona, Kaylynn; Reves, Randall; Parker, Matthew; Wall, Kirsten; Walter, Nicholas D.] Denver Publ Hlth Dept, Denver Metro TB Control Program, Denver, CO 80204 USA. [Lowenthal, Phillip; Flood, Jennifer] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, TB Control Branch, Richmond, CA USA. [Painter, John A.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Immigrant Refugee & Migrant Hlth Branch, Atlanta, GA USA. [Fu, Yunxin] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA. [Fu, Yunxin] Div Biostat, Houston, TX USA. [Walter, Nicholas D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA. RP Aiona, K (reprint author), Denver Publ Hlth Dept, Denver Metro TB Control Program, 605 Bannock St, Denver, CO 80204 USA. EM kaylynn.aiona@dhha.org NR 35 TC 1 Z9 1 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2015 VL 130 IS 5 BP 475 EP 484 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR1KX UT WOS:000361084800011 PM 26327726 ER PT J AU Smith, PJ Marcuse, EK Seward, JF Zhao, Z Orenstein, WA AF Smith, Philip J. Marcuse, Edgar K. Seward, Jane F. Zhao, Zhen Orenstein, Walter A. TI Children and Adolescents Unvaccinated Against Measles: Geographic Clustering, Parents' Beliefs, and Missed Opportunities SO PUBLIC HEALTH REPORTS LA English DT Article ID AGED 19-35 MONTHS; STATE VACCINATION COVERAGE; NATIONAL IMMUNIZATION SURVEY; AUGUST-SEPTEMBER 2011; UNITED-STATES; SAFETY CONCERNS; NORTH-CAROLINA; SAN-DIEGO; OUTBREAK; CALIFORNIA AB Objective. We evaluated the extent to which children and adolescents were not vaccinated against measles ("unvaccinated"), clustering within U.S. counties, and factors associated with unvaccination, including parents' vaccine-related beliefs and missed opportunities. Methods. We analyzed data from the 2010-2013 National Immunization Survey (NIS) and NIS-Teen Survey of households with 19- to 35-month-old children and 13- to 17-year-old adolescents, respectively. We used provider-reported vaccination histories to assess measles vaccination status. Results. In 2013, 7.5% of children and 4.5% of adolescents were unvaccinated against measles. Four-fifths (80.0%) of unvaccinated children lived in counties containing 41.9% of the nation's children, and 80.0% of unvaccinated adolescents lived in counties containing 30.4% of the nation's adolescents. Multivariable statistical analyses found that 74.6% of children who were unvaccinated against measles missed being vaccinated for reasons other than parents' negative vaccine-related beliefs, and 89.6% could be deemed as having at least one missed opportunity for being vaccinated against measles because they were administered at least one dose of other recommended vaccines after 12 months of age. Among adolescents, multivariable analyses found that only demographic factors, not vaccine-related parental beliefs, were independently associated with being unvaccinated. Conclusions. Reasons other than negative vaccine-related beliefs, including missed opportunities, accounted for the vast majority of unvaccinated children and adolescents. C1 [Smith, Philip J.; Seward, Jane F.; Zhao, Zhen] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Marcuse, Edgar K.] Univ Washington, Sch Med, Seattle Childrens Hosp, Seattle, WA USA. [Orenstein, Walter A.] Emory Univ, Atlanta, GA 30322 USA. RP Smith, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, MS A-19,16 Clifton Rd NE, Atlanta, GA 30333 USA. EM philipsmith@alumni.albany.edu NR 57 TC 8 Z9 8 U1 1 U2 7 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2015 VL 130 IS 5 BP 485 EP 504 PG 20 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR1KX UT WOS:000361084800012 PM 26327727 ER PT J AU Ford, CL Mulatu, MS Godette, DC Gaines, TL AF Ford, Chandra L. Mulatu, Mesfin S. Godette, Dionne C. Gaines, Tommi L. TI Trends in HIV Testing Among US Older Adults Prior to and Since Release of CDC's Routine HIV Testing Recommendations: National Findings from the BRFSS SO PUBLIC HEALTH REPORTS LA English DT Article ID HEALTH-CARE SETTINGS; PREVENTION CAPACITY; MEDICAL-CARE; AGE 50; HIV/AIDS; RISK; AIDS; COMMUNITIES; ACCESS; INTERVENTIONS AB Objective. This study examined temporal trends in HIV testing among U.S. older adults (50-64 years of age) before and after the release of CDC's routine HIV testing recommendations in 2006. Methods. The sample (n=872,797; 51.4% female) comprised 2003-2010 Behavioral Risk Factor Surveillance System respondents in the oldest categories to which the recommendations apply: 50-54 years (34.5%, n=301,519), 55-59 years (34.1%, n=297,865), and 60-64 years (31.3%, n=273,413). We calculated (1) four-year pooled prevalences of past-year HIV testing before and after 2006, when the recommendations were released; and (2) annual prevalences of HIV testing overall and by age category from 2003-2010. Using weighted, multivariable logistic regression analyses, we examined binary (pre- vs. post-recommendations) and annual changes in testing, controlling for covariates. We stratified the data by recent doctor visits, examined racial/ethnic differences, and tested for linear and quadratic temporal trends. Results. Overall and within age categories, the pooled prevalence of past-year HIV testing decreased following release of the recommendations (p<0.001). The annual prevalence decreased monotonically from 2003 (5.5%) to 2006 (3.6%) (beta=-0.16, p<0.001) and then increased immediately after release of the recommendations, but decreased to 3.7% after 2009 (beta=0.01, p<0.001). By race/ethnicity, testing increased over time among non-Hispanic black people only. Annual prevalence also increased among respondents with recent doctor visits. Conclusion. CDC's HIV testing recommendations were associated with a reversal in the downward trend in past-year HIV testing among older adults; however, the gains were neither universal nor sustained over time. C1 [Ford, Chandra L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90095 USA. [Mulatu, Mesfin S.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Godette, Dionne C.] NIAAA, NIH, Div Epidemiol & Prevent Res, Rockville, MD 20852 USA. [Gaines, Tommi L.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, San Diego, CA 92103 USA. RP Ford, CL (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Box 951772,650 Charles E Young Dr S, Los Angeles, CA 90095 USA. EM clford@ucla.edu FU University of California Los Angeles (UCLA) Faculty Career Development Award; Eunice Kennedy Shriver National Institute of Child Health and Human Development via the UCLA California Center for Population Research [5R24HD041022]; National Institute on Drug Abuse [K01DA034523-01] FX Chandra Ford received support from a University of California Los Angeles (UCLA) Faculty Career Development Award and the Eunice Kennedy Shriver National Institute of Child Health and Human Development via the UCLA California Center for Population Research (#5R24HD041022). Tommi Gaines received support from the National Institute on Drug Abuse (#K01DA034523-01). Mesfin Mulatu participated in this endeavor in his personal capacity. The authors acknowledge Ron Andersen, William Cunningham, Martin Shapiro, and Mignon Moore for feedback on an early draft of the article; and Julia T. Caldwell for assistance in preparing manuscript tables and figures. NR 47 TC 1 Z9 1 U1 0 U2 7 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2015 VL 130 IS 5 BP 514 EP 525 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR1KX UT WOS:000361084800014 PM 26327729 ER PT J AU Gross, C Allen-Bridson, K Anttila, A Brooks, JE Hebden, JN Leaptrot, D Morabit, S Wright, MO AF Gross, Cindy Allen-Bridson, Katherine Anttila, Angela Brooks, Janet E. Hebden, Joan N. Leaptrot, Denise Morabit, Susan Wright, Marc-Oliver TI Health Care-Associated Infections Studies Project Case #1: A 2015 American Journal of Infection Control and National Healthcare Safety Network data quality collaboration SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material C1 [Gross, Cindy; Anttila, Angela; Brooks, Janet E.; Leaptrot, Denise; Morabit, Susan] CACI Inc, Healthcare Solut Grp, Publ Hlth & Surveillance, Atlanta, GA USA. [Allen-Bridson, Katherine] Ctr Dis Control & Prevent, Natl Healthcare Safety Network, Div Healthcare Qual Promot, Atlanta, GA USA. [Hebden, Joan N.] Wolters Kluwer Hlth, Bellevue, WA USA. [Wright, Marc-Oliver] North Shore Univ Hlth Syst, Dept Infect Control, Evanston, IL USA. RP Gross, C (reprint author), 1600 Clifton Rd,MSA 24, Atlanta, GA 30333 USA. EM wja3@cdc.gov OI Gross, Cindy/0000-0002-5030-6556; Leaptrot, Denise/0000-0003-2461-208X FU Intramural CDC HHS [CC999999] NR 1 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP 1 PY 2015 VL 43 IS 9 BP 987 EP 988 DI 10.1016/j.ajic.2015.05.029 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CQ4FQ UT WOS:000360560200019 PM 26209338 ER PT J AU Jackson, DA Mailer, K Porter, KA Niemeier, RT Fearey, DA Pope, L Lambert, LA Mitruka, K de Perio, MA AF Jackson, David A. Mailer, Karen Porter, Kimberly A. Niemeier, R. Todd Fearey, Donna A. Pope, Linda Lambert, Lauren A. Mitruka, Kiren de Perio, Marie A. TI Challenges in assessing transmission of Mycobacterium tuberculosis in long-term-care facilities SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material ID GAMMA RELEASE ASSAYS; LATENT TUBERCULOSIS; UNITED-STATES; NURSING-HOME; OLDER-ADULTS; PULMONARY TUBERCULOSIS; INFECTION; RIFAMPIN; RECOMMENDATIONS; RIFAPENTINE C1 [Jackson, David A.] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA. [Jackson, David A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Mailer, Karen; Pope, Linda] Providence Hlth & Serv, Anchorage, AK USA. [Porter, Kimberly A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Alaska State Hlth Dept, Atlanta, GA USA. [Niemeier, R. Todd; de Perio, Marie A.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Fearey, Donna A.] Alaska Dept Hlth & Social Serv, Anchorage, AK USA. [Lambert, Lauren A.; Mitruka, Kiren] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP de Perio, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 1090 Tusculum Ave,R-10, Cincinnati, OH 45226 USA. EM mdeperio@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP 1 PY 2015 VL 43 IS 9 BP 992 EP 996 DI 10.1016/j.ajic.2015.03.035 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CQ4FQ UT WOS:000360560200021 PM 25952618 ER PT J AU Creanga, AA Bateman, BT Butwick, AJ Raleigh, L Maeda, A Kuklina, E Callaghan, WM AF Creanga, Andreea A. Bateman, Brian T. Butwick, Alexander J. Raleigh, Lindsay Maeda, Ayumi Kuklina, Elena Callaghan, William M. TI Morbidity associated with cesarean delivery in the United States: is placenta accreta an increasingly important contributor? SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE cesarean delivery; United States ID MATERNAL MORBIDITY; ABNORMAL PLACENTATION; HYSTERECTOMY; COMPLICATIONS; MORTALITY; OUTCOMES; TERM AB OBJECTIVE: The purpose of this study was to examine cesarean delivery morbidity and its predictors in the United States. STUDY DESIGN: We used 2000-2011 Nationwide Inpatient Sample data to identify cesarean deliveries and records with 12 potential cesarean delivery complications, including placenta accreta. We estimated cesarean delivery morbidity rates and rate changes from 2000-2011, and fitted Poisson regression models to assess the relative incidence of morbidity among repeat vs primary cesarean deliveries and explore its predictors. RESULTS: From 2000-2011, 76 in 1000 cesarean deliveries (97 in 1000 primary and 48 in 1000 repeat cesarean deliveries) were accompanied by >= 1 of 12 complications. The unadjusted composite cesarean delivery morbidity rate increased by 3.6% only among women with a primary cesarean delivery (P < .001); the unadjusted rate of placenta accreta increased by 30.8% only among women with a repeat cesarean deliveries (P = .025). The adjusted rate of overall composite cesarean delivery morbidity decreased by 1% annually from 2000-2011 (P < .001). Compared with women with a primary cesarean delivery, those women who underwent a repeat cesarean delivery were one-half as likely (incidence rate ratio, 0.50; 95% CI, 0.49-0.50) to experience a complication, but 2.13 (95% CI, 1.98-2.29) times more likely to have a placenta accreta diagnosis. Both cesarean delivery morbidity and placenta accreta were positively associated with age >30 years, non-Hispanic black race/ethnicity, the presence of a chronic medical condition, and delivery in urban, teaching, or larger hospitals. CONCLUSION: Overall, cesarean delivery morbidity declined modestly from 2000-2011, but placenta accreta became an increasingly important contributor to repeat cesarean delivery morbidity. Clinicians should maintain a high index of suspicion for abnormal placentation and make adequate preparations for patients who need cesarean deliveries. C1 [Creanga, Andreea A.; Kuklina, Elena; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. [Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. [Bateman, Brian T.] Harvard Univ, Sch Med, Boston, MA USA. [Bateman, Brian T.; Maeda, Ayumi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA. [Butwick, Alexander J.; Raleigh, Lindsay] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. RP Creanga, AA (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. EM acreanga@cdc.gov OI Butwick, Alexander/0000-0002-2048-0879 NR 29 TC 6 Z9 6 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2015 VL 213 IS 3 AR 384.e1 DI 10.1016/j.ajog.2015.05.002 PG 11 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CQ4CL UT WOS:000360551700027 PM 25957019 ER PT J AU Muhlenbruch, K Zhou, X Bardenheier, B Zhang, P Gregg, E Schulze, MB AF Muehlenbruch, K. Zhou, X. Bardenheier, B. Zhang, P. Gregg, E. Schulze, M. B. TI Using diabetes risk scores to select high-risk individuals for diabetes prevention in the United States: a cost-effectiveness analysis SO DIABETOLOGIA LA English DT Meeting Abstract CT 51st Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 14-18, 2015 CL Stockholm, SWEDEN SP European Assoc Study Diabet C1 [Muehlenbruch, K.; Schulze, M. B.] German Inst Human Nutr Potsdam Rehbrucke, Mol Epidemiol, Nuthetal, Germany. [Zhou, X.] Merck, N Wales, PA USA. [Bardenheier, B.; Zhang, P.; Gregg, E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2015 VL 58 SU 1 MA 363 BP S182 EP S182 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CP3ZE UT WOS:000359820901053 ER PT J AU Ly, KN Speers, S Klevens, RM Barry, V Vogt, TM AF Ly, Kathleen N. Speers, Suzanne Klevens, R. Monina Barry, Vaughn Vogt, Tara M. TI Measuring chronic liver disease mortality using an expanded cause of death definition and medical records in Connecticut, 2004 SO HEPATOLOGY RESEARCH LA English DT Article DE alcoholic liver disease; chronic liver disease mortality definition; hepatitis B; hepatitis C ID C VIRUS-INFECTION; UNITED-STATES; HEPATITIS-C; VIRAL-HEPATITIS AB AimChronic liver disease (CLD) is a leading cause of death and is defined based on a specific set of underlying cause-of-death codes on death certificates. This conventional approach to measuring CLD mortality underestimates the true mortality burden because it does not consider certain CLD conditions like viral hepatitis and hepatocellular carcinoma. We measured how much the conventional CLD mortality case definition will underestimate CLD mortality and described the distribution of CLD etiologies in Connecticut. MethodsWe used 2004 Connecticut death certificates to estimate CLD mortality two ways. One way used the conventional definition and the other used an expanded definition that included more conditions suggestive of CLD. We compared the number of deaths identified using this expanded definition with the number identified using the conventional definition. Medical records were reviewed to confirm CLD deaths. ResultsConnecticut had 29314 registered deaths in 2004. Of these, 282 (1.0%) were CLD deaths identified by the conventional CLD definition while 616 (2.1%) were CLD deaths defined by the expanded definition. Medical record review confirmed that most deaths identified by the expanded definition were CLD-related (550/616); this suggested a 15.8 deaths/100000 population mortality rate. Among deaths for which hepatitis B, hepatitis C and alcoholic liver disease were identified during medical record review, only 8.6%, 45.4% and 36.5%, respectively, had that specific cause-of-death code cited on the death certificate. ConclusionAn expanded CLD mortality case definition that incorporates multiple causes of death and additional CLD-related conditions will better estimate CLD mortality. C1 [Ly, Kathleen N.; Klevens, R. Monina; Barry, Vaughn; Vogt, Tara M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Vogt, Tara M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Speers, Suzanne] Connecticut Dept Publ Hlth, Hartford, CT USA. RP Ly, KN (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30333 USA. EM kathleenly@cdc.gov NR 20 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1386-6346 EI 1872-034X J9 HEPATOL RES JI Hepatol. Res. PD SEP PY 2015 VL 45 IS 9 BP 960 EP 968 DI 10.1111/hepr.12437 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CQ8GA UT WOS:000360843300004 ER PT J AU Schneider, JA Bouris, A Smith, DK AF Schneider, John A. Bouris, Alida Smith, Dawn K. TI Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID HIV PREVENTION; DISPARITIES; MEN; SEX C1 [Schneider, John A.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Schneider, John A.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Schneider, John A.; Bouris, Alida] Univ Chicago, Chicago Ctr HIV Eliminat, Chicago, IL 60637 USA. [Schneider, John A.] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA. [Bouris, Alida] Univ Chicago, Sch Social Serv Adm, Chicago, IL 60637 USA. [Smith, Dawn K.] Ctr Dis Control & Prevent, NCHHSTP, Div HIV AIDS Prevent, Atlanta, GA USA. RP Schneider, JA (reprint author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. NR 14 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2015 VL 70 IS 1 BP E30 EP E32 DI 10.1097/QAI.0000000000000670 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CQ1HO UT WOS:000360348100007 PM 25950209 ER PT J AU Schieve, LA Fountain, C Boulet, SL Yeargin-Allsopp, M Kissin, DM Jamieson, DJ Rice, C Bearman, P AF Schieve, Laura A. Fountain, Christine Boulet, Sheree L. Yeargin-Allsopp, Marshalyn Kissin, Dmitry M. Jamieson, Denise J. Rice, Catherine Bearman, Peter TI Does Autism Diagnosis Age or Symptom Severity Differ Among Children According to Whether Assisted Reproductive Technology was Used to Achieve Pregnancy? SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Infantile autism; Symptom severity; Diagnosis age; Assisted reproductive technology ID 2007 NATIONAL-SURVEY; SPECTRUM DISORDERS; POPULATION; BORN; PREVALENCE; CONCEPTION; CALIFORNIA; HEALTH; RISK; ASSOCIATION AB Previous studies report associations between conception with assisted reproductive technology (ART) and autism. Whether these associations reflect an ascertainment or biologic effect is undetermined. We assessed diagnosis age and initial autism symptom severity among > 30,000 children with autism from a linkage study of California Department of Developmental Services records, birth records, and the National ART Surveillance System. Median diagnosis age and symptom severity levels were significantly lower for ART-conceived than non-ART-conceived children. After adjustment for differences in the socio-demographic profiles of the two groups, the diagnosis age differentials were greatly attenuated and there were no differences in autism symptomatology. Thus, ascertainment issues related to SES, not ART per se, are likely the driving influence of the differences we initially observed. C1 [Schieve, Laura A.; Yeargin-Allsopp, Marshalyn; Rice, Catherine] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Fountain, Christine] Fordham Univ, Dept Sociol & Anthropol, New York, NY 10023 USA. [Boulet, Sheree L.; Kissin, Dmitry M.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Bearman, Peter] Columbia Univ, Interdisciplinary Ctr Innovat Theory & Empir INCI, New York, NY USA. RP Schieve, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, MS E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM LSchieve@cdc.gov RI Rice, Catherine/D-6305-2016 FU NIH part of the NIH Roadmap for Medical Research [1 DP1 OD003635-01]; National Institutes of Mental Health [R21MH096122] FX This research is partially supported by the NIH Director's Pioneer Award program, part of the NIH Roadmap for Medical Research, through Grant Number 1 DP1 OD003635-01 and the National Institutes of Mental Health Award Number R21MH096122. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 1 Z9 1 U1 1 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD SEP PY 2015 VL 45 IS 9 BP 2991 EP 3003 DI 10.1007/s10803-015-2462-1 PG 13 WC Psychology, Developmental SC Psychology GA CQ4AH UT WOS:000360545800027 PM 25997596 ER PT J AU Millman, AJ Duong, KK Lafond, K Green, NM Lippold, SA Jhung, MA AF Millman, Alexander J. Duong, Krista Kornylo Lafond, Kathryn Green, Nicole M. Lippold, Susan A. Jhung, Michael A. TI Influenza Outbreaks Among Passengers and Crew on Two Cruise Ships: A Recent Account of Preparedness and Response to an Ever-Present Challenge SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID METAANALYSIS; ILLNESS; INJURY; RISK AB BackgroundDuring spring 2014, two large influenza outbreaks occurred among cruise ship passengers and crew on trans-hemispheric itineraries. MethodsPassenger and crew information for both ships was obtained from components of the ship medical records. Data included demographics, diagnosis of influenza-like illness (ILI) or acute respiratory illness (ARI), illness onset date, passenger cabin number, crew occupation, influenza vaccination history, and rapid influenza diagnostic test (RIDT) result, if performed. ResultsIn total, 3.7% of passengers and 3.1% of crew on Ship A had medically attended acute respiratory illness (MAARI). On Ship B, 6.2% of passengers and 4.7% of crew had MAARI. In both outbreaks, passengers reported illness prior to the ship's departure. Influenza activity was low in the places of origin of the majority of passengers and both ships' ports of call. The median age of affected passengers on both ships was 70years. Diagnostic testing revealed three different co-circulating influenza viruses [influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B] on Ship A and one circulating influenza virus (influenza B) on Ship B. Both ships voluntarily reported the outbreaks to the Centers for Disease Control and Prevention (CDC) and implemented outbreak response plans including isolation of sick individuals and antiviral treatment and prophylaxis. ConclusionsInfluenza activity can become widespread during cruise ship outbreaks and can occur outside of traditional influenza seasons. Comprehensive outbreak prevention and control plans, including prompt antiviral treatment and prophylaxis, may mitigate the impact of influenza outbreaks on cruise ships. C1 [Millman, Alexander J.; Lafond, Kathryn; Jhung, Michael A.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Duong, Krista Kornylo; Lippold, Susan A.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30329 USA. [Green, Nicole M.] Los Angeles Cty Publ Hlth Lab, Downey, CA USA. RP Millman, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop A-32, Atlanta, GA 30329 USA. EM amill-man@cdc.gov FU Intramural CDC HHS [CC999999] NR 20 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD SEP-OCT PY 2015 VL 22 IS 5 BP 306 EP 311 DI 10.1111/jtm.12215 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CQ7EU UT WOS:000360766600004 PM 26031322 ER PT J AU Geoghegan, JL Tan, LV Kuhnert, D Halpin, RA Lin, XD Simenauer, A Akopov, A Das, SR Stockwell, TB Shrivastava, S Ngoc, NM Uyen, LTT Tuyen, NTK Thanh, TT Hang, VTT Qui, PT Hung, NT Khanh, TH Thinh, LQ Nhan, LNT Van, HMT Viet, DC Tuan, HM Viet, HL Hien, TT Chau, NVV Thwaites, G Grenfell, BT Stadler, T Wentworth, DE Holmes, EC Van Doorn, HR AF Geoghegan, Jemma L. Le Van Tan Kuehnert, Denise Halpin, Rebecca A. Lin, Xudong Simenauer, Ari Akopov, Asmik Das, Suman R. Stockwell, Timothy B. Shrivastava, Susmita Nghiem My Ngoc Le Thi Tam Uyen Nguyen Thi Kim Tuyen Tran Tan Thanh Vu Thi Ty Hang Phan Tu Qui Nguyen Thanh Hung Truong Huu Khanh Le Quoc Thinh Le Nguyen Thanh Nhan Hoang Minh Tu Van Do Chau Viet Ha Manh Tuan Ho Lu Viet Tran Tinh Hien Nguyen Van Vinh Chau Thwaites, Guy Grenfell, Bryan T. Stadler, Tanja Wentworth, David E. Holmes, Edward C. Van Doorn, H. Rogier TI Phylodynamics of Enterovirus A71-Associated Hand, Foot, and Mouth Disease in Viet Nam SO JOURNAL OF VIROLOGY LA English DT Article ID POLIOMYELITIS-LIKE DISEASE; 71 VACCINE; POPULATION-DYNAMICS; EPIDEMIC; INFECTION; CHINA; RECOMBINATION; OUTBREAKS; CHILDREN; TAIWAN AB Enterovirus A71 (EV-A71) is a major cause of hand, foot, and mouth disease (HFMD) and is particularly prevalent in parts of Southeast Asia, affecting thousands of children and infants each year. Revealing the evolutionary and epidemiological dynamics of EV-A71 through time and space is central to understanding its outbreak potential. We generated the full genome sequences of 200 EV-A71 strains sampled from various locations in Viet Nam between 2011 and 2013 and used these sequence data to determine the evolutionary history and phylodynamics of EV-A71 in Viet Nam, providing estimates of the effective reproduction number (R-e) of the infection through time. In addition, we described the phylogeography of EV-A71 throughout Southeast Asia, documenting patterns of viral gene flow. Accordingly, our analysis reveals that a rapid genogroup switch from C4 to B5 likely took place during 2012 in Viet Nam. We show that the R-e of subgenogroup C4 decreased during the time frame of sampling, whereas that of B5 increased and remained >1 at the end of 2013, corresponding to a rise in B5 prevalence. Our study reveals that the subgenogroup B5 virus that emerged into Viet Nam is closely related to variants that were responsible for large epidemics in Malaysia and Taiwan and therefore extends our knowledge regarding its associated area of endemicity. Subgenogroup B5 evidently has the potential to cause more widespread outbreaks across Southeast Asia. IMPORTANCE EV-A71 is one of many viruses that cause HFMD, a common syndrome that largely affects infants and children. HFMD usually causes only mild illness with no long-term consequences. Occasionally, however, severe infection may arise, especially in very young children, causing neurological complications and even death. EV-A71 is highly contagious and is associated with the most severe HFMD cases, with large and frequent epidemics of the virus recorded worldwide. Although major advances have been made in the development of a potential EV-A71 vaccine, there is no current prevention and little is known about the patterns and dynamics of EV-A71 spread. In this study, we utilize full-length genome sequence data obtained from HFMD patients in Viet Nam, a geographical region where the disease has been endemic since 2003, to characterize the phylodynamics of this important emerging virus. C1 [Geoghegan, Jemma L.; Holmes, Edward C.] Univ Sydney, Sch Biol Sci, Marie Bashir Inst Infect Dis & Biosecur, Charles Perkins Ctr, Sydney, NSW 2006, Australia. [Geoghegan, Jemma L.; Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. [Le Van Tan; Nguyen Thi Kim Tuyen; Tran Tan Thanh; Vu Thi Ty Hang; Tran Tinh Hien; Thwaites, Guy; Van Doorn, H. Rogier] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam. [Kuehnert, Denise] Swiss Fed Inst Technol, Dept Environm Syst Sci, Zurich, Switzerland. [Kuehnert, Denise; Stadler, Tanja] Swiss Inst Bioinformat, Lausanne, Switzerland. [Halpin, Rebecca A.; Lin, Xudong; Simenauer, Ari; Akopov, Asmik; Das, Suman R.; Stockwell, Timothy B.; Shrivastava, Susmita] J Craig Venter Inst, Rockville, MD USA. [Nghiem My Ngoc; Le Thi Tam Uyen; Phan Tu Qui; Nguyen Van Vinh Chau] Hosp Trop Dis, Ho Chi Minh City, Vietnam. [Nguyen Thanh Hung; Truong Huu Khanh; Le Quoc Thinh; Le Nguyen Thanh Nhan] Childrens Hosp 1, Ho Chi Minh City, Vietnam. [Do Chau Viet; Ha Manh Tuan; Ho Lu Viet] Childrens Hosp 2, Ho Chi Minh City, Vietnam. [Hoang Minh Tu Van; Thwaites, Guy; Van Doorn, H. Rogier] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England. [Grenfell, Bryan T.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA. [Grenfell, Bryan T.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Stadler, Tanja] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Zurich, Switzerland. [Wentworth, David E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Geoghegan, JL (reprint author), Univ Sydney, Sch Biol Sci, Marie Bashir Inst Infect Dis & Biosecur, Charles Perkins Ctr, Sydney, NSW 2006, Australia. RI Stadler, Tanja/J-4742-2013; OI Stadler, Tanja/0000-0001-6431-535X; Simenauer, Ari/0000-0003-0812-6049; Kuhnert, Denise/0000-0002-5657-018X; Le Van, Tan/0000-0002-1791-3901; Wentworth, David/0000-0002-5190-980X; Thwaites, Guy/0000-0002-2858-2087; Holmes, Edward/0000-0001-9596-3552 FU Wellcome Trust [101104/Z/13/Z, 089276/Z/09/Z]; Li Ka Shing Foundation-University of Oxford Global Health Program strategic award [LG23]; Judith and David Coffey fellowship from the Charles Perkins Centre; University of Sydney; ECH, NHMRC Australia Fellowship [AF30]; ETH Zurich postdoctoral fellowship; European Research Council under the 7th Framework Programme of the European Commission (PhyPD) [335529]; Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate; U.S. Department of Homeland Security; Fogarty International Center; National Institutes of Health; Bill and Melinda Gates Foundation; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C] FX This research was supported by the Wellcome Trust (101104/Z/13/Z and 089276/Z/09/Z) and the Li Ka Shing Foundation-University of Oxford Global Health Program strategic award (LG23). J.L.G. is supported by the Judith and David Coffey fellowship from the Charles Perkins Centre, University of Sydney, and ECH by an NHMRC Australia Fellowship (AF30). D.K. is supported by an ETH Zurich postdoctoral fellowship, T.S. was supported in part by the European Research Council under the 7th Framework Programme of the European Commission (PhyPD; grant agreement 335529), and B.T.G. was supported by grants from the Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate, the U.S. Department of Homeland Security, the Fogarty International Center, and the National Institutes of Health and by the Bill and Melinda Gates Foundation. This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract HHSN272200900007C. NR 54 TC 8 Z9 9 U1 5 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD SEP PY 2015 VL 89 IS 17 BP 8871 EP 8879 DI 10.1128/JVI.00706-15 PG 9 WC Virology SC Virology GA CQ6GZ UT WOS:000360703900019 PM 26085170 ER PT J AU Plucinski, MM Guilavogui, T Sidikiba, S Diakite, N Diakite, S Dioubate, M Bah, I Hennessee, I Butts, JK Halsey, ES McElroy, PD Kachur, SP Aboulhab, J James, R Keita, M AF Plucinski, Mateusz M. Guilavogui, Timothee Sidikiba, Sidibe Diakite, Nouman Diakite, Souleymane Dioubate, Mohamed Bah, Ibrahima Hennessee, Ian Butts, Jessica K. Halsey, Eric S. McElroy, Peter D. Kachur, S. Patrick Aboulhab, Jamila James, Richard Keita, Moussa TI Effect of the Ebola-virus-disease epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilities SO LANCET INFECTIOUS DISEASES LA English DT Article ID IMPACT AB Background The ongoing west Africa Ebola-virus-disease epidemic has disrupted the entire health-care system in affected countries. Because of the overlap of symptoms of Ebola virus disease and malaria, the care delivery of malaria is particularly sensitive to the indirect effects of the current Ebola-virus-disease epidemic. We therefore characterise malaria case management in the context of the Ebola-virus-disease epidemic and document the effect of the Ebola-virus-disease epidemic on malaria case management. Methods We did a cross-sectional survey of public health facilities in Guinea in December, 2014. We selected the four prefectures most affected by Ebola virus disease and selected four randomly from prefectures without any reported cases of the disease. 60 health facilities were sampled in Ebola-affected and 60 in Ebola-unaffected prefectures. Study teams abstracted malaria case management indicators from registers for January to November for 2013 and 2014 and interviewed health-care workers. Nationwide weekly surveillance data for suspect malaria cases reported between 2011 and 2014 were analysed independently. Data for malaria indicators in 2014 were compared with previous years. Findings We noted substantial reductions in all-cause outpatient visits (by 23 103 [11%] of 214 899), cases of fever (by 20249 [15%] of 131 330), and patients treated with oral (by 22 655 [24%] of 94 785) and injectable (by 5219 [30%] of 17 684) antimalarial drugs in surveyed health facilities. In Ebola-affected prefectures, 73 of 98 interviewed community health workers were operational (74%, 95% CI 65-83) and 35 of 73 were actively treating malaria cases (48%, 36-60) compared with 106 of 112 (95%, 89-98) and 102 of 106 (96%, 91-99), respectively, in Ebola-unaffected prefectures. Nationwide, the Ebola-virus-disease epidemic was estimated to have resulted in 74 000 (71 000-77 000) fewer malaria cases seen at health facilities in 2014. Interpretation The reduction in the delivery of malaria care because of the Ebola-virus-disease epidemic threatens malaria control in Guinea. Untreated and inappropriately treated malaria cases lead to excess malaria mortality and more fever cases in the community, impeding the Ebola-virus-disease response. C1 [Plucinski, Mateusz M.; Butts, Jessica K.; Halsey, Eric S.; McElroy, Peter D.; Kachur, S. Patrick; Aboulhab, Jamila] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30329 USA. [Plucinski, Mateusz M.; Butts, Jessica K.; Halsey, Eric S.; McElroy, Peter D.; Aboulhab, Jamila] Presidents Malaria Initiat, Atlanta, GA USA. [Guilavogui, Timothee; Diakite, Nouman; Diakite, Souleymane; Dioubate, Mohamed; Keita, Moussa] Minist Hlth, Natl Malaria Control Programme, Conakry, Guinea. [Sidikiba, Sidibe] Maferinyah Rural Hlth Res Ctr, Maferinyah, Guinea. [Bah, Ibrahima] Catholic Relief Serv, Conakry, Guinea. [Hennessee, Ian] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [James, Richard] Minist Hlth, Div Prevent & Dis Control, Conakry, Guinea. RP Plucinski, MM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM mplucinski@cdc.gov FU Global Fund to Fight AIDS, Tuberculosis and Malaria; President's Malaria Initiative FX Global Fund to Fight AIDS, Tuberculosis and Malaria, and President's Malaria Initiative. NR 14 TC 24 Z9 24 U1 3 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD SEP PY 2015 VL 15 IS 9 BP 1017 EP 1023 DI 10.1016/S1473-3099(15)00061-4 PG 7 WC Infectious Diseases SC Infectious Diseases GA CQ4AZ UT WOS:000360547800028 PM 26116183 ER PT J AU Riehle-Colarusso, T Autry, A Razzaghi, H Boyle, CA Mahle, WT Braun, KV Correa, A AF Riehle-Colarusso, Tiffany Autry, Andrew Razzaghi, Hilda Boyle, Coleen A. Mahle, William T. Braun, Kim Van Naarden Correa, Adolfo TI Congenital Heart Defects and Receipt of Special Education Services SO PEDIATRICS LA English DT Article ID BIRTH-DEFECTS; COGNITIVE-DEVELOPMENT; METROPOLITAN ATLANTA; NEURODEVELOPMENTAL OUTCOMES; CIRCULATORY ARREST; NORWOOD PROCEDURE; GREAT-ARTERIES; CHILDREN; DISEASE; REPAIR AB BACKGROUND: We investigated the prevalence of receipt of special education services among children with congenital heart defects (CHDs) compared with children without birth defects. METHODS: Children born from 1982 to 2004 in metropolitan Atlanta with CHDs (n = 3744) were identified from a population-based birth defect surveillance program; children without birth defects (n = 860 715) were identified from birth certificates. Cohorts were linked to special education files for the 1992-2012 school years to identify special education services. Children with noncardiac defects or genetic syndromes were excluded; children with CHDs were classified by presence or absence of critical CHDs (ie, CHDs requiring intervention by age one year). We evaluated the prevalence of receipt of special education services and prevalence rate ratios using children without birth defects as a reference. RESULTS: Compared with children without birth defects, children with CHDs were 50% more likely to receive special education services overall (adjusted prevalence rate ratio [aPRR] = 1.5; 95% confidence interval [CI]: 1.4-1.7). Specifically, they had higher prevalence of several special education categories including: intellectual disability (aPRR = 3.8; 95% CI: 2.8-5.1), sensory impairment (aPRR = 3.0; 95% CI: 1.8-5.0), other health impairment (aPRR = 2.8; 95% CI: 2.2-3.5), significant developmental delay (aPRR = 1.9; 95% CI: 1.3-2.8), and specific learning disability (aPRR = 1.4; 95% CI: 1.1-1.7). For most special education services, the excess prevalence did not vary by presence of critical CHDs. CONCLUSIONS: Children with CHDs received special education services more often than children without birth defects. These findings highlight the need for special education services and the importance of developmental screening for all children with CHDs. C1 [Riehle-Colarusso, Tiffany; Autry, Andrew; Razzaghi, Hilda; Boyle, Coleen A.; Braun, Kim Van Naarden] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Mahle, William T.] Emory Univ, Sch Med, Childrens Hlth Care Atlanta, Sibley Heart Ctr, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. RP Riehle-Colarusso, T (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop E-86, Atlanta, GA 30341 USA. EM tja4@cdc.gov FU Intramural CDC HHS [CC999999] NR 36 TC 10 Z9 10 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2015 VL 136 IS 3 BP 496 EP 504 DI 10.1542/peds.2015-0259 PG 9 WC Pediatrics SC Pediatrics GA CQ6IN UT WOS:000360708100037 PM 26283775 ER PT J AU Demment, MM Peters, K Dykens, JA Dozier, A Nawaz, H McIntosh, S Smith, JS Sy, A Irwin, T Fogg, TT Khaliq, M Blumenfeld, R Massoudi, M Dye, TD AF Demment, Margaret M. Peters, Karen Dykens, J. Andrew Dozier, Ann Nawaz, Haq McIntosh, Scott Smith, Jennifer S. Sy, Angela Irwin, Tracy Fogg, Thomas T. Khaliq, Mahmooda Blumenfeld, Rachel Massoudi, Mehran Dye, Timothy De Ver TI Developing the Evidence Base to Inform Best Practice: A Scoping Study of Breast and Cervical Cancer Reviews in Low- and Middle-Income Countries SO PLOS ONE LA English DT Review ID LIMITED-RESOURCE COUNTRIES; HUMAN-PAPILLOMAVIRUS VACCINATION; 2013 CONSENSUS STATEMENT; ONCOLOGY SUMMIT 2009; GUIDELINE IMPLEMENTATION; HEALTH-CARE; DEVELOPING-WORLD; HPV VACCINATION; GLOBAL HEALTH; PRECANCEROUS LESIONS AB Background Breast and cervical cancers have emerged as major global health challenges and disproportionately lead to excess morbidity and mortality in low- and middle-income countries (LMICs) when compared to high-income countries. The objective of this paper was to highlight key findings, recommendations, and gaps in research and practice identified through a scoping study of recent reviews in breast and cervical cancer in LMICs. Methods We conducted a scoping study based on the six-stage framework of Arskey and O'Malley. We searched PubMed, Cochrane Reviews, and CINAHL with the following inclusion criteria: 1) published between 2005-February 2015, 2) focused on breast or cervical cancer 3) focused on LMIC, 4) review article, and 5) published in English. Results Through our systematic search, 63 out of the 94 identified cervical cancer reviews met our selection criteria and 36 of the 54 in breast cancer. Cervical cancer reviews were more likely to focus upon prevention and screening, while breast cancer reviews were more likely to focus upon treatment and survivorship. Few of the breast cancer reviews referenced research and data from LMICs themselves; cervical cancer reviews were more likely to do so. Most reviews did not include elements of the PRISMA checklist. Conclusion Overall, a limited evidence base supports breast and cervical cancer control in LMICs. Further breast and cervical cancer prevention and control studies are necessary in LMICs. C1 [Demment, Margaret M.; Fogg, Thomas T.; Dye, Timothy De Ver] Univ Rochester, Clin & Translat Res Inst, Rochester, NY 14627 USA. [Peters, Karen] Univ Illinois, Div Community Hlth Sci, Chicago, IL USA. [Dykens, J. Andrew] Univ Illinois, Dept Family Med, Chicago, IL USA. [Dozier, Ann; McIntosh, Scott] Univ Rochester, Dept Publ Hlth Sci, Rochester, NY USA. [Smith, Jennifer S.] Griffin Hosp, Dept Med, New Haven, CT USA. [Nawaz, Haq] Yale Univ, Griffin Prevent Res Ctr, New Haven, CT USA. [Smith, Jennifer S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Sy, Angela] Univ Hawaii Manoa, Sch Nursing & Dent Hyg, Honolulu, HI 96822 USA. [Irwin, Tracy] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Khaliq, Mahmooda] Univ S Florida, Dept Community & Family Hlth, Tampa, FL USA. [Blumenfeld, Rachel; Massoudi, Mehran] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Dye, Timothy De Ver] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA. RP Dye, TD (reprint author), Univ Rochester, Clin & Translat Res Inst, Rochester, NY 14627 USA. EM tim_dye@urmc.rochester.edu OI Dykens, Andrew/0000-0002-4194-8725; McIntosh, Scott/0000-0002-5776-9617 FU Centers for Disease Control and Prevention, Prevention Research Centers Program [1U48DP005026-01S1, 1U48DP005010-01S1, 1U48DP005023-01S1]; U.S. Centers for Disease Control and Prevention (CDC) FX This work was supported and funded by the Centers for Disease Control and Prevention, Prevention Research Centers Program (Cooperative agreements: 1U48DP005026-01S1, 1U48DP005010-01S1, and 1U48DP005023-01S1). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This review falls under the scope of work for the U.S. Centers for Disease Control and Prevention (CDC) funded Global and Territorial Health Research Network through the Prevention Research Centers Program, with the goal to translate chronic disease prevention research into practice. In addition to several partnering institutions, the Global Network Steering Committee consists of two CDC representatives who participated in the study design and review of the manuscript. All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The corresponding author had final responsibility to submit the report for publication. NR 123 TC 3 Z9 3 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 1 PY 2015 VL 10 IS 9 AR e0134618 DI 10.1371/journal.pone.0134618 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CQ2NK UT WOS:000360437700012 PM 26325181 ER PT J AU Stenger, MR Kerani, RP Bauer, HM Burghardt, N Anschuetz, GL Klingler, E Schumacher, CM Simon, J Golden, M AF Stenger, Mark R. Kerani, Roxanne P. Bauer, Heidi M. Burghardt, Nicole Anschuetz, Greta L. Klingler, Ellen Schumacher, Christina M. Simon, Julie Golden, Matthew TI Patient-Reported Expedited Partner Therapy for Gonorrhea in the United States: Findings of the STD Surveillance Network 2010-2012 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; CHLAMYDIAL INFECTION; PHYSICIANS; PROGRAM AB Background Expedited partner therapy (EPT) has been shown to prevent reinfection in persons with gonorrhea and to plausibly reduce incidence. The Centers for Disease Control and Prevention recommends EPT as an option for treating sex partners of heterosexual patients. Few studies that examine how the reported use of this valuable intervention differs by patient and provider characteristics and by geography across multiple jurisdictions in the United States are currently available. Methods Case and patient interview data were obtained for a random sample of reported cases from 7 geographically disparate US jurisdictions participating in the Sexually Transmitted Disease (STD) Surveillance Network. These data were weighted to be representative of all reported gonorrhea cases in the 7 study sites. Patient receipt of EPT was estimated, and multivariate models were constructed separately to examine factors associated with receipt of EPT for heterosexuals and for men who have sex with men. Results Overall, 5.4% of patients diagnosed and reported as having gonorrhea reported receiving EPT to treat their sex partners. Heterosexual patients were more likely to have received EPT than men who have sex with men at 6.6% and 2.6% of patients, respectively. Receipt of EPT did not vary significantly by race, Hispanic ethnicity, or age for either group, although significant variation was observed in different provider settings, with patients from family planning/reproductive health and STD clinic settings more likely to report receiving EPT. Jurisdiction variations were also observed with heterosexual patients in Washington State most likely (35.5%), and those in New York City, Connecticut, and Philadelphia least likely to report receiving EPT (<2%). Conclusions With the exception of one jurisdiction in the STD Surveillance Network actively promoting EPT use, patient-reported receipt of the intervention remains suboptimal across the network. Additional efforts to promote EPT, especially for patients diagnosed in private provider and hospital settings, are needed to realize the full potential of this valuable gonorrhea control intervention. C1 [Stenger, Mark R.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Kerani, Roxanne P.; Golden, Matthew] Univ Washington, Sch Med Publ Hlth Seattle & King Cty, Seattle, WA 98195 USA. [Bauer, Heidi M.; Burghardt, Nicole] Calif Dept Publ Hlth, Sacramento, CA USA. [Anschuetz, Greta L.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Klingler, Ellen] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Schumacher, Christina M.] Johns Hopkins Univ, Sch Med, Baltimore City Hlth Dept, Baltimore, MD USA. [Simon, Julie] Washington State Dept Hlth, Olympia, WA USA. RP Stenger, MR (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. EM zpl4@cdc.gov FU NCHHSTP CDC HHS [PS08-0865]; NIAID NIH HHS [R01AI068107] NR 17 TC 2 Z9 2 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2015 VL 42 IS 9 BP 470 EP 474 DI 10.1097/OLQ.0000000000000329 PG 5 WC Infectious Diseases SC Infectious Diseases GA CQ1HQ UT WOS:000360348300002 PM 26267871 ER PT J AU Ludema, C Doherty, IA White, BL Villar-Loubet, O McLellan-Lemal, E O'Daniels, CM Adimora, AA AF Ludema, Christina Doherty, Irene A. White, Becky L. Villar-Loubet, Olga McLellan-Lemal, Eleanor O'Daniels, Christine M. Adimora, Adaora A. TI Characteristics of African American Women and Their Partners With Perceived Concurrent Partnerships in 4 Rural Counties in the Southeastern US SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; UNITED-STATES; SEX PARTNERS; RISK; BEHAVIOR; HEALTH; MONOGAMY; DISEASES; VIOLENCE; IMPACT AB Background To the individual with concurrent partners, it is thought that having concurrent partnerships confers no greater risk of acquiring HIV than having multiple consecutive partnerships. However, an individual whose partner has concurrent partnerships (partner's concurrency) is at increased risk for incident HIV infection. We sought to better understand relationships characterized by partner's concurrency among African American women. Methods A total of 1013 African American women participated in a cross-sectional survey from 4 rural Southeastern counties. Results Older age at first sex was associated with lower prevalence of partner's concurrency (prevalence ratio, 0.70; 95% confidence interval, 0.57-0.87), but the participant's age was not associated with partner's concurrency. After adjusting for covariates, ever having experienced intimate partner violence (IPV) and forced sex were most strongly associated with partner's concurrency (prevalence ratios, 1.61 [95% confidence intervals, 1.23-2.11] and 1.65 [1.20-2.26], respectively). Women in mutually monogamous partnerships were the most likely to receive economic support from their partners; women whose partners had concurrent partnerships did not report more economic benefit than did those whose partners were monogamous. Conclusions Associations between history of IPV and forced sex with partner's concurrency suggest that women with these experiences may particularly benefit from interventions to reduce partner's concurrency in addition to support for reducing IPV and other sexual risks. To inform these interventions, further research to understand partnerships characterized by partner's concurrency is warranted. C1 [Ludema, Christina; Doherty, Irene A.; White, Becky L.; Adimora, Adaora A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Doherty, Irene A.] RTI Int, Res Triangle Pk, NC USA. Univ Alabama Birmingham, Birmingham, AL USA. [Villar-Loubet, Olga] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [McLellan-Lemal, Eleanor; O'Daniels, Christine M.] Ctr Dis Control & Prevent, Off Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA USA. [O'Daniels, Christine M.] Carter Consulting Inc, Atlanta, GA USA. RP Ludema, C (reprint author), CB 7030,Bioinformat Bldg, Chapel Hill, NC USA. EM ludema@email.unc.edu OI Ludema, Christina/0000-0003-0779-810X FU NCHHSTP CDC HHS [1U01PS000094-01, PS000084, PS000097, PS05-107, U01 PS000084, U01 PS000097, PS000094, U01 PS000094]; NICHD NIH HHS [K24 HD059358, 1K24HD059358-01]; NIMH NIH HHS [K23 MH094250] NR 30 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2015 VL 42 IS 9 BP 498 EP 504 DI 10.1097/OLQ.0000000000000325 PG 7 WC Infectious Diseases SC Infectious Diseases GA CQ1HQ UT WOS:000360348300007 PM 26267876 ER PT J AU Nerlander, LMC Zapata, LB Yorick, R Skipalska, H Smith, RA Kissin, DM Jamieson, DJ Vitek, CR Hillis, SD AF Nerlander, Lina M. C. Zapata, Lauren B. Yorick, Roman Skipalska, Halyna Smith, Ruben A. Kissin, Dmitry M. Jamieson, Denise J. Vitek, Charles R. Hillis, Susan D. TI Behaviors Associated With a Risk of HIV Transmission From HIV-Positive Street Youth to Non-Street Youth in Ukraine SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SOCIAL NETWORK MEMBERS; RUNAWAY ADOLESCENTS; PARTNER REDUCTION; HOMELESS YOUTH; DRUG-USERS; SEROPREVALENCE; PREVENTION; PREDICTORS; KENYA AB Background Little is known about the extent to which HIV-infected street youth (living part or full time on the streets) exhibit behaviors associated with HIV transmission in their interactions with youth not living on the streets (non-street youth). We aimed to determine prevalences and predictors of such bridging behaviors: inconsistent condom use and needle sharing between HIV-positive street youth and non-street youth. Methods A total of 171 street youth in 3 Ukrainian cites were identified as HIV infected after testing of eligible participants aged 15 to 24 years after random selection of venues. Using data from these youth, we calculated prevalence estimates of bridging behaviors and assessed predictors using logistic regression. Results Overall, two-thirds of HIV-infected street youth exhibited bridging behaviors; subgroups with high prevalences of bridging included females (78.3%) and those involved in transactional sex (84.2%). In multivariable analysis, inconsistent condom use with non-street youth was associated with being female (adjusted prevalence ratio [aPR], 1.2; 95% confidence interval [CI], 1.1-1.4), working (aPR, 1.2; 95% CI, 1.03-1.4), multiple partners (aPR, 1.4; 95% CI, 1.2-1.6), and never (aPR, 1.4; 95% CI, 1.1-1.6) or sometimes (aPR, 1.3; 95% CI, 1.02-1.8) versus always sleeping on the street. Needle sharing with non-street youth was associated with being male (aPR, 1.4; 95% CI, 1.02-2.0), orphaned (aPR, 2.3; 95% CI, 1.8-3.0), and 2 years or less living on the streets (aPR, 1.8; 95% CI, 1.5-2.1). Conclusions Bridging behaviors between HIV-infected street youth and non-street youth are common. Addressing the comprehensive needs of street and other at-risk youth is a critical prevention strategy. C1 [Nerlander, Lina M. C.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Div Reprod Hlth, Atlanta, GA 30329 USA. [Zapata, Lauren B.; Smith, Ruben A.; Kissin, Dmitry M.; Jamieson, Denise J.; Hillis, Susan D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Vitek, Charles R.] Ctr Dis Control & Prevent, Div Global HIV AIDS Ukraine Russian Federat, Kiev, Ukraine. [Yorick, Roman] Pactworld, RESPOND Project, Kiev, Ukraine. [Skipalska, Halyna] HealthRight Int, Kiev, Ukraine. RP Nerlander, LMC (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS-E46, Atlanta, GA 30329 USA. EM vif7@cdc.gov NR 37 TC 0 Z9 0 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2015 VL 42 IS 9 BP 513 EP 520 DI 10.1097/OLQ.0000000000000326 PG 8 WC Infectious Diseases SC Infectious Diseases GA CQ1HQ UT WOS:000360348300009 PM 26267878 ER PT J AU Abad, N Baack, BN O'Leary, A Mizuno, Y Herbst, JH Lyles, CM AF Abad, Neetu Baack, Brittney N. O'Leary, Ann Mizuno, Yuko Herbst, Jeffrey H. Lyles, Cynthia M. TI A Systematic Review of HIV and STI Behavior Change Interventions for Female Sex Workers in the United States SO AIDS AND BEHAVIOR LA English DT Review DE HIV/STI prevention; Female sex workers; Behavioral interventions; Systematic review ID SEXUALLY-TRANSMITTED INFECTIONS; MIDDLE-INCOME COUNTRIES; AFRICAN-AMERICAN; RISK BEHAVIORS; CRACK COCAINE; PREVENTION INTERVENTION; TRANSACTIONAL SEX; SUBSTANCE USE; WOMEN; PROSTITUTION AB The lives of female sex workers (FSW) in the US are typically marked by substance abuse, violence, trauma, and poverty. These factors place FSW at risk for acquiring and transmitting HIV and other sexually transmitted infections (STIs). The purpose of this systematic review is to examine HIV/STI interventions conducted in the US that aim to reduce sexual- or drug-related risk behavior among FSW. Eighteen studies describing 19 unique interventions met our selection criteria: five exclusively targeted FSW, two reported stratified data for FSW, and 12 included at least 50 % FSW. Results indicate that 15 interventions provided HIV/STI information, 13 provided substance abuse prevention information, and few included content tailored to specific needs of FSW. Our findings suggest that current HIV/STI prevention efforts in the US do not adequately address the needs of FSW. Interventions are needed to address issues facing FSW in order to reduce HIV/STI transmission in this high-risk group. C1 [Abad, Neetu] Ctr Dis Control & Prevent, Div STD Prevent, NCHHSTP, Atlanta, GA 30333 USA. [Baack, Brittney N.; O'Leary, Ann; Mizuno, Yuko; Lyles, Cynthia M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. [Herbst, Jeffrey H.] Ctr Dis Control & Prevent, Div Violence Prevent, NCIPC, Atlanta, GA 30333 USA. RP Abad, N (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, NCHHSTP, 1600 Clifton Rd NE,Mailstop E-44, Atlanta, GA 30333 USA. EM vjx3@cdc.gov FU Division of HIV/AIDS Prevention in the National Centers for HIV, Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention in Atlanta, GA FX We would like to acknowledge Mary Mullins in the Prevention Research Branch in the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention in Atlanta, GA for her help with conducting the PRS systematic searches, providing the search strategy, and editing the search methods. We would also like to acknowledge Vyann Howell in the Capacity Building Branch in the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention in Atlanta, GA for her help with coding the interventions. We would also like to acknowledge Elizabeth DiNenno in the Behavioral and Clinical Surveillance Branch in the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention in Atlanta, GA for her help with the project. The primary author participated in the Communities of Color ORISE Fellowship Program in the Prevention Research Branch in the Division of HIV/AIDS Prevention in the National Centers for HIV, Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention in Atlanta, GA from 2011 to 2013, and this work was supported by this division. NR 68 TC 2 Z9 2 U1 8 U2 21 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD SEP PY 2015 VL 19 IS 9 BP 1701 EP 1719 DI 10.1007/s10461-015-1013-2 PG 19 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CQ2EG UT WOS:000360411600015 PM 25711295 ER PT J AU Wang, SC Sun, CL Zhang, SF Zhang, XZ Liu, Y Wang, Y Zhang, F Wu, XF Hu, RL AF Wang, Shuchao Sun, Chenglong Zhang, Shoufeng Zhang, Xiaozhuo Liu, Ye Wang, Ying Zhang, Fei Wu, Xianfu Hu, Rongliang TI Glycoprotein from street rabies virus BD06 induces early and robust immune responses when expressed from a non-replicative adenovirus recombinant SO ARCHIVES OF VIROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; ORAL VACCINATION; VACCINIA VIRUS; FLOW-CYTOMETRY; MICE; PATHOGENICITY; DOGS; APOPTOSIS; CHINA; IMMUNIZATION AB The rabies virus (RABV) glycoprotein (G) is responsible for inducing neutralizing antibodies against rabies virus. Development of recombinant vaccines using the G genes from attenuated strains rather than street viruses is a regular practice. In contrast to this scenario, we generated three human adenovirus type 5 recombinants using the G genes from the vaccine strains SRV9 and Flury-LEP, and the street RABV strain BD06 (nrAd5-SRV9-G, nrAd5-Flury-LEP-G, and nrAd5-BD06-G). These recombinants were non-replicative, but could grow up to similar to 10(8) TCID50/ml in helper HEK293AD cells. Expression of the G protein was verified by immunostaining, quantitative PCR and cytometry. Animal experiments revealed that immunization with nrAd5-BD06-G can induce a higher seroconversion rate, a higher neutralizing antibody level, and a longer survival time after rabies virus challenge in mice when compared with the other two recombinants. Moreover, the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) was significantly higher in mice immunized with nrAd5-BD06-G, which might also contribute to the increased protection. These results show that the use of street RABV G for non-replicative systems may be an alternative for developing effective recombinant rabies vaccines. C1 [Wang, Shuchao; Sun, Chenglong; Zhang, Shoufeng; Zhang, Xiaozhuo; Liu, Ye; Wang, Ying; Zhang, Fei; Hu, Rongliang] Acad Mil Med Sci, Vet Res Inst, Lab Epidemiol, Changchun 130122, Peoples R China. [Wang, Shuchao; Sun, Chenglong; Zhang, Shoufeng; Zhang, Xiaozhuo; Liu, Ye; Wang, Ying; Zhang, Fei; Hu, Rongliang] Acad Mil Med Sci, Vet Res Inst, Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun 130122, Peoples R China. [Wu, Xianfu] Ctr Dis Control & Prevent, Rabies PRB DHCPP, Atlanta, GA 30333 USA. RP Wu, XF (reprint author), Ctr Dis Control & Prevent, Rabies PRB DHCPP, Atlanta, GA 30333 USA. EM XAW6@cdc.gov; ronglianghu@hotmail.com FU National "973" project [2011CB504705]; National "863" project [2011AA10A212]; National Natural Science Foundation of China [30630049] FX This project was funded by the National "973" project (2011CB504705), National "863" project (2011AA10A212) and the Key Project of National Natural Science Foundation of China (30630049). NR 39 TC 1 Z9 1 U1 0 U2 9 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD SEP PY 2015 VL 160 IS 9 BP 2315 EP 2323 DI 10.1007/s00705-015-2512-1 PG 9 WC Virology SC Virology GA CQ3NC UT WOS:000360508000017 PM 26143474 ER PT J AU Yera, H Dupouy-Camet, J Jackson, JW Sriram, R Sweat, S Goldstein, JM Visvesvara, GS AF Yera, Helene Dupouy-Camet, Jean Jackson, Jonathan W. Sriram, Rama Sweat, Stacey Goldstein, Jason M. Visvesvara, Govinda S. TI In vitro growth, cytopathic effects and clearance of monolayers by clinical isolates of Balamuthia mandrillaris in human skin cell cultures SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Balamuthia mandrillaris; Human skin; Cell culture; Cytopathic effect ID FREE-LIVING AMEBAS; ACANTHAMOEBA-KERATITIS; AGENT; ENCEPHALITIS; MENINGOENCEPHALITIS; CYTOPATHOGENICITY; ANTIBODIES; ANIMALS; SAMPLES AB Balamuthia mandrillaris is a free-living ameba (FLA) that has been isolated or its DNA identified in soil, dust and water. It causes a fatal central nervous system infection in humans and animals. Although it is environmental as Acanthamoeba and Naegleria fowleri, the two other free-living amebae that also cause CNS infections in humans and other animals, Balamuthia does not feed on bacteria as the other FLA. In the laboratory, it can be grown on a variety of mammalian cell cultures. In this study we examined the ability of three different Balamuthia isolates to grow on several different human skin cell cultures including the WT/A keratinocyte cell cultures. A corneal isolate of Acanthamoeba castellanii was used for comparison. (C) 2015 Published by Elsevier Inc. C1 [Yera, Helene; Jackson, Jonathan W.; Sriram, Rama; Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Lab Free Living Amebae, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Yera, Helene; Jackson, Jonathan W.; Sriram, Rama; Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Environm & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Yera, Helene; Dupouy-Camet, Jean] Univ Paris 05, Lab Parasitol Mycol, Hop Cochin, AP HP,Hop Univ Paris Ctr,Fac Med, F-75014 Paris, France. [Sweat, Stacey; Goldstein, Jason M.] Ctr Dis Control & Prevent, Sci Prod & Support Branch, Div Sci Resources, Natl Ctr Environm & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Yera, H (reprint author), Ctr Dis Control & Prevent, Lab Free Living Amebae, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM helene.yera@cch.aphp.fr NR 29 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 EI 1090-2449 J9 EXP PARASITOL JI Exp. Parasitol. PD SEP PY 2015 VL 156 BP 61 EP 67 DI 10.1016/j.exppara.2015.05.004 PG 7 WC Parasitology SC Parasitology GA CQ0YB UT WOS:000360323400009 PM 25980370 ER PT J AU Chung, RT Davis, GL Jensen, DM Masur, H Saag, MS Thomas, DL Aronsohn, AI Charlton, MR Feld, JJ Fontana, RJ Ghany, MG Godofsky, EW Graham, CS Kim, AY Kiser, JJ Kottilil, S Marks, KM Martin, P Mitruka, K Morgan, TR Naggie, S Raymond, D Reau, NS Schooley, RT Sherman, KE Sulkowski, MS Vargas, HE Ward, JW Wyles, DL AF Chung, Raymond T. Davis, Gary L. Jensen, Donald M. Masur, Henry Saag, Michael S. Thomas, David L. Aronsohn, Andrew I. Charlton, Michael R. Feld, Jordan J. Fontana, Robert J. Ghany, Marc G. Godofsky, Eliot W. Graham, Camilla S. Kim, Arthur Y. Kiser, Jennifer J. Kottilil, Shyam Marks, Kristen M. Martin, Paul Mitruka, Kiren Morgan, Timothy R. Naggie, Susanna Raymond, Daniel Reau, Nancy S. Schooley, Robert T. Sherman, Kenneth E. Sulkowski, Mark S. Vargas, Hugo E. Ward, John W. Wyles, David L. CA AASLD IDSA HCV Guidance Panel TI Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus SO HEPATOLOGY LA English DT Article ID SUSTAINED VIROLOGICAL RESPONSE; SOFOSBUVIR PLUS RIBAVIRIN; GENOTYPE 1 INFECTION; TREATMENT-EXPERIENCED PATIENTS; ALL-CAUSE MORTALITY; LIVER FIBROSIS; ANTIVIRAL THERAPY; UNITED-STATES; NATURAL-HISTORY; TREATMENT-NAIVE C1 [Chung, Raymond T.] Massachusetts Gen Hosp, Hepatol, Boston, MA 02114 USA. [Chung, Raymond T.] Massachusetts Gen Hosp, Gastroenterol, Boston, MA 02114 USA. [Davis, Gary L.] Baylor Univ, Med Ctr, Hepatol, Dallas, TX USA. [Davis, Gary L.] Baylor Univ, Med Ctr, Liver Transplantat, Dallas, TX USA. [Jensen, Donald M.; Reau, Nancy S.] Univ Chicago, Med Ctr, Med, Chicago, IL 60637 USA. [Masur, Henry] NIH, Dept Crit Care Med, Med, Bethesda, MD 20892 USA. [Saag, Michael S.] Univ Alabama Birmingham, Sch Med, Med, Birmingham, AL USA. [Saag, Michael S.] Univ Alabama Birmingham, Sch Med, Global Hlth, Birmingham, AL USA. [Thomas, David L.; Sulkowski, Mark S.] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD USA. [Thomas, David L.] Johns Hopkins Univ, Sch Med, Infect Dis, Baltimore, MD USA. [Aronsohn, Andrew I.] Univ Chicago, Med Ctr, Med, Chicago, IL 60637 USA. [Charlton, Michael R.] Intermt Med Ctr, Hepatol, Murray, KY USA. [Charlton, Michael R.] Intermt Med Ctr, Liver Transplantat, Murray, KY USA. [Feld, Jordan J.] Toronto Western Hosp, Ctr Liver, Med, Toronto, ON M5T 2S8, Canada. [Feld, Jordan J.] Toronto Western Hosp, Ctr Liver, Med, Gastroenterol, Toronto, ON M5T 2S8, Canada. [Fontana, Robert J.] Univ Michigan, Sch Med, Med, Ann Arbor, MI USA. [Fontana, Robert J.] Univ Michigan, Sch Med, Liver Transplantat, Ann Arbor, MI USA. [Ghany, Marc G.] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Godofsky, Eliot W.] Bach & Godofsky, Infect Dis, Bradenton, FL USA. [Graham, Camilla S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Med, Boston, MA 02215 USA. [Kim, Arthur Y.] Harvard Univ, Sch Med, Med, Boston, MA USA. [Kim, Arthur Y.] Massachusetts Gen Hosp, ID Div, Viral Hepatitis Clin, Boston, MA 02114 USA. [Kiser, Jennifer J.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Pharmacol, Aurora, CO USA. [Kiser, Jennifer J.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Ctr Translat Pharmacokinet & Pharmacogen, Aurora, CO USA. [Kottilil, Shyam] Univ Maryland, Inst Human Virol, Med, Baltimore, MD 21201 USA. [Kottilil, Shyam] Univ Maryland, Inst Human Virol, Div Clin Care & Res, Baltimore, MD 21201 USA. [Marks, Kristen M.] Weill Cornell Med Coll, Med, New York, NY USA. [Martin, Paul] Univ Miami, Sch Med, Med, Miami, FL USA. [Martin, Paul] Univ Miami, Sch Med, Div Hepatol, Miami, FL USA. [Mitruka, Kiren; Ward, John W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Morgan, Timothy R.] Vet Affairs Long Beach Healthcare Syst, Hepatol, Long Beach, CA USA. [Naggie, Susanna] Duke Univ, Sch Med, Durham, NC USA. [Naggie, Susanna] Duke Clin Res Inst, Infect Dis Res, Durham, NC USA. [Raymond, Daniel] Community Representat, Harm Reduct Coalit, New York, NY USA. [Schooley, Robert T.] Univ Calif San Diego, Med, La Jolla, CA 92093 USA. [Schooley, Robert T.] Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA. [Sherman, Kenneth E.] Univ Cincinnati, Coll Med, Med, Cincinnati, OH USA. [Sherman, Kenneth E.] Univ Cincinnati, Div Digest Dis, Coll Med, Cincinnati, OH USA. [Sulkowski, Mark S.] Johns Hopkins Univ, Sch Med, Viral Hepatitis Ctr, Baltimore, MD USA. [Vargas, Hugo E.] Mayo Clin, Coll Med, Med, Phoenix, AZ USA. [Wyles, David L.] Univ Calif San Diego, Med, La Jolla, CA 92093 USA. RP Davis, GL (reprint author), 201 S Ocean Grande Dr,PH4, Ponte Vedra Beach, FL 32082 USA. EM rtchung@partners.org; davisgl@sbcglobal.net NR 127 TC 169 Z9 171 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD SEP PY 2015 VL 62 IS 3 BP 932 EP 954 DI 10.1002/hep.27950 PG 23 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CQ1RB UT WOS:000360375100028 ER PT J AU Novak, RM Hart, RLD Chmiel, JS Brooks, JT Buchacz, K AF Novak, Richard M. Hart, Rachel L. D. Chmiel, Joan S. Brooks, John T. Buchacz, Kate CA HIV Outpatient Study HOPS TI Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article ID UNITED-STATES; HEALTH DISPARITIES; RACIAL DISPARITIES; INFECTED PATIENTS; CARE PROVIDERS; ADHERENCE; DIAGNOSIS; THERAPY; TRUST; PREVENTION AB Objectives: The National HIV/AIDS Strategy emphasizes virologic suppression (VS) to reduce HIV incidence in the United States. We assessed temporal trends of and disparities in time to combination antiretroviral therapy (cART) initiation and HIV VS in a large demographically diverse cohort of HIV-infected patients. Design: We included antiretroviral-naive HIV Outpatient Study participants from 2000 to 2013 enrolled within 6 months of their HIV diagnosis who attended >= 2 HIV care-related visits. Methods: We evaluated time from HIV diagnosis to first use of cART, time from HIV diagnosis to VS, and time from first use of cART to VS. Kaplan-Meier time-to-event curves and Cox proportional hazards models were used to assess temporal trends and correlates of initiating cART and achieving HIV VS (<500 copies per milliliter). Results: Among 1156 HIV Outpatient Study patients [median age, 37 years; 43.2% non-Hispanic/Latino black (NHB), 14.1% Hispanic/Latino], estimated median times from HIV diagnosis to cART initiation and from HIV diagnosis to VS both shortened by >40% during the 13.5-year study period, reaching, respectively, 2.5 and 5.4 months. In multivariable analyses, NHB patients (as compared with non-Hispanic/Latino white) and those who had injected drugs (as compared with those who did not) initiated cART in a less timely fashion. After adjusting for CD4(+) cell count and viral load at cART initiation, NHB patients and those aged <30 years (compared with >= 40 years) had lower rates of VS. Conclusions: Despite improvements in HIV treatment over time, patients who were NHB, younger, or used injection drugs had less favorable outcomes. C1 [Novak, Richard M.] Univ Illinois, Dept Med, Div Infect Dis, Chicago, IL 60612 USA. [Hart, Rachel L. D.] Cerner Corp, Vienna, VA USA. [Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Brooks, John T.; Buchacz, Kate] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Novak, RM (reprint author), Univ Illinois, 808 South Wood St,Room 888,M-C 735, Chicago, IL 60612 USA. EM rmnovak@uic.edu FU Centers for Disease Control and Prevention [200-2001-00,133, 200-2006-18,797, 200-2011-41,872]; Merck; GSK; Bavarian-Nordique FX Supported by Centers for Disease Control and Prevention (contract nos. 200-2001-00,133, 200-2006-18,797, and 200-2011-41,872).; R.M.N. receives grant support from Merck, GSK, and Bavarian-Nordique, none of which are related to this work. The remaining authors have no conflicts of interest to disclose. NR 42 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2015 VL 70 IS 1 BP 23 EP 32 DI 10.1097/QAI.0000000000000652 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CQ1HM UT WOS:000360347900004 PM 25886926 ER PT J AU Ivy, W Nesheim, SR Paul, SM Ibrahim, AR Chan, M Niu, XL Lampe, MA AF Ivy, Wade, III Nesheim, Steve R. Paul, Sindy M. Ibrahim, Abdel R. Chan, Miranda Niu, Xiaoling Lampe, Margaret A. TI Cancer Among Children With Perinatal Exposure to HIV and Antiretroviral Medications-New Jersey, 1995-2010 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article ID VIRUS-UNINFECTED INFANTS; INFECTED WOMEN; MITOCHONDRIAL DYSFUNCTION; HIV-1-INFECTED MOTHERS; CELL COUNTS; TRANSMISSION; ZIDOVUDINE; BORN; THERAPY; COHORT AB Background: Concerns remain regarding the cancer risk associated with perinatal antiretroviral (ARV) exposure among infants. No excessive cancer risk has been found in short-term studies. Methods: Children born to HIV-infected women (HIV-exposed) in New Jersey from 1995 to 2008 were identified through the Enhanced HIV/AIDS Reporting System and cross-referenced with data from the New Jersey State Cancer Registry to identify new cases of cancer among children who were perinatally exposed to ARV. Matching of individuals in the Enhanced HIV/AIDS Reporting System to the New Jersey State Cancer Registry was conducted based on name, birth date, Social Security number, residential address, and sex using AutoMatch. Age- and sex-standardized incidence ratio (SIR) and exact 95% confidence intervals (CIs) were calculated using New Jersey (1979-2005) and US (1999-2009) cancer rates. Results: Among 3087 children (29,099 person-years; median follow-up: 9.8 years), 4 were diagnosed with cancer. Cancer incidence among HIV-exposed children who were not exposed to ARV prophylaxis (22.5 per 100,000 person-years) did not differ significantly from the incidence among children who were exposed to any perinatal ARV prophylaxis (14.3 per 100,000 person-years). Furthermore, the number of cases observed among individuals exposed to ARV did not differ significantly from cases expected based on state (SIR = 1.21; 95% CI: 0.25 to 3.54) and national (SIR = 1.27; 95% CI: 0.26 to 3.70) reference rates. Conclusions: Our findings are reassuring that current use of ARV for perinatal HIV prophylaxis does not increase cancer risk. We found no evidence to alter the current federal guidelines of 2014 that recommend ARV prophylaxis of HIV-exposed infants. C1 [Ivy, Wade, III; Nesheim, Steve R.; Lampe, Margaret A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Paul, Sindy M.; Ibrahim, Abdel R.] New Jersey Dept Hlth, Div HIV AIDS Serv, Trenton, NJ USA. [Chan, Miranda] New Jersey Dept Hlth, Communicable Dis Serv, Trenton, NJ USA. [Niu, Xiaoling] New Jersey Dept Hlth, Canc Epidemiol Serv, Trenton, NJ USA. RP Ivy, W (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-46, Atlanta, GA 30333 USA. EM ibw4@cdc.gov FU Centers for Disease Control and Prevention; New Jersey Department of Health FX Supported by the Centers for Disease Control and Prevention and the New Jersey Department of Health. NR 33 TC 3 Z9 3 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2015 VL 70 IS 1 BP 62 EP 66 DI 10.1097/QAI.0000000000000695 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CQ1HM UT WOS:000360347900008 PM 26017660 ER PT J AU Schuster, JE Miller, JO Selvarangan, R Weddle, G Thompson, MT Hassan, F Rogers, SL Oberste, MS Nix, WA Jackson, MA AF Schuster, Jennifer E. Miller, Jenna O. Selvarangan, Rangaraj Weddle, Gina Thompson, Marita T. Hassan, Ferdaus Rogers, Shannon L. Oberste, M. Steven Nix, W. Allan Jackson, Mary Anne TI Severe enterovirus 68 respiratory illness in children requiring intensive care management SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Acute respiratory tract infection; Asthma; Enterovirus; EV-D68; Intensive care unit; Respiratory virus ID PEDIATRIC-PATIENTS; TRACT INFECTIONS; YOUNG-CHILDREN; INFLUENZA-A; ASTHMA; VIRUSES; D68; PARALYSIS; EMERGENCE; SPECIMENS AB Background: Enterovirus 68 (EV-D68) causes acute respiratory tract illness in epidemic cycles, most recently in Fall 2014, but clinical characteristics of severe disease are not well reported. Objectives: Children with EV-D68 severe respiratory disease requiring pediatric intensive care unit (PICU) management were compared with children with severe respiratory disease from other enteroviruses/rhinoviruses. Study design: A retrospective review was performed of all children admitted to Children's Mercy Hospital PICU from August 1-September 15, 2014 with positive PCR testing for enterovirus/rhinovirus. Specimens were subsequently tested for the presence of EV-D68. We evaluated baseline characteristics, symptomatology, lab values, therapeutics, and outcomes of children with EV-D68 viral infection compared with enterovirus/rhinovirus-positive, EV-D68-negative children. Results: A total of 86 children with positive enterovirus/rhinovirus testing associated with respiratory symptoms were admitted to the PICU. Children with EV-D68 were older than their EV-D68-negative counterparts (7.1 vs. 3.5 years, P = 0.01). They were more likely to have a history of asthma or recurrent wheeze (68% vs. 42%, P = 0.03) and to present with cough (90% vs. 63%, P = 0.009). EV-D68 children were significantly more likely to receive albuterol (95% vs. 79%, P = 0.04), magnesium (75% vs. 42%, P = 0.004), and aminophylline (25% vs. 4%, P = 0.03). Other adjunctive medications used in EV-D68 children included corticosteroids, epinephrine, and heliox; 44% of EV-D68-positive children required non-invasive ventilatory support. Conclusions: EV-D68 causes severe disease in the pediatric population, particularly in children with asthma and recurrent wheeze; children may require multiple adjunctive respiratory therapies. (C) 2015 Elsevier B.V. All rights reserved. C1 [Schuster, Jennifer E.; Weddle, Gina; Jackson, Mary Anne] Childrens Mercy Hosp, Div Infect Dis, Kansas City, MO 64108 USA. [Miller, Jenna O.; Thompson, Marita T.] Childrens Mercy Hosp, Div Crit Care, Kansas City, MO 64108 USA. [Selvarangan, Rangaraj; Hassan, Ferdaus] Childrens Mercy Hosp, Div Pathol & Lab Med, Kansas City, MO 64108 USA. [Rogers, Shannon L.; Oberste, M. Steven; Nix, W. Allan] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Schuster, JE (reprint author), Childrens Mercy Hosp, 2401 Gillham Rd, Kansas City, MO 64108 USA. EM jeschuster@cmh.edu NR 42 TC 17 Z9 17 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2015 VL 70 BP 77 EP 82 DI 10.1016/j.jcv.2015.07.298 PG 6 WC Virology SC Virology GA CP7NO UT WOS:000360075100016 PM 26305825 ER PT J AU Masciotra, S Price, KA Sprinkle, P Wesolowski, L Owen, SM AF Masciotra, Silvina Price, Krystin A. Sprinkle, Patrick Wesolowski, Laura Owen, S. Michele TI Performance evaluation of the CHEMBIO DPP (R) (dual path platform) HIV-1/2 assay in early and established infections SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV-1/2; Diagnostics; Rapid test; DPP ID HIV; DIAGNOSIS; ALGORITHMS; TESTS AB Background: The availability of more accurate point-of-care technology could increase the number of persons aware of their HIV status. The DPP (R) HIV-1/2 assay is the first dual path platform rapid test (RT) approved in the U.S. that also received the Clinical Laboratory Improvement Amendments (CLIA) waiver for use with oral fluid and fingerstick and venous whole blood. Objective: To evaluate the performance of the DPP (R) HIV-1/2 assay with plasma specimens. Study design: Sensitivity and specificity of the assay were calculated from 696 HIV-1 groups M (B and non-B subtypes) and O and HIV-2 (groups A and B) specimens and 505 HIV-negative specimens, respectively. Analysis of the assay performance in HIV-1 early infections was assessed by estimating the relative sensitivity of the RT before the Western blot (WB) becomes positive using a 50% cumulative frequency analysis and by comparing the reactivity with other Food and Drug Administration (FDA)-approved RTs. Results: The sensitivity for established infection was 100% for HIV-1 and 100% for HIV-2. The specificity was 100%. The DPP (R) HIV-1/2 assay performs similarly to most antibody-based RT approved by FDA in early HIV-1 infections. Conclusions: The DPP (R) technology showed no significant improvement for detecting early infections over other lateral-flow RTs used in the U.S. Without more data on the DPP (R) HIV-1/2 assay, especially from whole blood and oral fluid specimens collected during the early phase of infection, its performance as point-of-care technology remains to be assessed. Published by Elsevier B.V. C1 [Masciotra, Silvina; Price, Krystin A.; Sprinkle, Patrick; Wesolowski, Laura; Owen, S. Michele] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP Masciotra, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd Mailstop A25, Atlanta, GA 30329 USA. EM svm6@cdc.gov NR 14 TC 1 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2015 VL 70 BP 97 EP 100 DI 10.1016/j.jcv.2015.07.005 PG 4 WC Virology SC Virology GA CP7NO UT WOS:000360075100020 PM 26305829 ER PT J AU Zhang, Y Coca, A Casa, DJ Antonio, J Green, JM Bishop, PA AF Zhang, Yang Coca, Aitor Casa, Douglas J. Antonio, Jose Green, James M. Bishop, Phillip A. TI Caffeine and diuresis during rest and exercise: A meta-analysis SO JOURNAL OF SCIENCE AND MEDICINE IN SPORT LA English DT Review DE Methylxanthine; Coffee; Diuretic; Fluid balance; Dehydration ID FLUID-ELECTROLYTE BALANCE; DIETARY CAFFEINE; PROLONGED EXERCISE; URINARY-EXCRETION; HYDRATION STATUS; HEAT TOLERANCE; REHYDRATION; SPORTS; SODIUM; WATER AB Objectives: Although ergogenic, acute caffeine ingestion may increase urine volume, prompting concerns about fluid balance during exercise and sport events. This meta-analysis evaluated caffeine induced diuresis in adults during rest and exercise. Design: Meta-analysis. Methods: A search of three databases was completed on November 1, 2013. Only studies that involved healthy adults and provided sufficient information concerning the effect size (ES) of caffeine ingestion on urine volume were included. Sixteen studies met the inclusion criteria, providing a total of 28 ESs for the meta-analysis. Heterogeneity was assessed using a random-effects model. Results: The median caffeine dosage was 300 mg. The overall ES of 0.29 (95% confidence interval (CI) = 0.11-0.48, p = 0.001) corresponds to an increase in urine volume of 109 +/- 195 mL or 16.0 +/- 19.2% for caffeine ingestion vs. non-caffeine conditions. Subgroup meta-analysis confirmed exercise as a strong moderator: active ES = 0.10, 95% CI = -0.07 to 0.27, p=0.248 vs. resting ES = 0.54, 95% CI = 0.22-0.85, p=0.001 (Cochran's Q, p = 0.019). Females (ES = 0.75, 95% CI=0.38-1.13, p<0.001) were more susceptible to diuretic effects than males (ES = 0.13, 95% CI = -0.05 to 0.31, p = 0.158) (Cochran's Q, p = 0.003). Conclusions: Caffeine exerted a minor diuretic effect which was negated by exercise. Concerns regarding unwanted fluid loss associated with caffeine consumption are unwarranted particularly when ingestion precedes exercise. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved. C1 [Zhang, Yang] Chinese Badminton Assoc, Zhejiang Jiaxing Branch, Beijing, Peoples R China. [Coca, Aitor] Ctr Dis Control & Prevent, Natl Personal Protect Technol Lab, Natl Inst Occupat Safety & Hlth, Atlanta, GA USA. [Casa, Douglas J.] Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, Storrs, CT USA. [Antonio, Jose] Nova SE Univ, Farquhar Coll Arts & Sci Exercise & Sports Sci, Ft Lauderdale, FL 33314 USA. [Green, James M.] Univ North Alabama, Dept Hlth Phys Educ & Recreat, Florence, AL USA. [Bishop, Phillip A.] Univ Alabama, Dept Kinesiol, Tuscaloosa, AL 35487 USA. RP Zhang, Y (reprint author), Chinese Badminton Assoc, Zhejiang Jiaxing Branch, Beijing, Peoples R China. EM dr.zhang.yang@qq.com FU Intramural CDC HHS [CC999999] NR 47 TC 2 Z9 2 U1 7 U2 46 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1440-2440 EI 1878-1861 J9 J SCI MED SPORT JI J. Sci. Med. Sport PD SEP PY 2015 VL 18 IS 5 BP 569 EP 574 DI 10.1016/j.jsams.2014.07.017 PG 6 WC Sport Sciences SC Sport Sciences GA CP9AM UT WOS:000360186100014 PM 25154702 ER PT J AU Mercado, CI Yang, QH Ford, ES Gregg, E Valderrama, AL AF Mercado, Carla I. Yang, Quanhe Ford, Earl S. Gregg, Edward Valderrama, Amy L. TI Gender- and race-specific metabolic score and cardiovascular disease mortality in adults: A structural equation modeling approachUnited States, 1988-2006 SO OBESITY LA English DT Article ID ALL-CAUSE MORTALITY; CONFIRMATORY FACTOR-ANALYSIS; CORONARY-HEART-DISEASE; 13-YEAR FOLLOW-UP; BLOOD-PRESSURE; RACIAL/ETHNIC DIFFERENCES; RISK; METAANALYSIS; ASSOCIATION; EVENTS AB ObjectiveConsider all metabolic syndrome (MetS) components [systolic (SBP) and diastolic (DBP) blood pressures, waist circumference, HDL cholesterol, triglycerides (TG), and fasting glucose] and gender/race differential risk when assessing cardiovascular disease (CVD) risk. MethodsWe estimated a gender- and race-specific continuous MetS score using structural equation modeling and tested its association with CVD mortality using data from National Health and Nutrition Examination Survey III linked with the National Death Index. Cox proportional hazard regression tested the association adjusted for sociodemographic and behavior characteristics. ResultsFor men, continuous MetS components associated with CVD mortality were SBP (hazard ratio=1.50, 95% confidence interval=1.14-1.96), DBP (1.48, 1.16-1.90), and TG (1.15, 1.12-1.16). In women, SBP (1.44, 1.27-1.63) and DBP (1.24, 1.02-1.51) were associated with CVD mortality. MetS score was not significantly associated with CVD mortality in men; but significant associations were found for all women (1.34, 1.06-1.68), non-Hispanic white women (1.29, 1.01-1.64), non-Hispanic black women (2.03, 1.12-3.69), and Mexican-American women (3.57, 2.21-5.76). Goodness-of-fit and concordance were overall better for models with the MetS score than MetS (yes/no). ConclusionsWhen assessing CVD mortality risk, MetS score provided additional information than MetS (yes/no). C1 [Mercado, Carla I.; Yang, Quanhe] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30329 USA. [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Gregg, Edward] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Valderrama, Amy L.] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. RP Mercado, CI (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30329 USA. EM cmercado@cdc.gov FU Intramural CDC HHS [CC999999] NR 40 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD SEP PY 2015 VL 23 IS 9 BP 1911 EP 1919 DI 10.1002/oby.21171 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CQ1VK UT WOS:000360388100026 PM 26308480 ER PT J AU Bruden, DJT Singleton, R Hawk, CS Bulkow, LR Bentley, S Anderson, LJ Herrmann, L Chikoyak, L Hennessy, TW AF Bruden, Dana J. T. Singleton, Rosalyn Hawk, Carolyn S. Bulkow, Lisa R. Bentley, Stephen Anderson, Larry J. Herrmann, Leslie Chikoyak, Lori Hennessy, Thomas W. TI Eighteen Years of Respiratory Syncytial Virus Surveillance Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article ID TRACT INFECTIONS; RISK-FACTORS; UNITED-STATES; PALIVIZUMAB PROPHYLAXIS; SYSTEMATIC ANALYSIS; YOUNG-CHILDREN; RURAL ALASKA; INFANTS; DISEASE; CLIMATE AB Background: Alaska Native infants from the Yukon-Kuskokwim Delta (YKD) experienced respiratory syncytial virus (RSV) hospitalization rates 5 times higher and an RSV season twice as long as the general US infant population. We describe trends in hospitalization rates and seasonality during 18 years of continuous RSV surveillance in this population and explore contributions of climate and sociodemographic factors. Methods: We abstracted clinical and RSV test information from computerized medical records at YKD Regional Hospital and Alaska Native Medical Center from 1994 to 2012 to determine hospitalization rates and RSV season timing. Descriptive village and weather data were acquired through the US Census and Alaska Climate Research Center, University of Alaska, Fairbanks, respectively. Results: During 1994-2012, YKD infant RSV hospitalization rates declined nearly 3-fold, from 177 to 65 per 1000 infants/yr. RSV season onset shifted later, from mid October to late December, contributing to a significantly decreased season duration, from 30 to 11 weeks. In a multivariate analysis, children from villages with more crowded households and lacking plumbed water had higher rates of RSV hospitalizations (relative rate, 1.17; P = 0.0005 and relative rate, 1.45; P = 0.0003). No association of temperature or dew point was found with the timing or severity of RSV season. Conclusions: Although the RSV hospitalization rate decreased 3-fold, YKD infants still experience a hospitalization rate 3-fold higher than the general US infant population. Overcrowding and lack of plumbed water were associated with RSV hospitalization. Dramatic changes occurred in RSV seasonality, not explained by changes in climate. C1 [Bruden, Dana J. T.; Singleton, Rosalyn; Bulkow, Lisa R.; Bentley, Stephen; Hennessy, Thomas W.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, NCEZID, Anchorage, AK USA. [Singleton, Rosalyn] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Anchorage, AK USA. [Hawk, Carolyn S.] Univ Washington, Sch Med, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Anderson, Larry J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Herrmann, Leslie; Chikoyak, Lori] Yukon Kuskokwim Hlth Corp, Dept Pediat, Bethel, AK USA. RP Singleton, R (reprint author), Arctic Invest Program CDC, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM Ris2@cdc.gov NR 43 TC 3 Z9 3 U1 4 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD SEP PY 2015 VL 34 IS 9 BP 945 EP 950 DI 10.1097/INF.0000000000000772 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CQ1ZH UT WOS:000360398600007 PM 26065863 ER PT J AU Gastanaduy, PA Vicuna, Y Salazar, F Broncano, N Gregoricus, N Vinje, J Chico, M Parashar, UD Cooper, PJ Lopman, B AF Gastanaduy, Paul A. Vicuna, Yosselin Salazar, Fabian Broncano, Nely Gregoricus, Nicole Vinje, Jan Chico, Martha Parashar, Umesh D. Cooper, Philip J. Lopman, Ben TI Transmission of Norovirus Within Households in Quininde, Ecuador SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article ID NORWALK VIRUS; RISK-FACTORS; GASTROENTERITIS AB We studied the transmission of norovirus infection in households in Quininde, Ecuador. Among household contacts of norovirus positive children with diarrhea, norovirus negative children with diarrhea and asymptomatic controls, infection attack rates were 33%, 8% and 18%, respectively (N = 45, 36, 83). Infection attack rates were higher when index children had a higher viral load. C1 [Gastanaduy, Paul A.; Gregoricus, Nicole; Vinje, Jan; Parashar, Umesh D.; Lopman, Ben] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Vicuna, Yosselin; Cooper, Philip J.] Fdn Ecuatoriana Invest Salud, Quininde, Esmeraldas Prov, Ecuador. [Vicuna, Yosselin; Salazar, Fabian; Broncano, Nely; Chico, Martha; Cooper, Philip J.] Pontificia Univ Catolica Ecuador, Ctr Invest Enfermedades Infecciosas, Quito, Ecuador. [Cooper, Philip J.] St Georges Univ London, Inst Infect & Immun, London, England. RP Gastanaduy, PA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-34, Atlanta, GA 30333 USA. EM pgastanaduy@cdc.gov FU Wellcome Trust [088862/Z/09/Z]; Centers for Disease Control and Prevention FX Supported by the Wellcome Trust (Grant 088862/Z/09/Z) and the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 13 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD SEP PY 2015 VL 34 IS 9 BP 1031 EP 1033 DI 10.1097/INF.0000000000000783 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CQ1ZH UT WOS:000360398600026 PM 26090575 ER PT J AU Leshem, E Givon-Lavi, N Vinje, J Gregoricus, N Parashar, U Dagan, R AF Leshem, Eyal Givon-Lavi, Noga Vinje, Jan Gregoricus, Nicole Parashar, Umesh Dagan, Ron TI Differences in Norovirus-Associated Hospital Visits Between Jewish and Bedouin Children in Southern Israel SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article ID GASTROENTERITIS; INFECTIONS; DIARRHEA AB Population-based surveillance during 2006-2013 showed that norovirus hospitalization rates among Bedouin (low-middle income settings) children < 5 years old were 13.9/10,000 person-years compared with 7.1/10,000 among Jewish (high-income settings) children who were < 5 years (rate ratio: 2.0, 95% confidence interval: 1.6-2.3). Differences were most prominent among infants (59.7 vs. 19.7/10,000, respectively; rate ratio: 3.0, 95% confidence interval: 2.5-3.8). GII.3 and GII.4 strains dominated (67%) in both populations. C1 [Leshem, Eyal; Vinje, Jan; Gregoricus, Nicole; Parashar, Umesh] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Givon-Lavi, Noga; Dagan, Ron] Ben Gurion Univ Negev, Fac Hlth Sci, Pediat Infect Dis Unit, Beer Sheva, Israel. [Givon-Lavi, Noga; Dagan, Ron] Soroka Univ, Med Ctr, IL-84101 Beer Sheva, Israel. RP Dagan, R (reprint author), Soroka Univ, Med Ctr, Pediat Infect Dis Unit, POB 151, IL-84101 Beer Sheva, Israel. EM rdagan@bgu.ac.il OI Leshem, Eyal/0000-0003-1267-6131 NR 9 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD SEP PY 2015 VL 34 IS 9 BP 1036 EP 1038 DI 10.1097/INF.0000000000000786 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CQ1ZH UT WOS:000360398600029 PM 26107344 ER PT J AU Feinman, SJ Ryan, PB Toth, B Honey, WA Gargano, JW AF Feinman, Shawna J. Ryan, P. Barry Toth, Barbara Honey, Wayne A. Gargano, Julia W. TI Primary Drinking Water Source and Acute Gastrointestinal Illness: New Mexico, 2007 SO WATER QUALITY EXPOSURE AND HEALTH LA English DT Article DE Groundwater; Drinking water; Behavioral surveillance; Acute gastrointestinal illness; Surveys ID UNITED-STATES; COMMUNITY OUTBREAK; BRITISH-COLUMBIA; DISEASE; GROUNDWATER; SYSTEM; CANADA; WELLS; CONTAMINATION; SURVEILLANCE AB The objectives of this study are to characterize New Mexico residents' primary drinking water sources, consumption, and filter use by demographic characteristics, and to compare the 30-day prevalence of self-reported acute gastrointestinal illness (AGI) by water sources. We analyzed data on 6,600 adults surveyed in the 2007 New Mexico Behavioral Risk Factor Surveillance System. We estimated population frequencies and evaluated associations using chi-square tests and weighted multivariable logistic regression modeling. Over half (55 %) of individuals used public water as their primary drinking water source, 18 % used private wells, and 27 % used bottled water. Overall, 43 % of residents said they filtered their home tap water, which did not differ significantly by source. Compared to public water users, private well users had key demographic differences, including age, marital status, race, and education. The overall 30-day prevalence of AGI was 15 %. In models adjusted for demographic characteristics and health status indicators, individuals using well water had a non-significantly decreased odds of reporting AGI and seeking medical attention for AGI (odds ratio (OR) 0.83, 95 % CI 0.65-1.06 and OR 0.85, 95 % CI 0.41-1.80). This baseline measure suggests private well users are not uniformly distributed throughout the New Mexico population. This information is useful when planning educational outreach to targeted populations. Our cross-sectional analyses did not reveal significant associations between primary drinking water source and AGI. Future epidemiologic studies including children and measuring the duration of exposure and water quality are needed to fully understand the health impacts of drinking untreated or undertreated water. C1 [Feinman, Shawna J.; Ryan, P. Barry] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Feinman, Shawna J.; Gargano, Julia W.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA 30329 USA. [Toth, Barbara; Honey, Wayne A.] New Mexico Dept Hlth, Epidemiol Response Div, Santa Fe, NM USA. RP Gargano, JW (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, 1600 Clifton Rd NE,MS C 09, Atlanta, GA 30329 USA. EM igc5@cdc.gov FU Centers for Disease Control and Prevention (CDC) [5U38EH000949, 5U38EH00097]; New Mexico BRFSS "DrinkingWater Module" from CDC [CA 1U38EH000183] FX The authors would like to thank Dr. Gordana Derado for methodological input and constructive comments on an earlier draft of the manuscript. The authors would also like to thank Sarah Collier and Heidi Krapfl for constructive comments on manuscript drafts. This publication was supported in part by Cooperative Agreements (CA) 5U38EH000949 and 5U38EH00097 from the Centers for Disease Control and Prevention (CDC); the New Mexico BRFSS "DrinkingWater Module" was supported by CA 1U38EH000183 from CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The manuscript does not contain clinical studies or patient data. NR 36 TC 0 Z9 0 U1 1 U2 11 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1876-1658 EI 1876-1666 J9 WATER QUAL EXPOS HEA JI Water Qual. Expos. Health PD SEP PY 2015 VL 7 IS 3 BP 285 EP 294 DI 10.1007/s12403-014-0148-0 PG 10 WC Water Resources SC Water Resources GA CQ1WQ UT WOS:000360391300003 ER PT J AU Martin, DL Lowe, KR McNeill, T Thiele, EA Roellig, DM Zajdowicz, J Hunter, SA Brubaker, SA AF Martin, Diana L. Lowe, Kory R. McNeill, Tyana Thiele, Elizabeth A. Roellig, Dawn M. Zajdowicz, Jan Hunter, Shawn A. Brubaker, Scott A. TI Potential sexual transmission of Trypanosoma cruzi in mice SO ACTA TROPICA LA English DT Article DE Trypanosome cruzi; Chagas disease; Sexually transmitted infection ID CHAGAS-DISEASE; UNITED-STATES; BLOOD-DONORS; LOS-ANGELES; BONE-MARROW; TRANSPLANTATION; INFECTION; RISK AB Infection with the protozoan parasite Trypanosoma cruzi, the etiologic agent of human Chagas disease, results in life-long infection. Infective trypomastigotes circulate in the bloodstream and have the capacity to infect any cell type, including reproductive tissue. This study sought to assess the potential for sexual transmission of T. cruzi in an experimental mouse model. The conditions used in this study, in which acutely infected males and immunosuppressing the females, created a worst-case scenario allowing for the greatest chance of measuring transmission through intercourse. Male BALB/c mice were infected and mated with uninfected females, and the females were subsequently examined for T. cruzi tissue parasitism. A single transmission event of 61 total matings was observed, indicating a low but non-zero risk potential for male-to-female sexual transmission of T. cruzi. Published by Elsevier B.V. C1 [Martin, Diana L.; Thiele, Elizabeth A.; Roellig, Dawn M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lowe, Kory R.] Emory Univ, Atlanta, GA 30322 USA. [McNeill, Tyana] South Carolina State Univ, Orangeburg, SC USA. [Zajdowicz, Jan] AlloSource, Centennial, CO USA. [Hunter, Shawn A.] Community Tissue Serv, Kettering, OH USA. [Brubaker, Scott A.] Amer Assoc Tissue Banks, Mclean, VA USA. RP Martin, DL (reprint author), MS D-65,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM hzx3@cdc.gov RI Thiele, Elizabeth/F-2590-2016 OI Thiele, Elizabeth/0000-0001-9235-2019 FU Scientific and Technical Affairs Committee of the American Association of Tissue Banks FX This research was supported by a grant from the Scientific and Technical Affairs Committee of the American Association of Tissue Banks. The authors would like to thank Kelvin Brockbank, Russell Marians, Yvonne Qvarnstrom, and Ryan Wiegand, for helpful advice and critical reading of the manuscript. The conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 25 TC 1 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X EI 1873-6254 J9 ACTA TROP JI Acta Trop. PD SEP PY 2015 VL 149 BP 15 EP 18 DI 10.1016/j.actatropica.2015.05.002 PG 4 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA CP5XA UT WOS:000359957500003 PM 25982870 ER PT J AU Luo, HB Sotnikov, S Winterbauer, N AF Luo, Huabin Sotnikov, Sergey Winterbauer, Nancy TI Provision of Personal Healthcare Services by Local Health Departments 2008-2013 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SAFETY-NET PROVIDERS; PUBLIC-HEALTH; NATIONAL-SURVEY; PRIVATIZATION; DISCONTINUATION; MANAGERIAL; DIRECTORS; BELIEFS; IMPACT AB Introduction: The scope of local health department (LHD) involvement in providing personal healthcare services versus population-based services has been debated for decades. A 2012 IOM report suggests that LHDs should gradually withdraw from providing personal healthcare services. The purpose of this study is to assess the level of LHD involvement in provision of personal healthcare services during 2008-2013 and examine the association between provision of personal healthcare services and per capita public health expenditures. Methods: Data are from the 2013 survey of LHDs and Area Health Resource Files. The number, ratio, and share of revenue from personal healthcare services were estimated. Both linear and panel fixed effects models were used to examine the association between provision of personal healthcare services and per capita public health expenditures. Data were analyzed in 2014. Results: The mean number of personal healthcare services provided by LHDs did not change significantly in 2008-2013. Overall, personal services constituted 28% of total service items. The share of revenue from personal services increased from 16.8% in 2008 to 20.3% in 2013. Results from the fixed effect panel models show a positive association between personal healthcare services' share of revenue and per capita expenditures (b=0.57, p < 0.001). Conclusions: A lower share of revenue from personal healthcare services is associated with lower per capita expenditures. LHDs, especially those serving <25,000 people, are highly dependent on personal healthcare revenue to sustain per capita expenditures. LHDs may need to consider strategies to replace lost revenue from discontinuing provision of personal healthcare services. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Luo, Huabin; Winterbauer, Nancy] E Carolina Univ, Brody Sch Med, Dept Publ Hlth, Greenville, NC 27834 USA. [Sotnikov, Sergey] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. RP Luo, HB (reprint author), E Carolina Univ, Brody Sch Med, Dept Publ Hlth, Greenville, NC 27834 USA. EM luoh@ecu.edu FU Intramural CDC HHS [CC999999] NR 26 TC 4 Z9 4 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 380 EP 386 DI 10.1016/j.amepre.2015.01.025 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200006 PM 25997902 ER PT J AU Levy, B Paulozzi, L Mack, KA Jones, CM AF Levy, Benjamin Paulozzi, Leonard Mack, Karin A. Jones, Christopher M. TI Trends in Opioid Analgesic-Prescribing Rates by Specialty, US, 2007-2012 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CHRONIC NONCANCER PAIN; UNITED-STATES AB Introduction: Opioid analgesic prescriptions are driving trends in drug overdoses, but little is known about prescribing patterns among medical specialties. We conducted this study to examine the opioid-prescribing patterns of the medical specialties over time. Methods: IMS Health's National Prescription Audit (NPA) estimated the annual counts of pharmaceutical prescriptions dispensed in the U.S. during 2007-2012. We grouped NPA prescriber specialty data by practice type for ease of analysis, and measured the distribution of total prescriptions and opioid prescriptions by specialty. We calculated the percentage of all prescriptions dispensed that were opioids, and evaluated changes in that rate by specialty during 2007-2012. The analysis was conducted in 2013. Results: In 2012, U.S. pharmacies and long-term care facilities dispensed 4.2 billion prescriptions, 289 million (6.8%) of which were opioids. Primary care specialties accounted for nearly half of all dispensed opioid prescriptions. The rate of opioid prescribing was highest for specialists in pain medicine (48.6%); surgery (36.5%); and physical medicine/rehabilitation (35.5%). The rate of opioid prescribing rose during 2007-2010 but leveled thereafter as most specialties reduced opioid use. The greatest percentage increase in opioid-prescribing rates during 2007-2012 occurred among physical medicine/rehabilitation specialists (+12.0%). The largest percentage drops in opioid-prescribing rates occurred in emergency medicine (-8.9%) and dentistry (-5.7%). Conclusions: The data indicate diverging trends in opioid prescribing among medical specialties in the U.S. during 2007-2012. Engaging the medical specialties individually is critical for continued improvement in the safe and effective treatment of pain. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Levy, Benjamin; Paulozzi, Leonard] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Mack, Karin A.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Jones, Christopher M.] US FDA, Off Publ Hlth Strategy & Anal, Off Commissioner, Silver Spring, MD USA. RP Levy, B (reprint author), CDC, Div Unintent Injury Prevent, 4770 Buford Highway MS-F62, Chamblee, GA 30341 USA. EM xew6@cdc.gov FU CDC FX CDC funded this study and supported the staff responsible for the design and conduct of the study; the collection, analysis, and interpretation of the data; and the preparation, review, and approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the official position of CDC or the U.S. Food and Drug Administration. NR 9 TC 21 Z9 22 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 409 EP 413 DI 10.1016/j.amepre.2015.02.020 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200010 PM 25896191 ER PT J AU Yartel, AK Morgan, RL Rein, DB Brown, KA Kil, NB Massoud, OI Fallon, MB Smith, BD AF Yartel, Anthony K. Morgan, Rebecca L. Rein, David B. Brown, Kimberly Ann Kil, Natalie B. Massoud, Omar I. Fallon, Michael B. Smith, Bryce D. TI HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEPATOCELLULAR-CARCINOMA; LIVER-DISEASE; UNITED-STATES; COINFECTION; MANAGEMENT; PROGRESSION; DIAGNOSIS; HEALTH; COHORT; HCV AB Introduction: Receipt of hepatitis C virus (HCV) RNA testing following a positive HCV antibody (anti-HCV+) test result to establish current infection is a quality indicator for HCV-related care. This study examines HIV infection status as a predictor of HCV RNA test receipt after an anti-HCV+ result in the primary care setting. Methods: Electronic medical records of anti-HCV+ patients from a multisite retrospective study of patients aged >= 18 years who utilized one or more primary care outpatient services during 2005-2010 were analyzed in 2014. A multivariable logistic regression model examined the independent relationships between patient characteristics and receipt of HCV RNA testing. Results: Among 1,115 anti-HCV+ patients, 133 (11.9%) were also HIV-positive. Of these, 77.4% (n=103) underwent HCV RNA testing to determine current infection status. By contrast, 66.7% (n=654/980) of anti-HCV+ patients who were HIV-negative received HCV RNA testing. Following multivariable adjustment, the odds of receiving HCV RNA testing were higher among anti-HCV+ patients who were also HIV-positive (AOR=1.9, 95% CI=1.2, 3.0), compared with their HIV-negative counterparts. Elevated alanine aminotransferase level was also associated with receipt of HCV RNA testing (AOR=1.9, 95% CI=1.4, 2.4). Black race was associated with decreased odds of receiving HCV RNA testing (AOR=0.7, 95% CI=0.5, 1.0). Conclusions: HIV infection status is independently associated with the likelihood of receiving HCV RNA testing following an anti-HCV+ result. One quarter of anti-HCV+ patients who were also HIV-positive and one third of their HIV-negative counterparts, respectively, did not receive testing to establish active HCV infection, which is imperative for appropriate care and treatment. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Yartel, Anthony K.] CDC Fdn, Atlanta, GA USA. [Morgan, Rebecca L.; Smith, Bryce D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rein, David B.] Univ Chicago, Dept Publ Hlth, NORC, Atlanta, GA USA. [Brown, Kimberly Ann] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA. [Kil, Natalie B.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Massoud, Omar I.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Fallon, Michael B.] Univ Texas Med Sch Houston, Dept Internal Med, Houston, TX USA. RP Yartel, AK (reprint author), 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM jqi0@cdc.gov FU CDC; CDC Foundation; Gilead; Bristol-Myers Squibb; Merck; Janssen; Abbvie; Vertex; Hyperion; Ikaria; CLD Foundation; AST Board of Directors; Novartis; Roche; Simply Speaking; Peer to Peer; HCV Viewpoints; Medscape; Blue Cross Centers for Transplant; NIH; American Gastroenterological Association; American Association for the Study of Liver Diseases FX Support for this study was provided by CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC.; DBR reports receiving funds from CDC Foundation, CDC, and Gilead. KAB reports receiving funds from CDC Foundation, Bristol-Myers Squibb, Merck, Gilead, Janssen, Abbvie, Vertex, Hyperion, Ikaria, CLD Foundation, AST Board of Directors, Novartis, Roche, Simply Speaking, Peer to Peer, HCV Viewpoints, Medscape, and Blue Cross Centers for Transplant. NBK reports grants from CDC Foundation. OIM reports grants from CDC Foundation. MBF reports receiving funds from CDC Foundation, NIH, American Gastroenterological Association, and American Association for the Study of Liver Diseases. NR 36 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 423 EP 427 DI 10.1016/j.amepre.2015.03.003 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200013 PM 25896194 ER PT J AU Mercy, JA Tharp, AT AF Mercy, James A. Tharp, Andra Teten TI Adolescent Dating Violence in Context SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID POLICY C1 [Mercy, James A.; Tharp, Andra Teten] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Mercy, JA (reprint author), 4770 Buford Hwy NE,MS F-64, Atlanta, GA 30341 USA. EM jmercy@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 441 EP 444 DI 10.1016/j.amepre.2015.02.028 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200016 PM 26296441 ER PT J AU Rothman, EF Bair-Merritt, MH Tharp, AT AF Rothman, Emily F. Bair-Merritt, Megan H. Tharp, Andra Teten TI Beyond the Individual Level Novel Approaches and Considerations for Multilevel Adolescent Dating Violence Prevention SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID HIGH-SCHOOL-STUDENTS; PARTNER VIOLENCE; RISK BEHAVIOR; HEALTH; VICTIMIZATION; INTERVENTIONS; ASSOCIATIONS; EDUCATION; IMPACT; YOUTH C1 [Rothman, Emily F.] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Bair-Merritt, Megan H.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA. [Tharp, Andra Teten] CDC, Div Violence Prevent, Atlanta, GA 30333 USA. RP Rothman, EF (reprint author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Crosstown Ctr, 801 Massachusetts Ave,Floor 4, Boston, MA 02118 USA. EM erothman@bu.edu NR 23 TC 1 Z9 1 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 445 EP 447 DI 10.1016/j.amepre.2015.05.019 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200017 PM 26296442 ER PT J AU Gressard, LA Swahn, MH Tharp, AT AF Gressard, Lindsay A. Swahn, Monica H. Tharp, Andra Teten TI A First Look at Gender Inequality as a Societal Risk Factor for Dating Violence SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PROTECTIVE FACTORS; UNITED-STATES; BEHAVIOR SURVEILLANCE; PREVENTION PROGRAM; HEALTH OUTCOMES; PERPETRATION; VICTIMIZATION; YOUTH; ASSOCIATIONS; PREDICTORS AB Introduction: One of ten U.S. high school students is a victim of adolescent dating violerice (ADV). Understanding ADV risk factors guides prevention efforts; however, research examining community- and societal-level risk factors is scant. Societal gender inequality is a known risk factor for violence against women, but has yet to be explored in relation to ADV. This study aims to determine whether the Gender Inequality Index (GII) correlates with levels of physical and sexual ADV victimization across U.S. states. Methods: State-representative prevalence rates of self-reported physical and sexual ADV victimization were obtained from the 2013 Youth Risk Behavior Survey. The state GII includes five indicators: (1) maternal mortality; (2) adolescent birth rate; (3) government representation; (4) educational attainment; and (5) labor force participation. Pearson correlation coefficients determined the association between physical and sexual ADV victimization, the GII, and GII indicators. Analyses were conducted in August 2014. Results: Among U.S. states, the prevalence of physical ADV victimization in 2013 ranged from 7.0% to 14.8%, and the prevalence of sexual ADV victimization ranged from 7.8% to 13.8%. The GII was significantly associated with the state prevalence of female physical ADV victimization (r=0.48, p < 0.01) but not female sexual ADV victimization. Neither physical nor sexual male ADV victimization was associated with the GII. Conclusions: This exploratory study suggests that gender inequality may be a societal-level risk factor for female physical ADV victimization. As ADV prevention strategies are implemented at the state level, further research examining the effect of gender inequality on ADV is needed. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Gressard, Lindsay A.; Swahn, Monica H.] Georgia State Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Atlanta, GA 30303 USA. [Tharp, Andra Teten] CDC, Div Violence Prevent, Atlanta, GA 30333 USA. RP Gressard, LA (reprint author), 4770 Buford Hwy NE,MS-F76, Atlanta, GA 30341 USA. EM lagressard@gmail.com NR 41 TC 4 Z9 4 U1 5 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 448 EP 457 DI 10.1016/j.amepre.2015.05.017 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200018 PM 26296443 ER PT J AU Reyes, HLM Foshee, VA Tharp, AT Ennett, ST Bauer, DJ AF Reyes, H. Luz McNaughton Foshee, Vangie A. Tharp, Andra T. Ennett, Susan T. Bauer, Daniel J. TI Substance Use and Physical Dating Violence The Role of Contextual Moderators SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID INTIMATE PARTNER VIOLENCE; OF-THE-LITERATURE; ALCOHOL-USE; COLLEGE-STUDENTS; INTERPERSONAL VIOLENCE; TEMPORAL ASSOCIATION; MARIJUANA USE; USE DISORDERS; PERPETRATION; AGGRESSION AB Introduction: Theoretic models suggest that associations between substance use and dating violence perpetration may vary in different social contexts, but few studies have examined this proposition. The current study examined whether social control and violence in the neighborhood, peer, and family contexts moderate the associations between substance use (heavy alcohol use, marijuana, and hard drug use) and adolescent physical dating violence perpetration. Methods: Adolescents in the eighth, ninth, and tenth grades completed questionnaires in 2004 and again four more times until 2007 when they were in the tenth, 11th, and 12th grades. Multilevel analysis was used to examine interactions between each substance and measures of neighborhood, peer, and family social control and violence as within-person (time-varying) predictors of physical dating violence perpetration across eighth through 12th grade (N=2,455). Analyses were conducted in 2014. Results: Physical dating violence perpetration increased at time points when heavy alcohol and hard drug use were elevated; these associations were weaker when neighborhood social control was higher and stronger when family violence was higher. Also, the association between heavy alcohol use and physical dating violence perpetration was weaker when teens had more-prosocial peer networks and stronger when teens' peers reported more physical dating violence. Conclusions: Linkages between substance use and physical dating violence perpetration depend on substance use type and levels of contextual violence and social control. Prevention programs that address substance use related dating violence should consider the role of social contextual variables that may condition risk by influencing adolescents' aggression propensity. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Reyes, H. Luz McNaughton; Foshee, Vangie A.; Ennett, Susan T.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC 27599 USA. [Tharp, Andra T.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Bauer, Daniel J.] Univ N Carolina, Dept Psychol, LL Thurstone Psychometr Lab, Chapel Hill, NC 27599 USA. RP Reyes, HLM (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, 319E Rosenau Hall CB 7440, Chapel Hill, NC 27599 USA. EM mcnaught@email.unc FU National Institute on Drug Abuse [R01 DA13459, 1R03DA033420-01A1]; CDC [R49CCV423114, 13IPA130569, 13IPA1303570] FX This research was funded by the National Institute on Drug Abuse (R01 DA13459, S Ennett, principal investigator [PI]) and CDC (R49CCV423114, V Foshee, PI). Secondary data analysis and manuscript writing was supported by the National Institute on Drug Abuse (1R03DA033420-01A1, H Reyes, PI) and by an inter-agency personnel agreement (IPA) between Dr. Reyes and CDC (13IPA130569) and between Dr. Foshee and CDC (13IPA1303570). The conclusions in this article are those of the authors and do not necessarily represent the official position of CDC. NR 57 TC 2 Z9 2 U1 3 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 467 EP 475 DI 10.1016/j.amepre.2015.05.018 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200020 PM 26296445 ER PT J AU Latzman, NE Vivolo-Kantor, AM Niolon, PH Ghazarian, SR AF Latzman, Natasha E. Vivolo-Kantor, Alana M. Niolon, Phyllis Holditch Ghazarian, Sharon R. TI Predicting Adolescent Dating Violence Perpetration Role of Exposure to Intimate Partner Violence and Parenting Practices SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DOMESTIC VIOLENCE; ROMANTIC RELATIONSHIPS; PROTECTIVE FACTORS; INTERPARENTAL CONFLICT; CHILD MALTREATMENT; MARITAL CONFLICT; CONDUCT PROBLEMS; RISK-FACTORS; AGGRESSION; PREVENTION AB Introduction: Exposure to adult intimate partner violence (IPV) places youth at risk for a range of outcomes, including perpetration of adolescent dating violence (ADV). However, there is variability in the effect of IPV exposure, as many youth who are exposed to IPV do not go on to exhibit problems. Thus, research is needed to examine contextual factors, such as parenting practices, to more fully explain heterogeneity in outcomes and better predict ADV perpetration. The current research draws from a multisite study to investigate the predictive power of IPV exposure and parenting practices on subsequent ADV perpetration. Methods: Participants included 417 adolescents (48.7% female) drawn from middle schools in high-risk, urban communities. IPV exposure, two types of parenting practices (positive parenting/involvement and parental knowledge of their child's dating), and five types of ADV perpetration (threatening behaviors, verbal/emotional abuse, relational abuse, physical abuse, and sexual abuse) were assessed at baseline (2012) and approximately 5 months later (2013) via adolescent report. Analyses (conducted in 2015) used a structural equation modeling approach. Results: Structural models indicated that IPV exposure was positively related only to relational abuse at follow-up. Further, adolescents who reported parents having less knowledge of dating partners were more likely to report perpetrating two types of ADV (physical and verbal/emotional abuse) at follow-up. Analyses did not demonstrate any significant interaction effects. Conclusions: Results fill a critical gap in understanding of important targets to prevent ADV in middle school and highlight the important role that parents may play in ADV prevention. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Latzman, Natasha E.; Vivolo-Kantor, Alana M.; Niolon, Phyllis Holditch; Ghazarian, Sharon R.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Latzman, NE (reprint author), CDC, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS-F64, Atlanta, GA 30341 USA. EM nlatzman@cdc.gov FU Alameda County Public Health Department [CE002052]; Baltimore City Health Department [CE002050]; Broward County Health Department [CE002048]; Chicago Department of Public Health [CE002054] FX The authors acknowledge the participation of students and schools in the Dating Matters (R) initiative. We also would like to acknowledge the contribution of our CDC Dating Matters (R) team and of each funded public health department, specifically the Alameda County Public Health Department (CE002052), Baltimore City Health Department (CE002050), Broward County Health Department (CE002048), and Chicago Department of Public Health (CE002054). Lastly, we acknowledge our contractors who manage program implementation and data collection efforts: NORC at the University of Chicago (Co. #: 200-2011-40998), Research Triangle Institute (Co. #: 200-2012-51959), and Ogilvy Public Relations (Co. #: 200-2007-20014/0015). NR 65 TC 2 Z9 2 U1 6 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 476 EP 482 DI 10.1016/j.amepre.2015.06.006 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200021 PM 26296446 ER PT J AU Grossman, DC Elder, RW AF Grossman, David C. Elder, Randy W. TI Aligning the Work of Two US Task Forces on Behavioral Counseling Recommendations SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID COMMUNITY-PREVENTIVE-SERVICES; SYSTEMATIC REVIEWS; GUIDE; INTERVENTIONS; HEALTH; CARE; IMPROVE; STATES AB This paper highlights the collaboration and alignment between topics and recommendations related to behavioral counseling interventions from the U.S. Preventive Services Task Force (USPSTF) and Community Preventive Services Task Force (CPSTF). Although the scope and mandates of the USPSTF and CPSTF differ, there are many similarities in the methods and approaches used to select topics and make recommendations to their key stakeholders. Behavioral counseling recommendations represent an important domain for both Task Forces, given the importance of behavior change in promoting healthful lifestyles. This paper explores opportunities for greater alignment between the two Task Forces and compares and contrasts the groups and their current approaches to making recommendations that involve behavioral counseling interventions. Opportunities to enhance behavioral counseling preventive services through closer coordination when developing and disseminating recommendations as well as future collaboration between the USPSTF and CPSTF are discussed. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Grossman, David C.] Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA 98101 USA. [Elder, Randy W.] CDC, Community Guide Branch, Atlanta, GA 30333 USA. RP Grossman, DC (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM grossman.d@ghc.org FU Agency for Healthcare Research and Quality (AHRQ); AHRQ [HHSA290-2010-00004i, TO 4] FX Publication of this article was supported by the Agency for Healthcare Research and Quality (AHRQ).; Administrative and logistical support for this paper was provided by AHRQ through contract HHSA290-2010-00004i, TO 4. NR 21 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 SU 2 BP S174 EP S183 DI 10.1016/j.amepre.2015.06.003 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP4UM UT WOS:000359878100007 PM 26296552 ER PT J AU Hlavsa, MC Roberts, VA Kahler, AM Hilborn, ED Mecher, TR Beach, MJ Wade, TJ Yoder, JS AF Hlavsa, Michele C. Roberts, Virginia A. Kahler, Amy M. Hilborn, Elizabeth D. Mecher, Taryn R. Beach, Michael J. Wade, Timothy J. Yoder, Jonathan S. TI Outbreaks of Illness Associated with Recreational Water-United States, 2011-2012 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID CRYPTOSPORIDIOSIS C1 [Hlavsa, Michele C.; Roberts, Virginia A.; Kahler, Amy M.; Mecher, Taryn R.; Beach, Michael J.; Yoder, Jonathan S.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Mecher, Taryn R.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Hlavsa, MC (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM mhlavsa@cdc.gov NR 10 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD SEP PY 2015 VL 15 IS 9 BP 2517 EP 2521 DI 10.1111/ajt.13473 PG 5 WC Surgery; Transplantation SC Surgery; Transplantation GA CP7JD UT WOS:000360062300030 ER PT J AU Williams, AJK Lampasona, V Schlosser, M Mueller, PW Pittman, DL Winter, WE Akolkar, B Wyatt, R Brigatti, C Krause, S Achenbach, P AF Williams, Alistair J. K. Lampasona, Vito Schlosser, Michael Mueller, Patricia W. Pittman, David L. Winter, William E. Akolkar, Beena Wyatt, Rebecca Brigatti, Cristina Krause, Stephanie Achenbach, Peter CA Participating Labs TI Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes SO DIABETES LA English DT Article ID GLUTAMIC-ACID DECARBOXYLASE; STIFF-MAN SYNDROME; STANDARDIZATION PROGRAM; INSULIN AUTOANTIBODIES; PROFICIENCY EVALUATION; EPITOPE RECOGNITION; ISLET ANTIGEN-2; AFFINITY; RISK; MELLITUS AB GAD autoantibodies (GADAs) are sensitive markers of islet autoimmunity and type 1 diabetes. They form the basis of robust prediction models and are widely used for the recruitment of subjects at high risk of type 1 diabetes to prevention trials. However, GADAs are also found in many individuals at low risk of diabetes progression. To identify the sources of diabetes-irrelevant GADA reactivity, we analyzed data from the 2009 and 2010 Diabetes Autoantibody Standardization Program GADA workshop and found that binding of healthy control sera varied according to assay type. The characterization of control sera found positive by radiobinding assay (RBA), but negative by ELISA, showed that many of these sera reacted to epitopes in the N-terminal region of the molecule. This finding prompted development of an N-terminally truncated GAD(65) radiolabel, S-35-GAD(65)(96-585), which improved the performance of most GADA RBAs participating in an Islet Autoantibody Standardization Program GADA substudy. These detailed workshop comparisons have identified a source of disease-irrelevant signals in GADA RBAs and suggest that N-terminally truncated GAD labels will enable more specific measurement of GADAs in type 1 diabetes. C1 [Williams, Alistair J. K.; Wyatt, Rebecca] Univ Bristol, Sch Clin Sci, Bristol, Avon, England. [Lampasona, Vito] Ist Sci San Raffaele, Div Genet & Cell Biol, I-20132 Milan, Italy. [Schlosser, Michael] Univ Med Ctr Greifswald, Dept Med Biochem & Mol Biol, Karlsburg, Germany. [Schlosser, Michael] Univ Med Ctr Greifswald, Inst Pathophysiol, Karlsburg, Germany. [Mueller, Patricia W.] Ctr Dis Control & Prevent, Mol Risk Assessment Lab, Atlanta, GA USA. [Pittman, David L.; Winter, William E.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA. [Akolkar, Beena] NIDDK, Div Diabet Endocrinol & Metab Dis, Bethesda, MD USA. [Brigatti, Cristina] Ist Sci San Raffaele, Diabet Res Inst, I-20132 Milan, Italy. [Krause, Stephanie; Achenbach, Peter] Tech Univ Munich, Klinikum Rechts Isar, Diabet Res Inst, Helmholtz Zentrum Munchen, Neuherberg, Germany. [Krause, Stephanie; Achenbach, Peter] Tech Univ Munich, Klinikum Rechts Isar, Forschergrp Diabet, Neuherberg, Germany. RP Williams, AJK (reprint author), Univ Bristol, Sch Clin Sci, Bristol, Avon, England. EM a.j.k.williams@bristol.ac.uk OI Lampasona, Vito/0000-0001-5162-8445; Williams, Alistair/0000-0002-3615-3899 FU Centers for Disease Control and Prevention [PL105-33, 106-310, 106-554, 107-360]; National Institute of Diabetes and Digestive and Kidney Diseases [93.847]; Associazione ltaliana per la Ricerca sul Cancro "AIRC bando 5 x 1000 N_12182" grant; German Federal Ministry of Education and Research (BMBF) [FKZ 01GI0805] FX The Diabetes Antibody Standardization Program was funded at the Centers for Disease Control and Prevention by grants PL105-33,106-310,106-554, and 107-360, which were administered by the National Institutes of Health. The Islet Autoantibody Standardization Program was funded at the University of Florida by Catalog of Federal Domestic Assistance grant #93.847: Diabetes, Digestive, and Kidney Diseases Extramural Research of the National Institute of Diabetes and Digestive and Kidney Diseases. V.L. and C.B worked within the framework of the Italian Ministry of Research "Ivascomar project, Cluster Tecnologico Nazionale Scienze della Vita ALISEI" and were supported by the Associazione ltaliana per la Ricerca sul Cancro "AIRC bando 5 x 1000 N_12182" grant. P.A. was supported by grants from the German Federal Ministry of Education and Research (BMBF) to the Competence Network for Diabetes Mellitus (FKZ 01GI0805) and to the German Center for Diabetes Research (DZD e.V.). NR 30 TC 9 Z9 9 U1 2 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD SEP PY 2015 VL 64 IS 9 BP 3239 EP 3246 DI 10.2337/db14-1693 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CP9AE UT WOS:000360185300022 PM 25972570 ER PT J AU Pinner, RW Lynfield, R Hadler, JL Schaffner, W Farley, MM Frank, ME Schuchat, A AF Pinner, Robert W. Lynfield, Ruth Hadler, James L. Schaffner, William Farley, Monica M. Frank, Mark E. Schuchat, Anne TI Cultivation of an Adaptive Domestic Network for Surveillance and Evaluation of Emerging Infections SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; POPULATION-BASED SURVEILLANCE; IMMUNIZATION PRACTICES ACIP; UNITED-STATES; MENINGOCOCCAL DISEASE; BACTERIAL-MENINGITIS; ADVISORY-COMMITTEE; PUBLIC-HEALTH; RISK-FACTORS; CHILDREN C1 [Pinner, Robert W.; Frank, Mark E.; Schuchat, Anne] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Hadler, James L.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA. RP Pinner, RW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D59, Atlanta, GA 30329 USA. EM rpinner@cdc.gov NR 39 TC 3 Z9 3 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1499 EP 1509 DI 10.3201/eid2109.150619 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000002 PM 26289824 ER PT J AU Langley, G Schaffner, W Farley, MM Lynfield, R Bennett, NM Reingold, A Thomas, A Harrison, LH Nichols, M Petit, S Miller, L Moore, MR Schrag, SJ Lessa, FC Skoff, TH MacNeil, JR Briere, EC Weston, EJ Van Beneden, C AF Langley, Gayle Schaffner, William Farley, Monica M. Lynfield, Ruth Bennett, Nancy M. Reingold, Arthur Thomas, Ann Harrison, Lee H. Nichols, Megin Petit, Susan Miller, Lisa Moore, Matthew R. Schrag, Stephanie J. Lessa, Fernanda C. Skoff, Tami H. MacNeil, Jessica R. Briere, Elizabeth C. Weston, Emily J. Van Beneden, Chris TI Twenty Years of Active Bacterial Core Surveillance SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INVASIVE PNEUMOCOCCAL DISEASE; A STREPTOCOCCAL DISEASE; STAPHYLOCOCCUS-AUREUS INFECTIONS; POPULATION-BASED SURVEILLANCE; TERM-CARE FACILITIES; UNITED-STATES; NEISSERIA-MENINGITIDIS; HOUSEHOLD CONTACTS; PNEUMONIAE; PREVENTION AB Active Bacterial Core surveillance (ABCs) was established in 1995 as part of the Centers for Disease Control and Prevention Emerging Infections Program (EIP) network to assess the extent of invasive bacterial infections of public health importance. ABCs is distinctive among surveillance systems because of its large, population-based, geographically diverse catchment area; active laboratory-based identification of cases to ensure complete case capture; detailed collection of epidemiologic information paired with laboratory isolates; infrastructure that allows for more in-depth investigations; and sustained commitment of public health, academic, and clinical partners to maintain the system. ABCs has directly affected public health policies and practices through the development and evaluation of vaccines and other prevention strategies, the monitoring of antimicrobial drug resistance, and the response to public health emergencies and other emerging infections. C1 [Langley, Gayle; Moore, Matthew R.; Schrag, Stephanie J.; Lessa, Fernanda C.; Skoff, Tami H.; MacNeil, Jessica R.; Briere, Elizabeth C.; Weston, Emily J.; Van Beneden, Chris] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA. [Farley, Monica M.] Atlanta VA Med Ctr, Atlanta, GA USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Bennett, Nancy M.] Univ Rochester, Rochester, NY USA. [Reingold, Arthur] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Thomas, Ann] Oregon Dept Human Serv, Portland, OR USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Nichols, Megin] New Mexico Dept Hlth, Santa Fe, NM USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. RP Langley, G (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C25, Atlanta, GA 30329 USA. EM fez7@cdc.gov NR 40 TC 6 Z9 6 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1520 EP 1528 DI 10.3201/eid2109.141333 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000005 PM 26292067 ER PT J AU Henao, OL Jones, TF Vugia, DJ Griffin, PM AF Henao, Olga L. Jones, Timothy F. Vugia, Duc J. Griffin, Patricia M. CA Foodborne Dis Active Surveillance TI Foodborne Diseases Active Surveillance Network-2 Decades of Achievements, 1996-2015 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID 10 US SITES; UNITED-STATES; FOODNET SITES; RISK-FACTORS; CAMPYLOBACTER INFECTION; POPULATION SURVEY; SALMONELLA; ILLNESS; OUTBREAK; PATHOGENS AB The Foodborne Diseases Active Surveillance Network (FoodNet) provides a foundation for food safety policy and illness prevention in the United States. FoodNet conducts active, population-based surveillance at 10 US sites for laboratory-confirmed infections of 9 bacterial and parasitic pathogens transmitted commonly through food and for hemolytic uremic syndrome. Through FoodNet, state and federal scientists collaborate to monitor trends in enteric illnesses, identify their sources, and implement special studies. FoodNet's major contributions include establishment of reliable, active population-based surveillance of enteric diseases; development and implementation of epidemiologic studies to determine risk and protective factors for sporadic enteric infections; population and laboratory surveys that describe the features of gastrointestinal illnesses, medical care-seeking behavior, frequency of eating various foods, and laboratory practices; and development of a surveillance and research platform that can be adapted to address emerging issues. The importance of FoodNet's ongoing contributions probably will grow as clinical, laboratory, and informatics technologies continue changing rapidly. C1 [Henao, Olga L.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Vugia, Duc J.] Calif Dept Publ Hlth, Richmond, CA USA. RP Henao, OL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. EM ohenao@cdc.gov NR 40 TC 2 Z9 2 U1 3 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1529 EP 1536 DI 10.3201/eid2109.150581 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000006 PM 26292181 ER PT J AU Magill, SS Dumyati, G Ray, SM Fridkin, SK AF Magill, Shelley S. Dumyati, Ghinwa Ray, Susan M. Fridkin, Scott K. TI Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTION; ACTIVE SURVEILLANCE; LABORATORY SURVEILLANCE; PREVALENCE; CANDIDEMIA; RESISTANCE; HOSPITALS; CITIES; RATES AB The Healthcare-Associated Infections Community Interface (HAIC), launched in 2009, is the newest major activity of the Emerging Infections Program. The HAIC activity addresses population- and laboratory-based surveillance for Clostridium difficile infections, candidemia, and multidrug-resistant gram-negative bacilli. Other activities include special projects: the multistate Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey and projects that evaluate new approaches for improving surveillance. The HAIC activity has provided information about the epidemiology and adverse health outcomes of health care associated infections and antimicrobial drug use in the United States and informs efforts to improve patient safety through prevention of these infections. C1 [Magill, Shelley S.; Fridkin, Scott K.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Dumyati, Ghinwa] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Dumyati, Ghinwa] New York Emerging Infect Program, Rochester, NY USA. [Ray, Susan M.] Emory Univ, Sch Med, Atlanta, GA USA. [Ray, Susan M.] Georgia Emerging Infect Program, Decatur, GA USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A14, Atlanta, GA 30329 USA. EM smagill@cdc.gov NR 34 TC 4 Z9 4 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1537 EP 1542 DI 10.3201/eid2109.150508 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000007 PM 26291035 ER PT J AU Chaves, SS Lynfield, R Lindegren, ML Bresee, J Finelli, L AF Chaves, Sandra S. Lynfield, Ruth Lindegren, Mary Lou Bresee, Joseph Finelli, Lyn TI The US Influenza Hospitalization Surveillance Network SO EMERGING INFECTIOUS DISEASES LA English DT Article ID LABORATORY-CONFIRMED INFLUENZA; A H1N1 VIRUS; IMMUNIZATION PRACTICES ACIP; GUILLAIN-BARRE-SYNDROME; NEW-HAVEN COUNTY; UNITED-STATES; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; SOCIOECONOMIC-STATUS; ANTIVIRAL TREATMENT AB In 2003, surveillance for influenza in hospitalized persons was added to the Centers for Disease Control and Prevention Emerging Infections Program network. This surveillance enabled monitoring of the severity of influenza seasons and provided a platform for addressing priority questions associated with influenza. For enhanced surveillance capacity during the 2009 influenza pandemic, new sites were added to this platform. The combined surveillance platform is called the Influenza Hospitalization Surveillance Network (FluSurv-NET). FluSurv-NET has helped to determine the risk for influenza-associated illness in various segments of the US population, define the severity of influenza seasons and the 2009 pandemic, and guide recommendations for treatment and vaccination programs. C1 [Chaves, Sandra S.; Bresee, Joseph; Finelli, Lyn] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Lindegren, Mary Lou] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Chaves, SS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30329 USA. EM schaves@cdc.gov FU CDC; [CDC-RFA-CK12-1202] FX FluSurv-NET is a collaboration of state health departments, academic institutions, and local partners, and is funded by CDC. This publication was supported in part by Cooperative Agreement no. CDC-RFA-CK12-1202. NR 40 TC 5 Z9 5 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1543 EP 1550 DI 10.3201/eid2109.141912 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000008 PM 26291121 ER PT J AU Moore, MR Whitney, CG AF Moore, Matthew R. Whitney, Cynthia G. TI Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program SO EMERGING INFECTIOUS DISEASES LA English DT Article ID IMMUNIZATION PRACTICES ACIP; IMMUNOCOMPROMISING CONDITIONS RECOMMENDATIONS; POLYSACCHARIDE VACCINE RECOMMENDATIONS; CONJUGATE VACCINE; UNITED-STATES; STREPTOCOCCUS-PNEUMONIAE; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; ADULTS; CHILDREN AB Two decades ago, the Emerging Infections Program of the US Centers for Disease Control and Prevention implemented what seemed like a simple yet novel idea: a population- and laboratory-based surveillance system designed to identify and characterize invasive bacterial infections, including those caused by Streptococcus pneumoniae. This system, known as Active Bacterial Core surveillance, has since served as a flexible platform for following trends in invasive pneumococcal disease and studying vaccination as the most effective method for prevention. We report the contributions of Active Bacterial Core surveillance to every pneumococcal vaccine policy decision in the United States during the past 20 years. C1 [Moore, Matthew R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Moore, MR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C23, Atlanta, GA 30329 USA. EM zdn4@cdc.gov FU Emerging Infections Program at the Centers for Disease Control and Prevention FX This study was supported by the Emerging Infections Program at the Centers for Disease Control and Prevention. NR 40 TC 6 Z9 6 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1551 EP 1556 DI 10.3201/eid2109.150395 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000009 PM 26291238 ER PT J AU Hariri, S Markowitz, LE Bennett, NM Niccolai, LM Schafer, S Bloch, K Park, IU Scahill, MW Julian, P Abdullah, N Levine, D Whitney, E Unger, ER Steinau, M Bauer, HM Meek, J Hadler, J Sosa, L Powell, SE Johnson, ML AF Hariri, Susan Markowitz, Lauri E. Bennett, Nancy M. Niccolai, Linda M. Schafer, Sean Bloch, Karen Park, Ina U. Scahill, Mary W. Julian, Pamela Abdullah, Nasreen Levine, Diane Whitney, Erin Unger, Elizabeth R. Steinau, Martin Bauer, Heidi M. Meek, James Hadler, James Sosa, Lynn Powell, Suzanne E. Johnson, Michelle L. CA HPV-IMPACT Working Grp TI Monitoring Effect of Human Papillomavirus,Vaccines in US Population, Emerging Infections Program, 2008-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HPV VACCINATION; CERVICAL ABNORMALITIES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; UNITED-STATES; CANCER; BURDEN; IMPACT; RECOMMENDATIONS; COVERAGE AB In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. The project involved active population-based surveillance of cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ as well as associated HPV types in women >= 18 years of age residing in defined catchment areas; collecting relevant clinical information and detailed HPV vaccination histories for women 18-39 years of age; and estimating the annual rate of cervical cancer screening among the catchment area population. The first few years of the project provided key information, including data on HPV type distribution, before expected effect of vaccine introduction. The project's success exemplifies the flexibility of EIP's network to expand core activities to include emerging surveillance needs beyond acute infectious diseases. Project results contribute key information regarding the impact of HPV vaccination in the United States. C1 [Hariri, Susan; Markowitz, Lauri E.; Unger, Elizabeth R.; Steinau, Martin; Powell, Suzanne E.; Johnson, Michelle L.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Bennett, Nancy M.; Scahill, Mary W.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Niccolai, Linda M.; Julian, Pamela; Meek, James; Hadler, James] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Schafer, Sean; Abdullah, Nasreen] Oregon Hlth Author, Portland, OR USA. [Bloch, Karen; Levine, Diane] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Park, Ina U.; Whitney, Erin; Bauer, Heidi M.] Calif Dept Publ Hlth, Richmond, CA USA. [Sosa, Lynn] Connecticut Dept Hlth, Hartford, CT USA. RP Hariri, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E02, Atlanta, GA 30329 USA. EM bse4@cdc.gov FU CDC [CIU01000307] FX This work was supported by the CDC cooperative agreement CIU01000307. NR 19 TC 4 Z9 4 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1557 EP 1561 DI 10.3201/eid2109.141841 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000010 PM 26291379 ER PT J AU Skoff, TH Baumbach, J Cieslak, PR AF Skoff, Tami H. Baumbach, Joan Cieslak, Paul R. TI Tracking Pertussis and Evaluating Control Measures through Enhanced Pertussis Surveillance, Emerging Infections Program, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BORDETELLA-PERTUSSIS; INFANTS; IMMUNIZATION; DIPHTHERIA AB Despite high coverage with pertussis-containing vaccines, pertussis remains endemic to the United States. There have been increases in reported cases in recent years, punctuated by striking epidemics and shifting epidemiology, both of which raise questions about current policies regarding its prevention and control. Limited data on pertussis reported through the National Notifiable Disease Surveillance System have proved insufficient to answer these questions. To address shortcomings of national pertussis data, the Emerging Infections Program at the US Centers for Disease Control and Prevention launched Enhanced Pertussis Surveillance (EPS), which is characterized by systematic case ascertainment, augmented data collection, and collection of Bordetella pertussis isolates. Data collected through EPS have been instrumental in understanding the rapidly evolving epidemiology and molecular epidemiology of pertussis and have contributed essential information regarding pertussis vaccines. EPS also serves as a platform for conducting critical and timely evaluations of pertussis prevention and control strategies, including targeting of vaccinations and antimicrobial prophylaxis. C1 [Skoff, Tami H.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [Cieslak, Paul R.] Oregon Hlth Author, Portland, OR USA. RP Skoff, TH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM tlh9@cdc.gov FU CDC cooperative agreement FX Enhanced Pertussis Surveillance and other pertussis special studies are supported through a CDC cooperative agreement. NR 19 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1568 EP 1573 DI 10.3201/eid2109.150023 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000012 PM 26291475 ER PT J AU Mead, P Hinckley, A Hook, S Beard, CB AF Mead, Paul Hinckley, Alison Hook, Sarah Beard, C. Ben TI TickNET-A Collaborative Public Health Approach to Tickborne Disease Surveillance and Research SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PREVENT LYME-DISEASE; ERYTHEMA MIGRANS; MISSOURI; BORRELIOSIS; VACCINE AB TickNET, a public health network, was created in 2007 to foster greater collaboration between state health departments, academic centers, and the Centers for Disease Control and Prevention on surveillance and prevention of tickborne diseases. Research activities are conducted through the Emerging Infections Program and include laboratory surveys, high-quality prevention trials, and pathogen discovery. C1 [Mead, Paul; Hinckley, Alison; Hook, Sarah; Beard, C. Ben] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Mead, P (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM pmead@cdc.gov NR 18 TC 5 Z9 5 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1574 EP 1577 DI 10.3201/eid2109.150301 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000013 PM 26291549 ER PT J AU Fridkin, SK Cleveland, AA See, I Lynfield, R AF Fridkin, Scott K. Cleveland, Angela A. See, Isaac Lynfield, Ruth TI Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance SO EMERGING INFECTIOUS DISEASES LA English DT Article ID STAPHYLOCOCCUS-AUREUS INFECTIONS; UNITED-STATES; STREPTOCOCCUS-PNEUMONIAE; LABORATORY SURVEILLANCE; EMERGENCE AB Across the United States, antimicrobial drug resistant infections affect a diverse population, and effective interventions require concerted efforts across various public health and clinical programs. Since its onset in 1994, the Centers for Disease Control and Prevention Emerging Infections Program has provided robust and timely data on antimicrobial drug resistant infections that have been used to inform public health action across a spectrum of partners with regard to many highly visible antimicrobial drug resistance threats. These data span several activities within the Program, including respiratory bacterial infections, health care associated infections, and some aspects of foodborne diseases. These data have contributed to estimates of national burden, identified populations at risk, and determined microbiological causes of infection and their outcomes, all of which have been used to inform national policy and guidelines to prevent antimicrobial drug resistant infections. C1 [Fridkin, Scott K.; Cleveland, Angela A.; See, Isaac] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Lynfield, Ruth] Minnesota Dept Publ Hlth, St Paul, MN USA. RP Fridkin, SK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A14, Atlanta, GA 30329 USA. EM skf0@cdc.gov NR 24 TC 3 Z9 3 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1578 EP 1581 DI 10.3201/eid2109.150512 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000014 PM 26291638 ER PT J AU Langley, G Besser, J Iwamoto, M Lessa, FC Cronquist, A Skoff, TH Chaves, S Boxrud, D Pinner, RW Harrison, LH AF Langley, Gayle Besser, John Iwamoto, Martha Lessa, Fernanda C. Cronquist, Alicia Skoff, Tami H. Chaves, Sandra Boxrud, Dave Pinner, Robert W. Harrison, Lee H. TI Effect of Culture-Independent Diagnostic Tests on Future Emerging Infections Program Surveillance SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTION; UNITED-STATES; BORDETELLA-PERTUSSIS; METHICILLIN-RESISTANT; QUANTITATIVE PCR; WHOLE-BLOOD; BACTERIAL; ASSAY; GENE; SUSCEPTIBILITY AB The Centers for Disease Control and Prevention Emerging Infections Program (EIP) network conducts population-based surveillance for pathogens of public health importance. Central to obtaining estimates of disease burden and tracking microbiological characteristics of these infections is accurate laboratory detection of pathogens. The use of culture-independent diagnostic tests (CIDTs) in clinical settings presents both opportunities and challenges to EIP surveillance. Because CIDTs offer better sensitivity than culture and are relatively easy to perform, their use could potentially improve estimates of disease burden. However, changes in clinical testing practices, use of tests with different sensitivities and specificities, and changes to case definitions make it challenging to monitor trends. Isolates are still needed for performing strain typing, antimicrobial resistance testing, and identifying other molecular characteristics of organisms. In this article, we outline current and future EIP activities to address issues associated with adoption of CIDTs, which may apply to other public health surveillance. C1 [Langley, Gayle; Besser, John; Iwamoto, Martha; Lessa, Fernanda C.; Skoff, Tami H.; Chaves, Sandra; Pinner, Robert W.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Cronquist, Alicia] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Boxrud, Dave] Minnesota Dept Hlth, St Paul, MN USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Langley, G (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C25, Atlanta, GA 30329 USA. EM fez7@cdc.gov NR 39 TC 5 Z9 5 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1582 EP 1588 DI 10.3201/eid2109.150570 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000015 PM 26291736 ER PT J AU Hadler, JL Vugia, DJ Bennett, NM Moore, MR AF Hadler, James L. Vugia, Duc J. Bennett, Nancy M. Moore, Matthew R. TI Emerging Infections Program Efforts to Address Health Equity SO EMERGING INFECTIOUS DISEASES LA English DT Article ID B STREPTOCOCCAL DISEASE; INVASIVE PNEUMOCOCCAL DISEASE; NEW-HAVEN COUNTY; UNITED-STATES; SOCIOECONOMIC-STATUS; PNEUMONIAE INFECTIONS; RACIAL/ETHNIC DISPARITIES; METROPOLITAN ATLANTA; RACIAL DISPARITIES; CONJUGATE VACCINE AB The Emerging Infections Program (EIP), a collaboration between (currently) 10 state health departments, their academic center partners, and the Centers for Disease Control and Prevention, was established in 1995. The EIP performs active, population-based surveillance for important infectious diseases, addresses new problems as they arise, emphasizes projects that lead to prevention, and develops and evaluates public health practices. The EIP has increasingly addressed the health equity challenges posed by Healthy People 2020. These challenges include objectives to increase the proportion of Healthy People-specified conditions for which national data are available by race/ethnicity and socioeconomic status as a step toward first recognizing and subsequently eliminating health inequities. EIP has made substantial progress in moving from an initial focus on monitoring social determinants exclusively through collecting and analyzing data by race/ethnicity to identifying and piloting ways to conduct population-based surveillance by using area-based socioeconomic status measures. C1 [Hadler, James L.] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT 06511 USA. [Vugia, Duc J.] Calif Dept Publ Hlth, Calif Emerging Infect Program, Richmond, CA USA. [Bennett, Nancy M.] Univ Rochester, Med Ctr, New York Emerging Infect Program, Rochester, NY 14642 USA. [Moore, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hadler, JL (reprint author), Yale Univ, Sch Publ Hlth, Emerging Infect Program, One Church St,7th Fl, New Haven, CT 06511 USA. EM hadler-epi@att.net FU Centers for Disease Control and Prevention (CDC) [5U50-CK000195] FX The work on this manuscript was supported directly by the Centers for Disease Control and Prevention (CDC) (M.R.M.) or by Cooperative Agreement 5U50-CK000195 from the CDC (J.L.H., D.J.V., N.M.B.). The authors have no conflicts of interest to disclose. NR 39 TC 3 Z9 3 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1589 EP 1594 DI 10.3201/eid2109.150275 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000016 PM 26291875 ER PT J AU Millman, AJ Reed, C Kirley, PD Aragon, D Meek, J Farley, MM Ryan, P Collins, J Lynfield, R Baumbach, J Zansky, S Bennett, NM Fowler, B Thomas, A Lindegren, ML Atkinson, A Finelli, L Chaves, SS AF Millman, Alexander J. Reed, Carrie Kirley, Pam Daily Aragon, Deborah Meek, James Farley, Monica M. Ryan, Patricia Collins, Jim Lynfield, Ruth Baumbach, Joan Zansky, Shelley Bennett, Nancy M. Fowler, Brian Thomas, Ann Lindegren, Mary L. Atkinson, Annette Finelli, Lyn Chaves, Sandra S. TI Improving Accuracy of Influenza-Associated Hospitalization Rate Estimates SO EMERGING INFECTIOUS DISEASES LA English DT Article ID LABORATORY-CONFIRMED INFLUENZA; RESPIRATORY-SYNCYTIAL-VIRUS; RAPID DIAGNOSIS; UNITED-STATES; CELL-CULTURE; B VIRUSES; CHILDREN; INFECTION; BURDEN; ASSAY AB Diagnostic test sensitivity affects rate estimates for laboratory-confirmed influenza associated hospitalizations. We used data from FluSurv-NET, a national population-based surveillance system for laboratory-confirmed influenza hospitalizations, to capture diagnostic test type by patient age and influenza season. We calculated observed rates by age group and adjusted rates by test sensitivity. Test sensitivity was lowest in adults >= 65 years of age. For all ages, reverse transcription PCR was the most sensitive test, and use increased from <10% during 2003-2008 to approximate to 70% during 2009-2013. Observed hospitalization rates per 100,000 persons varied by season: 7.3-50.5 for children <18 years of age, 3.0-30.3 for adults 18-64 years, and 13.6-181.8 for adults >= 65 years. After 2009, hospitalization rates adjusted by test sensitivity were approximate to 15% higher for children <18 years, approximate to 20% higher for adults 18-64 years, and approximate to 55% for adults >= 65 years of age. Test sensitivity adjustments improve the accuracy of hospitalization rate estimates. C1 [Millman, Alexander J.; Reed, Carrie; Finelli, Lyn; Chaves, Sandra S.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Kirley, Pam Daily] Calif Emerging Infect Program, Oakland, CA USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Meek, James] Connecticut Emerging Infect Program, New Haven, CT USA. [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA. [Farley, Monica M.] Atlanta Vet Adm Med Ctr, Atlanta, GA USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Collins, Jim] Michigan Dept Hlth & Human Serv, Lansing, MI USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Bennett, Nancy M.] Monroe Cty Dept Publ Hlth, Rochester, MN USA. [Fowler, Brian] Ohio Dept Hlth, Columbus, OH 43266 USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Lindegren, Mary L.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Atkinson, Annette] Utah Dept Hlth, Salt Lake City, UT 84116 USA. RP Millman, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30329 USA. EM irm6@cdc.gov FU CDC; [CDC-RFA-CK12-1202]; [5U38HM000414] FX FluSurv-NET is a collaboration of state health departments, academic institutions, and local partners and is funded by CDC. This publication was supported in part by cooperative agreement nos. CDC-RFA-CK12-1202 and 5U38HM000414. NR 39 TC 2 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1595 EP 1601 DI 10.3201/eid2109.141665 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000017 PM 26292017 ER PT J AU Chea, N Bulens, SN Kongphet-Tran, T Lynfield, R Shaw, KM Vagnone, PS Kainer, MA Muleta, DB Wilson, L Vaeth, E Dumyati, G Concannon, C Phipps, EC Culbreath, K Janelle, SJ Bamberg, WM Guh, AY Limbago, B Kallen, AJ AF Chea, Nora Bulens, Sandra N. Kongphet-Tran, Thiphasone Lynfield, Ruth Shaw, Kristin M. Vagnone, Paula Snippes Kainer, Marion A. Muleta, Daniel B. Wilson, Lucy Vaeth, Elisabeth Dumyati, Ghinwa Concannon, Cathleen Phipps, Erin C. Culbreath, Karissa Janelle, Sarah J. Bamberg, Wendy M. Guh, Alice Y. Limbago, Brandi Kallen, Alexander J. TI Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae SO EMERGING INFECTIOUS DISEASES LA English DT Article ID METALLO-BETA-LACTAMASE; KLEBSIELLA-PNEUMONIAE; UNITED-STATES; INFECTIONS AB Preventing transmission of carbapenemase-producing, carbapenem-resistant Enterobacteriaceae (CP-CRE) is a public health priority. A phenotype-based definition that reliably identifies CP-CRE while minimizing misclassification of non CP-CRE could help prevention efforts. To assess possible definitions, we evaluated enterobacterial isolates that had been tested and deemed nonsusceptible to >= 1 carbapenem at US Emerging Infections Program sites. We determined the number of non-CP isolates that met (false positives) and CP isolates that did not meet (false negatives) the Centers for Disease Control and Prevention CRE definition in use during our study: 30% (94/312) of CRE had carbapenemase genes, and 21% (14/67) of Klebsiella pneumoniae carbapenemase producing Klebsiella isolates had been misclassified as non-CP. A new definition requiring resistance to 1 carbapenem rarely missed CP strains, but 55% of results were false positive; adding the modified Hodge test to the definition decreased false positives to 12%. This definition should be considered for use in carbapenemase-producing CRE surveillance and prevention. C1 [Chea, Nora; Bulens, Sandra N.; Kongphet-Tran, Thiphasone; Guh, Alice Y.; Limbago, Brandi; Kallen, Alexander J.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Lynfield, Ruth; Shaw, Kristin M.; Vagnone, Paula Snippes] Minnesota Dept Hlth, St Paul, MN USA. [Kainer, Marion A.; Muleta, Daniel B.] Tennessee Dept Hlth, Nashville, TN USA. [Wilson, Lucy; Vaeth, Elisabeth] Maryland Emerging Infect Program, Baltimore, MD USA. [Dumyati, Ghinwa; Concannon, Cathleen] New York Rochester Emerging Infect Program, Rochester, NY USA. [Dumyati, Ghinwa; Concannon, Cathleen] Univ Rochester, Med Ctr, Rochester, NY 14627 USA. [Phipps, Erin C.; Culbreath, Karissa] Univ New Mexico, Albuquerque, NM 87131 USA. [Janelle, Sarah J.; Bamberg, Wendy M.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. RP Kallen, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A31, Atlanta, GA 30329 USA. EM ffp0@cdc.gov NR 16 TC 11 Z9 11 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1611 EP 1616 DI 10.3201/eid2109.150198 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000019 PM 26290955 ER PT J AU Nelson, CA Saha, S Kugeler, KJ Delorey, MJ Shankar, MB Hinckley, AF Mead, PS AF Nelson, Christina A. Saha, Shubhayu Kugeler, Kiersten J. Delorey, Mark J. Shankar, Manjunath B. Hinckley, Alison F. Mead, Paul S. TI Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SURVEILLANCE; BORRELIOSIS; ACCURACY AB National surveillance provides important information about Lyme disease (LD) but is subject to underreporting and variations in practice. Information is limited about the national epidemiology of LD from other sources. Retrospective analysis of a nationwide health insurance claims database identified patients from 2005-2010 with clinician-diagnosed LD using International Classification of Diseases, Ninth Revision, Clinical Modification, codes and antimicrobial drug prescriptions. Of 103,647,966 person-years, 985 inpatient admissions and 44,445 outpatient LD diagnoses were identified. Epidemiologic patterns were similar to US surveillance data overall. Outpatient incidence was highest among boys 5-9 years of age and persons of both sexes 60-64 years of age. On the basis of extrapolation to the US population and application of correction factors for coding, we estimate that annual incidence is 106.6 cases/100,000 persons and that approximate to 329,000 (95% credible interval 296,000-376,000) LD cases occur annually. LD is a major US public health problem that causes substantial use of health care resources. C1 [Nelson, Christina A.; Kugeler, Kiersten J.; Delorey, Mark J.; Hinckley, Alison F.; Mead, Paul S.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. [Saha, Shubhayu; Shankar, Manjunath B.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Nelson, CA (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA. EM wjel@cdc.gov NR 28 TC 31 Z9 31 U1 2 U2 17 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1625 EP 1631 DI 10.3201/eid2109.150417 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000021 PM 26291194 ER PT J AU Clayton, JL Jones, SG Dunn, JR Schaffner, W Jones, TF AF Clayton, Joshua L. Jones, Stephen G. Dunn, John R. Schaffner, William Jones, Timothy F. TI Enhancing Lyme Disease Surveillance by Using Administrative Claims Data, Tennessee, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article AB Lyme disease is underreported in the United States. We used insurance administrative claims data to determine the value of such data in enhancing case ascertainment in Tennessee during January 2011-June 2013. Although we identified approximate to 20% more cases of Lyme disease (5/year), the method was resource intensive and not sustainable in this low-incidence state. C1 [Clayton, Joshua L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Clayton, Joshua L.; Dunn, John R.; Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Jones, Stephen G.] Blue Cross Blue Shield Tennessee, Chattanooga, TN USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Clayton, JL (reprint author), Tennessee Dept Hlth, 4th Fl,Andrew Johnson Tower, Nashville, TN 37243 USA. EM xdc8@cdc.gov NR 9 TC 2 Z9 2 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1632 EP 1634 DI 10.3201/eid2109.150344 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000022 PM 26291336 ER PT J AU Schultz, MG Schaffner, W AF Schultz, Myron G. Schaffner, William TI Alexander Duncan Langmuir SO EMERGING INFECTIOUS DISEASES LA English DT Biographical-Item C1 [Schultz, Myron G.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Schultz, MG (reprint author), Ctr Dis Control & Prevent, Global Dis Detect Operat Ctr, CGH, 1600 Clifton Rd NE,Mailstop A05, Atlanta, GA 30329 USA. EM mgs1@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1636 EP 1637 DI 10.3201/eid2109.141445 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000023 ER PT J AU Perumpail, RB Ahmed, A Higgins, JP So, SK Cochran, JL Drobeniuc, J Mixson-Hayden, TR Teo, CG AF Perumpail, Ryan B. Ahmed, Aijaz Higgins, John P. So, Samuel K. Cochran, J. Lynn Drobeniuc, Jan Mixson-Hayden, Tonya R. Teo, Chong-Gee TI Fatal Accelerated Cirrhosis after Imported HEV Genotype 4 Infection SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID HEPATITIS-E VIRUS C1 [Perumpail, Ryan B.; Ahmed, Aijaz; Higgins, John P.; So, Samuel K.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Cochran, J. Lynn] Birmingham Gastroenterol Associates, Birmingham, AL USA. [Cochran, J. Lynn] Trinity Med Ctr, Birmingham, AL USA. [Drobeniuc, Jan; Mixson-Hayden, Tonya R.; Teo, Chong-Gee] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Perumpail, RB (reprint author), Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, 750 Welch Rd,Ste 210, Stanford, CA 94304 USA. EM rperumpail@gmail.com NR 8 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1679 EP 1681 DI 10.3201/eid2109.150300 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000036 PM 26291424 ER PT J AU Breedlove, B AF Breedlove, Byron TI Ceaseless Experimentation Sparks Fireworks, Art, and Science SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C17, Atlanta, GA 30329 USA. EM wbbl@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 5 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2015 VL 21 IS 9 BP 1690 EP 1691 DI 10.3201/eid2109.AC2109 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CP5AP UT WOS:000359894000041 ER PT J AU Aliabadi, N Lopman, BA Parashar, UD Hall, AJ AF Aliabadi, Negar Lopman, Ben A. Parashar, Umesh D. Hall, Aron J. TI Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations SO EXPERT REVIEW OF VACCINES LA English DT Review DE calciviridae; epidemiology; gastroenteritis; norovirus; Norwalk agent; vaccine development ID INFECTIOUS NONBACTERIAL GASTROENTERITIS; RECOMBINANT NORWALK VIRUS; CELLULAR IMMUNE-RESPONSES; UNITED-STATES; SPORADIC GASTROENTERITIS; FINNISH CHILDREN; HERD-IMMUNITY; IMMUNOCOMPROMISED PATIENTS; BLOCKING ANTIBODIES; INTESTINAL DISEASE AB Human norovirus infection causes significant medical and financial costs in the USA and abroad. Some populations, including young children, the elderly, and the immunocompromised, are at heightened risk of infection with this virus and subsequent complications, while others, such as healthcare workers and food handlers are at increased risk of transmitting it, and some are at risk of both. Human noroviruses are heterogeneous with new strains emerging periodically. In addition to viral diversity, incompletely understood characteristics, such as virus-host cell binding and duration of immunity after infection add to the challenges of creating a norovirus vaccine. Although much progress has been made in recent years, many questions remain to be answered. In this review, we discuss the important areas and relevant literature in considering human norovirus vaccine development and potential targets for implementation. C1 [Aliabadi, Negar; Lopman, Ben A.; Parashar, Umesh D.; Hall, Aron J.] Ctr Dis Control & Prevent, Div Viral Dis, Epidemiol Branch, Viral Gastroenterol Team, Atlanta, GA 30333 USA. RP Hall, AJ (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Epidemiol Branch, Viral Gastroenterol Team, Atlanta, GA 30333 USA. EM esg3@Cdc.Gov NR 119 TC 4 Z9 4 U1 1 U2 14 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1476-0584 EI 1744-8395 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD SEP PY 2015 VL 14 IS 9 BP 1241 EP 1253 DI 10.1586/14760584.2015.1073110 PG 13 WC Immunology SC Immunology GA CP5OE UT WOS:000359931400007 PM 26224658 ER PT J AU Jackson-Morris, A Fujiwara, PI Pevzner, E AF Jackson-Morris, A. Fujiwara, P. I. Pevzner, E. TI Clearing the smoke around the TB-HIV syndemic: smoking as a critical issue for TB and HIV treatment and care SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; HIV; tobacco; smoking; public health ID SOUTH-AFRICA; SUSPECTED TUBERCULOSIS; ANTIRETROVIRAL THERAPY; CIGARETTE-SMOKING; CONTROLLED-TRIAL; HIGH PREVALENCE; CLINICAL-TRIAL; CESSATION; INTERVENTION; ASSOCIATION AB The collision of the tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics has been described as a 'syndemic' due to the synergistic impact on the burden of both diseases. This paper explains the urgent need for practitioners and policy makers to address a third epidemic that exacerbates TB, HIV and TB-HIV. Tobacco use is the leading cause of preventable death worldwide. Smoking is more prevalent among persons diagnosed with TB or HIV. Smoking is associated with tuberculous infection, TB disease and poorer anti-tuberculosis treatment outcomes. It is also associated with an increased risk of smoking-related diseases among people living with HIV, and smoking SUMMARY may also inhibit the effectiveness of life-saving ART. In this paper, we propose integrating into TB and HIV programmes evidence-based strategies from the 'MPOWER' package recommended by the World Health Organization's Framework Convention on Tobacco Control. Specific actions that can be readily incorporated into current practice are recommended to improve TB and HIV outcomes and care, and reduce the unnecessary burden of 'death and disease due to smoking. C1 [Jackson-Morris, A.] The Union, Dept Tobacco Control, Int Union TB & Lung Dis, Edinburgh, Midlothian, Scotland. [Fujiwara, P. I.] The Union, Paris, France. [Pevzner, E.] US Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div TB Eliminat, Int Res & Programs Branch, Atlanta, GA USA. RP Jackson-Morris, A (reprint author), Int Union TB & Lung Dis, Dept Tobacco Control, 8 Randolph Crescent, Edinburgh EH3 7, Midlothian, Scotland. EM ajackson-morris@theunion.org FU Bloomberg Initiative to Reduce Tobacco Use FX The global tobacco control grants programme, managed jointly by the International Union Against Tuberculosis and Lung Disease (Edinburgh, Scotland, UK) and the Campaign for Tobacco Free Kids (Washington, DC, USA), is funded by the Bloomberg Initiative to Reduce Tobacco Use. NR 45 TC 3 Z9 3 U1 2 U2 8 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2015 VL 19 IS 9 BP 1003 EP 1006 DI 10.5588/ijtld.14.0813 PG 4 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CP5AT UT WOS:000359894400003 PM 26260816 ER PT J AU Bliven-Sizemore, EE Sterling, TR Shang, N Benator, D Schwartzman, K Reves, R Drobeniuc, J Bock, N Villarino, ME AF Bliven-Sizemore, E. E. Sterling, T. R. Shang, N. Benator, D. Schwartzman, K. Reves, R. Drobeniuc, J. Bock, N. Villarino, M. E. CA TB Trials Consortium TI Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE isoniazid; hepatitis C; aspartate amino-transferases ID LATENT TUBERCULOSIS INFECTION; PREVENTIVE THERAPY; UNITED-STATES; HEPATITIS-C; DRUG-USERS AB SETTING: Nine months of daily isoniazid (9H) and 3 months of once-weekly rifapentine plus isoniazid (3HP) are recommended treatments for latent tuberculous infection (LTBI). The risk profile for 3HP and the contribution of hepatitis C virus (HCV) infection to hepatotoxicity are unclear. OBJECTIVES: To evaluate the hepatotoxicity risk associated with 3HP compared to 9H, and factors associated with hepatotoxicity DESIGN: Hcpatotoxicity was defined as aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN) with symptoms (nausea, vomiting, jaundice, or fatigue), or AST >5 x ULN. We analyzed risk factors among adults who took at least 1 dose of their assigned treatment. A nested case-control study assessed the role of HCV. RESULTS: Of 6862 participants, 77 (1.1%) developed hepatotoxicity; 52 (0.8%) were symptomatic; 1.8% (61/3317) were on 9H and 0.4% (15/3545) were on 3HP (P < 0.0001). Risk factors for hepatotoxicity were age, female sex, white race, non-Hispanic ethnicity, decreased body mass index, elevated baseline AST, and 9H. In the case-control study, HCV infection was associated with hepatotoxicity when controlling for other factors. CONCLUSION: The risk of hepatotoxicity during LTBI treatment with 3HP was lower than the risk with 9H. HCV and elevated baseline AST were risk factors for hepatotoxicity. For persons with these risk factors, 3HP may be preferred. C1 [Bliven-Sizemore, E. E.; Shang, N.; Bock, N.; Villarino, M. E.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Sterling, T. R.] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37212 USA. [Benator, D.] George Washington Univ, Med Ctr, Vet Affairs Med Ctr, Div Infect Dis, Washington, DC 20037 USA. [Schwartzman, K.] McGill Univ, Montreal Chest Inst, Resp Epidemiol & Clin Res Unit, Montreal, PQ, Canada. [Reves, R.] Univ Colorado, Dept Med, Div Infect Dis, Denver, CO USA. [Reves, R.] Denver Hlth Hosp, Denver, CO USA. [Drobeniuc, J.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Bliven-Sizemore, EE (reprint author), US Ctr Dis Control & Prevent, Clin Res Branch, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM esizemore@cdc.gov OI Ocana, Inma/0000-0003-3699-0790; Millet, Joan Pau/0000-0003-0200-2459 FU US Centers for Disease Control and Prevention (CDC); Sanofi FX This work was supported by the US Centers for Disease Control and Prevention (CDC). Sanofi donated the RPT used in this study, and since 2007 has donated US$2.3 million to the CDC Foundation to supplement available US federal funding for RPT research. Sanofi did not participate in the design of the study; in the collection, analysis, or interpretation of data; in the writing of this manuscript; or in the decision to submit this manuscript for publication. NR 18 TC 10 Z9 10 U1 1 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2015 VL 19 IS 9 BP 1039 EP 1044 DI 10.5588/ijtld.14.0829 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CP5AT UT WOS:000359894400008 PM 26260821 ER PT J AU Salyer, SJ Fitter, DL Milo, R Blanton, C Ho, JL Geffrard, H Morose, W Marston, BJ AF Salyer, S. J. Fitter, D. L. Milo, R. Blanton, C. Ho, J. L. Geffrard, H. Morose, W. Marston, B. J. TI Evaluation of the national tuberculosis surveillance program in Haiti SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE TB; tuberculosis; surveillance; PNLT; Haiti AB OBJECTIVE: To assess the quality of tuberculosis (TB) surveillance in Haiti, including whether underreporting from facilities to the national level contributes to low national case registration. METHODS: We collected 2010 and 2012 TB case totals, reviewed laboratory registries, and abstracted individual TB case reports from 32 of 263 anti-tuberculosis treatment facilities randomly selected after stratification/weighting toward higher-volume facilities. We compared site results to national databases maintained by a non-governmental organization partner (International Child Care [ICC]) for 2010 and 2012, and the National TB Program (Programme National de Lutte contre la Tuberculose, PNLT) for 2012 only. RESULTS: Case registries were available at 30/32 facilities for 2010 and all 32 for 2012. Totals of 3711 (2010) and 4143 (2012) cases were reported at the facilities. Case totals per site were higher in site registries than in the national databases by 361 (9.7%) (ICC 2010), 28 (0.8%) (ICC 2012), and 31 (0.8%) cases (PNLT 2012). Of abstracted individual cases, respectively 11.8% and 6.8% were not recorded in national databases for 2010 (n = 323) and 2012 (n = 351). CONCLUSIONS: The evaluation demonstrated an improvement in reporting registered TB cases to the PNLT in Haiti between 2010 and 2012. Further improvement in case notification will require enhanced case detection and diagnosis. C1 [Salyer, S. J.; Fitter, D. L.; Blanton, C.; Marston, B. J.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30329 USA. [Salyer, S. J.] Epidem Intelligence Serv Program, Atlanta, GA USA. [Milo, R.; Morose, W.] Minist Sante Publ & Populat, Programme Natl Lutte Tuberculose, Port Au Prince, Haiti. [Ho, J. L.] Bothwell Reg Hlth Ctr, Sedalia, MO USA. [Geffrard, H.] Int Child Care, Port Au Prince, Haiti. RP Salyer, SJ (reprint author), Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Global Dis Detect Branch, Mailstop D-68,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM wig9@cdc.gov OI Salyer, Stephanie/0000-0001-7679-2006 FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 1 U2 7 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2015 VL 19 IS 9 BP 1045 EP 1050 DI 10.5588/ijtld.15.0051 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CP5AT UT WOS:000359894400009 PM 26260822 ER PT J AU Spengler, JR Stonecipher, S McManus, C Hughes-Garza, H Dow, M Zoran, DL Bissett, W Beckham, T Alves, DA Wolcott, M Tostenson, S Dorman, B Sidwa, TJ Knust, B Behravesh, CB AF Spengler, Jessica R. Stonecipher, Shelley McManus, Catherine Hughes-Garza, Holly Dow, Max Zoran, Debra L. Bissett, Wesley Beckham, Tammy Alves, Derron A. Wolcott, Mark Tostenson, Samantha Dorman, Bill Sidwa, Thomas J. Knust, Barbara Behravesh, Casey Barton TI Management of a pet dog after exposure to a human patient with Ebola virus disease SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID HEMORRHAGIC-FEVER; ASSAYS; ZAIRE AB In October 2014, a health-care worker who had been part of the treatment team for the first laboratory-confirmed case of Ebola virus disease imported to the United States developed symptoms of Ebola virus disease. A presumptive positive reverse transcription PCR assay result for Ebola virus RNA in a blood sample from the worker was confirmed by the CDC, making this the first documented occurrence of domestic transmission of Ebola virus in the United States. The Texas Department of State Health Services commissioner issued a control order requiring disinfection and decontamination of the health-care worker's residence. This process was delayed until the patient's pet dog (which, having been exposed to a human with Ebola virus disease, potentially posed a public health risk) was removed from the residence. This report describes the movement, quarantine, care, testing, and release of the pet dog, highlighting the interdisciplinary, one-health approach and extensive collaboration and communication across local, county, state, and federal agencies involved in the response. C1 [Spengler, Jessica R.; Knust, Barbara; Behravesh, Casey Barton] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Stonecipher, Shelley; Sidwa, Thomas J.] Texas Dept State Hlth Serv, Arlington, TX 76013 USA. [McManus, Catherine] Dallas Anim Serv, Dallas, TX 75212 USA. [Hughes-Garza, Holly; Dow, Max] Texas Anim Hlth Commiss, Austin, TX 78758 USA. [Zoran, Debra L.; Bissett, Wesley] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, College Stn, TX 77843 USA. [Beckham, Tammy] Inst Infect Anim Dis, Dept Homeland Secur, Sci & Technol Ctr Excellence, College Stn, TX 77845 USA. [Alves, Derron A.] Def Hlth Headquarters, Def Hlth Agcy Vet Serv, Falls Church, VA 22042 USA. [Wolcott, Mark; Tostenson, Samantha; Dorman, Bill] US Army, Med Res Inst Infect Dis, Special Pathogens Lab, Diagnost Syst Div, Ft Detrick, MD 21702 USA. RP Behravesh, CB (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM CBartonBehravesh@cdc.gov OI Spengler, Jessica R./0000-0002-5383-0513 NR 24 TC 0 Z9 0 U1 0 U2 10 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD SEP 1 PY 2015 VL 247 IS 5 BP 531 EP 538 PG 8 WC Veterinary Sciences SC Veterinary Sciences GA CP4ME UT WOS:000359855400037 PM 26295560 ER PT J AU Underwood, JM Lakhani, N Rohan, E Moore, A Stewart, SL AF Underwood, J. Michael Lakhani, Naheed Rohan, Elizabeth Moore, Angela Stewart, Sherri L. TI An evaluation of cancer survivorship activities across national comprehensive cancer control programs SO JOURNAL OF CANCER SURVIVORSHIP LA English DT Article DE Epidemiology; Cancer survivors; Comprehensive cancer control ID EPITHELIAL OVARIAN-CANCER; UNITED-STATES; CARE; PREVENTION; PLANS AB Centers for Disease Control and Prevention's (CDC) National Comprehensive Cancer Control Program (NCCCP) funds states, the District of Columbia, tribal organizations, territories, and jurisdictions across the USA develop and implement jurisdiction-specific comprehensive cancer control (CCC) plans. The objective of this study was to analyze NCCCP action plan data for incorporation and appropriateness of cancer survivorship-specific goals and objectives. In August 2013, NCCCP action plans maintained within CDC's Chronic Disease Management Information System (CDMIS) from years 2010 to 2013 were reviewed to assess the inclusion of cancer survivorship objectives. We used the CDMIS search engine to identify "survivorship" within each plan and calculated the proportion of programs that incorporate cancer survivorship-related content during the study period and in each individual year. Cancer survivorship objectives were then categorized by compatibility with nationally accepted, recommended strategies from the report A National Action Plan for Cancer Survivorship: Advancing Public Health Strategies (NAP). From 2010 to 2013, 94 % (n = 65) of NCCCP action plans contained survivorship content in at least 1 year during the time period and 38 % (n = 26) of all NCCCP action plans addressed cancer survivorship every year during the study period. Nearly 64 % (n = 44) of NCCCP action plans included cancer survivorship objectives recommended in NAP. Nearly all NCCCP action plans addressed cancer survivorship from 2010 to 2013, and most programs implemented recommended cancer survivorship efforts during the time period. NCCCP grantees can improve cancer survivorship support by incorporating recommended efforts within each year of their plans. C1 [Underwood, J. Michael; Lakhani, Naheed; Rohan, Elizabeth; Moore, Angela; Stewart, Sherri L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Underwood, JM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS-F76, Atlanta, GA 30333 USA. EM jmunderwood@cdc.gov FU Centers for Disease Control and Prevention's Division of Cancer Prevention and Control FX This work was supported by the Centers for Disease Control and Prevention's Division of Cancer Prevention and Control. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 30 TC 3 Z9 3 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 EI 1932-2267 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD SEP PY 2015 VL 9 IS 3 BP 554 EP 559 DI 10.1007/s11764-015-0432-4 PG 6 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA CP2ZF UT WOS:000359745900019 PM 25732543 ER PT J AU Kim, S Campbell, KA Fox, DJ Matthews, DJ Valdez, R AF Kim, Sunkyung Campbell, Kimberly A. Fox, Deborah J. Matthews, Dennis J. Valdez, Rodolfo CA MD STARnet TI Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE corticosteroid; Duchenne muscular dystrophy; ambulation; treatment duration ID LONG-TERM BENEFITS; NETWORK MD STARNET; SURVEILLANCE TRACKING; DEFLAZACORT TREATMENT; FOLLOW-UP; PREDNISONE; TRIAL; OUTCOMES; BOYS; CARE AB This population-based study examines the association between corticosteroid treatment and time to loss of ambulation, stratifying by treatment duration (short: 0.25-3 years, long: >3 years), among 477 Duchenne muscular dystrophy cases identified by the Muscular Dystrophy Surveillance Tracking and Research Network (MDSTARnet). Those cases who received short-term corticosteroid treatment had a time to loss of ambulation that was 0.8 years shorter (t test) and an annual risk of losing ambulation 77% higher than the untreated (Cox regression). Conversely, cases who received long-term corticosteroid treatment had a time to loss of ambulation that was 2 years longer and an annual risk of losing ambulation 82% lower than the untreated, up to age 11 years; after which the risks were not statistically different. The relationship of corticosteroids and time to loss of ambulation is more complex than depicted by previous studies limited to treatment responders or subjects who lost ambulation during study follow-up. C1 [Kim, Sunkyung; Valdez, Rodolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA USA. [Campbell, Kimberly A.; Fox, Deborah J.] New York State Dept Hlth, Albany, NY USA. [Matthews, Dennis J.] Childrens Hosp Colorado, Aurora, CO USA. RP Kim, S (reprint author), 1600 Clifton Rd NE,Mailstop E88, Atlanta, GA 30333 USA. EM wox0@cdc.gov FU Centers for Disease Control and Prevention (CDC) [5 U01 DD000191] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by Cooperative Agreement 5 U01 DD000191 from the Centers for Disease Control and Prevention (CDC). NR 33 TC 3 Z9 3 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 EI 1708-8283 J9 J CHILD NEUROL JI J. Child Neurol. PD SEP PY 2015 VL 30 IS 10 BP 1275 EP 1280 DI 10.1177/0883073814558120 PG 6 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA CP5JJ UT WOS:000359917100004 PM 25414237 ER PT J AU Barclay, L Yeargin, T Langley, C Kanwar, N Selvarangan, R Bryant, PW Beenhouwer, D Matthews-Greer, J Vinje, J AF Barclay, L. Yeargin, T. Langley, C. Kanwar, N. Selvarangan, R. Bryant, P. W. Beenhouwer, D. Matthews-Greer, J. Vinje, J. TI Multicenter evaluation of RIDA Gene Norovirus GI/GII assay for the detection of norovirus from stool specimens SO JOURNAL OF CLINICAL VIROLOGY LA English DT Meeting Abstract C1 [Barclay, L.; Yeargin, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Langley, C.; Vinje, J.] CDC, Div Viral Dis, Atlanta, GA 30333 USA. [Kanwar, N.; Selvarangan, R.] Childrens Mercy Hosp, Kansas City, MO 64108 USA. [Bryant, P. W.] Wadsworth Ctr, Albany, NY USA. [Beenhouwer, D.] VA Greater LA Healthcare Syst, Los Angeles, CA USA. [Matthews-Greer, J.] Michigan Dept Community Hlth, Bur Labs, Lansing, MI USA. NR 0 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2015 VL 70 SU 1 MA 1692 BP S60 EP S61 DI 10.1016/j.jcv.2015.07.143 PG 2 WC Virology SC Virology GA CP7QI UT WOS:000360082500134 ER PT J AU Hunter, CM Lewis, J Peter, D Begay, MG Ragin-Wilson, A AF Hunter, Candis M. Lewis, Johnnye Peter, Douglas Begay, Mae-Gilene Ragin-Wilson, Angela TI The Navajo Birth Cohort Study SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material ID DEPLETED URANIUM; UNITED-STATES C1 [Hunter, Candis M.] ATSDR, Div Toxicol & Human Hlth Sci, Environm Epidemiol Branch, Atlanta, GA 30341 USA. RP Hunter, CM (reprint author), ATSDR, Div Toxicol & Human Hlth Sci, Environm Epidemiol Branch, 4770 Buford Hwy NE,Mailstop F-57, Atlanta, GA 30341 USA. EM HLB8@cdc.gov NR 11 TC 0 Z9 0 U1 1 U2 7 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD SEP PY 2015 VL 78 IS 2 BP 42 EP 45 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CP5BB UT WOS:000359895200008 PM 26502566 ER PT J AU Ward, BW AF Ward, Brian W. TI Multiple chronic conditions and labor force outcomes: A population study of US adults SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE chronic disease; employment; work hours; sick days; personal earnings ID WORK DISABILITY; HEALTH; PARTICIPATION; PREVALENCE; MULTIMORBIDITY; COSTS; COMORBIDITY; EMPLOYMENT; QUALITY; IMPACT AB BackgroundAlthough 1-in-5 adults have multiple (2) chronic conditions, limited attention has been given to the association between multiple chronic conditions and employment. MethodsCross-sectional data (2011 National Health Interview Survey) and multivariate regression analyses were used to examine the association among multiple chronic conditions, employment, and labor force outcomes for U.S. adults aged 18-64 years, controlling for covariates. ResultsAmong U.S. adults aged 18-64 years (unweighted, n=25,458), having multiple chronic conditions reduced employment probability by 11-29%. Some individual chronic conditions decreased employment probability. Among employed adults (unweighted, n=16,096), having multiple chronic conditions increased the average number of work days missed due to injury/illness in the past year by 3-9 days. ConclusionsMultiple chronic conditions are a barrier to employment and increase the number of work days missed, placing affected individuals at a financial disadvantage. Researchers interested in examining consequences of multiple chronic conditions should give consideration to labor force outcomes.Am. J. Ind. Med. 58:943-954, 2015. Published 2015. This article is a U.S. Government work and is in the public domain in the USA. C1 [Ward, Brian W.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Ward, BW (reprint author), Natl Ctr Hlth Stat, Div Hlth Interview Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM bwward@cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 2 Z9 2 U1 4 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD SEP PY 2015 VL 58 IS 9 BP 943 EP 954 DI 10.1002/ajim.22439 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO8LB UT WOS:000359419500004 PM 26103096 ER PT J AU Afanou, KA Straumfors, A Skogstad, A Nayak, AP Skaar, I Hjeljord, L Tronsmo, A Eduard, W Green, BJ AF Afanou, Komlavi Anani Straumfors, Anne Skogstad, Asbjorn Nayak, Ajay P. Skaar, Ida Hjeljord, Linda Tronsmo, Arne Eduard, Wijnand Green, Brett James TI Indirect Immunodetection of Fungal Fragments by Field Emission Scanning Electron Microscopy SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID IN-HOUSE DUST; ASPERGILLUS-VERSICOLOR; AIRBORNE FUNGAL; OUTDOOR AIR; INDOOR AIR; SPORES; ALLERGENS; EXPOSURE; QUANTIFICATION; HOMES AB Submicronic fungal fragments have been observed in in vitro aerosolization experiments. The occurrence of these particles has therefore been suggested to contribute to respiratory health problems observed in mold-contaminated indoor environments. However, the role of submicronic fragments in exacerbating adverse health effects has remained unclear due to limitations associated with detection methods. In the present study, we report the development of an indirect immunodetection assay that utilizes chicken polyclonal antibodies developed against spores from Aspergillus versicolor and high-resolution field emission scanning electron microscopy (FESEM). Immunolabeling was performed with A. versicolor fragments immobilized and fixed onto poly-L-lysine-coated polycarbonate filters. Ninety percent of submicronic fragments and 1- to 2-mu m fragments, compared to 100% of > 2-mu m fragments generated from pure freeze-dried mycelial fragments of A. versicolor, were positively labeled. In proof-of-concept experiments, air samples collected from moldy indoor environments were evaluated using the immunolabeling technique. Our results indicated that 13% of the total collected particles were derived from fungi. This fraction comprises 79% of the fragments that were detected by immunolabeling and 21% of the spore particles that were morphologically identified. The methods reported in this study enable the enumeration of fungal particles, including submicronic fragments, in a complex heterogeneous environmental sample. C1 [Afanou, Komlavi Anani; Straumfors, Anne; Skogstad, Asbjorn; Eduard, Wijnand] Natl Inst Occupat Hlth, Dept Chem & Biol Work Environm, Oslo, Norway. [Skaar, Ida] Norwegian Vet Inst, Sect Mycol, Oslo, Norway. [Hjeljord, Linda; Tronsmo, Arne] Norwegian Univ Life Sci, Inst Chem Biotechnol & Food Sci, As, Norway. [Nayak, Ajay P.; Green, Brett James] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Morgantown, WV USA. RP Eduard, W (reprint author), Natl Inst Occupat Hlth, Dept Chem & Biol Work Environm, Oslo, Norway. EM wijnand.eduard@stami.no FU Norwegian Research Council [NFR196130/H10] FX The present study is a part of the project "Fungal particles in indoor air," which is financially supported by Norwegian Research Council grant number NFR196130/H10. NR 53 TC 1 Z9 1 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD SEP PY 2015 VL 81 IS 17 BP 5794 EP 5803 DI 10.1128/AEM.00929-15 PG 10 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA CO6HY UT WOS:000359259000015 PM 26092450 ER PT J AU Li, N Neumann, NF Ruecker, N Alderisio, KA Sturbaum, GD Villegas, EN Chalmers, R Monis, P Feng, YY Xiao, LH AF Li, Na Neumann, Norman F. Ruecker, Norma Alderisio, Kerri A. Sturbaum, Gregory D. Villegas, Eric N. Chalmers, Rachel Monis, Paul Feng, Yaoyu Xiao, Lihua TI Development and Evaluation of Three Real-Time PCR Assays for Genotyping and Source Tracking Cryptosporidium spp. in Water SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID OOCYSTS; PARVUM; DIFFERENTIATION; IDENTIFICATION; RESOLUTION; PARASITES; MIXTURES; SAMPLES; TOOLS AB The occurrence of Cryptosporidium oocysts in drinking source water can present a serious public health risk. To rapidly and effectively assess the source and human-infective potential of Cryptosporidium oocysts in water, sensitive detection and correct identification of oocysts to the species level (genotyping) are essential. In this study, we developed three real-time PCR genotyping assays, two targeting the small-subunit (SSU) rRNA gene (18S-LC1 and 18S-LC2 assays) and one targeting the 90-kDa heat shock protein (hsp90) gene (hsp90 assay), and evaluated the sensitivity and Cryptosporidium species detection range of these assays. Using fluorescence resonance energy transfer probes and melt curve analysis, the 18S-LC1 and hsp90 assays could differentiate common human-pathogenic species (C. parvum, C. hominis, and C. meleagridis), while the 18S-LC2 assay was able to differentiate nonpathogenic species (such as C. andersoni) from human-pathogenic ones commonly found in source water. In sensitivity evaluations, the 18S-LC2 and hsp90 genotyping assays could detect as few as 1 Cryptosporidium oocyst per sample. Thus, the 18S-LC2 and hsp90 genotyping assays might be used in environmental monitoring, whereas the 18S-LC1 genotyping assay could be useful for genotyping Cryptosporidium spp. in clinical specimens or wastewater samples. C1 [Li, Na; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Li, Na; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30341 USA. [Neumann, Norman F.] Alberta Prov Lab Publ Hlth, Edmonton, AB, Canada. [Neumann, Norman F.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada. [Ruecker, Norma] City Calgary, Water Qual Serv, Calgary, AB, Canada. [Alderisio, Kerri A.] New York City Dept Environm Protect, Valhalla, NY USA. [Sturbaum, Gregory D.] CH Diagnost & Consulting Serv, Berthoud, CO USA. [Villegas, Eric N.] US EPA, Natl Exposure Res Lab, Cincinnati, OH 45268 USA. [Chalmers, Rachel] Singleton Hosp, Publ Hlth Wales Microbiol, Cryptosporidium Reference Unit, Swansea SA2 8QA, W Glam, Wales. [Monis, Paul] South Australian Water Corp, Australian Water Qual Ctr, Adelaide, SA, Australia. RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30341 USA. EM lxiao@cdc.gov RI Neumann, Norman/J-8310-2015; Villegas, Eric/A-7373-2015; Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014; OI Villegas, Eric/0000-0002-8059-8588; Xiao, Lihua/0000-0001-8532-2727; Monis, Paul/0000-0002-9052-4742 FU Water Research Foundation [RFP4179]; Ministry of Science and Technology, China [2014ZX07104006] FX This study was supported in part by project RFP4179 from the Water Research Foundation and the Water Special Project (2014ZX07104006) from the Ministry of Science and Technology, China. NR 26 TC 0 Z9 1 U1 3 U2 22 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD SEP PY 2015 VL 81 IS 17 BP 5845 EP 5854 DI 10.1128/AEM.01699-15 PG 10 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA CO6HY UT WOS:000359259000020 PM 26092455 ER PT J AU Park, GW Lee, D Treffiletti, A Hrsak, M Shugart, J Vinje, J AF Park, Geun Woo Lee, David Treffiletti, Aimee Hrsak, Mario Shugart, Jill Vinje, Jan TI Evaluation of a New Environmental Sampling Protocol for Detection of Human Norovirus on Inanimate Surfaces SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID FELINE CALICIVIRUS; MURINE NOROVIRUS; GII.4 NOROVIRUS; NORWALK VIRUS; CRUISE SHIP; GASTROENTERITIS; OUTBREAK; RECOVERY; TRANSMISSION; SWABS AB Inanimate surfaces are regarded as key vehicles for the spread of human norovirus during outbreaks. ISO method 15216 involves the use of cotton swabs for environmental sampling from food surfaces and fomites for the detection of norovirus genogroup I (GI) and GII. We evaluated the effects of the virus drying time (1, 8, 24, or 48 h), swab material (cotton, polyester, rayon, macro-foam, or an antistatic wipe), surface (stainless steel or a toilet seat), and area of the swabbed surface (25.8 cm(2) to 645.0 cm(2)) on the recovery of human norovirus. Macrofoam swabs produced the highest rate of recovery of norovirus from surfaces as large as 645 cm(2). The rates of recovery ranged from 2.2 to 36.0% for virus seeded on stainless-steel coupons (645.0 cm(2)) to 1.2 to 33.6% for toilet seat surfaces (700 cm(2)), with detection limits of 3.5 log(10) and 4.0 log(10) RNA copies. We used macrofoam swabs to collect environmental samples from several case cabins and common areas of a cruise ship where passengers had reported viral gastroenteritis symptoms. Seventeen (18.5%) of 92 samples tested positive for norovirus GII, and 4 samples could be sequenced and had identical GII. 1 sequences. The viral loads of the swab samples from the cabins of the sick passengers ranged from 80 to 31,217 RNA copies, compared with 16 to 113 RNA copies for swab samples from public spaces. In conclusion, our swab protocol for norovirus may be a useful tool for outbreak investigations when no clinical samples are available to confirm the etiology. C1 [Park, Geun Woo; Lee, David; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30341 USA. [Lee, David] AREF, Atlanta, GA USA. [Treffiletti, Aimee; Shugart, Jill] Ctr Dis Control & Prevent, Vessel Sanitat Program, Atlanta, GA USA. [Hrsak, Mario] Carnival Cruise Lines, Miami, FL USA. RP Park, GW (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30341 USA. EM gpark@cdc.gov NR 40 TC 5 Z9 5 U1 1 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD SEP PY 2015 VL 81 IS 17 BP 5987 EP 5992 DI 10.1128/AEM.01657-15 PG 6 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA CO6HY UT WOS:000359259000034 PM 26116675 ER PT J AU Abrams, JY Schonberger, LB Maddox, RA Belay, ED AF Abrams, Joseph Y. Schonberger, Lawrence B. Maddox, Ryan A. Belay, Ermias D. TI Re: Examining the Association Between Kawasaki Disease and Pertussis SO EPIDEMIOLOGY LA English DT Letter ID JAPAN; IMMUNIZATION C1 [Abrams, Joseph Y.; Schonberger, Lawrence B.; Maddox, Ryan A.; Belay, Ermias D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. RP Abrams, JY (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. EM JAbrams@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD SEP PY 2015 VL 26 IS 5 BP E56 EP E57 DI 10.1097/EDE.0000000000000341 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP2SH UT WOS:000359726900004 PM 26181232 ER PT J AU Byram, R Gaultney, RA Floden, AM Hellekson, C Stone, BL Bowman, A Stevenson, B Johnson, BJB Brissette, CA AF Byram, Rebecca Gaultney, Robert A. Floden, Angela M. Hellekson, Christopher Stone, Brandee L. Bowman, Amy Stevenson, Brian Johnson, Barbara J. B. Brissette, Catherine A. TI Borrelia burgdorferi RevA Significantly Affects Pathogenicity and Host Response in the Mouse Model of Lyme Disease SO INFECTION AND IMMUNITY LA English DT Article ID FIBRONECTIN-BINDING PROTEIN; ACQUIRING SURFACE-PROTEINS; GENE-EXPRESSION; SENSITIVE QUANTIFICATION; EXTRACELLULAR-MATRIX; IXODES-SCAPULARIS; INDUCED ARTHRITIS; INFECTIOUS CYCLE; PLASMID CONTENT; MICE AB The Lyme disease spirochete, Borrelia burgdorferi, expresses RevA and numerous outer surface lipoproteins during mammalian infection. As an adhesin that promotes bacterial interaction with fibronectin, RevA is poised to interact with the extracellular matrix of the host. To further define the role(s) of RevA during mammalian infection, we created a mutant that is unable to produce RevA. The mutant was still infectious to mice, although it was significantly less well able to infect cardiac tissues. Complementation of the mutant with a wild-type revA gene restored heart infectivity to wild-type levels. Additionally, revA mutants led to increased evidence of arthritis, with increased fibrotic collagen deposition in tibiotarsal joints. The mutants also induced increased levels of the chemokine CCL2, a monocyte chemoattractant, in serum, and this increase was abolished in the complemented strain. Therefore, while revA is not absolutely essential for infection, deletion of revA had distinct effects on dissemination, arthritis severity, and host response. C1 [Byram, Rebecca; Johnson, Barbara J. B.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Gaultney, Robert A.; Floden, Angela M.; Hellekson, Christopher; Stone, Brandee L.; Brissette, Catherine A.] Univ N Dakota, Dept Basic Sci, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA. [Bowman, Amy; Stevenson, Brian] Univ Kentucky, Sch Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA. RP Brissette, CA (reprint author), Univ N Dakota, Dept Basic Sci, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA. EM catherine.brissette@med.und.edu OI Stone, Brandee/0000-0002-0685-1215 FU NIH/NIAID grant [K22AI093671] FX This work was supported by NIH/NIAID grant K22AI093671 to C.A.B. NR 68 TC 1 Z9 1 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD SEP PY 2015 VL 83 IS 9 BP 3675 EP 3683 DI 10.1128/IAI.00530-15 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CO8QP UT WOS:000359435600032 PM 26150536 ER PT J AU Callaghan, WM Creanga, AA Jamieson, DJ AF Callaghan, William M. Creanga, Andreea A. Jamieson, Denise J. TI Pregnancy-Related Mortality Resulting From Influenza in the United States During the 2009-2010 Pandemic SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID A H1N1 VIRUS; NEW-YORK-CITY; MATERNAL MORTALITY; ASIAN INFLUENZA; 2009-10 SEASON; WOMEN; EPIDEMIC; DEATHS AB OBJECTIVE:To estimate the burden of pregnancy-related mortality resulting from influenza A (H1N1)pdm09 virus infection during the 2009-2010 pandemic influenza season.METHODS:Data from the Centers for Disease Control and Prevention's Pregnancy Mortality Surveillance System were used to identify women whose death during or shortly after pregnancy was attributed or likely attributed to the influenza A (H1N1)pdm09 virus from April 15, 2009, through June 30, 2010. We report the characteristics of these women and enumerate cases resulting in death as the pandemic began, peaked, and resolved.RESULTS:During the pandemic season, we identified 915 pregnancy-related deaths and 4,911,297 live births. Seventy-five (8.2%) women died as a result of confirmed influenza A (H1N1)pdm09 infection deaths and 34 (3.7%) women as a result of possible influenza A (H1N1)pdm09 infection deaths. The pregnancy-related mortality ratio for confirmed and possible (combined) influenza A (H1N1)pdm09 infection deaths was 2.2 per 100,000 live births. Most deaths occurred during the 2009 calendar year with the peak of the distribution of deaths over time occurring in October 2009.CONCLUSION:Twelve percent of pregnancy-related deaths were attributed to confirmed or possible influenza A (H1N1)pdm09 infection during the 2009-2010 pandemic season. Because prediction of pandemics is difficult, planning for prevention of influenza and care for those women affected are critical for preventing associated severe maternal morbidity and mortality.LEVEL OF EVIDENCE:III C1 [Callaghan, William M.; Creanga, Andreea A.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Callaghan, WM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS F-74, Atlanta, GA 30341 USA. EM wgc0@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD SEP PY 2015 VL 126 IS 3 BP 486 EP 490 DI 10.1097/AOG.0000000000000996 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CP2KH UT WOS:000359705400006 PM 26244541 ER PT J AU Chang, J Boulet, S Jeng, G Flowers, L Kissin, D AF Chang, J. Boulet, S. Jeng, G. Flowers, L. Kissin, D. TI OUTCOMES OF IN VITRO FERTILIZATION WITH PREIMPLANTATION GENETIC DIAGNOSIS: AN ANALYSIS OF US ASSISTED REPRODUCTIVE TECHNOLOGY SURVEILLANCE DATA, 2011-2012 SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Chang, J.; Boulet, S.; Jeng, G.; Flowers, L.; Kissin, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA P-501 BP E277 EP E278 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900751 ER PT J AU Crawford, S Boulet, S Mneimneh, A Perkins, K Jamieson, DJ Zhang, Y Kissin, DM AF Crawford, S. Boulet, S. Mneimneh, A. Perkins, K. Jamieson, D. J. Zhang, Y. Kissin, D. M. TI COSTS OF ACHIEVING LIVE BIRTH FROM ASSISTED REPRODUCTIVE TECHNOLOGY (ART): A COMPARISON OF SEQUENTIAL SINGLE AND DOUBLE EMBRYO TRANSFER APPROACHES SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Crawford, S.; Boulet, S.; Mneimneh, A.; Perkins, K.; Jamieson, D. J.; Zhang, Y.; Kissin, D. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA P-236 BP E186 EP E186 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900496 ER PT J AU Hipp, H Crawford, S Kawwass, JF Chang, J Kissin, DM Jamieson, DJ AF Hipp, H. Crawford, S. Kawwass, J. F. Chang, J. Kissin, D. M. Jamieson, D. J. TI FIRST TRIMESTER PREGNANCY LOSS FOLLOWING FRESH AND FROZEN IN VITRO FERTILIZATION CYCLES SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Hipp, H.; Kawwass, J. F.] Emory Univ, Sch Med, Gynecol & Obstet, Atlanta, GA USA. [Hipp, H.; Crawford, S.; Kawwass, J. F.; Chang, J.; Kissin, D. M.; Jamieson, D. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA O-90 BP E36 EP E36 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900090 ER PT J AU Kawwass, JF Boulet, SL Hipp, HS Kissin, DM Session, DR Jamieson, DJ AF Kawwass, J. F. Boulet, S. L. Hipp, H. S. Kissin, D. M. Session, D. R. Jamieson, D. J. TI SEVERE DIMINISHED OVARIAN RESERVE: NATIONAL ART OUTCOMES BY AGE, 2004-2012. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Kawwass, J. F.; Hipp, H. S.; Session, D. R.] Emory Reprod Ctr, Reprod Endocrinol & Infertil, Atlanta, GA USA. [Kawwass, J. F.; Boulet, S. L.; Hipp, H. S.; Kissin, D. M.; Jamieson, D. J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Kissin, D. M.; Jamieson, D. J.] Emory Univ, GYN OB, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA P-633 BP E323 EP E323 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900878 ER PT J AU Kissin, DM Crawford, S Boulet, S Kulkarni, A Toner, JP Van Voorhis, B Jamieson, DJ AF Kissin, D. M. Crawford, S. Boulet, S. Kulkarni, A. Toner, J. P. Van Voorhis, B. Jamieson, D. J. TI TRENDS OF ASSISTED REPRODUCTIVE TECHNOLOGY ( ART) TREATMENT PRACTICES AND OUTCOMES, UNITED STATES, 1996-2013. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Kissin, D. M.; Crawford, S.; Boulet, S.; Kulkarni, A.; Jamieson, D. J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Toner, J. P.] Atlanta Ctr Reprod Med, Atlanta, GA USA. [Van Voorhis, B.] Univ Iowa, Dept Obstet & Gynecol, Carver Coll Med, Iowa City, IA 52242 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA P-326 BP E216 EP E217 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900584 ER PT J AU Lange, A Carignan, CC Minguez-Alarcon, L Williams, P Calafat, AM Toth, TL Hauser, R AF Lange, A. Carignan, C. C. Minguez-Alarcon, L. Williams, P. Calafat, A. M. Toth, T. L. Hauser, R. TI TRICLOSAN EXPOSURE AND TREATMENT OUTCOMES IN WOMEN UNDERGOING IN VITRO FERTILIZATION SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Lange, A.] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Carignan, C. C.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Minguez-Alarcon, L.; Williams, P.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Calafat, A. M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Toth, T. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hauser, R.] Harvard Chan Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA O-223 BP E86 EP E86 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900221 ER PT J AU Messerlian, C Wylie, B Williams, P Ford, JB Keller, M Calafat, AM Hauser, R AF Messerlian, C. Wylie, B. Williams, P. Ford, J. B. Keller, M. Calafat, A. M. Hauser, R. TI URINARY PHTHALATE METABOLITE CONCENTRATIONS WERE ASSOCIATED WITH PREGNANCY LOSS AMONG WOMEN CONCEIVING WITH MEDICALLY ASSISTED REPRODUCTION SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Messerlian, C.; Ford, J. B.; Keller, M.; Hauser, R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Wylie, B.; Hauser, R.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Williams, P.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Calafat, A. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA O-96 BP E38 EP E38 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900096 ER PT J AU Perkins, K Boulet, S Kissin, DM Jamieson, DJ AF Perkins, K. Boulet, S. Kissin, D. M. Jamieson, D. J. TI TRENDS AND OUTCOMES OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CYCLES USING GESTATIONAL CARRIERS IN THE UNITED STATES, 1998-2012 SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Perkins, K.; Boulet, S.; Kissin, D. M.; Jamieson, D. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA O-263 BP E100 EP E100 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900261 ER PT J AU Sunderam, S Kissin, DM Crawford, S Folger, S Jamieson, D Warner, L Barfield, W AF Sunderam, S. Kissin, D. M. Crawford, S. Folger, S. Jamieson, D. Warner, L. Barfield, W. TI OVERVIEW OF 2012 US ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT OUTCOMES AND CONTRIBUTION TO MULTIPLE BIRTH AND PRETERM INFANTS. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Sunderam, S.; Crawford, S.; Folger, S.; Jamieson, D.; Warner, L.; Barfield, W.] Ctr Dis Control & Prevent, Div Reprod Hlth, Chamblee, GA USA. [Kissin, D. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA P-109 BP E143 EP E143 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900377 ER PT J AU Veleva, Z Boulet, S Makinen, S Martikainen, H Tiitinen, A Tapanainen, J Kissin, DM AF Veleva, Z. Boulet, S. Makinen, S. Martikainen, H. Tiitinen, A. Tapanainen, J. Kissin, D. M. TI BLASTOCYST VERSUS CLEAVAGE-STAGE ELECTIVE SINGLE EMBRYO TRANSFER - A COMPARATIVE RETROSPECTIVE STUDY SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 71st Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 17-21, 2015 CL Baltimore, MD SP Amer Soc Reprod Med C1 [Veleva, Z.; Tiitinen, A.; Tapanainen, J.] Univ Helsinki, Ob Gyn, Helsinki, Finland. [Veleva, Z.; Tiitinen, A.; Tapanainen, J.] Univ Helsinki, Cent Hosp, Helsinki, Finland. [Boulet, S.; Kissin, D. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Makinen, S.] Family Federat Finland, Helsinki, Finland. [Makinen, S.] Oulu Infertil Clin, Helsinki, Finland. [Martikainen, H.] Univ Oulu, Ob Gyn, Oulu, Finland. [Martikainen, H.] Oulu Univ Hosp, Oulu, Finland. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2015 VL 104 IS 3 SU S MA P-221 BP E181 EP E182 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DR6NP UT WOS:000380018900481 ER PT J AU Durkin, MS Maenner, MJ Benedict, RE Braun, KV Christensen, D Kirby, RS Wingate, M Yeargin-Allsopp, M AF Durkin, Maureen S. Maenner, Matthew J. Benedict, Ruth E. Braun, Kim Van Naarden Christensen, Deborah Kirby, Russell S. Wingate, Martha Yeargin-Allsopp, Marshalyn TI The role of socio-economic status and perinatal factors in racial disparities in the risk of cerebral palsy SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY LA English DT Article ID DISABILITIES MONITORING NETWORK; SMALL BLACK INFANTS; BIRTH-WEIGHT; WHITE INFANTS; UNITED-STATES; PREVALENCE; INEQUALITIES; CHILDREN; AUTISM AB AimTo determine whether racial disparities in cerebral palsy (CP) risk among US children persist after controlling for socio-economic status (SES) (here indicated by maternal education) and perinatal risk factors. MethodA population-based birth cohort study was conducted using the Autism and Developmental Disabilities Monitoring Network surveillance and birth data for 8-year-old children residing in multi-county areas in Alabama, Georgia, Missouri, and Wisconsin between 2002 and 2008. The birth cohort comparison group included 458027 children and the case group included 1570 children with CP, 1202 with available birth records. (2) tests were performed to evaluate associations and logistic regression was used to calculate relative risks (RR) and adjusted odds ratios (OR) with 95% confidence intervals (CI). ResultsThe risk of spastic CP was more than 50% higher for black versus white children (RR 1.52, 95% CI 1.33-1.73), and this greater risk persisted after adjustment for SES (OR 1.35, 95% CI 1.18-1.55), but not after further adjustment for preterm birth and size for gestational age. The protective effect of maternal education remained after adjustment for race/ethnicity and perinatal factors. InterpretationMaternal education appears to independently affect CP risk but does not fully explain existing racial disparities in CP prevalence in the US. What this paper adds The risk of spastic cerebral palsy (CP) was higher in black relative to white children. Disparities in maternal education, an indicator of socio-economic status, did not fully explain the greater CP risk among black children. Factors associated with higher maternal education may help protect against the risk of spastic CP. This article is commented on by Oskoui on pages 791-792 of this issue. C1 [Durkin, Maureen S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA. [Durkin, Maureen S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53726 USA. [Durkin, Maureen S.; Maenner, Matthew J.; Benedict, Ruth E.] Univ Wisconsin, Waisman Ctr, Madison, WI 53726 USA. [Maenner, Matthew J.; Braun, Kim Van Naarden; Christensen, Deborah; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Benedict, Ruth E.] Univ Wisconsin, Dept Kinesiol, Occupat Therapy Program, Madison, WI USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. [Wingate, Martha] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA. RP Durkin, MS (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, 789 WARF,610 Walnut St, Madison, WI 53726 USA. EM mdurkin@wisc.edu FU Centers for Disease Control and Prevention [UR3/CCU523235, UR3/DD000078, UR3/DD000677]; University of Wisconsin-Madison; National Institute of Child Health and Human Development [P30HD03352] FX Funding for this work was provided by Centers for Disease Control and Prevention Cooperative Agreements UR3/CCU523235, UR3/DD000078, and UR3/DD000677, and by the University of Wisconsin-Madison and the National Institute of Child Health and Human Development Grant P30HD03352. We are grateful to the many staff, scientists, and clinicians that have contributed to the Autism and Developmental Disabilities Monitoring Network project. The authors have stated that they had no interests which might be perceived as posing a conflict or bias. NR 21 TC 6 Z9 6 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0012-1622 EI 1469-8749 J9 DEV MED CHILD NEUROL JI Dev. Med. Child Neurol. PD SEP PY 2015 VL 57 IS 9 BP 835 EP 843 DI 10.1111/dmcn.12746 PG 9 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA CO6XA UT WOS:000359299900016 PM 25808915 ER PT J AU Grosholz, JM Blake, S Daugherty, JD Ayers, E Omer, SB Polivka-West, L Howard, DH AF Grosholz, J. M. Blake, S. Daugherty, J. D. Ayers, E. Omer, S. B. Polivka-West, L. Howard, D. H. TI Accuracy of influenza vaccination rate estimates in United States nursing home residents SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Analysis of data; health statistics; influenza vaccines; vaccine policy development; vaccines ID BLACK AB The US Center for Medicare and Medicaid Services (CMS) requires nursing homes and long-term-care facilities to document residents' vaccination status on the Resident Assessment Instrument (RAI). Vaccinating residents can prevent costly hospital admissions and deaths. CMS and public health officials use RAI data to measure vaccination rates in long-term-care residents and assess the quality of care in nursing homes. We assessed the accuracy of RAI data against medical records in 39 nursing homes in Florida, Georgia, and Wisconsin. We randomly sampled residents in each home during the 2010-2011 and 2011-2012 influenza seasons. We collected data on receipt of influenza vaccination from charts and RAI data. Our final sample included 840 medical charts with matched RAI records. The agreement rate was 0.86. Using the chart as a gold standard, the sensitivity of the RAI with respect to influenza vaccination was 85% and the specificity was 77%. Agreement rates varied within facilities from 55% to 100%. Monitoring vaccination rates in the population is important for gauging the impact of programmes and policies to promote adherence to vaccination recommendations. Use of data from RAIs is a reasonable approach for gauging influenza vaccination rates in nursing-home residents. C1 [Grosholz, J. M.] Univ South Florida Sarasota Manatee, Sarasota, FL USA. [Blake, S.; Ayers, E.; Omer, S. B.; Howard, D. H.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Daugherty, J. D.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Polivka-West, L.] Florida Hlth Care Assoc, Tallahassee, FL USA. RP Howard, DH (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM david.howard@emory.edu FU Centers for Disease Control and Prevention [1U01IP000411-01] FX This study was supported by Centers for Disease Control and Prevention cooperative agreement 1U01IP000411-01. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 12 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD SEP PY 2015 VL 143 IS 12 BP 2588 EP 2595 DI 10.1017/S0950268814003434 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CO0ME UT WOS:000358844800013 PM 25519437 ER PT J AU Govender, NP Roy, M Mendes, JF Zulu, TG Chiller, TM Karstaedt, AS AF Govender, N. P. Roy, M. Mendes, J. F. Zulu, T. G. Chiller, T. M. Karstaedt, A. S. TI Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa SO HIV MEDICINE LA English DT Article DE cryptococcal antigen; cryptococcal meningitis; evaluation; screen-and-treat; South Africa ID SUB-SAHARAN AFRICA; INITIATING ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; EARLY MORTALITY; MENINGITIS; ADULTS; CARE; PREVALENCE; PROGRAM; DISEASE AB ObjectivesWe retrospectively evaluated clinic-based screening to determine the prevalence of cryptococcal antigenaemia and management and outcome of patients with antigenaemia. MethodsCryptococcal antigen (CrAg) screening of HIV-infected adults who attended the HIV clinic at Chris Hani Baragwanath Hospital was conducted over 19 months. Data collected from CrAg-positive patients included CD4 T-lymphocyte count at screening, prior or subsequent cryptococcal meningitis (CM), antifungal and antiretroviral treatment and outcome after at least 8 months. ResultsOf 1460 patients with no prior CM, 30 (2.1%) had a positive CrAg test. The prevalence of antigenaemia among patients with a CD4 count <100 cells/l and no prior CM was 2.8% (20 of 708). Of 29 evaluable CrAg-positive patients with no prior CM, 14 (48%) did not return for post-screening follow-up. Of these 14, five developed CM and one (7%) was known to be alive at follow-up. Of 15 patients who returned for follow-up, two already had evidence of nonmeningeal cryptococcosis. Overall, 11 received fluconazole, one did not and fluconazole treatment was unknown for three. Among these 15, one developed CM and 10 (67%) were known to be alive at follow-up. Overall, 18 (62%) of 29 CrAg-positive patients died or were lost to follow-up. Seven (0.5%) of 1430 CrAg-negative patients developed CM a median of 83 days post-screening (range 34 to 219 days). ConclusionsLoss to follow-up is the major operational issue relevant to scale-up of screen-and-treat. Patient outcomes may be improved by rapid access to CrAg results and focus on linkage to and retention in HIV care. C1 [Govender, N. P.; Zulu, T. G.] Natl Inst Communicable Dis, Ctr Opportunist Trop & Hosp Infect, ZA-2132 Johannesburg, South Africa. [Govender, N. P.; Mendes, J. F.; Karstaedt, A. S.] Univ Witwatersrand, Fac Hlth Sci, ZA-2050 Johannesburg, South Africa. [Roy, M.; Chiller, T. M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Mendes, J. F.] Gauteng Dept Hlth, Dept Community Hlth, Johannesburg, South Africa. [Karstaedt, A. S.] Chris Hani Baragwanath Hosp, Div Infect Dis, Dept Med, Soweto, South Africa. RP Govender, NP (reprint author), Natl Inst Communicable Dis, Ctr Opportunist Trop & Hosp Infect, Private Bag X4, ZA-2132 Johannesburg, South Africa. EM neleshg@nicd.ac.za FU National Institute for Communicable Diseases FX The work was fully supported by the National Institute for Communicable Diseases. Although CrAg tests were provided by Immuno-Mycologics, Inc. and Davies Diagnostics (Pty) Limited for the purposes of the clinic screen-and-treat programme, these companies had no role in study design, implementation or data collection and analysis. NR 31 TC 6 Z9 6 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD SEP PY 2015 VL 16 IS 8 BP 468 EP 476 DI 10.1111/hiv.12245 PG 9 WC Infectious Diseases SC Infectious Diseases GA CO6XT UT WOS:000359301800002 PM 25689352 ER PT J AU Ridenour, C Johnson, A Winne, E Hossain, J Mateu-Petit, G Balish, A Santana, W Kim, T Davis, C Cox, NJ Barr, JR Donis, RO Villanueva, J Williams, TL Chen, LM AF Ridenour, Callie Johnson, Adam Winne, Emily Hossain, Jaber Mateu-Petit, Guaniri Balish, Amanda Santana, Wanda Kim, Taejoong Davis, Charles Cox, Nancy J. Barr, John R. Donis, Ruben O. Villanueva, Julie Williams, Tracie L. Chen, Li-Mei TI Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Antigen yield; H7N9; hemagglutinin; influenza; serial passage; vaccine ID A H7N9 VIRUSES; MASS-SPECTROMETRY; BINDING; NEURAMINIDASE; H5N1; QUANTIFICATION; GENERATION; MIXTURES; SUBTYPE; ORIGIN AB BackgroundThe emergence of avian influenza A(H7N9) virus in poultry causing zoonotic human infections was reported on March 31, 2013. Development of A(H7N9) candidate vaccine viruses (CVV) for pandemic preparedness purposes was initiated without delay. Candidate vaccine viruses were derived by reverse genetics using the internal genes of A/Puerto/Rico/8/34 (PR8). The resulting A(H7N9) CVVs needed improvement because they had titers and antigen yields that were suboptimal for vaccine manufacturing in eggs, especially in a pandemic situation. MethodsTwo CVVs derived by reverse genetics were serially passaged in embryonated eggs to improve the hemagglutinin (HA) antigen yield. The total viral protein and HA antigen yields of six egg-passaged CVVs were determined by the BCA assay and isotope dilution mass spectrometry (IDMS) analysis, respectively. CVVs were antigenically characterized by hemagglutination inhibition (HI) assays with ferret antisera. ResultsImprovement of total viral protein yield was observed for the six egg-passaged CVVs; HA quantification by IDMS indicated approximately a twofold increase in yield of several egg-passaged viruses as compared to that of the parental CVV. Several different amino acid substitutions were identified in the HA of all viruses after serial passage. However, HI tests indicated that the antigenic properties of two CVVs remained unchanged. ConclusionsIf influenza A(H7N9) viruses were to acquire sustained human-to-human transmissibility, the improved HA yield of the egg-passaged CVVs generated in this study could expedite vaccine manufacturing for pandemic mitigation. C1 [Ridenour, Callie; Johnson, Adam; Hossain, Jaber; Mateu-Petit, Guaniri; Balish, Amanda; Kim, Taejoong; Davis, Charles; Cox, Nancy J.; Donis, Ruben O.; Villanueva, Julie; Chen, Li-Mei] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Winne, Emily; Santana, Wanda; Barr, John R.; Williams, Tracie L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Winne, Emily] Battelle Mem Inst, Atlanta, GA USA. RP Chen, LM (reprint author), Ctr Dis Control & Prevent, Influenza Div, MS-G16,1600, Atlanta, GA 30333 USA. EM Lchen1@cdc.gov NR 35 TC 3 Z9 3 U1 3 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2015 VL 9 IS 5 BP 263 EP 270 DI 10.1111/irv.12322 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CO3WO UT WOS:000359092100005 PM 25962412 ER PT J AU Smith, GJD Donis, RO AF Smith, Gavin J. D. Donis, Ruben O. CA World Health Organization World TI Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE clade nomenclature; H5 subtype; hemagglutinin; highly pathogenic avian influenza; molecular epidemiology; phylogenetics; viral evolution ID SOUTH-KOREA; MAXIMUM-LIKELIHOOD; MIGRATORY BIRDS; EASTERN CHINA; H5N8; DUCKS AB AimThe A/goose/Guangdong/1/96-like hemagglutinin (HA) genes of highly pathogenic avian influenza (HPAI) A(H5) viruses have continued to rapidly evolve since the most recent update to the H5 clade nomenclature by the WHO/OIE/FAO H5N1 Evolution Working Group. New clades diverging beyond established boundaries need to be identified and designated accordingly. MethodHemagglutinin sequences deposited in publicly accessible databases up to December 31, 2014, were analyzed by phylogenetic and average pairwise distance methods to identify new clades that merit nomenclature changes. ResultsThree new clade designations were recommended based on division of clade 2132a (Indonesia), 221 (Egypt), and 234 (widespread detection in Asia, Europe, and North America) that includes newly emergent HPAI virus subtypes H5N2, H5N3, H5N5, H5N6, and H5N8. ConclusionContinued global surveillance for HPAI A(H5) viruses in all host species and timely reporting of sequence data will be critical to quickly identify new clades and assess their potential impact on human and animal health. C1 [Smith, Gavin J. D.] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore, Singapore. [Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Donis, RO (reprint author), Ctr Dis Control & Prevent, Influenza Div, MS G16, Atlanta, GA 30333 USA. EM gavin.smith@duke-nus.edu.sg; rvd6@cdc.gov RI Zhu, Huachen/A-8252-2017; OI Zhu, Huachen/0000-0003-2711-0501; Smith, Gavin JD/0000-0001-5031-468X FU Australian Government Department of Health FX We thank the Writing Group (Ian H. Brown, Giovanni Cattoli, Todd Davis, Ruben O. Donis, Ron A.M. Fouchier, Yunho Jang, Tommy T.Y. Lam, Samuel Shepard, Gavin J.D. Smith, and Frank Wong) for drafting the manuscript on behalf of the H5N1 Evolution Working Group. We also thank Samuel Shepard, Tommy Lam, and Yunho Jang for performing sequence and phylogenetic analyses. We acknowledge the laboratories that provided virus samples and sequence data for access to information deposited into the GISAID database; authors and originating/submitting laboratories are listed in Supplementary Data S4. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), or the World Health Organization (WHO). NR 34 TC 31 Z9 32 U1 5 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2015 VL 9 IS 5 BP 271 EP 276 DI 10.1111/irv.12324 PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CO3WO UT WOS:000359092100006 PM 25966311 ER PT J AU Espelage, DL Basile, KC De La Rue, L Hamburger, ME AF Espelage, Dorothy L. Basile, Kathleen C. De La Rue, Lisa Hamburger, Merle E. TI Longitudinal Associations Among Bullying, Homophobic Teasing, and Sexual Violence Perpetration Among Middle School Students SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE bullying; sexual harassment; adolescents ID PSYCHOLOGICAL OUTCOMES; PEER VICTIMIZATION; PROTECTIVE FACTORS; GENDER AGGRESSION; EARLY ADOLESCENCE; DATING VIOLENCE; HARASSMENT; PREDICTORS; PREVALENCE; YOUTH AB Bullying perpetration and sexual harassment perpetration among adolescents are major public health issues. However, few studies have addressed the empirical link between being a perpetrator of bullying and subsequent sexual harassment perpetration among early adolescents in the literature. Homophobic teasing has been shown to be common among middle school youth and was tested as a moderator of the link between bullying and sexual harassment perpetration in this 2-year longitudinal study. More specifically, the present study tests the Bully-Sexual Violence Pathway theory, which posits that adolescent bullies who also participate in homophobic name-calling toward peers are more likely to perpetrate sexual harassment over time. Findings from logistical regression analyses (n = 979, 5th-7th graders) reveal an association between bullying in early middle school and sexual harassment in later middle school, and results support the Bully-Sexual Violence Pathway model, with homophobic teasing as a moderator, for boys only. Results suggest that to prevent bully perpetration and its later association with sexual harassment perpetration, prevention programs should address the use of homophobic epithets. C1 [Espelage, Dorothy L.; De La Rue, Lisa] Univ Illinois, Champaign, IL 61820 USA. [Basile, Kathleen C.; Hamburger, Merle E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Espelage, DL (reprint author), Univ Illinois, 226 Educ Bldg,1310 S 6th St, Champaign, IL 61820 USA. EM espelage@illinois.edu FU Centers for Disease Control [1U01/CE001677] FX The author(s) declared receipt of the following financial support for the research, authorship, and/or publication of this article: Funded by Centers for Disease Control #1U01/CE001677 (Espelage, PI) NR 52 TC 6 Z9 6 U1 9 U2 34 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 EI 1552-6518 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD SEP PY 2015 VL 30 IS 14 BP 2541 EP 2561 DI 10.1177/0886260514553113 PG 21 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA CO6JT UT WOS:000359263700009 PM 25315484 ER PT J AU Howland, RE Mulready-Ward, C Madsen, AM Sackoff, J Nyland-Funke, M Bombard, JM Tong, VT AF Howland, Renata E. Mulready-Ward, Candace Madsen, Ann M. Sackoff, Judith Nyland-Funke, Michael Bombard, Jennifer M. Tong, Van T. TI Reliability of Reported Maternal Smoking: Comparing the Birth Certificate to Maternal Worksheets and Prenatal and Hospital Medical Records, New York City and Vermont, 2009 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Birth certificates; Pregnancy; Reproducibility of results; Smoking; Vital statistics ID PREVALENCE; PREGNANCY; QUESTIONNAIRES; EPIDEMIOLOGY; VALIDATION; CESSATION; QUALITY AB Maternal smoking is captured on the 2003 US Standard Birth Certificate based on self-reported tobacco use before and during pregnancy collected on post-delivery maternal worksheets. Study objectives were to compare smoking reported on the birth certificate to maternal worksheets and prenatal and hospital medical records. The authors analyzed a sample of New York City (NYC) and Vermont women (n = 1,037) with a live birth from January to August 2009 whose responses to the Pregnancy Risk Assessment Monitoring System survey were linked with birth certificates and abstracted medical records and maternal worksheets. We calculated smoking prevalence and agreement (kappa) between sources overall and by maternal and hospital characteristics. Smoking before and during pregnancy was 13.7 and 10.4 % using birth certificates, 15.2 and 10.7 % using maternal worksheets, 18.1 and 14.1 % using medical records, and 20.5 and 15.0 % using either maternal worksheets or medical records. Birth certificates had "almost perfect" agreement with maternal worksheets for smoking before and during pregnancy (kappa = 0.92 and 0.89) and "substantial" agreement with medical records (kappa = 0.70 and 0.74), with variation by education, insurance, and parity. Smoking information on NYC and Vermont birth certificates closely agreed with maternal worksheets but was underestimated compared with medical records, with variation by select maternal characteristics. Opportunities exist to improve birth certificate smoking data, such as reducing the stigma of smoking, and improving the collection, transcription, and source of information. C1 [Howland, Renata E.; Mulready-Ward, Candace; Madsen, Ann M.; Sackoff, Judith] New York City Dept Hlth & Mental Hyg, New York, NY 10010 USA. [Nyland-Funke, Michael] Vermont Dept Hlth, Burlington, VT 05402 USA. [Bombard, Jennifer M.; Tong, Van T.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Howland, RE (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY 10010 USA. EM rroney@health.nyc.gov FU Centers for Disease Control (CDC) and Prevention [5U38HM000414-5]; CDC [3UR6DP000467-05W1, 3UR6DP000484-05W1] FX This work was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by the Centers for Disease Control (CDC) and Prevention (Cooperative Agreement Number 5U38HM000414-5). The Pregnancy Risk Assessment Monitoring System Data Quality Improvement Project was funded by the CDC [Cooperative Agreement Number 3UR6DP000467-05W1 (NYC) and 3UR6DP000484-05W1 (Vermont)]. NR 34 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2015 VL 19 IS 9 BP 1916 EP 1924 DI 10.1007/s10995-015-1722-1 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9CY UT WOS:000358745200003 PM 25676044 ER PT J AU Sharma, AJ Vesco, KK Bulkley, J Callaghan, WM Bruce, FC Staab, J Hornbrook, MC Berg, CJ AF Sharma, Andrea J. Vesco, Kimberly K. Bulkley, Joanna Callaghan, William M. Bruce, F. Carol Staab, Jenny Hornbrook, Mark C. Berg, Cynthia J. TI Associations of Gestational Weight Gain with Preterm Birth among Underweight and Normal Weight Women SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Pregnancy; Gestational weight gain; Weight gain measures; Preterm birth ID BODY-MASS INDEX; DELIVERY; PREGNANCY; RISK AB Studies report increased risk of preterm birth (PTB) among underweight and normal weight women with low gestational weight gain (GWG). However, most studies examined GWG over gestational periods that differ by term and preterm which may have biased associations because GWG rate changes over the course of pregnancy. Furthermore, few studies have specifically examined the amount and pattern of GWG early in pregnancy as a predictor of PTB. Within one integrated health care delivery system, we examined 12,526 singleton pregnancies between 2000 and 2008 among women with a body mass index < 25 kg/m(2), who began prenatal care in the first trimester and delivered a live-birth > 28 weeks gestation. Using self-reported pregravid weight and serial measured antenatal weights, we estimated GWG and the area under the GWG curve (AUC; an index of pattern of GWG) during the first and second trimesters of pregnancy (a parts per thousand currency sign28 weeks). Using logistic regression adjusted for covariates, we examined associations between each GWG measure, categorized into quartiles, and PTB (< 37 weeks gestation). We additionally examined associations according to the reason for PTB by developing a novel algorithm using diagnoses and procedure codes. Low GWG in the first and second trimesters was not associated with PTB [aOR 1.11, (95 % CI 0.90, 1.38) with GWG < 8.2 kg by 28 weeks compared to pregnancies with GWG > 12.9]. Similarly, pattern of GWG was not associated with PTB. Our findings do not support an association between GWG in the first and second trimester and PTB among underweight and normal weight women. C1 [Sharma, Andrea J.; Callaghan, William M.; Bruce, F. Carol; Berg, Cynthia J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Sharma, Andrea J.] US Public Hlth Serv Commissioned Corps, Atlanta, GA USA. [Vesco, Kimberly K.; Bulkley, Joanna; Staab, Jenny; Hornbrook, Mark C.] Kaiser Permanente Northwest, Ctr Hlth Res, Northwest Hawaii Southeast, Portland, OR USA. RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. EM AJSharma@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 13 TC 6 Z9 6 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2015 VL 19 IS 9 BP 2066 EP 2073 DI 10.1007/s10995-015-1719-9 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9CY UT WOS:000358745200020 PM 25652068 ER PT J AU Casal, C Alvarez, J Bezos, J Quick, H Diez-Guerrierce, A Romero, B Saez, JL Liandris, E Navarro, A Perez, A Dominguez, L de Juan, L AF Casal, Carmen Alvarez, Julio Bezos, Javier Quick, Harrison Diez-Guerrierce, Alberto Romero, Beatriz Saez, Jose L. Liandris, Emmanouil Navarro, Alejandro Perez, Andres Dominguez, Lucas de Juan, Lucia TI Effect of the inoculation site of bovine purified protein derivative (PPD) on the skin fold thickness increase in cattle from officially tuberculosis free and tuberculosis-infected herds SO PREVENTIVE VETERINARY MEDICINE LA English DT Article DE Bovine tuberculosis; Intradermal inoculation; Tuberculin test; bovine PPD ID GAMMA-INTERFERON ASSAY; MYCOBACTERIUM-BOVIS; IMMUNE-RESPONSES; DIAGNOSTIC-TECHNIQUES; DISEASE-CONTROL; RISK-FACTORS; CAUDAL FOLD; TESTS; SENSITIVITY; ERADICATION AB The official technique for diagnosis of bovine tuberculosis (bTB) worldwide is the tuberculin skin test, based on the evaluation of the skin thickness increase after the intradermal inoculation of a purified protein derivative (PPD) in cattle. A number of studies performed on experimentally infected or sensitized cattle have suggested that the relative sensitivity of the cervical test (performed in the neck) may vary depending on the exact location in which the PPD is injected. However, quantitative evidence on the variation of the test accuracy associated to changes in the site of inoculation in naturally infected animals (the population in which performance of the test is most critical for disease eradication) is lacking. Here, the probability of obtaining a positive reaction (>2 or 4 millimeters and/or presence of local clinical signs) after multiple inoculations of bovine PPD in different cervical and scapular locations was assessed in animals from five bTB-infected herds (818 cattle receiving eight inoculations) using a hierarchical Bayesian logistic regression model and adjusting for the potential effect of age and sex. The effect of the inoculation site was also assessed qualitatively in animals from four officially tuberculosis free (OTF) herds (two inoculations in 210 animals and eight inoculations in 38 cattle). Although no differences in the qualitative outcome of the test were observed in cattle from OTF herds, a statistically important association between the test outcome and the inoculation site in animals from infected herds was observed, with higher probabilities of positive results when the test was performed in the neck anterior area. Our results suggest that test sensitivity may be maximized by considering the area of the neck in which the test is applied, although lack of effect of the inoculation site in the specificity of the test should be confirmed in a larger sample. (C) 2015 Elsevier B.V. All rights reserved. C1 [Casal, Carmen; Romero, Beatriz; Liandris, Emmanouil; Navarro, Alejandro; Dominguez, Lucas; de Juan, Lucia] Univ Complutense Madrid, VISAVET Hlth Surveillance Ctr, Mycobacteria Unit, E-28040 Madrid, Spain. [Alvarez, Julio; Perez, Andres] Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA. [Bezos, Javier; Diez-Guerrierce, Alberto] MAEVA SERVET SL, Madrid 28749, Spain. [Quick, Harrison] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Diez-Guerrierce, Alberto; Dominguez, Lucas; de Juan, Lucia] Univ Complutense Madrid, Fac Vet Med, Dept Anim Hlth, E-28040 Madrid, Spain. [Saez, Jose L.] Minist Agr Food & Environm, Madrid 28071, Spain. RP Alvarez, J (reprint author), Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA. EM jalvarez@umn.edu RI Account for bibliometric studies, IT VISAVET/C-3115-2014; Casal Comendador, Carmen/E-8998-2016; de Juan, Lucia/I-6465-2016; Romero, Beatriz/J-5942-2015; Bezos, Javier/K-1335-2014; Navarro, Alejandro/Q-5750-2016; Alvarez, Julio/H-8292-2013 OI Account for bibliometric studies, IT VISAVET/0000-0003-3319-0050; Casal Comendador, Carmen/0000-0003-2433-2870; de Juan, Lucia/0000-0002-7070-6872; Romero, Beatriz/0000-0001-5263-1806; Bezos, Javier/0000-0003-1913-0545; Navarro, Alejandro/0000-0003-2694-853X; Alvarez, Julio/0000-0002-8999-9417 FU European Union (WildTBVac); University of Minnesota Office of the Vice President for Research (OVPR); Global Food Venture MnDrive initiatives FX This study was partially funded by the Collaborative project FP7-KBBE-2013-7-single-stage of European Union (WildTBVac)and the the University of Minnesota Office of the Vice President for Research (OVPR) and Global Food Venture MnDrive initiatives. We thank the regional authorities to facilitate the performance of the study and Mycobacteria and Computer and Communication Units for their technical support. Further gratitude is expressed to Ana Alonso-Lasheras, Cristina Gomez, PilarPozo and Juan M. Lomillos for their technical assistance. NR 43 TC 1 Z9 1 U1 4 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-5877 EI 1873-1716 J9 PREV VET MED JI Prev. Vet. Med. PD SEP 1 PY 2015 VL 121 IS 1-2 BP 86 EP 92 DI 10.1016/j.prevetmed.2015.07.001 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA CO5BC UT WOS:000359173600010 PM 26189005 ER PT J AU Boyoglu-Barnum, S Todd, SO Chirkova, T Barnum, TR Gaston, KA Haynes, LM Tripp, RA Moore, ML Anderson, LJ AF Boyoglu-Barnum, Seyhan Todd, Sean O. Chirkova, Tatiana Barnum, Thomas R. Gaston, Kelsey A. Haynes, Lia M. Tripp, Ralph A. Moore, Martin L. Anderson, Larry J. TI An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice SO VIROLOGY LA English DT Article DE RSV; Anti-viral; RSV G protein; RSV F protein ID RESPIRATORY-SYNCYTIAL-VIRUS; SECRETED GLYCOPROTEIN-G; SOLUBLE G-PROTEIN; HIGH-RISK INFANTS; SUBSTANCE-P; CX3C MOTIF; INFECTION; PATHOGENESIS; INFLAMMATION; EXPRESSION AB Respiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single most important cause of serious lower respiratory tract infections in young children, yet no highly effective treatment or vaccine is available. To clarify the potential for an anti-G mAb, 131-2G which has both anti-viral and anti-inflammatory effects, to effectively treat RSV disease, we determined the kinetics of its effect compared to the effect of the anti-F mAb, 143-6C on disease in mice. Treatment administered three days after RSV rA2-line19F (r19F) infection showed 131-2G decreased breathing effort, pulmonary mucin levels, weight loss, and pulmonary inflammation earlier and more effectively than treatment with mAb 143-6C. Both mAbs stopped lung virus replication at day 5 post-infection. These data show that, in mice, anti-G protein mAb is superior to treating disease during RSV infection than an anti-F protein mAb similar to Palivizumab. This combination of anti-viral and anti-inflammatory activity makes 131-2G a promising candidate for treating for active human RSV infection. (C) 2015 Elsevier Inc. All rights reserved. C1 [Boyoglu-Barnum, Seyhan; Todd, Sean O.; Chirkova, Tatiana; Gaston, Kelsey A.; Moore, Martin L.; Anderson, Larry J.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Boyoglu-Barnum, Seyhan; Todd, Sean O.; Chirkova, Tatiana; Gaston, Kelsey A.; Moore, Martin L.; Anderson, Larry J.] Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. [Haynes, Lia M.] CDC, Div Viral Dis, NCIRD, Atlanta, GA 30333 USA. [Tripp, Ralph A.] Univ Georgia, Dept Infect Dis, Anim Hlth Res Ctr, Athens, GA 30602 USA. [Barnum, Thomas R.] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. RP Anderson, LJ (reprint author), Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. EM larry.anderson@emory.edu FU NIH [1U19AI095227, 1R01AI087798]; Immunology Core and Flow core of Emory+Children's Pediatric Research Center; Emory Vaccinology Training Grant (VTP) [T32 5T32AI074492-03]; Trellis RSV Holdings, Inc. [0000019070]; Children's Healthcare of Atlanta FX This work was supported by NIH 1U19AI095227 grant awarded to MLM and LJA, NIH 1R01AI087798 (MLM), funding from Children's Healthcare of Atlanta, support from the Immunology Core and Flow core of Emory+Children's Pediatric Research Center, and the Emory Vaccinology Training Grant (VTP) T32 5T32AI074492-03. This study was also supported through a grant to Emory University from Trellis RSV Holdings, Inc. (0000019070). NR 49 TC 6 Z9 6 U1 3 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD SEP PY 2015 VL 483 BP 117 EP 125 DI 10.1016/j.virol.2015.02.035 PG 9 WC Virology SC Virology GA CO2HG UT WOS:000358976200012 PM 25965801 ER PT J AU Wako, E Elliott, L De Jesus, S Zotti, ME Swahn, MH Beltrami, J AF Wako, Etobssie Elliott, Leah De Jesus, Stacy Zotti, Marianne E. Swahn, Monica H. Beltrami, John TI Conflict, Displacement, and IPV: Findings From Two Congolese Refugee Camps in Rwanda SO VIOLENCE AGAINST WOMEN LA English DT Article DE intimate partner violence; outsider violence; conflict; displacement; refugee; Democratic Republic of Congo; Rwanda ID INTIMATE PARTNER VIOLENCE; GENDER-BASED VIOLENCE; DOMESTIC VIOLENCE; WOMENS HEALTH; MARRIED-WOMEN; MENTAL-HEALTH; HUMAN-RIGHTS; PREVALENCE; MULTICOUNTRY; CONSEQUENCES AB This study describes the prevalence and correlates of past-year intimate partner violence (IPV) among displaced women. We used bivariate and multivariate analyses to assess the relationships between IPV and select variables of interest. Multivariate logistic regression modeling revealed that women who had experienced outsider violence were 11 times as likely (adjusted odds ratio [AOR] = 11.21; confidence interval, CI [5.25, 23.96]) to have reported IPV than women who had not experienced outsider violence. IPV in conflict-affected settings is a major public health concern that requires effective interventions; our results suggest that women who had experienced outsider violence are at greater risk of IPV. C1 [Wako, Etobssie] Ctr Dis Control & Prevent CDC, Div Reprod Hlth, Program Emergency Preparedness & Response, Atlanta, GA 30341 USA. [De Jesus, Stacy; Zotti, Marianne E.; Beltrami, John] Ctr Dis Control & Prevent CDC, Atlanta, GA 30341 USA. [Elliott, Leah] ICF Macro Int, Fairfax, VA USA. [Swahn, Monica H.] Georgia State Univ, Sch Publ Hlth & Partnership Urban Hlth Res, Div Epidemiol & Biostat, Atlanta, GA 30303 USA. RP Wako, E (reprint author), Ctr Dis Control & Prevent CDC, NCCDPHP, 4770 Buford Highway NE,MS K-22, Atlanta, GA 30341 USA. EM ewako@cdc.gov NR 40 TC 0 Z9 0 U1 8 U2 19 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-8012 EI 1552-8448 J9 VIOLENCE AGAINST WOM JI Violence Against Women PD SEP PY 2015 VL 21 IS 9 BP 1087 EP 1101 DI 10.1177/1077801215590669 PG 15 WC Women's Studies SC Women's Studies GA CN7DJ UT WOS:000358593900003 PM 26084543 ER PT J AU Hunter, E Burton, K Iqbal, A Birchall, D Jackson, M Rogathe, J Jusabani, A Gray, W Aris, E Kamuyu, G Wilkins, PP Newton, CR Walker, R AF Hunter, Ewan Burton, Kathryn Iqbal, Ahmed Birchall, Daniel Jackson, Margaret Rogathe, Jane Jusabani, Ahmed Gray, William Aris, Eric Kamuyu, Gathoni Wilkins, Patricia P. Newton, Charles R. Walker, Richard TI Cysticercosis and epilepsy in rural Tanzania: a community-based case-control and imaging study SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE cysticercosis; epilepsy; neuroimaging; Tanzania; serology; sub-Saharan Africa ID SUB-SAHARAN AFRICA; LINKED IMMUNOELECTROTRANSFER BLOT; ACTIVE CONVULSIVE EPILEPSY; TAENIA-SOLIUM; RISK-FACTORS; CLINICAL CHARACTERISTICS; PORCINE CYSTICERCOSIS; MBEYA REGION; NEUROCYSTICERCOSIS; PREVALENCE AB ObjectiveTo assess the contribution of neurocysticercosis (NCC) to the burden of epilepsy in a rural Tanzanian population. MethodsWe identified adult people with epilepsy (PWE) in a door-to-door study in an established demographic surveillance site. PWE and community controls were tested for antibodies to Taenia solium, the causative agent of NCC, and all PWE were offered a computed tomography (CT) head scan. Data on household occupancy and sanitation, pig-keeping and pork consumption were collected from PWE and controls and associations with epilepsy were assessed using chi-square or Fisher's exact tests. ResultsSix of 218 PWE had antibodies to T.solium (2.8%; 95% CI 0.6-4.9), compared to none of 174 controls (Fisher's exact test, P=0.04). Lesions compatible with NCC were seen in eight of 200 CT scans (4.0%; 95% CI 1.3-6.7). A total of 176 PWE had both investigations of whom two had positive serology along with NCC-compatible lesions on CT (1.1%; 95% 0.3-4.0). No associations between epilepsy and any risk factors for NCC were identified. ConclusionsNeurocysticercosis is present in this population but at a lower prevalence than elsewhere in Tanzania and sub-Saharan Africa. Insights from low-prevalence areas may inform public health interventions designed to reduce the burden of preventable epilepsy. ObjectifEvaluer la contribution de la neurocysticercose (NCC) a la charge de l'epilepsie dans une population rurale de la Tanzanie. MethodesNous avons identifie les personnes adultes souffrant d'epilepsie (PSE) dans une etude de porte-a-porte dans un site etabli de surveillance demographique. Les PSE et des temoins communautaires ont ete testes pour les anticorps de Taenia solium, l'agent causal de la NCC et toutes les PSE ont ete offertes une tomodensitometrie (TDM) de la tete. Les donnees sur l'occupation des menages et l'assainissement, l'elevage et la consommation de porc ont ete recueillies chez les PSE et les temoins et les associations avec l'epilepsie ont ete evaluees en utilisant les tests Exacts de Fisher ou de Chi-carre. ResultatsSix des 218 PSE avaient des anticorps de T. Solium (2,8%; IC95%: 0,6 a 4,9) compares a aucun des 174 temoins (test Exact de Fisher, p = 0,04). Les lesions compatibles avec la NCC ont ete observees dans 8 des 200 TDM (4,0%; IC95%: 1,3 a 6,7). Les deux investigations ont ete menees chez 176 PSE, dont deux avaient une serologie positive ainsi que des lesions compatibles avec la NCC sur la TDM (1,1%; IC95%: 0,3 a 4,0). Aucune association entre l'epilepsie et les facteurs de risque categorises pour la NCC n'a ete identifiee. ConclusionsLa NCC est presente dans cette population, mais a un taux de prevalence plus faible qu'ailleurs en Tanzanie et en Afrique subsaharienne. Les donnees des zones a faible prevalence pourraient eclairer les interventions de sante publique visant a reduire la charge evitable de l'epilepsie. ObjetivoEvaluar la contribucion de la neurocisticercosis (NCC) a la carga de epilepsia entre la poblacion rural de Tanzania. MetodosIdentificamos a adultos con epilepsia (ACE) en un estudio puerta-a-puerta, en un lugar con vigilancia demografica establecida. A los ACE y a los controles comunitarios se les realizaron pruebas en busca de anticuerpos contra Taenia solium, el agente causal de la NCC, y a todos los ACE se les ofrecio una tomografia computarizada de la cabeza (TC). Se recolectaron los datos sobre ocupacion del hogar y saneamiento, la crianza y consumo del cerdo de los ACE y de los controles, y se evaluaron las asociaciones con la epilepsia utilizando las pruebas del Chi-cuadrado y de Fisher. ResultadosSeis de 218 PCE tenian anticuerpos contra T. solium (2.8%; IC 95% 0.6 a 4.9), comparado con ninguno de los 174 controles (prueba de Fisher, p=0.04). Las lesiones compatibles con la NCC se observaron en ocho de 200 TC (4.0%; IC95% 1.3 a 6.7). A 176 ACE se les realizaron ambas pruebas, y de estos, dos tenian una serologia positiva junto con lesiones compatibles con NCC en la TC (1.1%; 95% 0.3 a 4.0). No se identificaron asociaciones entre la epilepsia y factores de riesgo categoricos para NCC. ConclusionesLa NCC esta presente en esta poblacion, pero en una menor prevalencia que en cualquier otro lugar en Tanzania y africa subsahariana. La comprension de lo que sucede en areas de baja prevalencia podria informar intervenciones de salud publica disenadas para reducir la carga de epilepsia prevenible. C1 [Hunter, Ewan] Univ London London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, London WC1E 7HT, England. [Burton, Kathryn] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England. [Iqbal, Ahmed] So Gen Hosp, Inst Neurosci, Glasgow G51 4TF, Lanark, Scotland. [Birchall, Daniel; Jackson, Margaret] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England. [Rogathe, Jane; Jusabani, Ahmed] Kilimanjaro Christian Med Ctr, Moshi, Tanzania. [Gray, William; Walker, Richard] Northumbria Healthcare NHS Fdn Trust, North Shields, Tyne & Wear, England. [Aris, Eric] Muhimbili Natl Hosp, Dar Es Salaam, Tanzania. [Kamuyu, Gathoni; Newton, Charles R.] Ctr Geog Med Coast, Kilifi, Kenya. [Wilkins, Patricia P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Newton, Charles R.] Muhimbili Univ Hlth & Allied Sci, Muhimbili Wellcome Programme, Dar Es Salaam, Tanzania. [Newton, Charles R.] Univ Oxford, Dept Psychiat, Oxford, England. [Walker, Richard] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. RP Hunter, E (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England. EM ewan.hunter@lshtm.ac.uk OI Newton, Charles/0000-0002-6999-5507 FU Helen H Lawson Grant; Wellcome Trust; Northumbria Healthcare NHS Foundation Trust, United Kingdom FX Funding for this study was provided by the Helen H Lawson Grant, administered by BMA Charities, and by the Wellcome Trust. Charles Newton is funded by the Wellcome Trust. We gratefully acknowledge Professor Newton's assistance in organising serological analysis, and we thank the field staff in Hai, members of the Hai District Community Health Management Team and members of staff in the radiology department at KCMC. The study was sponsored by Northumbria Healthcare NHS Foundation Trust, United Kingdom. NR 36 TC 0 Z9 0 U1 1 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2015 VL 20 IS 9 BP 1171 EP 1179 DI 10.1111/tmi.12529 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CN3OQ UT WOS:000358336600005 PM 25940786 ER PT J AU Wu, FT Chen, HC Yen, C Wu, CY Katayama, K Park, Y Hall, AJ Vinje, J Huang, JC Wu, HS AF Wu, Fang-Tzy Chen, Hsieh-Cheng Yen, Catherine Wu, Ching-Yi Katayama, Kazuhiko Park, YoungBin Hall, Aron J. Vinje, Jan Huang, Jason C. Wu, Ho-Sheng TI Epidemiology and molecular characteristics of norovirus GII.4 Sydney outbreaks in Taiwan, January 2012-December 2013 SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE norovirus GII; 4 Sydney; epidemiology; outbreak; phylogenetic analysis ID UNITED-STATES; GASTROENTERITIS; GII.4/SYDNEY/2012; MUTATIONS; EMERGENCE AB In 2012, a new norovirus GII.4 variant (GII.4 Sydney) emerged and caused the majority of the acute gastroenteritis outbreaks in Australia, Asia, Europe, and North America. We examined the epidemiologic and molecular virologic characteristics of reported acute gastroenteritis outbreaks determined to be caused by norovirus in Taiwan from January 2012 to December 2013. A total of 253 (45.7%) of 552 reported acute gastroenteritis outbreaks tested positive for norovirus, of which 165 (65.5%) were typed as GII.4 Sydney. GII.4 Sydney outbreaks were reported from all geographic areas of Taiwan and occurred most frequently in schools (35.8%) and long-term care facilities (24.2%). Person-to-person transmission was identified in 116 (70.3%) of the outbreaks. Phylogenetic analyses of full-length ORF2 of eight specimens indicated that GII.4 Sydney strains detected in Taiwan were closely related to strains detected globally. Continued outbreak surveillance and strain typing are needed to provide information on epidemiologic and virologic trends of novel norovirus strains. J. Med. Virol. 87:1462-1470, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Wu, Fang-Tzy; Chen, Hsieh-Cheng; Wu, Ching-Yi; Wu, Ho-Sheng] Ctr Dis Control, Taipei, Taiwan. [Wu, Fang-Tzy; Huang, Jason C.] Natl Yang Ming Univ, Taipei 112, Taiwan. [Yen, Catherine; Hall, Aron J.; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Katayama, Kazuhiko; Park, YoungBin] Natl Inst Infect Dis, Tokyo, Japan. [Wu, Ho-Sheng] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan. RP Wu, HS (reprint author), Ctr Dis Control, Taipei, Taiwan. EM jchuang2@ym.edu.tw; wuhs@cdc.gov.tw FU Taiwan Centers for Disease Control [DOH101-DC-2016, MOHW103-CDC-C-315-00020]; Ministry of Health, Labor, and Welfare of Japan; Japan Society for the Promotion of Science (JSPS KAKENHI) FX Grant sponsor: Taiwan Centers for Disease Control; Grant numbers: DOH101-DC-2016; MOHW103-CDC-C-315-00020.; Grant sponsor: Ministry of Health, Labor, and Welfare of Japan; Grant sponsor: Japan Society for the Promotion of Science (JSPS KAKENHI Grant) NR 28 TC 4 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD SEP PY 2015 VL 87 IS 9 BP 1462 EP 1470 DI 10.1002/jmv.24208 PG 9 WC Virology SC Virology GA CM8JC UT WOS:000357944900004 PM 25946552 ER PT J AU Lerro, CC Koutros, S Andreotti, G Hines, CJ Blair, A Lubin, J Ma, XM Zhang, YW Beane Freeman, LE AF Lerro, Catherine C. Koutros, Stella Andreotti, Gabriella Hines, Cynthia J. Blair, Aaron Lubin, Jay Ma, Xiaomei Zhang, Yawei Beane Freeman, Laura E. TI Use of acetochlor and cancer incidence in the Agricultural Health Study SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE acetochlor; Agricultural Health Study; pesticides; cancer ID PESTICIDE APPLICATORS; PANCREATIC-CANCER; OCCUPATIONAL-EXPOSURE; CUTANEOUS MELANOMA; RISK; ALACHLOR; COHORT; METABOLITES; ATRAZINE; HUMANS AB Since its registration in 1994 acetochlor has become a commonly used herbicide in the US, yet no epidemiologic study has evaluated its carcinogenicity in humans. We evaluated the use of acetochlor and cancer incidence among licensed pesticide applicators in the Agricultural Health Study. In telephone interviews administered during 1999-2005, participants provided information on acetochlor use, use of other pesticides and additional potential confounders. We used Poisson regression to estimate relative risks (RR) and 95% confidence intervals (95% CI) for cancers that occurred from the time of interview through 2011 in Iowa and 2010 in North Carolina. Among 33,484 men, there were 4,026 applicators who used acetochlor and 3,234 incident cancers, with 304 acetochlor-exposed cases. Increased risk of lung cancer was observed among acetochlor users (RR=1.74; 95% CI: 1.07-2.84) compared to nonusers, and among individuals who reported using acetochlor/atrazine product mixtures (RR=2.33; 95% CI: 1.30-4.17), compared to nonusers of acetochlor. Colorectal cancer risk was significantly elevated among the highest category of acetochlor users (RR=1.75; 95% CI: 1.08-2.83) compared to never users. Additionally, borderline significantly increased risk of melanoma (RR=1.61; 95% CI: 0.98-2.66) and pancreatic cancer (RR=2.36; 95% CI: 0.98-5.65) were observed among acetochlor users. The associations between acetochlor use and lung cancer, colorectal cancer, melanoma and pancreatic cancer are suggestive, however the lack of exposure-response trends, small number of exposed cases and relatively short time between acetochlor use and cancer development prohibit definitive conclusions. What's new? Acetochlor is a commonly used herbicide in the U.S., yet no epidemiologic research has evaluated its carcinogenicity in humans. In this study, the authors examined the relationship between occupational exposure to acetochlor and human cancer risk in a large prospective cohort. Acetochlor use was associated with an increased risk of lung and colorectal cancer, and possibly pancreatic cancer and melanoma. Use of mixtures of acetochlor and atrazine, another widely used herbicide often applied concurrently with acetochlor, was also associated with an increased risk of lung cancer. C1 [Lerro, Catherine C.; Koutros, Stella; Andreotti, Gabriella; Blair, Aaron; Beane Freeman, Laura E.] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Lerro, Catherine C.; Zhang, Yawei] Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA. [Hines, Cynthia J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Lubin, Jay] NCI, Div Canc Epidemiol & Genet, Biostat Branch, Bethesda, MD 20892 USA. [Ma, Xiaomei] Yale Univ, Sch Publ Hlth, Chron Dis Epidemiol Dept, New Haven, CT USA. RP Lerro, CC (reprint author), NCI, Occupat & Environm Epidemiol Branch, 9609 Med Ctr Dr, Bethesda, MD 20892 USA. EM lerrocc@mail.nih.gov RI Beane Freeman, Laura/C-4468-2015 OI Beane Freeman, Laura/0000-0003-1294-4124 FU Intramural Research Program of the National Institutes of Health; National Cancer Institute [Z01-CP010119]; National Institute of Environmental Health Sciences [Z01-ES049030] FX Grant sponsor: Intramural Research Program of the National Institutes of Health; Grant sponsor: National Cancer Institute; Grant number: Z01-CP010119; Grant sponsor: National Institute of Environmental Health Sciences; Grant number: Z01-ES049030 NR 39 TC 7 Z9 8 U1 2 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD SEP 1 PY 2015 VL 137 IS 5 BP 1167 EP 1175 DI 10.1002/ijc.29416 PG 9 WC Oncology SC Oncology GA CK7RE UT WOS:000356429000017 PM 25559664 ER PT J AU Enose-Akahata, Y Caruso, B Haner, B Massoud, R Billioux, BJ Ohayon, J Switzer, WM Jacobson, S AF Enose-Akahata, Yoshimi Caruso, Breanna Haner, Benjamin Massoud, Raya Billioux, Bridgette Jeanne Ohayon, Joan Switzer, William M. Jacobson, Steven TI Development of HTLV-1 associated myelopathy/tropical spastic paraparesis in a patient with simian T-lymphotropic virus type 1-like infection SO RETROVIROLOGY LA English DT Meeting Abstract C1 [Enose-Akahata, Yoshimi; Caruso, Breanna; Haner, Benjamin; Massoud, Raya; Billioux, Bridgette Jeanne; Ohayon, Joan; Jacobson, Steven] NINDS, Viral Immunol Sect, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA. [Switzer, William M.] Ctr Dis Control & Prevent, Lab Branch, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. EM jacobsons@ninds.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD AUG 28 PY 2015 VL 12 SU 1 MA O30 PG 1 WC Virology SC Virology GA DA0EC UT WOS:000367468500029 ER PT J AU Whitfield, GP Paul, P Wendel, AM AF Whitfield, Geoffrey P. Paul, Prabasaj Wendel, Arthur M. TI Active Transportation Surveillance - United States, 1999-2012 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID PHYSICAL-ACTIVITY; ADULTS; PREVALENCE; WALKING AB Problem/Condition: Physical activity is a health-enhancing behavior, and most U.S. adults do not meet the 2008 Physical Activity Guidelines for Americans. Active transportation, such as by walking or bicycling, is one way that persons can be physically active. No comprehensive, multiyear assessments of active transportation surveillance in the United States have been conducted. Period Covered: 1999-2012. Description of Systems: Five surveillance systems assess one or more components of active transportation. The American Community Survey and the National Household Travel Survey (NHTS) both assess the mode of transportation to work in the past week. From these systems, the proportion of respondents who reported walking or bicycling to work can be calculated. NHTS and the American Time Use Survey include 1-day assessments of trips or activities. With that information, the proportion of respondents who report any walking or bicycling for transportation can be calculated. The National Health and Nutrition Examination Survey and the National Health Interview Survey both assess recent (i.e., in the past week or past month) habitual physical activity behaviors, including those performed during active travel. From these systems, the proportion of respondents who report any recent habitual active transportation can be calculated. Results: The prevalence of active transportation as the primary commute mode to work in the past week ranged from 2.6% to 3.4%. The 1-day assessment indicated that the prevalence of any active transportation ranged from 10.5% to 18.5%. The prevalence of any habitual active transportation ranged from 23.9% to 31.4%. No consistent trends in active transportation across time periods and surveillance systems were identified. Among systems, active transportation was usually more common among men, younger respondents, and minority racial/ethnic groups. Among education groups, the highest prevalence of active transportation was usually among the least or most educated groups, and active transportation tended to be more prevalent in densely populated, urban areas. Interpretation: Active transportation is assessed in a wide variety of ways in multiple surveillance systems. Different assessment techniques and construct definitions result in widely discrepant estimates of active transportation; however, some consistent patterns were detected across covariates. Although each type of assessment (i.e., transportation to work, single day, and habitual behavior) measures a different active transportation component, all can be used to monitor population trends in active transportation participation. Public Health Action: An understanding of the strengths, limitations, and lack of comparability of active transportation assessment techniques is necessary to correctly evaluate findings from the various surveillance systems. When used appropriately, these systems can be used by public health and transportation professionals to monitor population participation in active transportation and plan and evaluate interventions that influence active transportation. C1 [Whitfield, Geoffrey P.; Wendel, Arthur M.] Natl Ctr Environm Hlth, Off Noncommunicable Dis Injury & Environm Hlth, Div Emergency & Environm Hlth Serv, Hlth Community Design Initiat, Atlanta, GA USA. [Paul, Prabasaj] Natl Ctr Chron Dis Prevent & Hlth Promot, Off Noncommunicable Dis Injury & Environm Hlth, Div Nutr Phys Act & Obes, Phys Act & Hlth Branch, Atlanta, GA USA. RP Whitfield, GP (reprint author), CDC, Off Noncommunicable Dis Injury & Environm Hlth, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Atlanta, GA 30333 USA. EM xdh5@cdc.gov NR 30 TC 2 Z9 2 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD AUG 28 PY 2015 VL 64 IS 7 BP 1 EP 17 PG 17 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS7DI UT WOS:000362243900001 PM 26313567 ER PT J AU Hill, HA Elam-Evans, LD Yankey, D Singleton, JA Kolasa, M AF Hill, Holly A. Elam-Evans, Laurie D. Yankey, David Singleton, James A. Kolasa, Maureen TI National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IMMUNIZATION; MEASLES C1 [Hill, Holly A.; Elam-Evans, Laurie D.; Yankey, David; Singleton, James A.; Kolasa, Maureen] CDC, Natl Ctr Immunizat & Resp, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Hill, HA (reprint author), CDC, Natl Ctr Immunizat & Resp, Immunizat Serv Div, Atlanta, GA 30333 USA. EM hah4@cdc.gov NR 12 TC 32 Z9 33 U1 1 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 28 PY 2015 VL 64 IS 33 BP 889 EP 896 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP8JA UT WOS:000360138500001 PM 26313470 ER PT J AU Seither, R Calhoun, K Knighton, CL Mellerson, J Meador, S Tippins, A Greby, SM Dietz, V AF Seither, Ranee Calhoun, Kayla Knighton, Cynthia L. Mellerson, Jenelle Meador, Seth Tippins, Ashley Greby, Stacie M. Dietz, Vance TI Vaccination Coverage Among Children in Kindergarten - United States, 2014-15 School Year SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Seither, Ranee; Knighton, Cynthia L.; Greby, Stacie M.; Dietz, Vance] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Calhoun, Kayla; Mellerson, Jenelle; Tippins, Ashley] Carter Consulting Inc, Atlanta, GA USA. [Meador, Seth] Leidos, Atlanta, GA USA. RP Seither, R (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. EM rseither@cdc.gov NR 9 TC 14 Z9 14 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 28 PY 2015 VL 64 IS 33 BP 897 EP 904 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP8JA UT WOS:000360138500002 PM 26313471 ER PT J AU Merlo, C Brener, N Kann, L McManus, T Harris, D Mugavero, K AF Merlo, Caitlin Brener, Nancy Kann, Laura McManus, Tim Harris, Diane Mugavero, Kristy TI School-Level Practices to Increase Availability of Fruits, Vegetables, and Whole Grains, and Reduce Sodium in School Meals - United States, 2000, 2006, and 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Merlo, Caitlin] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. [Brener, Nancy; Kann, Laura; McManus, Tim] CDC, Div Adolescent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Brener, Nancy; Kann, Laura; McManus, Tim] CDC, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Harris, Diane] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Mugavero, Kristy] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. RP Merlo, C (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. EM cmerlo@cdc.gov NR 10 TC 7 Z9 7 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 28 PY 2015 VL 64 IS 33 BP 905 EP 908 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP8JA UT WOS:000360138500003 PM 26313472 ER PT J AU Melnikova, N Orr, MF Wu, J Christensen, B AF Melnikova, Natalia Orr, Maureen F. Wu, Jennifer Christensen, Bryan TI Injuries from Methamphetamine-Related Chemical Incidents - Five States, 2001-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Melnikova, Natalia; Orr, Maureen F.; Wu, Jennifer] CDC, Natl Ctr Environm Hlth, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. [Christensen, Bryan] CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. RP Melnikova, N (reprint author), CDC, Natl Ctr Environm Hlth, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. EM nmelnikova@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 28 PY 2015 VL 64 IS 33 BP 909 EP 912 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP8JA UT WOS:000360138500004 PM 26313473 ER PT J AU Kwit, N Nelson, C Kugeler, K Petersen, J Plante, L Yaglom, H Kramer, V Schwartz, B House, J Colton, L Feldpausch, A Drenzek, C Baumbach, J DiMenna, M Fisher, E Debess, E Buttke, D Weinburke, M Percy, C Schriefer, M Gage, K Mead, P AF Kwit, Natalie Nelson, Christina Kugeler, Kiersten Petersen, Jeannine Plante, Lydia Yaglom, Hayley Kramer, Vicki Schwartz, Benjamin House, Jennifer Colton, Leah Feldpausch, Amanda Drenzek, Cherie Baumbach, Joan DiMenna, Mark Fisher, Emily Debess, Emilio Buttke, Danielle Weinburke, Matthew Percy, Christopher Schriefer, Martin Gage, Ken Mead, Paul TI Human Plague - United States, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kwit, Natalie; Fisher, Emily] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Kwit, Natalie; Nelson, Christina; Kugeler, Kiersten; Petersen, Jeannine; Schriefer, Martin; Gage, Ken; Mead, Paul] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. [Plante, Lydia; Yaglom, Hayley] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Kramer, Vicki] Calif State Dept Hlth, Urbana, IL USA. [Schwartz, Benjamin] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [House, Jennifer; Colton, Leah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Feldpausch, Amanda; Drenzek, Cherie] Georgia Dept Publ Hlth, Atlanta, GA USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [DiMenna, Mark] Albuquerque Environm Hlth Dept, Albuquerque, NM USA. [Fisher, Emily; Debess, Emilio] Oregon Hlth Author, Chicago, IL USA. [Buttke, Danielle; Weinburke, Matthew] Natl Pk Serv, Johnson City, TN USA. [Percy, Christopher] Indian Hlth Serv, Navajo Area, Rockville, MD USA. RP Kwit, N (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM nkwit@cdc.gov NR 5 TC 9 Z9 9 U1 2 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 28 PY 2015 VL 64 IS 33 BP 918 EP 919 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP8JA UT WOS:000360138500006 PM 26313475 ER PT J AU Diaz, LA Goni, SE Iserte, JA Quaglia, AI Singh, A Logue, CH Powers, AM Contigiani, MS AF Diaz, Luis A. Goni, Sandra E. Iserte, Javier A. Quaglia, Agustn I. Singh, Amber Logue, Christopher H. Powers, Ann M. Contigiani, Marta S. TI Exploring Genomic, Geographic and Virulence Interactions among Epidemic and Non-Epidemic St. Louis Encephalitis Virus (Flavivirus) Strains SO PLOS ONE LA English DT Article ID WEST-NILE-VIRUS; PHYLOGENETIC ANALYSIS; SECONDARY STRUCTURE; BUENOS-AIRES; ARGENTINA; RNA; EVOLUTION; OUTBREAK; TRANSLATION; DISPERSAL AB St. Louis encephalitis virus (SLEV) is a re-emerging arbovirus in South America. In 2005, an encephalitis outbreak caused by SLEV was reported in Argentina. The reason for the outbreak remains unknown, but may have been related to virological factors, changes in vectors populations, avian amplifying hosts, and/or environmental conditions. The main goal of this study was to characterize the complete genome of epidemic and non-epidemic SLEV strains from Argentina. Seventeen amino acid changes were detected; ten were non-conservative and located in proteins E, NS1, NS3 and NS5. Phylogenetic analysis showed two major clades based on geography: the North America and northern Central America (NAnCA) clade and the South America and southern Central America (SAsCA) clade. Interestingly, the presence of SAsCA genotype V SLEV strains in the NAnCA clade was reported in California, Florida and Texas, overlapping with known bird migration flyways. This work represents the first step in understanding the molecular mechanisms underlying virulence and biological variation among SLEV strains. C1 [Diaz, Luis A.; Quaglia, Agustn I.; Contigiani, Marta S.] Univ Nacl Cordoba, Fac Ciencias Med, Inst Virol Dr JM Vanella, Lab Arbovirus, RA-5000 Cordoba, Argentina. [Diaz, Luis A.] Univ Nacl Cordoba, CONICET, Inst Invest Biol & Tecnol, RA-5000 Cordoba, Argentina. [Goni, Sandra E.] Univ Nacl Quilmes, Inst Microbiol Basica & Aplicada, Lab Ingn Genet & Biol Celular & Mol, Dept Ciencia Tecnol,Area Virosis Emergentes & Zoo, Buenos Aires, DF, Argentina. [Iserte, Javier A.] CABA, Fdn Inst Leloir, Lab Bioinformat Estruct, Buenos Aires, DF, Argentina. [Singh, Amber; Powers, Ann M.] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Logue, Christopher H.] Publ Hlth England, Novel & Dangerous Pathogens Training, Porton Down, England. RP Diaz, LA (reprint author), Univ Nacl Cordoba, Fac Ciencias Med, Inst Virol Dr JM Vanella, Lab Arbovirus, RA-5000 Cordoba, Argentina. EM adrian.diaz@conicet.gov.ar FU Agencia Nacional de Promocion Cientifica y Tecnologica, Fondo Nacional de Ciencia y Tecnologia (ANPCYT-FONCYT) [2010/38060, 2013/1779]; Consejo Nacional de Investigaciones Cientificas y Tecnologicas (CONICET); Secretaria de Ciencia y Tecnica -Universidad Nacional de Cordoba (SECYT-UNC); International Society for Infectious Diseases; UNESCO-IUMS-SGM (United Nations Educational, Scientific and Cultural Organization, International Union Microbiology Societies-Society of General Microbiology); Bunge y Born Foundation [FBBEI8/10]; US Centers for Disease Control and Prevention FX This project was supported by Agencia Nacional de Promocion Cientifica y Tecnologica, Fondo Nacional de Ciencia y Tecnologia (ANPCYT-FONCYT) Grant number 2010/38060 and 2013/1779 (www.agencia.mincyt.gob.ar), Consejo Nacional de Investigaciones Cientificas y Tecnologicas (CONICET) (www.conicet.gov.ar), Secretaria de Ciencia y Tecnica -Universidad Nacional de Cordoba (SECYT-UNC) (http://www.unc.edu.ar/investigacion/cienciaytecnologia/novedades-inform acion-cyt), International Society for Infectious Diseases (http:// www.isid.org/), UNESCO-IUMS-SGM (United Nations Educational, Scientific and Cultural Organization, International Union Microbiology Societies-Society of General Microbiology) (http://www.iums.org/), Bunge y Born Foundation (FBBEI8/10) (http://www.fundacionbyb.org), and the US Centers for Disease Control and Prevention (www.cdc.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 1 Z9 1 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 27 PY 2015 VL 10 IS 8 AR e0136316 DI 10.1371/journal.pone.0136316 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP8KZ UT WOS:000360144000054 PM 26312485 ER PT J AU Sserwanga, A Sears, D Kapella, BK Kigozi, R Rubahika, D Staedke, SG Kamya, M Yoon, SS Chang, MA Dorsey, G Mpimbaza, A AF Sserwanga, Asadu Sears, David Kapella, Bryan K. Kigozi, Ruth Rubahika, Denis Staedke, Sarah G. Kamya, Moses Yoon, Steven S. Chang, Michelle A. Dorsey, Grant Mpimbaza, Arthur TI Anti-malarial prescription practices among children admitted to six public hospitals in Uganda from 2011 to 2013 SO MALARIA JOURNAL LA English DT Article DE Anti-malarial; Treatment; Children; Hospitals; Uganda ID RAPID DIAGNOSTIC-TEST; MALARIA-TREATMENT; AFRICAN CHILDREN; PLASMODIUM-FALCIPARUM; RANDOMIZED-TRIAL; OVERDIAGNOSIS; GUIDELINES; TANZANIA; MANAGEMENT; CLINICIAN AB Background: In 2011, Uganda's Ministry of Health switched policy from presumptive treatment of malaria to recommending parasitological diagnosis prior to treatment, resulting in an expansion of diagnostic services at all levels of public health facilities including hospitals. Despite this change, anti-malarial drugs are often prescribed even when test results are negative. Presented is data on anti-malarial prescription practices among hospitalized children who underwent diagnostic testing after adoption of new treatment guidelines. Methods: Anti-malarial prescription practices were collected as part of an inpatient malaria surveillance program generating high quality data among children admitted for any reason at government hospitals in six districts. A standardized medical record form was used to collect detailed patient information including presenting symptoms and signs, laboratory test results, admission and final diagnoses, treatments administered, and final outcome upon discharge. Results: Between July 2011 and December 2013, 58,095 children were admitted to the six hospitals (hospital range 3294-20,426). A total of 56,282 (96.9 %) patients were tested for malaria, of which 26,072 (46.3 %) tested positive (hospital range 5.9-57.3 %). Among those testing positive, only 84 (0.3 %) were first tested after admission and 295 of 30,389 (1.0 %) patients who tested negative at admission later tested positive. Of 30,210 children with only negative test results, 11,977 (39.6 %) were prescribed an anti-malarial (hospital range 14.5-53.6 %). The proportion of children with a negative test result who were prescribed an anti-malarial fluctuated over time and did not show a significant trend at any site with the exception of one hospital where a steady decline was observed. Among those with only negative test results, children 6-12 months of age (aOR 3.78; p < 0.001) and those greater than 12 months of age (aOR 4.89; p < 0.001) were more likely to be prescribed an anti-malarial compared to children less than 6 months of age. Children with findings suggestive of severe malaria were also more likely to be prescribed an anti-malarial after a negative test result (aOR 1.98; p < 0.001). Conclusions: Despite high testing rates for malaria at all sites, prescription of anti-malarials to patients with negative test results remained high, with the exception of one site where a steady decline occurred. C1 [Sserwanga, Asadu; Kigozi, Ruth; Staedke, Sarah G.; Kamya, Moses; Mpimbaza, Arthur] Infect Dis Res Collaborat, Kampala, Uganda. [Sears, David; Dorsey, Grant] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA. [Kapella, Bryan K.; Yoon, Steven S.; Chang, Michelle A.] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Rubahika, Denis] Minist Hlth Uganda, Natl Malaria Control Programme, Kampala, Uganda. [Staedke, Sarah G.] London Sch Hyg & Trop Med, London WC1, England. [Kamya, Moses; Mpimbaza, Arthur] Makerere Univ, Child Hlth & Dev Ctr, Coll Hlth Sci, Kampala, Uganda. RP Sserwanga, A (reprint author), Infect Dis Res Collaborat, Kampala, Uganda. EM asadusserwanga@gmail.com FU National Institutes of Health as part of the International Centers of Excellence in Malaria Research (ICMER) programme [U19AI089674] FX The authors would like to thank the hard working staff at the six hospitals, Tororo, Apac, Jinja, Kabale, Kambuga and Mubende. We would also like to thank the Uganda Malaria Surveillance data officers; Anthony Ekisa, William Wanyi, YasinKasimbira, Peace Kirabo, Edison Nyionzima and Mercy Issali. We are indebted to all the health workers in the respective hospitals for embracing the programme and efforts in improving the quality of medical records at the sites. We would like to thank the President's Malaria Initiative, U.S. Agency for International Development, which provided support for the malaria surveillance programme in Uganda, under the terms of an Interagency Agreement with CDC (1U51CK000117). Funding was also provided by the National Institutes of Health as part of the International Centers of Excellence in Malaria Research (ICMER) programme (U19AI089674). The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the funding agencies. NR 38 TC 2 Z9 2 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD AUG 27 PY 2015 VL 14 AR 331 DI 10.1186/s12936-015-0851-8 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CP7ZG UT WOS:000360108500001 PM 26306395 ER PT J AU Ampofo, WK Azziz-Baumgartner, E Bashir, U Cox, NJ Fasce, R Giovanni, M Grohmann, G Huang, S Katz, J Mironenko, A MokhtariAzad, T Sasono, PM Rahman, M Sawanpanyalert, P Siqueira, M Waddell, AL Waiboci, L Wood, J Zhang, WQ Ziegler, T AF Ampofo, William K. Azziz-Baumgartner, Eduardo Bashir, Uzma Cox, Nancy J. Fasce, Rodrigo Giovanni, Maria Grohmann, Gary Huang, Sue Katz, Jackie Mironenko, Alla MokhtariAzad, Talat Sasono, Pretty Multihartina Rahman, Mahmudur Sawanpanyalert, Pathom Siqueira, Marilda Waddell, Anthony L. Waiboci, Lillian Wood, John Zhang, Wenqing Ziegler, Thedi CA WHO Writing Grp TI Strengthening the influenza vaccine virus selection and development process Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014 SO VACCINE LA English DT Article DE Influenza vaccine viruses; Vaccine virus selection; WHO recommendations ID SEASONALITY AB Despite long-recognized challenges and constraints associated with their updating and manufacture, influenza vaccines remain at the heart of public health preparedness and response efforts against both seasonal and potentially pandemic influenza viruses. Globally coordinated virological and epidemiological surveillance is the foundation of the influenza vaccine virus selection and development process. Although national influenza surveillance and reporting capabilities are being strengthened and expanded, sustaining and building upon recent gains has become a major challenge. Strengthening the vaccine virus selection process additionally requires the continuation of initiatives to improve the timeliness and representativeness of influenza viruses shared by countries for detailed analysis by the WHO Global Influenza Surveillance and Response System (GISRS). Efforts are also continuing at the national, regional, and global levels to better understand the dynamics of influenza transmission in both temperate and tropical regions. Improved understanding of the degree of influenza seasonality in tropical countries of the world should allow for the strengthening of national vaccination policies and use of the most appropriate available vaccines. There remain a number of limitations and difficulties associated with the use of HAI assays for the antigenic characterization and selection of influenza vaccine viruses by WHOCCs. Current approaches to improving the situation include the more-optimal use of HAI and other assays; improved understanding of the data produced by neutralization assays; and increased standardization of serological testing methods. A number of new technologies and associated tools have the potential to revolutionize influenza surveillance and response activities. These include the increasingly routine use of whole genome next-generation sequencing and other high-throughput approaches. Such approaches could not only become key elements in outbreak investigations but could drive a new surveillance paradigm. However, despite the advances made, significant challenges will need to be addressed before next-generation technologies become routine, particularly in low-resource settings. Emerging approaches and techniques such as synthetic genomics, systems genetics, systems biology and mathematical modelling are capable of generating potentially huge volumes of highly complex and diverse datasets. Harnessing the currently theoretical benefits of such bioinformatics ("big data") concepts for the influenza vaccine virus selection and development process will depend upon further advances in data generation, integration, analysis and dissemination. Over the last decade, growing awareness of influenza as an important global public health issue has been coupled to ever-increasing demands from the global community for more-equitable access to effective and affordable influenza vaccines. The current influenza vaccine landscape continues to be dominated by egg-based inactivated and live attenuated vaccines, with a small number of cell-based and recombinant vaccines. Successfully completing each step in the annual influenza vaccine manufacturing cycle will continue to rely upon timely and regular communication between the WHO GISRS, manufacturers and regulatory authorities. While the pipeline of influenza vaccines appears to be moving towards a variety of niche products in the near term, it is apparent that the ultimate aim remains the development of effective "universal" influenza vaccines that offer longer-lasting immunity against a broad range of influenza A subtypes. (C) 2015 The Authors. Published by Elsevier Ltd. C1 [Ampofo, William K.] Noguchi Mem Inst Med Res, Accra, Ghana. [Azziz-Baumgartner, Eduardo; Cox, Nancy J.; Katz, Jackie] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Bashir, Uzma] NIH, Islamabad, Pakistan. [Fasce, Rodrigo] Natl Influenza Ctr, Publ Hlth Inst Chile, Santiago, Chile. [Giovanni, Maria] NIH, Bethesda, MD 20892 USA. [Grohmann, Gary] Therapeut Goods Adm, Symonston, Australia. [Huang, Sue] Natl Influenza Ctr, Upper Hutt, New Zealand. [Mironenko, Alla] Reference Influenza Lab, Kiev, Ukraine. [MokhtariAzad, Talat] Natl Influenza Ctr, Tehran, Iran. [Sasono, Pretty Multihartina] Natl Inst Hlth Res & Dev, Jakarta, Indonesia. [Rahman, Mahmudur] Inst Epidemiol, Dis Control & Res, Dhaka, Bangladesh. [Sawanpanyalert, Pathom] Natl Inst Hlth, Bangkok, Thailand. [Siqueira, Marilda] Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil. [Waiboci, Lillian] CDC Kenya, Nairobi, Kenya. [Wood, John] Formerly Natl Inst Biol Stand & Control NIBSC, Potters Bar, Herts, England. [Zhang, Wenqing] World Hlth Org, Geneva, Switzerland. [Ziegler, Thedi] Natl Influenza Ctr, Helsinki, Finland. RP Zhang, WQ (reprint author), World Hlth Org, Geneva, Switzerland. EM GISRS-WHOHQ@who.int OI Laurie, Karen/0000-0001-5186-8342 FU World Health Organization [001] NR 12 TC 11 Z9 12 U1 4 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD AUG 26 PY 2015 VL 33 IS 36 BP 4368 EP 4382 DI 10.1016/j.vaccine.2015.06.090 PG 15 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CQ8OK UT WOS:000360867500003 PM 26148877 ER PT J AU Shimabukuro, TT Nguyen, M Martin, D DeStefano, F AF Shimabukuro, Tom T. Nguyen, Michael Martin, David DeStefano, Frank TI Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) SO VACCINE LA English DT Review DE Vaccination; Vaccine adverse event; Adverse event following immunization; Adverse reaction; Adverse effect; Spontaneous reporting; Passive surveillance; Vaccine safety; Vaccine Adverse Event Reporting System (VAERS) ID HUMAN-PAPILLOMAVIRUS VACCINE; A H1N1 2009; UNITED-STATES; FEBRILE SEIZURES; ROTAVIRUS VACCINATION; MONOVALENT VACCINES; IMMUNIZATION SAFETY; INFLUENZA VACCINE; SURVEILLANCE; SIGNAL AB The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) conduct post-licensure vaccine safety monitoring using the Vaccine Adverse Event Reporting System (VAERS), a spontaneous (or passive) reporting system. This means that after a vaccine is approved, CDC and FDA continue to monitor safety while it is distributed in the marketplace for use by collecting and analyzing spontaneous reports of adverse events that occur in persons following vaccination. Various methods and statistical techniques are used to analyze VAERS data, which CDC and FDA use to guide further safety evaluations and inform decisions around vaccine recommendations and regulatory action. VAERS data must be interpreted with caution due to the inherent limitations of passive surveillance. VAERS is primarily a safety signal detection and hypothesis generating system. Generally, VAERS data cannot be used to determine if a vaccine caused an adverse event. VAERS data interpreted alone or out of context can lead to erroneous conclusions about cause and effect as well as the risk of adverse events occurring following vaccination. CDC makes VAERS data available to the public and readily accessible online. We describe fundamental vaccine safety concepts, provide an overview of VAERS for healthcare professionals who provide vaccinations and might want to report or better understand a vaccine adverse event, and explain how CDC and FDA analyze VAERS data. We also describe strengths and limitations, and address common misconceptions about VAERS. Information in this review will be helpful for healthcare professionals counseling patients, parents, and others on vaccine safety and benefit-risk balance of vaccination. Published by Elsevier Ltd. C1 [Shimabukuro, Tom T.; DeStefano, Frank] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Hlth Care Qual Promot, Immunizat Safety Off, Atlanta, GA 30329 USA. [Nguyen, Michael; Martin, David] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA. RP Shimabukuro, TT (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30329 USA. EM TShimabukuro@cdc.gov FU Intramural CDC HHS [CC999999] NR 69 TC 14 Z9 14 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD AUG 26 PY 2015 VL 33 IS 36 BP 4398 EP 4405 DI 10.1016/j.vaccine.2015.07.035 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CQ8OK UT WOS:000360867500008 PM 26209838 ER PT J AU Sukumaran, L McCarthy, NL Li, RX Weintraub, ES Jacobsen, SJ Hambidge, SJ Jackson, LA Naleway, AL Chan, B Tao, BW Gee, J AF Sukumaran, Lakshmi McCarthy, Natalie L. Li, Rongxia Weintraub, Eric S. Jacobsen, Steven J. Hambidge, Simon J. Jackson, Lisa A. Naleway, Allison L. Chan, Berwick Tao, Biwen Gee, Julianne TI Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population SO VACCINE LA English DT Article DE Vaccine Safety Datalink; Demographics; Census; Medicaid ID INACTIVATED INFLUENZA VACCINE; AFFORDABLE CARE ACT; ROTAVIRUS VACCINE; FEBRILE SEIZURES; OBSTETRIC EVENTS; ADVERSE EVENTS; RISK; IMMUNIZATION; INTUSSUSCEPTION; IDENTIFICATION AB Background: The Vaccine Safety Datalink (VSD) is a collaboration between CDC and nine integrated health care systems that serves as a cornerstone of US post-licensure vaccine safety monitoring. Given concerns that potential differences between the insured VSD population and the US population could limit the generalizability of VSD study findings, we performed a comparison of the demographic characteristics between the two populations. Methods: We collected data from medical records and administrative files at VSD sites in 2010 to compare sex, age, race, ethnicity, income, and educational attainment to the 2010 US Census population. We also compared data on the 2012 VSD Medicaid population to 2012 US Medicaid data. Results: The VSD population included over eight million individuals in 2010, which represented 2.6% of the total US population. All major demographic groups were represented in the VSD. We found no major differences in comparing sex, race, ethnicity, and educational attainment between the VSD and the US population. Middle income populations were comparable between the VSD and the US. While the percentage of lower income populations was less in the VSD compared to the US, the VSD had over two million individuals in this group. Additionally, there were over 600,000 Medicaid members in the VSD in 2012, which represented 1.1% of the US Medicaid population. Conclusions: We found that the VSD population is representative of the general US population on several key demographic and socioeconomic variables. Despite a few specific groups being underrepresented in the VSD compared to the US, the absolute number of VSD members is large enough to ensure significant representation of these groups in vaccine safety studies that use VSD data. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Sukumaran, Lakshmi; McCarthy, Natalie L.; Li, Rongxia; Weintraub, Eric S.; Tao, Biwen; Gee, Julianne] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Sukumaran, Lakshmi] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Hambidge, Simon J.] Univ Colorado, Dept Pediat, Kaiser Permanente Colorado, Dept Ambulatory Care Serv,Denver Hlth,Inst Hlth R, Denver, CO 80202 USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Chan, Berwick] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. RP Sukumaran, L (reprint author), 1600 Clifton Rd NE,Bldg 16,MS D-26, Atlanta, GA 30333 USA. EM xfq3@cdc.gov OI Jacobsen, Steven/0000-0002-8174-8533 FU Centers for Disease Control and Prevention (CDC); National Institute of Allergy and Infectious Diseases [T32AI074492] FX The project described was supported by the Centers for Disease Control and Prevention (CDC) and Award Number T32AI074492 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official policy or position of the Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. NR 24 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD AUG 26 PY 2015 VL 33 IS 36 BP 4446 EP 4450 DI 10.1016/j.vaccine.2015.07.037 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CQ8OK UT WOS:000360867500014 PM 26209836 ER PT J AU Coughlin, MM Collins, M Saxon, G Jarrahian, C Zehrung, D Cappello, C Dhere, R Royals, M Papania, M Rota, PA AF Coughlin, Melissa M. Collins, Marcus Saxon, Gene Jarrahian, Courtney Zehrung, Darin Cappello, Chris Dhere, Rajeev Royals, Michael Papania, Mark Rota, Paul A. TI Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model SO VACCINE LA English DT Article DE Jet injection; MMR; Alternative vaccine delivery ID INACTIVATED POLIOVIRUS VACCINE; HEPATITIS-A VACCINE; INFLUENZA VACCINE; CLINICAL SPECIMENS; DNA VACCINE; IMMUNOGENICITY; SAFETY; TRIAL; ELIMINATION; VIRUS AB Disposable-syringe jet injectors (DSJIs) with single-use, auto disable, needle-free syringes offer the opportunity to avoid hazards associated with injection using a needle and syringe. Clinical studies have evaluated DSJIs for vaccine delivery, but most studies have focused on inactivated, subunit, or DNA vaccines. Questions have been raised about possible damage to live attenuated viral vaccines by forces generated during the jet injection process. This study examines the effect of jet injection on the integrity of measles, mumps, and rubella vaccine (MMR), measured by viral RNA content and infectivity. Three models of DSJIs were evaluated, each generating a different ejection force. Following jet injection, the RNA content for each of the vaccine components was measured using RT-qPCR immediately after injection and following passage in Vero cells. Jet injection was performed with and without pig skin as a simulation of human skin. There was little to no reduction of RNA content immediately following jet injection with any of the three DSJIs. Samples passaged in Vero cells showed no loss in infectivity of the measles vaccine following jet injection. Mumps vaccine consistently showed increased replication following jet injection. Rubella vaccine showed no loss after jet injection alone but some infectivity loss following injection through pig skin with two of the devices. Overall, these data demonstrated that forces exerted on a live attenuated MMR vaccine did not compromise vaccine infectivity. The bench model and protocol used in this study can be applied to evaluate the impact of jet injection on other live virus vaccines. Published by Elsevier Ltd. C1 [Coughlin, Melissa M.; Collins, Marcus; Papania, Mark; Rota, Paul A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Saxon, Gene; Jarrahian, Courtney; Zehrung, Darin] PATH, Seattle, WA 98121 USA. [Cappello, Chris; Royals, Michael] PharmaJet, Golden, CO 80401 USA. [Dhere, Rajeev] Serum Inst India, Pune 411028, Maharashtra, India. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,M-S C22, Atlanta, GA 30333 USA. EM prota@cdc.gov NR 38 TC 1 Z9 1 U1 1 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD AUG 26 PY 2015 VL 33 IS 36 BP 4540 EP 4547 DI 10.1016/j.vaccine.2015.07.013 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CQ8OK UT WOS:000360867500027 PM 26192359 ER PT J AU Garg, S Jain, S Dawood, FS Jhung, M Perez, A D'Mello, T Reingold, A Gershman, K Meek, J Arnold, KE Farley, MM Ryan, P Lynfield, R Morin, C Baumbach, J Hancock, EB Zansky, S Bennett, N Thomas, A Schaffner, W Finelli, L AF Garg, Shikha Jain, Seema Dawood, Fatimah S. Jhung, Michael Perez, Alejandro D'Mello, Tiffany Reingold, Arthur Gershman, Ken Meek, James Arnold, Kathryn E. Farley, Monica M. Ryan, Patricia Lynfield, Ruth Morin, Craig Baumbach, Joan Hancock, Emily B. Zansky, Shelley Bennett, Nancy Thomas, Ann Schaffner, William Finelli, Lyn TI Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008 SO BMC INFECTIOUS DISEASES LA English DT Article DE Influenza; Pneumonia; Hospitalizations ID RESPIRATORY-TRACT COMPLICATIONS; COMMUNITY-ACQUIRED PNEUMONIA; STAPHYLOCOCCUS-AUREUS; PULMONARY COMPLICATIONS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; DISEASES-SOCIETY; A H1N1; CHILDREN; RECOMMENDATIONS AB Background: Influenza and pneumonia combined are the leading causes of death due to infectious diseases in the United States. We describe factors associated with pneumonia among adults hospitalized with influenza. Methods: Through the Emerging Infections Program, we identified adults >= 18 years, who were hospitalized with laboratory-confirmed influenza during October 2005 through April 2008, and had a chest radiograph (CXR) performed. Pneumonia was defined as the presence of a CXR infiltrate and either an ICD-9-CM code or discharge summary diagnosis of pneumonia. Results: Among 4,765 adults hospitalized with influenza, 1392 (29 %) had pneumonia. In multivariable analysis, factors associated with pneumonia included: age >= 75 years, adjusted odds ratio (AOR) 1.27 (95 % confidence interval 1.10-1.46), white race AOR 1.24 (1.03-1.49), nursing home residence AOR 1.37 (1.14-1.66), chronic lung disease AOR 1.37 (1.18-1.59), immunosuppression AOR 1.45 (1.19-1.78), and asthma AOR 0.76 (0.62-0.92). Patients with pneumonia were significantly more likely to require intensive care unit (ICU) admission (27 % vs. 10 %), mechanical ventilation (18 % vs. 5 %), and to die (9 % vs. 2 %). Conclusions: Pneumonia was present in nearly one-third of adults hospitalized with influenza and was associated with ICU admission and death. Among patients hospitalized with influenza, older patients and those with certain underlying conditions are more likely to have pneumonia. Pneumonia is common among adults hospitalized with influenza and should be evaluated and treated promptly. C1 [Garg, Shikha; Jain, Seema; Dawood, Fatimah S.; Jhung, Michael; Perez, Alejandro; D'Mello, Tiffany; Finelli, Lyn] CDC, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA 30329 USA. [Garg, Shikha] CDC, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA 94612 USA. [Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO 80246 USA. [Meek, James] Yale Univ, Connecticut Emerging Infect Program, New Haven, CT 06510 USA. [Arnold, Kathryn E.] Georgia Div Publ Hlth, Atlanta, GA 30303 USA. [Arnold, Kathryn E.] Georgia Emerging Infect Program, Atlanta, GA 30303 USA. [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Farley, Monica M.] Atlanta VAMC, Atlanta, GA 30322 USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Lynfield, Ruth; Morin, Craig] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Baumbach, Joan; Hancock, Emily B.] New Mexico Dept Hlth, Santa Fe, NM 87502 USA. [Zansky, Shelley] New York State Dept Hlth, ESP, Emerging Infect Program, Albany, NY 12237 USA. [Bennett, Nancy] Univ Rochester, Sch Med & Dent, Dept Med, New York, NY 14620 USA. [Bennett, Nancy] Dept Publ Hlth, Monroe Cty, Rochester, NY 14620 USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR 97232 USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [D'Mello, Tiffany] Atlanta Res & Educ Fdn, Atlanta, GA 30329 USA. RP Garg, S (reprint author), CDC, Epidemiol & Prevent Branch, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM izj7@cdc.gov NR 33 TC 2 Z9 2 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD AUG 26 PY 2015 VL 15 AR 369 DI 10.1186/s12879-015-1004-y PG 9 WC Infectious Diseases SC Infectious Diseases GA CP6FG UT WOS:000359979600002 PM 26307108 ER PT J AU Fulmer, EB Neilands, TB Dube, SR Kuiper, NM Arrazola, RA Glantz, SA AF Fulmer, Erika B. Neilands, Torsten B. Dube, Shanta R. Kuiper, Nicole M. Arrazola, Rene A. Glantz, Stanton A. TI Protobacco Media Exposure and Youth Susceptibility to Smoking Cigarettes, Cigarette Experimentation, and Current Tobacco Use among US Youth SO PLOS ONE LA English DT Article ID HIGH-SCHOOL-STUDENTS; ADOLESCENT SMOKING; ENTERTAINMENT MEDIA; UNITED-STATES; MOVIES; ATTITUDES; MIDDLE; ONSET; FIT AB Purpose Youth are exposed to many types of protobacco influences, including smoking in movies, which has been shown to cause initiation. This study investigates associations between different channels of protobacco media and susceptibility to smoking cigarettes, cigarette experimentation, and current tobacco use among US middle and high school students. Methods By using data from the 2012 National Youth Tobacco Survey, structural equation modeling was performed in 2013. The analyses examined exposure to tobacco use in different channels of protobacco media on smoking susceptibility, experimentation, and current tobacco use, accounting for perceived peer tobacco use. Results In 2012, 27.9% of respondents were never-smokers who reported being susceptible to trying cigarette smoking. Cigarette experimentation increased from 6.3% in 6th grade to 37.1% in 12th grade. Likewise, current tobacco use increased from 5.2% in 6th grade to 33.2% in 12th grade. Structural equation modeling supported a model in which current tobacco use is associated with exposure to static advertising through perception of peer use, and by exposure to tobacco use depicted on TV and in movies, both directly and through perception of peer use. Exposure to static advertising appears to directly increase smoking susceptibility but indirectly (through increased perceptions of peer use) to increase cigarette experimentation. Models that explicitly incorporate peer use as a mediator can better discern the direct and indirect effects of exposure to static advertising on youth tobacco use initiation. Conclusions These findings underscore the importance of reducing youth exposure to smoking in TV, movies, and static advertising. C1 [Fulmer, Erika B.; Kuiper, Nicole M.; Arrazola, Rene A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Neilands, Torsten B.] Univ Calif San Francisco, Ctr AIDS Prevent Studies CAPS, Dept Med, San Francisco, CA 94105 USA. [Dube, Shanta R.] Georgia State Univ, Sch Publ Hlth, Epidemiol & Biostat, Atlanta, GA 30303 USA. [Glantz, Stanton A.] Univ Calif San Francisco, Dept Med, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA. RP Fulmer, EB (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway,NE,MS F-79, Atlanta, GA 30341 USA. EM efulmer@cdc.gov NR 38 TC 2 Z9 2 U1 2 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 26 PY 2015 VL 10 IS 8 AR e0134734 DI 10.1371/journal.pone.0134734 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP7LO UT WOS:000360069400034 PM 26308217 ER PT J AU Soebiyanto, RP Gross, D Jorgensen, P Buda, S Bromberg, M Kaufman, Z Prosenc, K Socan, M Alonso, TV Widdowson, MA Kiang, RK AF Soebiyanto, Radina P. Gross, Diane Jorgensen, Pernille Buda, Silke Bromberg, Michal Kaufman, Zalman Prosenc, Katarina Socan, Maja Alonso, Tomas Vega Widdowson, Marc-Alain Kiang, Richard K. TI Associations between Meteorological Parameters and Influenza Activity in Berlin (Germany), Ljubljana (Slovenia), Castile and Leon (Spain) and Israeli Districts SO PLOS ONE LA English DT Article AB Background Studies in the literature have indicated that the timing of seasonal influenza epidemic varies across latitude, suggesting the involvement of meteorological and environmental conditions in the transmission of influenza. In this study, we investigated the link between meteorological parameters and influenza activity in 9 sub-national areas with temperate and subtropical climates: Berlin (Germany), Ljubljana (Slovenia), Castile and Leon (Spain) and all 6 districts in Israel. Methods We estimated weekly influenza-associated influenza-like-illness (ILI) or Acute Respiratory Infection (ARI) incidence to represent influenza activity using data from each country's sentinel surveillance during 2000-2011 (Spain) and 2006-2011 (all others). Meteorological data was obtained from ground stations, satellite and assimilated data. Two generalized additive models (GAM) were developed, with one using specific humidity as a covariate and another using minimum temperature. Precipitation and solar radiation were included as additional covariates in both models. The models were adjusted for previous weeks' influenza activity, and were trained separately for each study location. Results Influenza activity was inversely associated (p<0.05) with specific humidity in all locations. Minimum temperature was inversely associated with influenza in all 3 temperate locations, but not in all subtropical locations. Inverse associations between influenza and solar radiation were found in most locations. Associations with precipitation were location-dependent and inconclusive. We used the models to estimate influenza activity a week ahead for the 2010/2011 period which was not used in training the models. With exception of Ljubljana and Israel's Haifa District, the models could closely follow the observed data especially during the start and the end of epidemic period. In these locations, correlation coefficients between the observed and estimated ranged between 0.55 to 0.91and the model-estimated influenza peaks were within 3 weeks from the observations. Conclusion Our study demonstrated the significant link between specific humidity and influenza activity across temperate and subtropical climates, and that inclusion of meteorological parameters in the surveillance system may further our understanding of influenza transmission patterns. C1 [Soebiyanto, Radina P.] Univ Space Res Associat, Goddard Earth Sci Technol & Res, Columbia, MD USA. [Soebiyanto, Radina P.; Kiang, Richard K.] NASA Goddard Space Flight Ctr, Global Change Data Ctr, Greenbelt, MD 20771 USA. [Gross, Diane; Jorgensen, Pernille] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. [Gross, Diane; Widdowson, Marc-Alain] US Ctr Dis Control & Prevent CDC, Influenza Div, Atlanta, GA USA. [Buda, Silke] Robert Koch Inst, Berlin, Germany. [Bromberg, Michal; Kaufman, Zalman] Minist Hlth, Israel Ctr Dis Control, Tel Hashomer, Israel. [Prosenc, Katarina] Natl Inst Publ Hlth Slovenia, Virol Lab, Ljubljana, Slovenia. [Socan, Maja] Natl Inst Publ Hlth, Communicable Dis & Environm Hlth Care, Ljubljana, Slovenia. [Alonso, Tomas Vega] Publ Hlth Directorate, Dept Hlth, Valladolid, Spain. RP Kiang, RK (reprint author), NASA Goddard Space Flight Ctr, Global Change Data Ctr, Greenbelt, MD 20771 USA. EM richard.k.kiang@nasa.gov FU NASA Applied Sciences Public Health program; CDC Influenza Division FX This study was supported by NASA Applied Sciences Public Health program and CDC Influenza Division. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 0 TC 0 Z9 0 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 26 PY 2015 VL 10 IS 8 AR e0134701 DI 10.1371/journal.pone.0134701 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP7LO UT WOS:000360069400031 PM 26309214 ER PT J AU Tang, CT Liao, MY Chiu, CY Shen, WF Chiu, CY Cheng, PC Chang, GJJ Wu, HC AF Tang, Chung-Tao Liao, Mei-Ying Chiu, Chien-Yu Shen, Wen-Fan Chiu, Chiung-Yi Cheng, Ping-Chang Chang, Gwong-Jen J. Wu, Han-Chung TI Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein SO PLOS ONE LA English DT Article ID DOMAIN-III; NEUTRALIZING ANTIBODIES; DEPENDENT ENHANCEMENT; IN-VIVO; INFECTION; GLYCOPROTEIN; CHALLENGES; PEPTIDE; FUSION; ORGANIZATION AB The four serotypes of dengue virus (DENV1-4) pose a serious threat to global health. Cross-reactive and non-neutralizing antibodies enhance viral infection, thereby exacerbating the disease via antibody-dependent enhancement (ADE). Studying the epitopes targeted by these enhancing antibodies would improve the immune responses against DENV infection. In order to investigate the roles of antibodies in the pathogenesis of dengue, we generated a panel of 16 new monoclonal antibodies (mAbs) against DENV4. Using plaque reduction neutralization test (PRNT), we examined the neutralizing activity of these mAbs. Furthermore, we used the in vitro and in vivo ADE assay to evaluate the enhancement of DENV infection by mAbs. The results indicate that the cross-reactive and poorly neutralizing mAbs, DD11-4 and DD18-5, strongly enhance DENV1-4 infection of K562 cells and increase mortality in AG129 mice. The epitope residues of these enhancing mAbs were identified using virus-like particle (VLP) mutants. W212 and E26 are the epitope residues of DD11-4 and DD18-5, respectively. In conclusion, we generated and characterized 16 new mAbs against DENV4. DD11-4 and D18-5 possessed non-neutralizing activities and enhanced viral infection. Moreover, we identified the epitope residues of enhancing mAbs on envelope protein. These results may provide useful information for development of safe dengue vaccine. C1 [Tang, Chung-Tao; Liao, Mei-Ying; Chiu, Chien-Yu; Shen, Wen-Fan; Chiu, Chiung-Yi; Cheng, Ping-Chang; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan. [Chang, Gwong-Jen J.] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Infect Dis, Publ Hlth Serv,US Dept HHS, Ft Collins, CO USA. RP Wu, HC (reprint author), Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan. EM hcw0928@gate.sinica.edu.tw RI Wu, Han-Chung/B-1209-2011 OI Wu, Han-Chung/0000-0002-5185-1169 FU Academia Sinica; Ministry of Science and Technology [104-0210-01-09-02]; National Science Council, Taiwan [NSC102-2325-B-001-010] FX This funding was supported by grants from Academia Sinica, Ministry of Science and Technology (104-0210-01-09-02) and the National Science Council (NSC102-2325-B-001-010), Taiwan (to H-C Wu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 0 Z9 0 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 26 PY 2015 VL 10 IS 8 AR e0136328 DI 10.1371/journal.pone.0136328 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP7LO UT WOS:000360069400108 PM 26309127 ER PT J AU Lacher, DA Hughes, JP AF Lacher, David A. Hughes, Jeffery P. TI Total, free, and complexed prostate-specific antigen levels among US men, 2007-2010 SO CLINICA CHIMICA ACTA LA English DT Article DE Prostate-specific antigen; National health survey; Prostate cancer ID BODY-MASS INDEX; MULTICENTER CLINICAL-TRIAL; CANCER SCREENING TRIAL; RANDOMIZED PROSTATE; FOLLOW-UP; TOTAL PSA; OBESITY; MORTALITY; IMPROVES; SERUM AB Background: Screening for prostate cancer using prostate-specific antigen (PSA) is common. Prostate cancer has been associated with higher total PSA (tPSA), lower free PSA (fPSA), lower percent free PSA (MPSA), and higher complexed PSA (cPSA). Methods: Total, free and complexed PSAs were performed on 3251 men 40 years in the 2007-2010 National Health and Nutrition Examination Survey. Distributions of the PSA tests were examined by age, race and ethnicity, and body mass index (BMI) groups. Percentages of men at PSA thresholds were examined. Results: Total PSA geometric mean was 0.96 mu g/l among men aged >= 40 years and increased from 0.741 mu g/l for men 40-49 years, to 1.82 mu g/l for men 80 years and older. Non-Hispanic Whites had lower age-adjusted mean tPSA (1.03 mu g/l) and cPSA (0.56 mu g/l) than non-Hispanic Blacks (tPSA 1.25 mu g/l and cPSA 0.72 mu g/l). Obese men had lower age-adjusted mean total, free and complexed PSAs (0.94, 0.27, and 0.51 mu g/l, respectively) than men with normal BMI (tPSA 1.21, fPSA 0.32, and cPSA 0.68 mu g/l, respectively). Conclusion: Total, free and complexed PSAs increased with age; tPSA and cPSAs were highest in non-Hispanic Blacks; and total, free, and complexed PSAs were lowest in obese men. Published by Elsevier B.V. C1 [Lacher, David A.; Hughes, Jeffery P.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Lacher, DA (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM dol2@cdc.gov NR 40 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD AUG 25 PY 2015 VL 448 BP 220 EP 227 DI 10.1016/j.cca.2015.06.009 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CQ8OZ UT WOS:000360869300036 PM 26093340 ER PT J AU Nasrullah, M Oraka, E Chavez, PR Valverde, E Dinenno, E AF Nasrullah, Muazzam Oraka, Emeka Chavez, Pollyanna R. Valverde, Eduardo Dinenno, Elizabeth TI Nonvolitional sex and HIV-related sexual risk behaviours among MSM in the United States SO AIDS LA English DT Article DE HIV; MSM; violence ID HUMAN-IMMUNODEFICIENCY-VIRUS; BISEXUAL MEN; PARTNER ABUSE; GAY; VIOLENCE; HEALTH; INFECTION; DISCRIMINATION; EXPERIENCES; PREVALENCE AB Objective: We estimated the prevalence of lifetime nonvolitional sex (NVS) among MSM by demographic characteristics, and characterized its association with HIV-related sexual risk behaviours among MSM in the United States. Design: The National Survey of Family Growth (NSFG) is a nationally representative cross-sectional survey of the United States. Methods: NSFG data from recent cycles 2002, and 2006-2010 were weighted and analysed for men aged 18-44 years who reported ever having anal or oral intercourse with another male. Associations of lifetime NVS (forced sex by men or women) and age of first NVS experience (< 18 vs. >= 18 years), with HIV-related sexual risk behaviour outcomes in the past 12 months (i. e. sex with two or more male sex partners; exchanged sex for money or drugs; sex with IDU; sex with HIV-positive person; sex with two or more female sex partners) were assessed using adjusted prevalence ratios (aPR). Results: An estimated 3 226 872 or 5.8% of men aged 18-44 years were identified as MSM with 24.6% of them reporting ever experiencing NVS. MSM reporting NVS at age 18 years or older were more likely to have had sex with an IDU [aPR = 4.40; 95% confidence interval (95% CI) 1.78-10.88] and exchanged sex for money or drugs (aPR = 2.52; 95% CI 1.17-5.43) in the past 12 months compared with those not reporting NVS. NVS for MSM less than 18 years of age was associated with exchanging sex for money or drugs. Conclusion: Effective interventions to raise awareness of NVS among MSM and to offer support for MSM who have experienced NVS are needed. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Nasrullah, Muazzam; Chavez, Pollyanna R.; Valverde, Eduardo; Dinenno, Elizabeth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30329 USA. [Oraka, Emeka] Ctr Dis Control & Prevent, ICF Int, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. RP Nasrullah, M (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30329 USA. EM snasrullah@cdc.gov FU Division of HIV/AIDS Prevention (DHAP), National Center for HIV, Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia FX Division of HIV/AIDS Prevention (DHAP), National Center for HIV, Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia partially funds the National Survey of Family Growth (NSFG) through inter-agency agreement between CDC's National Center for Health Statistics and DHAP. NR 36 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD AUG 24 PY 2015 VL 29 IS 13 BP 1673 EP 1680 DI 10.1097/QAD.0000000000000631 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DC2TZ UT WOS:000369071100012 PM 26372278 ER PT J AU Deshmukh, RD Dhande, DJ Sachdeva, KS Sreenivas, A Kumar, AMV Satyanarayana, S Parmar, M Moonan, PK Lo, TQ AF Deshmukh, Rajesh D. Dhande, D. J. Sachdeva, Kuldeep Singh Sreenivas, Achuthan Kumar, A. M. V. Satyanarayana, Srinath Parmar, Malik Moonan, Patrick K. Lo, Terrence Q. TI Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India SO PLOS ONE LA English DT Article ID TUBERCULOSIS TREATMENT; RUSSIAN-FEDERATION; PROGRAM; DEFAULT; TOMSK AB Introduction Multidrug-resistant Tuberculosis (MDR TB) is emerging public health concern globally. Lost to follow-up (LTFU) is one of the key challenge in MDRTB treatment. In 2013, 18% of MDR TB patients were reported LTFU in India. A qualitative study was conducted to obtain better understanding of both patient and provider related factors for LTFU among MDR TB treatment. Methods Qualitative semi-structured personal interviews were conducted with 20 MDRTB patients reported as LTFU and 10 treatment providers in seven districts linked to Nagpur Drug resistant TB Centre (DRTBC) during August 2012-February 2013. Interviews were transcribed and inductive content analysis was performed to derive emergent themes. Results We found multiple factors influencing MDR TB treatment adherence. Barriers to treatment adherence included drug side effects, a perceived lack of provider support, patient financial constraints, conflicts with the timing of treatment services, alcoholism and social stigma. Conclusions Patient adherence to treatment is multi-factorial and involves individual patient factors, provider factors, and community factors. Addressing issue of LTFU during MDRTB treatment requires enhanced efforts towards resolving medical problems like adverse drug effects, developing short duration treatment regimens, reducing pill burden, motivational counselling, flexible timings for DOT services, social, family support for patients & improving awareness about disease. C1 [Deshmukh, Rajesh D.; Sreenivas, Achuthan; Parmar, Malik] World Hlth Org, Country Off India, New Delhi, India. [Dhande, D. J.] Lata Mangeshkar Hosp, Drug Resistant TB Ctr, Dept Pulm Med, Nagpur, Maharashtra, India. [Sachdeva, Kuldeep Singh] Minist Hlth & Family Welf, Cent TB Div, New Delhi, India. [Kumar, A. M. V.] South East Asia Off, Int Union TB & Lung Dis, New Delhi, India. [Moonan, Patrick K.; Lo, Terrence Q.] US Ctr Dis Control & Prevent, Div TB Eliminat, Int Res Programs Branch, Atlanta, GA USA. [Satyanarayana, Srinath] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada. RP Deshmukh, RD (reprint author), Minist Hlth & Family Welf, Dept AIDS Control NACO, New Delhi, India. EM pohivtb.naco@gmail.com FU Central TB division New Delhi; National TB institute Bangalore; State TB cell Maharashtra; State TB demonstration centre Nagpur FX This training project was conceived and implemented jointly by Central TB Division (Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India), The National TB Institute (Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India Bangalore, India), World Health Organization (India Country Office), The International Union Against Tuberculosis and Lung Diseases (The Union, South-East Asia Regional Office, New Delhi, India) and U.S. Centers for Disease Control and Prevention (Division of TB Elimination, Atlanta, USA). We acknowledge support of the Central TB division New Delhi, National TB institute Bangalore, State TB cell Maharashtra, State TB demonstration centre Nagpur. We also appreciate the help of Gaikwad P, Chavan. H, Kamble.M and Khan.N. NR 17 TC 6 Z9 6 U1 3 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 24 PY 2015 VL 10 IS 8 AR e0135802 DI 10.1371/journal.pone.0135802 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP5VA UT WOS:000359951900031 PM 26301748 ER PT J AU Cisse, MBM Keita, C Dicko, A Dengela, D Coleman, J Lucas, B Mihigo, J Sadou, A Belemvire, A George, K Fornadel, C Beach, R AF Cisse, Moussa B. M. Keita, Chitan Dicko, Abdourhamane Dengela, Dereje Coleman, Jane Lucas, Bradford Mihigo, Jules Sadou, Aboubacar Belemvire, Allison George, Kristen Fornadel, Christen Beach, Raymond TI Characterizing the insecticide resistance of Anopheles gambiae in Mali SO MALARIA JOURNAL LA English DT Article DE Anopheles gambiae; Insecticide-based malaria vector control; Vector-insecticide resistance; Resistance monitoring; Mali ID KNOCK-DOWN-RESISTANCE; SOUTH-WESTERN NIGERIA; MOLECULAR CHARACTERIZATION; PYRETHROID INSECTICIDES; URBAN POPULATIONS; BURKINA-FASO; TREATED NETS; COTE-DIVOIRE; AFRICA; S.S AB Background: The impact of indoor residual spraying (IRS) and long-lasting insecticide nets (LLINs), key components of the national malaria control strategy of Mali, is threatened by vector insecticide resistance. The objective of this study was to assess the level of insecticide resistance in Anopheles gambiae sensu lato populations from Mali against four classes of insecticide recommended for IRS: organochlorines (OCs), pyrethroids (PYs), carbamates (CAs) and organophosphates (OPs). Characterization of resistance was done in 13 sites across southern Mali and assessed presence and distribution of physiological mechanisms that included target-site modifications: knockdown resistance (kdr) and altered acetycholinesterase (AChE), and/or metabolic mechanisms: elevated esterases, glutathione S-transferases (GSTs), and monooxygenases. Methods: The World Health Organization (WHO) tube test was used to determine phenotypic resistance of An. gambiae s.I. to: dichlorodiphenyltrichloroethane (DDT) (OC), deltamethrin (PY), lambda-cyhalothrin (PY), bendiocarb (CA), and fenitrothion (OP). Identification of sibling species and presence of the ace-1(R) and Leu-Phe kdr, resistance-associated mutations, were determined using polymerase chain reaction (PCR) technology. Biochemical assays were conducted to detect increased activity of GSTs, oxidases and esterases. Results: Populations tested showed high levels of resistance to DDT in all 13 sites, as well as increased resistance to deltamethrin and lambda-cyhalothrin in 12 out of 13 sites. Resistance to fenitrothion and bendiocarb was detected in 1 and 4 out of 13 sites, respectively. Anopheles coluzzii, An. gambiae sensu stricto and Anopheles arabiensis were identified with high allelic frequencies of kdr in all sites where each of the species were found (13, 12 and 10 sites, respectively). Relatively low allelic frequencies of ace-1(R) were detected in four sites where this assessment was conducted. Evidence of elevated insecticide metabolism, based on oxidase, GSTs and esterase detoxification, was also documented. Conclusion: Multiple insecticide-resistance mechanisms have evolved in An. coluzzii, An. gambiae s.s. and An. arabiensis in Mali. These include at least two target site modifications: kdr, and ace-1(R), as well as elevated metabolic detoxification systems (monooxygenases and esterases). The selection pressure for resistance could have risen from the use of these insecticides in agriculture, as well as in public health. Resistance management strategies, based on routine resistance monitoring to inform insecticide-based malaria vector control in Mali, are recommended. C1 [Cisse, Moussa B. M.; Keita, Chitan] Abt Associates Inc, PMI Africa Indoor Residual Spraying Project, Bamako, Mali. [Dicko, Abdourhamane] Natl Malaria Control Programme, Bamako, Mali. [Dengela, Dereje; Coleman, Jane; Lucas, Bradford] Abt Associates Inc, PMI Africa Indoor Residual Spraying Project, Bethesda, MD 20814 USA. [Mihigo, Jules; Sadou, Aboubacar] Presidents Malaria Initiat USAID, Bamako, Mali. [Belemvire, Allison; George, Kristen; Fornadel, Christen] Presidents Malaria Initiat USAID, Washington, DC USA. [Beach, Raymond] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Cisse, MBM (reprint author), Abt Associates Inc, PMI Africa Indoor Residual Spraying Project, Cite Niger BP 34, Bamako, Mali. EM Moussa_Cisse@africairs.net FU President's Malaria Initiative FX We wish to thank Josepha Iraore, Seydou Iraore, and Elie Bankineza for making substantial contributions to conception, design, acquisition of data; all technicians who participated in the field collection of larvae and provided support during the testing; Laura McCarty who critically read the manuscript and provided inputs, and Ben Johns who supported the statistical analysis of the data. Our thanks are addressed to the Mali Ministry of Health as well as to local leaders, health providers, community health workers and residents at the assessment sites. This study was conducted by the United States Agency for International Development's Africa Indoor Residual Spraying Project with financial support of the President's Malaria Initiative. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the Government of Mali or USAID. NR 46 TC 6 Z9 6 U1 3 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD AUG 22 PY 2015 VL 14 AR 327 DI 10.1186/s12936-015-0847-4 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CP4EC UT WOS:000359833800001 PM 26296644 ER PT J AU Cope, JR Collier, SA Rao, MM Chalmers, R Mitchell, GL Richdale, K Wagner, H Kinoshita, BT Lam, DY Sorbara, L Zimmerman, A Yoder, JS Beach, MJ AF Cope, Jennifer R. Collier, Sarah A. Rao, Maya M. Chalmers, Robin Mitchell, G. Lynn Richdale, Kathryn Wagner, Heidi Kinoshita, Beth T. Lam, Dawn Y. Sorbara, Luigina Zimmerman, Aaron Yoder, Jonathan S. Beach, Michael J. TI Contact Lens Wearer Demographics and Risk Behaviors for Contact Lens-Related Eye Infections - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MICROBIAL KERATITIS C1 [Cope, Jennifer R.; Collier, Sarah A.; Rao, Maya M.; Yoder, Jonathan S.; Beach, Michael J.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Chalmers, Robin; Mitchell, G. Lynn; Richdale, Kathryn; Wagner, Heidi; Kinoshita, Beth T.; Lam, Dawn Y.; Sorbara, Luigina; Zimmerman, Aaron] CLAY, Atlanta, GA USA. [Mitchell, G. Lynn; Wagner, Heidi; Zimmerman, Aaron] Ohio State Univ, Coll Optometry, Columbus, OH 43210 USA. [Richdale, Kathryn] SUNY Coll Optometry, New York, NY 10036 USA. [Kinoshita, Beth T.] Univ Pacific, Coll Optometry, Forest Grove, OR USA. [Lam, Dawn Y.] Marshall B Ketchum Univ, Southern Calif Coll Optometry, Fullerton, CA USA. [Sorbara, Luigina] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON N2L 3G1, Canada. RP Cope, JR (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jcope@cdc.gov RI Wagner, Heidi/H-1422-2016; OI Sorbara, Luigina/0000-0002-6451-8509 NR 10 TC 13 Z9 14 U1 5 U2 15 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 21 PY 2015 VL 64 IS 32 BP 865 EP 870 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP6LL UT WOS:000359998700002 PM 26292204 ER PT J AU Demirjian, A Sanchez, GV Finkelstein, JA Ling, SM Srinivasan, A Pollack, LA Hicks, LA Iskander, JK AF Demirjian, Alicia Sanchez, Guillermo V. Finkelstein, Jonathan A. Ling, Shari M. Srinivasan, Arjun Pollack, Lori A. Hicks, Lauri A. Iskander, John K. TI CDC Grand Rounds: Getting Smart About Antibiotics SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; CARE; INFECTIONS; ADULTS C1 [Demirjian, Alicia] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Demirjian, Alicia; Sanchez, Guillermo V.; Hicks, Lauri A.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Finkelstein, Jonathan A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA. [Finkelstein, Jonathan A.] Harvard Univ, Sch Med, Dept Pediat & Populat Med, Boston, MA 02115 USA. [Pollack, Lori A.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Iskander, John K.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. RP Demirjian, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM alicia.demirjian@post.harvard.edu NR 15 TC 4 Z9 4 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 21 PY 2015 VL 64 IS 32 BP 871 EP 873 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP6LL UT WOS:000359998700003 PM 26292205 ER PT J AU Etsano, A Gunnala, R Shuaib, F Damisa, E Mkanda, P Ticha, JM Banda, R Korir, C Chevez, AE Enemaku, O Corkum, M Davis, LB Nganda, GW Burns, CC Wassilak, SGF Vertefeuille, JF AF Etsano, Andrew Gunnala, Rajni Shuaib, Faisal Damisa, Eunice Mkanda, Pascal Ticha, Johnson M. Banda, Richard Korir, Charles Chevez, Ana Elena Enemaku, Ogu Corkum, Melissa Davis, Lora B. Nganda, Gatei-wa Burns, Cara C. Wassilak, Steven G. F. Vertefeuille, John F. TI Progress Toward Poliomyelitis Eradication - Nigeria, January 2014-July 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POLIO ERADICATION; WORLDWIDE; VACCINE C1 [Gunnala, Rajni; Davis, Lora B.; Nganda, Gatei-wa; Wassilak, Steven G. F.; Vertefeuille, John F.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Burns, Cara C.] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Gunnala, R (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM rgunnala@cdc.gov NR 10 TC 9 Z9 9 U1 2 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 21 PY 2015 VL 64 IS 32 BP 878 EP 882 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP6LL UT WOS:000359998700005 PM 26292207 ER PT J AU Meiman, J Thiboldeaux, R Anderson, H AF Meiman, Jon Thiboldeaux, Robert Anderson, Henry TI Lead Poisoning and Anemia Associated with Use of Ayurvedic Medications Purchased on the Internet - Wisconsin, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Meiman, Jon] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Meiman, J (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM xdf5@cdc.gov NR 4 TC 2 Z9 2 U1 1 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 21 PY 2015 VL 64 IS 32 BP 883 EP 883 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP6LL UT WOS:000359998700006 PM 26292208 ER PT J AU Talundzic, E Chenet, SM Goldman, IF Patel, DS Nelson, JA Plucinski, MM Barnwell, JW Udhayakumar, V AF Talundzic, Eldin Chenet, Stella M. Goldman, Ira F. Patel, Dhruviben S. Nelson, Julia A. Plucinski, Mateusz M. Barnwell, John W. Udhayakumar, Venkatachalam TI Genetic Analysis and Species Specific Amplification of the Artemisinin Resistance-Associated Kelch Propeller Domain in P. falciparum and P-vivax SO PLOS ONE LA English DT Article ID REAL-TIME PCR; WESTERN CAMBODIA; SOUTHEAST-ASIA; MALARIA; CLEARANCE; PROVINCE AB Plasmodium falciparum resistance to artemisinin has emerged in the Greater Mekong Sub-region and now poses a threat to malaria control and prevention. Recent work has identified mutations in the kelch propeller domain of the P. falciparum K13 gene to be associated artemisinin resistance as defined by delayed parasite clearance and ex vivo ring stage survival assays. Species specific primers for the two most prevalent human malaria species, P. falciparum and P. vivax, were designed and tested on multiple parasite isolates including human, rodent, and non-humans primate Plasmodium species. The new protocol described here using the species specific primers only amplified their respective species, P. falciparum and P. vivax, and did not cross react with any of the other human malaria Plasmodium species. We provide an improved species specific PCR and sequencing protocol that could be effectively used in areas where both P. falciparum and P. vivax are circulating. To design this improved protocol, the kelch gene was analyzed and compared among different species of Plasmodium. The kelch propeller domain was found to be highly conserved across the mammalian Plasmodium species. C1 [Talundzic, Eldin; Chenet, Stella M.; Goldman, Ira F.; Patel, Dhruviben S.; Plucinski, Mateusz M.; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Talundzic, Eldin; Nelson, Julia A.] Atlanta Res & Educ Fdn, VA Med Ctr, Decatur, GA USA. [Plucinski, Mateusz M.] Presidents Malaria Initiat, Atlanta, GA USA. RP Talundzic, E (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, 1600 Clifton Rd,Mail Stop D-67, Atlanta, GA 30329 USA. EM etalundzic@cdc.gov FU CDC Advanced Molecular Detection Initiative; Atlanta Research and Education Foundation; American Society of Microbiology postdoctoral fellowship FX The authors acknowledge funding support from the CDC Advanced Molecular Detection Initiative. ET is supported by the Atlanta Research and Education Foundation and SMC by the American Society of Microbiology postdoctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 7 Z9 7 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 20 PY 2015 VL 10 IS 8 AR e0136099 DI 10.1371/journal.pone.0136099 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP5KH UT WOS:000359919900054 PM 26292024 ER PT J AU Wang, RP Zhu, LP Yan, W Zeng, G Michael, E AF Wang, Ruiping Zhu, Liping Yan, Wei Zeng, Guang Michael, Engelgau TI The influence of estimated retail tobacco sale price increase on smokers' smoking habit in Jiangxi province, China: a cross-sectional study SO TOBACCO INDUCED DISEASES LA English DT Article DE Smoking habit change; Tobacco retail price increase; Tobacco law legislation ID CIGARETTE PRICES; DISPLAYS; EXPOSURE; SUPPORT; INCOME; TAX AB Introduction: China is the biggest tobacco producer and consumer in the world. Raising cigarette taxes and increasing tobacco retail prices have been prove as effective strategies to reduce tobacco consumption and the prevalence of smoking in western countries. But in China, it is uncertain how an increase of cigarette retail price will influence the tobacco consumption. Methods: From April to July, 2012, we selected 4025 residents over 15 years by a three stage random sampling in four cities, Jiangxi Province, China. We conducted interviews of their current smoking habits and how they would change their smoking behavior if tobacco retail prices increase. Results: Overall, the prevalence of smoking is 27 % (47 % for male, 3.1 % for female). 15 % of smokers have tried to quit smoking in the past but all relapsed (168/1088), and over 50 % of current smokers do not want to quit, The average cigarette price per pack is 1.1 USD (range = 0.25-5.0). If retail cigarette prices increases by 50 %, 45 % of smokers say they will smoke fewer cigarettes, 20 % will change to cheaper brands and 5 % will attempt to quit smoking. Smokers who have intention to quit smoking are more sensitive to retail cigarette price increase. With retail cigarette price increases, more smokers will attempt to quit smoking. Conclusion: Chinese smokers will change their smoking habits if tobacco retail prices increase. Consequently the Chinese government should enact tobacco laws which increase the retail cigarette price. The implementation of new tobacco laws could result in lowering the prevalence of smoking. Meanwhile, price increase measures need to apply to all cigarette brands to avoid smokers switching cigarettes to cheaper brands. C1 [Wang, Ruiping] Songjiang Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Wang, Ruiping; Zeng, Guang; Michael, Engelgau] China Field Epidemiol Training Program, Beijing, Peoples R China. [Zhu, Liping; Yan, Wei] Jiangxi Prov Ctr Dis Control & Prevent, Nanchang, Peoples R China. [Michael, Engelgau] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Wang, RP (reprint author), Songjiang Ctr Dis Control & Prevent, 1050 North Xilin Rd, Shanghai, Peoples R China. EM w19830901@126.com; zlp210@126.com NR 29 TC 2 Z9 2 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1617-9625 J9 TOB INDUC DIS JI Tob. Induc. Dis. PD AUG 19 PY 2015 VL 13 AR 25 DI 10.1186/s12971-015-0043-x PG 9 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CP2LM UT WOS:000359708500001 PM 26300716 ER PT J AU Scott, JC Shah, N Porco, T Flood, J AF Scott, James C. Shah, Neha Porco, Travis Flood, Jennifer TI Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study SO PLOS ONE LA English DT Article ID LATENT TUBERCULOSIS INFECTION; RESISTANT TUBERCULOSIS; ADVERSE EVENTS; MDR-TB; METAANALYSIS; SAFETY; REGIMENS; RIFAMPIN; THERAPY AB Background From 2012 through 2014, the United States experienced acute shortages and price escalations of several first-line anti-tuberculosis (TB) medications. Because secondary TB drug regimens are longer and adverse events occur more frequently with them, we sought to conservatively estimate the cost, to patients and the health care system, of TB treatment and medication adverse events from alternative regimens during drug shortages. Methods We assessed the cost of treatment for TB disease in the absence of isoniazid (INH), rifampin (RIF), or pyrazinamide (PZA), or both INH and RIF. We simulated adverse events based on published probabilities using a monthly discrete-time stochastic model. For total costs, we summed costs of medications, routine testing, and treatment of adverse events using procedural terminology codes. We report average cost ratios of TB treatment during drug shortages to standard TB treatment. Results The cost ratio of TB treatment without INH, RIF, or PZA to standard treatment was 1.7 (Range: 1.2, 2.3), 4.9 (Range: 3.2, 7.3), and 1.1 (Range: 0.7, 1.7) times higher, respectively. Without both INH and RIF, the cost ratio was 18.6 (Range: 10.0, 39.0) times higher. When the prices for INH, RIF and PZA were increased, the cost for standard treatment increased by a factor of 2.7 (Range: 1.9, 3.0). The percentage of patients experiencing at least one adverse event while taking standard therapy was 3.9% (Range: 1.3%, 11.8%). This percentage increased to 51.5%(Range: 20.1%, 83.8%) when RIF was unavailable, and increased to 82.5% (Range: 41.2%, 98.5%) when both INH and RIF were unavailable. Conclusions Our conservative model illustrates that an interruption in first-line anti-TB medications leads to appreciable additional costs and adverse events for patients. The availability of these drugs in the United States should be ensured. Models that incorporate the effectiveness of alternative regimens, delays in treatment initiation, and TB transmission can provide broader perspectives on the impact of drug shortages. C1 [Scott, James C.] Colby Coll, Dept Math & Stat, Waterville, ME 04901 USA. [Scott, James C.; Porco, Travis] Francis I Proctor Fdn, San Francisco, CA USA. [Shah, Neha; Flood, Jennifer] Calif Dept Hlth TB Control Branch, Richmond, CA 94804 USA. [Shah, Neha] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Porco, Travis] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Shah, N (reprint author), Calif Dept Hlth TB Control Branch, Richmond, CA 94804 USA. EM nshah6@cdc.gov FU NIGMS NIH HHS [U01-GM087728] NR 33 TC 2 Z9 2 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 18 PY 2015 VL 10 IS 8 AR e0134597 DI 10.1371/journal.pone.0134597 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP1VY UT WOS:000359666100012 PM 26284924 ER PT J AU Mphaphlele, M Dharmadhikari, AS Jensen, PA Rudnick, SN van Reenen, TH Pagano, MA Leuschner, W Sears, TA Milonova, SP van der Walt, M Stoltz, AC Weyer, K Nardell, EA AF Mphaphlele, Matsie Dharmadhikari, Ashwin S. Jensen, Paul A. Rudnick, Stephen N. van Reenen, Tobias H. Pagano, Marcello A. Leuschner, Wilhelm Sears, Tim A. Milonova, Sonya P. van der Walt, Martie Stoltz, Anton C. Weyer, Karin Nardell, Edward A. TI Institutional Tuberculosis Transmission Controlled Trial of Upper Room Ultraviolet Air Disinfection: A Basis for New Dosing Guidelines SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE tuberculosis transmission; infection control; air disinfection; ultraviolet irradiation; tuberculosis prevention ID GERMICIDAL IRRADIATION SYSTEM; DRUG-RESISTANT TUBERCULOSIS; WARD; MICROORGANISMS; INFECTIVITY; ENVIRONMENT; LIGHT AB Rationale: Transmission is driving the global tuberculosis epidemic, especially in congregate settings. Worldwide, natural ventilation is the most common means of air disinfection, but it is inherently unreliable and of limited use in cold climates. Upper room germicidal ultraviolet (UV) air disinfection with air mixing has been shown to be highly effective, but improved evidence-based dosing guidelines are needed. Objectives: To test the efficacy of upper room germicidal air disinfection with air mixing to reduce tuberculosis transmission under real hospital conditions, and to define the application parameters responsible as a basis for proposed new dosing guidelines. Methods: Over an exposure period of 7 months, 90 guinea pigs breathed only untreated exhaust ward air, and another 90 guinea pigs breathed only air from the same six-bed tuberculosis ward on alternate days when upper room germicidal air disinfection was turned on throughout the ward. Measurements and Main Results: The tuberculin skin test conversion rates (>6 mm) of the two chambers were compared. The hazard ratio for guinea pigs in the control chamber converting their skin test to positive was 4.9 (95% confidence interval, 2.8-8.6), with an efficacy of approximately 80%. Conclusions: Upper room germicidal UV air disinfection with air mixing was highly effective in reducing tuberculosis transmission under hospital conditions. These data support using either a total fixture output (rather than electrical or UV lamp wattage) of 15-20 mW/m(3) total room volume, or an average whole-room UV irradiance (fluence rate) of 5-7 p6W/cm(2), calculated by a lighting computer-assisted design program modified for UV use. C1 [Mphaphlele, Matsie] JHPIEGO, MDR TB Program, Pretoria, South Africa. [Dharmadhikari, Ashwin S.; Nardell, Edward A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Nardell, Edward A.] Brigham & Womens Hosp, Div Global Hlth Equity, Dept Med, Boston, MA 02115 USA. [Jensen, Paul A.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, CDC Div TB Eliminat, Atlanta, GA USA. [Rudnick, Stephen N.; Milonova, Sonya P.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [van Reenen, Tobias H.] CSIR, Pretoria, South Africa. [Pagano, Marcello A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Leuschner, Wilhelm] Univ Pretoria, Dept Elect & Comp Engn, ZA-0002 Pretoria, South Africa. [Sears, Tim A.] Acuity Brands Lighting, Connors, GA USA. [van der Walt, Martie] MRC, Pretoria, South Africa. [Stoltz, Anton C.] Univ Pretoria, Sch Med, Div Infect Dis, Internal Med, ZA-0002 Pretoria, South Africa. [Weyer, Karin] WHO, Global TB Programme, CH-1211 Geneva, Switzerland. RP Nardell, EA (reprint author), Brigham & Womens Hosp, Div Global Hlth Equity, 641 Huntington Ave,3A-03, Boston, MA 02115 USA. EM enardell@partners.org FU CDC/National Institute for Occupational Safety and Health [1RO1 OH009050]; National Institutes of Health/Fogarty International [1D43TW009379] FX Supported by CDC/National Institute for Occupational Safety and Health grant 1RO1 OH009050 and National Institutes of Health/Fogarty International grant 1D43TW009379. NR 38 TC 7 Z9 7 U1 2 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD AUG 15 PY 2015 VL 192 IS 4 BP 477 EP 484 DI 10.1164/rccm.201501-0060OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CP9AS UT WOS:000360186700014 PM 25928547 ER PT J AU Kramer, MR Casper, M AF Kramer, Michael R. Casper, Michele TI Kramer and Casper Respond to "A-P-C ... It's Easy as 1-2-3!" SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material C1 [Kramer, Michael R.; Casper, Michele] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Kramer, Michael R.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. RP Kramer, MR (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM mkram02@emory.edu FU NICHD NIH HHS [K01 HD074726, K01HD074726] NR 4 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD AUG 15 PY 2015 VL 182 IS 4 BP 318 EP 319 DI 10.1093/aje/kwv049 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP1VU UT WOS:000359665600005 PM 26199383 ER PT J AU Lawman, HG Ogden, CL Hassink, S Mallya, G Vander Veur, S Foster, GD AF Lawman, Hannah G. Ogden, Cynthia L. Hassink, Sandra Mallya, Giridhar Vander Veur, Stephanie Foster, Gary D. TI Comparing Methods for Identifying Biologically Implausible Values in Height, Weight, and Body Mass Index Among Youth SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE biologically implausible values; body mass index; obesity; youth ID INCOME PRESCHOOL-CHILDREN; FOR-DISEASE-CONTROL; EXTREME OBESITY; SCHOOL-CHILDREN; PREVALENCE; ADOLESCENTS; OVERWEIGHT; CHILDHOOD; TRENDS; RISK AB As more epidemiologic data on childhood obesity become available, researchers are faced with decisions regarding how to determine biologically implausible values (BIVs) in height, weight, and body mass index. The purpose of the current study was 1) to track how often large, epidemiologic studies address BIVs, 2) to review BIV identification methods, and 3) to apply those methods to a large data set of youth to determine the effects on obesity and BIV prevalence estimates. Studies with large samples of anthropometric data (n > 1,000) were reviewed to track whether and how BIVs were defined. Identified methods were then applied to a longitudinal sample of 13,662 students (65% African American, 52% male) in 55 urban, low-income schools that enroll students from kindergarten through eighth grade (ages 5-13 years) in Philadelphia, Pennsylvania, during 2011-2012. Using measured weight and height at baseline and 1-year follow-up, we compared descriptive statistics, weight status prevalence, and BIV prevalence estimates. Eleven different BIV methods were identified. When these methods were applied to a large data set, severe obesity and BIV prevalence ranged from 7.2% to 8.6% and from 0.04% to 1.68%, respectively. Approximately 41% of large epidemiologic studies did not address BIV identification, and existing identification methods varied considerably. Increased standardization of the identification and treatment of BIVs may aid in the comparability of study results and accurate monitoring of obesity trends. C1 [Lawman, Hannah G.; Vander Veur, Stephanie; Foster, Gary D.] Temple Univ, Sch Med, Ctr Obes Res & Educ, Philadelphia, PA 19122 USA. [Lawman, Hannah G.; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Hassink, Sandra] Nemours Alfred I duPont Hosp Children, Dept Pediat, Wilmington, DE USA. [Mallya, Giridhar] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. RP Lawman, HG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Surveys, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM hlawman@cdc.gov FU Centers for Disease Control and Prevention [3U58DP002626-01S1]; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [1-P60-DK020541, 1-F32-DK100248-01] FX This work was supported by a grant (cooperative agreement 3U58DP002626-01S1) from the Centers for Disease Control and Prevention and by grants (1-P60-DK020541 and 1-F32-DK100248-01) from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. NR 37 TC 0 Z9 0 U1 5 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD AUG 15 PY 2015 VL 182 IS 4 BP 359 EP 365 DI 10.1093/aje/kwv057 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP1VU UT WOS:000359665600012 PM 26182944 ER PT J AU Kraft, CS Hewlett, AL Koepsell, S Winkler, AM Kratochvil, CJ Larson, L Varkey, JB Mehta, AK Lyon, M Friedman-Moraco, RJ Marconi, VC Hill, CE Sullivan, JN Johnson, DW Lisco, SJ Mulligan, MJ Uyeki, TM McElroy, AK Sealy, T Campbell, S Spiropoulou, C Stroher, U Crozier, I Sacra, R Connor, MJ Sueblinvong, V Franch, HA Smith, PW Ribner, BS AF Kraft, Colleen S. Hewlett, Angela L. Koepsell, Scott Winkler, Anne M. Kratochvil, Christopher J. Larson, LuAnn Varkey, Jay B. Mehta, Aneesh K. Lyon, Marshall, III Friedman-Moraco, Rachel J. Marconi, Vincent C. Hill, Charles E. Sullivan, James N. Johnson, Daniel W. Lisco, Steven J. Mulligan, Mark J. Uyeki, Timothy M. McElroy, Anita K. Sealy, Tara Campbell, Shelley Spiropoulou, Christina Stroeher, Ute Crozier, Ian Sacra, Richard Connor, Michael J., Jr. Sueblinvong, Viranuj Franch, Harold A. Smith, Philip W. Ribner, Bruce S. CA Nebraska Biocontainment Unit Emory Serious Communicable Dis Uni TI The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE TKM-Ebola; convalescent plasma; convalescent serum; Ebola virus; Ebola virus disease ID HEMORRHAGIC-FEVER; POSTEXPOSURE PROTECTION; NONHUMAN-PRIMATES; RNA INTERFERENCE; PROPHYLAXIS; CHALLENGE; INFECTION; ANTIBODY AB Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management. Methods. We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma. Results. While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date. Conclusions. It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD. C1 [Kraft, Colleen S.; Winkler, Anne M.; Hill, Charles E.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Kraft, Colleen S.; Varkey, Jay B.; Mehta, Aneesh K.; Lyon, Marshall, III; Friedman-Moraco, Rachel J.; Marconi, Vincent C.; Mulligan, Mark J.; Ribner, Bruce S.] Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30322 USA. [Hewlett, Angela L.; Smith, Philip W.] Univ Nebraska Med Ctr, Div Infect Dis, Dept Internal Med, Omaha, NE USA. [Koepsell, Scott] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA. [Kratochvil, Christopher J.] Univ Nebraska Med Ctr, Off Vice Chancellor Res, Omaha, NE USA. [Larson, LuAnn] Univ Nebraska Med Ctr, Ctr Clin & Translat Res, Omaha, NE USA. [Sullivan, James N.; Johnson, Daniel W.; Lisco, Steven J.] Univ Nebraska Med Ctr, Div Crit Care, Dept Anesthesiol, Omaha, NE USA. [Uyeki, Timothy M.; McElroy, Anita K.; Sealy, Tara; Campbell, Shelley; Spiropoulou, Christina; Stroeher, Ute] Ctr Dis Control & Prevent, Atlanta, GA USA. [Crozier, Ian] WHO, Kenema Hosp, Freetown, Sierra Leone. [Sacra, Richard] Univ Massachusetts, Sch Med, Worcester, MA USA. [Connor, Michael J., Jr.; Sueblinvong, Viranuj] Emory Univ, Div Pulm, Atlanta, GA 30322 USA. [Connor, Michael J., Jr.; Sueblinvong, Viranuj] Emory Univ, Div Allergy, Atlanta, GA 30322 USA. [Connor, Michael J., Jr.; Sueblinvong, Viranuj] Emory Univ, Div Crit Care, Atlanta, GA 30322 USA. [Connor, Michael J., Jr.; Sueblinvong, Viranuj; Franch, Harold A.] Emory Univ, Renal Med, Dept Med, Atlanta, GA 30322 USA. RP Kraft, CS (reprint author), Emory Univ, Dept Pathol & Lab Med, Dept Med, Div Infect Dis, 1364 Clifton Rd NE,F-145C, Atlanta, GA 30322 USA. EM colleen.kraft@emory.edu RI Mehta, Aneesh/B-8054-2012; Marconi, Vincent/N-3210-2014; OI Mehta, Aneesh/0000-0002-6552-9162; Marconi, Vincent/0000-0001-8409-4689; Connor, Michael/0000-0001-7613-5583 FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454] FX Emory's participation was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000454 (Atlanta Clinical and Translational Science Institute). NR 27 TC 40 Z9 40 U1 4 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2015 VL 61 IS 4 BP 496 EP 502 DI 10.1093/cid/civ334 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MT UT WOS:000359344200003 PM 25904375 ER PT J AU Sterling, TR Moro, RN Borisov, AS Phillips, E Shepherd, G Adkinson, NF Weis, S Ho, C Villarino, ME AF Sterling, Timothy R. Moro, Ruth N. Borisov, Andrey S. Phillips, Elizabeth Shepherd, Gillian Adkinson, Newton Franklin Weis, Stephen Ho, Christine Villarino, Margarita Elsa CA Tuberculosis Trials Consortium TI Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE treatment of latent M. tuberculosis infection; flu-like syndrome; adverse drug reaction; rifapentine; isoniazid ID PULMONARY TUBERCULOSIS; ADVERSE REACTIONS; RIFAMPICIN; REGIMENS; CHEMOTHERAPY; ANAPHYLAXIS; CHEESE; TWICE AB Background. Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome. Methods. We identified clinically significant systemic drug reactions (SDR) and evaluated risk factors in patients who did not complete treatment in the PREVENT Tuberculosis study. Results. Among 7552 persons who received >= 1 dose of study drug, 153 had a SDR: 138/3893 (3.5%) with 3HP vs 15/3659 (0.4%) with 9H (P < .001). In the 3HP arm, 87 (63%) had flu-like syndrome and 23 (17%) had cutaneous reactions; 13/3893 (0.3%) had severe reactions (6 were hypotensive) and 6 reported syncope. Symptoms occurred after a median of 3 doses, and 4 hours after the dose; median time to resolution was 24 hours. There were no deaths. In multivariate logistic regression analysis, factors independently associated with SDR included receipt of 3HP (adjusted odds ratio [aOR] 9.4; 95% confidence interval [CI], 5.5, 16.2), white non-Hispanic race/ethnicity (aOR 3.3; 95% CI, 2.3, 4.7), female sex (aOR 2.0; 95% CI, 1.4, 2.9), age >= 35 years (aOR 2.0; 95% CI, 1.4, 2.9), and lower body mass index (body mass index [BMI]; P = .009). In a separate multivariate analysis among persons who received 3HP, severe SDR were associated with white non-Hispanic race/ethnicity (aOR 5.4; 95% CI, 1.8, 16.3), and receipt of concomitant non-study medications (aOR 5.9; 95% CI, 1.3, 27.1). Conclusions. SDR were more common with 3HP, and mostly flu-like. Persons of white race, female sex, older age, and lower BMI were at increased risk. Severe reactions were rare and associated with 3HP, concomitant medication, and white race. The underlying mechanism is unclear. C1 [Sterling, Timothy R.; Phillips, Elizabeth] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Moro, Ruth N.; Borisov, Andrey S.; Ho, Christine; Villarino, Margarita Elsa] Ctr Dis Control & Prevent, Atlanta, GA USA. [Moro, Ruth N.] CDC Fdn, Res Collaborat, Atlanta, GA USA. [Phillips, Elizabeth] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia. [Shepherd, Gillian] New York Presbyterian Hospital, Weill Cornell Med Ctr, New York, NY USA. [Adkinson, Newton Franklin] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Weis, Stephen] Univ N Texas, Hlth Sci Ctr, Ft Worth, TX USA. RP Sterling, TR (reprint author), A2209 Med Ctr North,1161 21st Ave S, Nashville, TN 37232 USA. EM timothy.sterling@vanderbilt.edu OI Heilig, Charles/0000-0003-1075-1310 FU CDC FX This work was supported by the CDC. Sanofi donated the rifapentine used in this study, and donated $2.5 million to the CDC Foundation to supplement available US federal funding for rifapentine research. Details on the uses of these funds are available. Ruth N. Moro is employed by the CDC Foundation. NR 44 TC 6 Z9 9 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2015 VL 61 IS 4 BP 527 EP 535 DI 10.1093/cid/civ323 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MT UT WOS:000359344200008 PM 25904367 ER PT J AU Iqbal, K Klevens, RM Kainer, MA Baumgartner, J Gerard, K Poissant, T Sweet, K Vonderwahl, C Knickerbocker, T Khudyakov, Y Xia, GL Roberts, H Teshale, E AF Iqbal, Kashif Klevens, R. Monina Kainer, Marion A. Baumgartner, Jennifer Gerard, Kristin Poissant, Tasha Sweet, Kristin Vonderwahl, Candace Knickerbocker, Tracey Khudyakov, Yury Xia, Guo-liang Roberts, Henry Teshale, Eyasu TI Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis B; drug use; incidence; surveillance; genotype ID VIRAL-HEPATITIS; VACCINATION COVERAGE; VIRUS-INFECTIONS; HBV INFECTION; DRUG-USERS; GENOTYPES; CARE; TRANSMISSION; PREVALENCE; INJECTION AB Background. An estimated 20 000 new hepatitis B virus (HBV) infections occur each year in the United States. We describe the results of enhanced surveillance for acute hepatitis B at 7 federally funded sites over a 6-year period. Methods. Health departments in Colorado, Connecticut, Minnesota, Oregon, Tennessee, 34 counties in New York state, and New York City were supported to conduct enhanced, population-based surveillance for acute HBV from 2006 through 2011. Demographic and risk factor data were collected on symptomatic cases using a standardized form. Serum samples from a subset of cases were also obtained for molecular analysis. Results. In the 6-year period, 2220 acute hepatitis B cases were reported from the 7 sites. For all sites combined, the incidence rate of HBV infection declined by 19%, but in Tennessee incidence increased by 90%, mainly among persons of white race/ethnicity and those aged 40-49 years. Of all reported cases, 66.1% were male, 57.1% were white, 58.4% were aged 30-49 years, and 60.1% were born in the United States. The most common risk factor identified was any drug use, notably in Tennessee; healthcare exposure was also frequently reported. The most common genotype for all reported cases was HBV genotype A (82%). Conclusions. Despite an overall decline in HBV infection, attributable to successful vaccination programs, a rise in incident HBV infection related to drug use is an increasing concern in some localities. C1 [Iqbal, Kashif; Klevens, R. Monina; Khudyakov, Yury; Xia, Guo-liang; Roberts, Henry; Teshale, Eyasu] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Kainer, Marion A.] Tennessee Dept Hlth, Nashville, TN USA. [Baumgartner, Jennifer] New York Dept Hlth & Mental Hyg, Queens, NY USA. [Gerard, Kristin] Connecticut Dept Publ Hlth, Hartford, CT USA. [Poissant, Tasha] Oregon Hlth Author, Portland, OR USA. [Sweet, Kristin] Minnesota Dept Hlth, Minneapolis, MN USA. [Vonderwahl, Candace] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Knickerbocker, Tracey] New York State Dept Publ Hlth, Albany, NY USA. RP Iqbal, K (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS G-37, Atlanta, GA 30333 USA. EM kai9@cdc.gov FU CDC FX This work was supported by the CDC. NR 36 TC 4 Z9 4 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2015 VL 61 IS 4 BP 584 EP 592 DI 10.1093/cid/civ332 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MT UT WOS:000359344200015 PM 25904365 ER PT J AU Fiebelkorn, AP Redd, SB Kuhar, DT AF Fiebelkorn, Amy Parker Redd, Susan B. Kuhar, David T. TI Measles in Healthcare Facilities in the United States During the Postelimination Era, 2001-2014 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE measles transmission; vaccine failure; economic; healthcare personnel; healthcare facilities ID VACCINE FAILURE; HIGH-RISK; OUTBREAK; TRANSMISSION; ELIMINATION; POPULATION; SCHOOL AB Between 2001 and 2014, 78 reported measles cases resulted from transmission in US healthcare facilities, and 29 healthcare personnel were infected from occupational exposure, 1 of whom transmitted measles to a patient. The economic impact of preventing and controlling measles transmission in healthcare facilities was $19 000-$11 4286 per case. C1 [Fiebelkorn, Amy Parker; Redd, Susan B.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Kuhar, David T.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Fiebelkorn, AP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM afiebelkorn@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2015 VL 61 IS 4 BP 615 EP 618 DI 10.1093/cid/civ387 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MT UT WOS:000359344200020 PM 25979309 ER PT J AU Pacilli, M Cortese, MM Smith, S Siston, A Samala, U Bowen, MD Parada, JP Tam, KI Rungsrisuriyachai, K Roy, S Esona, MD Black, SR AF Pacilli, Massimo Cortese, Margaret M. Smith, Shamika Siston, Alicia Samala, Usha Bowen, Michael D. Parada, Jorge P. Tam, Ka Ian Rungsrisuriyachai, Kunchala Roy, Sunando Esona, Mathew D. Black, Stephanie R. TI Outbreak of Gastroenteritis in Adults Due to Rotavirus Genotype G12P[8] SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE outbreak; rotavirus; adults; genotype; G12P[8] ID CHILDREN LESS-THAN-5 YEARS; UNITED-STATES; INDIRECT PROTECTION; OLDER CHILDREN; VACCINE ERA; INFECTION; DIARRHEA; STRAIN; HOSPITALIZATIONS; AGE AB Background. Rotavirus infection in adults is poorly understood and few rotavirus outbreaks among US adults have been reported in the literature. We describe an outbreak due to genotype G12P[8] rotavirus among medical students, faculty, and guests who attended a formal dinner event in April 2013. Methods. A web-based questionnaire was distributed to event attendees to collect symptom and exposure data. A clinical case was defined as a person who developed diarrhea after attending the formal event. A laboratory-confirmed case was defined as a clinical case who attended the formal event, with rotavirus detected in stool by enzyme immunoassay or reverse transcription-polymerase chain reaction (RT-PCR) assay. Results. Among 334 dinner attendees, 136 (41%) completed the web-based questionnaire; 58 (43%) respondents reported illness. Symptom onset ranged from 1 to 8 days, with peak onset 3 days after the event. In addition to diarrhea, predominant symptoms included fever (91%), abdominal pain (84%), and vomiting (49%). The median duration of illness was 2.5 days. Thirteen (22%) of 58 cases sought medical attention; none were hospitalized. Analysis of food exposures among questionnaire respondents did not identify significant associations between any specific food or drink item and illness. Stool specimens were negative for bacterial pathogens by culture and negative for norovirus by RT-PCR assay; 4 specimens were positive for rotavirus by enzyme immunoassay or PCR. G12P[8]R1-C1-M1-A1-N1-T1-E1-H1 was identified as the causative full-genome genotype. Conclusions. Rotavirus outbreaks can occur among adults, including young adults. Health professionals should consider rotavirus as a cause of acute gastroenteritis in adults. C1 [Pacilli, Massimo; Smith, Shamika; Siston, Alicia; Samala, Usha; Black, Stephanie R.] Chicago Dept Publ Hlth, Chicago, IL 60612 USA. [Cortese, Margaret M.; Bowen, Michael D.; Tam, Ka Ian; Rungsrisuriyachai, Kunchala; Roy, Sunando; Esona, Mathew D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Parada, Jorge P.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. RP Pacilli, M (reprint author), Chicago Dept Publ Hlth, 2160 W Ogden Ave, Chicago, IL 60612 USA. EM massimo.pacilli@cityofchicago.org NR 27 TC 5 Z9 5 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2015 VL 61 IS 4 BP E20 EP E25 DI 10.1093/cid/civ294 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MT UT WOS:000359344200001 PM 25870322 ER PT J AU Mwandama, D Gutman, J Wolkon, A Luka, M Jafali, J Ali, D Mathanga, DP Skarbinski, J AF Mwandama, Dyson Gutman, Julie Wolkon, Adam Luka, Madalitso Jafali, James Ali, Doreen Mathanga, Don P. Skarbinski, Jacek TI The use of intermittent preventive treatment in pregnancy and insecticide-treated bed nets for malaria prevention by women of child-bearing age in eight districts in Malawi SO MALARIA JOURNAL LA English DT Article DE Malaria; Intermittent preventive treatment in pregnancy; Insecticide-treated nets; Malawi ID LOW-BIRTH-WEIGHT; METAANALYSIS; MORTALITY; BEDNETS; AFRICA; ANEMIA AB Background: Intermittent preventive treatment in pregnancy (IPTp) and insecticide-treated bed nets (ITNs) can reduce the morbidity and mortality associated with malaria in pregnancy. Although the coverage for both IPTp and ITN use have been described in Malawi, the analysis of factors associated with IPTp receipt and ITN use is lacking. This analysis was conducted to assess IPTp and ITN use and predictors of use by women of child-bearing age (WOCBA). Methods: A two-stage cluster-sample cross-sectional survey was conducted April 16-30, 2009 in eight districts across Malawi. Information on receipt of two or more doses of IPTp, ITN ownership, and ITN use the night before the survey was collected. Multivariate logistic regression was used to assess predictors of IPTp and ITN use. Results: Data were collected from 7407 households containing 6985 WOCBA and 3213 recently pregnant women (women who reported a completed pregnancy in the 2 years before the survey). Most recently pregnant women (96 %) had at least one antenatal care (ANC) clinic visit; 91 % reported receiving at least one dose of IPTp, and 72 % reported receiving two or more doses of IPTp. Women in Phalombe, Rumphi, and Lilongwe were more likely to receive two doses of IPTp than those in Blantyre [adjusted odds ratio (aOR) 2.5 (95 % CI 1.5-4.5), 2.5 (95 % CI 1.5-4.3), and 2.0 (95 % CI 1.2-3.1), respectively]. Educated women were more likely to have received IPTp compared to women with no education [aOR 1.6 (95 % CI 1.0-2.6) for those who completed primary school, aOR1.9 (95 % CI 1.1-3.3) for some secondary school, and aOR 4.1 (95 % CI 1.9-8.7) for completed secondary school or above], and women in the poorest socioeconomic status quintile were less likely to receive IPTp than those in the least poor quintile [aOR 0.68 (95 % CI 0.48-0.97)]. In all, 53 % of WOCBA used an ITN the previous night. Women in Nkhotkhota and Phalombe were less likely to have slept under an ITN the previous night compared to those in Blantyre [aOR 0.52 (95 % CI 0.39-0.69) and aOR 0.67 (95 % CI 0.47-0.95), respectively]. In addition, age [aOR 0.61 (95 % CI 0.45-0.83) for women 15-19 years old], and either being currently pregnant [aOR 1.5 (95 % CI 1.2-2.0)] or having been pregnant in the previous 2 years [aOR 2.4, (95 % CI 2.1-2.8)] were associated with ITN use. Conclusion: In Malawi in 2009, IPTp and ITN use in WOCBA fell short of national and international goals. Adoption of new guidelines encouraging administration of IPTp at every scheduled ANC visit might increase IPTp use. Increasing health promotion activities to encourage earlier attendance at ANC clinics and create demand for IPTp and ITNs might improve overall IPTp and ITN use. C1 [Mwandama, Dyson; Luka, Madalitso; Jafali, James; Mathanga, Don P.] Univ Malawi, Malaria Alert Ctr, Coll Med, Blantyre, Malawi. [Gutman, Julie; Wolkon, Adam; Skarbinski, Jacek] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Ali, Doreen] Minist Hlth, Natl Malaria Control Programme, Lilongwe, Malawi. [Mathanga, Don P.] Coll Med, Malawi & Dept Community Hlth, Lilongwe, Malawi. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30329 USA. EM jgutman@cdc.gov NR 23 TC 1 Z9 1 U1 3 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD AUG 15 PY 2015 VL 14 AR 316 DI 10.1186/s12936-015-0840-y PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CP0VJ UT WOS:000359593900001 PM 26272067 ER PT J AU Hariri, S Johnson, ML Bennett, NM Bauer, HM Park, IU Schafer, S Niccolai, LM Unger, ER Markowitz, LE AF Hariri, Susan Johnson, Michelle L. Bennett, Nancy M. Bauer, Heidi M. Park, Ina U. Schafer, Sean Niccolai, Linda M. Unger, Elizabeth R. Markowitz, Lauri E. CA HPV-IMPACT Working Grp TI Population-Based Trends in High-Grade Cervical Lesions in the Early Human Papillomavirus Vaccine Era in the United States SO CANCER LA English DT Article DE cervical cancer screening; cervical intraepithelial neoplasia (CIN); cervical precancers; high-grade cervical lesions; human papillomavirus (HPV); human papillomavirus vaccine effectiveness; human papillomavirus vaccines ID INTRAEPITHELIAL NEOPLASIA; HPV VACCINATION; IMPACT; ABNORMALITIES; EFFICACY; PROGRAM; TRIAL AB BACKGROUND: Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN2+) lesions can be monitored as early indicators of human papillomavirus (HPV) vaccine impact. Changes to screening utilization will affect observed reductions in CIN2+ rates and complicate the interpretation of vaccine impact. METHODS: From 2008 to 2012, 9119 cases of CIN2+ among 18- to 39-year-old residents of catchment areas in California, Connecticut, New York, and Oregon were reported to the HPV-IMPACT Project, a sentinel system for monitoring the population impact of HPV vaccine. Age-stratified CIN2+ incidence rates were calculated for each catchment. Annual cervical screening was estimated for California, New York, and Oregon catchments with administrative and survey data. The Cochran-Armitage test was used to examine trends. RESULTS: From 2008 to 2012, the incidence of CIN2+ significantly decreased among 18- to 20-year-olds (California, from 94 to 5 per 100,000 women; Connecticut, from 450 to 57 per 100,000 women; New York, from 299 to 43 per 100,000 women; and Oregon, from 202 to 37 per 100,000 women; P-trend<.0001) and among 21- to 29-year-olds in Connecticut (from 762 to 589 per 100,000 women) and New York (from 770 to 465 per 100,000 women; P-trend<.001); rates did not differ among 30- to 39-year-olds. During the same period, screening rates also declined, with the largest decreases among 18- to 20-year-olds (from 67% in Oregon to 88% in California) and with smaller declines among 21- to 29-year-olds (13%-27%) and 30- to 39-year-olds (3%-21%). CONCLUSIONS: The declines in CIN2+ detection in young women were likely due to reduced screening but could also reflect the impact of vaccination. These data illustrate challenges in interpreting CIN2+ ecologic trends in the new era of cervical cancer prevention and emphasize the importance of information such as HPV types detected in lesions to assess the impact of HPV vaccine on cervical precancers. (C) 2015 American Cancer Society. C1 [Hariri, Susan; Johnson, Michelle L.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, 2, Rochester, NY USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, 2, Rochester, NY USA. [Bauer, Heidi M.; Park, Ina U.] Calif Dept Publ Hlth, Ctr Publ Hlth Practice, STD Control Branch, HIV STD TB, Richmond, CA USA. [Schafer, Sean] Oregon Publ Hlth Div, Ctr Publ Hlth Practice, HIV STD TB Program, Portland, OR USA. [Niccolai, Linda M.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Unger, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Hariri, S (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd Northeast,MS E-02, Atlanta, GA 30333 USA. EM bse4@cdc.gov FU Centers for Disease Control and Prevention [CIU01000307] FX Sean Schafer, Linda M. Niccolai, Ina U. Park, Heidi M. Bauer, and Nancy M. Bennett were supported by the Centers for Disease Control and Prevention through cooperative agreement CIU01000307. NR 13 TC 7 Z9 7 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD AUG 15 PY 2015 VL 121 IS 16 BP 2775 EP 2781 DI 10.1002/cncr.29266 PG 7 WC Oncology SC Oncology GA CO5HO UT WOS:000359190400018 PM 26098295 ER PT J AU Washington, S Owuor, K Turan, JM Steinfeld, RL Onono, M Shade, SB Bukusi, EA Ackers, ML Cohen, CR AF Washington, Sierra Owuor, Kevin Turan, Janet M. Steinfeld, Rachel L. Onono, Maricianah Shade, Starley B. Bukusi, Elizabeth A. Ackers, Marta L. Cohen, Craig R. TI Implementation and Operational Research: Effect of Integration of HIV Care and Treatment Into Antenatal Care Clinics on Mother-to-Child HIV Transmission and Maternal Outcomes in Nyanza, Kenya: Results From the SHAIP Cluster Randomized Controlled Trial SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article ID ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; PREVENTION; SERVICES; ACCEPTABILITY; CHALLENGES; ZIDOVUDINE; MOZAMBIQUE; NEVIRAPINE; RETENTION AB Background: Many HIV-infected pregnant women identified during antenatal care (ANC) do not enroll in long-term HIV care, resulting in deterioration of maternal health and continued risk of HIV transmission to infants. Methods: We performed a cluster randomized trial to evaluate the effect of integrating HIV care into ANC clinics in rural Kenya. Twelve facilities were randomized to provide either integrated services (ANC, prevention of mother-to-child transmission, and HIV care delivered in the ANC clinic; n = 6 intervention facilities) or standard ANC services (including prevention of mother-to-child transmission and referral to a separate clinic for HIV care; n = 6 control facilities). Results: There were high patient attrition rates over the course of this study. Among study participants who enrolled in HIV care, there was 12-month follow-up data for 256 of 611 (41.8%) women and postpartum data for only 325 of 1172 (28%) women. By 9 months of age, 382 of 568 (67.3%) infants at intervention sites and 338 of 594 (57.0%) at control sites had tested for HIV [odds ratio (OR) 1.45, 95% confidence interval (CI): 0.71 to 2.82]; 7.3% of infants tested HIV positive at intervention sites compared with 8.0% of infants at control sites (OR 0.89, 95% CI: 0.56 to 1.43). The composite clinical/immunologic progression into AIDS was similar in both arms (4.9% vs. 5.1%, OR 0.83, 95% CI: 0.41 to 1.68). Conclusions: Despite the provision of integrated services, patient attrition was substantial in both arms, suggesting barriers beyond lack of service integration. Integration of HIV services into the ANC clinic was not associated with a reduced risk of HIV transmission to infants and did not appear to affect short-term maternal health outcomes. C1 [Washington, Sierra] Albert Einstein Coll Med, Dept Obstet & Gynecol, New York, NY 10461 USA. [Owuor, Kevin; Onono, Maricianah; Bukusi, Elizabeth A.] Kenya Med Res Inst KEMRI, Ctr Microbiol Res, Nairobi, Kenya. [Turan, Janet M.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA. [Steinfeld, Rachel L.; Bukusi, Elizabeth A.; Cohen, Craig R.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Shade, Starley B.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Ackers, Marta L.] US Ctr Dis Control & Prevent CDC, CGH, Div Global HIV AIDS DGHA, Atlanta, GA USA. RP Washington, S (reprint author), Albert Einstein Coll Med, Dept Obstet & Gynecol, New York, NY 10461 USA. EM sierra.washington@gmail.com FU Kenyan Ministry of Health FX The authors thank the Kenyan women who participated in the study. They acknowledge the important logistical support of the KEMRI-UCSF Collaborative Group and especially Family AIDS Care and Education Services (FACES). They gratefully acknowledge the Director of KEMRI, the Director of KEMRI's Centre for Microbiology, and the Kenyan Ministry of Health for their support in conducting this research. They also thank John Oguda, Peter Manwari, George O'chieng, Pheobe Anyango, Kevin Owuor, Cinthia Blat, Jayne Kulzer, Nicole Schmidt, Katie Schwartz, Lisa Dillabaugh, Benard Otieno, and Evelyn Interis for their important contributions to this research. The project described was supported as a Public Health Evaluation by the President's Emergency Plan for AIDS Relief (PEPFAR)/Centers for Disease Control and Prevention (CDC). NR 34 TC 6 Z9 6 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2015 VL 69 IS 5 BP e164 EP e171 DI 10.1097/QAI.0000000000000656 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN1VS UT WOS:000358209100003 PM 25886930 ER PT J AU Widen, EM Bentley, ME Chasela, CS AF Widen, E. M. Bentley, M. E. Chasela, C. S. TI Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding (vol 69, pg 319, 2015) SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Correction ID POSTEXPOSURE PROPHYLAXIS; IMMUNODEFICIENCY-VIRUS; TENOFOVIR; LOPINAVIR/RITONAVIR; SEROCONVERSION; EMTRICITABINE; TOLERABILITY; COMBINATION; MANAGEMENT; SAFETY C1 [Widen, E. M.; Bentley, M. E.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. [Chasela, C. S.] Univ Witwatersrand, Fac Hlth Sci, Parktown, South Africa. [Chasela, C. S.] UNC Project, Lilongwe, Malawi. US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. ARS, USDA, Western Human Nutr Res Ctr, Davis, CA USA. Univ N Carolina, Dept Med, Chapel Hill, NC USA. RP Widen, EM (reprint author), Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2015 VL 69 IS 5 BP e184 EP e184 DI 10.1097/QAI.0000000000000749 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN1VS UT WOS:000358209100006 ER PT J AU Sunderam, S Kissin, DM Crawford, SB Folger, SG Jamieson, DJ Warner, L Barfield, WD AF Sunderam, Saswati Kissin, Dmitry M. Crawford, Sara B. Folger, Suzanne G. Jamieson, Denise J. Warner, Lee Barfield, Wanda D. TI Assisted Reproductive Technology Surveillance - United States, 2012 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID SINGLE-EMBRYO-TRANSFER; IN-VITRO FERTILIZATION; MULTIPLE-BIRTH RISK; INSURANCE MANDATES; INFERTILITY TREATMENTS; PRETERM BIRTH; PREGNANCIES; OUTCOMES; GESTATION; IVF AB Problem/Condition: Since the first U.S. infant conceived with Assisted Reproductive Technology (ART) was born in 1981, both the use of advanced technologies to overcome infertility and the number of fertility clinics providing ART services have increased steadily in the United States. ART includes fertility treatments in which eggs or embryos are handled in the laboratory (i.e., in vitro fertilization [IVF] and related procedures). Because more than one embryo might be transferred during a procedure, women who undergo ART procedures, compared with those who conceive naturally, are more likely to deliver multiple birth infants. Multiple births pose substantial risks to both mothers and infants, including obstetric complications, preterm delivery, and low birthweight infants. This report provides state-specific information for the United States (including Puerto Rico) on ART procedures performed in 2012 and compares infant outcomes that occurred in 2012 (resulting from ART procedures performed in 2011 and 2012) with outcomes for all infants born in the United States in 2012. Period Covered: 2012. Description of System: In 1996, CDC began collecting data on ART procedures performed in fertility clinics in the United States, as mandated by the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA) (Public Law 102-493). Data are collected through the National ART Surveillance System, a web-based data collecting system developed by CDC. This report includes data from 52 reporting areas (the 50 states, the District of Columbia [DC], and Puerto Rico). Results: In 2012, a total of 157,635 ART procedures performed in 456 U.S. fertility clinics were reported to CDC. These procedures resulted in 51,261 live-birth deliveries and 65,151 infants. The largest numbers of ART procedures were performed among residents of six states: California (20,241), New York (19,618), Illinois (10,449), Texas (10,281), Massachusetts (9,754), and New Jersey (8,590). These six states also had the highest number of live-birth deliveries as a result of ART procedures, and together they accounted for 50.1% of all ART procedures performed, 48.3% of all infants born from ART, and 48.3% of all ART multiple live-birth deliveries. Nationally, the total number of ART procedures performed per 1 million women of reproductive age (15-44 years), which is a proxy indicator of ART use, was 2,483. This indicator of ART use exceeded the national ratio in 13 reporting areas (California, Connecticut, Delaware, Hawaii, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, Virginia, and DC) and was more than twice the national ratio in three reporting areas (Massachusetts, New Jersey, and DC). Nationally, among ART cycles with patients using fresh embryos from their own eggs, in which at least one embryo was transferred, the average number of embryos transferred increased with the increasing age of the woman (1.9 among women aged <35 years, 2.2 among women aged 35-40 years, and 2.7 among women aged >40 years). The percentage of elective single-embryo transfer (eSET) procedures varied substantially between reporting areas for all ages. Among women aged <35 years, who are typically considered to be good candidates for eSET procedures, the national eSET rate was 15.3% (range: 2.1% in Oklahoma to 60.4% in Delaware). Overall, ART contributed to 1.5% of all infants born in the United States (range: 0.2% in Puerto Rico to 4.7% in Massachusetts) with the highest rates (>= 3.0% of all infants born) observed in four reporting areas (Connecticut, Massachusetts, New Jersey, and DC). Infants conceived with ART comprised 19.6% of all multiple-birth infants (range: 5.5% in Maine to 39.3% in Massachusetts), 19.2% of all twin infants (range: 4.4% in Puerto Rico to 39.1% in Massachusetts), and 29.6% of all triplet or higher order infants (range: 0 in West Virginia to 69.7% in Idaho). Among infants conceived with ART, 43.6% were born in multiple-birth deliveries (range: 18.7% in Delaware to 56.0% in Idaho), compared with only 3.4% among all infants born in the general population (range: 2.1% in Puerto Rico to 4.5% in New Jersey). Approximately 41% of ART-conceived infants were twin infants, and 2% were triplet and higher order infants. Nationally, infants conceived with ART comprised 5.7% of all low birthweight (<2,500 grams) infants (range: 0.8% in Puerto Rico to 15.3% in Massachusetts) and 5.8% of all very low birthweight (<1,500 grams) infants (range: 0 in West Virginia to 15.1% in New Jersey). Overall, among ART-conceived infants, 30.2% were low birthweight (range: 18.8% in DC to 45.1% in New Mexico), compared with 8.0% among all infants (range: 5.6% in Alaska to 11.6% in Mississippi and Puerto Rico); 5.5% of ART infants were very low birthweight (range: 0 in West Virginia to 12.9% in Puerto Rico), compared with 1.4% among all infants (range: 0.9% in Alaska and Idaho to 2.1% in Mississippi). ART-conceived infants comprised 4.6% of all preterm (<37 weeks) infants (range: 0.7% in Puerto Rico to 13.4% in Massachusetts) and 5.2% of all very preterm (<32 weeks) infants (range: 1.0% in Puerto Rico to 14.9% in Vermont). Overall, among infants conceived with ART, 34.9% were born preterm (range: 20.8% in Delaware and DC to 49.4% in Puerto Rico), compared with 11.6% among all infants born in the general population (range: 8.7% in Vermont to 17.1% in Mississippi); 6.5% of ART infants were born very preterm (range: 3.3% in Nevada to 14.8% in South Dakota), compared with 1.9% among all infants born in the general population (range: 1.1% in Vermont to 2.9% in Mississippi). The percentage of infants conceived with ART who were low birthweight varied from 9.3% (range: 4.1% in South Carolina to 20.9% in Puerto Rico) among singletons, to 55.2% (range: 41.5% in New Hampshire to 83.3% in South Dakota) among twins, and 95.3% (range: 85.2% in Oklahoma to 100% in several reporting areas) among triplets or higher-order multiples; comparable percentages for all infants were 6.3% (range: 4.5% in Alaska to 10.3% in Puerto Rico), 55.4% (range: 46.0% in Alaska to 69.0% in Puerto Rico), and 91.6% (range: 80.6% in Missouri to 100% in several reporting areas), respectively. The percentage of ART infants who were preterm varied from 13.2% (range: 9.4% in West Virginia to 25.4% in North Dakota) among singletons, to 61.0% (range: 47.8% in DC to 80.0% in Maine and West Virginia) among twins, and 97.7% (range: 92.7% in Massachusetts to 100% in several reporting areas) among triplets or higher-order multiples; comparable percentages for all infants were 9.9% (range: 7.3% in Vermont to 15.8% in Puerto Rico), 56.8% (range: 47.2% in Connecticut to 67.2% in Puerto Rico), and 92.6% (range: 36.4% in Oregon to 96.8% in Ohio), respectively. Interpretation: The percentage of infants conceived with ART varied considerably by reporting area. In most reporting areas, multiples from ART comprised a substantial proportion of all twin, triplet, and higher-order infants born, and the rates of low birthweight and preterm infants were disproportionately higher among ART infants than in the birth population overall. Among women aged <35 years, eSET procedures warrant consideration because these patients might have extra embryos available for cryopreservation, which is a good predictor of embryo quality, and might have a more favorable prognosis for a live birth than older patients. However, on average, two embryos were transferred per cycle in ART procedures among women aged <35 years, influencing the overall multiple-birth rates in the United States. Compared with ART singletons, ART twins were approximately four and a half times more likely to be born preterm, and approximately six times more likely to be born with low birthweight. Singleton infants conceived with ART had slightly higher rates of preterm delivery and low birthweight than all singleton infants born in the United States. ART use per population unit was geographically varied, with 12 states showing ART use above the national rate. Of the four states (Illinois, Massachusetts, New Jersey, and Rhode Island) with comprehensive statewide-mandated health insurance coverage for ART procedures (e.g., coverage for at least four cycles of in vitro fertilization), two states (Massachusetts and New Jersey) had rates of ART use exceeding twice the national level. This type of mandated insurance has been associated with greater use of ART and might account for some of the difference in per capita ART use observed among states. Public Health Actions: Reducing the number of embryos transferred per ART procedure and increasing use of eSET, when clinically appropriate (typically age <35 years), might reduce multiple births and related adverse consequences of ART. Improved patient education and counseling on the maternal and infant health risks of having twins are needed given that twins account for the majority of ART-conceived multiple births. Although ART contributes to increasing rates of multiple births, it does not explain all of the increases. Other explanations for multiple births not investigated in this report might include age-related factors and the role of non-ART fertility treatments, and warrant further study. C1 [Sunderam, Saswati; Kissin, Dmitry M.; Crawford, Sara B.; Folger, Suzanne G.; Jamieson, Denise J.; Warner, Lee; Barfield, Wanda D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Sunderam, S (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. EM msunderam@cdc.gov NR 63 TC 3 Z9 5 U1 2 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD AUG 14 PY 2015 VL 64 IS 6 BP 1 EP 29 PG 29 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO9DN UT WOS:000359473000001 ER PT J AU Vargo, J Gerhardstein, BG Whitfield, GP Wendel, A AF Vargo, Jason Gerhardstein, Benjamin G. Whitfield, Geoffrey P. Wendel, Arthur TI Bicyclist Deaths Associated with Motor Vehicle Traffic - United States, 1975-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POLICIES C1 [Vargo, Jason] Univ Wisconsin Madison, Global Hlth Inst, Madison, WI 53706 USA. [Whitfield, Geoffrey P.; Wendel, Arthur] CDC, Natl Ctr Environm Hlth, Hlth Community Design Initiat, Atlanta, GA 30333 USA. RP Vargo, J (reprint author), Univ Wisconsin Madison, Global Hlth Inst, Madison, WI 53706 USA. EM javargo@wisc.edu NR 10 TC 4 Z9 4 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 14 PY 2015 VL 64 IS 31 BP 837 EP 841 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO9DD UT WOS:000359471900001 PM 26270058 ER PT J AU Beer, KD Gargano, JW Roberts, VA Hill, VR Garrison, LE Kutty, PK Hilborn, ED Wade, TJ Fullerton, KE Yoder, JS AF Beer, Karlyn D. Gargano, Julia W. Roberts, Virginia A. Hill, Vincent R. Garrison, Laurel E. Kutty, Preeta K. Hilborn, Elizabeth D. Wade, Timothy J. Fullerton, Kathleen E. Yoder, Jonathan S. TI Surveillance for Waterborne Disease Outbreaks Associated with Drinking Water - United States, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Beer, Karlyn D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Beer, Karlyn D.; Gargano, Julia W.; Roberts, Virginia A.; Hill, Vincent R.; Fullerton, Kathleen E.; Yoder, Jonathan S.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Garrison, Laurel E.; Kutty, Preeta K.] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Beer, KD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM kbeer@cdc.gov NR 8 TC 27 Z9 27 U1 4 U2 20 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 14 PY 2015 VL 64 IS 31 BP 842 EP 848 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO9DD UT WOS:000359471900002 PM 26270059 ER PT J AU Beer, KD Gargano, JW Roberts, VA Reses, HE Hill, VR Garrison, LE Kutty, PK Hilborn, ED Wade, TJ Fullerton, KE Yoder, JS AF Beer, Karlyn D. Gargano, Julia W. Roberts, Virginia A. Reses, Hannah E. Hill, Vincent R. Garrison, Laurel E. Kutty, Preeta K. Hilborn, Elizabeth D. Wade, Timothy J. Fullerton, Kathleen E. Yoder, Jonathan S. TI Outbreaks Associated With Environmental and Undetermined Water Exposures - United States, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DRINKING-WATER; DISEASE; SURVEILLANCE C1 [Beer, Karlyn D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Beer, Karlyn D.; Gargano, Julia W.; Roberts, Virginia A.; Reses, Hannah E.; Hill, Vincent R.; Fullerton, Kathleen E.; Yoder, Jonathan S.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Garrison, Laurel E.; Kutty, Preeta K.] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Beer, KD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM kbeer@cdc.gov NR 5 TC 1 Z9 1 U1 2 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 14 PY 2015 VL 64 IS 31 BP 849 EP 851 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO9DD UT WOS:000359471900003 PM 26270060 ER PT J AU Camden, TL Maruffo, D Santos, N Nava, JJ Alcantara, C AF Camden, Tommy L. Maruffo, Dora Santos, Norma Nava, John J. Alcantara, Carlos TI Investigation of Tuberculosis in a High School - San Antonio, Texas, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Camden, Tommy L.; Maruffo, Dora; Santos, Norma; Nava, John J.] San Antonio Metropolitan Hlth Dist, San Antonio, TX 78223 USA. [Alcantara, Carlos] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. RP Camden, TL (reprint author), San Antonio Metropolitan Hlth Dist, San Antonio, TX 78223 USA. EM tommy.camden@sanantonio.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 14 PY 2015 VL 64 IS 31 BP 856 EP 856 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO9DD UT WOS:000359471900005 PM 26270062 ER PT J AU Elbadawi, LI Haupt, T Reisdorf, E Danz, T Davis, JP AF Elbadawi, Lina I. Haupt, Thomas Reisdorf, Erik Danz, Tonya Davis, Jeffrey P. TI Use and Interpretation of a Rapid Respiratory Syncytial Virus Antigen Detection Test Among Infants Hospitalized in a Neonatal Intensive Care Unit - Wisconsin, March 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID RSV C1 [Elbadawi, Lina I.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Elbadawi, LI (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM uxt2@cdc.gov NR 3 TC 1 Z9 1 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 14 PY 2015 VL 64 IS 31 BP 857 EP 857 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO9DD UT WOS:000359471900006 PM 26270063 ER PT J AU Miller, CH AF Miller, Connie H. TI Game, set, match for factor VIII mismatch? SO BLOOD LA English DT Editorial Material ID HEMOPHILIA INHIBITOR GENETICS; HIGS COMBINED COHORT; F8 C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Miller, CH (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. OI Miller, Connie H/0000-0002-3989-7973 FU Intramural CDC HHS [CC999999] NR 11 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD AUG 13 PY 2015 VL 126 IS 7 BP 829 EP 830 DI 10.1182/blood-2015-02-625574 PG 4 WC Hematology SC Hematology GA CQ3VC UT WOS:000360530800003 PM 26272046 ER PT J AU Heitbrink, WA Lo, LM AF Heitbrink, William A. Lo, Li-Ming TI Effect of carbon nanotubes upon emissions from cutting and sanding carbon fiber-epoxy composites SO JOURNAL OF NANOPARTICLE RESEARCH LA English DT Article DE Nanomaterial manufacturing; Airborne nanoparticles; Nanoparticle characterization; Engineering controls; Exposure prevention; Environmental and health effects ID ULTRAFINE PARTICLES; ELEMENTAL CARBON; VACUUM CLEANERS; EXPOSURE LIMITS; AIR-QUALITY; NANOFIBERS; NANOCOMPOSITES; GENERATION; TOXICITY; DIAMETER AB Carbon nanotubes (CNTs) are being incorporated into structural composites to enhance material strength. During fabrication or repair activities, machining nanocomposites may release CNTs into the workplace air. An experimental study was conducted to evaluate the emissions generated by cutting and sanding on three types of epoxy-composite panels: Panel A containing graphite fibers, Panel B containing graphite fibers and carbon-based mat, and Panel C containing graphite fibers, carbon-based mat, and multi-walled CNTs. Aerosol sampling was conducted with direct-reading instruments, and filter samples were collected for measuring elemental carbon (EC) and fiber concentrations. Our study results showed that cutting Panel C with a band saw did not generate detectable emissions of fibers inspected by transmission electron microscopy but did increase the particle mass, number, and EC emission concentrations by 20-80 % compared to Panels A and B. Sanding operation performed on two Panel C resulted in fiber emission rates of 1.9 x 10(8) and 2.8 x 10(6) fibers per second (f/s), while no free aerosol fibers were detected from sanding Panels A and B containing no CNTs. These free CNT fibers may be a health concern. However, the analysis of particle and EC concentrations from these same samples cannot clearly indicate the presence of CNTs, because extraneous aerosol generation from machining the composite epoxy material increased the mass concentrations of the EC. C1 [Heitbrink, William A.] LMK OSH Consulting LLC, Cincinnati, OH 45233 USA. [Lo, Li-Ming] Ctr Dis Control & Prevent CDC, NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Lo, LM (reprint author), Ctr Dis Control & Prevent CDC, NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. EM LLo@cdc.gov FU National Institute for Occupational Safety and Health under Nanotechnology Research Center [927ZJLR] FX The authors would like to acknowledge the support and cooperation from the management and the staff of the study site, and wish to thank Alberto Garcia for his assistance with field study. The authors are grateful to Laura Hodson, Arthur Miller, Appavoo Rengasamy, Jennifer Topmiller, Michael Gressel, and Cathy Rotunda for their insightful comments and suggestions on the early version of the manuscript. This research was funded by the National Institute for Occupational Safety and Health under the Nanotechnology Research Center Project 927ZJLR. NR 56 TC 1 Z9 1 U1 1 U2 14 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1388-0764 EI 1572-896X J9 J NANOPART RES JI J. Nanopart. Res. PD AUG 13 PY 2015 VL 17 IS 8 AR 335 DI 10.1007/s11051-015-3140-0 PG 17 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA CP0CE UT WOS:000359542600001 ER PT J AU Podewils, LJ Bantubani, N Bristow, C Bronner, LE Peters, A Pym, A Mametja, LD AF Podewils, Laura Jean Bantubani, Nonkqubela Bristow, Claire Bronner, Liza E. Peters, Annatjie Pym, Alexander Mametja, Lerole David TI Completeness and Reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System SO BMC PUBLIC HEALTH LA English DT Article AB Background: Accurate surveillance data are paramount to effective TB control. The Republic of South Africa's National TB Control Program (NTP) has conducted TB surveillance since 1995 and adopted the Electronic TB Register (ETR) in 2005. This evaluation aimed to determine the completeness and reliability of data in the Republic of South Africa's TB Surveillance System. Methods: Three of nine provinces, three subdistricts per province, and 54 health facilities were selected by stratified random sampling. At each facility, 30 (or all if <30) patients diagnosed in Quarter 1 2009 were randomly selected for review. Patient information was evaluated across two paper and four electronic sources. Completeness of program indicators between paper and electronic sources was compared with chi-square tests. The kappa statistic was used to evaluate agreement of values. Results: Over one-third (33.7 %) of all persons with presumptive TB recorded as smear positive in the TB Suspect Register did not have any records documenting notification, treatment, or management for TB disease. Of 1339 persons with a record as a TB patient at the facility, 1077 (80 %) were recorded in all data sources. Over 98 % of records contained complete age and sex data. Completeness varied for HIV status (53-86 %; p < 0.001) and DOT during the intensive phase of treatment (17-54 %; p < 0.001). Agreement for sex was excellent across sources (kappa 0.94); moderate for patient type (0.78), treatment regimen (0.79), treatment outcome (0.71); and poor for HIV status (0.33). Conclusions: The current evaluation revealed that one-third of persons diagnosed with TB disease may not have been notified of their disease or initiated on treatment ('initial defaulters'). The ETR is not capturing all TB patients. Further, among patients with a TB record, completeness and reliability of information in the TB Surveillance System is inconsistent across data sources. Actions are urgently needed to ensure that all diagnosed patients are treated and managed and improve the integrity of surveillance information. C1 [Podewils, Laura Jean; Bronner, Liza E.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30322 USA. [Bantubani, Nonkqubela; Bronner, Liza E.; Pym, Alexander] Med Res Council South Africa, Unit Clin & Biomed TB Res Unit, Durban, South Africa. [Bristow, Claire; Peters, Annatjie] US Ctr Dis Control & Prevent, Global AIDS Program, Pretoria, South Africa. [Mametja, Lerole David] Republ South Africa Natl Dept Hlth, Dept TB Control, Pretoria, South Africa. [Podewils, Laura Jean] Ctr Dis Control & Prevent, Div Global HIV AIDS & TB, Global TB Branch, Atlanta, GA 30333 USA. RP Podewils, LJ (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30322 USA. EM lpp8@cdc.gov OI Pym, Alexander/0000-0002-6260-8180 FU Centers for Disease Control and Prevention; South African Medical Research Council [5 U51 PS000729-05, PAS07-006] FX This work was supported by the Centers for Disease Control and Prevention and the South African Medical Research Council [Cooperative Agreement 5 U51 PS000729-05, PAS07-006]. NR 13 TC 4 Z9 5 U1 4 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD AUG 11 PY 2015 VL 15 AR 765 DI 10.1186/s12889-015-2117-3 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO5NB UT WOS:000359204700001 PM 26259599 ER PT J AU Helb, DA Tetteh, KKA Felgner, PL Skinner, J Hubbard, A Arinaitwe, E Mayanja-Kizza, H Ssewanyana, I Kamya, MR Beeson, JG Tappero, J Smith, DL Crompton, PD Rosenthal, PJ Dorsey, G Drakeley, CJ Greenhouse, B AF Helb, Danica A. Tetteh, Kevin K. A. Felgner, Philip L. Skinner, Jeff Hubbard, Alan Arinaitwe, Emmanuel Mayanja-Kizza, Harriet Ssewanyana, Isaac Kamya, Moses R. Beeson, James G. Tappero, Jordan Smith, David L. Crompton, Peter D. Rosenthal, Philip J. Dorsey, Grant Drakeley, Christopher J. Greenhouse, Bryan TI Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE Plasmodium falciparum malaria; antigen discovery; serology; immunoepidemiology; epidemiology ID MALARIA TRANSMISSION INTENSITY; ENTOMOLOGICAL INOCULATION RATE; SPOROZOITE SURFACE-ANTIGENS; ANTIBODY-RESPONSES; MEROZOITE ANTIGENS; YOUNG-CHILDREN; WESTERN KENYA; CONTROL PROGRAMS; RECOVERY RATES; NORTHERN GHANA AB Tools to reliably measure Plasmodium falciparum (Pf) exposure in individuals and communities are needed to guide and evaluate malaria control interventions. Serologic assays can potentially produce precise exposure estimates at low cost; however, current approaches based on responses to a few characterized antigens are not designed to estimate exposure in individuals. Pf-specific antibody responses differ by antigen, suggesting that selection of antigens with defined kinetic profiles will improve estimates of Pf exposure. To identify novel serologic biomarkers of malaria exposure, we evaluated responses to 856 Pf antigens by protein microarray in 186 Ugandan children, for whom detailed Pf exposure data were available. Using data-adaptive statistical methods, we identified combinations of antibody responses that maximized information on an individual's recent exposure. Responses to three novel Pf antigens accurately classified whether an individual had been infected within the last 30, 90, or 365 d (cross-validated area under the curve = 0.86-0.93), whereas responses to six antigens accurately estimated an individual's malaria incidence in the prior year. Cross-validated incidence predictions for individuals in different communities provided accurate stratification of exposure between populations and suggest that precise estimates of community exposure can be obtained from sampling a small subset of that community. In addition, serologic incidence predictions from cross-sectional samples characterized heterogeneity within a community similarly to 1 y of continuous passive surveillance. Development of simple ELISA-based assays derived from the successful selection strategy outlined here offers the potential to generate rich epidemiologic surveillance data that will be widely accessible to malaria control programs. C1 [Helb, Danica A.; Rosenthal, Philip J.; Dorsey, Grant; Greenhouse, Bryan] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. [Helb, Danica A.] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA. [Helb, Danica A.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94158 USA. [Tetteh, Kevin K. A.; Drakeley, Christopher J.] Univ London London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1E 7HT, England. [Felgner, Philip L.] Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine, CA 92697 USA. [Skinner, Jeff; Crompton, Peter D.] NIAID, Lab Immunogenet, NIH, Rockville, MD 20852 USA. [Hubbard, Alan] Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA. [Arinaitwe, Emmanuel; Ssewanyana, Isaac] Infect Dis Res Collaborat, Kampala, Uganda. [Mayanja-Kizza, Harriet; Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Beeson, James G.] Burnet Inst Med Res & Publ Hlth, Ctr Biomed Res, Melbourne, VIC 3004, Canada. [Tappero, Jordan] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. [Smith, David L.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England. [Smith, David L.] Sanaria Inst Global Hlth & Trop Med, Rockville, MD 20850 USA. RP Greenhouse, B (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. EM bryan.greenhouse@ucsf.edu RI Crompton, Peter/N-1130-2016; OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Skinner, Jeff/0000-0001-5697-0442 FU President's Emergency Plan for AIDS Relief through Centers for Disease Control and Prevention Cooperative [OCCU024421]; NIH as part of International Centers of Excellence in Malaria Research Program [U19AI089674]; Doris Duke Charitable Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH; National Health and Medical Research Council of Australia; Doris Duke Clinical Scientist Development Award; National Health and Medical Research Council Independent Research Institutes Infrastructure Support Scheme; Victoria State Government Operational Infrastructure FX We thank the individuals who participated in this study and their families. We also thank Rie Sasaki, Li Liang, and Jozelyn Pablo for cloning and generating the microarray data, Robin Anders and Christine Langer for providing recombinant proteins, and Nathan Woody for image production. We thank the study team and the Makerere University-University of California, San Francisco Research Collaboration and Infectious Diseases Research Collaboration for administrative and technical support. This research has been supported by the President's Emergency Plan for AIDS Relief through Centers for Disease Control and Prevention Cooperative Agreement Number OCCU024421, the NIH as part of International Centers of Excellence in Malaria Research Program U19AI089674, and the Doris Duke Charitable Foundation. J.S. and P.D.C. are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH. J.G.B. was supported by the National Health and Medical Research Council of Australia. B.G. is the recipient of a Doris Duke Clinical Scientist Development Award. The Burnet Institute is supported by National Health and Medical Research Council Independent Research Institutes Infrastructure Support Scheme and a Victoria State Government Operational Infrastructure Support Grant. NR 109 TC 24 Z9 24 U1 0 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 11 PY 2015 VL 112 IS 32 BP E4438 EP E4447 DI 10.1073/pnas.1501705112 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO6RY UT WOS:000359285100015 PM 26216993 ER PT J AU Dobard, CW Sharma, S Cong, ME West, R Makarova, N Holder, A Pau, CP Hanson, DL Novembre, FJ Garcia-Lerma, JG Heneine, W AF Dobard, Charles W. Sharma, Sunita Cong, Mian-er West, Rolieria Makarova, Natalia Holder, Angela Pau, Chou-Pong Hanson, Debra L. Novembre, Francis J. Garcia-Lerma, Jose Gerardo Heneine, Walid TI Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques SO RETROVIROLOGY LA English DT Article DE Pre-exposure prophylaxis; HIV-1 drug resistance; Tenofovir; Microbicides ID SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS; INTERMITTENT PROPHYLAXIS; DISOPROXIL FUMARATE; K65R MUTATION; EMTRICITABINE; PREVENTION; NUCLEOSIDE; PROTECTION; INFECTION; THERAPY AB Background: Topically delivered tenofovir (TFV) from intravaginal rings, tablets, or gels is being evaluated for HIV prevention. We previously demonstrated that TFV delivered vaginally by gel protected macaques from vaginal infection with SHIV. Here we investigated efficacy of the TFV gel against vaginal transmission of a TFV-resistant SHIV containing the K65R mutation (SHIV162P3(K65R)) and its relationship to drug levels in vaginal tissues. Results: SHIV162P3(K65R) shows approximately a 5-fold reduction in susceptibility to TFV compared to wild-type SHIV. Efficacy was evaluated in pig-tailed macaques exposed vaginally twice-weekly (up to 10 weeks) to SHIV162P3(K65R) 30 min after receiving placebo (n = 6) or 1% TFV (n = 6) gel. Four of the six controls were infected after a median of 5 exposures. In contrast, five of six macaques that received TFV gel remained uninfected after 20 vaginal SHIV162P3(K65R) exposures, resulting in an estimated efficacy of 75%. The mean intracellular TFV-diphosphate (TFV-DP) concentrations in vaginal lymphocytes 4 h after a single gel dose were found to be high (1,631 fmol/10(6) cells, range 492-3,847) and within the in vitro IC75 range (1,206 fmol/106 cells) for SHIV162P3(K65R). Conclusion: Both the modest resistance conferred by K65R and the high TFV-DP exposure in vaginal lymphocytes, likely explain the observed protection. The findings in this model do not predict complete loss of protection by topical TFV against vaginal exposure to HIV-1(K65R) viruses and provide a tissue drug target for high efficacy. These data will facilitate the development of TFV delivery platforms that have high activity on both wild-type and TFV-resistant viruses. C1 [Dobard, Charles W.; Sharma, Sunita; Cong, Mian-er; West, Rolieria; Makarova, Natalia; Holder, Angela; Pau, Chou-Pong; Garcia-Lerma, Jose Gerardo; Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Hanson, Debra L.] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Novembre, Francis J.] Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA. RP Dobard, CW (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, MS G45,1600 Clifton Rd, Atlanta, GA 30329 USA. EM cdobard@cdc.gov OI dobard, charles/0000-0002-9194-1775 FU Centers for Disease Control and Prevention [Y1-AI-0681-02]; National Institute of Health (NIH) [Y1-AI-0681-02] FX We thank Stephanie Ehnert, Christopher Souder, Elizabeth Strobert, and the animal care staff at the Yerkes National Primate Center (Emory University) as well as James Mitchell, Elizabeth Sweeney, and Shanon Ellis at the CDC for monitoring, maintaining, and performing animal procedures using our macaque cohort. We thank Jim Rooney at Gilead Sciences for providing tenofovir. Authors listed herein neither had nor do not have a commercial or other association that might pose a conflict of interest. This work was partially supported by Interagency Agreement Y1-AI-0681-02 between Centers for Disease Control and Prevention and National Institute of Health (NIH). NR 25 TC 3 Z9 3 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD AUG 8 PY 2015 VL 12 AR 69 DI 10.1186/s12977-015-0195-z PG 8 WC Virology SC Virology GA CO4EM UT WOS:000359113500002 PM 26253002 ER PT J AU Wheaton, AG Ferro, GA Croft, JB AF Wheaton, Anne G. Ferro, Gabrielle A. Croft, Janet B. TI School Start Times for Middle School and High School Students - United States, 2011-12 School Year SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID SLEEP; ADOLESCENTS C1 [Wheaton, Anne G.; Ferro, Gabrielle A.; Croft, Janet B.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Wheaton, AG (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM awheaton@cdc.gov NR 10 TC 7 Z9 7 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 7 PY 2015 VL 64 IS 30 BP 809 EP 813 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO6UT UT WOS:000359292900001 PM 26247433 ER PT J AU Jewett, A Shults, RA Banerjee, T Bergen, G AF Jewett, Amy Shults, Ruth A. Banerjee, Tanima Bergen, Gwen TI Alcohol-Impaired Driving Among Adults - United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Jewett, Amy; Shults, Ruth A.; Bergen, Gwen] CDC, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Banerjee, Tanima] Univ Michigan, Injury Ctr, Ann Arbor, MI 48109 USA. RP Jewett, A (reprint author), CDC, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. EM acjewett@cdc.gov NR 10 TC 6 Z9 7 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 7 PY 2015 VL 64 IS 30 BP 814 EP 817 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO6UT UT WOS:000359292900002 PM 26247434 ER PT J AU Grohskopf, LA Sokolow, LZ Olsen, SJ Bresee, JS Broder, KR Karron, RA AF Grohskopf, Lisa A. Sokolow, Leslie Z. Olsen, Sonja J. Bresee, Joseph S. Broder, Karen R. Karron, Ruth A. TI Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID 6-TO 23-MONTH-OLD CHILDREN; EGG-ALLERGIC PATIENTS; RELATIVE EFFICACY; YOUNG-CHILDREN; TRIVALENT; IMMUNOGENICITY; VACCINATION; REACTOGENICITY; PERSISTENCE; ANTIBODY C1 [Grohskopf, Lisa A.; Sokolow, Leslie Z.; Olsen, Sonja J.; Bresee, Joseph S.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Sokolow, Leslie Z.] Battelle Mem Inst, Atlanta, GA USA. [Broder, Karen R.] CDC, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Baltimore, MD USA. [Karron, Ruth A.] Johns Hopkins Univ, Baltimore, MD USA. RP Grohskopf, LA (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lgrohskopf@cdc.gov NR 40 TC 82 Z9 83 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 7 PY 2015 VL 64 IS 30 BP 818 EP 825 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO6UT UT WOS:000359292900003 PM 26247435 ER PT J AU Jones, J Klein, R Popescu, S Rose, K Kretschmer, M Carrigan, A Trembath, F Koski, L Zabel, K Ostdiek, S Rowell-Kinnard, P Munoz, E Sunenshine, R Sylvester, T AF Jones, Jefferson Klein, Ron Popescu, Saskia Rose, Karen Kretschmer, Melissa Carrigan, Alice Trembath, Felicia Koski, Lia Zabel, Karen Ostdiek, Scott Rowell-Kinnard, Paula Munoz, Esther Sunenshine, Rebecca Sylvester, Tammy TI Lack of Measles Transmission to Susceptible Contacts from a Health Care Worker with Probable Secondary Vaccine Failure - Maricopa County, Arizona, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAK C1 [Jones, Jefferson] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Jones, Jefferson; Klein, Ron; Rose, Karen; Kretschmer, Melissa; Carrigan, Alice; Trembath, Felicia; Koski, Lia; Zabel, Karen; Sunenshine, Rebecca; Sylvester, Tammy] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. [Popescu, Saskia; Ostdiek, Scott; Rowell-Kinnard, Paula; Munoz, Esther] Phoenix Childrens Hosp, Phoenix, AZ USA. [Trembath, Felicia] CDC, Hlth Syst Integrat Program, Atlanta, GA 30333 USA. [Sunenshine, Rebecca] CDC, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA. RP Jones, J (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM JJones10@cdc.gov NR 7 TC 4 Z9 4 U1 3 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 7 PY 2015 VL 64 IS 30 BP 832 EP 833 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO6UT UT WOS:000359292900005 PM 26247437 ER PT J AU Chatterjee, A Ratner, DM Ryan, CM Johnson, PJ O'Keefe, BR Secor, WE Anderson, DJ Robbins, PW Samuelson, J AF Chatterjee, Aparajita Ratner, Daniel M. Ryan, Christopher M. Johnson, Patricia J. O'Keefe, Barry R. Secor, W. Evan Anderson, Deborah J. Robbins, Phillips W. Samuelson, John TI Anti-Retroviral Lectins Have Modest Effects on Adherence of Trichomonas vaginalis to Epithelial Cells In Vitro and on Recovery of Tritrichomonas foetus in a Mouse Vaginal Model SO PLOS ONE LA English DT Article ID MANNOSE-BINDING LECTIN; CHLAMYDIA-TRACHOMATIS; INNATE IMMUNITY; LINKED GLYCANS; CYANOVIRIN-N; INFECTION; EXPRESSION; HIV-1; GRIFFITHSIN; VACCINE AB Trichomonas vaginalis causes vaginitis and increases the risk of HIV transmission by heterosexual sex, while Tritrichomonas foetus causes premature abortion in cattle. Our goals were to determine the effects, if any, of anti-retroviral lectins, which are designed to prevent heterosexual transmission of HIV, on adherence of Trichomonas to ectocervical cells and on Tritrichomonas infections in a mouse model. We show that Trichomonas Asn-linked glycans (N-glycans), like those of HIV, bind the mannose-binding lectin (MBL) that is part of the innate immune system. N-glycans of Trichomonas and Tritrichomonas bind anti-retroviral lectins (cyanovirin-N and griffithsin) and the 2G12 monoclonal antibody, each of which binds HIV N-glycans. Binding of cyanovirin-N appears to be independent of susceptibility to metronidazole, the major drug used to treat Trichomonas. Anti-retroviral lectins, MBL, and galectin-1 cause Trichomonas to self-aggregate and precipitate. The anti-retroviral lectins also increase adherence of ricin-resistant mutants, which are less adherent than parent cells, to ectocervical cell monolayers and to organotypic EpiVaginal tissue cells. Topical application of either anti-retroviral lectins or yeast N-glycans decreases by 40 to 70% the recovery of Tritrichomonas from the mouse vagina. These results, which are explained by a few simple models, suggest that the anti-retroviral lectins have a modest potential for preventing or treating human infections with Trichomonas. C1 [Chatterjee, Aparajita; Ratner, Daniel M.; Robbins, Phillips W.; Samuelson, John] Boston Univ, Dept Mol & Cell Biol, Sch Dent Med, Boston, MA 02215 USA. [Ryan, Christopher M.; Johnson, Patricia J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [O'Keefe, Barry R.] Frederick Natl Lab Canc Res, Ctr Canc Res, Mol Targets Lab, Frederick, MD USA. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Anderson, Deborah J.] Boston Med Ctr, Dept Obstet & Gynecol, Boston, MA USA. RP Samuelson, J (reprint author), Boston Univ, Dept Mol & Cell Biol, Sch Dent Med, Boston, MA 02215 USA. EM jsamuels@bu.edu FU Boston University Flow Cytometry Core Facility; National Institutes of Health, General Medical Science; National Institutes of Allergy and Infectious Diseases [GM031318, AI105779] FX This work was supported by the Boston University Flow Cytometry Core Facility, the National Institutes of Health, General Medical Science, GM031318 National Institutes of Allergy and Infectious Diseases, AI105779. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 60 TC 1 Z9 1 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 7 PY 2015 VL 10 IS 8 AR e0135340 DI 10.1371/journal.pone.0135340 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO4HF UT WOS:000359121100154 PM 26252012 ER PT J AU Wang, J Geiss, LS Williams, DE Gregg, EW AF Wang, Jing Geiss, Linda S. Williams, Desmond E. Gregg, Edward W. TI Trends in Emergency Department Visit Rates for Hypoglycemia and Hyperglycemic Crisis among Adults with Diabetes, United States, 2006-2011 SO PLOS ONE LA English DT Article ID TO-TARGET TRIAL; NPH INSULIN; GLUCOSE CONTROL; OLDER-ADULTS; TYPE-2; MELLITUS; THERAPY; COMPLICATIONS; ASSOCIATION; SOCIETY AB Background Despite concerns about hypoglycemia events from overly aggressive glycemic reduction, population trends in hypoglycemia and hyperglycemic crisis incidence are unclear. To address this gap, we examined changes in emergency department (ED) visit rates for hypoglycemia and hyperglycemic crisis 2006-2011. Methods Using data from the Nationwide Emergency Department Sample, we estimated the number of ED visits for hypoglycemia and hyperglycemic crisis via ICD-9-CM among adults with diabetes. Using data from the National Health Interview Survey, we estimated the population of adults with diabetes and calculated ED visit rates. Results From 2006 to 2011, ED visit rates for hypoglycemia declined by 22% from 1.8 to 1.4 per 100 adults (p = 0.003). The rates decreased in all age groups (all P<0.05) except those aged 18 to 44 years (P = 0.31). Hypoglycemia rates displayed a J-shaped curve across age, with the highest rates among adults aged 75 years or older (P <0.001). ED visit rates for hyperglycemic crisis did not change overall but increased 17% for adults aged 65 to 74 years (P = 0.02) and 29% for women (P = 0.01). Hyperglycemic crisis rates were highest among adults aged 18 to 44 years (P <0.001). Conclusions Hypoglycemia rates have declined for all adults but persons aged 18-44 years while rates for hyperglycemic crisis remained stable. Future preventive efforts should target on the susceptible population of adults aged 18 to 44 years and those aged 75 years or older. C1 [Wang, Jing; Geiss, Linda S.; Williams, Desmond E.; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. RP Wang, J (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. EM zrr4@cdc.gov NR 30 TC 5 Z9 6 U1 3 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 7 PY 2015 VL 10 IS 8 AR e0134917 DI 10.1371/journal.pone.0134917 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO4HF UT WOS:000359121100085 PM 26252486 ER PT J AU Otieno, G Marinda, E Barnighausen, T Tanser, F AF Otieno, George Marinda, Edmore Baernighausen, Till Tanser, Frank TI High rates of homicide in a rural South African population (2000-2008): findings from a population-based cohort study SO POPULATION HEALTH METRICS LA English DT Article ID GLOBAL BURDEN; DEATH; HEALTH; VIOLENCE; SURVEILLANCE; MORTALITY; INJURIES; TANZANIA; VALIDITY; SYSTEM AB Background: South Africa has continued to receive increasing attention due to unprecedented high levels of violence. Homicide-related violence accounts for a significant proportion of unnatural deaths and contributes significantly to loss of years of expected life. We investigated levels and factors associated with homicide-related deaths and identify communities with excessively high homicide risk in a typical rural South African population. Method: Data drawn from verbal autopsies conducted on all deaths recorded during annual demographic and health surveillance in KwaZulu Natal, South Africa were used to derive the cumulative probability of death from homicide over a nine-year period (2000-2008). Weibull regression methods were used to investigate factors associated with homicide deaths. A Kulldorff spatial scan statistic was used to identify spatial clusters of homicide-related deaths. Results: With 536 homicide-related deaths, and a median seven years of follow-up, the study found an overall homicide incidence rate of 66 deaths per 100, 000 person-years of observation (PYOs) (95 % CI 60-72) for the period under study. Death related to the use of firearms was the leading reported method of homicide (65 %) and most deaths occurred over weekends (43 %). Homicides are the second-most common cause of death in men aged 25-34 after HIV-related deaths (including TB) in this community, at 210 deaths per 100,000 PYOs, and was highest among 55-64 year old women, at 78 deaths per 100,000 PYOs. Residency status, age, socioeconomic status, and highest education level attained independently predicted the risk of homicide death. The spatial distribution of homicide deaths was not homogenous and the study identified two clear geographical clusters with significantly elevated homicide risk. Conclusion: The high rates of homicide observed in this typical rural South African population - particularly among men - underscore the need for urgent interventions to reduce this tragic and theoretically preventable loss of life in this population and similar South African settings. C1 [Otieno, George] Kenya Govt Med Res Ctr, Kisumu 40100, Kenya. [Otieno, George] Ctr Dis Control & Prevent, Atlanta, GA USA. [Baernighausen, Till; Tanser, Frank] Wellcome Trust Africa Ctr Hlth & Populat Studies, Mtubatuba, South Africa. [Baernighausen, Till] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Otieno, George; Marinda, Edmore] Univ Witwatersrand, Sch Publ Hlth, ZA-2193 Johannesburg, South Africa. RP Otieno, G (reprint author), Kenya Govt Med Res Ctr, POB 1578, Kisumu 40100, Kenya. EM georgeomondiotieno@gmail.com FU INDEPTH Network; National Institute of Child Health and Human Development (NICHD) [1R01-HD058482-01]; Wellcome Trust, UK [082384/Z/07/Z] FX This study could not have been conducted without financial support from INDEPTH Network. FT and TB were supported by grant 1R01-HD058482-01 from the National Institute of Child Health and Human Development (NICHD). Funding for the Africa Centre's Demographic Surveillance Information System was received from the Wellcome Trust, UK (grant # 082384/Z/07/Z). A special word of thanks goes to Africa Centre for Health and Population Studies, and more so to the field staff who participated in the data collection. NR 45 TC 2 Z9 2 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7954 J9 POPUL HEALTH METR JI Popul. Health Metr. PD AUG 7 PY 2015 VL 13 AR 20 DI 10.1186/s12963-015-0054-0 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO3FV UT WOS:000359043100001 PM 26300697 ER PT J AU Shioda, K Kambhampati, A Hall, AJ Lopman, BA AF Shioda, Kayoko Kambhampati, Anita Hall, Aron J. Lopman, Ben A. TI Global age distribution of pediatric norovirus cases SO VACCINE LA English DT Article DE Norovirus; Gastroenteritis; Age distribution; Vaccines; Vaccine; Socioeconomic factors ID VACCINE; GASTROENTERITIS; CHILDREN; DISEASE AB Norovirus is increasingly recognized as a major cause of acute gastroenteritis among children <5 years of age. We searched for publications that reported detailed age distributions of pediatric norovirus cases, and assessed associations between age distribution and socio-demographic factors to identify the most critical age periods to prevent norovirus cases among young children. Approximately 70% of pediatric norovirus cases occurred between 6 and 23 months of age. A younger age distribution was found in lower income countries and inpatient settings. These findings suggest that a norovirus immunization schedule completed by 6 months could have the potential to prevent about 85% of pediatric cases, while a vaccine delivered at 12 months of age would only have the potential to prevent about 50% of pediatric cases. With a younger age distribution in lower income settings, early prevention would be even more critical. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Shioda, Kayoko; Kambhampati, Anita; Hall, Aron J.; Lopman, Ben A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Shioda, Kayoko; Kambhampati, Anita] Oak Ridge Inst Sci & Technol, Oak Ridge, TN 37831 USA. RP Shioda, K (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM yji4@cdc.gov; wyc4@cdc.gov; esg3@cdc.gov; iow4@cdc.gov FU Food-borne Disease Burden Epidemiology Reference Group (FERG) of the World Health Organization (WHO) FX This research was supported by (a) an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC (to K.S. and A.K.) and (b) the Food-borne Disease Burden Epidemiology Reference Group (FERG) of the World Health Organization (WHO). We thank Marion Koopmans and Linda Verhoef at the National Institute for Public Health and the Environment in the Netherlands for their previous contribution to developing the database. NR 14 TC 7 Z9 7 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD AUG 7 PY 2015 VL 33 IS 33 BP 4065 EP 4068 DI 10.1016/j.vaccine.2015.05.051 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CO2FD UT WOS:000358970600005 PM 26051514 ER PT J AU Thor, SW Nguyen, H Balish, A Hoang, AN Gustin, KM Nhung, PT Jones, J Thu, NN Davis, W Ngoc, TNT Jang, YH Sleeman, K Villanueva, J Kile, J Gubareva, LV Lindstrom, S Tumpey, TM Davis, CT Long, NT AF Thor, Sharmi W. Nguyen, Hieu Balish, Amanda Anh Nguyen Hoang Gustin, Kortney M. Pham Thi Nhung Jones, Joyce Ngoc Nguyen Thu Davis, William Thao Nguyen Thi Ngoc Jang, Yunho Sleeman, Katrina Villanueva, Julie Kile, James Gubareva, Larisa V. Lindstrom, Stephen Tumpey, Terrence M. Davis, C. Todd Nguyen Thanh Long TI Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013 SO PLOS ONE LA English DT Article ID INFLUENZA-A H5N1; RECEPTOR-BINDING SPECIFICITY; SINGLE AMINO-ACID; PROINFLAMMATORY CYTOKINES; INCREASED VIRULENCE; MOLECULAR-BASIS; HEMAGGLUTININ; PATHOGENICITY; PATHOGENESIS; INFECTION AB Highly pathogenic avian influenza (HPAI) H5N1 is endemic in Vietnamese poultry and has caused sporadic human infection in Vietnam since 2003. Human infections with HPAI H5N1 are of concern due to a high mortality rate and the potential for the emergence of pandemic viruses with sustained human-to-human transmission. Viruses isolated from humans in southern Vietnam have been classified as clade 1 with a single genome constellation (VN3) since their earliest detection in 2003. This is consistent with detection of this clade/genotype in poultry viruses endemic to the Mekong River Delta and surrounding regions. Comparison of H5N1 viruses detected in humans from southern Vietnamese provinces during 2012 and 2013 revealed the emergence of a 2013 reassortant virus with clade 1.1.2 hemagglutinin (HA) and neuraminidase (NA) surface protein genes but internal genes derived from clade 2.3.2.1a viruses (A/Hubei/1/2010-like; VN12). Closer analysis revealed mutations in multiple genes of this novel genotype (referred to as VN49) previously associated with increased virulence in animal models and other markers of adaptation to mammalian hosts. Despite the changes identified between the 2012 and 2013 genotypes analyzed, their virulence in a ferret model was similar. Antigenically, the 2013 viruses were less cross-reactive with ferret antiserum produced to the clade 1 progenitor virus, A/Vietnam/1203/2004, but reacted with antiserum produced against a new clade 1.1.2 WHO candidate vaccine virus (A/Cambodia/W0526301/2012) with comparable hemagglutination inhibition titers as the homologous antigen. Together, these results indicate changes to both surface and internal protein genes of H5N1 viruses circulating in southern Vietnam compared to 2012 and earlier viruses. C1 [Thor, Sharmi W.; Balish, Amanda; Gustin, Kortney M.; Jones, Joyce; Davis, William; Jang, Yunho; Sleeman, Katrina; Villanueva, Julie; Kile, James; Gubareva, Larisa V.; Lindstrom, Stephen; Tumpey, Terrence M.; Davis, C. Todd] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30322 USA. [Nguyen, Hieu; Anh Nguyen Hoang; Pham Thi Nhung; Ngoc Nguyen Thu; Thao Nguyen Thi Ngoc; Nguyen Thanh Long] Natl Influenza Ctr 2, Inst Pasteur Ho Chi Minh City, Ho Chi Minh City, Vietnam. [Kile, James] Ctr Dis Control & Prevent Vietnam, Influenza Program, Hanoi, Vietnam. RP Davis, CT (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30322 USA. EM ctdavis@cdc.gov; longpasteurhcm@yahoo.com NR 74 TC 3 Z9 3 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 5 PY 2015 VL 10 IS 8 AR e0133867 DI 10.1371/journal.pone.0133867 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO3MH UT WOS:000359061400056 PM 26244768 ER PT J AU Canary, LA Klevens, RM Holmberg, SD AF Canary, Lauren A. Klevens, R. Monina Holmberg, Scott D. TI Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID UNITED-STATES; LIVER-DISEASE; INFECTION C1 [Canary, Lauren A.; Klevens, R. Monina; Holmberg, Scott D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Canary, LA (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Fdn, Mailstop G-37, Atlanta, GA 30329 USA. EM lcanary@cdc.gov NR 7 TC 31 Z9 31 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 4 PY 2015 VL 163 IS 3 BP 226 EP + DI 10.7326/M15-0320 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CO6EX UT WOS:000359251100012 PM 26121095 ER PT J AU Baldwin, GT Houry, D AF Baldwin, Grant T. Houry, Debra TI Getting Everyone to Buckle Up on Every Trip: What More Can Be Done? SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Baldwin, Grant T.; Houry, Debra] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Baldwin, GT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway F-62, Atlanta, GA 30341 USA. EM gfb3@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 4 PY 2015 VL 163 IS 3 BP 234 EP + DI 10.7326/M15-1278 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CO6EX UT WOS:000359251100016 PM 26098664 ER PT J AU Sumner, SA Mercy, JA Dahlberg, LL Hillis, SD Klevens, J Houry, D AF Sumner, Steven A. Mercy, James A. Dahlberg, Linda L. Hillis, Susan D. Klevens, Joanne Houry, Debra TI Violence in the United States Status, Challenges, and Opportunities SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; INTIMATE PARTNER VIOLENCE; OF-THE-LITERATURE; ADVERSE CHILDHOOD EXPERIENCES; PEDIATRIC PRIMARY-CARE; PREVENTING VIOLENCE; SAFE ENVIRONMENT; YOUTH VIOLENCE; INTERVENTION; MALTREATMENT AB IMPORTANCE Interpersonal violence, which includes child abuse and neglect, youth violence, intimate partner violence, sexual violence, and elder abuse, affects millions of US residents each year. However, surveillance systems, programs, and policies to address violence often lack broad, cross-sector collaboration, and there is limited awareness of effective strategies to prevent violence. OBJECTIVES To describe the burden of interpersonal violence in the United States, explore challenges to violence prevention efforts and to identify prevention opportunities. DATA SOURCES We reviewed data from health and law enforcement surveillance systems including the National Vital Statistics System, the Federal Bureau of Investigation's Uniform Crime Reports, the US Justice Department's National Crime Victimization Survey, the National Survey of Children's Exposure to Violence, the National Child Abuse and Neglect Data System, the National Intimate Partner and Sexual Violence Survey, the Youth Risk Behavior Surveillance System, and the National Electronic Injury Surveillance System-All Injury Program. RESULTS Homicide rates have decreased from a peak of 10.7 per 100 000 persons in 1980 to 5.1 per 100 000 in 2013. Aggravated assault rates have decreased from a peak of 442 per 100 000 in 1992 to 242 per 100 000 in 2012. Nevertheless, annually, there are more than 16 000 homicides and 1.6 million nonfatal assault injuries requiring treatment in emergency departments. More than 12 million adults experience intimate partner violence annually and more than 10 million children younger than 18 years experience some form of maltreatment from a caregiver, ranging from neglect to sexual abuse, but only a small percentage of these violent incidents are reported to law enforcement, health care clinicians, or child protective agencies. Moreover, exposure to violence increases vulnerability to a broad range of mental and physical health problems over the life course; for example, meta-analyses indicate that exposure to physical abuse in childhood is associated with a 54% increased odds of depressive disorder, a 78% increased odds of sexually transmitted illness or risky sexual behavior, and a 32% increased odds of obesity. Rates of violence vary by age, geographic location, sex, and race/ethnicity, and significant disparities exist. Homicide is the leading cause of death for non-Hispanic blacks from age 1 through 44 years, whereas it is the fifth most common cause of death among non-Hispanic whites in this age range. Additionally, efforts to understand, prevent, and respond to interpersonal violence have often neglected the degree to which many forms of violence are interconnected at the individual level, across relationships and communities, and even intergenerationally. The most effective violence prevention strategies include parent and family-focused programs, early childhood education, school-based programs, therapeutic or counseling interventions, and public policy. For example, a systematic review of early childhood home visitation programs found a 38.9% reduction in episodes of child maltreatment in intervention participants compared with control participants. CONCLUSIONS AND RELEVANCE Progress has been made in reducing US rates of interpersonal violence even though a significant burden remains. Multiple strategies exist to improve violence prevention efforts, and health care providers are an important part of this solution. C1 [Sumner, Steven A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA. [Sumner, Steven A.; Mercy, James A.; Dahlberg, Linda L.; Klevens, Joanne] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30341 USA. [Hillis, Susan D.; Houry, Debra] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Sumner, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Hwy NE,Mailstop F-63, Atlanta, GA 30341 USA. EM hvo5@cdc.gov FU Intramural CDC HHS [CC999999] NR 86 TC 17 Z9 18 U1 9 U2 55 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 4 PY 2015 VL 314 IS 5 BP 478 EP 488 DI 10.1001/jama.2015.8371 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CO1OI UT WOS:000358924500012 PM 26241599 ER PT J AU Klevens, J Sadowski, LS Kee, R Garcia, D Lokey, C AF Klevens, Joanne Sadowski, Laura S. Kee, Romina Garcia, Diana Lokey, Colby TI Effect of Screening for Partner Violence on Use of Health Services at 3-Year Follow-up of a Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID CARE SETTINGS C1 [Klevens, Joanne; Lokey, Colby] US Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Sadowski, Laura S.; Kee, Romina; Garcia, Diana] John H Stroger Jr Hosp Cook Cty, Collaborat Res Unit, Chicago, IL USA. RP Klevens, J (reprint author), US Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Hwy,Mailstop F-63, Atlanta, GA 30341 USA. EM jklevens@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 1 Z9 1 U1 2 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 4 PY 2015 VL 314 IS 5 BP 515 EP 516 DI 10.1001/jama.2015.6755 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CO1OI UT WOS:000358924500016 PM 26241603 ER PT J AU Turner, J Hernandez, M Snawder, JE Handorean, A McCabe, KM AF Turner, Jane Hernandez, Mark Snawder, John E. Handorean, Alina McCabe, Kevin M. TI A Toxicology Suite Adapted for Comparing Parallel Toxicity Responses of Model Human Lung Cells to Diesel Exhaust Particles and Their Extracts SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID BRONCHIAL EPITHELIAL-CELLS; AIR-LIQUID INTERFACE; AIRBORNE PARTICULATE MATTER; IN-VITRO; CELLULAR-RESPONSE; ORGANIC EXTRACT; EXPOSURE; P53; COMPONENTS; CYCLE AB Epidemiological studies have shown that exposure to airborne particulate matter (PM) can be an important risk factor for some common respiratory diseases. While many studies have shown that PM exposures are associated with inflammatory reactions, the role of specific cellular responses in the manifestation of primary hypersensitivities and the progression of respiratory diseases remains unclear. In order to better understand mechanisms by which PM can exert adverse health effects, more robust approaches to support in vitro studies are warranted. In response to this need, a group of accepted toxicology assays was adapted to create an analytical suite for screening and evaluating the effects of important, ubiquitous atmospheric pollutants on two model human lung cell lines (epithelial and immature macrophage). To demonstrate the utility of this suite, responses to intact diesel exhaust particles (DEP) and mass-based equivalent doses of their organic extracts were examined. Results suggest that extracts have the potential to induce greater biological responses than those associated with their colloidal counterpart. Additionally, macrophage cells appear to be more susceptible to the cytotoxic effects of both intact DEP and their organic extract, than epithelial cells tested in parallel. As designed, the suite provided a more robust basis for characterizing toxicity mechanisms than the analysis of any individual assay. Findings suggest that cellular responses to PM are cell line dependent, and show that the collection and preparation of PM and/or their extracts have the potential to impact cellular responses relevant to screening fundamental elements of respiratory toxicity. Copyright 2015 American Association for Aerosol Research C1 [Turner, Jane; Hernandez, Mark; Handorean, Alina] Univ Colorado, Dept Civil Environm & Architectural Engn, Boulder, CO 80303 USA. [Snawder, John E.] NIOSH, Biomonitoring Res, Cincinnati, OH 45226 USA. [McCabe, Kevin M.] Columbia Gorge Community Coll, Dept Biol, The Dalles, OR USA. RP Hernandez, M (reprint author), Univ Colorado, Dept Civil Environm & Architectural Engn, 4355 Butler Circle, Boulder, CO 80303 USA. EM mark.hernandez@colorado.edu FU Intramural CDC HHS [CC999999] NR 49 TC 1 Z9 1 U1 4 U2 22 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0278-6826 EI 1521-7388 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PD AUG 3 PY 2015 VL 49 IS 8 BP 599 EP 610 DI 10.1080/02786826.2015.1053559 PG 12 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA CK6FB UT WOS:000356322800005 PM 26412929 ER PT J AU Clarke, TC AF Clarke, Tainya C. TI The use of complementary health approaches among US cancer survivors SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Clarke, Tainya C.] Ctr Dis Control & Prevent, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 3723 DI 10.1158/1538-7445.AM2015-3723 PG 2 WC Oncology SC Oncology GA DF8HA UT WOS:000371597102260 ER PT J AU Lane, C Kennedy, A Brotzman, M Miller, A Lai, G Khoury, M Seminara, D AF Lane, Crystal Kennedy, Amy Brotzman, Michelle Miller, Amy Lai, Gabriel Khoury, Muin Seminara, Daniela TI Supporting cancer epidemiology research through cohort registration: NCI's cancer epidemiology cohort descriptive database SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Lane, Crystal; Kennedy, Amy; Lai, Gabriel; Seminara, Daniela] NCI, Rockville, MD USA. [Brotzman, Michelle; Miller, Amy] WESTAT Corp, Rockville, MD 20850 USA. [Khoury, Muin] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA LB-195 DI 10.1158/1538-7445.AM2015-LB-195 PG 3 WC Oncology SC Oncology GA DF8HA UT WOS:000371597100294 ER PT J AU Qadir, XV Clyne, M Lam, TK Khoury, MJ Schully, SD AF Qadir, Ximena V. Clyne, Mindy Lam, Tram K. Khoury, Muin J. Schully, Sheri D. TI The landscape of published cancer meta-analyses: a descriptive look from 2008-2013 SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Qadir, Ximena V.; Clyne, Mindy; Lam, Tram K.; Schully, Sheri D.] NCI, NIH, Div Canc Control & Populat Sci, Epidemiol & Genom Res Program, Rockville, MD USA. [Khoury, Muin J.] CDC, Off Publ Hlth Genom, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 3698 DI 10.1158/1538-7445.AM2015-3698 PG 2 WC Oncology SC Oncology GA DF8HA UT WOS:000371597102236 ER PT J AU McDonald, JA Argotsinger, B Mojarro, O Rochat, R Amatya, A AF McDonald, Jill A. Argotsinger, Brittany Mojarro, Octavio Rochat, Roger Amatya, Anup TI First Trimester Initiation of Prenatal Care in the US-Mexico Border Region SO MEDICAL CARE LA English DT Article DE prenatal care; birth certificates; Mexico; Southwestern United States; health status disparities ID WELFARE-REFORM; HEALTH-CARE; COVERAGE; DISPARITIES; INSURANCE; MORTALITY; ADEQUACY; IMPACT AB Objectives: To systematically examine prevalence of first trimester prenatal care (FTPNC) in the 44 US counties and 80 Mexican municipios of the binational border region; and to describe disparities between border and nonborder areas within states, border states, and countries. Methods: We combined 2009 records of singleton live births from the 10 US-Mexico border states (N = 1,370,206) into a single file. We included FTPNC; county/municipio, state, and country of maternal residence; and demographic variables common to all records. We computed prevalence of FTPNC for border and nonborder residents by state and country. Using multivariable regression, we computed adjusted prevalence ratios (aPR) for FTPNC in border relative to nonborder residents, states relative to one another, and the US relative to Mexico. Results: In 2009, 68.8% of US-Mexico border mothers and 72.9% of nonborder mothers received FTPNC. After adjustment, nonborder residents had higher prevalence of FTPNC than border residents in Sonora, New Mexico, Arizona, Coahuila, and Chihuahua (aPR = 1.09-124). In US states, prevalence was 13%-36% higher in New Mexico, Arizona, and California than Texas. In Mexico, when compared with Coahuila, adjusted prevalence was 12%-20% higher in neighboring states. Between countries, FTPNC prevalence in border counties/municipios was higher in Mexico among women with low parity/low education and in the United States among women with high parity/high education. Conclusions: In the US and Mexico, women in border counties/municipios receive less timely prenatal care than their nonborder counterparts, but the magnitude of the disparity varies by state. Lack of a consistent, binational approach to birth data collection requires cautious interpretation of findings. C1 [McDonald, Jill A.; Amatya, Anup] New Mexico State Univ, Coll Hlth & Social Serv, MSC 3446,POB 30001, Las Cruces, NM 88003 USA. [McDonald, Jill A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, El Paso, TX USA. [Argotsinger, Brittany; Rochat, Roger] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Mojarro, Octavio] CECOFIN SC, Guadalajara, Jalisco, Mexico. RP McDonald, JA (reprint author), New Mexico State Univ, Coll Hlth & Social Serv, MSC 3446,POB 30001, Las Cruces, NM 88003 USA. EM jillmcd@nmsu.edu NR 39 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD AUG PY 2015 VL 53 IS 8 BP 700 EP 707 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DD0UR UT WOS:000369636000008 PM 26125417 ER PT J AU Tsegaye, TS Butler, K Luo, W Radzio, J Srinivasan, P Sharma, S Aubert, RD Hanson, DL Dobard, C Garcia-Lerma, JG Heneine, W McNicholl, JM Kersh, EN AF Tsegaye, Theodros S. Butler, Katherine Luo, Wei Radzio, Jessica Srinivasan, Priya Sharma, Sunita Aubert, Rachael D. Hanson, Debra L. Dobard, Charles Garcia-Lerma, Jose Gerardo Heneine, Walid McNicholl, Janet M. Kersh, Ellen N. TI Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 19th Conference on Retroviruses and Opportunistic Infections (CROI) CY MAR 05-08, 2012 CL Seattle, WA DE SHIV; preexposure prophylaxis; T-cell immune response; exposed uninfected; pigtail macaques ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIGHLY PATHOGENIC SIV; INJECTING DRUG-USERS; INTERIM GUIDANCE; HIV PREVENTION; ANTIRETROVIRAL PROPHYLAXIS; TYPE-1 INFECTION; RHESUS MACAQUES; TENOFOVIR GEL; INTERVENTIONS AB Background: Preexposure prophylaxis (PrEP) for HIV prevention is a novel biomedical prevention method. We have previously modeled PrEP during rectal SHIV exposures in macaques and identified that Simian/Human Immunodeficiency Virus chimera (SHIV)-specific T-cell responses were induced in the presence of antiretroviral drugs, an observation previously termed T-cell chemovaccination. This report expands those initial findings by examining a larger group of macaques that were given oral or topical PrEP during repeated vaginal virus exposure. Methods: Thirty-six female pigtail macaques received up to 20 repeat low-dose vaginal inoculations with wild-type (WT) SHIVSF162P3 (n = 24) or a clonal derivative with the tenofovir (TFV) K65R drug-resistant mutation (n = 12). PrEP consisted of oral Truvada (n = 6, WT), TFV vaginal gel (n = 6, K65R), or TFV intravaginal ring (n = 6, WT). The remaining animals were PrEP-inexperienced controls (n = 12, WT; n = 6, K65R). SHIV-specific T cells were identified and characterized using interferon gamma Enzyme-Linked ImmunoSpot (ELISPOT) and multiparameter flow cytometry. Results: Of 9 animals that were on PrEP and remained uninfected during WT SHIV vaginal challenges, 8 (88.9%) developed virusspecific T-cell responses. T cells were in CD4 and CD8 compartments, reached up to 4900 interferon gamma-producing cells per million peripheral blood mononuclear cells, and primarily pol directed. In contrast, the replication-impaired K65R virus did not induce detectable T-cell responses, likely reflecting the need for adequate replication. Conclusions: Virus-specific T-cell responses occur frequently in oral or topical PrEP-protected pigtail macaques after vaginal exposure to WT SHIV virus. The contribution of such immune responses to protection from infection during and after PrEP warrants further investigation. C1 [Tsegaye, Theodros S.; Butler, Katherine; Luo, Wei; Radzio, Jessica; Srinivasan, Priya; Sharma, Sunita; Aubert, Rachael D.; Hanson, Debra L.; Dobard, Charles; Garcia-Lerma, Jose Gerardo; Heneine, Walid; McNicholl, Janet M.; Kersh, Ellen N.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, NCHHSTP, Branch Lab, Atlanta, GA 30333 USA. RP Kersh, EN (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop A25, Atlanta, GA 30333 USA. EM egk6@cdc.gov FU Intramural CDC HHS [CC999999]; NIAID NIH HHS [Y01 AI000681, Y01 AI000681-02, Y1-AI-0681-02] NR 49 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2015 VL 69 IS 4 BP 385 EP 394 DI 10.1097/QAI.0000000000000642 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DC5HK UT WOS:000369251900006 PM 25886925 ER PT J AU Laffoon, BT Hall, HI Babu, AS Benbow, N Hsu, LC Hu, YYW AF Laffoon, Benjamin T. Hall, H. Irene Babu, Aruna Surendera Benbow, Nanette Hsu, Ling C. Hu, Yunyin W. CA Urban Areas HIV Surveillance Workg TI HIV Infection and Linkage to HIV-Related Medical Care in Large Urban Areas in the United States, 2009 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; linkage to care; HIV care indicators; HIV infection; HIV in urban areas ID MANAGEMENT AB Background: Residents of urban areas have accounted for the majority of persons diagnosed with HIV disease in the United States. Linking persons recently diagnosed with HIV to primary medical care is an important indicator in the National HIV/AIDS Strategy. Methods: We analyzed data reported to the HIV Surveillance System in 18 urban areas in the United States. Standardized executable SAS programs were distributed to determine the number of HIV cases living through 2008, number of HIV cases diagnosed in 2009, and the percentage of those diagnosed in 2009 who had reported CD4 lymphocyte or HIV viral load test results within 3 months of HIV diagnosis. Data were presented by jurisdiction, age group at diagnosis, race/ethnicity, sex at birth, birth country, disease stage, and transmission category. Results: By jurisdiction, the percentage of persons diagnosed in 2009 with at least 1 CD4 or HIV viral load test within 3 months of diagnosis ranged from 48.5% to 92.5% (median: 70.9). The percentage of persons linked to care varied by age group and by racial/ethnic groups. Fourteen of the 18 areas reported that the percentage of persons linked to care was greater than 65%, the baseline measure indicated in the National HIV/AIDS Strategy. Conclusions: A wide range in percent linked to HIV medical care was observed between residents of 18 urban areas in the United States with noted age and racial disparities. Routine testing and linkage efforts and intensified prevention efforts should be considered to increase access to primary HIV- related medical care. C1 [Laffoon, Benjamin T.; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Babu, Aruna Surendera] ICF Macro Int Inc, Atlanta, GA USA. [Benbow, Nanette] Chicago Dept Publ Hlth, HIV STI Serv Div, Chicago, IL USA. [Hsu, Ling C.] San Francisco Dept Publ Hlth, Populat Hlth Div, San Francisco, CA USA. [Hu, Yunyin W.] Los Angeles Cty Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA USA. RP Laffoon, BT (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E47, Atlanta, GA 30329 USA. EM blaffoon@cdc.gov NR 12 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2015 VL 69 IS 4 BP 487 EP 492 DI 10.1097/QAI.0000000000000619 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DC5HK UT WOS:000369251900019 PM 25844695 ER PT J AU Dick, RB Lowe, BD Lu, ML Krieg, EF AF Dick, Robert B. Lowe, Brian D. Lu, Ming-Lun Krieg, Edward F. TI Further Trends in Work-Related Musculoskeletal Disorders A Comparison of Risk Factors for Symptoms Using Quality of Work Life Data From the 2002, 2006, and 2010 General Social Survey SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SHOULDER; NECK AB Objective: To report trends for the risk of musculoskeletal disorders. Methods: Three Quality of Work Life surveys examine the risk factors for musculoskeletal disorders. Results: Findings similar for several risk factors, but differences across the reporting years may reflect economic conditions. Respondent numbers in 2010 were reduced, some risk factors had pattern changes, and there were sex and age differences. Trend analysis showed most significant changes were for the "work fast" risk factor. New 2010 "physical effort" item showed sex differences, and items reflective of total worker health showed strong associations with "back pain" and "pain in arms." Conclusions: Intervention strategies should focus on physical exposures and psychosocial risk factors (work stress, safety climate, job satisfaction, supervisor support, work fast, work freedom, work time) that have been consistently related to reports of musculoskeletal disorders. Economic conditions will influence some psychosocial risk factors. C1 Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Cincinnati, OH USA. Natl Inst Safety & Occupat Hlth, Div Appl Res & Technol, Org Sci & Human Factors Branch, Cincinnati, OH USA. RP Dick, RB (reprint author), NIOSH, DART, OSHFB, Mail Stop C-24,1150 Tusculum Ave, Cincinnati, OH 45226 USA. EM RBD1@cdc.gov FU National Institute for Occupational Safety and Health FX Supported by the National Institute for Occupational Safety and Health. NR 19 TC 0 Z9 0 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD AUG PY 2015 VL 57 IS 8 BP 910 EP 928 DI 10.1097/JOM.0000000000000501 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD0UE UT WOS:000369634700014 PM 26247646 ER PT J AU Al Agili, DE Griffin, SO AF Al Agili, Dania E. Griffin, Susan O. TI Effect of Family Income on the Relationship Between Parental Education and Sealant Prevalence, National Health and Nutrition Examination Survey, 2005-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID EXAMINATION SURVEY NHANES; ORAL-HEALTH; QUALITY-ASSURANCE; DENTAL INSURANCE; MEDICAL-CARE; COMPONENT; LITERACY; ACCESS; MODEL AB Introduction We examined the association between sealant prevalence and parental education for different levels of family income, controlling for other covariates. Methods We combined data from 2005-2006, 2007-2008, and 2009-2010 cycles of the National Health and Nutrition Examination Survey. The study sample was 7,090 participants aged 6 to 19 years. Explanatory variables, chosen on the basis of Andersen and Aday's framework of health care utilization, were predisposing variables - child's age, sex, race/ethnicity, and parental education (high school diploma); enabling variables - family income (<100% of the federal poverty level [FPL]; 100%-200% of the FPL; and >200% of the FPL), health insurance status, and regular source of medical care; and a need variable - future need for care (perceived child health status is excellent/very good, good, fair/poor). We conducted bivariate and multivariate analyses and included a term for interaction between education and income in the multivariate model. We report significant findings (P =.05). Results Sealant prevalence was associated with all explanatory variables in bivariate and multivariate analyses. In bivariate analyses, higher parental education and family income were independently associated with higher sealant prevalence. In the multivariate analysis, higher parental education was associated with sealant prevalence among higher income children, but not among low-income children (<100% FPL). Sealant prevalence was higher among children with parental education greater than a high school diploma versus less than a high school diploma in families with income >= 100% FPL. Conclusion Our findings suggest that income modifies the association of parental education on sealant prevalence. Recognition of this relationship may be important for health promotion efforts. C1 [Griffin, Susan O.] Ctr Dis Control & Prevent, Div Oral Hlth, Mail Stop F-80,4770 Buford Highway NE, Atlanta, GA 30341 USA. [Al Agili, Dania E.] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia. RP Griffin, SO (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, Mail Stop F-80,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM sig1@cdc.gov RI Alagili, Dania/C-6280-2017 NR 29 TC 1 Z9 1 U1 2 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2015 VL 12 AR E138 DI 10.5888/pcd12.150037 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZQ UT WOS:000368664600016 PM 26312383 ER PT J AU Farren, L Belza, B Allen, P Brolliar, S Brown, DR Cormier, ML Janicek, S Jones, DL King, DK Marquez, DX Rosenberg, DE AF Farren, Laura Belza, Basia Allen, Peg Brolliar, Sarah Brown, David R. Cormier, Marc L. Janicek, Sarah Jones, Dina L. King, Diane K. Marquez, David X. Rosenberg, Dori E. TI Mall Walking Program Environments, Features, and Participants: A Scoping Review SO PREVENTING CHRONIC DISEASE LA English DT Article ID PHYSICAL-ACTIVITY; OLDER-ADULTS; BUILT ENVIRONMENT; HEALTH; NEIGHBORHOOD; INTERVENTIONS; POPULATION; COMMUNITY; BARRIERS; DESIGN AB Introduction Walking is a preferred and recommended physical activity for middle-aged and older adults, but many barriers exist, including concerns about safety (ie, personal security), falling, and inclement weather. Mall walking programs may overcome these barriers. The purpose of this study was to summarize the evidence on the health-related value of mall walking and mall walking programs. Methods We conducted a scoping review of the literature to determine the features, environments, and benefits of mall walking programs using the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance). The inclusion criteria were articles that involved adults aged 45 years or older who walked in indoor or outdoor shopping malls. Exclusion criteria were articles that used malls as laboratory settings or focused on the mechanics of walking. We included published research studies, dissertations, theses, conference abstracts, syntheses, nonresearch articles, theoretical papers, editorials, reports, policy briefs, standards and guidelines, and nonresearch conference abstracts and proposals. Websites and articles written in a language other than English were excluded. Results We located 254 articles on mall walking; 32 articles met our inclusion criteria. We found that malls provided safe, accessible, and affordable exercise environments for middle-aged and older adults. Programmatic features such as program leaders, blood pressure checks, and warm-up exercises facilitated participation. Individual benefits of mall walking programs included improvements in physical, social, and emotional well-being. Limited transportation to the mall was a barrier to participation. Conclusion We found the potential for mall walking programs to be implemented in various communities as a health promotion measure. However, the research on mall walking programs is limited and has weak study designs. More rigorous research is needed to define best practices for mall walking programs' reach, effectiveness, adoption, implementation, and maintenance. C1 [Farren, Laura; Belza, Basia; Brolliar, Sarah; Rosenberg, Dori E.] Univ Washington, Hlth Promot Res Ctr, 1107 NE 45th St,Suite 200,Box 354804, Seattle, WA 98105 USA. [Allen, Peg] Washington Univ, Brown Sch, St Louis, MO USA. [Brown, David R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Janicek, Sarah; Marquez, David X.] Univ Illinois, Chicago, IL USA. [Jones, Dina L.] W Virginia Univ, Dept Orthopaed, Div Phys Therapy, Morgantown, WV 26506 USA. [Cormier, Marc L.; Jones, Dina L.] W Virginia Univ, Injury Control Res Ctr, Morgantown, WV 26506 USA. [King, Diane K.] Univ Alaska Anchorage, Ctr Behav Hlth Res & Serv, Anchorage, AK USA. RP Farren, L (reprint author), Univ Washington, Hlth Promot Res Ctr, 1107 NE 45th St,Suite 200,Box 354804, Seattle, WA 98105 USA. EM laf2163@columbia.edu FU University of Washington Health Promotion Research Center, a Centers for Disease Control and Prevention (CDC) Prevention Research Center [U48-DP001911, 13-070] FX The authors thank Yuki Durham, Michael Kelly, Christina E. Miyawaki, Jeremy Thurston, and Rebecca Tiffany for their contributions to this project. This work was supported by the University of Washington Health Promotion Research Center, a Centers for Disease Control and Prevention (CDC) Prevention Research Center (cooperative agreement no. U48-DP001911 and special interest project [no. 13-070], Development of an Evidence-Informed Mall Walking Resource Guide). The findings and conclusions in this publication are those of the author(s) and do not necessarily represent CDC's official position. NR 53 TC 2 Z9 2 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2015 VL 12 AR E129 DI 10.5888/pcd12.150027 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZQ UT WOS:000368664600007 PM 26270743 ER PT J AU Jamal, A Dube, SR King, BA AF Jamal, Ahmed Dube, Shanta R. King, Brian A. TI Tobacco Use Screening and Counseling During Hospital Outpatient Visits Among US Adults, 2005-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID CURRENT CIGARETTE-SMOKING; UNITED-STATES; HEALTH-CARE; CESSATION; PHYSICIANS; BARRIERS AB Introduction Physicians and health care providers play an important role in educating their patients about the health risks of tobacco use and in providing effective cessation interventions. Little is known about these practices in hospital outpatient settings. The objective of the study was to assess the prevalence, correlates, and trends of tobacco use screening and cessation assistance offered to US adults during their hospital outpatient clinic visits. Methods Data for aggregated hospital outpatient visits among patients aged 18 years or older (N = 148,727) from the 2005-2010 National Hospital Ambulatory Medical Care Survey were analyzed. Tobacco use screening was defined as documentation of screening for either current tobacco use (cigarettes, cigars, snuff, or chewing tobacco) or no current use on the patient record form. Tobacco cessation assistance was defined as documentation of either tobacco counseling or cessation medications. Results Tobacco use screening was reported for 63.0% (estimated 271 million visits) of hospital outpatient visits, and cessation assistance was reported for 24.5% (estimated 17.1 million visits) of visits among current tobacco users. From 2005 through 2010, tobacco use screening (P for trend =.06) and cessation assistance (P for trend =.17) did not change significantly. Conclusion From 2005 through 2010, more than one-third of hospital outpatient visits had no screening for tobacco use, and among current tobacco users, only 1 in 4 received any cessation assistance. Health care providers should consistently identify and document their patients' tobacco use status and provide them with appropriate tobacco cessation assistance. Opportunities also exist to expand the coverage for tobacco cessation. C1 [Jamal, Ahmed; Dube, Shanta R.; King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mail Stop F79, Atlanta, GA 30341 USA. RP Jamal, A (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mail Stop F79, Atlanta, GA 30341 USA. EM jze1@cdc.gov NR 24 TC 2 Z9 2 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2015 VL 12 AR E132 DI 10.5888/pcd12.140529 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZQ UT WOS:000368664600010 PM 26292063 ER PT J AU Petrescu-Prahova, M Belza, B Leith, K Allen, P Coe, NB Anderson, LA AF Petrescu-Prahova, Miruna Belza, Basia Leith, Katherine Allen, Peg Coe, Norma B. Anderson, Lynda A. TI Using Social Network Analysis to Assess Mentorship and Collaboration in a Public Health Network SO PREVENTING CHRONIC DISEASE LA English DT Article ID CHRONIC DISEASE; SYSTEMS; CAPACITY; SERVICES AB Introduction Addressing chronic disease burden requires the creation of collaborative networks to promote systemic changes and engage stake-holders. Although many such networks exist, they are rarely assessed with tools that account for their complexity. This study examined the structure of mentorship and collaboration relationships among members of the Healthy Aging Research Network (HAN) using social network analysis (SNA). Methods We invited 97 HAN members and partners to complete an online social network survey that included closed-ended questions about HAN-specific mentorship and collaboration during the previous 12 months. Collaboration was measured by examining the activity of the network on 6 types of products: published articles, in-progress manuscripts, grant applications, tools, research projects, and presentations. We computed network-level measures such as density, number of components, and centralization to assess the cohesiveness of the network. Results Sixty-three respondents completed the survey (response rate, 65%). Responses, which included information about collaboration with nonrespondents, suggested that 74% of HAN members were connected through mentorship ties and that all 97 members were connected through at least one form of collaboration. Mentorship and collaboration ties were present both within and across boundaries of HAN member organizations. Conclusion SNA of public health collaborative networks provides understanding about the structure of relationships that are formed as a result of participation in network activities. This approach may offer members and funders a way to assess the impact of such networks that goes beyond simply measuring products and participation at the individual level. C1 [Petrescu-Prahova, Miruna] Univ Washington, Sch Publ Hlth, 1107 NE 45th St,Suite 200, Seattle, WA 98105 USA. [Belza, Basia; Coe, Norma B.] Univ Washington, Seattle, WA 98195 USA. [Leith, Katherine] Univ S Carolina, Columbia, SC 29208 USA. [Allen, Peg] Washington Univ, St Louis, MO USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Atlanta, GA 30322 USA. RP Petrescu-Prahova, M (reprint author), Univ Washington, Sch Publ Hlth, 1107 NE 45th St,Suite 200, Seattle, WA 98105 USA. EM mirunapp@uw.edu FU CDC Healthy Aging Program; CDC's PRC Program [U48-DP-001911, U48-DP-001936] FX We thank Gwen Moni and Stephanie Potts for their logistical support for this project and Valerie Edwards and Daniela Friedman for their early input on the analyses. This study is the result of work conducted by the CDC HAN. The CDC HAN is a PRC program funded by the CDC Healthy Aging Program. Efforts were supported in part by cooperative agreements from CDC's PRC Program: U48-DP-001911 and U48-DP-001936. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 28 TC 1 Z9 1 U1 4 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2015 VL 12 AR E130 DI 10.5888/pcd12.150103 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZQ UT WOS:000368664600008 PM 26292061 ER PT J AU Evenson, KR Dorn, JM Camplain, R Pate, RR Brown, DR AF Evenson, Kelly R. Dorn, Joan M. Camplain, Ricky Pate, Russell R. Brown, David R. TI Evaluation of the Physical Activity and Public Health Course for Researchers SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE education; epidemiology; exercise; leisure activities; policy; practitioner ID INACTIVITY AB Background: From 1995-2013, an 8-day Physical Activity and Public Health Course for Researchers has been offered yearly in the United States. Methods: In 2013, an evaluation quantified time that fellows spent in different course offerings, surveyed fellows on course impact, documented grant funding, and identified fellow participation on leading physical activity-related journals. Results: The number of fellows that attended the course ranged from 20 per year to 35 per year. Fellows who participated in the web survey (n = 322) agreed that the course: met their expectations (99%), had a positive impact on the physical activity research or practice work they did (98%), and helped increase their professional networking in the field (93%). Following the course, 73% of fellows had further contact with course faculty and 71% had further contact with other fellows. From the National Institutes of Health, 117 grants were awarded to 82 fellows (21% of eligible fellows). Out of 14 journals reviewed, 11 had at least 1 fellow on their staff as editor, associate editor, or editorial board member. Conclusion: The Physical Activity and Public Health Course for Researchers helps address a training need by providing instruction and building capacity in the US and abroad for conducting research on physical activity and public health. C1 [Evenson, Kelly R.; Camplain, Ricky] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA. [Evenson, Kelly R.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC 27515 USA. [Dorn, Joan M.; Brown, David R.] Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Pate, Russell R.] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. RP Evenson, KR (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA. EM kelly_evenson@unc.edu FU CDC [U48/DP000059] FX This work was supported through a grant from the CDC to the University of North Carolina-Chapel Hill Prevention Research Center (#U48/DP000059). NR 9 TC 2 Z9 2 U1 0 U2 0 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD AUG PY 2015 VL 12 IS 8 BP 1052 EP 1060 DI 10.1123/jpah.2014-0284 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CY1CZ UT WOS:000366145600002 PM 25271475 ER PT J AU Gounder, PP Zulz, T Desai, S Stenz, F Rudolph, K Tsang, R Tyrrell, GJ Bruce, MG AF Gounder, Prabhu P. Zulz, Tammy Desai, Shalini Stenz, Flemming Rudolph, Karen Tsang, Raymond Tyrrell, Gregory J. Bruce, Michael G. TI Epidemiology of bacterial meningitis in the North American Arctic, 2000-2010 SO JOURNAL OF INFECTION LA English DT Article DE Bacterial meningitis; Epidemiology; Haemophilus influenzae; Neisseria meningitidis; Streptococcus pneumoniae ID QUALITY-CONTROL PROGRAM; HAEMOPHILUS-INFLUENZAE; INVASIVE DISEASE; UNITED-STATES; SURVEILLANCE; ALASKA; CHILDREN; RISK AB Objective: To determine the incidence of meningitis caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in the North American Arctic during 2000-2010. Methods: Surveillance data were obtained from the International Circumpolar Surveillance network. We defined a case of bacterial meningitis caused by H. influenzae, N. meningitidis, or S. pneumoniae as a culture-positive isolate obtained from a normally sterile site in a resident with a meningitis diagnosis. Results: The annual incidence/100,000 persons for meningitis caused by H. influenzae, N. meningitidis, and S. pneumoniae among all North American Arctic residents was: 0.6, 0.5, and 1.5, respectively; the meningitis incidence among indigenous persons in Alaska and Canada (indigenous status not recorded in Greenland) for those three bacteria was: 2.1, 0.8, and 2.4, respectively. The percentage of pneumococcal isolates belonging to a 7-valent pneumococcal conjugate vaccine serotype declined from 2000-2004 to 2005-2010 (31%-2%, p-value <0.01). During 2005-2010, serotype a caused 55% of H. influenzae meningitis and serogroup B caused 86% of meningococcal meningitis. Conclusions: Compared with all North American Arctic residents, indigenous people suffer disproportionately from bacterial meningitis. Arctic residents could benefit from the development of an H. influenzae serotype a vaccine and implementation of a meningococcal serogroup B vaccine. Published by Elsevier Ltd on behalf of The British Infection Association. C1 [Gounder, Prabhu P.; Zulz, Tammy; Rudolph, Karen; Bruce, Michael G.] Ctr Dis Control & Prevent, Arctic Investigat Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Desai, Shalini] Publ Hlth Agcy Canada, Ctr Immunizat & Resp Infect Dis, Ottawa, ON, Canada. [Stenz, Flemming] Govt Greenland, Natl Board Hlth, Nuuk 3900, Greenland. [Tsang, Raymond] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. [Tyrrell, Gregory J.] Walter Mackenzie Hlth Sci Ctr, Prov Lab Publ Hlth Microbiol, Edmonton, AB, Canada. RP Gounder, PP (reprint author), 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM pgounder@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention (in-kind support only, no grant). NR 22 TC 4 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 EI 1532-2742 J9 J INFECTION JI J. Infect. PD AUG PY 2015 VL 71 IS 2 BP 179 EP 187 DI 10.1016/j.jinf.2015.04.001 PG 9 WC Infectious Diseases SC Infectious Diseases GA CW6VY UT WOS:000365137700005 PM 25864638 ER PT J AU Bayleyegn, TM Schnall, AH Ballou, SG Zane, DF Burrer, SL Noe, RS Wolkin, AF AF Bayleyegn, Tesfaye M. Schnall, Amy H. Ballou, Shimere G. Zane, David F. Burrer, Sherry L. Noe, Rebecca S. Wolkin, Amy F. TI Use of Community Assessments for Public Health Emergency Response (CASPERs) to Rapidly Assess Public Health Issues - United States, 2003-2012 SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE assessment; CASPER; disaster; preparedness; response ID SAMPLING METHOD; NEEDS AB Introduction: Community Assessment for Public Health Emergency Response (CASPER) is an epidemiologic technique designed to provide quick, inexpensive, accurate, and reliable household-based public health information about a community's emergency response needs. The Health Studies Branch at the Centers for Disease Control and Prevention (CDC) provides in-field assistance and technical support to state, local, tribal, and territorial (SLTT) health departments in conducting CASPERs during a disaster response and in non-emergency settings. Data from CASPERs conducted from 2003 through 2012 were reviewed to describe uses of CASPER, ascertain strengths of the CASPER methodology, and highlight significant findings. Methods: Through an assessment of the CDC's CASPER metadatabase, all CASPERs that involved CDC support performed in US states and territories from 2003 through 2012 were reviewed and compared descriptively for differences in geographic distribution, sampling methodology, mapping tool, assessment settings, and result and action taken by decision makers. Results: For the study period, 53 CASPERs were conducted in 13 states and one US territory. Among the 53 CASPERS, 38 (71.6%) used the traditional 2-stage cluster sampling methodology, 10 (18.8%) used a 3-stage cluster sampling, and two (3.7%) used a simple random sampling methodology. Among the CASPERs, 37 (69.9%) were conducted in response to specific natural or human-induced disasters, including 14 (37.8%) for hurricanes. The remaining 16 (30.1%) CASPERS were conducted in non-disaster settings to assess household preparedness levels or potential effects of a proposed plan or program. The most common recommendations resulting from a disaster-related CASPER were to educate the community on available resources (27; 72.9%) and provide services (18; 48.6%) such as debris removals and refills of medications. In preparedness CASPERs, the most common recommendations were to educate the community in disaster preparedness (5; 31.2%) and to revise or improve preparedness plans (5; 31.2%). Twenty-five (47.1%) CASPERs documented on the report or publications the public health action has taken based on the result or recommendations. Findings from 27 (50.9%) of the CASPERs conducted with CDC assistance were published in peer-reviewed journals or elsewhere. Conclusion: The number of CASPERs conducted with CDC assistance has increased and diversified over the past decade. The CASPERs' results and recommendations supported the public health decisions that benefitted the community. Overall, the findings suggest that the CASPER is a useful tool for collecting household-level disaster preparedness and response data and generating information to support public health action. C1 [Bayleyegn, Tesfaye M.; Schnall, Amy H.; Burrer, Sherry L.; Noe, Rebecca S.; Wolkin, Amy F.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Hlth Studies Branch, Chamblee, GA USA. [Ballou, Shimere G.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Zane, David F.] Texas Dept State Hlth Serv, Community Preparedness Sect, Austin, TX USA. RP Bayleyegn, TM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Chamblee, GA 30341 USA. EM bvy7@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 2 Z9 2 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD AUG PY 2015 VL 30 IS 4 BP 374 EP 381 DI 10.1017/S1049023X15004938 PG 8 WC Emergency Medicine SC Emergency Medicine GA CW0VU UT WOS:000364708700009 PM 26193798 ER PT J AU Gargano, LM Hajjeh, R Cookson, ST AF Gargano, Lisa M. Hajjeh, Rana Cookson, Susan T. TI Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE cost-effectiveness; Haemophilus influenzae type b; humanitarian emergency; PCV10; Streptococcus pneumoniae ID STREPTOCOCCUS-PNEUMONIAE; ECONOMIC-EVALUATION; CHILDREN YOUNGER; DISEASE; BURDEN; COUNTRIES; EFFICACY; GAMBIA; STATE AB Background: Pneumonia is a leading cause of death among children less than five years old during humanitarian emergencies. Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae are the leading causes of bacterial pneumonia. Vaccines for both of these pathogens are available to prevent pneumonia. Problem: This study describes an economic analysis from a publicly funded health care system perspective performed on a birth cohort in Somalia, a country that has experienced a protracted humanitarian emergency. Methods: An impact and cost-effectiveness analysis was performed comparing: no vaccine, Hib vaccine only, pneumococcal conjugate vaccine 10 (PCV10) only, and both together administered through supplemental immunization activities (SIAs). The main summary measure was the incremental cost per disability-adjusted life-years (DALYs) averted. One-way sensitivity analysis was conducted for uncertainty in parameter values. Results: Each SIA would avert a substantial number of cases and deaths. Compared with no vaccine, the DALYs averted by two SIAs for two doses of Hib vaccine was US $202.93 (lower and upper limits: $121.80-$623.52), two doses of PCV10 was US $161.51 ($107.24-$227.21), and two doses of both vaccines was US $152.42 ($101.20-$214.42). Variables that influenced the cost-effectiveness for each strategy most substantially were vaccine effectiveness, case fatality rates (CFRs), and disease burden. Conclusions: The World Health Organization (WHO) defines a cost-effective intervention as costing one to three times the per capita gross domestic product (GDP; in 2011, for Somalia = US $112). Based on the presented model, Hib vaccine alone, PCV10 alone, or Hib vaccine and PCV10 given together in SIAs are cost-effective interventions in Somalia. The WHO/Strategic Advisory Group of Experts decision-making factors for vaccine deployment appear to have all been met: the disease burden is large, the vaccine-related risk is low, prevention in this setting is more feasible than treatment, the vaccine duration probably is sufficient for the vulnerable period of the child's life, cost is reasonable, and herd immunity is possible. C1 [Gargano, Lisa M.; Cookson, Susan T.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Hajjeh, Rana] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Gargano, LM (reprint author), 4770 Buford Highway, Atlanta, GA 30341 USA. EM lisa.gargano@gmail.com NR 37 TC 3 Z9 3 U1 0 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD AUG PY 2015 VL 30 IS 4 BP 402 EP 411 DI 10.1017/S1049023X15004781 PG 10 WC Emergency Medicine SC Emergency Medicine GA CW0VU UT WOS:000364708700014 PM 26061190 ER PT J AU Amesty, S Crawford, ND Nandi, V Perez-Figueroa, R Rivera, A Sutton, M Weidle, PJ Willis, L Smith, DK Hernandez, C Harripersaud, K Lewis, CF AF Amesty, Silvia Crawford, Natalie D. Nandi, Vijay Perez-Figueroa, Rafael Rivera, Alexis Sutton, Madeline Weidle, Paul J. Willis, Leigh Smith, Dawn K. Hernandez, Carolyn Harripersaud, Katherine Lewis, Crystal Fuller TI Evaluation of Pharmacy-Based HIV Testing in a High-Risk New York City Community SO AIDS PATIENT CARE AND STDS LA English DT Article ID HEALTH-CARE SETTINGS; INJECTION-DRUG USERS; ANTIRETROVIRAL THERAPY; EMERGENCY-DEPARTMENT; GENDER-DIFFERENCES; PERSONS AWARE; NEIGHBORHOOD; PREVENTION; INTERVENTION; SERVICES AB Blacks/Hispanics face limited access to HIV testing. We examined in-pharmacy HIV testing among customers in pharmacies participating in a nonprescription syringe program in New York City. Participants were recruited in two pharmacies to complete a survey and receive an optional HIV test. Bivariate and multivariable analyses were performed to examine associations of demographics and risk behaviors with receiving in-pharmacy HIV testing. Most participants were male (55%), black (80%), had used hard drugs (88%), and 39.5% received in-pharmacy HIV testing. Being female (AOR=2.24; 95%CI 1.24-4.05), having multiple sex partners (AOR=1.20; 95% CI 1.06-1.35), having an HIV test more than 12 months ago (AOS=4.06; CI 1.85-8.91), injecting drugs in last 3 months (AOR=2.73; 95% CI 1.31-5.69) and having continuous care (AOR=0.32; 95% CI 0.17-0.58) were associated with receiving in-pharmacy HIV test. These data provide evidence of in-pharmacy HIV testing reaching persons at risk of HIV. HIV testing in pharmacies may complement existing strategies. C1 [Amesty, Silvia] Columbia Univ Coll Phys & Surg, Ctr Family & Community Med, New York, NY 10032 USA. [Amesty, Silvia; Perez-Figueroa, Rafael] Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, New York, NY USA. [Crawford, Natalie D.] Emory Univ, Behav Sci Hlth Educ, Atlanta, GA 30322 USA. [Nandi, Vijay] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA. [Perez-Figueroa, Rafael] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA. [Rivera, Alexis; Hernandez, Carolyn; Harripersaud, Katherine; Lewis, Crystal Fuller] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Sutton, Madeline; Weidle, Paul J.; Willis, Leigh; Smith, Dawn K.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Amesty, S (reprint author), Columbia Univ Coll Phys & Surg, Ctr Family & Community Med, 100 Haven Ave,27D, New York, NY 10032 USA. EM sc1242@columbia.edu FU Centers for Disease Control and Prevention; Minority HIV/AIDS Research Initiative (MARI) [3U01PS000698, 2007-12] FX Funding: Centers for Disease Control and Prevention, Minority HIV/AIDS Research Initiative (MARI)- (3U01PS000698), 2007-12. NR 44 TC 2 Z9 2 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD AUG 1 PY 2015 VL 29 IS 8 BP 437 EP 444 DI 10.1089/apc.2015.0017 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CV0TR UT WOS:000363966700002 PM 26217930 ER PT J AU Boulet, SL Crawford, S Zhang, YJ Sunderam, S Cohen, B Bernson, D McKane, P Bailey, MA Jamieson, DJ Kissin, DM AF Boulet, Sheree L. Crawford, Sara Zhang, Yujia Sunderam, Saswati Cohen, Bruce Bernson, Dana McKane, Patricia Bailey, Marie A. Jamieson, Denise J. Kissin, Dmitry M. CA States Monitoring ART Collaborativ TI Embryo transfer practices and perinatal outcomes by insurance mandate status SO FERTILITY AND STERILITY LA English DT Article DE Assisted reproductive technology; embryo transfer; insurance coverage; multiple birth ID ASSISTED REPRODUCTIVE TECHNOLOGY; INFERTILITY TREATMENTS; MULTIPLE BIRTHS; FERTILITY; COVERAGE; POLICY AB Objective: To use linked assisted reproductive technology (ART) surveillance and birth certificate data to compare ET practices and perinatal outcomes for a state with a comprehensive mandate requiring coverage of IVF services versus states without a mandate. Design: Retrospective cohort study. Setting: Not applicable. Patient(s): Live-birth deliveries ascertained from linked 2007-2009 National ART Surveillance System and birth certificate data for a state with an insurance mandate (Massachusetts) and two states without a mandate (Florida and Michigan). Intervention(s): None. Main Outcome Measure(s): Number of embryos transferred, multiple births, low birth weight, preterm delivery. Result(s): Of the 230,038 deliveries in the mandate state and 1,026,804 deliveries in the nonmandate states, 6,651 (2.9%) and 8,417 (0.8%), respectively, were conceived by ART. Transfer of three or more embryos was more common in nonmandate states, although the effect was attenuated for women 35 years or older (33.6% vs. 39.7%; adjusted relative risk [RR], 1.46; 95% confidence interval [CI], 1.17-1.81) versus women younger than 35 (7.0% vs. 26.9%; adjusted RR, 4.18; 95% CI, 2.74-6.36). Lack of an insurance mandate was positively associated with triplet/higher order deliveries (1.0% vs. 2.3%; adjusted RR, 2.44; 95% CI, 1.81-3.28), preterm delivery (22.6% vs. 30.7%; adjusted RR, 1.31; 95% CI, 1.20-1.42), and low birth weight (22.3% vs. 29.5%; adjusted RR, 1.28; 95% CI, 1.17-1.40). Conclusion(s): Compared with nonmandate states, the mandate state had higher overall rates of ART use. Among ART births, lack of an infertility insurance mandate was associated with increased risk for adverse perinatal outcomes. (C) 2015 by American Society for Reproductive Medicine. C1 [Boulet, Sheree L.; Crawford, Sara; Zhang, Yujia; Sunderam, Saswati; Jamieson, Denise J.; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Cohen, Bruce; Bernson, Dana] Massachusetts Dept Publ Hlth, Boston, MA USA. [McKane, Patricia] Michigan Dept Community Hlth, Lansing, MI USA. [Bailey, Marie A.] Florida Dept Hlth, Tallahassee, FL USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-74, Atlanta, GA 30341 USA. EM sboulet@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 7 Z9 7 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD AUG PY 2015 VL 104 IS 2 BP 403 EP + DI 10.1016/j.fertnstert.2015.05.015 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CV0PX UT WOS:000363954000023 PM 26051096 ER PT J AU Vassilieva, EV Kalluri, H McAllister, D Taherbhai, MT Esser, ES Pewin, WP Pulit-Penaloza, JA Prausnitz, MR Compans, RW Skountzou, I AF Vassilieva, Elena V. Kalluri, Haripriya McAllister, Devin Taherbhai, Misha T. Esser, E. Stein Pewin, Winston P. Pulit-Penaloza, Joanna A. Prausnitz, Mark R. Compans, Richard W. Skountzou, Ioanna TI Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH LA English DT Article DE Dissolving microneedle patches; Metal microneedle arrays; Skin immunization; Influenza vaccines; Mouse model ID SINGLE-RADIAL-IMMUNODIFFUSION; VIRUS-LIKE PARTICLES; INTRADERMAL VACCINATION; ANTIBODY-RESPONSES; SERUM ANTIBODIES; SKIN VACCINATION; OLDER-ADULTS; IMMUNIZATION; PROTECTION; CHILDREN AB Prevention of seasonal influenza epidemics and pandemics relies on widespread vaccination coverage to induce protective immunity. In addition to a good antigenic match with the circulating viruses, the effectiveness of individual strains represented in the trivalent vaccines depends on their immunogenicity. In this study, we evaluated the immunogenicity of H1N1, H3N2, and B seasonal influenza virus vaccine strains delivered individually with a novel dissolving microneedle patch and the stability of this formulation during storage at 25 degrees C. Our data demonstrate that all strains retained their antigenic activity after incorporation in the dissolving patches as measured by single radial diffusion (SRID) assay and immune responses to vaccination in BALB/c mice. After a single immunization, all three antigens delivered with microneedle patches induced superior neutralizing antibody titers compared to intramuscular immunization. Cutaneous antigen delivery was especially beneficial for the less immunogenic B strain. Mice immunized with dissolving microneedle patches encapsulating influenza A/Brisbane/59/07 (H1N1) vaccine were fully protected against lethal challenge by homologous mouse-adapted influenza virus. All vaccine components retained activity during storage at room temperature for at least 3 months as measured in vitro by SRID assay and in vivo by mouse immunization studies. Our data demonstrate that dissolving microneedle patches are a promising advance for influenza cutaneous vaccination due to improved immune responses using less immunogenic influenza antigens and enhanced stability. C1 [Vassilieva, Elena V.; Taherbhai, Misha T.; Esser, E. Stein; Pulit-Penaloza, Joanna A.; Compans, Richard W.; Skountzou, Ioanna] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Vassilieva, Elena V.; Taherbhai, Misha T.; Esser, E. Stein; Pulit-Penaloza, Joanna A.; Compans, Richard W.; Skountzou, Ioanna] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Kalluri, Haripriya; McAllister, Devin; Pewin, Winston P.; Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA. [Pulit-Penaloza, Joanna A.] Ctr Dis Control, Influenza Div, Atlanta, GA 30322 USA. RP Skountzou, I (reprint author), Emory Univ, Sch Med, Dept Microbiol & Immunol, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM iskount@emory.edu FU US National Institutes of Health [EB012495] FX We thank Dahnide Taylor-Williams for her valuable technical support. We thank Derek O'Hagan, Sushma Kommareddy, and their colleagues at Novartis Vaccines and Diagnostics for providing influenza vaccine monobulks. The work was supported by US National Institutes of Health grant EB012495. NR 61 TC 7 Z9 7 U1 4 U2 22 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 2190-393X EI 2190-3948 J9 DRUG DELIV TRANSL RE JI Drug Deliv. Transl. Res. PD AUG PY 2015 VL 5 IS 4 BP 360 EP 371 DI 10.1007/s13346-015-0228-0 PG 12 WC Instruments & Instrumentation; Medicine, Research & Experimental; Pharmacology & Pharmacy SC Instruments & Instrumentation; Research & Experimental Medicine; Pharmacology & Pharmacy GA CU2XP UT WOS:000363387300005 PM 25895053 ER PT J AU Bakulski, KM Lee, H Feinberg, JI Wells, EM Brown, S Herbstman, JB Witter, FR Halden, RU Caldwell, K Mortensen, ME Jaffe, AE Moye, J Caulfield, LE Pan, Y Goldman, LR Feinberg, AP Fallin, MD AF Bakulski, Kelly M. Lee, HwaJin Feinberg, Jason I. Wells, Ellen M. Brown, Shannon Herbstman, Julie B. Witter, Frank R. Halden, Rolf U. Caldwell, Kathleen Mortensen, Mary Ellen Jaffe, Andrew E. Moye, John, Jr. Caulfield, Laura E. Pan, Yi Goldman, Lynn R. Feinberg, Andrew P. Fallin, M. Daniele TI Prenatal mercury concentration is associated with changes in DNA methylation at TCEANC2 in newborns SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE DNA methylation; mercury exposure; epigenetics; cord blood; methylmercury ID CORD BLOOD; EPIGENETIC EPIDEMIOLOGY; WIDE ASSOCIATION; MATERNAL BLOOD; WHOLE-BLOOD; METHYLMERCURY; EXPOSURE; HETEROGENEITY; EXPRESSION; BALTIMORE AB Background: Human exposure to the widespread environmental contaminant mercury is a known risk factor for common diseases such as cancer, cardiovascular disease and neurological disorders through poorly characterized mechanisms. Evidence suggests mercury exposure may alter DNA methylation levels, but to date, the effects in early life on a genome-wide scale have not been investigated. Methods: A study sample of 141 newborns was recruited in Baltimore, MD, USA and total mercury and methylmercury were measured in cord blood samples. We quantified genome-wide DNA methylation data using CHARM 2.0, an array-based method, and used region-finding analyses to identify concentration-associated differentially methylated regions (DMRs). To test for replication of these identified DMRs in the pilot, or Vanguard, phase of the National Children's Study (NCS), we compared bisulfite-pyrosequenced DNA at candidate regions from 85 whole cord blood samples with matched first trimester maternal mercury concentration measures. Results: Total mercury concentration was associated with methylation at DMRs inside ANGPT2 and near PRPF18 genes [false discovery rate (FDR) < 0.05], as well as DMRs near FOXD2 and within TCEANC2 (FDR<0.1) genes. Methylmercury concentration was associated with an overlapping DMR within TCEANC2 (FDR<0.05). In NCS replication analyses, methylation levels at three of four cytosine-guanine DNA dinucleotides (CpG sites) within the TCEANC2 DMR were associated with total mercury concentration (P<0.05), and this association was diminished after adjusting for estimated cell proportions. Conclusions: Evidence for an association between mercury and DNA methylation at the TCEANC2 region was found, which may represent a mercury-associated shift in cord blood cell composition or a change in methylation within blood cell types. Further confirmatory studies are needed. C1 [Bakulski, Kelly M.; Feinberg, Jason I.; Brown, Shannon; Herbstman, Julie B.; Caulfield, Laura E.; Goldman, Lynn R.; Feinberg, Andrew P.; Fallin, M. Daniele] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Lee, HwaJin; Feinberg, Jason I.; Witter, Frank R.; Halden, Rolf U.; Jaffe, Andrew E.; Feinberg, Andrew P.; Fallin, M. Daniele] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Wells, Ellen M.] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA. [Herbstman, Julie B.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Halden, Rolf U.] Arizona State Univ, Fulton Sch Engn, Tempe, AZ USA. [Caldwell, Kathleen; Mortensen, Mary Ellen; Pan, Yi] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Jaffe, Andrew E.] Lieber Inst Brain Dev, Baltimore, MD USA. [Moye, John, Jr.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Goldman, Lynn R.] George Washington Univ, Sch Publ Hlth, Washington, DC USA. RP Fallin, MD (reprint author), 624 N Broadway,Hampton House 850, Baltimore, MD 21205 USA. EM dfallin@jhu.edu RI Halden, Rolf/F-9562-2010; Jaffe, Andrew/L-3089-2016; OI Halden, Rolf/0000-0001-5232-7361; Jaffe, Andrew/0000-0001-6886-1454; Wells, Ellen/0000-0002-7293-1395; moye, john/0000-0001-9976-8586 FU National Institute for Environmental Health Sciences at the National Institutes for Health [ES017646]; Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health [HHSN27520080033C, HHSN275200503414C, HHSN275200503411C, HHSN275200603416C, HHSN275200503415C, HHSN275200503413C, HHSN275200503410C, HHSN275200503396C, HHSN275201000121U, HHSN275200900010C]; National Center for Environmental Health, Centers for Disease Control and Prevention FX This work was supported by the National Institute for Environmental Health Sciences at the National Institutes for Health (ES017646). The National Children's Study (NCS) Initial Vanguard Centers from which the samples were collected, the NCS biospecimen team and the NCS repository were supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health contracts numbers: HHSN27520080033C, HHSN275200503414C, HHSN275200503411C, HHSN275200603416C, HHSN275200503415C, HHSN275200503413C, HHSN275200503410C, HHSN275200503396C, HHSN275201000121U and HHSN275200900010C. Funding for the blood mercury analyses was provided by the National Center for Environmental Health, Centers for Disease Control and Prevention. NR 45 TC 8 Z9 8 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 EI 1464-3685 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD AUG PY 2015 VL 44 IS 4 BP 1249 EP 1262 DI 10.1093/ije/dyv032 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT8JK UT WOS:000363061500023 PM 25906783 ER PT J AU Antao, VC Muravov, OI Sapp, J Larson, TC Pallos, LL Sanchez, ME Williamson, GD Horton, DK AF Antao, Vinicius C. Muravov, Oleg I. Sapp, James, II Larson, Theodore C. Pallos, L. Laszlo Sanchez, Marchelle E. Williamson, G. David Horton, D. Kevin TI Considerations Before Establishing an Environmental Health Registry SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID AMYOTROPHIC-LATERAL-SCLEROSIS; NATIONAL EXPOSURE REGISTRY; CHERNOBYL ACCIDENT; DISEASE; RISK AB Public health registries can provide valuable information when health consequences of environmental exposures are uncertain or will likely take long to develop. They can also aid research on diseases that may have environmental causes that are not completely well defined. We discuss factors to consider when deciding whether to create an environmental health registry. Those factors include public health significance, purpose and outcomes, duration and scope of data collection and availability of alternative data sources, timeliness, availability of funding and administrative capabilities, and whether the establishment of a registry can adequately address specific health concerns. We also discuss difficulties, limitations, and benefits of exposure and disease registries, based on the experience of the Agency for Toxic Substances and Disease Registry. C1 [Antao, Vinicius C.; Muravov, Oleg I.; Sapp, James, II; Larson, Theodore C.; Pallos, L. Laszlo; Sanchez, Marchelle E.; Williamson, G. David; Horton, D. Kevin] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. RP Antao, VC (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 4770 Buford Highway NE,Mailstop F-58, Atlanta, GA 30341 USA. EM vinicius.antao@att.net FU Intramural CDC HHS [CC999999] NR 27 TC 1 Z9 1 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2015 VL 105 IS 8 BP 1543 EP 1551 DI 10.2105/AJPH.2015.302642 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6VL UT WOS:000362950400037 PM 26066912 ER PT J AU Haderxhanaj, LT Rhodes, SD Romaguera, RA Bloom, FR Leichliter, JS AF Haderxhanaj, Laura T. Rhodes, Scott D. Romaguera, Raul A. Bloom, Fred R. Leichliter, Jami S. TI Hispanic Men in the United States: Acculturation and Recent Sexual Behaviors With Female Partners, 2006-2010 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HETEROSEXUAL ANAL INTERCOURSE; LATINO MEN; RISK BEHAVIORS; YOUNG-ADULTS; PUERTO-RICAN; CONDOM USE; TRANSMITTED INFECTIONS; REPRODUCTIVE HEALTH; LOS-ANGELES; HIV AB Objectives. We examined Hispanic men's recent risky and protective sexual behaviors with female partners by acculturation. Methods. Using the 2006-2010 National Survey of Family Growth, we performed bivariate analyses to compare acculturation groups (Hispanic Spanish-speaking immigrants, Hispanic English-speaking immigrants, Hispanic US natives, and non-Hispanic White men) by demographics and recent sexual behaviors with women. Multivariable logistic regression models for sexual behaviors by acculturation group were adjusted for demographics. Results. Compared with Hispanic Spanish-speaking immigrants, non-Hispanic White men were less likely to report exchange of money or drugs for sex (adjusted odds ratio [AOR] = 0.3; 95% confidence interval [CI] = 0.1, 0.9), but were also less likely to report condom use at last vaginal (AOR = 0.6; 95% CI = 0.4, 0.8) and anal sex (AOR = 0.4; 95% CI = 0.3, 0.7). Hispanic US natives were less likely to report condom use at last vaginal sex than were Spanish-speaking immigrants (AOR = 0.6; 95% CI = 0.4, 0.8). English-and Spanish-speaking immigrants did not differ in risky or protective sexual behaviors. Conclusions. Our findings suggest that targeted interventions focusing on unique sexual risks and sociodemographic differences by acculturation level, particularly nativity, may be helpful for preventing sexually transmitted infections. C1 [Haderxhanaj, Laura T.; Romaguera, Raul A.; Bloom, Fred R.; Leichliter, Jami S.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA USA. [Rhodes, Scott D.] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Serv, Winston Salem, NC USA. RP Haderxhanaj, LT (reprint author), Sch Publ Hlth, Dept Appl Hlth Sci, 1025 East 7th St 111, Bloomington, IN 47405 USA. EM lthaderx@indiana.edu NR 63 TC 1 Z9 1 U1 1 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2015 VL 105 IS 8 BP E126 EP E133 DI 10.2105/AJPH.2014.302524 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6VL UT WOS:000362950400024 PM 26066961 ER PT J AU Jones, CM Campopiano, M Baldwin, G McCance-Katz, E AF Jones, Christopher M. Campopiano, Melinda Baldwin, Grant McCance-Katz, Elinore TI National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEPATITIS-C VIRUS; UNITED-STATES; PRESCRIBING BUPRENORPHINE; ADDICTION TREATMENT; TREATMENT PROGRAMS; OVERDOSE DEATHS; PAIN RELIEVERS; HEROIN USE; ABUSE; PHYSICIANS AB Objectives. We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. Methods. We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data. Results. Nationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more. Conclusions. Significant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed. C1 [Jones, Christopher M.] US FDA, Off Publ Hlth Strategy & Anal, Off Commissioner, Silver Spring, MD 20993 USA. [Campopiano, Melinda] Subst Abuse & Mental Hlth Serv Adm, Div Pharmacol Therapies, Ctr Subst Abuse Treatment, Rockville, MD USA. [Baldwin, Grant] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [McCance-Katz, Elinore] Subst Abuse & Mental Hlth Serv Adm, Off Policy Planning & Innovat, Rockville, MD USA. RP Jones, CM (reprint author), US FDA, Off Publ Hlth Strategy & Anal, Off Commissioner, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA. EM christopher.m.jones@fda.hhs.gov NR 60 TC 29 Z9 30 U1 9 U2 18 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2015 VL 105 IS 8 BP E55 EP E63 DI 10.2105/AJPH.2015.302664 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6VL UT WOS:000362950400014 PM 26066931 ER PT J AU Schulte, PA Guerin, RJ Schill, AL Bhattacharya, A Cunningham, TR Pandalai, SP Eggerth, D Stephenson, CM AF Schulte, Paul A. Guerin, Rebecca J. Schill, Anita L. Bhattacharya, Anasua Cunningham, Thomas R. Pandalai, Sudha P. Eggerth, Donald Stephenson, Carol M. TI Considerations for Incorporating "Well-Being" in Public Policy for Workers and Workplaces SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID OCCUPATIONAL-SAFETY; RESEARCH AGENDA; POSITIVE AFFECT; HEALTH; PRESENTEEISM; PRODUCTIVITY; HAPPINESS; DISEASE; ENVIRONMENT; POPULATION AB Action to address workforce functioning and productivity requires a broader approach than the traditional scope of occupational safety and health. Focus on "well-being" may be one way to develop a more encompassing objective. Well-being is widely cited in public policy pronouncements, but often as "... and well-being" (e.g., health and well-being). It is generally not defined in policy and rarely operationalized for functional use. Many definitions of well-being exist in the occupational realm. Generally, it is a synonym for health and a summative term to describe a flourishing worker who benefits from a safe, supportive workplace, engages in satisfying work, and enjoys a fulfilling work life. We identified issues for considering well-being in public policy related to workers and the workplace. C1 [Schulte, Paul A.; Guerin, Rebecca J.; Bhattacharya, Anasua; Cunningham, Thomas R.; Pandalai, Sudha P.; Eggerth, Donald; Stephenson, Carol M.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Schill, Anita L.] NIOSH, Off Director, Washington, DC USA. RP Schulte, PA (reprint author), NIOSH, 1150 Tusculum Ave,MS-C14, Cincinnati, OH 45226 USA. EM pschulte@cdc.gov NR 152 TC 6 Z9 6 U1 5 U2 19 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2015 VL 105 IS 8 BP E31 EP E44 DI 10.2105/AJPH.2015.302616 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6VL UT WOS:000362950400010 PM 26066933 ER PT J AU Rajeevan, MS Dimulescu, I Murray, J Falkenberg, VR Unger, ER AF Rajeevan, Mangalathu S. Dimulescu, Irina Murray, Janna Falkenberg, Virginia R. Unger, Elizabeth R. TI Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome SO HUMAN IMMUNOLOGY LA English DT Article DE Chronic fatigue syndrome; Genetics; Inflammation; Complement activation; Innate immunity ID COMPLEMENT ACTIVATION; MACULAR DEGENERATION; ALLELIC EXPRESSION; ASSOCIATION; ENCEPHALOMYELITIS; INFECTION; EXERCISE; MODEL; INTERLEUKIN-18; ABNORMALITIES AB Recent evidence suggests immune and inflammatory alterations are important in chronic fatigue syndrome (CFS). This study was done to explore the association of functionally important genetic variants in inflammation and immune pathways with CFS. Peripheral blood DNA was isolated from 50 CFS and 121 non-fatigued (NF) control participants in a population-based study. Genotyping was performed with the Affymetrix Immune and Inflammation Chip that covers 11 K single nucleotide polymorphisms (SNPs) following the manufacturer's protocol. Genotyping accuracy for specific genes was validated by pyrosequencing. Golden Helix SVS software was used for genetic analysis. SNP functional annotation was done using SPOT and GenomePipe programs. CFS was associated with 32 functionally important SNPs: 11 missense variants, 4 synonymous variants, 11 untranslated regulatory region (UTR) variants and 6 intronic variants. Some of these SNPs were in genes within pathways related to complement cascade (SERPINA5, CFB, CFH, MASF1 and C6), chemokines (CXCL16, CCR4, CCL27), cytokine signaling (IL18, IL17B, IL2RB), and toll-like receptor signaling (TIRAP, IRAK4). Of particular interest is association of CFS with two missense variants in genes of complement activation, rs4151667 (L9H) in CFB and rs1061170 (Y402H) in CFH. A 5' UTR polymorphism (rs11214105) in IL18 also associated with physical fatigue, body pain and score for CFS case defining symptoms. This study identified new associations of CFS with genetic variants in pathways including complement activation providing additional support for altered innate immune response in CFS. Additional studies are needed to validate the findings of this exploratory study. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/). C1 [Rajeevan, Mangalathu S.; Dimulescu, Irina; Murray, Janna; Falkenberg, Virginia R.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Rajeevan, MS (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM mor4@cdc.gov FU research participation program at the Centers for Disease Control and Prevention (CDC), Division of High-Consequence Pathogens Pathology FX Support for J. Murray was provided by the research participation program at the Centers for Disease Control and Prevention (CDC), Division of High-Consequence Pathogens & Pathology, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. NR 48 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 EI 1879-1166 J9 HUM IMMUNOL JI Hum. Immunol. PD AUG PY 2015 VL 76 IS 8 BP 553 EP 560 DI 10.1016/j.humimm.2015.06.014 PG 8 WC Immunology SC Immunology GA CT7NG UT WOS:000363001100004 PM 26116897 ER PT J AU Gordon, SC Lamerato, LE Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Teshale, E Xu, FJ Boscarino, JA Vijayadeva, V Schmidt, MA Oja-Tebbe, N Lu, M AF Gordon, Stuart C. Lamerato, Lois E. Rupp, Loralee B. Holmberg, Scott D. Moorman, Anne C. Spradling, Philip R. Teshale, Eyasu Xu, Fujie Boscarino, Joseph A. Vijayadeva, Vinutha Schmidt, Mark A. Oja-Tebbe, Nancy Lu, Mei CA CHeCS Investigators TI Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID SIMPLE NONINVASIVE INDEX; LONG-TERM MORTALITY; NON-B-HEPATITIS; VIRUS-INFECTION; NON-A; FOLLOW-UP; POSTTRANSFUSION HEPATITIS; FIBROSIS PROGRESSION; NATURAL-HISTORY; LIVER FIBROSIS AB OBJECTIVES: The severity of liver disease in the hepatitis C virus (HCV)-infected population in the United States remains uncertain. We estimated the prevalence of cirrhosis in adults with chronic hepatitis C (CHC) using multiple parameters including liver biopsy, diagnosis/procedure codes, and a biomarker. METHODS: Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received health services during 2006-2010 were included. Cirrhosis was identified through liver biopsy reports, diagnosis/procedure codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) scores >= 5.88. Demographic and clinical characteristics associated with cirrhosis were identified through multivariable logistic modeling. RESULTS: Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy identified cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure codes for cirrhosis and hepatic decompensation identified cirrhosis in 2,194 (22%), 557 (6%), and 482 (5%) patients, respectively. Among 661 patients with biopsy-confirmed cirrhosis, only 356 (54%) had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 infection, HIV coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were independently associated with higher odds of cirrhosis (all, P < 0.05). Conversely, private health insurance coverage, black race, and HCV genotype 2 were associated with lower odds of cirrhosis. CONCLUSIONS: A high proportion of patients with biopsy-confirmed cirrhosis are not assigned ICD-9 codes for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of the prevalence of cirrhosis in cohort studies. Use of additional parameters suggests a fourfold higher prevalence of cirrhosis than is revealed by biopsy alone. These findings suggest that cirrhosis in CHC patients may be significantly underdocumented and underdiagnosed. C1 [Gordon, Stuart C.] Henry Ford Hlth Syst, Div Gastroenterol & Hepatol, Detroit, MI 48202 USA. [Lamerato, Lois E.; Oja-Tebbe, Nancy; Lu, Mei] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI 48202 USA. [Rupp, Loralee B.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI 48202 USA. [Holmberg, Scott D.; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu; Xu, Fujie] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. RP Gordon, SC (reprint author), Henry Ford Hlth Syst, Div Gastroenterol & Hepatol, 2799 West Grand Blvd K-7, Detroit, MI 48202 USA. EM sgordon3@hfhs.org FU CDC Foundation; AbbVie; Gilead Sciences; Janssen Pharmaceuticals; Bristol-Myers Squibb FX CHeCS is funded by the CDC Foundation, which currently receives grants from AbbVie, Gilead Sciences, and Janssen Pharmaceuticals. Past funders include Genentech, A Member of the Roche Group, and Vertex Pharmaceuticals. Past partial funders include Bristol-Myers Squibb. Granting corporations do not have access to CHeCS data and do not contribute to data analysis or writing of manuscripts. NR 53 TC 6 Z9 6 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD AUG PY 2015 VL 110 IS 8 BP 1169 EP 1177 DI 10.1038/ajg.2015.203 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT1PL UT WOS:000362571700011 PM 26215529 ER PT J AU Song, M Carroll, DD Lee, SM Fulton, JE AF Song, MinKyoung Carroll, Dianna D. Lee, Sarah M. Fulton, Janet E. TI Active Gaming Among High School Students-United States, 2010 SO GAMES FOR HEALTH JOURNAL LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PROMOTE PHYSICAL-ACTIVITY; SEDENTARY SCREEN TIME; VIDEO GAMES; ENERGY-EXPENDITURE; CHILDREN; YOUTH; ADOLESCENTS; BEHAVIOR AB Objectives: Our study is the first to describe the prevalence and correlates (demographics, body mass index [BMI], sedentary behaviors, and physical activity) of high school youth who report active videogame playing (active gaming) in a U.S. representative sample. Materials and Methods: The National Youth Physical Activity and Nutrition Study of 2010 provided data for this study. Active gaming was assessed as the number of days in the 7 days prior to the survey that students in grades 9-12 (14-18 years of age) reported participating in active videogames (e.g., Wii Fit [Nintendo, Kyoto, Japan], Dance Dance Revolution [Konami, Osaka, Japan]). Students reporting 1 days were classified as active gamers. Logistic regression was used to examine the association among active gaming and demographic characteristics, BMI, sedentary behaviors, and physical activity. Results: Among 9125 U.S. high school students in grades 9-12 surveyed, 39.9 percent (95 percent confidence interval=37.9 percent, 42.0 percent) reported active gaming. Adjusting for covariates, the following characteristics were positively associated (P<0.05) with active gaming: being in 9th and 10th grades compared with being in 12th grade; being of black, non-Hispanic race/ethnicity; being overweight or obese; watching DVDs >0 hours/day; watching TV >0 hours/day; and meeting guidelines for aerobic and muscle-strengthening physical activity. Conclusions: Four out of 10 U.S. high school students report participating in active gaming. Active gamers tend to spend more time watching DVDs or TV, meet guidelines for physical activity, and/or be overweight or obese compared with nonactive gamers. These findings may serve to provide a baseline to track active gaming in U.S. youth and inform interventions that target sedentary behaviors and/or physical activity. C1 [Song, MinKyoung] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Song, MinKyoung] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Song, MinKyoung; Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Carroll, Dianna D.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Atlanta, GA USA. [Lee, Sarah M.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Carroll, Dianna D.] US PHS, Commissioned Corps, Atlanta, GA USA. RP Song, M (reprint author), Univ Michigan, Sch Nursing, 400 North Ingalls,Suite 2172, Ann Arbor, MI 48109 USA. EM songmin@med.umich.edu NR 37 TC 1 Z9 1 U1 2 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2161-783X EI 2161-7856 J9 GAMES HEALTH J JI Games Health J. PD AUG 1 PY 2015 VL 4 IS 4 BP 325 EP 331 DI 10.1089/g4h.2014.0126 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CS6FH UT WOS:000362172800010 PM 26182221 ER PT J AU Zhou, CM Plass, T Jacksha, R Waynert, JA AF Zhou, Chenming Plass, Timothy Jacksha, Ronald Waynert, Joseph A. TI RF Propagation in Mines and Tunnels Extensive measurements for vertically, horizontally, and cross-polarized signals in mines and tunnels. SO IEEE ANTENNAS AND PROPAGATION MAGAZINE LA English DT Article ID ELECTROMAGNETIC-WAVE PROPAGATION; UHF RADIO-WAVES; RECTANGULAR TUNNELS; UNDERGROUND MINE; ROAD TUNNELS; GUIDE; MODEL C1 [Zhou, Chenming; Plass, Timothy] NIOSH, Atlanta, GA 30329 USA. [Zhou, Chenming] US Dept HHS, Ctr Dis Control & Prevent, Washington, DC USA. [Zhou, Chenming] NIOSH, Wireless Commun & Tracking Project, Atlanta, GA 30329 USA. [Waynert, Joseph A.] NIOSH, Elect Syst Safety & Commun Team, Atlanta, GA 30329 USA. RP Zhou, CM (reprint author), NIOSH, Atlanta, GA 30329 USA. NR 39 TC 3 Z9 3 U1 1 U2 8 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1045-9243 EI 1558-4143 J9 IEEE ANTENN PROPAG M JI IEEE Antennas Propag. Mag. PD AUG PY 2015 VL 57 IS 4 BP 88 EP 102 DI 10.1109/MAP.2015.2453881 PG 15 WC Engineering, Electrical & Electronic; Telecommunications SC Engineering; Telecommunications GA CS3YJ UT WOS:000362011400008 ER PT J AU Brennan, B Weber, F Kormelink, R Schnettler, E Bouloy, M Failloux, AB Weaver, SC Fazakerley, JK Fragkoudis, R Harris, M Barr, JN Palese, P Garcia-Sastre, A Dalzie, RG Dutia, BM Lowen, AC Steel, J Randall, RE Duprex, WP Rice, CM Tesh, RB Murphy, FA Ebihara, H Vasconcelos, PFC Nunes, MR Fooks, AR Smith, GL Goodfellow, I Pappu, HR Lamb, RA Paterson, RG Higgs, S Vanlandingham, DL Dietzgen, RG Lodmell, JS Nichol, ST Daly, J Ullman, DE Plyusnin, A Plyusnina, A Efstathiou, S Hewson, R Tordo, N Cherry, S Boutell, C Hosie, MJ Murcia, PR Neil, JC Palmarini, M Patel, AH Willett, BJ Kohl, A McLauchlan, J AF Brennan, Benjamin Weber, Friedemann Kormelink, Richard Schnettler, Esther Bouloy, Michele Failloux, Anna-Bella Weaver, Scott C. Fazakerley, John K. Fragkoudis, Rennos Harris, Mark Barr, John N. Palese, Peter Garcia-Sastre, Adolfo Dalzie, Robert G. Dutia, Bernadette M. Lowen, Anice C. Steel, John Randall, Richard E. Duprex, W. Paul Rice, Charles M. Tesh, Robert B. Murphy, Frederick A. Ebihara, Hideki Vasconcelos, Pedro F. C. Nunes, Marcio R. Fooks, Anthony R. Smith, Geoffrey L. Goodfellow, Ian Pappu, Hanu R. Lamb, Robert A. Paterson, Reay G. Higgs, Stephen Vanlandingham, Dana L. Dietzgen, Ralf G. Lodmell, J. Stephen Nichol, Stuart T. Daly, Janet Ullman, Diane E. Plyusnin, Alexander Plyusnina, Angelina Efstathiou, Stacey Hewson, Roger Tordo, Noel Cherry, Sara Boutell, Chris Hosie, Margaret J. Murcia, Pablo R. Neil, James C. Palmarini, Massimo Patel, Arvind H. Willett, Brian J. Kohl, Alain McLauchlan, John TI In memoriam - Richard M. Elliott (1954-2015) SO JOURNAL OF GENERAL VIROLOGY LA English DT Biographical-Item C1 [Brennan, Benjamin; Schnettler, Esther; Boutell, Chris; Hosie, Margaret J.; Murcia, Pablo R.; Neil, James C.; Palmarini, Massimo; Patel, Arvind H.; Willett, Brian J.; Kohl, Alain; McLauchlan, John] Univ Glasgow, MRC, Ctr Virus Res, Glasgow G61 1QH, Lanark, Scotland. [Weber, Friedemann] Univ Giessen, Inst Virol, Vet Med FB10, D-35392 Giessen, Germany. [Kormelink, Richard] Wageningen Univ, Dept Plant Sci, Virol Lab, NL-6708 PB Wageningen, Netherlands. [Bouloy, Michele; Failloux, Anna-Bella] Inst Pasteur, F-75724 Paris 15, France. [Weaver, Scott C.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. [Fazakerley, John K.; Fragkoudis, Rennos] Pirbright Inst, Woking GU24 0NF, Surrey, England. [Harris, Mark; Barr, John N.] Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England. [Palese, Peter; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dalzie, Robert G.; Dutia, Bernadette M.] Univ Edinburgh, Roslin Inst, Easter Bush EH25 9RG, Midlothian, Scotland. [Lowen, Anice C.; Steel, John] Emory Univ, Sch Med, Rollins Res Ctr, Atlanta, GA 30322 USA. [Randall, Richard E.] Univ St Andrews, Biomol Sci Res Complex, St Andrews KY16 9ST, Fife, Scotland. [Duprex, W. Paul] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA. [Duprex, W. Paul] Boston Univ, Natl Emerging Infect Dis Labs, Boston, MA 02118 USA. [Rice, Charles M.] Rockefeller Univ, Lab Virol & Infect Dis, New York, NY 10065 USA. [Tesh, Robert B.; Murphy, Frederick A.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Ebihara, Hideki] NIAID, Virol Lab, Div Intramural Res, NIH, Hamilton, MT 59840 USA. [Vasconcelos, Pedro F. C.; Nunes, Marcio R.] Minist Saude, Inst Evandro Chagas, Secao Arbovirol & Febres Haemorrag, BR-67030000 Ananindeua, Para, Brazil. [Fooks, Anthony R.] APHA Weybridge, Addlestone KT15 3NB, Surrey, England. [Smith, Geoffrey L.; Goodfellow, Ian] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Virol, Cambridge CB2 2QQ, England. [Pappu, Hanu R.] Washington State Univ, Dept Plant Pathol, Pullman, WA 99164 USA. [Lamb, Robert A.; Paterson, Reay G.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA. [Higgs, Stephen] Kansas State Univ, Biosecur Res Inst, Manhattan, KS 66506 USA. [Vanlandingham, Dana L.] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA. [Dietzgen, Ralf G.] Univ Queensland, St Lucia, Qld 4072, Australia. [Lodmell, J. Stephen] Univ Montana, Div Biol Sci, Missoula, MT 59812 USA. [Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. [Daly, Janet] Univ Nottingham, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England. [Ullman, Diane E.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Plyusnin, Alexander; Plyusnina, Angelina] Univ Helsinki, Dept Virol, FIN-00014 Helsinki, Finland. [Efstathiou, Stacey] Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England. [Hewson, Roger] Publ Hlth England Microbiol Serv, Salisbury SP4 0JG, Wilts, England. [Tordo, Noel] WHO Collaborat Ctr Arboviruses & Viral Haemorrhag, OIE Reference Lab RVFV, F-75724 Paris 15, France. [Tordo, Noel] Inst Pasteur, CCHFV, F-75724 Paris 15, France. [Cherry, Sara] Univ Penn, Philadelphia, PA 19104 USA. RP Brennan, B (reprint author), Univ Glasgow, MRC, Ctr Virus Res, Glasgow G61 1QH, Lanark, Scotland. RI Fooks, Anthony/F-5418-2010; Weaver, Scott/D-6490-2011; OI Palese, Peter/0000-0002-0337-5823; Fazakerley, John/0000-0001-7071-105X; Boutell, Chris/0000-0002-2970-7785; Garcia-Sastre, Adolfo/0000-0002-6551-1827; Daly, Janet/0000-0002-1912-4500; Goodfellow, Ian/0000-0002-9483-510X; Brennan, Benjamin/0000-0003-4707-726X FU Wellcome Trust [097997] NR 1 TC 1 Z9 1 U1 0 U2 8 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD AUG PY 2015 VL 96 BP 1975 EP 1978 DI 10.1099/jgv.0.000241 PN 8 PG 4 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA CS7CZ UT WOS:000362243000001 PM 26315040 ER PT J AU Purdy, MA Forbi, JC Sue, A Layden, JE Switzer, WM Opare-Sem, OK Phillips, RO Khudyakov, YE AF Purdy, Michael A. Forbi, Joseph C. Sue, Amanda Layden, Jennifer E. Switzer, William M. Opare-Sem, Ohene K. Phillips, Richard O. Khudyakov, Yury E. TI A re-evaluation of the origin of hepatitis C virus genotype 2 in West Africa SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID INFECTION; EPIDEMIC; CAMEROON; TRANSMISSION; DIVERSITY; DYNAMICS AB Hepatitis C virus (HCV) is classified into seven genotypes based on genetic diversity, and most genotypes have been found in Africa. Infections with HCV genotype 2 (HCV2) are most prevalent in West Africa and it was suggested that HCV2 originated in West Africa. To better understand the evolutionary epidemiology of HCV2 in Africa, we examined new NS5B sequences of HCV2 strains obtained from Cote d'Ivoire, Ghana and Nigeria sequenced at the Centers for Disease Control and Prevention with those available from West, North and Central Africa. Bayesian phylogeographic analysis using a discrete trait model showed that Ghana was the most likely geographical region for the origin of HCV2. Spread of HCV2 from Ghana did not appear to be through diffusion to adjacent countries along the coast. Rather, it was transmitted from Ghana to many distant countries in Africa, suggesting that certain routes of geographical dissemination were historically more efficient than mere proximity and that the HCV2 epidemic history in West Africa is extremely complex. C1 [Purdy, Michael A.; Forbi, Joseph C.; Sue, Amanda; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Layden, Jennifer E.] Loyola Univ, Dept Publ Hlth Sci, Chicago, IL 60660 USA. [Switzer, William M.] Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA 30333 USA. [Opare-Sem, Ohene K.; Phillips, Richard O.] Kwame Nkrumah Univ Sci & Technol, Dept Med, Kumasi, Ghana. RP Purdy, MA (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM MPurdy@cdc.gov FU Intramural CDC HHS [CC999999]; Medical Research Council [MR/J01477X/1] NR 22 TC 1 Z9 1 U1 1 U2 2 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD AUG PY 2015 VL 96 BP 2157 EP 2164 DI 10.1099/vir.0.000153 PN 8 PG 8 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA CS7CZ UT WOS:000362243000019 PM 25888623 ER PT J AU Friedman, DB Becofsky, K Anderson, LA Bryant, LL Hunter, RH Ivey, SL Belza, B Logsdon, RG Brannon, S Vandenberg, AE Lin, SY AF Friedman, Daniela B. Becofsky, Katie Anderson, Lynda A. Bryant, Lucinda L. Hunter, Rebecca H. Ivey, Susan L. Belza, Basia Logsdon, Rebecca G. Brannon, Sarah Vandenberg, Ann E. Lin, Shih-Yin TI Public perceptions about risk and protective factors for cognitive health and impairment: a review of the literature SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Review DE cognition; Alzheimer's disease; dementia; scoping review; public perceptions; risk factors; protective factors ID ALZHEIMER-DISEASE; OLDER-ADULTS; TRANSLATING SCIENCE; ETHNIC-DIFFERENCES; FAMILY CAREGIVERS; PHYSICAL-ACTIVITY; AGING POPULATION; UNITED-STATES; BRAIN HEALTH; BELIEFS AB Background: Preventing and/or delaying cognitive impairment is a public health priority. To increase awareness of and participation in behaviors that may help maintain cognitive function or reduce risk of impairment, we need to understand public perceptions about risk and protective factors. Methods: We conducted a scoping review of studies examining the public's perceptions about risk and protective factors related to cognitive health and impairment published since the 2007 National Public Health Road Map to Maintaining Cognitive Health. Results: A search of five databases yielded 1,115 documents published between June 2007 and December 2013. Initial review of abstracts identified 90 potentially eligible studies. After full-article review, 30 met inclusion criteria; four additional articles identified in reference lists also met inclusion criteria. Of the 34, 16 studies addressed Alzheimer's disease (AD) specifically, 15 dementia broadly, 5 mild to moderate cognitive impairment, and 8 normal functioning, with some content overlap. Across studies, respondents reported genetics (n = 14 studies), older age (n = 8), stress (n = 7), brain/head injury (n = 6), and mental illness/brain disease (n = 6) as perceived risk factors for AD and dementia. Protective factors most commonly identified for maintaining cognitive health were intellectual/mental stimulation (n = 13), physical activity (n = 12), healthy diet (n = 10), and social/leisure activities (n = 10). Conclusions: Studies identified genetics and older age as key perceived risk factors more so than behaviors such as smoking. Individuals perceived that numerous lifestyle factors (e.g. intellectual stimulation, physical activity) could protect against cognitive impairment, AD, and/or dementia. Results can inform national and international education efforts about AD and other dementias. C1 [Friedman, Daniela B.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA. [Becofsky, Katie] Univ S Carolina, Arnold Sch Publ Hlth, Dept Exercise Sci, Columbia, SC 29208 USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Hlth Aging Program, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Bryant, Lucinda L.; Brannon, Sarah] Univ Colorado, Dept Community & Behav Hlth, Colorado Sch Publ Hlth, Aurora, CO USA. [Hunter, Rebecca H.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Ivey, Susan L.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Belza, Basia] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. [Belza, Basia; Lin, Shih-Yin] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Logsdon, Rebecca G.] Univ Washington, Sch Nursing, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. [Vandenberg, Ann E.] Emory Univ, Dept Med, Ctr Hlth Aging, Atlanta, GA 30322 USA. RP Friedman, DB (reprint author), Univ S Carolina, Arnold Sch Publ Hlth, 915 Greene St,Suite 235, Columbia, SC 29208 USA. EM dbfriedman@sc.edu FU CDC Healthy Aging Program; CDC's Prevention Research Centers Program [U48-DP-001908, U48-DP001938, U48-DP-001944, U48-DP-001936, U48-DP-001911] FX This research is the result of work conducted by the Centers for Disease Control and Prevention (CDC) Healthy Aging Research Network. The CDC Healthy Aging Research Network is a Prevention Research Centers program funded by the CDC Healthy Aging Program. The research was supported in part by cooperative agreements from CDC's Prevention Research Centers Program: U48-DP-001908, U48-DP001938, U48-DP-001944, U48-DP-001936, and U48-DP-001911. NR 52 TC 3 Z9 3 U1 5 U2 21 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD AUG PY 2015 VL 27 IS 8 BP 1263 EP 1275 DI 10.1017/S1041610214002877 PG 13 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CR5LR UT WOS:000361384500004 PM 25592720 ER PT J AU Falkinham, JO Hilborn, ED Arduino, MJ Pruden, A Edwards, MA AF Falkinham, Joseph O., III Hilborn, Elizabeth D. Arduino, Matthew J. Pruden, Amy Edwards, Marc A. TI Epidemiology and Ecology of Opportunistic Premise Plumbing Pathogens: Legionella pneumophila, Mycobacterium avium, and Pseudomonas aeruginosa SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review ID INTENSIVE-CARE-UNIT; NOSOCOMIAL LEGIONNAIRES-DISEASE; WATER DISTRIBUTION-SYSTEMS; MUNICIPAL DRINKING-WATER; ACQUIRED IMMUNODEFICIENCY SYNDROME; COMPLEX PULMONARY-DISEASE; NONTUBERCULOUS MYCOBACTERIA; CYSTIC-FIBROSIS; HOSPITAL WATER; TAP WATER AB BACKGROUND: Legionella pneumophila, Mycobacterium avium, and Pseudomonas aeruginosa are opportunistic premise plumbing pathogens (OPPPs) that persist and grow in household plumbing, habitats they share with humans. Infections caused by these OPPPs involve individuals with preexisting risk factors and frequently require hospitalization. OBJECTIVES: The objectives of this report are to alert professionals of the impact of OPPPs, the fact that 30% of the population may be exposed to OPPPs, and the need to develop means to reduce OPPP exposure. We herein present a review of the epidemiology and ecology of these three bacterial OPPPs, specifically to identify common and unique features. METHODS: A Water Research Foundation-sponsored workshop gathered experts from across the United States to review the characteristics of OPPPs, identify problems, and develop a list of research priorities to address critical knowledge gaps with respect to increasing OPPP-associated disease. DISCUSSION: OPPPs share the common characteristics of disinfectant resistance and growth in biofilms in water distribution systems or premise plumbing. Thus, they share a number of habitats with humans (e.g., showers) that can lead to exposure and infection. The frequency of OPPP-infected individuals is rising and will likely continue to rise as the number of at-risk individuals is increasing. Improved reporting of OPPP disease and increased understanding of the genetic, physiologic, and structural characteristics governing the persistence and growth of OPPPs in drinking water distribution systems and premise plumbing is needed. CONCLUSIONS: Because broadly effective community-level engineering interventions for the control of OPPPs have yet to be identified, and because the number of at-risk individuals will continue to rise, it is likely that OPPP-related infections will continue to increase. However, it is possible that individuals can take measures (e.g., raise hot water heater temperatures and filter water) to reduce home exposures. C1 [Falkinham, Joseph O., III] Virginia Tech, Dept Biol Sci, Blacksburg, VA 24061 USA. [Hilborn, Elizabeth D.] US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Arduino, Matthew J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pruden, Amy; Edwards, Marc A.] Virginia Tech, Dept Civil & Environm Engn, Blacksburg, VA 24061 USA. RP Falkinham, JO (reprint author), Virginia Tech, Dept Biol Sci, Blacksburg, VA 24061 USA. EM jofiii@vt.edu RI Edwards, Marc/J-3557-2012 FU Water Research Foundation [4379] FX A multidisciplinary workshop expert panel authored this review based on the proceedings of the workshop "Research Needs for Opportunistic Pathogens in Premise Plumbing." The workshop was organized and co-chaired by A.P, M.A.E., and J.O.F. III and sponsored by a grant from the Water Research Foundation (Project 4379). NR 169 TC 19 Z9 21 U1 17 U2 68 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD AUG PY 2015 VL 123 IS 8 BP 749 EP 758 DI 10.1289/ehp.1408692 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CQ6CX UT WOS:000360693100015 PM 25793551 ER PT J AU Carlin, DJ Larson, TC Pfau, JC Gavett, SH Shukla, A Miller, A Hines, R AF Carlin, Danielle J. Larson, Theodore C. Pfau, Jean C. Gavett, Stephen H. Shukla, Arti Miller, Aubrey Hines, Ronald TI Current Research and Opportunities to Address Environmental Asbestos Exposures SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID LIBBY AMPHIBOLE EXPOSURE; ANTINUCLEAR AUTOANTIBODIES; MALIGNANT MESOTHELIOMA; CARDIOVASCULAR-DISEASE; FIBROBLAST PHENOTYPE; RADIOGRAPHIC CHANGES; RESPIRATORY-DISEASE; FISCHER-344 RATS; IRON OVERLOAD; C57BL/6 MICE AB Asbestos-related diseases continue to result in approximately 120,000 deaths every year in the United States and worldwide. Although extensive research has been conducted on health effects of occupational exposures to asbestos, many issues related to environmental asbestos exposures remain unresolved. For example, environmental asbestos exposures associated with a former mine in Libby, Montana, have resulted in high rates of nonoccupational asbestos-related disease. Additionally, other areas with naturally occurring asbestos deposits near communities in the United States and overseas are undergoing investigations to assess exposures and potential health risks. Some of the latest public health, epidemiological, and basic research findings were presented at a workshop on asbestos at the 2014 annual meeting of the Society of Toxicology in Phoenix, Arizona. The following focus areas were discussed: a) mechanisms resulting in fibrosis and/or tumor development; b) relative toxicity of different forms of asbestos and other hazardous elongated mineral particles (EMPs); c) proper dose metrics (e.g., mass, fiber number, or surface area of fibers) when interpreting asbestos toxicity; d) asbestos exposure to susceptible populations; and e) using toxicological findings for risk assessment and remediation efforts. The workshop also featured asbestos research supported by the National Institute of Environmental Health Sciences, the Agency for Toxic Substances and Disease Registry, and the U.S. Environmental Protection Agency. Better protection of individuals from asbestos-related health effects will require stimulation of new multidisciplinary research to further our understanding of what constitutes hazardous exposures and risk factors associated with toxicity of asbestos and other hazardous EMPs (e.g., nanomaterials). C1 [Carlin, Danielle J.] NIEHS, Div Extramural Res & Training, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Larson, Theodore C.] ATSDR, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. [Pfau, Jean C.] Idaho State Univ, Dept Biol Sci, Pocatello, ID 83209 USA. [Gavett, Stephen H.; Hines, Ronald] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA. [Shukla, Arti] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT USA. [Miller, Aubrey] NIEHS, Off Director, NIH, DHHS, Bethesda, MD USA. RP Carlin, DJ (reprint author), NIEHS, Div Extramural Res & Training, NIH, 530 Davis Dr,Rm 3102, Morrisville, NC 27560 USA. EM danielle.carlin@nih.gov FU NIEHS NIH HHS [R01 ES021110]; NIGMS NIH HHS [P20 GM103408] NR 57 TC 3 Z9 3 U1 5 U2 24 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD AUG PY 2015 VL 123 IS 8 BP A194 EP A197 DI 10.1289/ehp.1409662 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CQ6CX UT WOS:000360693100001 PM 26230287 ER PT J AU Marks, M Vahi, V Sokana, O Chi, KH Puiahi, E Kilua, G Pillay, A Dalipanda, T Bottomley, C Solomon, AW Mabey, DC AF Marks, Michael Vahi, Ventis Sokana, Oliver Chi, Kai-Hua Puiahi, Elliot Kilua, Georgina Pillay, Allan Dalipanda, Tenneth Bottomley, Christian Solomon, Anthony W. Mabey, David C. TI Impact of Community Mass Treatment with Azithromycin for Trachoma Elimination on the Prevalence of Yaws SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID SINGLE-DOSE AZITHROMYCIN; PAPUA-NEW-GUINEA; HAEMOPHILUS-DUCREYI; TREPONEMA-PALLIDUM; SOLOMON-ISLANDS; SKIN ULCERS; CHILDREN; INFECTION; TRIAL AB Background Community mass treatment with 30mg/kg azithromycin is central to the new WHO strategy for eradicating yaws. Both yaws and trachoma-which is earmarked for elimination by 2020 using a strategy that includes mass treatment with 20mg/kg azithromycin-are endemic in the Pacific, raising the possibility of an integrated approach to disease control. Community mass treatment with azithromycin for trachoma elimination was conducted in the Solomon Islands in 2014. Methods We conducted a study to assess the impact of mass treatment with 20mg/kg azithromycin on yaws. We examined children aged 5-14 years and took blood and lesion samples for yaws diagnosis. Results We recruited 897 children, 6 months after mass treatment. There were no cases of active yaws. Serological evidence of current infection was found in 3.6% (95% CI=2.5-5.0%). This differed significantly between individuals who had and had not received azithromycin (2.8% vs 6.5%, p=0.015); the prevalence of positive serology in 5-14 year-olds had been 21.7% (95% CI=14.6%-30.9%) 6 months prior to mass treatment. Not receiving azithromycin was associated with an odds of 3.9 for infection (p=0.001). National figures showed a 57% reduction in reported cases of yaws following mass treatment. Discussion Following a single round of treatment we did not identify any cases of active yaws in a previously endemic population. We found a significant reduction in latent infection. Our data support expansion of the WHO eradication strategy and suggest an integrated approach to the control of yaws and trachoma in the Pacific may be viable. C1 [Marks, Michael; Solomon, Anthony W.; Mabey, David C.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. [Marks, Michael; Solomon, Anthony W.; Mabey, David C.] Mortimer Market Ctr, Hosp Trop Dis, London, England. [Vahi, Ventis; Sokana, Oliver; Puiahi, Elliot; Dalipanda, Tenneth] Minist Hlth & Med Serv, Honiara, Solomon Islands. [Chi, Kai-Hua; Pillay, Allan] Ctr Dis Control & Prevent, Mol Diagnost & Typing Lab, Lab Reference & Res Branch, DSTDP, Atlanta, GA USA. [Kilua, Georgina] WHO, Western Pacific Reg Off, Honiara, Solomon Islands. [Bottomley, Christian] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England. RP Marks, M (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. EM Michael.marks@lshtm.ac.uk OI Mabey, David/0000-0002-0031-8276; Marks, Michael/0000-0002-7585-4743; Solomon, Anthony/0000-0001-7101-6649 FU Wellcome Trust Clinical Research Fellowship [102807, 098521]; CDC FX MM is supported by a Wellcome Trust Clinical Research Fellowship - 102807. AWS was supported by a Wellcome Trust Intermediate Clinical Fellowship - 098521. Laboratory analyses of swab specimens was funded by CDC. The funders had no role in design or conduct of the studies, the preparation of the manuscript or the decision to submit it for publication. NR 24 TC 6 Z9 6 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD AUG PY 2015 VL 9 IS 8 AR e0003988 DI 10.1371/journal.pntd.0003988 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CQ6IO UT WOS:000360708200063 PM 26241484 ER PT J AU Morin, CW Monaghan, AJ Hayden, MH Barrera, R Ernst, K AF Morin, Cory W. Monaghan, Andrew J. Hayden, Mary H. Barrera, Roberto Ernst, Kacey TI Meteorologically Driven Simulations of Dengue Epidemics in San Juan, PR SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID AEDES-AEGYPTI DIPTERA; TEXAS-MEXICO BORDER; MARK-RELEASE-RECAPTURE; PUERTO-RICO; CLIMATE VARIABILITY; HEMORRHAGIC-FEVER; CULEX-QUINQUEFASCIATUS; POPULATION PARAMETERS; VERTICAL TRANSMISSION; MALARIA TRANSMISSION AB Meteorological factors influence dengue virus ecology by modulating vector mosquito population dynamics, viral replication, and transmission. Dynamic modeling techniques can be used to examine how interactions among meteorological variables, vectors and the dengue virus influence transmission. We developed a dengue fever simulation model by coupling a dynamic simulation model for Aedes aegypti, the primary mosquito vector for dengue, with a basic epidemiological Susceptible-Exposed-Infectious-Recovered (SEIR) model. Employing a Monte Carlo approach, we simulated dengue transmission during the period of 2010-2013 in San Juan, PR, where dengue fever is endemic. The results of 9600 simulations using varied model parameters were evaluated by statistical comparison (r(2)) with surveillance data of dengue cases reported to the Centers for Disease Control and Prevention. To identify the most influential parameters associated with dengue virus transmission for each period the top 1% of best-fit model simulations were retained and compared. Using the top simulations, dengue cases were simulated well for 2010 (r(2) = 0.90, p = 0.03), 2011 (r(2) = 0.83, p = 0.05), and 2012 (r(2) = 0.94, p = 0.01); however, simulations were weaker for 2013 (r(2) = 0.25, p = 0.25) and the entire four-year period (r(2) = 0.44, p = 0.002). Analysis of parameter values from retained simulations revealed that rain dependent container habitats were more prevalent in best-fitting simulations during the wetter 2010 and 2011 years, while human managed (i.e. manually filled) container habitats were more prevalent in best-fitting simulations during the drier 2012 and 2013 years. The simulations further indicate that rainfall strongly modulates the timing of dengue (e.g., epidemics occurred earlier during rainy years) while temperature modulates the annual number of dengue fever cases. Our results suggest that meteorological factors have a time-variable influence on dengue transmission relative to other important environmental and human factors. C1 [Morin, Cory W.] NASA, George C Marshall Space Flight Ctr, Earth Sci Off, Huntsville, AL 35812 USA. [Monaghan, Andrew J.; Hayden, Mary H.] Natl Ctr Atmospher Res, Res Applicat Lab, Boulder, CO USA. [Barrera, Roberto] Ctr Dis Control & Prevent, Dengue Branch, Entomol & Ecol Act, San Juan, PR USA. [Ernst, Kacey] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA. RP Morin, CW (reprint author), NASA, George C Marshall Space Flight Ctr, Earth Sci Off, Huntsville, AL 35812 USA. EM cory.morin@nasa.gov OI Monaghan, Andrew/0000-0002-8170-2359 FU National Oceanic and Atmospheric Administration Regional Integrated Sciences and Assessments program; National Institutes of Health [IR56AI091843, IR01AI091843]; National Institute of Allergy and Infectious Disease; National Science Foundation FX This research was supported in part by the National Oceanic and Atmospheric Administration (noaa.gov) Regional Integrated Sciences and Assessments program (CWM), as well as grants IR56AI091843 and IR01AI091843 from the National Institutes of Health (nih.gov), National Institute of Allergy and Infectious Disease (KE). The National Center for Atmospheric Research (AJM and MHH) is partially funded by the National Science Foundation (nsf.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 78 TC 4 Z9 4 U1 2 U2 20 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD AUG PY 2015 VL 9 IS 8 AR e0004002 DI 10.1371/journal.pntd.0004002 PG 24 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CQ6IO UT WOS:000360708200043 PM 26275146 ER PT J AU Coutts, C Hahn, M AF Coutts, Christopher Hahn, Micah TI Green Infrastructure, Ecosystem Services, and Human Health SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Review DE health; nature; natural environment; greenspace; green infrastructure; urban planning; built environment; ecology ID QUALITY-OF-LIFE; CULEX-TARSALIS DIPTERA; URBAN HEAT-ISLAND; LAND-USE CHANGE; CLIMATE-CHANGE; INFECTIOUS-DISEASES; PHYSICAL-ACTIVITY; NEIGHBORHOOD GREENNESS; NATURAL-ENVIRONMENT; COMMON SPACES AB Contemporary ecological models of health prominently feature the natural environment as fundamental to the ecosystem services that support human life, health, and well-being. The natural environment encompasses and permeates all other spheres of influence on health. Reviews of the natural environment and health literature have tended, at times intentionally, to focus on a limited subset of ecosystem services as well as health benefits stemming from the presence, and access and exposure to, green infrastructure. The sweeping influence of green infrastructure on the myriad ecosystem services essential to health has therefore often been underrepresented. This survey of the literature aims to provide a more comprehensive picturein the form of a primerof the many simultaneously acting health co-benefits of green infrastructure. It is hoped that a more accurately exhaustive list of benefits will not only instigate further research into the health co-benefits of green infrastructure but also promote consilience in the many fields, including public health, that must be involved in the landscape conservation necessary to protect and improve health and well-being. C1 [Coutts, Christopher] Florida State Univ, Dept Urban & Reg Planning, Ctr Demog & Populat Hlth, Tallahassee, FL 32306 USA. [Hahn, Micah] Natl Ctr Atmospher Res, Boulder, CO 80305 USA. [Hahn, Micah] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Coutts, C (reprint author), Florida State Univ, Dept Urban & Reg Planning, Ctr Demog & Populat Hlth, 113 Collegiate Way, Tallahassee, FL 32306 USA. EM ccoutts@fsu.edu; micah.hahn@gmail.com RI Duello, Theresa/P-5752-2015 NR 156 TC 6 Z9 7 U1 20 U2 148 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD AUG PY 2015 VL 12 IS 8 BP 9768 EP 9798 DI 10.3390/ijerph120809768 PG 31 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CQ4PT UT WOS:000360587800075 PM 26295249 ER PT J AU Platt, RN Amman, BR Keith, MS Thompson, CW Bradley, RD AF Platt, Roy N., II Amman, Brian R. Keith, Megan S. Thompson, Cody W. Bradley, Robert D. TI What Is Peromyscus? Evidence from nuclear and mitochondrial DNA sequences suggests the need for a new classification SO JOURNAL OF MAMMALOGY LA English DT Article DE Habromys; Megadontomys; Neotomodon; Osgoodomys; Peromyscus; phylogeny; Podomys; species group; systematics; taxonomy ID CYTOCHROME-B SEQUENCES; PHYLOGENETIC TREE SELECTION; SPECIES GROUP RODENTIA; BIOCHEMICAL SYSTEMATICS; MOLECULAR SYSTEMATICS; MAXIMUM-LIKELIHOOD; GENE; MURIDAE; BOYLII; MEXICO AB The evolutionary relationships between Peromyscus, Habromys, Isthmomys, Megadontomys, Neotomodon, Osgoodomys, and Podomys are poorly understood. In order to further explore the evolutionary boundaries of Peromyscus and compare potential taxonomic solutions for this diverse group and its relatives, we conducted phylogenetic analyses of DNA sequence data from alcohol dehydrogenase (Adh1-I2), beta fibrinogen (Fgb-I7), interphotoreceptor retinoid-binding protein (Rbp3), and cytochrome-b (Cytb). Phylogenetic analyses of mitochondrial and nuclear genes produced similar topologies although levels of nodal support varied. The best-supported topology was obtained by combining nuclear and mitochondrial sequences. No monophyletic Peromyscus clade was supported. Instead, support was found for a clade containing Habromys, Megadontomys, Neotomodon, Osgoodomys, Podomys, and Peromyscus suggesting paraphyly of Peromyscus and confirming previous observations. Our analyses indicated an early divergence of Isthmomys from Peromyscus (approximately 8 million years ago), whereas most other peromyscine taxa emerged within the last 6 million years. To recover a monophyletic taxonomy from Peromyscus and affiliated lineages, we detail 3 taxonomic options in which Habromys, Megadontomys, Neotomodon, Osgoodomys, and Podomys are retained as genera, subsumed as subgenera, or subsumed as species groups within Peromyscus. Each option presents distinct taxonomic challenges, and the appropriate taxonomy must reflect the substantial levels of morphological divergence that characterize this group while maintaining the monophyletic relationships obtained from genetic data. C1 [Platt, Roy N., II] Mississippi State Univ, Dept Biochem Mol Biol Plant Pathol & Entomol, Mississippi State, MS 39762 USA. [Platt, Roy N., II] Mississippi State Univ, Inst Genom Biocomp & Biotechnol, Mississippi State, MS 39762 USA. [Amman, Brian R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [Platt, Roy N., II; Keith, Megan S.; Bradley, Robert D.] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. [Thompson, Cody W.] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA. [Thompson, Cody W.] Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA. [Bradley, Robert D.] Texas Tech Univ Museum, Lubbock, TX 79409 USA. RP Platt, RN (reprint author), Mississippi State Univ, Dept Biochem Mol Biol Plant Pathol & Entomol, 32 Creelman St, Mississippi State, MS 39762 USA. EM neal.platt@gmail.com FU National Institutes of Health [DHHS A141435-01]; National Science Foundation [MCB-0841821, DEB-1020865]; Mississippi Agricultural and Forestry Experiment Station FX We thank D. S. Rogers, M. D. Engstrom, and J. R. Miller for the generation of many of the sequences available in GenBank. We thank J. Light (Texas Cooperative Wildlife Collection, Texas A&M University) and R. J. Baker (Natural Science Research Laboratory, Museum, Texas Tech University) for kindly providing tissue loans. H. R. Huynh, M. R. Mauldin, N. O. Ordonez-Garza, and E. K. Roberts provided helpful comments on previous versions of this manuscript. This research was supported in part by grants from the National Institutes of Health (DHHS A141435-01 to RDB) and the National Science Foundation (MCB-0841821 and DEB-1020865 to RNP). Additional support was provided by the Mississippi Agricultural and Forestry Experiment Station. NR 67 TC 3 Z9 3 U1 4 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2372 EI 1545-1542 J9 J MAMMAL JI J. Mammal. PD AUG PY 2015 VL 96 IS 4 BP 708 EP 719 DI 10.1093/jmammal/gyv067 PG 12 WC Zoology SC Zoology GA CQ4NW UT WOS:000360582700009 PM 26937047 ER PT J AU Deslauriers, C Navon, L AF Deslauriers, Carol Navon, Livia TI A Regional Poison Center's experience in establishing an Ebola hotline SO CLINICAL TOXICOLOGY LA English DT Meeting Abstract DE Poison center; Public health; Ebola hotline C1 [Deslauriers, Carol] Illinois Poison Ctr, Chicago, IL USA. [Navon, Livia] CDC, Off Publ Hlth Preparedness & Response, Chicago, IL USA. EM cdeslaur@ilpoison.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1556-3650 EI 1556-9519 J9 CLIN TOXICOL JI Clin. Toxicol. PD AUG PY 2015 VL 53 IS 7 MA 246 BP 752 EP 752 PG 1 WC Toxicology SC Toxicology GA CP4WN UT WOS:000359883400256 ER PT J AU Guo, X Heflich, RH Dial, SL De, M Richter, PA Mei, N AF Guo, X. Heflich, R. H. Dial, S. L. De, M. Richter, P. A. Mei, N. TI Quantitative Analysis of In Vitro Mutagenicity Induced by Five Chemical Constituents of Tobacco Smoke. SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Meeting Abstract C1 [Guo, X.; Heflich, R. H.; Dial, S. L.; Mei, N.] Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. [De, M.] Ctr Tobacco Prod, Rockville, MD USA. [Richter, P. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 EI 1098-2280 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD AUG PY 2015 VL 56 SU 1 MA 20 BP S54 EP S54 PG 1 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA CP9PJ UT WOS:000360226400097 ER PT J AU Boneva, RS Lin, JMS Unger, ER AF Boneva, Roumiana S. Lin, Jin-Mann S. Unger, Elizabeth R. TI Early menopause and other gynecologic risk indicators for chronic fatigue syndrome in women SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Chronic fatigue syndrome; Hysterectomy; Menopause; Endometriosis; Menstrual abnormalities; Pelvic pain ID HYSTERECTOMY; PROGESTERONE; FIBROMYALGIA; ESTROGEN; NEUROPROTECTION; OOPHORECTOMY; REPLACEMENT; STEROIDS; BRAIN; PAIN AB Objective This study aims to examine whether gynecologic conditions are associated with chronic fatigue syndrome (CFS). Methods This study includes a subset of 157 women from a population-based case-control study in Georgia, United States, conducted in 2004-2009. Gynecologic history was collected using a self-administered questionnaire. Crude odds ratios (ORs) with 95% CIs and ORs adjusted for body mass index and other covariates, where relevant, were estimated for gynecologic conditions between 84 CFS cases and 73 healthy controls. Results Cases and controls were of similar age. Women with CFS reported significantly more gynecologic conditions and surgical operations than controls: menopause status (61.9% vs 37.0%; OR, 2.37; 95% CI, 1.21-4.66), earlier mean age at menopause onset (37.6 vs 48.6 y; adjusted OR, 1.22; 95% CI, 1.09-1.36), excessive menstrual bleeding (73.8% vs 42.5%; adjusted OR, 3.33; 95% CI, 1.66-6.70), bleeding between periods (48.8% vs 23.3%; adjusted OR, 3.31; 95% CI, 1.60-6.86), endometriosis (29.8% vs 12.3%; adjusted OR, 3.67; 95% CI, 1.53-8.84), use of noncontraceptive hormonal preparations (57.1% vs 26.0%; adjusted OR, 2.95; 95% CI, 1.36-6.38), nonmenstrual pelvic pain (26.2% vs 2.7%; adjusted OR, 11.98; 95% CI, 2.57-55.81), and gynecologic surgical operation (65.5% vs 31.5%; adjusted OR, 3.33; 95% CI, 1.66-6.67), especially hysterectomy (54.8% vs 19.2%; adjusted OR, 3.23; 95% CI, 1.46-7.17). Hysterectomy and oophorectomy occurred at a significantly younger mean age in the CFS group than in controls and occurred before CFS onset in 71% of women with records of date of surgical operation and date of CFS onset. Conclusions Menstrual abnormalities, endometriosis, pelvic pain, hysterectomy, and early/surgical menopause are all associated with CFS. Clinicians should be aware of the association between common gynecologic problems and CFS in women. Further work is warranted to determine whether these conditions contribute to the development and/or perpetuation of CFS in some women. C1 [Boneva, Roumiana S.; Lin, Jin-Mann S.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Boneva, RS (reprint author), Ctr Dis Control & Prevent, Mailstop A-30,1600 Clifton Rd, Atlanta, GA 30333 USA. EM rboneva@cdc.gov FU US Government FX This study was supported by the US Government. NR 40 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD AUG PY 2015 VL 22 IS 8 BP 826 EP 834 DI 10.1097/GME.0000000000000411 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CP4KN UT WOS:000359850500007 PM 25647777 ER PT J AU Gutierrez, H Shewade, A Dai, M Mendoza-Arana, P Gomez-Dantes, O Jain, N Khonelidze, I Nabyonga-Orem, J Saleh, K Teerawattananon, Y Nishtar, S Hornberger, J AF Gutierrez, Hialy Shewade, Ashwini Dai, Minghan Mendoza-Arana, Pedro Gomez-Dantes, Octavio Jain, Nishant Khonelidze, Irma Nabyonga-Orem, Juliet Saleh, Karima Teerawattananon, Yot Nishtar, Sania Hornberger, John TI Health Care Coverage Decision Making in Low- and Middle-Income Countries: Experiences from 25 Coverage Schemes SO POPULATION HEALTH MANAGEMENT LA English DT Article ID DISEASE AB Lessons learned by countries that have successfully implemented coverage schemes for health services may be valuable for other countries, especially low- and middle-income countries (LMICs), which likewise are seeking to provide/expand coverage. The research team surveyed experts in population health management from LMICs for information on characteristics of health care coverage schemes and factors that influenced decision-making processes. The level of coverage provided by the different schemes varied. Nearly all the health care coverage schemes involved various representatives and stakeholders in their decision-making processes. Maternal and child health, cardiovascular diseases, cancer, and HIV were among the highest priorities guiding coverage development decisions. Evidence used to inform coverage decisions included medical literature, regional and global epidemiology, and coverage policies of other coverage schemes. Funding was the most commonly reported reason for restricting coverage. This exploratory study provides an overview of health care coverage schemes from participating LMICs and contributes to the scarce evidence base on coverage decision making. Sharing knowledge and experiences among LMICs can support efforts to establish systems for accessible, affordable, and equitable health care. (Population Health Management 2015;18:265-271) C1 [Gutierrez, Hialy; Shewade, Ashwini; Dai, Minghan; Hornberger, John] Cedar Associates LLC, Menlo Pk, CA USA. [Gutierrez, Hialy] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Mendoza-Arana, Pedro] Natl Major Univ San Marcos, Jorge Basadre Headquarters, Lima, Peru. [Gomez-Dantes, Octavio] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Jain, Nishant] Deutsch Gesell Int Zusammenarbeit GIZ GmbH, New Delhi, India. [Khonelidze, Irma] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nabyonga-Orem, Juliet] WHO Uganda Country Off, Hlth Syst & Serv Cluster, Kampala, Uganda. [Saleh, Karima] World Bank, Washington, DC 20433 USA. [Teerawattananon, Yot] Minist Publ Hlth, Int Hlth Policy Program, Nonthaburi, Thailand. [Nishtar, Sania] Heartfile, Islamabad, Pakistan. [Hornberger, John] Stanford Univ, Sch Med, Stanford, CA USA. RP Hornberger, J (reprint author), 3715 Haven Ave Suite 100, Menlo Pk, CA 94305 USA. EM ujch@stanford.edu OI Mendoza-Arana, Pedro/0000-0002-2750-1804 FU Rockefeller Foundation FX The authors received the following financial support for the research, authorship, and/or publication of this article: This work was supported by a research grant from the Rockefeller Foundation. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication. Dr. Hornberger, Ms. Gutierrez, Ms. Dai, and Ms. Shewade are/were employees of Cedar Associates LLC, and received the research grant from the Rockefeller Foundation. Drs. Mendoza-Arana, Gomez-Dantes, Jain, Teerawattananon, and Nabyonga-Orem received honoraria from Cedar Associates LLC for their participation in the current research. Ms. Khonelidze and Dr. Saleh may have previously received research grants and/or honoraria from the Rockefeller Foundation. Dr. Nishtar has previously received research grants and/or honoraria from the Rockefeller Foundation. NR 29 TC 3 Z9 3 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD AUG 1 PY 2015 VL 18 IS 4 BP 265 EP 271 DI 10.1089/pop.2014.0099 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CP5FN UT WOS:000359906800005 PM 25393442 ER PT J AU Miller, ER Shimabukuro, TT Hibbs, BF Moro, PL Broder, KR Vellozzi, C AF Miller, Elaine R. Shimabukuro, Tom T. Hibbs, Beth F. Moro, Pedro L. Broder, Karen R. Vellozzi, Claudia TI Vaccine Safety Resources for Nurses SO AMERICAN JOURNAL OF NURSING LA English DT Article ID GUILLAIN-BARRE-SYNDROME; EVENT REPORTING SYSTEM; UNITED-STATES; IMMUNIZATION; INFLUENZA; CHILDREN; MEASLES; RISK AB The CDC supports nurses in promoting vaccination. C1 [Miller, Elaine R.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30329 USA. [Shimabukuro, Tom T.; Hibbs, Beth F.; Moro, Pedro L.; Broder, Karen R.] Clin Immunizat Safety Assessment Project, Atlanta, GA USA. [Vellozzi, Claudia] CDCs, Div Viral Hepatitis, Prevent Branch, Atlanta, GA USA. RP Miller, ER (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30329 USA. EM emiller@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-936X EI 1538-7488 J9 AM J NURS JI Am. J. Nurs. PD AUG PY 2015 VL 115 IS 8 BP 55 EP 58 DI 10.1097/01.NAJ.0000470404.74424.ee PG 4 WC Nursing SC Nursing GA CP3ND UT WOS:000359785600002 PM 26222474 ER PT J AU Hao, YP Balluz, L Strosnider, H Wen, XJ Li, CY Qualters, JR AF Hao, Yongping Balluz, Lina Strosnider, Heather Wen, Xiao Jun Li, Chaoyang Qualters, Judith R. TI Ozone, Fine Particulate Matter, and Chronic Lower Respiratory Disease Mortality in the United States SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE air pollution; chronic lower respiratory disease mortality; Bayesian hierarchical spatial models ID AIR-POLLUTION; ASSOCIATION; EXPOSURE; RISK; INFLAMMATION; MORBIDITY; CITIES AB Rationale: Short-term effects of air pollution exposure on respiratory disease mortality are well established. However, few studies have examined the effects of long-term exposure, and among those that have, results are inconsistent. Objectives: To evaluate long-term association between ambient ozone, fine particulate matter (PM2.5, particles with an aerodynamic diameter of 2.5 mu m or less), and chronic lower respiratory disease (CLRD) mortality in the contiguous United States. Methods: We fit Bayesian hierarchical spatial Poisson models, adjusting for five county-level covariates (percentage of adults aged >= 65 years, poverty, lifetime smoking, obesity, and temperature), with random effects at state and county levels to account for spatial heterogeneity and spatial dependence. Measurements and Main Results: We derived county-level average daily concentration levels for ambient ozone and PM2.5 for 2001-2008 from the U.S. Environmental Protection Agency's down-scaled estimates and obtained 2007-2008 CLRD deaths from the National Center for Health Statistics. Exposure to ambient ozone was associated with an increased rate of CLRD deaths, with a rate ratio of 1.05 (95% credible interval, 1.01-1.09) per 5-ppb increase in ozone; the association between ambient PM2.5 and CLRD mortality was positive but statistically insignificant (rate ratio, 1.07; 95% credible interval, 0.99-1.14). Conclusions: This study links air pollution exposure data with CLRD mortality for all 3,109 contiguous U.S. counties. Ambient ozone may be associated with an increased rate of death from CLRD in the contiguous United States. Although we adjusted for selected county-level covariates and unobserved influences through Bayesian hierarchical spatial modeling, the possibility of ecologic bias remains. C1 [Hao, Yongping; Balluz, Lina; Strosnider, Heather; Wen, Xiao Jun; Li, Chaoyang; Qualters, Judith R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. RP Hao, YP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C-25, Atlanta, GA 30329 USA. EM yhao@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 5 Z9 6 U1 6 U2 28 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD AUG 1 PY 2015 VL 192 IS 3 BP 337 EP 341 DI 10.1164/rccm.201410-1852OC PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CO5CZ UT WOS:000359178500015 PM 26017067 ER PT J AU Osoro, EM Munyua, P Omulo, S Ogola, E Ade, F Mbatha, P Mbabu, M Ng'ang'a, Z Kairu, S Maritim, M Thumbi, SM Bitek, A Gaichugi, S Rubin, C Njenga, K Guerra, M AF Osoro, Eric Mogaka Munyua, Peninah Omulo, Sylvia Ogola, Eric Ade, Fredrick Mbatha, Peter Mbabu, Murithi Ng'ang'a, Zipporah Kairu, Salome Maritim, Marybeth Thumbi, Samuel M. Bitek, Austine Gaichugi, Stella Rubin, Carol Njenga, Kariuki Guerra, Marta TI Strong Association between Human and Animal Brucella Seropositivity in a Linked Study in Kenya, 2012-2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RISK-FACTORS; LIVESTOCK BRUCELLOSIS; BOVINE BRUCELLOSIS; CATTLE; SEROPREVALENCES; AREA; EPIDEMIOLOGY; PREVALENCE; INFECTION; DISTRICT AB Brucellosis is a common bacterial zoonotic infection but data on the prevalence among humans and animals is limited in Kenya. A cross-sectional survey was conducted in three counties practicing different livestock production systems to simultaneously assess the seroprevalence of, and risk factors for brucellosis among humans and their livestock (cattle, sheep, camels, and goats). A two-stage cluster sampling method with random selection of sublocations and households was conducted. Blood samples were collected from humans and animals and tested for Brucella immunoglobulin G (IgG) antibodies. Human and animal individual seroprevalence was 16% and 8%, respectively. Household and herd seroprevalence ranged from 5% to 73% and 6% to 68%, respectively. There was a 6-fold odds of human seropositivity in households with a seropositive animal compared with those without. Risk factors for human seropositivity included regular ingestion of raw milk (adjusted odds ratio [aOR] = 3.5, 95% confidence interval [CI] = 2.8-4.4), exposure to goats (herding, milking, and feeding) (aOR = 3.1, 95% Cl = 2.5-3.8), and handling of animal hides (aOR = 1.8, 95% CI = 1.5-2.2). Attaining at least high school education and above was a protective factor for human seropositivity (aOR = 0.3, 95% CI = 0.3-0.4). This linked study provides evidence of a strong association between human and animal seropositivity at the household level. C1 [Osoro, Eric Mogaka] Minist Hlth, Dept Prevent & Promot Hlth, Nairobi, Kenya. [Munyua, Peninah; Rubin, Carol; Njenga, Kariuki] Ctr Dis Control & Prevent Kenya, Div Global Hlth Protect, Nairobi, Kenya. [Omulo, Sylvia; Thumbi, Samuel M.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA. Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya. [Mbatha, Peter; Mbabu, Murithi; Kairu, Salome; Bitek, Austine; Gaichugi, Stella] Minist Agr Livestock & Fisheries, Directorate Vet Serv, Nairobi, Kenya. [Ng'ang'a, Zipporah] Jomo Kenyatta Univ Agr & Technol, Coll Hlth Sci, Nairobi, Kenya. [Maritim, Marybeth] Univ Nairobi, Coll Hlth Sci, Nairobi, Kenya. US Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA USA. RP Osoro, EM (reprint author), Minist Hlth, Zoonot Dis Unit, Dept Prevent & Promot Hlth, POB 20811-00202, Nairobi, Kenya. EM eosoro@zdukenya.org; ikg2@cdc.gov; sylvia.omulo@email.wsu.edu; eogola@kemricdc.org; fade@kemricdc.org; mbathapeterm@yahoo.com; murithimbabu@yahoo.com; zipnganga@gmail.com; swwanyoike@yahoo.com; mcmaritim@yahoo.com; thumbi.mwangi@wsu.edu; abitek@zdukenya.org; gaichugi@yahoo.com; carolrubin.dvm@gmail.com; knjenga@kemri.org; hzg4@cdc.gov FU U.S. Department of Defense's Defense Threat Reduction Agency; U.S. Centers for Disease Control and Prevention FX Financial support was provided by the U.S. Department of Defense's Defense Threat Reduction Agency and U.S. Centers for Disease Control and Prevention. NR 43 TC 5 Z9 5 U1 2 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2015 VL 93 IS 2 BP 224 EP 231 DI 10.4269/ajtmh.15-0113 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CO7GK UT WOS:000359327400007 PM 26101275 ER PT J AU Eberhard, ML Thiele, EA Yembo, GE Yibi, MS Cama, VA Ruiz-Tiben, E AF Eberhard, Mark L. Thiele, Elizabeth A. Yembo, Gole E. Yibi, Makoy S. Cama, Vitaliano A. Ruiz-Tiben, Ernesto TI Case Report: Thirty-Seven Human Cases of Sparganosis from Ethiopia and South Sudan Caused by Spirometra Spp. SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID LIONS PANTHERA-LEO; COPROLOGICAL SURVEY; CROCUTA-CROCUTA; EAST-AFRICA; IDENTIFICATION; PARASITE; MEDINENSIS; TAPEWORMS; EMERGENCE; NUCLEAR AB Thirty-seven unusual specimens, three from Ethiopia and 34 from South Sudan, were submitted since 2012 for further identification by the Ethiopian Dracunculiasis Eradication Program (EDEP) and the South Sudan Guinea Worm Eradication Program (SSGWEP), respectively. Although the majority of specimens emerged from sores or breaks in the skin, there was concern that they did not represent bona fide cases of Dracunadus medinensis and that they needed detailed examination and identification as provided by the World Health Organization Collaborating Center (WHO CC) at Centers for Disease Control and Prevention (CDC). All 37 specimens were identified on microscopic study as larval tapeworms of the spargana type, and DNA sequence analysis of seven confirmed the identification of Spirometra sp. Age of cases ranged between 7 and 70 years (mean 25 years); 21 (57%) patients were male and 16 were female. The presence of spargana in open skin lesions is somewhat atypical, but does confirm the fact that populations living in these remote areas are either ingesting infected copepods in unsafe drinking water or, more likely, eating poorly cooked paratenic hosts harboring the parasite. C1 [Eberhard, Mark L.; Thiele, Elizabeth A.; Cama, Vitaliano A.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. Fed Minist Hlth, Ethiopia Dracunculiasis Eradicat Program, Addis Ababa, Ethiopia. Minist Hlth, South Sudan Guinea Worm Eradicat Program, Juba, Sudan. [Ruiz-Tiben, Ernesto] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. RP Eberhard, ML (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM mlel@cdc.gov; xas4@cdc.gov; gole_ejeta@yahoo.com; makoy@cartercenter-ssudan.com; vec5@cdc.gov; eruizt@emory.edu RI Thiele, Elizabeth/F-2590-2016 OI Thiele, Elizabeth/0000-0001-9235-2019 NR 26 TC 3 Z9 3 U1 1 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2015 VL 93 IS 2 BP 350 EP 355 DI 10.4269/ajtmh.15-0236 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CO7GK UT WOS:000359327400029 PM 26055739 ER PT J AU Pastula, DM Johnson, DKH White, JL Dupuis, AP Fischer, M Staples, JE AF Pastula, Daniel M. Johnson, Diep K. Hoang White, Jennifer L. Dupuis, Alan P., II Fischer, Marc Staples, J. Erin TI Jamestown Canyon Virus Disease in the United States-2000-2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID WHITE-TAILED DEER; BUNYAMWERA SEROGROUP VIRUSES; SNOWSHOE HARE VIRUSES; CALIFORNIA GROUP; SEROLOGIC EVIDENCE; NEUTRALIZING ANTIBODIES; AEDES MOSQUITOS; ENZOOTIC FOCUS; ARBOVIRUS SURVEILLANCE; DELMARVA PENINSULA AB Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus in the California serogroup that can cause an acute febrile illness, meningitis, or meningoencephalitis. We describe epidemiologic and clinical features for JCV disease cases occurring in the United States during 2000-2013. A case of JCV disease was defined as an acute illness in a person with laboratory evidence of a recent JCV infection. During 2000-2013, we identified 31 cases of JCV disease in residents of 13 states. The median age was 48 years (range, 10-69) and 21(68%) were male. Eleven (35%) case patients had meningoencephalitis, 6 (19%) meningitis, 7 (23%) fever without neurologic involvement, and 7 (23%) had an unknown clinical syndrome. Fifteen (48%) were hospitalized and there were no deaths. Health-care providers and public health officials should consider JCV disease in the differential diagnoses of viral meningitis and encephalitis, obtain appropriate specimens for testing, and report cases to public health authorities. C1 Ctr Dis Control & Prevent, EIS Program Off, Atlanta, GA USA. Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Johnson, Diep K. Hoang] Wisconsin Dept Hlth Serv, Div Publ Hlth, Madison, WI USA. [White, Jennifer L.] New York State Dept Hlth, Albany, NY USA. Wadsworth Ctr, Albany, NY USA. RP Staples, JE (reprint author), CDC, Arboviral Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd,Mailstop P-02, Ft Collins, CO 80521 USA. EM dpastula@cdc.gov; Dicp.HoangJohnson@dhs.wisconsin.gov; jennifer.white@health.ny.gov; alan.dupuis@health.ny.gov; mfischer@cdc.gov; estaples@cdc.gov FU Centers for Disease Control and Prevention Epidemiology Laboratory and Capacity Cooperative Agreement FX This study was funded in part by the Centers for Disease Control and Prevention Epidemiology Laboratory and Capacity Cooperative Agreement. NR 52 TC 4 Z9 4 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2015 VL 93 IS 2 BP 384 EP 389 DI 10.4269/ajtmh.15-0196 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CO7GK UT WOS:000359327400035 PM 26033022 ER PT J AU Nolen, LD Osadebe, L Katomba, J Likofata, J Mukadi, D Monroe, B Doty, J Kalemba, L Malekani, J Kabamba, J Bomponda, PL Lokota, JI Balilo, MP Likafi, T Lushima, RS Tamfum, JJM Okitolonda, EW McCollum, AM Reynolds, MG AF Nolen, Leisha Diane Osadebe, Lynda Katomba, Jacques Likofata, Jacques Mukadi, Daniel Monroe, Benjamin Doty, Jeffrey Kalemba, Lem's Malekani, Jean Kabamba, Joelle Bomponda, Pierre Lokwa Lokota, Jules Inonga Balilo, Marcel Pie Likafi, Toutou Lushima, Robert Shongo Tamfum, Jean-Jacques Muyembe Okitolonda, Emile Wemakoy McCollum, Andrea M. Reynolds, Mary G. TI Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID VIRUS; TRANSMISSION; ORTHOPOXVIRUS; SMALLPOX; OUTBREAK; FEATURES; AFRICA; ASSAYS AB An increased incidence of monkeypox (MPX) infections in the Democratic Republic of the Congo was noted by the regional surveillance system in October 2013. Little information exists regarding how MPX is introduced into the community and the factors associated with transmission within the household. Sixty-eight wild animals were collected and tested for Orthopoxvirus. Two of three rope squirrels (Funisciurus sp.) were positive for antibodies to Orthopoxviruses; however, no increased risk was associated with the consumption or preparation of rope squirrels. A retrospective cohort investigation and a case control investigation were performed to identify risk factors affecting the introduction of monkeypox virus (MPXV) into the community and transmission within the home. School-age males were the individuals most frequently identified as the first person infected in the household and were the group most frequently affected overall. Risk factors of acquiring MPXV in a household included sleeping in the same room or bed, or using the same plate or cup as the primary case. There was no significant risk associated with eating or processing of wild animals. Activities associated with an increased risk of MPXV transmission all have potential for virus exposure to the mucosa. C1 [Nolen, Leisha Diane] US Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA 30329 USA. US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Osadebe, Lynda; Monroe, Benjamin; Doty, Jeffrey; Kabamba, Joelle; McCollum, Andrea M.; Reynolds, Mary G.] US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. Minstere Sante, Kinshasa, DEM REP CONGO. US Ctr Dis Control & Prevent, Field Epidemiol Training Program, Kinshasa, DEM REP CONGO. Natl Inst Biomed Res, Kinshasa, DEM REP CONGO. US Ctr Dis Control & Prevent Kinshasa, Kinshasa, DEM REP CONGO. [Kalemba, Lem's; Malekani, Jean] Univ Kinshasa, Dept Biol, Kinshasa, DEM REP CONGO. Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO. [Katomba, Jacques; Likofata, Jacques] Minist Sante, Dept Epidemiol, Kinshasa, DEM REP CONGO. [Mukadi, Daniel] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Kinshasa, DEM REP CONGO. [Balilo, Marcel Pie; Likafi, Toutou] Minist Sante, Tshuapa Hlth Dist, Dept Hemorrhag Fever & Monkeypox, Tshuapa, DEM REP CONGO. [Lushima, Robert Shongo] Minist Hlth, Surveillance, Kinshasa, DEM REP CONGO. [Tamfum, Jean-Jacques Muyembe] Minist Hlth, Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO. [Okitolonda, Emile Wemakoy] Univ Kinshasa, Ctr HIV AIDS Strateg Informat, Kinshasa, DEM REP CONGO. RP Nolen, LD (reprint author), US Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM xdf8@cdc.gov; losadebe@gmail.com; jxkk2000@gmail.com; jacqueslikofata@gmail.com; drmukadi@gmail.com; ihd2@cdc.gov; uwb7@cdc.gov; lemskalemba@yahoo.com; elevagefaune@yahoo.fr; jlz7@cdc.gov; Plbompond@yahoo.fr; JulnLokoto@yahoo.fr; marcelbalilopie@yahoo.fr; toutoulikafi@gmail.com; robert_shongo@yahoo.fr; muyembejj@gmail.com; okitow@yahoo.fr; azv4@cdc.gov; nzr6@cdc.gov NR 19 TC 3 Z9 3 U1 2 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2015 VL 93 IS 2 BP 410 EP 415 DI 10.4269/ajtmh.15-0168 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CO7GK UT WOS:000359327400042 PM 26013374 ER PT J AU Moore, CA Yoon, PW Edmonds, LD Erickson, JD AF Moore, Cynthia A. Yoon, Paula W. Edmonds, Larry D. Erickson, J. David TI Editorial perspectives from the founding CDC leadership of the National Birth Defects Prevention study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Editorial Material ID NEURAL-TUBE DEFECTS C1 [Moore, Cynthia A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Yoon, Paula W.] Ctr Dis Control & Prevent, Div Hlth Informat & Surveillance, Atlanta, GA USA. [Edmonds, Larry D.; Erickson, J. David] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Moore, CA (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM cam0@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD AUG PY 2015 VL 103 IS 8 BP 649 EP 651 DI 10.1002/bdra.23393 PG 3 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CP2XJ UT WOS:000359740800001 PM 26069218 ER PT J AU Reefhuis, J Gilboa, SM Anderka, M Browne, ML Feldkamp, ML Hobbs, CA Jenkins, MM Langlois, PH Newsome, KB Olshan, AF Romitti, PA Shapira, SK Shaw, GM Tinker, SC Honein, MA AF Reefhuis, Jennita Gilboa, Suzanne M. Anderka, Marlene Browne, Marilyn L. Feldkamp, Marcia L. Hobbs, Charlotte A. Jenkins, Mary M. Langlois, Peter H. Newsome, Kimberly B. Olshan, Andrew F. Romitti, Paul A. Shapira, Stuart K. Shaw, Gary M. Tinker, Sarah C. Honein, Margaret A. CA Natl Birth Defects Prevention Stud TI The national birth defects prevention study: A review of the methods SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defects; case-control; congenital anomalies; epidemiology; genetics; methods; pregnancy ID POLYCYCLIC AROMATIC-HYDROCARBONS; CONGENITAL HEART-DEFECTS; OCCUPATIONAL-EXPOSURE; BUCCAL CYTOBRUSHES; MATERNAL SMOKING; LIFE EVENTS; DNA; MALFORMATIONS; COLLECTION; MUTATIONS AB BackgroundThe National Birth Defects Prevention Study (NBDPS) is a large population-based multicenter case-control study of major birth defects in the United States. MethodsData collection took place from 1998 through 2013 on pregnancies ending between October 1997 and December 2011. Cases could be live born, stillborn, or induced terminations, and were identified from birth defects surveillance programs in Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah. Controls were live born infants without major birth defects identified from the same geographical regions and time periods as cases by means of either vital records or birth hospitals. Computer-assisted telephone interviews were completed with women between 6 weeks and 24 months after the estimated date of delivery. After completion of interviews, families received buccal cell collection kits for the mother, father, and infant (if living). ResultsThere were 47,832 eligible cases and 18,272 eligible controls. Among these, 32,187 (67%) and 11,814 (65%), respectively, provided interview information about their pregnancies. Buccal cell collection kits with a cytobrush for at least one family member were returned by 19,065 case and 6,211 control families (65% and 59% of those who were sent a kit). More than 500 projects have been proposed by the collaborators and over 200 manuscripts published using data from the NBDPS through December 2014. ConclusionThe NBDPS has made substantial contributions to the field of birth defects epidemiology through its rigorous design, including case classification, detailed questionnaire and specimen collection, large study population, and collaborative activities across Centers. Birth Defects Research (Part A) 103:656-669, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Reefhuis, Jennita; Gilboa, Suzanne M.; Jenkins, Mary M.; Newsome, Kimberly B.; Shapira, Stuart K.; Tinker, Sarah C.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Anderka, Marlene] Massachusetts Dept Publ Hlth, Boston, MA USA. [Browne, Marilyn L.] New York State Dept Hlth, Albany, NY USA. [Browne, Marilyn L.] Univ Albany, Sch Publ Hlth, Rensselaer, NY USA. [Feldkamp, Marcia L.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Hobbs, Charlotte A.] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA. [Langlois, Peter H.] Texas Dept State Hlth Serv, Austin, TX USA. [Olshan, Andrew F.] Univ N Carolina, Chapel Hill, NC USA. [Romitti, Paul A.] Univ Iowa, Iowa City, IA USA. [Shaw, Gary M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Reefhuis, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30333 USA. EM nzr5@cdc.gov FU Centers for Disease Control and Prevention; NIH [DK56350] FX The Centers for Disease Control and Prevention supported the National Birth Defects Prevention Study and the analysis of data from this study. Funds for part of the nutrient database work were provided by NIH DK56350 granted to the University of North Carolina Department of Nutrition Clinical Research Center, Nutrition Epidemiology Core. Coding of drug information in NBDPS used the Slone Drug Dictionary, under license from the Slone Epidemiology Center at Boston University, Boston, MA. NR 29 TC 18 Z9 18 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD AUG PY 2015 VL 103 IS 8 BP 656 EP 669 DI 10.1002/bdra.23384 PG 14 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CP2XJ UT WOS:000359740800003 PM 26033852 ER PT J AU Dawson, AL Razzaghi, H Arth, A Canfield, MA Parker, SE Reefhuis, J AF Dawson, April L. Razzaghi, Hilda Arth, Annelise Canfield, Mark A. Parker, Samantha E. Reefhuis, Jennita CA Natl Birth Defects Prevention Stud TI Maternal exposures in the National Birth Defects Prevention Study: Time trends of selected exposures SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defects; case control studies; maternal exposure ID BODY-MASS INDEX; UNITED-STATES; RISK-FACTORS; FOLIC-ACID; PREPREGNANCY OBESITY; PREGNANCY; PARTICIPATION; MALFORMATIONS; MEDICATION; WOMEN AB BackgroundOur objective was to describe time trends in selected pregnancy exposures in the National Birth Defects Prevention Study (NBDPS). MethodsWe analyzed data from the NBDPS, a multi-site case-control study of major birth defects, for mothers of live-born infants without birth defects (controls), with an expected date of delivery (EDD) from 1998 to 2011. Mothers from the 10 participating centers across the United States were interviewed by phone between 6 weeks and 2 years after the EDD. We focused on maternal race/ethnicity and five maternal risk factors: obesity, use of folic acid-containing multivitamins, opioid analgesics, selective serotonin reuptake inhibitors, and loratadine because of their prevalence of use and some reports of associations with major birth defects. Prevalence time trends were examined using the Kendall's test statistic. ResultsThe exposure trend analysis included 11,724 control mothers with EDDs from 1998 to 2011. We observed a significant increase in obesity prevalence among control mothers, as well as use of selective serotonin reuptake inhibitors and loratadine. We also observed an increase in periconceptional use of folic acid-containing multivitamins. Some of the time trends varied by race/ethnicity. No remarkable trend in the overall use of opioid analgesics was observed. The racial/ethnic distribution of mothers changed slightly during the study period. ConclusionLong-term, population-based case-control studies continue to be an effective way to assess exposure-birth defects associations and provide guidance to health care providers. However, investigators examining rare outcomes covering many years of data collection need to be cognizant of time trends in exposures. Birth Defects Research (Part A) 103:703-712, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Dawson, April L.; Razzaghi, Hilda; Arth, Annelise; Reefhuis, Jennita] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Arth, Annelise] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Parker, Samantha E.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Dawson, AL (reprint author), 1600 Clifton Rd,MS-E86, Atlanta, GA 30333 USA. EM isp3@cdc.gov OI /0000-0002-7193-077X FU Oak Ridge Institute for Science and Education; Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001] FX Contract grant sponsor: Oak Ridge Institute for Science and Education.; Contract grant sponsor: Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study; contract grant numbers: PA 96043; PA 02081; FOA DD09-001. NR 44 TC 2 Z9 2 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD AUG PY 2015 VL 103 IS 8 BP 703 EP 712 DI 10.1002/bdra.23377 PG 10 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CP2XJ UT WOS:000359740800007 PM 25884728 ER PT J AU Tinker, SC Carmichael, SL Anderka, M Browne, ML Conway, KMC Meyer, RE Nembhard, WN Olney, RS Reefhuis, J AF Tinker, Sarah C. Carmichael, Suzan L. Anderka, Marlene Browne, Marilyn L. Conway, Kristin M. Caspers Meyer, Robert E. Nembhard, Wendy N. Olney, Richard S. Reefhuis, Jennita CA Birth Defects Study Evaluate Pregn TI Next steps for birth defects research and prevention: The birth defects study to evaluate pregnancy exposures (BD-STEPS) SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defects; congenital anomalies; case-control; epidemiology; pregnancy ID ASTHMA MEDICATION USE; UNITED-STATES; BLOOD SPOTS; RISK; ADULTS; PREVALENCE; OVERWEIGHT; DEPRESSION; OBESITY AB BackgroundThe Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS) is a population-based, multi-Center case-control study of modifiable risk factors for selected birth defects in the United States. BD-STEPS is the second major research effort of the Centers for Birth Defects Research and Prevention, which extends and expands the initial research effort, the National Birth Defects Prevention Study (NBDPS). MethodsBD-STEPS focuses on 17 categories of structural birth defects selected based on severity, prevalence, consistent ascertainment, and previous findings that warrant additional research. Cases are identified through existing birth defects surveillance programs; controls are from vital records or birth hospital logs from the same catchment area. BD-STEPS uses a standardized computer-assisted telephone interview to collect information from case and control mothers on topics including demographics, health conditions, and medication use. Following the maternal interview, selected Centers request permission to sample residual newborn screening blood spots from state repositories for genetic analyses. New components planned for BD-STEPS include linkages with external datasets and use of online questionnaires to collect in-depth information on selected exposures. ResultsBD-STEPS extends NBDPS by continuing to collect data on many exposures that were assessed in NBDPS, allowing data from both studies to be combined and providing an unprecedented sample size to analyze rare exposures. BD-STEPS expands upon NBDPS by collecting more detailed information on existing exposures as well as new exposures. ConclusionThe goal of BD-STEPS is to provide women and healthcare providers with information they need to make decisions to promote the healthiest pregnancy possible. Birth Defects Research (Part A) 103:733-740, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Tinker, Sarah C.; Olney, Richard S.; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Carmichael, Suzan L.] Stanford Univ, Dept Pediat, Div Neonatal & Dev Med, Stanford, CA 94305 USA. [Anderka, Marlene] Massachusetts Dept Publ Hlth, Ctr Birth Defects Res & Prevent, Boston, MA USA. [Browne, Marilyn L.] New York State Dept Hlth, Congenital Malformat Registry, Albany, NY USA. [Conway, Kristin M. Caspers] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Meyer, Robert E.] State Ctr Hlth Stat, North Carolina Div Publ Hlth, Birth Defects Monitoring Program, Raleigh, NC USA. [Nembhard, Wendy N.] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA. RP Tinker, SC (reprint author), 1600 Clifton Rd NE,Mail Stop E86, Atlanta, GA 30333 USA. EM zzu9@cdc.gov FU Centers for Disease Control and Prevention [FOA DD-13-003] FX This work was supported through a cooperative agreement under FOA DD-13-003 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention for participation in the Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS). NR 38 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD AUG PY 2015 VL 103 IS 8 BP 733 EP 740 DI 10.1002/bdra.23373 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CP2XJ UT WOS:000359740800012 PM 25846741 ER PT J AU Vu, AT Taylor, KM Holman, MR Ding, YS Hearn, B Watson, CH AF Vu, An T. Taylor, Kenneth M. Holman, Matthew R. Ding, Yan S. Hearn, Bryan Watson, Clifford H. TI Polycyclic Aromatic Hydrocarbons in the Mainstream Smoke of Popular US Cigarettes SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Article ID TOTAL PARTICULATE MATTER; TOBACCO-SMOKE; BENZO(A)PYRENE AB The mainstream smoke yields of 14 polycyclic aromatic hydrocarbons (PAHs) were determined for 50 commercial U.S. cigarettes using a validated GC/MS method with the International Organization of Standardization (ISO) and Canadian Intense (CI) smoking machine regimens. PAN mainstream smoke deliveries vary widely among the commercial cigarettes with the ISO smoking regimen primarily because of differing filter ventilation. The more abundant, lower molecular weight PAHs such as naphthalene, fluorene, and phenanthrene predominantly comprise the total PAN yields. In contrast, delivery yields of high molecular weight PAHs such as benzo [b]fluoranthene, benzo[e]pyrene, benzo[k]fluoranthene, and benzo[a]pyrene (BaP) are much lower. Comparative analysis of PAHs deliveries shows brand specific differences. Correlation analysis shows strong positive associations between BaP and most of the other PAHs as well as total PAHs. The results suggest that BaP may be a representative marker for other PAN constituents in cigarette smoke generated from similarly blended tobacco, particularly those PAHs with similar molecular weights and chemical structures. C1 [Vu, An T.; Taylor, Kenneth M.; Holman, Matthew R.] US FDA, Off Sci, Ctr Tobacco Prod, Silver Spring, MD 20993 USA. [Ding, Yan S.; Hearn, Bryan; Watson, Clifford H.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Taylor, KM (reprint author), US FDA, Off Sci, Ctr Tobacco Prod, 10903 New Hampshire Ave,Bldg 32, Silver Spring, MD 20993 USA. EM Kenneth.Taylor@fda.hhs.gov FU U.S. Food and Drug Administration, Center for Tobacco Products FX This research was funded by the U.S. Food and Drug Administration, Center for Tobacco Products. NR 21 TC 5 Z9 5 U1 5 U2 21 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0893-228X EI 1520-5010 J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD AUG PY 2015 VL 28 IS 8 BP 1616 EP 1626 DI 10.1021/acs.chemrestox.5b00190 PG 11 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA CP4AL UT WOS:000359824300012 PM 26158771 ER PT J AU Davis, NL Barnett, EJ Miller, WC Dow, A Chasela, CS Hudgens, MG Kayira, D Tegha, G Ellington, SR Kourtis, AP van der Horst, C Jamieson, DJ Juliano, JJ AF Davis, Nicole L. Barnett, Eric J. Miller, William C. Dow, Anna Chasela, Charles S. Hudgens, Michael G. Kayira, Dumbani Tegha, Gerald Ellington, Sascha R. Kourtis, Athena P. van der Horst, Charles Jamieson, Denise J. Juliano, Jonathan J. TI Impact of Daily Cotrimoxazole on Clinical Malaria and Asymptomatic Parasitemias in HIV-Exposed, Uninfected Infants SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE antifolate resistance; cotrimoxazole; HIV; infant; malaria ID PLASMODIUM-FALCIPARUM PARASITEMIA; INSECTICIDE-TREATED BEDNETS; SUB-SAHARAN AFRICA; UGANDAN CHILDREN; TRIMETHOPRIM-SULFAMETHOXAZOLE; PROPHYLACTIC TREATMENT; HIV-1-INFECTED ADULTS; HEALTH OUTCOMES; TRANSMISSION; RESISTANCE AB Background. Cotrimoxazole preventive therapy (CPT) is recommended for all human immunodeficiency virus (HIV)-exposed infants to avoid opportunistic infections. Cotrimoxazole has antimalarial effects and appears to reduce clinical malaria infections, but the impact on asymptomatic malaria infections is unknown. Methods. We conducted an observational cohort study using data and dried blood spots (DBSs) from the Breastfeeding, Antiretrovirals and Nutrition study to evaluate the impact of CPT on malaria infection during peak malaria season in Lilongwe, Malawi. We compared malaria incidence 1 year before and after CPT implementation (292 and 682 CPT-unexposed and CPT-exposed infants, respectively), including only infants who remained HIV negative by 36 weeks of age. Malaria was defined as clinical, asymptomatic (using DBSs at 12, 24, and 36 weeks), or a composite outcome of clinical or asymptomatic. Linear and binomial regression with generalized estimating equations were used to estimate the association between CPT and malaria. Differences in characteristics of parasitemias and drug resistance polymorphisms by CPT status were also assessed in the asymptomatic infections. Results. CPT was associated with a 70% (95% confidence interval, 53%-81%) relative reduction in the risk of asymptomatic infection between 6 and 36 weeks of age. CPT appeared to provide temporary protection against clinical malaria and more sustained protection against asymptomatic infections, with no difference in parasitemia characteristics. Conclusions. CPT appears to reduce overall malaria infections, with more prolonged impacts on asymptomatic infections. Asymptomatic infections are potentially important reservoirs for malaria transmission. Therefore, CPT prophylaxis may have important individual and public health benefits. C1 [Davis, Nicole L.; Miller, William C.; Dow, Anna] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Davis, Nicole L.; Barnett, Eric J.; Miller, William C.; van der Horst, Charles; Juliano, Jonathan J.] Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA. [Chasela, Charles S.] Univ Witwatersrand, Sch Publ Hlth, Div Epidemiol & Biostat, Parktown, South Africa. [Hudgens, Michael G.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA. [Kayira, Dumbani; Tegha, Gerald] Univ N Carolina, UNC Project, Lilongwe, Malawi. [Ellington, Sascha R.; Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Davis, NL (reprint author), Univ N Carolina, Dept Epidemiol, 135 Dauer Dr,2101 McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA. EM nld@unc.edu FU National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) [R03AI100694-A1]; Prevention Research Centers Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; NIAID; University of North Carolina Center for AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 TW01039-06]; NIH Fogarty AIDS International Training and Research Program (Fogarty International Clinical Research Scholars Program) [R24 TW007988]; NIH Fogarty AIDS International Training and Research Program (American Recovery and Reinvestment Act); Infectious Disease Epidemiology Training Grant [5T32AI070114]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; US Agency for International Development FX This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) (R03AI100694-A1). The BAN Study was supported by grants from the Prevention Research Centers Special Interest Project of the CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01); NIAID; the University of North Carolina Center for AIDS Research (P30-AI50410); the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 TW01039-06, the Fogarty International Clinical Research Scholars Program R24 TW007988, the American Recovery and Reinvestment Act); and the Infectious Disease Epidemiology Training Grant (5T32AI070114). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the US Agency for International Development. NR 30 TC 4 Z9 4 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2015 VL 61 IS 3 BP 368 EP 374 DI 10.1093/cid/civ309 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MM UT WOS:000359343500010 PM 25900173 ER PT J AU Doney, B Hnizdo, E Dillon, CF Paulose-Ram, R Tilert, T Wolz, M Beeckman-Wagner, LA AF Doney, Brent Hnizdo, Eva Dillon, Charles F. Paulose-Ram, Ryne Tilert, Timothy Wolz, Michael Beeckman-Wagner, Lu-Ann TI Prevalence of Airflow Obstruction in US Adults Aged 40-79 Years: NHANES Data 1988-1994 and 2007-2010 SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE airflow obstruction; chronic obstructive pulmonary disease; NHANES; spirometry ID CURRENT CIGARETTE-SMOKING; LUNG-FUNCTION; UNITED-STATES; PULMONARY-DISEASE; REFERENCE VALUES; SPIROMETRY USE; RISK-FACTORS; COPD; BURDEN; POPULATION AB Background: The study evaluated the change in the prevalence of airflow obstruction in the U.S. population 40-79 years of age from years 1988-1994 to 2007-2010. Methods: Spirometry data from two representative samples of the U.S. population, the National Health and Nutrition Examination Surveys (NHANES) conducted in 1988-1994 and 2007-2010, were used. The American Thoracic Society/European Respiratory Society (ATS/ERS) criteria were used to define airflow obstruction. Results: Based on ATS/ERS criteria, the overall age-adjusted prevalence of airflow obstruction among adults aged 40-79 years decreased from 16.6% to 14.5% (p < 0.05). Significant decreases were observed for the older age category 60-69 years (20.2% vs. 15.4%; p < 0.01), for males (19.0% vs. 15.4%; p < 0.01), and for Mexican American adults (12.7% vs. 8.4%; p < 0.001). The prevalence of moderate and more severe airflow obstruction decreased also (6.4% vs. 4.4%; p < 0.01). Based on ATS/ERS criteria, during 2007-2010, an estimated 18.3 million U.S. adults 40-79 years had airflow obstruction, 5.6 million had moderate or severe airflow obstruction and 1.4 million had severe airflow obstruction. Conclusions: The overall age-adjusted prevalence of airflow obstruction among U.S. adults aged 40-79 years decreased from 1988-1994 to 2007-2010, especially among older adults, Mexican Americans, and males. C1 [Doney, Brent; Hnizdo, Eva; Beeckman-Wagner, Lu-Ann] NIOSH, Div Repiratory Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Dillon, Charles F.; Paulose-Ram, Ryne; Tilert, Timothy] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Wolz, Michael] NHLBI, NIH, Bethesda, MD 20892 USA. RP Doney, B (reprint author), NIOSH, Div Repiratory Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM bdoney@cdc.gov FU National Institute for Occupational Safety and Health, National Center for Health Statistics; National Heart, Lung, and Blood Institute FX The authors have no financial, consulting, and personal relationships that could influence this work product. The National Institute for Occupational Safety and Health, National Center for Health Statistics, or National Heart, Lung, and Blood Institute supported the salaries of the authors. This work was performed by U.S. Federal Government employees as part of their work; no non-governmental funding supported this work. The authors alone are responsible for the content and writing of the paper. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Heart, Lung, and Blood Institute. NR 40 TC 5 Z9 5 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1541-2555 EI 1541-2563 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD AUG PY 2015 VL 12 IS 4 BP 355 EP 365 DI 10.3109/15412555.2014.948998 PG 11 WC Respiratory System SC Respiratory System GA CP4JY UT WOS:000359849000002 PM 25244575 ER PT J AU Ebor, M Murray, A Gaul, Z Sutton, M AF Ebor, Megan Murray, Ashley Gaul, Zaneta Sutton, Madeline TI HIV Awareness and Knowledge among Viewers of a Documentary Film about HIV among Racial- or Ethnic-Minority Older Adults SO HEALTH & SOCIAL WORK LA English DT Article DE documentaries; HIV; older adults; racial or ethnic minorities; sexual health ID IMMUNODEFICIENCY-VIRUS-INFECTION; PRIMARY-CARE PHYSICIANS; SEXUAL HISTORY; PUBLIC-HEALTH; HIV/AIDS PREVENTION; AGED 50; SUPERINFECTION; BELIEFS; PATIENT; PEOPLE AB A documentary film on HIV was developed based on social cognitive theory and entertainment educational methods in an effort to increase awareness and encourage protective behavior change related to HIV among older adults. The documentary includes perspectives from racial- or ethnic-minority older adults who are living with HIV and those of health care providers, and was screened in several venues. Authors of this article conducted thematic content analysis of a anonymous, written, open-ended responses from 341 film viewers (clinicians and laypeople) who described what they learned about HIV after viewing the film. Four key themes emerged from the analysis: (1) increased awareness about the epidemiology of HIV among older, minority groups and about sexuality among older people: (2) improved general HIV knowledge, including risk reduction strategies and details about I HIV testing; (3) awareness of lack of sexual health education among health care providers, and that a call to action is needed; and (4) awareness that HIV reinfection can occur in certain circumstances with people who are already infected. Findings suggest that an educational documentary can be used to effectively increase awareness and knowledge about the impact of HIV among minority older adults, and may also encourage HIV prevention action steps by providers. C1 [Ebor, Megan] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA USA. [Murray, Ashley; Sutton, Madeline] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Gaul, Zaneta] ICE Int, Washington, DC USA. RP Sutton, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-45, Atlanta, GA 30329 USA. EM msutton@cdc.gov NR 56 TC 1 Z9 1 U1 3 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-7283 EI 1545-6854 J9 HEALTH SOC WORK JI Health Soc. Work PD AUG PY 2015 VL 40 IS 3 BP 217 EP 224 DI 10.1093/hsw/hlv041 PG 8 WC Social Work SC Social Work GA CP2GH UT WOS:000359695000015 PM 26285361 ER PT J AU Steiner, RJ Rasberry, CN AF Steiner, Riley J. Rasberry, Catherine N. TI Brief report: Associations between in-person and electronic bullying victimization and missing school because of safety concerns among US high school students SO JOURNAL OF ADOLESCENCE LA English DT Article DE Bullying; Cyberbullying; Adolescence; School absenteeism ID PSYCHOSOCIAL ADJUSTMENT; UNITED-STATES; BEHAVIORS; HEALTH; YOUTH AB Although associations between bullying and health risk behaviors are well-documented, research on bullying and education-related outcomes, including school attendance, is limited. This study examines associations between bullying victimization (in-person and electronic) and missing school because of safety concerns among a nationally representative sample of U.S. high school students. We used logistic regression analyses to analyze data from the 2013 national Youth Risk Behavior Survey of students in grades 9-12. In-person and electronic victimization were each associated with increased odds of missing school due to safety concerns compared to no bullying victimization. Having been bullied both in-person and electronically was associated with greater odds of missing school compared to electronic bullying only for female students and in-person bullying only for male students. Collaborations between health professionals and educators to prevent bullying may improve school attendance. Published by Elsevier Ltd on behalf of The Foundation for Professionals in Services for Adolescents. C1 [Steiner, Riley J.; Rasberry, Catherine N.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Steiner, RJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE Mailstop E-75, Atlanta, GA 30329 USA. EM rsteiner@cdc.gov RI Rasberry, Catherine/P-1984-2016 OI Rasberry, Catherine/0000-0001-8256-6961 NR 13 TC 2 Z9 2 U1 2 U2 15 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0140-1971 EI 1095-9254 J9 J ADOLESCENCE JI J. Adolesc. PD AUG PY 2015 VL 43 BP 1 EP 4 DI 10.1016/j.adolescence.2015.05.005 PG 4 WC Psychology, Developmental SC Psychology GA CO7HT UT WOS:000359330900001 PM 26043166 ER PT J AU Buchacz, K Young, B Palella, FJ Armon, C Brooks, JT AF Buchacz, Kate Young, Benjamin Palella, Frank J., Jr. Armon, Carl Brooks, John T. CA HOPS Investigators TI Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011 SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE HIV infection; genotype; mutation; epidemiology; primary; transmitted ID NEW-YORK-CITY; INFECTED PATIENTS; EPIDEMIOLOGY; PREVALENCE; MUTATIONS; SURVEILLANCE; TRANSMISSION; MULTICENTER; UPDATE AB Background: Monitoring antiretroviral drug resistance can inform treatment recommendations; however, there are few such data from US patients before they initiate ART. Methods: We analysed data from HIV Outpatient Study (HOPS) participants from nine US HIV clinics who were diagnosed with HIV infection during 1999-2011. Using the IAS-USA December 2010 guidelines, we assessed the frequency of major drug resistance mutations (mDRMs) related to antiretroviral agents in viral isolates from patients who underwent commercial genotypic testing (GT) for resistance before initiating ART. We employed general linear regression models to assess factors associated with having undergone GT, and then factors associated with having mDRM. Results: Among 1531 eligible patients, 758 (49.5%) underwent GT before first ART, increasing from 15.5% in 1999-2002 to 75.9% in 2009-11 (P<0.001). GT was carried out a median of 1.2 months after the diagnosis of HIV. In adjusted regression analyses, patients with pre-ART CD4+ T lymphocyte counts >= 200 cells/mm(3) or with HIV RNA levels >5.0 log(10) copies/mL and those with a first HOPS visit in 2006 or later were significantly (P<0.05) more likely to have undergone GT. Of the 758 patients, 114 (15.0%) had mDRMs; mutations relating to NRTIs, NNRTIs and PIs were present in 8.0%, 7.1% and 2.6%, respectively. There was no temporal change in the frequency of mDRM, and mDRMs were associated with an HIV RNA level <4.0 log(10) copies/mL. Conclusions: During 1999-2011, GT use among antiretroviral-naive patients became more common, but a quarter of patients in recent years remained untested. The frequency of mDRMs remained stable over time at about 15%. C1 [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Young, Benjamin] APEX Family Med, Denver, CO USA. [Young, Benjamin] Int Assoc Providers AIDS Care, Washington, DC USA. [Palella, Frank J., Jr.] Northwestern Univ, Chicago, IL 60611 USA. [Armon, Carl] Cerner Corp, Vienna, VA USA. RP Buchacz, K (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM acu7@cdc.gov FU US Centers for Disease Control and Prevention [200-2001-00133, 200-2006-18797, 200-2011-41872] FX The work was supported by the US Centers for Disease Control and Prevention (contract numbers 200-2001-00133, 200-2006-18797 and 200-2011-41872). NR 37 TC 2 Z9 2 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD AUG PY 2015 VL 70 IS 8 BP 2337 EP 2346 DI 10.1093/jac/dkv120 PG 10 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA CP2RB UT WOS:000359723600026 PM 25979729 ER PT J AU Garrett, BE Dube, SR Babb, S McAfee, T AF Garrett, Bridgette E. Dube, Shanta R. Babb, Stephen McAfee, Tim TI Addressing the Social Determinants of Health to Reduce Tobacco-Related Disparities SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SECONDHAND SMOKE EXPOSURE; CURRENT CIGARETTE-SMOKING; UNITED-STATES; CESSATION; POLICY; PEOPLE; ADULTS AB Introduction: Comprehensive tobacco prevention and control efforts that include implementing smoke-free air laws, increasing tobacco prices, conducting hard-hitting mass media campaigns, and making evidence-based cessation treatments available are effective in reducing tobacco use in the general population. However, if these interventions are not implemented in an equitable manner, certain population groups may be left out causing or exacerbating disparities in tobacco use. Disparities in tobacco use have, in part, stemmed from inequities in the way tobacco control policies and programs have been adopted and implemented to reach and impact the most vulnerable segments of the population that have the highest rates of smokings (e.g., those with lower education and incomes). Methods: Education and income are the 2 main social determinants of health that negatively impact health. However, there are other social determinants of health that must be considered for tobacco control policies to be effective in reducing tobacco-related disparities. This article will provide an overview of how tobacco control policies and programs can address key social determinants of health in order to achieve equity and eliminate disparities in tobacco prevention and control. Results: Tobacco control policy interventions can be effective in addressing the social determinants of health in tobacco prevention and control to achieve equity and eliminate tobacco-related disparities when they are implemented consistently and equitably across all population groups. Conclusions: Taking a social determinants of health approach in tobacco prevention and control will be necessary to achieve equity and eliminate tobacco-related disparities. C1 [Garrett, Bridgette E.; Babb, Stephen; McAfee, Tim] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Dube, Shanta R.] Georgia State Univ, Div Epidemiol & Biostat, Atlanta, GA 30303 USA. RP Garrett, BE (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F-79, Atlanta, GA 30341 USA. EM bgarrett@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 8 Z9 8 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD AUG PY 2015 VL 17 IS 8 BP 892 EP 897 DI 10.1093/ntr/ntu266 PG 6 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CP1SH UT WOS:000359655000002 PM 25516538 ER PT J AU Seth, P Wingood, GM Robinson, LS Raiford, JL DiClemente, RJ AF Seth, Puja Wingood, Gina M. Robinson, LaShun S. Raiford, Jerris L. DiClemente, Ralph J. TI Abuse Impedes Prevention: The Intersection of Intimate Partner Violence and HIV/STI Risk Among Young African American Women SO AIDS AND BEHAVIOR LA English DT Article DE Intimate partner violence; HIV; Sexually; transmitted infection; Risky sexual behavior; African American; Women ID RANDOMIZED-CONTROLLED-TRIAL; TRICHOMONAS-VAGINALIS INFECTIONS; SEXUALLY-TRANSMITTED INFECTIONS; JUSTICE SYSTEM INVOLVEMENT; HIV RISK; UNITED-STATES; HUMAN-PAPILLOMAVIRUS; FEMALE ADOLESCENTS; REDUCING HIV; INTERVENTIONS AB Intimate partner violence (IPV) is associated with risky sexual behavior and STIs among diverse groups of women. IPV was examined as a moderator of efficacy for an HIV/STI intervention. 848 African American women, 18-29, were randomly assigned to an HIV/STI intervention or control condition. Participants completed measures on sociodemographics, IPV, risky sexual behavior and received STI testing. IPV predicted inconsistent condom use and a risky sexual partner over 12-month follow-up. A significant interaction indicated that among women who experienced IPV, those in the intervention were more likely to test positive for Trichomonas vaginalis (TV). Among intervention participants, those who experienced IPV were more likely to test TV-positive than those who did not. In an HIV intervention that did not specifically address IPV, women in the control condition were less likely to acquire TV than those in the intervention. Consideration of contextual/interpersonal factors is essential when developing HIV intervention programs. C1 [Seth, Puja; Raiford, Jerris L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Wingood, Gina M.; Robinson, LaShun S.; DiClemente, Ralph J.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Wingood, Gina M.; DiClemente, Ralph J.] Emory Ctr AIDS Res, Atlanta, GA USA. [DiClemente, Ralph J.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis Epidemiol & Immunol, Atlanta, GA USA. RP Seth, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30333 USA. EM pseth@cdc.gov FU National Institutes of Health [R01-MH062717] FX This study was supported by Grant R01-MH062717 from the National Institutes of Health awarded to Dr. Gina Wingood. The authors also would like to acknowledge the statistical consultation from Dr. James Hardin of the University of South Carolina. NR 38 TC 1 Z9 1 U1 3 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD AUG PY 2015 VL 19 IS 8 BP 1438 EP 1445 DI 10.1007/s10461-014-0940-7 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CO2VM UT WOS:000359014800008 PM 25399033 ER PT J AU Rhodes, SD Alonzo, J Mann, L Freeman, A Sun, CJ Garcia, M Painter, TM AF Rhodes, Scott D. Alonzo, Jorge Mann, Lilli Freeman, Arin Sun, Christina J. Garcia, Manuel Painter, Thomas M. TI ENHANCEMENT OF A LOCALLY DEVELOPED HIV PREVENTION INTERVENTION FOR HISPANIC/LATINO MSM: A PARTNERSHIP OF COMMUNITY-BASED ORGANIZATIONS, A UNIVERSITY, AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION SO AIDS EDUCATION AND PREVENTION LA English DT Article ID IMMIGRANT LATINO MEN; BEHAVIORAL INTERVENTIONS; PARTICIPATORY RESEARCH; HIV/AIDS PREVENTION; RISK BEHAVIORS; FEMALE CONDOM; UNITED-STATES; REDUCE HIV; SEX; POPULATIONS AB Hispanic/Latino men who have sex with men (MSM) in the United States are disproportionately affected by HIV and other sexually transmitted diseases (STDs); however, no efficacious behavioral HIV/STD prevention interventions are currently available for use with this vulnerable population. We describe the enhancement of HOLA en Grupos, a community-based behavioral HIV/STD prevention intervention for Spanish-speaking Hispanic/Latino MSM that is currently being implemented and evaluated in North Carolina with support from the Centers of Disease Control and Prevention (CDC). Our intervention enhancement process included incorporating local data on risks and context; identifying community needs and priorities; defining intervention core elements and key characteristics; developing a logic model; developing an intervention logo; enhancing intervention activities and materials; scripting intervention delivery; expanding the comparison intervention; and establishing a materials review committee. If the CDC-sponsored evaluation determines that HOLA en Grupos is efficacious, it will be the first such behavioral HIV/STD prevention intervention to be identified for potential use with Hispanic/Latino MSM, thereby contributing to the body of evidence-based resources that may be used for preventing HIV/STD infection among these MSM and their sex partners. C1 [Rhodes, Scott D.; Alonzo, Jorge; Mann, Lilli; Sun, Christina J.; Garcia, Manuel] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Social Sci & Hlth Policy, Winston Salem, NC 27157 USA. [Freeman, Arin; Painter, Thomas M.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr Hepatitis HIV STD & TB Prevent, Atlanta, GA USA. RP Rhodes, SD (reprint author), Wake Forest Sch Med, Div Publ Hlth Sci, Dept Social Sci & Hlth Policy, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM srhodes@wakehealth.edu FU Centers for Disease Control and Prevention (CDC) [U01PS001570] FX Funding for the enhancement process and the evaluation study described herein was provided by the Centers for Disease Control and Prevention (CDC) to Wake Forest School of Medicine under cooperative agreement U01PS001570. NR 54 TC 2 Z9 2 U1 3 U2 9 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD AUG PY 2015 VL 27 IS 4 BP 312 EP 332 PG 21 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA CN9ZB UT WOS:000358808600003 PM 26241382 ER PT J AU Grabbe, KL Courtenay-Quirk, C Baughman, AL Djomand, G Pedersen, B Lerotholi, M Nkonyana, J Ramphalla-Phatela, P Marum, E AF Grabbe, Kristina L. Courtenay-Quirk, Cari Baughman, Andrew L. Djomand, Gaston Pedersen, Brian Lerotholi, Mankhala Nkonyana, John Ramphalla-Phatela, Puleng Marum, Elizabeth TI RE-TESTING AND SEROCONVERSION AMONG HIV TESTING AND COUNSELING CLIENTS IN LESOTHO SO AIDS EDUCATION AND PREVENTION LA English DT Article ID RISK BEHAVIORS; INFECTION; TESTERS; UGANDA AB HIV testing and counseling (HTC) is an essential component of comprehensive HIV programs. Retrospective HTC program data from 2006 to 2010 were examined to determine patterns of re-testing and seroconversion in Lesotho. Among 104,662 initially negative clients, 6,777 (6.5%) were re-testers. Predictors of re-testing included being male, age 25 years, divorced/separated, having more than a high school education, being tested as a couple, testing in the year 2006, testing in the capital city, and awareness of partner's recent testing behavior. Among re-testers who seroconverted (N 259), predictors included being female and having less than a high school education. There is a critical need for more effectively targeting HIV re-testing messages to align with WHO (2010) guidelines and identify persons at highest risk for HIV, to increase timely diagnoses and link persons to appropriate HIV prevention, care, and treatment services. C1 [Grabbe, Kristina L.; Courtenay-Quirk, Cari; Baughman, Andrew L.; Djomand, Gaston; Marum, Elizabeth] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Nkonyana, John; Ramphalla-Phatela, Puleng] Minist Hlth, Maseru, Lesotho. RP Courtenay-Quirk, C (reprint author), 1600 Clifton Rd,Mailstop E-04, Atlanta, GA 30333 USA. EM ccourtenayquirk@cdc.gov FU Centers for Disease Control and Prevention FX This project was funded through the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention. NR 23 TC 1 Z9 1 U1 0 U2 1 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD AUG PY 2015 VL 27 IS 4 BP 350 EP 361 PG 12 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA CN9ZB UT WOS:000358808600005 PM 26241384 ER PT J AU Kim, S Ward, E Dicianno, BE Clayton, GH Sawin, KJ Beierwaltes, P Thibadeau, J AF Kim, Sunkyung Ward, Elisabeth Dicianno, Brad E. Clayton, Gerald H. Sawin, Kathleen J. Beierwaltes, Patricia Thibadeau, Judy CA Natl Spina Bifida Patient Registry TI Factors Associated With Pressure Ulcers in Individuals With Spina Bifida SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Pressure ulcer; Rehabilitation; Risk factors; Spinal cord injuries ID YOUNG-ADULTS; MYELOMENINGOCELE; CARE; PREVALENCE AB Objective: To describe factors associated with pressure ulcers in individuals with spina bifida (SB) enrolled in the National Spina Bifida Patient Registry (NSBPR). Design: Unbalanced longitudinal multicenter cohort study. Setting: Nineteen SB clinics. Participants: Individuals with SB (N=3153) enrolled in 19 clinic sites that participate in the NSBPR. Interventions: Not applicable. Main Outcome Measures: Pressure ulcer status (yes/no) at the annual visit between 2009 and 2012. Results: Of 3153 total participants, 19% (n = 603) reported ulcers at their most recent annual clinic visit. Seven factors level of lesion, wheelchair use, urinary incontinence, shunt presence, above the knee orthopedic surgery, recent surgery, and male sex were significantly associated with the presence of pressure ulcers. Of these factors, level of lesion, urinary incontinence, recent surgery, and male sex were included in the final logistic regression model. The 3 adjusting variables SB type, SB clinic, and age group were significant in all analyses (all P<.001). Conclusions: By adjusting for SB type, SB clinic, and age group, we found that 7 factors level of lesion, wheelchair use, urinary incontinence, shunt presence, above the knee orthopedic surgery, recent surgery, and male sex were associated with pressure ulcers. Identifying key factors associated with the onset of pressure ulcers can be incorporated into clinical practice in ways that prevent and enhance treatment of pressure ulcers in the population with SB. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Kim, Sunkyung; Thibadeau, Judy] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Ward, Elisabeth] Carter Consulting Inc, Atlanta, GA USA. [Dicianno, Brad E.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Clayton, Gerald H.] Univ Colorado Denver, Dept Phys Med & Rehabil, Aurora, CO USA. [Clayton, Gerald H.] Childrens Hosp Colorado, Aurora, CO USA. [Sawin, Kathleen J.] Univ Wisconsin, Coll Nursing, Milwaukee, WI 53201 USA. [Sawin, Kathleen J.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Beierwaltes, Patricia] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Beierwaltes, Patricia] Wayne State Univ, Detroit, MI USA. RP Kim, S (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,Mailstop E88, Atlanta, GA 30333 USA. EM wox0@cdc.gov FU National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA [1UO1DDD000744.01] FX Supported by the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA (grant no. 1UO1DDD000744.01). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 28 TC 1 Z9 1 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD AUG PY 2015 VL 96 IS 8 BP 1435 EP 1441 DI 10.1016/j.apmr.2015.02.029 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CO3CU UT WOS:000359035000009 PM 25796136 ER PT J AU Drawz, PE Archdeacon, P McDonald, CJ Powe, NR Smith, KA Norton, J Williams, DE Patel, UD Narva, A AF Drawz, Paul E. Archdeacon, Patrick McDonald, Clement J. Powe, Neil R. Smith, Kimberly A. Norton, Jenna Williams, Desmond E. Patel, Uptal D. Narva, Andrew TI CKD as a Model for Improving Chronic Disease Care through Electronic Health Records SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; INCIDENT HEMODIALYSIS-PATIENTS; INFORMATION-TECHNOLOGY; CONTROLLED-TRIAL; AMBULATORY-CARE; CLINICAL-TRIALS; CHRONIC ILLNESS; BLOOD-PRESSURE; UNITED-STATES; MORTALITY AB Electronic health records have the potential to improve the care of patients with chronic medical conditions. CKD provides a unique opportunity to show this potential: the disease is common in the United States, there is significant room to improve CKD detection and management, CKD and its related conditions are defined primarily by objective laboratory data, CKD care requires collaboration by a diverse team of health care professionals, and improved access to CKD-related data would enable identification of a group of patients at high risk for multiple adverse outcomes. However, to realize the potential for improvement in CKD-related care, electronic health records will need to provide optimal functionality for providers and patients and interoperability across multiple health care settings. The goal of the National Kidney Disease Education Program Health Information Technology Working Group is to enable and support the widespread interoperability of data related to kidney health among health care software applications to optimize CKD detection and management. Over the course of the last 2 years, group members met to identify general strategies for using electronic health records to improve care for patients with CKD. This paper discusses these strategies and provides general goals for appropriate incorporation of CKD-related data into electronic health records and corresponding design features that may facilitate (1) optimal care of individual patients with CKD through improved access to clinical information and decision support, (2) clinical quality improvement through enhanced population management capabilities, (3) CKD surveillance to improve public health through wider availability of population-level CKD data, and (4) research to improve CKD management practices through efficiencies in study recruitment and data collection. Although these strategies may be most effectively applied in the setting of CKD, because it is primarily defined by laboratory abnormalities and therefore, an ideal computable electronic health record phenotype, they may also apply to other chronic diseases. C1 [Drawz, Paul E.] Univ Minnesota, Div Renal Dis & Hypertens, Minneapolis, MN USA. [Archdeacon, Patrick] US FDA, Off Med Policy, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [McDonald, Clement J.] Natl Lib Med, Lister Hill Natl Ctr Biomed Commun, Bethesda, MD USA. [Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Smith, Kimberly A.] Ctr Medicare & Medicaid Serv, Ctr Clin Stand & Qual, Baltimore, MD USA. [Norton, Jenna; Narva, Andrew] NIDDK, Natl Kidney Dis Educ Program, Bethesda, MD 20892 USA. [Williams, Desmond E.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Patel, Uptal D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. RP Narva, A (reprint author), NIDDK, Natl Kidney Dis Educ Program, NIH, Bldg 31,Room 9A27 MSC 2560,31 Ctr Dr, Bethesda, MD 20892 USA. EM narvaa@niddk.nih.gov FU National Institutes of Health (NIH) [R01-DK093938, R34-DK102166]; NKDEP HIT Intern FX U.D.P. was supported by National Institutes of Health (NIH) Grants R01-DK093938 and R34-DK102166.; Thanks for support from the NKDEP HIT Intern, Jessica Pereira. NR 56 TC 1 Z9 1 U1 1 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2015 VL 10 IS 8 BP 1488 EP 1499 DI 10.2215/CJN.00940115 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA CO5AU UT WOS:000359172800025 PM 26111857 ER PT J AU McCaffery, JM Anderson, A Bantle, JP Berkowitz, RI Bray, GA Cheskin, L Clark, JM Curtis, JM Delahanty, LM Evans, M Foreyt, JP Glasser, S Gregg, EW Hanson, RL Hazuda, HP Hill, JO Horton, ES Huggins, GS Jakicic, JM Jeffery, RW Johnson, KC Kahn, SE Kelley, DE Kitabchi, AE Knowler, WC Lewis, CE Montez, MG Kure, A Nathan, DM Nyenwe, E Pajewski, NM Papandonatos, GD Patricio, J Peter, I Peters, A Pi-Sunyer, X Pownall, H Wadden, TA Wagenknecht, LE Wing, RR Wyatt, H AF McCaffery, Jeanne M. Anderson, Andrea Bantle, John P. Berkowitz, Robert I. Bray, George A. Cheskin, Lawrence Clark, Jeanne M. Curtis, Jeffrey M. Delahanty, Linda M. Evans, Mary Foreyt, John P. Glasser, Stephen Gregg, Edward W. Hanson, Robert L. Hazuda, Helen P. Hill, James O. Horton, Edward S. Huggins, Gordon S. Jakicic, John M. Jeffery, Robert W. Johnson, Karen C. Kahn, Steven E. Kelley, David E. Kitabchi, Abbas E. Knowler, William C. Lewis, Cora E. Montez, Maria G. Kure, Anne Nathan, David M. Nyenwe, Ebenezer Pajewski, Nicholas M. Papandonatos, George D. Patricio, Jennifer Peter, Inga Peters, Anne Pi-Sunyer, Xavier Pownall, Henry Wadden, Thomas A. Wagenknecht, Lynne E. Wing, Rena R. Wyatt, Holly CA Look AHEAD Res Grp TI Prospective association of a genetic risk score and lifestyle intervention with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD randomised controlled trial SO DIABETOLOGIA LA English DT Article DE Cardiovascular disease; Genetics; Lifestyle intervention; Myocardial infarction; Obesity; Stroke; Type 2 diabetes; Weight loss ID CORONARY-HEART-DISEASE; UNRELATED INDIVIDUALS; CLINICAL-TRIAL; WEIGHT-LOSS; WIDE ASSOCIATION; HEALTH; PREDICTION; ATHEROSCLEROSIS; INFERENCE; OBESITY AB Aims/hypothesis Both obesity and genetics contribute to cardiovascular disease (CVD). We examined whether a genetic risk score (GRS) prospectively predicted cardiovascular morbidity andmortality among overweight/obese individuals with type 2 diabetes and whether behavioural weight loss could diminish this association. Methods Look AHEAD (Action for Health in Diabetes) is a randomised controlled trial to determine the effects of intensive lifestyle intervention (ILI), including weight loss and physical activity, relative to diabetes support and education, on cardiovascular outcomes among overweight/obese individuals with type 2 diabetes. Of the participants, 4,016 provided consent for genetic analyses and had DNA samples passing quality control procedures. These secondary data analyses focused on whether a GRS derived from 153 single nucleotide polymorphisms (SNPs) associated with coronary artery disease in the most recent genome-wide association study predicted cardiovascular morbidity and mortality over a median of 9.6 years of follow-up, and whether ILI would diminish this association. Results The GRS significantly predicted the primary composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for angina in the full sample (HR, 95% CI per 1 SD increase in GRS: 1.19 [1.10, 1.28]) and among individuals with no known history of CVD at baseline (HR 1.18 [95% CI 1.07, 1.30]). In no case did ILI significantly alter this association. Conclusions/interpretation A GRS comprised of SNPs significantly predicts cardiovascular morbidity and mortality over 9.6 years of follow-up in Look AHEAD. Lifestyle intervention did not alter the genetic association. C1 [McCaffery, Jeanne M.; Wing, Rena R.] Brown Univ, Alpert Sch Med, Miriam Hosp, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Anderson, Andrea; Pajewski, Nicholas M.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Bantle, John P.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Berkowitz, Robert I.; Wadden, Thomas A.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Dept Clin Obes, Baton Rouge, LA 70808 USA. [Cheskin, Lawrence] Johns Hopkins, Johns Hopkins Bloomberg Sch Publ Hlth, Global Obes Prevent Ctr, Hlth Behav & Soc, Baltimore, MD USA. [Clark, Jeanne M.] Johns Hopkins Univ, Dept Med Gen Internal Med & Epidemiol, Baltimore, MD USA. [Curtis, Jeffrey M.] St Josephs Hosp, Dept Family Med, Phoenix, AZ USA. [Curtis, Jeffrey M.] NIDDK, Southwest Amer Indian Ctr, NIH, Phoenix, AZ USA. [Delahanty, Linda M.] Massachusetts Gen Hosp, Dept Med, Ctr Diabet, Boston, MA 02114 USA. [Delahanty, Linda M.; Nathan, David M.] Harvard Univ, Sch Med, Boston, MA USA. [Evans, Mary] NIDDK, Dept Digest Dis & Nutr, Bethesda, MD 20892 USA. [Foreyt, John P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Glasser, Stephen] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Hanson, Robert L.] NIDDK, Diabet Epidemiol & Clin Res Sect, Phoenix, AZ USA. [Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Hill, James O.] Univ Colorado, Anschutz Hlth & Wellness Ctr, Aurora, CO USA. [Horton, Edward S.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Horton, Edward S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Huggins, Gordon S.] Tufts Med Ctr, MCRI Ctr Translat Genom, Boston, MA USA. [Jakicic, John M.] Univ Pittsburgh, Dept Hlth & Phys Act, Pittsburgh, PA USA. [Jeffery, Robert W.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Johnson, Karen C.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.; Kure, Anne] Univ Washington, Seattle, WA 98195 USA. [Kelley, David E.] Univ Pittsburgh, Dept Hlth & Phys Act, Pittsburgh, PA USA. [Kitabchi, Abbas E.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA. [Knowler, William C.] NIDDK, Phoenix, AZ USA. [Lewis, Cora E.] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Montez, Maria G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Kure, Anne] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Nathan, David M.] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Ctr Diabet, Boston, MA 02114 USA. [Nyenwe, Ebenezer] Univ Tennessee, Ctr Hlth Sci, Div Endocrinol Diabet & Metab, Memphis, TN 38163 USA. [Papandonatos, George D.] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA. [Patricio, Jennifer; Pi-Sunyer, Xavier] Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York Obes Res Ctr, New York, NY USA. [Peter, Inga] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Peters, Anne] Roybal Comprehens Hlth Ctr, Los Angeles, CA USA. [Pownall, Henry] Methodist Hosp, Res Inst, Dept Cardiol, Houston, TX 77030 USA. [Wagenknecht, Lynne E.] Wake Forest Sch Med, Dept Publ Hlth Serv, Winston Salem, NC USA. [Wyatt, Holly] Univ Colorado, Anschutz Hlth & Wellness Ctr, Aurora, CO USA. RP McCaffery, JM (reprint author), Miriam Hosp, Weight Control & Diabet Res Ctr, 196 Richmond St, Providence, RI 02903 USA. RI Hanson, Robert/O-3238-2015 OI Hanson, Robert/0000-0002-4252-7068 FU National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; Centers for Disease Control and Prevention; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center; Massachusetts Institute of Technology General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Cl inical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center (GCRC) [M01RR000056]; Clinical Translational Research Center (CTRC) - Clinical and Translational Science Award [UL1 RR 024153]; NIH grant [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center [M01RR01346] FX Funded by the National Institutes of Health through cooperative agreements with the National Institute of Diabetes and Digestive and Kidney Diseases: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135 and DK56992. Additional funding was provided by the National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (I.H.S.) provided personnel, medical oversight and use of facilities. The opinions expressed in this paper are those of the authors and do not necessarily reflect the views of the I.H.S. or other funding sources.; Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Cl inical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (GCRC) (M01RR000056); the Clinical Translational Research Center (CTRC) funded by the Clinical and Translational Science Award (UL1 RR 024153) and NIH grant (DK 046204); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346). NR 35 TC 1 Z9 1 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD AUG PY 2015 VL 58 IS 8 BP 1803 EP 1813 DI 10.1007/s00125-015-3610-z PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CO0XN UT WOS:000358877300020 ER PT J AU Tamers, SL Okechukwu, C Marino, M Gueguen, A Goldberg, M Zins, M AF Tamers, Sara L. Okechukwu, Cassandra Marino, Miguel Gueguen, Alice Goldberg, Marcel Zins, Marie TI Effect of stressful life events on changes in smoking among the French: longitudinal findings from GAZEL SO EUROPEAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CESSATION; PATTERNS; RELAPSE; COHORT; STYLE; BASE AB Background: Changes in life events may play a contributing role in changes in smoking behaviors. The objective was to examine the impact of stressful life events (SLEs) on smoking among French adults. Methods: We examined smoking prevalence in 20 625 employees of the French GAZEL cohort for up to 5 years before and after a SLE during three time periods (years -1 vs. -5; years +1 vs. -1; years +5 vs. +1). Repeated measures analysis of time series data indexed to events were used, employing generalized estimating equations. Results: For women, comparing 1 year after vs. 1 year before SLEs, decreased odds of smoking were found for employment promotion (OR: 0.80; 95% CI = 0.67-0.95), marriage (OR: 0.57; 95% CI = 0.48-0.68) and divorce (OR: 0.78; 95% CI = 0.68-0.90). Comparing 5 years after to 1 year after SLEs, women had decreased odds of smoking for important purchase (OR: 0.87; 95% CI = 0.79-0.96), children leaving home (OR: 0.83; 95% CI = 0.74-0.93), retirement (OR: 0.73; 95% CI = 0.64-0.83) and death of loved one (OR: 0.86; 95% CI = 0.79-0.93). For men, decreased odds of smoking were observed in all three time periods for all SLEs except when comparing 1 year before to 5 years before marriage (OR: 1.66; 95% CI = 1.09-2.52) and divorce (OR: 1.49; 95% CI = 1.25-1.77). Conclusion: Time surrounding SLEs during which individuals are susceptible to changing smoking behaviors may be an important consideration. C1 [Tamers, Sara L.; Okechukwu, Cassandra] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. [Tamers, Sara L.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Marino, Miguel] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA. [Marino, Miguel] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA. [Gueguen, Alice; Goldberg, Marcel; Zins, Marie] Ctr Res Epidemiol & Populat Hlth, INSERM, Epidemiol Occupat & Social Determinants Hlth, U1018, F-94807 Villejuif, France. [Gueguen, Alice; Goldberg, Marcel; Zins, Marie] Univ Versailles St Quentin, UMRS 1018, Versailles, France. RP Tamers, SL (reprint author), NIOSH, Off Total Worker Hlth Coordinat & Res Support, Off Director, Ctr Dis Control & Prevent, 395 E St,SW,Suite 9200, Washington, DC 20201 USA. EM STamers@cdc.gov FU EDF-GDF; l'INSERM; l'Association de la Recherche sur le Cancer; la Fondation de France; le Ministere de la Sante; NIH/NCI Harvard Education Program in Cancer Prevention [R25 CA057713]; NIH/NCI Reducing Social Disparities in Cancer Risk [K05 CA108663-05] FX The authors express their gratitude to the EDF-GDF and acknowledge the invaluable assistance of the GAZEL cohort study team. This research was supported by the EDF-GDF, l'INSERM, l'Association de la Recherche sur le Cancer, la Fondation de France, le Ministere de la Sante, the NIH/NCI Harvard Education Program in Cancer Prevention (R25 CA057713) and the NIH/NCI Reducing Social Disparities in Cancer Risk (K05 CA108663-05). NR 35 TC 2 Z9 2 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1101-1262 EI 1464-360X J9 EUR J PUBLIC HEALTH JI Eur. J. Public Health PD AUG PY 2015 VL 25 IS 4 BP 711 EP 715 DI 10.1093/eurpub/ckv036 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO4VV UT WOS:000359159900033 PM 25762691 ER PT J AU Mercy, JA Freire, KE AF Mercy, James A. Freire, Kimberley E. TI DELTA PREP: Building Capacity to Meet the Public Health Urgency of Intimate Partner Violence SO HEALTH EDUCATION & BEHAVIOR LA English DT Editorial Material ID PREVENTION; IMPLEMENTATION C1 [Mercy, James A.; Freire, Kimberley E.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Mercy, JA (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,MS F-64, Atlanta, GA 30341 USA. EM jmercy@cdc.gov NR 11 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD AUG PY 2015 VL 42 IS 4 BP 433 EP 435 DI 10.1177/1090198115595250 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO8GX UT WOS:000359406300001 PM 26245931 ER PT J AU Freire, KE Zakocs, R Le, B Hill, JA Brown, P Wheaton, J AF Freire, Kimberley E. Zakocs, Ronda Le, Brenda Hill, Jessica A. Brown, Pamela Wheaton, Jocelyn TI Evaluation of DELTA PREP: A Project Aimed at Integrating Primary Prevention of Intimate Partner Violence Within State Domestic Violence Coalitions SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE diffusion of innovations; evaluation; injury prevention; safety; violent behavior and prevention; women's health ID RANDOMIZED CONTROLLED-TRIAL; PUBLIC-HEALTH; ORGANIZATIONAL READINESS; MANAGEMENT ACADEMY; SAFE DATES; PROGRAM; CAPACITY; IMPLEMENTATION; FRAMEWORK; DISEASE AB Background. Intimate partner violence (IPV) has been recognized as a public health problem since the late 20th century. To spur IPV prevention efforts nationwide, the DELTA PREP Project selected 19 state domestic violence coalitions to build organizational prevention capacity and catalyze IPV primary prevention strategies within their states. Objective. DELTA PREP's summative evaluation addressed four major questions: (1) Did coalitions improve their prevention capacity during the project period? (2) Did coalitions serve as catalysts for prevention activities within their states during the project period? (3) Was initial prevention capacity associated with the number of prevention activity types initiated by coalitions by the end of the project? (4) Did coalitions sustain their prevention activities 6 months after the end of the project period? Results. DELTA PREP achieved its capacity-building goal, with all 19 participant coalitions integrating prevention within their organizations and serving as catalysts for prevention activities in their states. At 6 months follow up, coalitions had sustained almost all prevention activities they initiated during the project. Baseline prevention capacity (Beginner vs. Intermediate) was not associated with the number of prevention activity types coalitions implemented by the end of the project. Conclusion. Service and treatment organizations are increasingly asked to integrate a full spectrum of prevention strategies. Selecting organizations that have high levels of general capacity and readiness for an innovation like integrating a public health approach to IPV prevention will likely increase success in building an innovation-specific capacity, and in turn implementing an innovation. C1 [Freire, Kimberley E.; Le, Brenda; Brown, Pamela; Wheaton, Jocelyn] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Zakocs, Ronda] Insight Evaluat LLC, Portland, OR USA. [Hill, Jessica A.] Sunflower Grp LLC, Atlanta, GA USA. RP Freire, KE (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F-64, Atlanta, GA 30341 USA. EM hbx8@cdc.gov FU Robert Wood Johnson Foundation FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The DELTA PREP Project was funded by the Robert Wood Johnson Foundation through a grant to the CDC Foundation and implemented in partnership with the CDC Division of Violence Prevention. NR 34 TC 4 Z9 4 U1 3 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD AUG PY 2015 VL 42 IS 4 BP 436 EP 448 DI 10.1177/1090198115579413 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO8GX UT WOS:000359406300002 PM 26245932 ER PT J AU Zakocs, R Freire, KE AF Zakocs, Ronda Freire, Kimberley E. TI The DELTA PREP Initiative: Accelerating Coalition Capacity for Intimate Partner Violence Prevention SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE coalitions; diffusion of innovations; evaluation; injury prevention; safety; process evaluation; qualitative methods; violent behavior and prevention; women's health ID MANAGEMENT ACADEMY; PUBLIC-HEALTH; IMPLEMENTATION; ORGANIZATIONS; IMPACT AB Background. The DELTA PREP Project aimed to build the prevention capacity of 19 state domestic violence coalitions by offering eight supports designed to promote prevention integration over a 3-year period: modest grant awards, training events, technical assistance, action planning, coaching hubs, the Coalition Prevention Capacity Assessment, an online workstation, and the online documentation support system. Objectives. Using quantitative and qualitative data, we sought to explain how coalitions integrated prevention within their structures and functions and document how DELTA PREP supports contributed to coalitions' integration process. Results. We found that coalitions followed a common pathway to integrate prevention. First, coalitions exhibited precursors of organizational readiness, especially having prevention champions. Second, coalitions engaged in five critical actions: engaging in dialogue, learning about prevention, forming teams, soliciting input from the coalition, and action planning. Last, by engaging in these critical actions, coalitions enhanced two key organizational readiness factorsdeveloping a common understanding of prevention and an organizational commitment to prevention. We also found that DELTA PREP supports contributed to coalitions' abilities to integrate prevention by supporting learning about prevention, fostering a prevention team, and engaging in action planning by leveraging existing opportunities. Two DELTA PREP supportscoaching hubs and the workstationdid not work as initially intended. From the DELTA PREP experience, we offer several lessons to consider when designing future prevention capacity-building initiatives. C1 [Zakocs, Ronda] Insight Evaluat LLC, Portland, OR 97219 USA. [Freire, Kimberley E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zakocs, R (reprint author), Insight Evaluat LLC, 5036 SW Florida St, Portland, OR 97219 USA. EM rzakocs@comcast.net FU Robert Wood Johnson Foundation FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The DELTA PREP Project was funded by the Robert Wood Johnson Foundation through a grant to the CDC Foundation and implemented in partnership with the CDC Division of Violence Prevention. NR 29 TC 3 Z9 3 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD AUG PY 2015 VL 42 IS 4 BP 458 EP 470 DI 10.1177/1090198115577133 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO8GX UT WOS:000359406300004 PM 26245934 ER PT J AU Zakocs, R Hill, JA Brown, P Wheaton, J Freire, KE AF Zakocs, Ronda Hill, Jessica A. Brown, Pamela Wheaton, Jocelyn Freire, Kimberley E. TI The Data-to-Action Framework: A Rapid Program Improvement Process SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE developmental evaluation; evaluation; process evaluation; quality improvement; utilization evaluation; violent behavior and prevention ID QUALITY IMPROVEMENT; PUBLIC-HEALTH; ACCREDITATION; CULTURE; SYSTEMS AB Although health education programs may benefit from quality improvement methods, scant resources exist to help practitioners apply these methods for program improvement. The purpose of this article is to describe the Data-to-Action framework, a process that guides practitioners through rapid-feedback cycles in order to generate actionable data to improve implementation of ongoing programs. The framework was designed while implementing DELTA PREP, a 3-year project aimed at building the primary prevention capacities of statewide domestic violence coalitions. The authors describe the framework's main steps and provide a case example of a rapid-feedback cycle and several examples of rapid-feedback memos produced during the project period. The authors also discuss implications for health education evaluation and practice. C1 [Zakocs, Ronda] Insight Evaluat LLC, Portland, OR USA. [Hill, Jessica A.] Sunflower Grp LLC, Decatur, GA USA. [Brown, Pamela; Wheaton, Jocelyn; Freire, Kimberley E.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Freire, KE (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F-64, Atlanta, GA 30341 USA. EM hbx8@cdc.gov NR 23 TC 5 Z9 5 U1 3 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD AUG PY 2015 VL 42 IS 4 BP 471 EP 479 DI 10.1177/1090198115595010 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO8GX UT WOS:000359406300005 PM 26245935 ER PT J AU Caini, S Huang, QS Ciblak, MA Kusznierz, G Owen, R Wangchuk, S Henriques, CMP Njouom, R Fasce, RA Yu, HJ Feng, LZ Zambon, M Clara, AW Kosasih, H Puzelli, S Kadjo, HA Emukule, G Heraud, JM Ang, LW Venter, M Mironenko, A Brammer, L Mai, LTQ Schellevis, F Plotkin, S Paget, J AF Caini, Saverio Huang, Q. Sue Ciblak, Meral A. Kusznierz, Gabriela Owen, Rhonda Wangchuk, Sonam Henriques, Claudio M. P. Njouom, Richard Fasce, Rodrigo A. Yu, Hongjie Feng, Luzhao Zambon, Maria Clara, Alexey W. Kosasih, Herman Puzelli, Simona Kadjo, Herve A. Emukule, Gideon Heraud, Jean-Michel Ang, Li Wei Venter, Marietjie Mironenko, Alla Brammer, Lynnette Le Thi Quynh Mai Schellevis, Francois Plotkin, Stanley Paget, John CA Global Influenza B Study TI Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Burden of disease; epidemiology; Global Influenza B Study (GIBS); influenza; vaccination; vaccine mismatch ID SEASONAL INFLUENZA; UNITED-STATES; MORTALITY; IMPACT; VIRUS; LINEAGES; VACCINE; BURDEN AB Introduction Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. Methods Twenty-six countries in the Southern (n=5) and Northern (n=7) hemispheres and intertropical belt (n=14) provided virological and epidemiological data. We calculated the proportion of influenza cases due to type B and Victoria and Yamagata lineages in each country and season; tested the correlation between proportion of influenza B and maximum weekly influenza-like illness (ILI) rate during the same season; determined the frequency of vaccine mismatches; and described the age distribution of cases by virus type. Results The database included 935673 influenza cases (2000-2013). Overall median proportion of influenza B was 226%, with no statistically significant differences across seasons. During seasons where influenza B was dominant or co-circulated (>20% of total detections), Victoria and Yamagata lineages predominated during 64% and 36% of seasons, respectively, and a vaccine mismatch was observed in approximate to 25% of seasons. Proportion of influenza B was inversely correlated with maximum ILI rate in the same season in the Northern and (with borderline significance) Southern hemispheres. Patients infected with influenza B were usually younger (5-17years) than patients infected with influenza A. Conclusion Influenza B is a common disease with some epidemiological differences from influenza A. This should be considered when optimizing control/prevention strategies in different regions and reducing the global burden of disease due to influenza. C1 [Caini, Saverio; Schellevis, Francois; Paget, John] Netherlands Inst Hlth Serv Res NIVEL, NL-3513 CR Utrecht, Netherlands. [Huang, Q. Sue] Inst Environm Sci & Res, Wellington, New Zealand. [Ciblak, Meral A.] Istanbul Univ, Istanbul, Turkey. [Kusznierz, Gabriela] Inst Nacl Enfermedades Resp Dr Emilio Coni, Santa Fe, Argentina. [Owen, Rhonda] Off Hlth Protect, Surveillance Branch, Influenza Surveillance Sect, Dept Hlth & Ageing, Woden, ACT, Australia. [Wangchuk, Sonam] Minist Hlth, Dept Publ Hlth, Publ Hlth Lab, Thimphu, Bhutan. [Henriques, Claudio M. P.] Minist Hlth, Brasilia, DF, Brazil. [Njouom, Richard] Ctr Pasteur Cameroun, Serv Virol, Yaounde, Cameroon. [Fasce, Rodrigo A.] Inst Salud Publ Chile, Secc Virus Resp & Exantemat, Santiago, Chile. [Yu, Hongjie; Feng, Luzhao] Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R China. [Zambon, Maria] Publ Hlth England, Resp Virus Unit, Colindale, England. [Clara, Alexey W.] US Ctr Dis Control, Cent Amer Reg, Guatemala City, Guatemala. [Kosasih, Herman] US Naval Med Res Unit 2, Jakarta, Indonesia. [Puzelli, Simona] Ist Super Sanita, Natl Influenza Ctr, I-00161 Rome, Italy. [Kadjo, Herve A.] Pasteur Inst Cote Ivoire, Resp Viruses Unit, Abidjan, Cote Ivoire. [Emukule, Gideon] US Ctr Dis Control & Prevent, Nairobi, Kenya. [Heraud, Jean-Michel] Inst Pasteur Madagascar, Virol Unit, Natl Influenza Ctr, Antananarivo, Madagascar. [Ang, Li Wei] Minist Hlth, Epidemiol & Dis Control Div, Singapore, Singapore. [Venter, Marietjie] US CDC, Global Dis Detect, Pretoria, South Africa. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, ZA-0001 Pretoria, South Africa. [Mironenko, Alla] Natl Acad Med Sci Ukraine, LV Gromashevsky Inst Epidemiol & Infect Dis, Kiev, Ukraine. [Brammer, Lynnette] Ctr Dis Control & Prevent, Influenza Div, Epidemiol & Prevent Branch, Atlanta, GA USA. [Le Thi Quynh Mai; Plotkin, Stanley] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. [Plotkin, Stanley] Univ Penn, Philadelphia, PA 19104 USA. RP Paget, J (reprint author), Netherlands Inst Hlth Serv Res NIVEL, Otterstr 118-124, NL-3513 CR Utrecht, Netherlands. EM j.paget@nivel.nl RI HERAUD, Jean-Michel/O-1464-2013; Venter, Marietjie/P-9604-2016; OI HERAUD, Jean-Michel/0000-0003-1107-0859; Venter, Marietjie/0000-0003-2696-824X; Pebody, Richard/0000-0002-9069-2885 FU Sanofi Pasteur FX We thank Douglas Fleming [Royal College of General Practitioners (RCGP), Birmingham, UK] for discussions regarding the age distribution of influenza A and B cases, and Peter Spreeuwenberg (NIVEL) for statistical advice. We also thank Mark Thompson, Marc-Alain Widdowson, Jazmin Duque, Stacey Spivey-Blackford, Eduardo Azziz-Baumgartner, and Alexey W. Clara from the US Centers for Disease Control and Prevention (CDC) for their support in contacting countries potentially interested in participating in the GIBS and for their valuable suggestions on data analysis. Finally, we thank Clotilde El Guerche Seblain from Sanofi Pasteur for her valuable support. NR 26 TC 17 Z9 18 U1 5 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD AUG PY 2015 VL 9 SU 1 SI SI BP 3 EP 12 DI 10.1111/irv.12319 PG 10 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CO7WX UT WOS:000359375300002 PM 26256290 ER PT J AU Cheng, PY Palekar, R Azziz-Baumgartner, E Iuliano, D Alencar, AP Bresee, J Oliva, O de Souza, MDM Widdowson, MA AF Cheng, Po-Yung Palekar, Rakhee Azziz-Baumgartner, Eduardo Iuliano, Danielle Alencar, Airlane P. Bresee, Joseph Oliva, Otavio Marinho de Souza, Maria de Fatima Widdowson, Marc-Alain TI Burden of influenza-associated deaths in the Americas, 2002-2008 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Americas; influenza; model; mortality ID RESPIRATORY SYNCYTIAL VIRUS; SEASONAL INFLUENZA; UNITED-STATES; MORTALITY; INFECTIONS; CHILDREN; DISEASE AB Background Influenza disease is a vaccine-preventable cause of morbidity and mortality. The Pan American Health Organization (PAHO) region has invested in influenza vaccines, but few estimates of influenza burden exist to justify these investments. We estimated influenza-associated deaths for 35 PAHO countries during 2002-2008. Methods Annually, PAHO countries report registered deaths. We used respiratory and circulatory (R&C) codes from seven countries with distinct influenza seasonality and high-quality mortality data to estimate influenza-associated mortality rates by age group (0-64, 65-74, and 75years) with a Serfling regression model or a negative binomial model. We calculated the percent of all R&C deaths attributable to influenza by age group in these countries (etiologic fraction) and applied it to the age-specific mortality in 13 countries with good mortality data but poorly defined seasonality. Lastly, we grouped the remaining 15 countries into WHO mortality strata and applied the age and mortality stratum-specific rate of influenza mortality calculated from the 20 countries. We summed each country's estimate to arrive at an average total annual number and rate of influenza deaths in the Americas. Results For the 35 PAHO countries, we estimated an annual mean influenza-associated mortality rate of 21/100000 among <65-year olds, 319/100000 among those 65-74years, and 1618/100000 among those 75years. We estimated that annually between 40880 and 160270 persons (mean, 85100) die of influenza illness in the PAHO region. Conclusion Influenza remains an important cause of mortality in the Americas. C1 [Cheng, Po-Yung; Palekar, Rakhee; Azziz-Baumgartner, Eduardo; Iuliano, Danielle; Bresee, Joseph; Widdowson, Marc-Alain] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Palekar, Rakhee; Oliva, Otavio; Marinho de Souza, Maria de Fatima] Pan Amer Hlth Org, Washington, DC USA. [Alencar, Airlane P.] Univ Sao Paulo, Inst Math & Stat, Sao Paulo, Brazil. RP Cheng, PY (reprint author), US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM pcheng@cdc.gov NR 25 TC 2 Z9 2 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD AUG PY 2015 VL 9 SU 1 SI SI BP 13 EP 21 DI 10.1111/irv.12317 PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CO7WX UT WOS:000359375300003 PM 26256291 ER PT J AU Flax, VL Adair, LS Allen, LH Shahab-Ferdows, S Hampel, D Chasela, CS Tegha, G Daza, EJ Corbett, A Davis, NL Kamwendo, D Kourtis, AP van der Horst, CM Jamieson, DJ Bentley, ME AF Flax, Valerie L. Adair, Linda S. Allen, Lindsay H. Shahab-Ferdows, Setarah Hampel, Daniela Chasela, Charles S. Tegha, Gerald Daza, Eric J. Corbett, Amanda Davis, Nicole L. Kamwendo, Deborah Kourtis, Athena P. van der Horst, Charles M. Jamieson, Denise J. Bentley, Margaret E. CA BAN Study Team TI Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women SO JOURNAL OF NUTRITION LA English DT Article DE highly active antiretroviral therapy; lipid-based nutrient supplements; micronutrient; HIV; mothers ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; INJECTION-DRUG USERS; T-CELL COUNTS; PROTEASE INHIBITORS; VITAMIN-A; POSITIVE PATIENTS; HIV-1-INFECTED WOMEN AB Background: Little is known about the influence of antiretroviral therapy with or without micronutrient supplementation on the micronutrient concentrations of HIV-infected lactating women in resource-constrained settings. Objective: We examined associations of highly active antiretroviral therapy (HAART) and lipid-based nutrient supplements (LNS) with concentrations of selected micronutrients in HIV-infected Malawian women at 24 wk postpartum. Methods: Plasma micronutrient concentrations were measured in a subsample (n = 690) of Breastfeeding, Antiretrovirals, and Nutrition (BAN) study participants who were randomly assigned at delivery to receive HAART, LNS, HAART+LNS, or no HAART/no LNS (control). HAART consisted of protease inhibitor-based triple therapy. LNS (140 g/d) met energy and micronutrient requirements of lactation. Multivariable linear regression tested the association of HAART and LNS, plus their interaction, with micronutrient concentrations, controlling for season, baseline viral load, and baseline CD4 count. Results: We found significant HAART by LNS interactions for folate (P = 0.051), vitamin B-12 (P < 0.0011, and transferrin receptors (TfRs)(P = 0.085). HAART was associated with lower folate (with LNS: -27%, P < 0.001; without LNS: -12%, P = 0.040) and higher TfR concentrations (with LNS: +14%, P = 0.004; without LNS: +28%, P < 0.001), indicating iron deficiency. LNS increased folate (with HAART: +17%, P = 0.037; without HAART: +39%, P < 0.001) and decreased TfR concentrations (with HAART only: 112%, P = 0.023(. HAART was associated with lower vitamin B-12 concentrations only when LNS was present (-18%, P = 0.001), whereas LNS increased vitamin B-12 only when no HAART was present (+27%, P < 0.001). HAART, but not LNS, was associated with higher retinol-binding protein (RBP; +10%, P = 0.0071. We detected no association of HAART or LNS with selenium, ferritin, or hemoglobin. Conclusion: The association of HAART with lower folate, iron deficiency, and higher RBP plus the attenuation of LNS effects on folate. and vitamin B-12 when combined with HAART has implications for the health of lactating HIV-infected women taking HAART in prevention of mother-to-child transmission programs. This trial was registered at clinicaltrials.gov as NCT00164736. C1 [Flax, Valerie L.; Adair, Linda S.; Bentley, Margaret E.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27514 USA. [Flax, Valerie L.; Adair, Linda S.; Daza, Eric J.; Davis, Nicole L.; Bentley, Margaret E.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Corbett, Amanda] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA. [van der Horst, Charles M.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Allen, Lindsay H.; Shahab-Ferdows, Setarah; Hampel, Daniela] USDA ARS, Western Human Nutr Res Ctr, Davis, CA USA. [Chasela, Charles S.; Tegha, Gerald; Kamwendo, Deborah] UNC Project, Lilongwe, Malawi. [Chasela, Charles S.] Univ Witwatersrand, Sch Publ Hlth, Parktown, South Africa. [Kourtis, Athena P.; Jamieson, Denise J.] US CDC, Atlanta, GA USA. RP Flax, VL (reprint author), Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27514 USA. EM flax@unc.edu OI Flax, Valerie/0000-0003-0200-3355 FU Prevention Research Center's Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; Bill & Melinda Gates Foundation [OPP53107]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; Carolina Population Center [R24 HD050924]; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 TW001039]; Fogarty International (the American Recovery and Reinvestment Act) [R24TW007988]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; US Agency for International Development FX The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study was supported by grants from the Prevention Research Center's Special Interest Project of the CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01), the Bill & Melinda Gates Foundation (OPP53107), the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (P30-AI50410), the Carolina Population Center (R24 HD050924), the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 TW001039), and Fogarty International Clinical Research Scholars (R24TW007988; the American Recovery and Reinvestment Act). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action Prevention of Mother-to-Child Transmission Program, from which BAN mothers were recruited, was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the US Agency for International Development. NR 63 TC 1 Z9 1 U1 2 U2 3 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD AUG PY 2015 VL 145 IS 8 BP 1950 EP 1957 DI 10.3945/jn.115.212290 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CO3DT UT WOS:000359037500035 PM 26156797 ER PT J AU Oster, AM Sternberg, M Lansky, A Broz, D Wejnert, C Paz-Bailey, G AF Oster, Alexandra M. Sternberg, Maya Lansky, Amy Broz, Dita Wejnert, Cyprian Paz-Bailey, Gabriela TI Population Size Estimates for Men who Have Sex with Men and Persons who Inject Drugs SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE HIV infection; Men who have sex with men; Persons who inject drugs; Risk factors; Gay and bisexual men AB Understanding geographic variation in the numbers of men who have sex with men (MSM) and persons who inject drugs (PWID) is critical to targeting and scaling up HIV prevention programs, but population size estimates are not available at generalizable sub-national levels. We analyzed 1999-2010 National Health and Nutrition Examination Survey data on persons aged 18-59 years. We estimated weighted prevalence of recent (past 12 month) male-male sex and injection drug use by urbanicity (the degree to which a geographic area is urban) and US census region and calculated population sizes. Large metro areas (population a parts per thousand yen1,000,000) had higher prevalence of male-male sex (central areas, 4.4 % of men; fringe areas, 2.5 %) compared with medium/small metro areas (1.4 %) and nonmetro areas (1.1 %). Injection drug use did not vary by urbanicity and neither varied by census region. Three-quarters of MSM, but only half of PWID, resided in large metro areas. Two-thirds of MSM and two-thirds of PWID resided in the South and West. Efforts to reach MSM would benefit from being focused in large metro areas, while efforts to reach PWID should be delivered more broadly. These data allow for more effective allocation of funds for prevention programs. C1 [Oster, Alexandra M.; Lansky, Amy; Broz, Dita; Wejnert, Cyprian; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30322 USA. [Sternberg, Maya] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Oster, AM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30322 USA. EM aoster@cdc.gov NR 15 TC 6 Z9 6 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 EI 1468-2869 J9 J URBAN HEALTH JI J. Urban Health PD AUG PY 2015 VL 92 IS 4 BP 733 EP 743 DI 10.1007/s11524-015-9970-3 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CO2DS UT WOS:000358966100010 PM 26115985 ER PT J AU Olson, D Watkins, LKF Demirjian, A Lin, X Robinson, CC Pretty, K Benitez, AJ Winchell, JM Diaz, MH Miller, LA Foo, TA Mason, MD Lauper, UL Kupfer, O Kennedy, J Glode, MP Kutty, PK Dominguez, SR AF Olson, Daniel Watkins, Louise K. Francois Demirjian, Alicia Lin, Xia Robinson, Christine C. Pretty, Kristin Benitez, Alvaro J. Winchell, Jonas M. Diaz, Maureen H. Miller, Lisa A. Foo, Teresa A. Mason, Melanie D. Lauper, Ursula L. Kupfer, Oren Kennedy, Jeffrey Glode, Mary P. Kutty, Preeta K. Dominguez, Samuel R. TI Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome SO PEDIATRICS LA English DT Article ID TOXIC EPIDERMAL NECROLYSIS; MINIMAL SKIN MANIFESTATIONS; REAL-TIME PCR; ERYTHEMA MULTIFORME; FUCHS-SYNDROME; MACROLIDE RESISTANCE; RESPIRATORY ILLNESS; COMMUNITY OUTBREAK; LESIONS; INFECTION AB BACKGROUND: Stevens-Johnson syndrome (SJS) is an uncommon, sporadic disease and outbreaks are rare. In November 2013, an outbreak of SJS was identified at Children's Hospital Colorado. METHODS: Outbreak cases were children aged 5-21 with a discharge diagnosis of SJS admitted from September 1 to November 30, 2013. Medical charts were reviewed using standardized data collection forms. Respiratory specimens were tested for viruses and Mycoplasma pneumoniae (Mp) by polymerase chain reaction (PCR). We conducted a separate 4-year retrospective case-control study comparing hospitalized SJS cases with and without evidence of Mp infection. RESULTS: During the outbreak, 8 children met SJS criteria. Median age was 11.5 years (range 8-16 years); 5 (63%) were boys and 5 (63%) were Mp-PCR-positive. Of the 5 PCR-positive children, none had preceding medication exposure, and all had radiographic pneumonia. All outbreak Mp isolates were macrolide susceptible. The retrospective case-control analysis showed that Mp-associated SJS episodes (n = 17) were more likely to have pneumonia (odds ratio [OR] 10.0, confidence interval [CI] 1.3-5.1), preceding respiratory symptoms (OR 30.0, CI 1.6-72.6), an erythrocyte sedimentation rate >= 35 mg/dL (OR 22.8, CI 2.1-244.9), and <= 3 affected skin sites (OR 4.5, CI 1.2-17.4) than non-Mp-associated SJS episodes (n = 23). CONCLUSIONS: We report the largest outbreak of SJS in children, which was also predominately associated with Mp infection. Mp-associated SJS was associated with a distinct clinical presentation that included less extensive skin disease, an elevated erythrocyte sedimentation rate, and evidence of a preceding respiratory infection. C1 [Olson, Daniel; Kupfer, Oren; Glode, Mary P.; Dominguez, Samuel R.] Univ Colorado, Sch Publ Hlth, Dept Pediat, Aurora, CO USA. [Mason, Melanie D.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Kennedy, Jeffrey] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA. [Foo, Teresa A.] Univ Colorado, Sch Med, Aurora, CO USA. [Watkins, Louise K. Francois; Demirjian, Alicia; Lin, Xia; Benitez, Alvaro J.; Winchell, Jonas M.; Diaz, Maureen H.; Kutty, Preeta K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Watkins, Louise K. Francois; Demirjian, Alicia; Lin, Xia] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA. [Robinson, Christine C.; Pretty, Kristin] Childrens Hosp Colorado, Dept Pathol & Lab Med, Aurora, CO USA. [Miller, Lisa A.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Lauper, Ursula L.] New York State Dept Hlth, Albany, NY USA. RP Olson, D (reprint author), Childrens Hosp Colorado, Dept Pediat Infect Dis, 13123 East 16th Ave,Box 055, Aurora, CO 80045 USA. EM Daniel.Olson@childrenscolorado.org FU NIH/NCATS Colorado CTSI Grant [UL1 TR001082]; National Institutes of Health FX Dr Olson is supported by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. Funded by the National Institutes of Health. NR 62 TC 6 Z9 6 U1 2 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD AUG PY 2015 VL 136 IS 2 BP E386 EP E394 DI 10.1542/peds.2015-0278 PG 9 WC Pediatrics SC Pediatrics GA CN9SA UT WOS:000358788100011 PM 26216320 ER PT J AU Kostova, D Dave, D AF Kostova, Deliana Dave, Dhaval TI Smokeless tobacco use in India: Role of prices and advertising SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE India; Smokeless tobacco use; Tobacco prices; Tobacco advertising; Health production ID SAMPLE SELECTION; 2-PART MODELS; CONSUMPTION; PRODUCTS; PREVALENCE; MADAGASCAR; SMOKING; DEMAND; METALS; IMPACT AB Although the primary form of tobacco use worldwide is cigarette smoking, the large majority of users in India consume smokeless forms of tobacco. There is little evidence on the role of policy-related factors in shaping the demand for smokeless tobacco (ST) in India. This study evaluates the relationship between two such factors, prices and advertising, and ST use in India, using data on 67,737 individuals from the Global Adult Tobacco Survey (GATS) India 2009. We find that ST advertising is more likely to influence ST consumption in women than men, while men are more likely to respond to changes in ST price. We estimate that among adult males in India, the total price elasticity of ST demand is -0.212, which is close to estimates reported for males in the U.S. We do not find strong direct evidence on the economic substitutability or complementarity of smoked and smokeless products. However, the positive association between former smoking and current smokeless use may point to temporal substitutability at the individual level. The findings have implications on the relative effectiveness of policy tools across genders in India increasing the prices of ST products may discourage ST use particularly among men, and advertising restrictions may play a relatively larger role in the consumption behavior of women in India. Published by Elsevier Ltd. C1 [Kostova, Deliana] Ctr Dis Control & Prevent, Atlanta, GA 30332 USA. [Dave, Dhaval] Bentley Univ, Waltham, MA 02452 USA. [Dave, Dhaval] NBER, Cambridge, MA 02138 USA. RP Kostova, D (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30332 USA. EM kiv0@cdc.gov; ddave@bentley.edu NR 28 TC 1 Z9 1 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD AUG PY 2015 VL 138 BP 82 EP 90 DI 10.1016/j.socscimed.2015.05.036 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CO0BX UT WOS:000358816200012 PM 26069951 ER PT J AU Moulton-Meissner, H Noble-Wang, J Gupta, N Hocevar, S Kallen, A Arduino, M AF Moulton-Meissner, Heather Noble-Wang, Judith Gupta, Neil Hocevar, Susan Kallen, Alex Arduino, Matthew TI Laboratory replication of filtration procedures associated with Serratia marcescens bloodstream infections in patients receiving compounded amino acid solutions SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article ID CONTAMINATED PARENTERAL-NUTRITION; INTENSIVE-CARE-UNIT; MULTISTATE OUTBREAK; INTRAVENOUS FENTANYL; MEMBRANE FILTERS; PART II; PHARMACY; STERILE; WATER; SEPTICEMIA AB Purpose. Specific deviations from United States Pharmacopeia standards were analyzed to investigate the factors allowing an outbreak of Serratia marcescens bloodstream infections in patients receiving compounded amino acid solutions. Methods. Filter challenge experiments using the outbreak strain of S. marcescens were compared with those that used the filter challenge organism recommended by ASTM International (Brevundimonas diminuta ATCC 19162) to determine the frequency and degree of organism breakthrough. Disk and capsule filters (0.22- and 0.2-mu m nominal pore size, respectively) were challenged with either the outbreak strain of S. marcescens or B. diminuta ATCC 19162. The following variables were compared: culture conditions in which organisms were grown overnight or cultured in sterile water (starved), solution type (15% amino acid solution or sterile water), and filtration with or without a 0.5-mu m prefilter. Results. Small-scale, syringe-driven, disk-filtration experiments of starved bacterial cultures indicated that approximately 1 in every 1,000 starved S. marcescens cells (0.12%) was able to pass through a 0.22-mu m nominal pore-size filter, and about 1 in every 1,000,000 cells was able to pass through a 0.1-mu m nominal pore-size filter. No passage of the B. diminuta ATCC 19162 cells was observed with either filter. In full-scale experiments, breakthrough was observed only when 0.2-mu m capsule filters were challenged with starved S. marcescens in 15% amino acid solution without a 0.5-mu m prefiltration step. Conclusion. Laboratory simulation testing revealed that under certain conditions, bacteria can pass through 0.22- and 0.2-mu m filters intended for sterilization of an amino acid solution. Bacteria did not pass through 0.2-mu m filters when a 0.5-mu m prefilter was used. C1 [Moulton-Meissner, Heather] Ctr Dis Control & Prevent, DHQP, Atlanta, GA 30333 USA. [Noble-Wang, Judith; Gupta, Neil; Hocevar, Susan; Kallen, Alex] Ctr Dis Control & Prevent, Atlanta, GA USA. [Arduino, Matthew] Ctr Dis Control & Prevent, DHQP, Clin Environm Microbiol, Atlanta, GA USA. RP Moulton-Meissner, H (reprint author), Ctr Dis Control & Prevent, DHQP, Atlanta, GA 30333 USA. EM ftw2@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX Supported by the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. Use of trade names is for identification only and does not imply endorsement by CDC or the U.S. Department of Health and Human Services. NR 36 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 EI 1535-2900 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD AUG 1 PY 2015 VL 72 IS 15 BP 1285 EP 1291 DI 10.2146/ajhp150141 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CO0BN UT WOS:000358815200012 PM 26195654 ER PT J AU Fischer, WA Uyeki, TM Tauxe, RV AF Fischer, William A., II Uyeki, Timothy M. Tauxe, Robert V. TI Ebola virus disease: What clinicians in the United States need to know SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Personal protection equipment; Person under investigation; Viral hemorrhagic fever ID HEMORRHAGIC-FEVER; NONHUMAN-PRIMATES; MARBURG VIRUSES; CONGO; INFECTIONS; MANAGEMENT; KIKWIT; PERSISTENCE; EPIDEMIC; OUTBREAK AB In March 2014 the World Health Organization was notified of an outbreak of Ebola virus disease (EVD) in the forest region of Guinea. As of May 2015, the outbreak had become the most devastating EVD epidemic in history with more than 27,000 cases and more than 11,000 deaths. The introduction of EVD into noncontiguous countries, including the United States, from infected travelers highlights the importance of preparedness of all health care providers. Early identification and rapid isolation of patients suspected with EVD is critical to limiting the spread of Ebola virus. Additionally, enhanced understanding of EVD case definitions, clinical presentation, treatment procedures, and infection control strategies will improve the ability of health care workers to provide safe care for patients with EVD. Copyright (C) 2015 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Fischer, William A., II] Univ N Carolina, Div Pulm & Crit Care Med, Chapel Hill, NC 27599 USA. [Uyeki, Timothy M.; Tauxe, Robert V.] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA USA. RP Fischer, WA (reprint author), Univ N Carolina, Div Pulm & Crit Care Med, 104 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM william_fischer@med.unc.edu FU NCATS NIH HHS [KL2TR001109, KL2 TR001109]; NIA NIH HHS [R03 AG045088] NR 45 TC 2 Z9 2 U1 4 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD AUG 1 PY 2015 VL 43 IS 8 BP 788 EP 793 DI 10.1016/j.ajic.2015.05.005 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CN9WY UT WOS:000358802400004 PM 26116335 ER PT J AU Thompson, ND Edwards, JR Bamberg, W Beldavs, ZG Dumyati, G Godine, D Maloney, M Kainer, M Ray, S Thompson, D Wilson, L Magill, SS AF Thompson, Nicola D. Edwards, Jonathan R. Bamberg, Wendy Beldavs, Zintars G. Dumyati, Ghinwa Godine, Deborah Maloney, Meghan Kainer, Marion Ray, Susan Thompson, Deborah Wilson, Lucy Magill, Shelley S. TI Estimating central line-associated bloodstream infection incidence rates by sampling of denominator data: A prospective, multicenter evaluation SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Surveillance; Denominator; Methods; Central line-associated bloodstream infection; National Healthcare Safety Network ID SAFETY; SURVEILLANCE AB Background: Large-scale, prospective, evaluation of sampling for central line-associated bloodstream infection (CLABSI) denominator data was necessary prior to National Healthcare Safety Network (NHSN) implementation. Methods: In a sample of volunteer hospitals from states in the Emerging Infections Program, prospective collection of CLABSI denominators (patient days, central line days [CLDs]) was performed in eligible locations for >= 6 and >= 12 consecutive months using the current NHSN method (daily collection) and also by a second data collector who sampled the denominator data 1 d/wk. The quality of the sampled data was evaluated and used to calculate estimated CLDs and CLABSI rates, which were compared with actual CLDs and CLABSI rates (daily counts). Results: In total, 89 locations in 66 acute care hospitals participated. Sampled data were collected as intended 88% of the time; the quality of the data was comparable with the data collected daily. In locations with higher CLDs per month (>= 75), estimated CLDs and CLABSI rates were similar to actual CLDs and CLABSI rates; however, there were significant differences in actual and estimated values among locations with lower (<= 74) CLDs per month. Sampling was successfully implemented, but significant differences in the accuracy of estimated CLDs and CLABSI rates, based on the actual number of CLDs per month, were noted. Conclusion: For locations with a higher number of CLDs per month, sampling 1 d/wk is a valid and accurate alternative to daily collection of CLABSI denominator data. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Thompson, Nicola D.; Edwards, Jonathan R.; Magill, Shelley S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Bamberg, Wendy] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Beldavs, Zintars G.] Oregon Hlth Author, Portland, OR USA. [Dumyati, Ghinwa] Univ Rochester, Rochester, NY USA. [Godine, Deborah] Calif Emerging Infect Program, Oakland, CA USA. [Maloney, Meghan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Kainer, Marion] Tennessee Dept Hlth, Nashville, TN USA. [Ray, Susan] Georgia Emerging Infect Program, Atlanta, GA USA. [Thompson, Deborah] New Mexico Dept Hlth, Santa Fe, NM USA. [Wilson, Lucy] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. RP Thompson, ND (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM ndthompson@cdc.gov FU Centers for Disease Control and Prevention Emerging Infection Program Cooperative Agreement FX This evaluation was funded by the Centers for Disease Control and Prevention Emerging Infection Program Cooperative Agreement. NR 13 TC 2 Z9 2 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD AUG 1 PY 2015 VL 43 IS 8 BP 853 EP 856 DI 10.1016/j.ajic.2015.03.031 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CN9WY UT WOS:000358802400016 PM 26004907 ER PT J AU Shapira, SK Tian, LH Aylsworth, AS Elias, ER Hoover-Fong, JE Meeks, NJ Souders, MC Tsai, ACH Zackai, EH Alexander, AA Schieve, LA AF Shapira, S. K. Tian, L. H. Aylsworth, A. S. Elias, E. R. Hoover-Fong, J. E. Meeks, N. J. Souders, M. C. Tsai, A. C. -H. Zackai, E. H. Alexander, A. A. Schieve, L. A. TI DEVELOPMENT OF A NOVEL PROTOCOL FOR CHARACTERIZING DYSMORPHOLOGY BASED ON MINOR MALFORMATIONS TO ENHANCE THE PHENOTYPIC CLASSIFICATION OF AUTISM SPECTRUM DISORDER SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Meeting Abstract CT 35th Annual David W Smith Workshop on Malformations and Morphogenesis CY JUL 25-30, 2014 CL Univ Wisconsin, Madison, WI HO Univ Wisconsin C1 [Shapira, S. K.; Tian, L. H.; Alexander, A. A.; Schieve, L. A.] CDC, Atlanta, GA 30333 USA. [Aylsworth, A. S.] UNC Sch Med, Chapel Hill, NC USA. [Elias, E. R.; Meeks, N. J.; Tsai, A. C. -H.] Univ Colorado, Sch Med, Aurora, CO USA. [Hoover-Fong, J. E.] Johns Hopkins Univ, Baltimore, MD USA. [Souders, M. C.; Zackai, E. H.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Tsai, A. C. -H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD AUG PY 2015 VL 167 IS 8 BP 1690 EP 1690 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA CN7ER UT WOS:000358597400015 ER PT J AU Honein, MA Simeone, RM Reefhuis, J Tinker, SC Waller, DK Moore, CA AF Honein, Margaret A. Simeone, Regina M. Reefhuis, Jennita Tinker, Sarah C. Waller, D. Kim Moore, Cynthia A. TI ASSESSING THE IMPACT OF RACE/ETHNICITY ON THE ASSOCIATION BETWEEN PRE-PREGNANCY OBESITY AND SELECTED BIRTH DEFECTS SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Meeting Abstract CT 35th Annual David W Smith Workshop on Malformations and Morphogenesis CY JUL 25-30, 2014 CL Univ Wisconsin, Madison, WI HO Univ Wisconsin C1 [Honein, Margaret A.; Simeone, Regina M.; Reefhuis, Jennita; Tinker, Sarah C.; Moore, Cynthia A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Waller, D. Kim] Univ Texas Houston, Sch Publ Hlth, Houston Hlth Sci Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD AUG PY 2015 VL 167 IS 8 BP 1736 EP 1736 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA CN7ER UT WOS:000358597400125 ER PT J AU Edwards, RK Tang, Y Raglan, GB Szychowski, JM Schulkin, J Schrag, SJ AF Edwards, Rodney K. Tang, Ying Raglan, Greta B. Szychowski, Jeff M. Schulkin, Jay Schrag, Stephanie J. TI Survey of American obstetricians regarding group B streptococcus: opinions and practice patterns SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE early-onset neonatal infection; group B streptococcus intrapartum antibiotic prophylaxis; screening ID SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS; VAGINAL-RECTAL CULTURES; UNITED-STATES; DISEASE; TRANSMISSION; PREVENTION; LABOR AB OBJECTIVE: The objective of the study was to evaluate attitudes and practice patterns of obstetricians related to screening for group B streptococcal colonization and providing intrapartum antibiotic prophylaxis against early-onset neonatal infections with group B streptococcus. STUDY DESIGN: We mailed a survey to 546 members of the American College of Obstetricians and Gynecologists, including members of the Collaborative Ambulatory Research Network and non-Collaborative Ambulatory Research Network members. Stratified random selection was used to generate samples from both of these groups. RESULTS: The survey response rate was 60% for Collaborative Ambulatory Research Network members and 42% for nonCollaborative Ambulatory Research Network members. Of the 206 respondents who reported providing prenatal care, 97% collect screening samples at 35-37 weeks' gestational age. Anatomic sites used to collect samples were more variable: 62% include lower vagina and rectum, 26% include lower vagina and perianal skin but not rectum, and 5% include neither the perianal skin nor the rectum. Firstline agents for intrapartum antibiotic prophylaxis were penicillin (71%), ampicillin (27%), and cefazolin (2%). For patients reporting a nonanaphylactic penicillin allergy, drugs used for intrapartum antibiotic prophylaxis were more varied: cefazolin (51%), clindamycin (36%), vancomycin (8%), and erythromycin (5%). For patients undergoing a labor induction starting with a cervical ripening agent, less than 40% typically give the first dose of intrapartum antibiotic prophylaxis before or at the time of cervical ripening agent administration, and 15% wait until the patient reaches the active phase of labor. CONCLUSION: Gaps in knowledge and reported practice related to the prevention of early-onset neonatal group B streptococcus infections were similar to gaps in implementation of guidelines demonstrated in past studies. New approaches to improve implementation are warranted. C1 [Edwards, Rodney K.; Tang, Ying; Szychowski, Jeff M.] Univ Alabama Birmingham, Ctr Womens Reprod Hlth, Birmingham, AL 35233 USA. [Raglan, Greta B.; Schulkin, Jay] Amer Coll Obstetricians & Gynecologists, Washington, DC USA. [Schrag, Stephanie J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Edwards, RK (reprint author), Univ Alabama Birmingham, Ctr Womens Reprod Hlth, Birmingham, AL 35233 USA. EM rke@uab.edu FU Maternal and Child Health Bureau [UA6MC19010]; Department of Health and Human Services FX G.B.R. and J.S. were supported by grant UA6MC19010 from the Maternal and Child Health Bureau (Title V, Social Security Act, Health Resources and Services Administration) and the Department of Health and Human Services. Other authors were supported by departmental funds. NR 19 TC 3 Z9 4 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD AUG PY 2015 VL 213 IS 2 AR 229.e1 DI 10.1016/j.ajog.2015.03.047 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CN6NG UT WOS:000358550900030 PM 25816787 ER PT J AU Ko, JY Farr, SL Tong, VT Creanga, AA Callaghan, WM AF Ko, Jean Y. Farr, Sherry L. Tong, Van T. Creanga, Andreea A. Callaghan, William M. TI Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE correlates; dependence; marijuana; pregnant; prevalence ID CANNABIS USE; BIRTH-OUTCOMES; UNITED-STATES; ALCOHOL; ASSOCIATIONS; ABUSE AB OBJECTIVE: The objective of the study was to provide national prevalence, patterns, and correlates of marijuana use in the past month and past 2-12 months among women of reproductive age by pregnancy status. STUDY DESIGN: Data from 2007-2012 National Surveys on Drug Use and Health, a cross-sectional nationally representative survey, identified pregnant (n = 4971) and nonpregnant (n = 88,402) women 18-44 years of age. Women self-reported marijuana use in the past month and past 2-12 months (use in the past year but not in the past month). chi(2) statistics and adjusted prevalence ratios were estimated using a weighting variable to account for the complex survey design and probability of sampling. RESULTS: Among pregnant women and nonpregnant women, respectively, 3.9% (95% confidence interval [CI], 3.2-4.7) and 7.6% (95% CI, 7.3-7.9) used marijuana in the past month and 7.0% (95% CI, 6.0-8.2) and 6.4% (95% CI, 6.2-6.6) used in the past 2-12 months. Among past-year marijuana users (n = 17,934), use almost daily was reported by 16.2% of pregnant and 12.8% of nonpregnant women; and 18.1% of pregnant and 11.4% of nonpregnant women met criteria for abuse and/or dependence. Approximately 70% of both pregnant and nonpregnant women believe there is slight or no risk of harm from using marijuana once or twice a week. Smokers of tobacco, alcohol users, and other illicit drug users were 2-3 times more likely to use marijuana in the past year than respective nonusers, adjusting for sociodemographic characteristics. CONCLUSION: More than 1 in 10 pregnant and nonpregnant women reported using marijuana in the past 12 months. A considerable percentage of women who used marijuana in the past year were daily users, met abuse and/or dependence criteria, and were polysubstance users. Comprehensive screening, treatment for use of multiple substances, and additional research and patient education on the possible harms of marijuana use are needed for all women of reproductive age. C1 [Ko, Jean Y.; Farr, Sherry L.; Tong, Van T.; Creanga, Andreea A.; Callaghan, William M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30329 USA. RP Ko, JY (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30329 USA. EM JeanKo@cdc.gov NR 32 TC 5 Z9 5 U1 3 U2 11 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD AUG PY 2015 VL 213 IS 2 AR 201.e1 DI 10.1016/j.ajog.2015.03.021 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CN6NG UT WOS:000358550900018 PM 25772211 ER PT J AU Atmar, RL Bernstein, DI Lyon, GM Treanor, JJ Al-Ibrahim, MS Graham, DY Vinje, J Jiang, X Gregoricus, N Frenck, RW Moe, CL Chen, WH Ferreira, J Barrett, J Opekun, AR Estes, MK Borkowski, A Baehner, F Goodwin, R Edmonds, A Mendelmank, PM AF Atmar, Robert L. Bernstein, David I. Lyon, G. Marshall Treanor, John J. Al-Ibrahim, Mohamed S. Graham, David Y. Vinje, Jan Jiang, Xi Gregoricus, Nicole Frenck, Robert W. Moe, Christine L. Chen, Wilbur H. Ferreira, Jennifer Barrett, Jill Opekun, Antone R. Estes, Mary K. Borkowski, Astrid Baehner, Frank Goodwin, Robert Edmonds, Anthony Mendelmank, Paul M. TI Serological Correlates of Protection against a GII.4 Norovirus SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID NORWALK VIRUS-INFECTION; BLOOD GROUP ANTIGENS; UNITED-STATES; VACCINE; BINDING; GASTROENTERITIS; SUSCEPTIBILITY; IMMUNOGENICITY; EPIDEMIOLOGY; RESISTANCE AB Noroviruses are the leading cause of acute gastroenteritis worldwide, and norovirus vaccine prevention strategies are under evaluation. The immunogenicity of two doses of bivalent genogroup 1 genotype 1 (GI.1)/GII.4 (50 mu g of virus-like particles [VLPs] of each strain adjuvanted with aluminum hydroxide and 3-O-desacyl-4' monophosphoryl lipid A [MPL]) norovirus vaccine administered to healthy adults in a phase 1/2 double-blind placebo-controlled trial was determined using virus-specific serum total antibody enzyme-linked immunosorbent assay (ELISA), IgG, IgA, and histoblood group antigen (HBGA)-blocking assays. Trial participants subsequently received an oral live virus challenge with a GII.4 strain, and the vaccine efficacy results were reported previously (D.I. Bernstein et al., J Infect Dis 211:870-878, 2014, doi:10.1093/infdis/jiu497). This report assesses the impact of prechallenge serum antibody levels on infection and illness outcomes. Serum antibody responses were observed in vaccine recipients by all antibody assays, with first-dose seroresponse frequencies ranging from 88 to 100% for the GI.1 antigen and from 69 to 84% for the GII.4 antigen. There was little increase in antibody levels after the second vaccine dose. Among the subjects receiving the placebo, higher prechallenge serum anti-GII.4 HBGA-blocking and IgA antibody levels, but not IgG or total antibody levels, were associated with a lower frequency of virus infection and associated illness. Notably, some placebo subjects without measurable serum antibody levels prechallenge did not become infected after norovirus challenge. In vaccinees, anti-GII.4 HBGA-blocking antibody levels of > 1:500 were associated with a lower frequency of moderate-to-severe vomiting or diarrheal illness. In this study, prechallenge serum HBGA antibody titers correlated with protection in subjects receiving the placebo; however, other factors may impact the likelihood of infection and illness after virus exposure. C1 [Atmar, Robert L.; Graham, David Y.; Opekun, Antone R.; Estes, Mary K.] Baylor Coll Med, Houston, TX 77030 USA. [Graham, David Y.; Opekun, Antone R.] Michael E DeBakey VAMC, Houston, TX USA. [Bernstein, David I.; Jiang, Xi; Frenck, Robert W.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Lyon, G. Marshall] Emory Univ, Sch Med, Atlanta, GA USA. [Moe, Christine L.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Treanor, John J.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Al-Ibrahim, Mohamed S.] Shin Nippon Biomed Labs, Baltimore, MD USA. [Vinje, Jan; Gregoricus, Nicole] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chen, Wilbur H.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Ferreira, Jennifer; Barrett, Jill] EMMES Corp, Rockville, MD USA. [Borkowski, Astrid; Baehner, Frank; Goodwin, Robert; Edmonds, Anthony; Mendelmank, Paul M.] Takeda Vaccines Inc, Deerfield, IL USA. RP Atmar, RL (reprint author), Baylor Coll Med, Houston, TX 77030 USA. EM ratmar@bcm.edu FU Takeda Vaccines, Inc.; John S. Dunn Research Foundation FX This study was supported by Takeda Vaccines, Inc.; R.L.A. also receives support from the John S. Dunn Research Foundation. NR 37 TC 18 Z9 18 U1 3 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD AUG PY 2015 VL 22 IS 8 BP 923 EP 929 DI 10.1128/CVI.00196-15 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CN8DR UT WOS:000358668600011 PM 26041041 ER PT J AU Laurie, KL Engelhardt, OG Wood, J Heath, A Katz, JM Peiris, M Hoschler, K Hungnes, O Zhang, WQ Van Kerkhove, MD AF Laurie, Karen L. Engelhardt, Othmar G. Wood, John Heath, Alan Katz, Jacqueline M. Peiris, Malik Hoschler, Katja Hungnes, Olav Zhang, Wenqing Van Kerkhove, Maria D. CA CONSISE Lab Working Grp Participan TI International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1) pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID SEROLOGIC ASSAYS; INFECTION; ANTIBODY; REPRODUCIBILITY; H5N1 AB The microneutralization assay is commonly used to detect antibodies to influenza virus, and multiple protocols are used worldwide. These protocols differ in the incubation time of the assay as well as in the order of specific steps, and even within protocols there are often further adjustments in individual laboratories. The impact these protocol variations have on influenza serology data is unclear. Thus, a laboratory comparison of the 2-day enzyme-linked immunosorbent assay (ELISA) and 3-day hemagglutination (HA) microneutralization (MN) protocols, using A(H1N1) pdm09, A(H3N2), and A(H5N1) viruses, was performed by the CONSISE Laboratory Working Group. Individual laboratories performed both assay protocols, on multiple occasions, using different serum panels. Thirteen laboratories from around the world participated. Within each laboratory, serum sample titers for the different assay protocols were compared between assays to determine the sensitivity of each assay and were compared between replicates to assess the reproducibility of each protocol for each laboratory. There was good correlation of the results obtained using the two assay protocols in most laboratories, indicating that these assays may be interchangeable for detecting antibodies to the influenza A viruses included in this study. Importantly, participating laboratories have aligned their methodologies to the CONSISE consensus 2-day ELISA and 3-day HA MN assay protocols to enable better correlation of these assays in the future. C1 [Laurie, Karen L.] WHO, Collaborating Ctr Reference & Res Influenza, Victorian Infect Dis Reference Lab, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia. [Engelhardt, Othmar G.] Med & Healthcare Prod Regulatory Agcy, Natl Inst Biol Stand & Control, Potters Bar, Herts, England. [Wood, John; Heath, Alan] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England. [Katz, Jacqueline M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Peiris, Malik] Univ Hong Kong, Sch Publ Hlth, Pok Fu Lam, Hong Kong, Peoples R China. [Hoschler, Katja] Publ Hlth England, London, England. [Hungnes, Olav] Norwegian Inst Publ Hlth, Oslo, Norway. [Zhang, Wenqing] WHO, CH-1211 Geneva, Switzerland. [Van Kerkhove, Maria D.] Inst Pasteur, Ctr Global Hlth, Paris, France. RP Laurie, KL (reprint author), WHO, Collaborating Ctr Reference & Res Influenza, Victorian Infect Dis Reference Lab, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia. EM Karen.Laurie@influenzacentre.org RI MONTOMOLI, EMANUELE/Q-2122-2015; CASTRUCCI, MARIA RITA/C-2535-2016; OI MONTOMOLI, EMANUELE/0000-0001-7595-4974; Laurie, Karen/0000-0001-5186-8342 FU Australian Government Department of Health; Area of Excellence Scheme of the University Grants Committee of Hong Kong at the University of Hong Kong [AoE/M-12/96]; UK Medical Research Council; United States Armed Forces Health Surveillance Center's Global Emerging Infections Surveillance and Response System for the Naval Medical Research Center; Naval Health Research Center; Italian Ministry of Health; IFPMA (International Federation of Pharmaceutical Manufacturers Associations); Juvaris Bio-Therapeutics, Inc.; Bill and Melinda Gates Foundation; Glaxo SmithKline FX The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by a grant from the Australian Government Department of Health to K.L.L. This work was also supported by a grant from the Area of Excellence Scheme of the University Grants Committee of Hong Kong (AoE/M-12/96) to M.P. at the University of Hong Kong, by grants from the UK Medical Research Council and the Bill and Melinda Gates Foundation to M.D.V.K., and by the United States Armed Forces Health Surveillance Center's Global Emerging Infections Surveillance and Response System for the Naval Medical Research Center and the Naval Health Research Center and the Italian Ministry of Health (virological surveillance of epidemic and pandemic influenza) for the Istituto Superiore di Sanita.; K.L.L., J.W., A.H., M.P., K.H., O.H., W.Z., and M.D.V.K. declare no conflicts of interest. O.G.E. reports grants from IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) outside the submitted work. J.M.K. reports grants from Juvaris Bio-Therapeutics, Inc., and Glaxo SmithKline outside the submitted work. J.M.K. has several patents (18-20). NR 20 TC 3 Z9 3 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD AUG PY 2015 VL 22 IS 8 BP 957 EP 964 DI 10.1128/CVI.00278-15 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CN8DR UT WOS:000358668600016 PM 26108286 ER PT J AU Heiman, KE Mody, RK Johnson, SD Griffin, PM Gould, LH AF Heiman, Katherine E. Mody, Raja K. Johnson, Shacara D. Griffin, Patricia M. Gould, L. Hannah TI Escherichia coli O157 Outbreaks in the United States, 2003-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEMOLYTIC-UREMIC SYNDROME; FOODBORNE DISEASE OUTBREAKS; RISK-FACTORS; BEEF-CATTLE; SURVEILLANCE; INFECTIONS; PREVALENCE; EPIDEMIOLOGY; TRANSMISSION; CONSUMPTION AB Infections with the Shiga toxin-producing bacterium Escherichia coli 0157 can cause severe illness and death. We summarized reported outbreaks of E. coli 0157 infections in the United States during 2003-2012, including demographic characteristics of patients and epidemiologic findings by transmission mode and food category. We identified 390 outbreaks, which included 4,928 illnesses, 1,272 hospitalizations, and 33 deaths. Transmission was through food (255 outbreaks, 65%), person-to-person contact (39, 10%), indirect or direct contact with animals (39, 10%), and water (15, 4%); 42 (11%) had a different or unknown mode of transmission. Beef and leafy vegetables, combined, were the source of >25% of all reported E. coli outbreaks and of >40% of related illnesses. Outbreaks attributed to foods generally consumed raw caused higher hospitalization rates than those attributed to foods generally consumed cooked (35% vs. 28%). Most (87%) water-borne E. coli outbreaks occurred in states bordering the Mississippi River. C1 [Heiman, Katherine E.] Ctr Dis Control & Prevent, Outbreak Response & Prevent Branch, Atlanta, GA 30329 USA. [Mody, Raja K.; Johnson, Shacara D.; Griffin, Patricia M.; Gould, L. Hannah] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Heiman, KE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30329 USA. EM uwj0@cdc.gov NR 40 TC 9 Z9 9 U1 3 U2 28 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1293 EP 1301 DI 10.3201/eid2108.141364 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300002 PM 26197993 ER PT J AU Sharp, TM Moreira, R Soares, MJ da Costa, LM Mann, J DeLorey, M Hunsperger, E Munoz-Jordan, JL Colon, C Margolis, HS de Caravalho, A Tomashek, KM AF Sharp, Tyler M. Moreira, Rosa Soares, Maria Jose da Costa, Luis Miguel Mann, Jennifer DeLorey, Mark Hunsperger, Elizabeth Munoz-Jordan, Jorge L. Colon, Candimar Margolis, Harold S. de Caravalho, Adelaide Tomashek, Kay M. TI Underrecognition of Dengue during 2013 Epidemic in Luanda, Angola SO EMERGING INFECTIOUS DISEASES LA English DT Article ID VIRUS TRANSMISSION; AEDES-AEGYPTI; THAI VILLAGES; PUERTO-RICO; CHILDREN; FEVER; TIME; INFECTION; OUTBREAK; CLUSTER AB During the 2013 dengue epidemic in Luanda, Angola, 811 dengue rapid diagnostic test-positive cases were reported to the Ministry of Health. To better understand the magnitude of the epidemic and identify risk factors for dengue virus (DENV) infection, we conducted cluster surveys around households of case-patients and randomly selected households 6 weeks after the peak of the epidemic. Of 173 case cluster participants, 16 (9%) exhibited evidence of recent DENV infection. Of 247 random cluster participants, 25 (10%) had evidence of recent DENV infection. Of 13 recently infected participants who had a recent febrile illness, 7 (54%) had sought medical care, and 1 (14%) was hospitalized with symptoms consistent with severe dengue; however, none received a diagnosis of dengue. Behavior associated with protection from DENV infection included recent use of mosquito repellent or a bed net. These findings suggest that the 2013 dengue epidemic was larger than indicated by passive surveillance data. C1 [Sharp, Tyler M.; Hunsperger, Elizabeth; Munoz-Jordan, Jorge L.; Colon, Candimar; Margolis, Harold S.; Tomashek, Kay M.] Ctr Dis Control & Prevent, San Juan, PR 00920 USA. [Moreira, Rosa] Ctr Dis Control & Prevent, Field Epidemiol & Lab Training Program, Luanda, Angola. [Soares, Maria Jose; da Costa, Luis Miguel; de Caravalho, Adelaide] Minist Hlth Angola, Luanda, Angola. [Mann, Jennifer] Ctr Dis Control & Prevent, Ctr Global Hlth, Luanda, Angola. [DeLorey, Mark] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. EM tsharp@cdc.gov FU CDC Global Disease Detection Operations Center Outbreak Response Contingency Fund FX We acknowledge the CDC Global Disease Detection Operations Center Outbreak Response Contingency Fund for financial support of the field investigation. NR 36 TC 6 Z9 6 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1311 EP 1316 DI 10.3201/eid2108.150368 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300004 PM 26196224 ER PT J AU Oyong, K Coelho, L Bancroft, E Terashita, D AF OYong, Kelsey Coelho, Laura Bancroft, Elizabeth Terashita, Dawn TI Health Care-Associated Infection Outbreak Investigations in Outpatient Settings, Los Angeles County, California, USA, 2000-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID VIRUS-INFECTIONS AB Health care services are increasingly delivered in outpatient settings. However, infection control oversight in outpatient settings to ensure patient safety has not improved and literature quantifying reported health care-associated infection outbreaks in outpatient settings is scarce. The objective of this analysis was to characterize investigations of suspected and confirmed outbreaks in outpatient settings in Los Angeles County, California, USA, reported during 2000-2012, by using internal logs; publications; records; and correspondence of outbreak investigations by characteristics of the setting, number, and type of infection control breaches found during investigations, outcomes of cases, and public health responses. Twenty-eight investigations met the inclusion criteria. Investigations occurred frequently, in diverse settings, and required substantial public health resources. Most outpatient settings investigated had >= 1 infection control breach. Lapses in infection control were suspected to be the outbreak source for 16 of the reviewed investigations. C1 [OYong, Kelsey; Terashita, Dawn] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA 90012 USA. [Coelho, Laura] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Oyong, K (reprint author), Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control Program, 313 North Figueroa St,Rm 222, Los Angeles, CA 90012 USA. EM koyong@ph.lacounty.gov NR 17 TC 0 Z9 0 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1317 EP 1321 DI 10.3201/eid2108.141251 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300005 PM 26196293 ER PT J AU Lim, SM Brault, AC van Amerongen, G Bosco-Lauth, AM Romo, H Sewbalaksing, VD Bowen, RA Osterhaus, ADME Koraka, P Martina, BEE AF Lim, Stephanie M. Brault, Aaron C. van Amerongen, Geert Bosco-Lauth, Angela M. Romo, Hannah Sewbalaksing, Varsha D. Bowen, Richard A. Osterhaus, Albert D. M. E. Koraka, Penelope Martina, Byron E. E. TI Susceptibility of Carrion Crows to Experimental Infection with Lineage 1 and 2 West Nile Viruses SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NORTH-AMERICAN BIRDS; NEW-YORK; CENTRAL-EUROPE; STRAINS; CALIFORNIA; MOSQUITOS AB West Nile virus (WNV) outbreaks in North America have been characterized by substantial die-offs of American crows (Corvus brachyrhynchos). In contrast, a low incidence of bird deaths has been observed during WNV epidemic activity in Europe. To examine the susceptibility of the western European counterpart of American crows, we inoculated carrion crows (Corvus corone) with WNV strains isolated in Greece (Gr-10), Italy (FIN and Ita09), and Hungary (578/10) and with the highly virulent North American genotype strain (NY99). We also inoculated American crows with a selection of these strains to examine the strains' virulence in a highly susceptible bird species. Infection with all strains, except WNV FIN, resulted in high rates of death and high-level viremia in both. bird species and virus dissemination to several organs. These results suggest that carrion crows are highly susceptible to WNV and may potentially be useful as part of dead bird surveillance for early warning of WNV activity in Europe. C1 [Lim, Stephanie M.] Erasmus MC, Dept Virosci, NL-3000 CA Rotterdam, Netherlands. [Brault, Aaron C.; Bosco-Lauth, Angela M.; Romo, Hannah] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Bowen, Richard A.] Colorado State Univ, Ft Collins, CO 80523 USA. [Osterhaus, Albert D. M. E.; Koraka, Penelope; Martina, Byron E. E.] Artemis One Hlth Res Inst, Utrecht, Netherlands. RP Martina, BEE (reprint author), Erasmus MC, Dept Virosci, Postbus 2040, NL-3000 CA Rotterdam, Netherlands. EM b.martina@erasmusmc.nl FU European Community; European Commission [261466] FX The research leading to these results has received complete funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under the project "VECTORIE," European Commission grant agreement number 261466. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 5 Z9 5 U1 2 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1357 EP 1365 DI 10.3201/eid2108.140714 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300010 PM 26197093 ER PT J AU Trock, SC Burke, SA Cox, NJ AF Trock, Susan C. Burke, Stephen A. Cox, Nancy J. TI Development of Framework for Assessing Influenza Virus Pandemic Risk SO EMERGING INFECTIOUS DISEASES LA English DT Article ID H3N2 VARIANT VIRUS; UNITED-STATES; HUMAN INFECTIONS; VACCINE AB Although predicting which influenza virus subtype will cause the next pandemic is not yet possible, public health authorities must continually assess the pandemic risk associated with animal influenza viruses, particularly those that have caused infections in humans, and determine what resources should be dedicated to mitigating that risk. To accomplish this goal, a risk assessment framework was created in collaboration with an international group of influenza experts. Compared with the previously used approach, this framework, named the Influenza Risk Assessment Tool, provides a systematic and transparent approach for assessing and comparing threats posed primarily by avian and swine influenza viruses. This tool will be useful to the international influenza community and will remain flexible and responsive to changing information. C1 [Trock, Susan C.; Burke, Stephen A.; Cox, Nancy J.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Burke, Stephen A.] Battelle Mem Inst, Atlanta, GA USA. RP Trock, SC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A20, Atlanta, GA 30329 USA. EM sct1@cdc.gov NR 18 TC 10 Z9 10 U1 1 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1372 EP 1378 DI 10.3201/eid2108.141086 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300012 PM 26196098 ER PT J AU Kratz, MM Weiss, D Ridpath, A Zucker, JR Geevarughese, A Rakeman, J Varma, JK AF Kratz, Molly M. Weiss, Don Ridpath, Alison Zucker, Jane R. Geevarughese, Anita Rakeman, Jennifer Varma, Jay K. TI Community-Based Outbreak of Neisseria meningitidis Serogroup C Infection in Men who Have Sex with Men, New York City, New York, USA, 2010-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MENINGOCOCCAL DISEASE AB In September 2012, the New York City Department of Health and Mental Hygiene identified an outbreak of Neisseria meningitidis serogroup C invasive meningococcal disease among men who have sex with men (MSM). Twenty-two case-patients and 7 deaths were identified during August 2010-February 2013. During this period, 7 cases in non-MSM were diagnosed. The slow-moving outbreak was linked to the use of websites and mobile phone applications that connect men with male sexual partners, which complicated the epidemiologic investigation and prevention efforts. We describe the outbreak and, steps taken to interrupt transmission, including an innovative and wide-ranging outreach campaign that involved direct, internet-based, and media-based communications; free vaccination events; and engagement of community and government partners. We conclude by discussing the challenges of managing an outbreak affecting a discrete community of MSM and the benefits of using social networking technology to reach this at-risk population. C1 [Kratz, Molly M.] New York City Dept Hlth & Mental Hyg, Off Deputy Commissioner Dis Control, New York, NY USA. [Kratz, Molly M.; Weiss, Don; Ridpath, Alison; Zucker, Jane R.; Geevarughese, Anita; Rakeman, Jennifer; Varma, Jay K.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Ridpath, Alison; Zucker, Jane R.; Varma, Jay K.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kratz, MM (reprint author), New York City Dept Hlth & Mental Hyg, 42-09 28th St,CN-22, Long Isl City, NY 11101 USA. EM mkratz@health.nyc.gov NR 20 TC 8 Z9 8 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1379 EP 1386 DI 10.3201/eid2108.141837 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300013 PM 26197087 ER PT J AU Siciliano, RF Castelli, JB Mansur, AJ dos Santos, FP Colombo, S do Nascimento, EM Paddock, CD Brasil, RA Velho, PENF Drummond, MR Grinberg, M Strabelli, TMV AF Siciliano, Rinaldo Focaccia Castelli, Jussara Bianchi Mansur, Alfredo Jose dos Santos, Fabiana Pereira Colombo, Silvia do Nascimento, Elvira Mendes Paddock, Christopher D. Brasil, Roosecelis Araujo Neves Ferreira Velho, Paulo Eduardo Drummond, Marina Rovani Grinberg, Max Varejao Strabelli, Tania Mara TI Bartonella spp. and Coxiella burnetii Associated with Community-Acquired, Culture-Negative Endocarditis, Brazil SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTIVE ENDOCARDITIS; DIAGNOSIS AB We evaluated culture-negative, community-acquired endocarditis by using indirect immunofluorescent assays and molecular analyses for Bartonella spp. and Coxiella burnetii and found a prevalence of 19.6% and 7.8%, respectively. Our findings reinforce the need to study these organisms in patients with culture-negative, community-acquired endocarditis, especially B. henselae in cat owners. C1 [Siciliano, Rinaldo Focaccia; Castelli, Jussara Bianchi; Mansur, Alfredo Jose; Grinberg, Max; Varejao Strabelli, Tania Mara] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. [dos Santos, Fabiana Pereira; Colombo, Silvia; do Nascimento, Elvira Mendes; Brasil, Roosecelis Araujo] Adolfo Lutz Inst, Sao Paulo, Brazil. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Neves Ferreira Velho, Paulo Eduardo; Drummond, Marina Rovani] Univ Estadual Campinas, Sch Med, Campinas, Brazil. RP Siciliano, RF (reprint author), Av Dr Eneas de Carvalho Aguiar,44,Bloco 1,Sala, BR-05403000 Sao Paulo, Brazil. EM rinaldo_focaccia@uol.com.br RI Castelli, Jussara/I-4798-2013; Strabelli, Tania/B-1857-2015 OI Castelli, Jussara/0000-0002-8414-4161; Strabelli, Tania/0000-0003-1955-1008 NR 14 TC 5 Z9 5 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1429 EP 1432 DI 10.3201/eid2108.140343 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300022 PM 26197233 ER PT J AU Kugeler, KJ Farley, GM Forrester, JD Mead, PS AF Kugeler, Kiersten J. Farley, Grace M. Forrester, Joseph D. Mead, Paul S. TI Geographic Distribution and Expansion of Human Lyme Disease, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NEW-YORK; PATTERNS AB Lyme disease occurs in specific geographic regions of the United States. We present a method for defining high-risk counties based on observed versus expected number of reported human Lyme disease cases. Applying this method to successive periods shows substantial geographic expansion of counties at high risk for Lyme disease. C1 [Kugeler, Kiersten J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80521 USA. [Kugeler, Kiersten J.; Farley, Grace M.; Forrester, Joseph D.; Mead, Paul S.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Kugeler, KJ (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop PO2, Ft Collins, CO 80521 USA. EM kkugeler@cdc.gov NR 15 TC 19 Z9 20 U1 2 U2 18 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1455 EP 1457 DI 10.3201/eid2108.141878 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300029 PM 26196670 ER PT J AU Ridpath, A Greene, SK Robinson, BF Weiss, D AF Ridpath, Alison Greene, Sharon K. Robinson, Byron F. Weiss, Don CA Meningococcal Invest Team TI Risk Factors for Serogroup C Meningococcal Disease during Outbreak among Men who Have Sex with Men, New York City, New York, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES AB Risk factors for illness during a serogroup C meningococcal disease outbreak among men who have sex with men in New York City, New York, USA, in 2012-2013 included methamphetamine and cocaine use and sexually transmitted infections. Outbreak investigations should consider routinely capturing information regarding drug use and sex-related risk factors. C1 [Ridpath, Alison; Greene, Sharon K.; Weiss, Don] New York City Dept Hlth & Mental Hyg, Queens, NY USA. [Ridpath, Alison; Robinson, Byron F.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ridpath, A (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,Mailstop F60, Chamblee, GA 30341 USA. EM etf4@cdc.gov NR 14 TC 2 Z9 2 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1458 EP 1461 DI 10.3201/eid2108.141932 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300030 PM 26196855 ER PT J AU Breedlove, B Friedberg, J AF Breedlove, Byron Friedberg, Jared TI Beyond First Impressions SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Friedberg, Jared] Northrop Grumman, Atlanta, GA USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C17, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 4 TC 0 Z9 0 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1490 EP 1491 DI 10.3201/eid2108.AC2108 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300043 ER PT J AU Guy, GP Lipscomb, J Gillespie, TW Goodman, M Richardson, LC Ward, KC AF Guy, Gery P., Jr. Lipscomb, Joseph Gillespie, Theresa W. Goodman, Michael Richardson, Lisa C. Ward, Kevin C. TI Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia SO HEALTH SERVICES RESEARCH LA English DT Article DE Quality assessment; quality of care; rural health; breast cancer; cancer care ID CLINICAL-PRACTICE GUIDELINES; SOCIOECONOMIC-STATUS; OLDER WOMEN; MARITAL-STATUS; RANDOMIZED-TRIALS; 15-YEAR SURVIVAL; INSURANCE STATUS; UNITED-STATES; CHEMOTHERAPY; CARE AB ObjectiveTo examine factors associated with guideline-concordant adjuvant therapy among breast cancer patients in a rural region of the United States and to present an advancement in quality-of-care assessment in the context of multiple treatments. Data SourcesChart abstraction on initial therapy received by 868 women diagnosed with primary, invasive, early-stage breast cancer in a largely rural region of southwest Georgia. Study DesignUsing multivariable logistic regression, we examined predictors of adjuvant chemo-, radiation, and hormonal therapy regimens defined as guideline-concordant according to the 2000 National Institutes of Health Consensus Development Conference Statement. Principal FindingsOverall, 35.2 percent of women received guideline-concordant care for all three adjuvant therapies. Higher socioeconomic status was associated with receiving guideline-concordant care for all three adjuvant therapies jointly, and for chemotherapy. Compared with private insurance, having Medicaid was associated with guideline-concordant chemotherapy. Unmarried women were more likely to be nonconcordant for chemotherapy and radiation therapy. Increased age predicted nonconcordance for adjuvant therapies jointly, for chemotherapy, and for hormonal therapy. ConclusionsA number of factors were independently associated with receiving guideline-concordant adjuvant therapy. Identifying and addressing factors that lead to nonconcordance may reduce disparities in treatment and survival. C1 [Guy, Gery P., Jr.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Lipscomb, Joseph; Goodman, Michael; Ward, Kevin C.] Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Winship Canc Inst, Atlanta, GA 30322 USA. [Gillespie, Theresa W.] Emory Univ, Sch Med, Dept Surg, Winship Canc Inst, Atlanta, GA 30322 USA. [Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA 30341 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford HighwayNE,MS F76 Chamblee, Atlanta, GA 30341 USA. EM irm2@cdc.gov FU Centers for Disease Control and Prevention [U48 DP000043] FX Joint Acknowledgment/Disclosure Statement: Funding was made possible by cooperative agreement U48 DP000043 for the Emory Prevention Research Center, from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 44 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2015 VL 50 IS 4 BP 1088 EP 1108 DI 10.1111/1475-6773.12269 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CN7KG UT WOS:000358612600009 PM 25491350 ER PT J AU Buchacz, K Wiegand, R Armon, C Chmiel, JS Wood, K Brooks, JT Palella, FJ AF Buchacz, Kate Wiegand, Ryan Armon, Carl Chmiel, Joan S. Wood, Kathleen Brooks, John T. Palella, Frank J., Jr. CA HIV Outpatient Study HOPS Investig TI Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study SO HIV CLINICAL TRIALS LA English DT Article DE Raltegravir; Mortality; Viremia; Viral load; Clinical outcomes; HIV cohort ID OPTIMIZED BACKGROUND THERAPY; PROPENSITY-SCORE; EFFICACY; SAFETY; COHORT; INFECTION; INHIBITOR; BENCHMRK; TRIALS; MODELS AB Objectives: Raltegravir (RAL)-containing antiretroviral therapy (ART) produced better immunologic and virologic responses than optimized background ART in clinical trials of heavily ART-experienced patients, but few data exist on long-term outcomes in routine HIV care. Methods: We studied ART-experienced HIV outpatient study (HOPS) participants seen at 10 US HIV-specialty clinics during 2007-2011. We identified patients who started (baseline date) either continuous >= 30 days of RAL-containing or RAL-sparing ART, and used propensity score (PS) matching methods to account for baseline clinical and demographic differences. We used Kaplan-Meier methods and log-rank tests for the matched subsets to evaluate probability of death, achieving HIV RNA <50 copies/ml, and CD4 cell count (CD4) increase of >= 50 cells mm(-3) during follow-up. Results: Among 784 RAL-exposed and 1062 RAL-unexposed patients, 472 from each group were matched by PS. At baseline, the 472 RAL-exposed patients (mean nadir CD4, 205 cells mm(-3); mean baseline CD4, 460 cells mm(-3); HIV RNA <50 copies ml(-1) in 61%; mean years on prescribed ART, 7.5) were similar to RAL unexposed. During a mean follow-up of over 3 years, mortality rates and immunologic and virologic trajectories did not differ between the two groups. Among patients with detectable baseline HIV RNA levels, 76% of RAL-exposed and 63% of RAL-unexposed achieved HIV RNA <50 copies ml(-1) (P=0.51); 69 and 58%, respectively, achieved a CD4 increase >= 50 cells mm(-3) (P=0.70). Discussion: In our large cohort of US ART-experienced patients with a wide spectrum of clinical history, similar outcomes were observed when prescribed RAL containing versus other contemporary ART. C1 [Buchacz, Kate; Wiegand, Ryan; Brooks, John T.] Ctr Dis Control & Prevent CDC, Atlanta, GA 30329 USA. [Armon, Carl; Wood, Kathleen] Cerner Corp, Vienna, VA USA. [Chmiel, Joan S.; Palella, Frank J., Jr.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Buchacz, K (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,MS E-45, Atlanta, GA 30329 USA. EM acu7@cdc.gov FU Centers for Disease Control and Prevention [200-2001-00133, 200-2006-18797, 200-2011-41872] FX Contracts 200-2001-00133, 200-2006-18797, and 200-2011-41872 from the Centers for Disease Control and Prevention. NR 27 TC 0 Z9 0 U1 0 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1528-4336 EI 1945-5771 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD AUG PY 2015 VL 16 IS 4 BP 139 EP 146 DI 10.1179/1528433614Z.0000000019 PG 8 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA CN8ZB UT WOS:000358733700003 PM 26126549 ER PT J AU Hirsch-Moverman, Y Cronin, WA Chen, B Moran, JA Munk, E Reichler, MR AF Hirsch-Moverman, Y. Cronin, W. A. Chen, B. Moran, J. A. Munk, E. Reichler, M. R. CA TB Epidemiological Studies Consort TI HIV counseling and testing in tuberculosis contact investigations in the United States and Canada SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE TB; contact investigation; HIV; HIV testing ID IMMUNODEFICIENCY-VIRUS-INFECTION; MYCOBACTERIUM-TUBERCULOSIS; SEROPREVALENCE; FEASIBILITY; ALBERTA AB BACKGROUND: Determining the human immunodeficiency virus (HIV) status of tuberculosis (TB) patients and contacts is important. Despite existing guidelines, not all patients are tested, and testing of contacts is rarely performed. METHODS:In a study conducted at nine US/Canadian sites, we introduced formal procedures for offering HIV testing to TB patients and contacts. Data were collected via interviews and medical record review. Characteristics associated with offering and accepting HIV testing were examined. RESULTS: Of 651 TB patients, 601 (92%) were offered testing, 511 (85%) accepted, and 51 (10%) were HIV-infected. Of 4152 contacts, 3099 (75%) were offered testing, 1202 (39%) accepted, and 24 (2%) were HIV-infected. Contacts aged 15-64 years, non-Whites, foreign-born persons, smokers, those with positive TB screening, and household contacts were more likely to be offered testing, whereas contacts exposed to HIVnegative patients were less likely to be offered testing. Contacts aged 15-64 years, smokers, drug/alcohol users, diabetics, and those with positive TB screening were more likely to accept testing. Foreign-born persons, Blacks, Hispanics, and contacts exposed to HIV-positive patients were less likely to accept testing. CONCLUSIONS: High rates of HIV were detected among patients and contacts. Despite structured procedures to offer HIV testing, some patients and most contacts did not accept testing. Strategies are needed to improve testing acceptance rates. C1 [Hirsch-Moverman, Y.; Moran, J. A.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA. [Cronin, W. A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Chen, B.; Reichler, M. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Munk, E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Hirsch-Moverman, Y (reprint author), Columbia Univ, Mailman Sch Publ Hlth, ICAP, 215 West 125th St, New York, NY 10027 USA. EM yh154@columbia.edu; mrr3@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention through funding to the Tuberculosis Epidemiologic Studies Consortium (TBESC). NR 26 TC 0 Z9 0 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD AUG PY 2015 VL 19 IS 8 BP 943 EP 953 DI 10.5588/ijtld.14.0642 PG 11 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CN6OC UT WOS:000358553100014 PM 26162361 ER PT J AU Schieve, LA Clayton, HB Durkin, MS Wingate, MS Drews-Botsch, C AF Schieve, Laura A. Clayton, Heather B. Durkin, Maureen S. Wingate, Martha S. Drews-Botsch, Carolyn TI Comparison of Perinatal Risk Factors Associated with Autism Spectrum Disorder (ASD), Intellectual Disability (ID), and Co-occurring ASD and ID SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism spectrum disorder; Intellectual disability; Preterm birth; Low birth weight; Intrauterine growth retardation; Risk factors ID FOR-GESTATIONAL-AGE; LOW-BIRTH-WEIGHT; MENTAL-RETARDATION; CHILDREN; PREVALENCE; PRETERM; HEALTH; GROWTH AB While studies report associations between perinatal outcomes and both autism spectrum disorder (ASD) and intellectual disability (ID), there has been little study of ASD with versus without co-occurring ID. We compared perinatal risk factors among 7547 children in the 2006-2010 Autism and Developmental Disability Monitoring Network classified as having ASD + ID, ASD only, and ID only. Children in all three groups had higher rates of preterm birth (PTB), low birth weight, small-for-gestational-age, and low Apgar score than expected based on the US birth cohort adjusted for key socio-demographic factors. Associations with most factors, especially PTB, were stronger for children with ID only than children with ASD + ID or ASD only. Associations were similar for children with ASD + ID and ASD only. C1 [Schieve, Laura A.; Clayton, Heather B.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Durkin, Maureen S.] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA. [Wingate, Martha S.] Univ Alabama Birmingham, Coll Publ Hlth, Birmingham, AL USA. [Drews-Botsch, Carolyn] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Schieve, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, MS E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM LSchieve@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 6 Z9 6 U1 1 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD AUG PY 2015 VL 45 IS 8 BP 2361 EP 2372 DI 10.1007/s10803-015-2402-0 PG 12 WC Psychology, Developmental SC Psychology GA CN4FI UT WOS:000358385400008 PM 25739693 ER PT J AU Bissel, SJ Auer, RN Chiang, CH Kofler, J Murdoch, GH Nix, WA Painter, M Richer, M Sartelet, H Wang, GJ Wiley, CA AF Bissel, Stephanie J. Auer, Roland N. Chiang, Cheng-Hsuan Kofler, Julia Murdoch, Geoffrey H. Nix, W. Allan Painter, Michael Richer, Maxime Sartelet, Herve Wang, Guoji Wiley, Clayton A. TI Human Parechovirus 3 Meningitis and Fatal Leukoencephalopathy SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article ID RT-PCR; ENTEROVIRUS INFECTION; ENCEPHALITIS; TIME; EPIDEMIOLOGY; ECHOVIRUSES; MYOCARDITIS; CHILDREN; INFANTS; DISEASE AB Human parechovirus 3 (HPeV3) is a picornavirus associated with neurologic disease in neonates. Human parechovirus 3 infection of preterm and term infants is associated with seizures and destructive periventricular white matter lesions. Despite unremarkable cerebrospinal fluid (CSF), HPeV3 RNA can be amplified from CSF and nasopharyngeal and rectal swabs. We report pathologic findings in 2 autopsy cases of infants with active HPeV3 infection. Both children were born approximately 1 month premature and were neurologically intact but, after a few weeks, developed seizures and radiologic evidence of white matter lesions. Neuropathologic examination demonstrated classic severe periventricular leukomalacia in the absence of an immune response. Human parechovirus 3 sequences were identified in RNA extracted from CSF, sera, and tissues. Human parechovirus 3 in situ hybridization detection of infected cells was limited to meninges and associated blood vessels in addition to smooth muscle of pulmonary vessels. Ultrastructural evaluation of meninges demonstrated dense core structures compatible with picornavirus virions. These findings suggest that encephalopathic changes are secondary to infection of meninges and potential compromise of vascular perfusion. Thus, parechovirus infection of vascular smooth muscle may be a more general pathogenic process. C1 [Bissel, Stephanie J.; Chiang, Cheng-Hsuan; Kofler, Julia; Murdoch, Geoffrey H.; Wang, Guoji; Wiley, Clayton A.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Bissel, Stephanie J.; Chiang, Cheng-Hsuan; Kofler, Julia; Murdoch, Geoffrey H.; Wang, Guoji; Wiley, Clayton A.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA. [Auer, Roland N.; Sartelet, Herve] Univ Montreal, Hop Ste Justine, Dept Pathol, Montreal, PQ, Canada. [Nix, W. Allan] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Atlanta, GA USA. [Richer, Maxime] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada. RP Bissel, SJ (reprint author), UPMC, Presbyterian Hosp, Div Neuropathol, S758 Scaife Hall 200 Lothrop St, Pittsburgh, PA 15213 USA. EM sjb75@pitt.edu RI Auer, Roland/G-7164-2011 OI Auer, Roland/0000-0001-9044-3419 NR 44 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD AUG PY 2015 VL 74 IS 8 BP 767 EP 777 DI 10.1097/NEN.0000000000000215 PG 11 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA CN8AB UT WOS:000358657300002 PM 26115191 ER PT J AU Singh, E Ruff, P Babb, C Sengayi, M Beery, M Khoali, L Kellett, P Underwood, JM AF Singh, Elvira Ruff, Paul Babb, Chantal Sengayi, Mazvita Beery, Moira Khoali, Lerato Kellett, Patricia Underwood, J. Michael TI Establishment of a cancer surveillance programme: the South African experience SO LANCET ONCOLOGY LA English DT Article ID EASTERN CAPE PROVINCE; HEALTH; POPULATION; REGISTRY; BRICS AB Cancer is projected to become a leading cause of morbidity and mortality in low-income and middle-income countries in the future. However, cancer incidence in South Africa is largely under-reported because of a lack of nationwide cancer surveillance networks. We describe present cancer surveillance activities in South Africa, and use the International Agency for Research on Cancer framework to propose the development of four population-based cancer registries in South Africa. These registries will represent the ethnic and geographical diversity of the country. We also provide an update on a cancer surveillance pilot programme in the Ekurhuleni Metropolitan District, and the successes and challenges in the implementation of the IARC framework in a local context. We examine the development of a comprehensive cancer surveillance system in a middle-income country, which might serve to assist other countries in establishing population-based cancer registries in a resource-constrained environment. C1 [Singh, Elvira; Babb, Chantal; Sengayi, Mazvita; Beery, Moira; Khoali, Lerato; Kellett, Patricia] Natl Hlth Lab Serv, Natl Canc Registry, Canc Epidemiol Res Grp, ZA-2000 Johannesburg, South Africa. [Ruff, Paul] Univ Witwatersrand, Div Med Oncol, Johannesburg, South Africa. [Singh, Elvira; Ruff, Paul; Babb, Chantal] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Beery, Moira] Univ Pretoria, Sch Publ Hlth, South African Field Epidemiol & Lab Training Prog, ZA-0002 Pretoria, South Africa. [Underwood, J. Michael] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. RP Singh, E (reprint author), Natl Hlth Lab Serv, Natl Canc Registry, Canc Epidemiol Res Grp, ZA-2000 Johannesburg, South Africa. EM elvira.singh@nioh.nhls.ac.za FU Intramural CDC HHS [CC999999] NR 30 TC 2 Z9 3 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD AUG PY 2015 VL 16 IS 8 BP E414 EP E421 PG 8 WC Oncology SC Oncology GA CN6OS UT WOS:000358554700024 PM 26248849 ER PT J AU Zane, S Creanga, AA Berg, CJ Pazol, K Suchdev, DB Jamieson, DJ Callaghan, WM AF Zane, Suzanne Creanga, Andreea A. Berg, Cynthia J. Pazol, Karen Suchdev, Danielle B. Jamieson, Denise J. Callaghan, William M. TI Abortion-Related Mortality in the United States 1998-2010 SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID PREGNANCY-RELATED MORTALITY; LEGAL INDUCED-ABORTION; CLOSTRIDIUM-SORDELLII; MEDICAL ABORTION; SURVEILLANCE; RATES AB OBJECTIVE: To examine characteristics and causes of legal induced abortion-related deaths in the United States between 1998 and 2010. METHODS: Abortion-related deaths were identified through the national Pregnancy Mortality Surveillance System with enhanced case-finding. We calculated the abortion mortality rate by race, maternal age, and gestational age and the distribution of causes of death by gestational age and procedure. RESULTS: During the period from 1998-2010, of approximately 16.1 million abortion procedures, 108 women died, for a mortality rate of 0.7 deaths per 100,000 procedures overall, 0.4 deaths for non-Hispanic white women, 0.5 deaths for Hispanic women, and 1.1 deaths for black women. The mortality rate increased with gestational age, from 0.3 to 6.7 deaths for procedures performed at 8 weeks or less and at 18 weeks or greater, respectively. A majority of abortion-related deaths at 13 weeks of gestation or less were associated with anesthesia complications and infection, whereas a majority of abortion-related deaths at more than 13 weeks of gestation were associated with infection and hemorrhage. In 20 of the 108 cases, the abortion was performed as a result of a severe medical condition where continuation of the pregnancy threatened the woman's life. CONCLUSION: Deaths associated with legal induced abortion continue to be rare events-less than 1 per 100,000 procedures. Primary prevention of unintended pregnancy, including those in women with serious pre-existing medical conditions, and increased access to abortion services at early gestational ages may help to further decrease abortion-related mortality in the United States. LEVEL OF EVIDENCE: III C1 [Zane, Suzanne; Creanga, Andreea A.; Berg, Cynthia J.; Pazol, Karen; Suchdev, Danielle B.; Jamieson, Denise J.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Zane, S (reprint author), Ctr Dis Control & Prevent CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mail Stop F-74, Atlanta, GA 30341 USA. EM saz3@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 20 Z9 21 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD AUG PY 2015 VL 126 IS 2 BP 258 EP 265 DI 10.1097/AOG.0000000000000945 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CN2WF UT WOS:000358282400006 PM 26241413 ER PT J AU Wang, C Sen, A Plegue, M Ruffin, MT O'Neill, SM Rubinstein, WS Acheson, LS Yoon, PW Valdez, R Irizarry-De La Cruz, M Khoury, MJ Jorgensen, C Scheuner, MT Rubinstein, WS O'Neill, SM Rothrock, N Beaumont, JL Khan, S Ali, D Ruffin, MT Nease, D Acheson, LS Zyzanski, SJ Wiesner, GL Werner, J Pace, WD Galliher, JM Brandt, E Wang, C Gramling, R Starzyk, EJ AF Wang, Catharine Sen, Ananda Plegue, Melissa Ruffin, Mack T. O'Neill, Suzanne M. Rubinstein, Wendy S. Acheson, Louise S. Yoon, Paula W. Valdez, Rodolfo Irizarry-De la Cruz, Margie Khoury, Muin J. Jorgensen, Cynthia Scheuner, Maren T. Rubinstein, Wendy S. O'Neill, Suzanne M. Rothrock, Nan Beaumont, Jennifer L. Khan, Shaheen Ali, Dawood Ruffin, Mack T. Nease, Donald Acheson, Louise S. Zyzanski, Stephen J. Wiesner, Georgia L. Werner, James Pace, Wilson D. Galliher, James M. Brandt, Elias Wang, Catharine Gramling, Robert Starzyk, Erin J. CA Family Healthware Impact Trial TI Impact of family history assessment on communication with family members and health care providers: A report from the Family Healthware (TM) Impact Trial (FHITr) SO PREVENTIVE MEDICINE LA English DT Article DE Family history assessment; Family communication; Provider communication; Dose effects; Chronic disease ID COMMON CHRONIC DISEASES; PATIENT BEHAVIOR; RISK-ASSESSMENT; PERCEIVED RISK; PUBLIC-HEALTH; CANCER; PERCEPTIONS; TOOL; OREGONIANS; PREVENTION AB Objective. This study examines the impact of Family Healthware (TM) on communication behaviors; specifically, communication with family members and health care providers about family health history. Methods. A total of 3786 participants were enrolled in the Family Healthware (TM) Impact Trial (FHITr) in the United States from 2005-7. The trial employed a two-arm cluster-randomized design, with primary care practices serving as the unit of randomization. Using generalized estimating equations (GEE), analyses focused on communication behaviors at 6 month follow-up, adjusting for age, site and practice clustering. Results. A significant interaction was observed between study arm and baseline communication status for the family communication outcomes (p's <.01), indicating that intervention had effects of different magnitude between those already communicating at baseline and those who were not. Among participants who were not communicating at baseline, intervention participants had higher odds of communicating with family members about family history risk (OR = 124, p = 0.042) and actively collecting family history information at follow-up (OR = 2.67, p = 0.026). Family Healthware (TM) did not have a significant effect on family communication among those already communicating at baseline, or on provider communication, regardless of baseline communication status. Greater communication was observed among those at increased familial risk for a greater number of diseases. Conclusion. Family Healthware (TM) prompted more communication about family history with family members, among those who were not previously communicating. Efforts are needed to identify approaches to encourage greater sharing of family history information, particularly with health care providers. (C) 2015 Elsevier Inc. All rights reserved. C1 [Yoon, Paula W.; Valdez, Rodolfo; Irizarry-De la Cruz, Margie; Khoury, Muin J.; Jorgensen, Cynthia] CDC, Atlanta, GA 30333 USA. [Scheuner, Maren T.] Univ Calif Los Angeles, Ctr Hlth Policy Res, Los Angeles, CA 90024 USA. [O'Neill, Suzanne M.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA. [Rothrock, Nan; Beaumont, Jennifer L.; Khan, Shaheen; Ali, Dawood] NorthShore Univ HealthSyst, Highland Pk, IL USA. [Ruffin, Mack T.] Univ Michigan, Ann Arbor, MI 48109 USA. [Nease, Donald] Univ Colorado Denver, Denver, CO USA. [Acheson, Louise S.; Zyzanski, Stephen J.; Wiesner, Georgia L.; Werner, James] Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH USA. [Pace, Wilson D.; Galliher, James M.; Brandt, Elias] Amer Acad Family Phys Natl Res Network, Leawood, KS USA. [Wang, Catharine] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Gramling, Robert] Univ Rochester, Rochester, NY 14627 USA. [Starzyk, Erin J.] Univ Illinois, Chicago, IL USA. [Wang, Catharine] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Sen, Ananda] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Plegue, Melissa] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA. [Sen, Ananda; Plegue, Melissa; Ruffin, Mack T.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [O'Neill, Suzanne M.] Northwestern Univ, Dept Med, Feinberg Sch Med, Evanston, IL USA. [Rubinstein, Wendy S.] NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA. [Acheson, Louise S.] Case Western Reserve Univ, Dept Family Med & Community Hlth, Cleveland, OH 44106 USA. [Acheson, Louise S.] Case Western Reserve Univ, Dept Reprod Biol, Cleveland, OH 44106 USA. [Acheson, Louise S.] Univ Hosp Case Med Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA. RP Wang, C (reprint author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Crosstown Ctr, 801 Massachusetts Ave,3rd Floor, Boston, MA 02118 USA. EM clwang@bu.edu RI Nease, Donald/B-6206-2013; OI Nease, Donald/0000-0001-8323-3720; Wang, Catharine/0000-0001-8584-2781 FU CDC [U50/CCU300860 TS-1216]; Association for Prevention Teaching and Research (ENH) [U50/CCU300860 TS-1216]; American Association of Medical Colleges (UM) [U36/CCU319276 MM-0789]; American Association of Medical Colleges (CWR) [U36/CCU319276 MM0630]; National Cancer Institute [K07 CA086958, K07 CA131103] FX The Family Healthware (TM) Impact Trial (FHITr) was supported through cooperative agreements between the CDC and the Association for Prevention Teaching and Research (ENH-#U50/CCU300860 TS-1216) and the American Association of Medical Colleges (UM#U36/CCU319276 MM-0789 and CWR# U36/CCU319276 MM0630). Dr. Acheson received salary support from the National Cancer Institute (K07 CA086958). Dr. Wang is also supported by the National Cancer Institute (K07 CA131103) and a Peter T. Paul career development professorship from Boston University. Trial Registration: NCT00164658 'Evaluating Tools for Health Promotion and Disease Prevention'. NR 37 TC 2 Z9 2 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD AUG PY 2015 VL 77 BP 28 EP 34 DI 10.1016/j.ypmed.2015.04.007 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN4HQ UT WOS:000358391600006 PM 25901453 ER PT J AU Bronder, KL Dooyema, CA Onufrak, SJ Foltz, JL AF Bronder, Kayla L. Dooyema, Carrie A. Onufrak, Stephen J. Foltz, Jennifer L. TI Electronic health records to support obesity-related patient care: Results from a survey of United States physicians SO PREVENTIVE MEDICINE LA English DT Article DE Electronic health records; Obesity; Body mass index ID WEIGHT AB Objective. Obesity-related electronic health record functions increase the rates of measuring Body Mass Index, diagnosing obesity, and providing obesity services. This study describes the prevalence of obesity-related electronic health record functions in clinical practice and analyzes characteristics associated with increased obesity-related electronic health record sophistication. Methods. Data were analyzed from DocStyles, a web-based panel survey administered to 1507 primary care providers practicing in the United States in June, 2013. Physicians were asked if their electronic health record has specific obesity-related functions. Logistical regression analyses identified characteristics associated with improved obesity-related electronic health record sophistication. Results. Of the 88% of providers with an electronic health record, 83% of electronic health records calculate Body Mass Index, 52% calculate pediatric Body Mass Index percentile, and 32% flag patients with abnormal Body Mass Index values. Only 36% provide obesity-related decision support and 17% suggest additional resources for obesity-related care. Characteristics associated with having a more sophisticated electronic health record include age <= 45 years old, being a pediatrician or family practitioner, and practicing in a larger, outpatient practice. Conclusions. Few electronic health records optimally supported physician's obesity-related clinical care. The low rates of obesity-related electronic health record functions currently in practice highlight areas to improve the clinical health information technology in primary care practice. More work can be done to develop, implement, and promote the effective utilization of obesity-related electronic health record functions to improve obesity treatment and prevention efforts. Published by Elsevier Inc. C1 [Dooyema, Carrie A.; Onufrak, Stephen J.; Foltz, Jennifer L.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Bronder, Kayla L.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, CDC Experience Appl Epidemiol Fellowship, Atlanta, GA USA. [Foltz, Jennifer L.] US Public Hlth Serv Commissioned Corps, Atlanta, GA USA. RP Bronder, KL (reprint author), Univ Michigan, 1500 E Med Ctr Dr,D3230 MPB,SPC 5718, Ann Arbor, MI 48109 USA. EM kaylabronder@gmail.com FU CDC; External Medical Affairs; Pfizer Inc. FX Kayla Bronder receives funding from The CDC Experience, a one-year fellowship in applied epidemiology at CDC made possible by a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. Jennifer Foltz, Stephen Onufrak, and Carrie Dooyema have no funding sources or conflicts of interest to disclose. NR 7 TC 0 Z9 0 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD AUG PY 2015 VL 77 BP 41 EP 47 DI 10.1016/j.ypmed.2015.04.018 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN4HQ UT WOS:000358391600008 PM 25952053 ER PT J AU Cunningham, TJ Ford, ES Chapman, DP Liu, Y Croft, JB AF Cunningham, Timothy J. Ford, Earl S. Chapman, Daniel P. Liu, Yong Croft, Janet B. TI Independent and joint associations of race/ethnicity and educational attainment with sleep-related symptoms in a population-based US sample SO PREVENTIVE MEDICINE LA English DT Article DE Ethnic groups; Minority health; Educational status; Socioeconomic status; Sleeplessness; Insomnia; Fatigue ID SOCIOECONOMIC-STATUS; INSUFFICIENT SLEEP; HEALTH; INSOMNIA; DISPARITIES; DURATION; RACE; METAANALYSIS; DISORDERS; AMERICANS AB Objective. Prior studies have documented disparities in short and long sleep duration, excessive daytime sleepiness, and insomnia by educational attainment and race/ethnicity separately. We examined both independent and interactive effects of these factors with a broader range of sleep indicators in a racially/ethnically diverse sample. Methods. We analyzed 2012 National Health Interview Survey data from 33,865 adults aged >= 18 years. Sleep-related symptomatology included short sleep duration (<= 6 h), long sleep duration (>= 9 h), fatigue >3 days, excessive daytime sleepiness, and insomnia. Bivariate analyses with chi-square tests and log-linear regression were performed. Results. The overall age-adjusted prevalence was 29.1% for short sleep duration, 8.5% for long sleep duration, 15.1% for fatigue, 12.6% for excessive daytime sleepiness, and 18.8% for insomnia. Educational attainment and race/ethnicity were independently related to the five sleep-related symptoms. Among Whites, the likelihood of most sleep indicators increased as educational attainment decreased; relationships varied for the other racial/ethnic groups. For short sleep duration, the educational attainment-by-race/ethnicity interaction effect was significant for African Americans (p <0.0001), Hispanics (p <0.0001), and Asians (p = 0.0233) compared to Whites. For long sleep duration, the interaction was significant for Hispanics only (p = 0.0003). Conclusions. Our results demonstrate the importance of examining both educational attainment and race/ethnicity simultaneously to more fully understand disparities in sleep health. Increased understanding of the mechanisms linking sociodemographic factors to sleep health is needed to determine whether policies and programs to increase educational attainment may also reduce these disparities within an increasingly diverse population. Published by Elsevier Inc. C1 [Cunningham, Timothy J.; Ford, Earl S.; Chapman, Daniel P.; Liu, Yong; Croft, Janet B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. RP Cunningham, TJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, 4770 Buford Hwy,Mailstop F78, Atlanta, GA 30341 USA. EM tsc2@cdc.gov; esf2@cdc.gov; dpc2@cdc.gov; ikd8@cdc.gov; jbc0@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 3 Z9 3 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD AUG PY 2015 VL 77 BP 99 EP 105 DI 10.1016/j.ypmed.2015.05.008 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN4HQ UT WOS:000358391600014 PM 26004167 ER PT J AU Maciosek, MV Xu, X Butani, AL Pechacek, TF AF Maciosek, Michael V. Xu, Xin Butani, Amy L. Pechacek, Terry F. TI Smoking-attributable medical expenditures by age, sex, and smoking status estimated using a relative risk approach SO PREVENTIVE MEDICINE LA English DT Article DE Health care costs; Health expenditures; Smoking; Tobacco; Smoking/economics; Health expenditures/statistics & numerical data; Health services/utilization ID HEALTH-CARE COSTS; CURRENT CIGARETTE-SMOKING; UNITED-STATES; CESSATION; ADULTS AB Objective. To accurately assess the benefits of tobacco control interventions and to better inform decision makers, knowledge of medical expenditures by age, gender, and smoking status is essential. Method. We propose an approach to distribute smoking-attributable expenditures by age, gender, and cigarette smoking status to reflect the known risks of smoking. We distribute hospitalization days for smoking-attributable diseases according to relative risks of smoking-attributable mortality, and use the method to determine national estimates of smoking-attributable expenditures by age, sex, and cigarette smoking status. Sensitivity analyses explored assumptions of the method. Results. Both current and former smokers ages 75 and over have about 12 times the smoking-attributable expenditures of their current and former smoker counterparts 35-54 years of age. Within each age group, the expenditures of formers smokers are about 70% lower than current smokers. In sensitivity analysis, these results were not robust to large changes to the relative risks of smoking-attributable mortality which were used in the calculations. Conclusion. Sex- and age-group-specific smoking expenditures reflect observed disease risk differences between current and former cigarette smokers and indicate that about 70% of current smokers' excess medical care costs is preventable by quitting. (C) 2015 Elsevier Inc. All rights reserved. C1 [Maciosek, Michael V.; Butani, Amy L.] HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA. [Xu, Xin; Pechacek, Terry F.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. RP Maciosek, MV (reprint author), HealthPartners Inst Educ & Res, Mail Stop 21111R,POB 1524, Minneapolis, MN 55440 USA. EM Michael.V.Maciosek@HealthPartners.com FU Intramural CDC HHS [CC999999] NR 29 TC 3 Z9 3 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD AUG PY 2015 VL 77 BP 162 EP 167 DI 10.1016/j.ypmed.2015.05.019 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN4HQ UT WOS:000358391600024 PM 26051203 ER PT J AU Ford, CL Godette, DC Mulatu, MS Gaines, TL AF Ford, Chandra L. Godette, Dionne C. Mulatu, Mesfin S. Gaines, Tommi L. TI Recent HIV Testing Prevalence, Determinants, and Disparities Among US Older Adult Respondents to the Behavioral Risk Factor Surveillance System SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HEALTH-CARE SETTINGS; AGED 50; HIV/AIDS; STATES; DIAGNOSIS; AMERICANS; SERVICES; DISEASE; PEOPLE AB Background Although routine human immune deficiency virus (HIV) testing during health care visits is recommended for most adults, many older adults (i.e., ages 50-64 years) do not receive it. This study identified factors associated with HIV testing in the past 12 months (i.e., recent HIV testing) among US adults in the 3 categories of older adulthood (50-54, 55-59, and 60-64 years) for which routine HIV testing is recommended. Method This was a cross-sectional analysis of data from US older adult respondents to the 2010 Behavioral Risk Factor Surveillance System. We calculated prevalence (proportions) of HIV testing by age category and race/ethnicity. Using multiple logistic regression, we identified predisposing, enabling, and need factors associated with recent HIV testing within and across age categories, by race/ethnicity and controlling for covariates. Results HIV testing prevalence was low (<5%), varied by race/ethnicity, and decreased with age. Within and across age categories, the odds of testing were highest among blacks (odds ratio [OR], 3.47; 95% confidence interval [CI], 2.82-4.25) and higher among Latinos (OR, 2.06; 95% CI, 1.50-2.84) and the oldest and youngest categories of American Indians/Alaska Natives (OR, 2.48; 95% CI, 1.11-5.55; OR, 2.98; 95% CI, 1.49-5.95) than among whites. Those reporting a recent doctor visit (OR, 2.32; 95% CI, 1.92-2.74) or HIV risk behaviors (OR, 3.50; 95% CI, 2.67-4.59) had higher odds of HIV testing. Conclusion Regardless of risk, the oldest older adults, whites, and older women may forego HIV testing. Doctor visits may facilitate HIV testing. Additional research is needed to understand why eligible older adults seen by providers may not be screened for HIV infection. C1 [Ford, Chandra L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90095 USA. [Godette, Dionne C.] NIAAA, Div Epidemiol & Prevent Res, NIH, Rockville, MD 20852 USA. [Mulatu, Mesfin S.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Gaines, Tommi L.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, San Diego, CA 92103 USA. RP Ford, CL (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Box 951772, Los Angeles, CA 90095 USA. EM clford@ucla.edu FU UCLA Faculty Career Development Award; Eunice Kennedy Schriver National Institute of Child Health and Human Development via UCLA California Center for Population Research [5R24HD041022]; National Institute on Drug Abuse [K01DA034523-01] FX Dr Ford received support from an UCLA Faculty Career Development Award and the Eunice Kennedy Schriver National Institute of Child Health and Human Development via the UCLA California Center for Population Research (5R24HD041022). Dr Gaines received support from the National Institute on Drug Abuse (K01DA034523-01). Dr Mulatu's participation represents a personal endeavor not conducted on behalf of the Centers for Disease Control and Prevention. NR 30 TC 3 Z9 3 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2015 VL 42 IS 8 BP 405 EP 410 DI 10.1097/OLQ.0000000000000305 PG 6 WC Infectious Diseases SC Infectious Diseases GA CN2YW UT WOS:000358290300001 PM 26165428 ER PT J AU Garrett, TA Davies-Cole, J Furness, B AF Garrett, Tiana A. Davies-Cole, John Furness, Bruce TI Laboratory Capacity for Antimicrobial Susceptibility Surveillance of Neisseria gonorrhoeae-District of Columbia, 2007-2012 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; CHLAMYDIA-TRACHOMATIS; GONOCOCCAL INFECTIONS; TREATMENT-GUIDELINES; NO LONGER; RESISTANCE; UPDATE; WOMEN AB Background In the District of Columbia (DC), Neisseria gonorrhoeae (gonorrhea) infections accounted for more than 25% of 9321 incident sexually transmitted infections reported in 2011; untreated infections can lead to reproductive complications and a higher risk for HIV transmission. In DC, limited capacity to measure the prevalence of antibiotic-resistant N. gonorrhoeae is available; culture-based antibiotic susceptibility testing (AST) is needed to monitor antimicrobial resistance. We examined the capacity of laboratories that report to the DC Department of Health to perform AST for ongoing surveillance of antibiotic-resistant N. gonorrhoeae and to identify suspected treatment failures. Methods We created a survey about diagnostic methods for gonorrhea testing and identified 33 laboratories that reported gonorrhea results to Department of Health in 2007 to 2012. Laboratories were assessed for use of bacterial culture or nucleic acid amplification testing (NAAT) for gonorrhea testing, prevalence of AST on gonorrhea-positive cultures, and types of antibiotics tested during AST. We estimated the prevalence of laboratory practices on the basis of self-report by staff. Results Nineteen (58%) laboratories completed the survey, representing 92% of the gonorrhea reporting. Seventeen (89%) of 19 laboratories conducted testing by culture; only 6 (35%) performed AST; 79% performed NAAT. Barriers to AST included longer completion times and limited number of provider requests for AST. Commercial laboratories (32%) were more likely to conduct both culture and NAAT, compared with health care facilities (11%). Conclusions We report a low prevalence of laboratories performing AST because of multiple barriers. State-specific strategies addressing these barriers are needed to improve detection of antibiotic-resistant gonorrhea stains circulating among the population. C1 [Garrett, Tiana A.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA USA. [Garrett, Tiana A.; Davies-Cole, John; Furness, Bruce] Dist Columbia Dept Hlth, Washington, DC 20002 USA. [Furness, Bruce] CDC, Div STD Prevent, NCHHSTP, Atlanta, GA 30333 USA. RP Garrett, TA (reprint author), Dist Columbia Dept Hlth, 899 North Capitol St NE,Suite 580, Washington, DC 20002 USA. EM garrett.tiana@gmail.com NR 15 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2015 VL 42 IS 8 BP 413 EP 416 DI 10.1097/OLQ.0000000000000304 PG 4 WC Infectious Diseases SC Infectious Diseases GA CN2YW UT WOS:000358290300003 PM 26165430 ER PT J AU Llata, E Bernstein, KT Kerani, RP Pathela, P Schwebke, JR Schumacher, C Stenger, M Weinstock, HS AF Llata, Eloisa Bernstein, Kyle T. Kerani, Roxanne P. Pathela, Preeti Schwebke, Jane R. Schumacher, Christina Stenger, Mark Weinstock, Hillard S. TI Management of Pelvic Inflammatory Disease in Selected US Sexually Transmitted Disease Clinics: Sexually Transmitted Disease Surveillance Network, January 2010-December 2011 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID GENITOURINARY MEDICINE CLINICS; TREATMENT GUIDELINES; AUDIT; FERTILITY; ADHERENCE; DIAGNOSIS; WOMEN; UK AB Background Pelvic inflammatory disease (PID) remains an important source of preventable reproductive morbidity, but no recent studies have singularly focused on US sexually transmitted disease (STD) clinics in relationship to established guidelines for diagnosis and treatment. Methods Of the 83,076 female patients seen in 14 STD clinics participating in the STD Surveillance Network, 1080 (1.3%) were diagnosed as having PID from 2010 to 2011. A random sample of 219 (20%) women were selected, and medical records were reviewed for clinical history, examination findings, treatment, and diagnostic testing. Our primary outcomes were to evaluate how well PID diagnosis and treatment practices in STD clinic settings follow the Centers for Disease Control and Prevention (CDC) treatment guidelines and to describe age group-specific rates of laboratory-confirmed Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) in patients clinically diagnosed as having PID in the last 12 months, inclusive of the PID visit. Results Among the 219 women, 70.3% of the cases met the CDC treatment case definition for PID, 90.4% had testing for CT and GC on the PID visit, and 68.0% were treated with a CDC-recommended outpatient regimen. In the last 12 months, 95.4% were tested for CT or GC, and positivity for either organism was 43.9% in women aged 25 years or younger with PID, compared with 19.4% of women older than 25 years with PID. Conclusions Compliance with CDC guidelines was documented for many of the women with PID, though not all. Our findings underscore the need for continued efforts to optimize quality of care and adherence to current guidance for PID management given the anticipated expertise of providers in these settings. C1 [Llata, Eloisa; Stenger, Mark; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Surveillance & Data Management Branch, Div STD Prevent NCCHSTP, Atlanta, GA USA. [Bernstein, Kyle T.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Kerani, Roxanne P.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Kerani, Roxanne P.] Univ Washington, Dept Med, Seattle, WA USA. [Pathela, Preeti] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Schwebke, Jane R.] Univ Alabama Birmingham, Birmingham, AL USA. [Schumacher, Christina] Baltimore City Dept Hlth, Baltimore, MD USA. [Schumacher, Christina] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Llata, E (reprint author), Div STD Prevent, 1600 Clifton Rd,MS E-63, Atlanta, GA 30329 USA. EM gge3@cdc.gov NR 27 TC 1 Z9 1 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2015 VL 42 IS 8 BP 429 EP 433 DI 10.1097/OLQ.0000000000000309 PG 5 WC Infectious Diseases SC Infectious Diseases GA CN2YW UT WOS:000358290300007 PM 26165434 ER PT J AU Kidd, S Moore, PC Kirkcaldy, RD Philip, SS Wiesenfeld, HC Papp, JR Kerndt, PR Venkatasubramanian, L Ghanem, KG Hook, EW AF Kidd, Sarah Moore, Page C. Kirkcaldy, Robert D. Philip, Susan S. Wiesenfeld, Harold C. Papp, John R. Kerndt, Peter R. Venkatasubramanian, Lalitha Ghanem, Khalil G. Hook, Edward W. TI Comparison of Antimicrobial Susceptibility of Urogenital Neisseria gonorrhoeae Isolates Obtained From Women and Men SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID DISEASES-TREATMENT-GUIDELINES; RISK-FACTORS; RESISTANT; PREVALENCE; AZITHROMYCIN; INFECTIONS AB Background The US system for gonococcal antimicrobial susceptibility surveillance monitors trends exclusively among men with urethral infection, the population from whom the yield of gonococcal culture is highest. Little is known about the susceptibility of female urogenital isolates, and it is unclear whether gonococcal susceptibility among men who report sex exclusively with women (MSW) is representative of susceptibility among women. Methods Using isolates collected during a recent treatment trial in 5 US cities, we performed a secondary analysis to compare antimicrobial susceptibilities of Neisseria gonorrhoeae urogenital isolates obtained from women, MSW, and men who have sex with men (MSM). Pretreatment isolates were collected from trial participants; minimum inhibitory concentrations (MICs) were determined by agar dilution. Geometric mean MICs were adjusted for geographic location using general linear models. Results Susceptibility data for urogenital isolates from 56 women, 252 MSW, and 170 MSM were studied. The adjusted geometric mean ceftriaxone MIC was similar among women (0.0067 mu g/mL; 95% confidence interval [CI], 0.0049-0.0092 mu g/mL) and MSW (0.0060 mu g/mL; 95% CI, 0.0053-0.0066 mu g/mL). In contrast, the adjusted geometric mean ceftriaxone MIC was higher among MSM (0.0098 mu g/mL; 95% CI, 0.0082-0.0119 mu g/mL) than among MSW. This same pattern was observed for other antimicrobials, including cefixime and azithromycin Conclusions Ceftriaxone, cefixime, and azithromycin MICs were higher among MSM than among MSW, but were similar among women and MSW. These findings suggest that gonococcal antimicrobial susceptibility surveillance based on urethral isolates from MSW may adequately represent susceptibility of urogenital N. gonorrhoeae in women. C1 [Kidd, Sarah; Kirkcaldy, Robert D.; Papp, John R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Moore, Page C.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Philip, Susan S.] San Francisco Dept Hlth, San Francisco, CA USA. [Wiesenfeld, Harold C.] Univ Pittsburgh, Pittsburgh, PA USA. [Wiesenfeld, Harold C.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA. [Kerndt, Peter R.] Cty Los Angeles, Dept Publ Hlth, Los Angeles, CA USA. [Venkatasubramanian, Lalitha] FHI360, Durham, NC USA. [Ghanem, Khalil G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Hook, Edward W.] Univ Alabama Birmingham, Birmingham, AL USA. [Hook, Edward W.] Jefferson Cty Dept Hlth, Birmingham, AL USA. RP Kidd, S (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton R NE,MS E-02, Atlanta, GA 30333 USA. EM skidd@cdc.gov FU National Institute of Allergy and Infectious Diseases at the National Institutes of Health [HHSN 26620040073C] FX This work was supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (Grant No. HHSN 26620040073C). NR 25 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2015 VL 42 IS 8 BP 434 EP 439 DI 10.1097/OLQ.0000000000000312 PG 6 WC Infectious Diseases SC Infectious Diseases GA CN2YW UT WOS:000358290300008 PM 26165435 ER PT J AU Tongtoyai, J Todd, CS Chonwattana, W Pattanasin, S Chaikummao, S Varangrat, A Lokpichart, S Holtz, TH van Griensven, F Curlin, ME AF Tongtoyai, Jaray Todd, Catherine S. Chonwattana, Wannee Pattanasin, Sarika Chaikummao, Supaporn Varangrat, Anchalee Lokpichart, Somchai Holtz, Timothy H. van Griensven, Frits Curlin, Marcel E. TI Prevalence and Correlates of Chlamydia trachomatis and Neisseria gonorrhoeae by Anatomic Site Among Urban Thai Men Who Have Sex With Men SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; ACID AMPLIFICATION TESTS; HIV-INFECTION; RECTAL GONORRHEA; HOMOSEXUAL-MEN; TRANSMISSION; URETHRITIS; GUIDELINES; TANZANIA; CLINICS AB Background Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infection are prevalent among men who have sex with men (MSM) and may infect multiple anatomic sites. We measured site-specific prevalence and correlates of CT and NG infection among Bangkok MSM Cohort Study participants. Methods In April 2006 to November 2010, 1744 men enrolled in the Bangkok MSM Cohort Study. Participants provided historical information and underwent physical examination. Rectal, urethral, and pharyngeal CT and NG screening were performed by nucleic acid amplification and/or culture. Logistic regression was used to identify correlates of site-specific CT, NG, and coinfection. Results Among 1743 participants, 19.2% were infected with CT and/or NG. CT, NG, and CT-NG coinfection were detected in 11.6%, 4.6%, and 2.9%, of participants, respectively. Rectal, urethral, and pharyngeal CT infections were detected in 9.5%, 4.5%, and 3.6% of cases. N. gonorrhoeae was present at these sites in 6.1%, 1.8%, and 0.5% of cases. Most infections were asymptomatic (CT: 95.3%, NG: 83.2%). Rectal CT and NG infections were mutually associated (CT: adjusted odds ratio [AOR], 5.4; 95% confidence interval [CI], 3.4-8.7; NG: AOR, 2.4; 95% CI, 1.1-5.2) and independently associated with HIV infection (CT: AOR, 1.6, 95% CI, 1.0-2.4; NG: AOR, 2.0, 95% CI, 1.3-3.1). Numerous behavioral correlates of infection were observed. Conclusions CT and NG infections are highly prevalent among MSM in Bangkok, most frequently affect the rectum, and are most often asymptomatic. Routine screening of asymptomatic MSM for CT and NG infection should include rectal sampling and focus on men with HIV and a history of other sexually transmitted infections. C1 [Tongtoyai, Jaray; Todd, Catherine S.; Chonwattana, Wannee; Pattanasin, Sarika; Chaikummao, Supaporn; Varangrat, Anchalee; Holtz, Timothy H.; van Griensven, Frits; Curlin, Marcel E.] Thailand Minist Publ Hlth Ctr Dis Control & Preve, Bangkok, Thailand. [Todd, Catherine S.] FHI 360 Asia Pacific Reg Off, Bangkok, Thailand. [Todd, Catherine S.] AVRAM Corp, Miami, FL USA. [Lokpichart, Somchai] Minist Publ Hlth, Dept Communicable Dis Control, Thai Bur AIDS TB & STD, Bangkok, Thailand. [Holtz, Timothy H.; Curlin, Marcel E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [van Griensven, Frits] Thai Red Cross Soc AIDS Res Ctr, Bangkok, Thailand. [Curlin, Marcel E.] Oregon Hlth & Sci Univ, Dept Med, Div Infect Dis, Portland, OR 97239 USA. RP Curlin, ME (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Infect Dis, MC L457,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM curlin@ohsu.edu FU US Centers for Disease Control and Prevention FX This study was supported by the US Centers for Disease Control and Prevention. NR 32 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2015 VL 42 IS 8 BP 440 EP 449 DI 10.1097/OLQ.0000000000000311 PG 10 WC Infectious Diseases SC Infectious Diseases GA CN2YW UT WOS:000358290300009 PM 26165436 ER PT J AU Mansergh, G Spikes, P Flores, SA Koblin, BA McKirnan, D Hudson, SM Colfax, GN AF Mansergh, Gordon Spikes, Pilgrim Flores, Stephen A. Koblin, Beryl A. McKirnan, David Hudson, Sharon M. Colfax, Grant N. CA Project MIX Study Grp TI Internalised homophobia is differentially associated with sexual risk behaviour by race/ethnicity and HIV serostatus among substance-using men who have sex with men in the United States SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID YOUNG MEN; GAY AB Objectives There is a continuing need to identify factors associated with risk for HIV transmission among men who have sex with men (MSM), including a need for further research in the ongoing scientific debate about the association of internalised homophobia and sexual risk due partly to the lack of specificity in analysis. We assess the association of internalised homophobia by race/ethnicity within HIV serostatus for a large sample of substance-using MSM at high risk of HIV acquisition or transmission. Methods Convenience sample of substance-using (non-injection) MSM reporting unprotected anal sex in the prior 6 months residing in Chicago, Los Angeles, New York and San Francisco. The analytic sample included HIV-negative and HIV-positive black (n=391), Latino (n=220), and white (n=458) MSM. Internalised homophobia was assessed using a published four-item scale focusing on negative self-perceptions and feelings of their own sexual behaviour with men, or for being gay or bisexual. Analyses tested associations of internalised homophobia with recent risk behaviour, stratified by laboratory-confirmed HIV serostatus within race/ethnicity, and controlling for other demographic variables. Results In multivariate analysis, internalised homophobia was inversely associated (p<0.05) with recent unprotected anal sex among black MSM, and not significantly associated with sexual risk behaviour among white and Latino MSM. Conclusions More research is needed to further identify nuanced differences in subpopulations of MSM, but these results suggest differentially targeted intervention messages for MSM by race/ethnicity. C1 [Mansergh, Gordon; Spikes, Pilgrim; Flores, Stephen A.] CDC Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Koblin, Beryl A.] New York Blood Ctr, New York, NY 10021 USA. [McKirnan, David] Univ Illinois, Chicago, IL USA. [Hudson, Sharon M.] Hlth Res Assoc, Los Angeles, CA USA. [Colfax, Grant N.] San Francisco Dept Publ Hlth, San Francisco, CA USA. RP Mansergh, G (reprint author), CDC Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E37, Atlanta, GA 30333 USA. EM gcm2@cdc.gov FU Centers for Disease Control and Prevention [U65/CCU922215, U65/CCU922213, U65/CCU222309, U65/CCU522209] FX This work was supported by the Centers for Disease Control and Prevention, under cooperative agreement numbers U65/CCU922215, U65/CCU922213, U65/CCU222309 and U65/CCU522209. NR 16 TC 3 Z9 3 U1 1 U2 8 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD AUG PY 2015 VL 91 IS 5 BP 324 EP 328 DI 10.1136/sextrans-2014-051827 PG 5 WC Infectious Diseases SC Infectious Diseases GA CN7DQ UT WOS:000358594600005 PM 25512667 ER PT J AU Watson, NF Badr, MS Belenky, G Bliwise, DL Buxton, OM Buysse, D Dinges, DF Gangwisch, J Grandner, MA Kushida, C Malhotra, RK Martin, JL Patel, SR Quan, SF Tasali, E Twery, M Croft, JB Maher, E Barrett, JA Thomas, SM Heald, JL AF Watson, Nathaniel F. Badr, M. Safwan Belenky, Gregory Bliwise, Donald L. Buxton, Orfeu M. Buysse, Daniel Dinges, David F. Gangwisch, James Grandner, Michael A. Kushida, Clete Malhotra, Raman K. Martin, Jennifer L. Patel, Sanjay R. Quan, Stuart F. Tasali, Esra Twery, Michael Croft, Janet B. Maher, Elise Barrett, Jerome A. Thomas, Sherene M. Heald, Jonathan L. TI Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society on the Recommended Amount of Sleep for a Healthy Adult: Methodology and Discussion SO SLEEP LA English DT Article DE sleep duration; consensus; recommendation; adult; health ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; ALL-CAUSE MORTALITY; POPULATION-BASED COHORT; QUALITY-OF-LIFE; NUTRITION EXAMINATION SURVEY; ACUTE MYOCARDIAL-INFARCTION; IMPAIRED GLUCOSE-TOLERANCE; AMBULATORY BLOOD-PRESSURE AB The American Academy of Sleep Medicine and Sleep Research Society recently released a Consensus Statement regarding the recommended amount of sleep to promote optimal health in adults. This paper describes the methodology, background literature, voting process, and voting results for the consensus statement. In addition, we address important assumptions and challenges encountered during the consensus process. Finally, we outline future directions that will advance our understanding of sleep need and place sleep duration in the broader context of sleep health. C1 [Watson, Nathaniel F.] Univ Washington, Seattle, WA 98195 USA. [Badr, M. Safwan] Wayne State Univ, Detroit, MI USA. [Belenky, Gregory] Washington State Univ, Spokane, WA USA. [Bliwise, Donald L.] Emory Univ, Atlanta, GA 30322 USA. [Buxton, Orfeu M.] Penn State Univ, University Pk, PA USA. [Buysse, Daniel] Univ Pittsburgh, Pittsburgh, PA USA. [Dinges, David F.; Grandner, Michael A.] Univ Penn, Philadelphia, PA 19104 USA. [Gangwisch, James] Columbia Univ, New York, NY USA. [Kushida, Clete] Stanford Univ, Stanford, CA 94305 USA. [Malhotra, Raman K.] St Louis Univ, St Louis, MO 63103 USA. [Martin, Jennifer L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Patel, Sanjay R.; Quan, Stuart F.] Harvard Univ, Sch Med, Boston, MA USA. [Tasali, Esra] Univ Chicago, Chicago, IL 60637 USA. [Twery, Michael] Blood Inst, Natl Heart, Lung, NIH, Bethesda, MD USA. [Croft, Janet B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Maher, Elise] Sleep Disorders Inst, New York, NY USA. [Barrett, Jerome A.; Thomas, Sherene M.; Heald, Jonathan L.] Amer Acad Sleep Med, Darien, IL USA. RP Watson, NF (reprint author), 2510 N Frontage Rd, Darien, IL 60561 USA. EM research@aasmnet.org OI Patel, Sanjay/0000-0002-9142-5172 FU American Academy of Sleep Medicine; Centers for Disease Control and Prevention (CDC) [1U50DP004930-01]; NIH; Inspire Medical; ResMed; Jawbone; Cephalon; Aerial BioPharma; Impax Laboratories, Inc.; Equinox Fitness; American Sleep Medicine Foundation; ResMed Foundation; American College of Physicians; Sleep Research Society FX Funding for this project was provided by the American Academy of Sleep Medicine and Sleep Research Society, and supported by the cooperative agreement number 1U50DP004930-01 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.; The authors declare the following conflicts of interest: Dr. Watson has received grant/research support from NIH. He has also served on the Board of Directors for the AASM, ASMF, and ABSM. Dr. Badr has received grant/research support provided by Inspire Medical. Dr. Belenky has no conflicts of interest to disclose. Dr. Bliwise has served as a consultant for New England Research Institute, Ferring Pharmaceuticals, Morehouse School of Medicine, Vantia Therapeutics, Georgia Institute of Technology, and Merck. Dr. Buxton has no conflicts of interest to disclose. Dr. Buysse has served as a consultant for Merck, Purdue Pharm, Emmi, and Philips Respironics. He has also contributed towards CME educational program development for Medscape, CME Outfitters, and WebMD. Additionally he has received grant/research support provided by NIH. Dr. Dinges is a scientific advisor to MARS, Inc. He also receives salary as the Editor-in-Chief of SLEEP. Dr. Gangwisch has no conflicts of interest to disclose. Dr. Grandner has served as a consultant to Bayer and Nexalin. Dr. Kushida has received grant/research support provided by ResMed, Jawbone, Cephalon, Aerial BioPharma, and Impax Laboratories, Inc. He has also served as a consultant for Sephyr Sleep Technologies, Philips-Respironics, Morphy Smart Bed, and Nokia. Dr. Malhotra has served as a member of the speaker's bureau for Teva Pharmaceuticals. Dr. Martin has received grant/research support provided by Equinox Fitness and has served as a consultant to Equinox Fitness. Dr. Patel has received grant/research support provided by American Sleep Medicine Foundation, and ResMed Foundation. He has also received a stipend for chairing AASM Young Investigator Research Forum, and a stipend for authorship from the American College of Physicians. Dr. Quan has served as a consultant to Global Corporate Challenge. Dr Tasali has no conflicts of interest to disclose. NR 360 TC 22 Z9 22 U1 6 U2 25 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD AUG 1 PY 2015 VL 38 IS 8 BP 1161 EP 1183 AR PII sp-00367-15 DI 10.5665/sleep.4886 PG 23 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CO0JV UT WOS:000358838100006 ER PT J AU Brittain, AW Williams, JR Zapata, LB Pazol, K Romero, LM Weik, TS AF Brittain, Anna W. Williams, Jessica R. Zapata, Lauren B. Pazol, Karen Romero, Lisa M. Weik, Tasmeen S. TI Youth-Friendly Family Planning Services for Young People A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID HEALTH-CARE NEEDS; SEXUAL HEALTH; ADOLESCENT HEALTH; PREGNANCY PREVENTION; TEEN FRIENDLINESS; VIEWS; CONFIDENTIALITY; RECOMMENDATIONS; PERSPECTIVES; KNOWLEDGE AB Context: "Youth-friendly" family planning services, services tailored to meet the particular sexual and reproductive health needs of young people (aged 10-24 years), may improve reproductive health outcomes, including reduction of unintended pregnancy. The objectives of this systematic review were to summarize the evidence of the effect of youth-friendly family planning services on reproductive health outcomes and to describe key characteristics of youth-friendly family planning interventions. The review, conducted in 2011, was used to inform national recommendations on quality family planning services. Evidence acquisition: Several electronic bibliographic databases, including PubMed, PsycINFO, and Popline, were used to identify relevant articles published from January 1985 through February 2011. Evidence synthesis: Nineteen articles met the inclusion criteria. Of these, six evaluated outcomes relevant to unintended pregnancy, contraceptive use, and knowledge or patient satisfaction. The 13 remaining studies identified perspectives on youth-friendly characteristics. Of the studies examining outcomes, most had a positive effect (two of three for unintended pregnancy, three of three for contraceptive use, and three of three for knowledge and/or patient satisfaction). Remaining studies described nine key characteristics of youth-friendly family planning services. Conclusions: This review demonstrates that there is limited evidence that youth-friendly services may improve reproductive health outcomes for young people and identifies service characteristics that might increase their receptivity to using these services. Although more rigorous studies are needed, the interventions and characteristics identified in this review should be considered in the development and evaluation of youth-friendly family planning interventions in clinical settings. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Brittain, Anna W.; Zapata, Lauren B.; Pazol, Karen; Romero, Lisa M.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Williams, Jessica R.] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL 33124 USA. [Williams, Jessica R.] Manila Consulting Grp Inc, Mclean, VA USA. [Weik, Tasmeen S.] USDHHS, Off Populat Affairs, Washington, DC USA. RP Brittain, AW (reprint author), CDC, 4770 Buford Highway,Mailstop F-74, Chamblee, GA 30341 USA. EM abrittain@cdc.gov OI Williams, Jessica/0000-0001-6105-0296 FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was Supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 47 TC 9 Z9 9 U1 3 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S73 EP S84 DI 10.1016/j.amepre.2015.03.019 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800009 PM 26190850 ER PT J AU Brittain, AW Williams, JR Zapata, LB Moskosky, SB Weik, TS AF Brittain, Anna W. Williams, Jessica R. Zapata, Lauren B. Moskosky, Susan B. Weik, Tasmeen S. TI Confidentiality in Family Planning Services for Young People A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID SEXUAL HEALTH-SERVICES; ADOLESCENT MEDICINE; POSITION PAPER; CARE; SOCIETY; ACCESS; RECOMMENDATIONS; COMMUNICATION; INFORMATION; PHYSICIANS AB Context: Family planning services are essential for reducing high rates of unintended pregnancies among young people, yet a perception that providers will not preserve confidentiality may deter youth from accessing these services. This systematic review, conducted in 2011, summarizes the evidence on the effect of assuring confidentiality in family planning services to young people on reproductive health outcomes. The review was used to inform national recommendations on providing quality family planning services. Evidence acquisition: Multiple databases were searched to identify articles addressing confidentiality in family planning services to youth aged 10-24 years. Included studies were published, from January 1985 through February 2011. Studies conducted outside the U.S., Canada, Europe, Australia, or New Zealand, and those that focused exclusively on HIV or sexually transmitted diseases, were excluded. Evidence synthesis: The search strategy identified 19,332 articles, nine of which met the inclusion criteria. Four studies examined outcomes. Examined outcomes included use of clinical services and intention to use services. Of the four outcome studies, three found a positive association between assurance of confidentiality and at least one outcome of interest. Five studies provided information on youth perspectives and underscored the idea that young people greatly value confidentiality when receiving family planning services. Conclusions: This review demonstrates that there is limited research examining whether confidentiality in family planning services to young people affects reproductive health outcomes. A robust research agenda is needed, given the importance young people place on confidentiality. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Brittain, Anna W.; Zapata, Lauren B.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Williams, Jessica R.] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL 33124 USA. [Williams, Jessica R.] Manila Consulting Grp Inc, Mclean, VA USA. [Moskosky, Susan B.; Weik, Tasmeen S.] USDHHS, Off Populat Affairs, Washington, DC USA. RP Brittain, AW (reprint author), CDC, 4770 Buford Highway,Mailstop F-74, Chamblee, GA 30341 USA. EM abrittain@cdc.gov OI Williams, Jessica/0000-0001-6105-0296 FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 30 TC 6 Z9 6 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S85 EP S92 DI 10.1016/j.amepre.2015.04.001 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800010 PM 26190851 ER PT J AU Carter, MW Tregear, ML Lachance, CR AF Carter, Marion W. Tregear, Michelle L. Lachance, Christina R. TI Community Engagement in Family Planning in the US A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID PUBLIC-HEALTH; EMERGENCY CONTRACEPTION; CONSUMER INVOLVEMENT; PATIENT INFORMATION; SERVICE DEVELOPMENT; PARTICIPATION; PHOTOVOICE; EXPERIENCE; PROMOTION; BARRIERS AB Context: Community engagement may include activities that involve community members in the design, implementation, and evaluation of services. The objective of this systematic review was to evaluate the evidence on this kind of community engagement in U.S. family planning programs, including its effects on various health outcomes, its perceived value, and the barriers and facilitators to implementation. Evidence acquisition: Using an analytic approach drawn from U.S. Preventive Services Task Force, multiple databases were searched for articles published from 1985 through February 2011 that described studies about community engagement related to family planning. In 2011, relevant articles were reviewed, summarized, and assessed for potential bias using a standardized abstraction process. An updated, targeted review for the 2011-2014 period was conducted in early 2015. Evidence synthesis: Eleven papers related to family planning were included. All were qualitative, descriptive, and at high risk for bias. Engagement strategies involved various methods for developing educational materials, program development, or program evaluation. All studies reported benefits to community engagement, such as more-appropriate educational materials or more community support for programs. Barriers to engagement included the substantial time and resources required. Four more articles were identified in the targeted, additional search. Conclusions: Community engagement is described as beneficial across the included studies, but the body of evidence for community engagement in family planning is relatively small. Given the high value ascribed to community engagement, more research and documentation of the various approaches taken and their relative strengths and weaknesses are needed. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Carter, Marion W.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Tregear, Michelle L.] Manila Consulting Grp Inc, Mclean, VA USA. [Lachance, Christina R.] US DHHS, Off Populat Affairs, Rockville, MD USA. RP Carter, MW (reprint author), CDC, Div STD Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM MCarter1@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 32 TC 5 Z9 5 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S116 EP S123 DI 10.1016/j.amepre.2015.03.029 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800013 PM 26190842 ER PT J AU Carter, MW Tregear, ML Moskosky, SB AF Carter, Marion W. Tregear, Michelle L. Moskosky, Susan B. TI Community Education for Family Planning in the US A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID EMERGENCY CONTRACEPTIVE PILLS; RANDOMIZED CONTROLLED-TRIAL; REPRODUCTIVE HEALTH; ADOLESCENT PREGNANCY; PREVENTIVE-SERVICES; MEDIA CAMPAIGN; SEXUAL HEALTH; YOUNG-PEOPLE; IMPACT; INTERVENTIONS AB Context: Community education may involve activities that seek to raise awareness and promote behavior change, using mass media, social media, and other media or interpersonal methods in community settings. This systematic review evaluated the evidence of the effects of community education on select short- and medium-term family planning outcomes. Evidence acquisition: Using an analytic approach drawn from the U.S. Preventive Services Task Force, multiple databases were searched for articles published from January 1985 through February 2011 describing studies of community education related to family planning in the U.S. Included articles were reviewed and assessed for potential bias using a standardized process in 2011. An updated, targeted review for the 2011-2014 period was conducted in early 2015. Evidence synthesis: Seventeen papers were identified. Most (nine) related to mass media interventions; three involved targeted print media, two involved text messaging or e-mail, two described outcome workers conducting community education, and one involved community theater. Study designs, strength of evidence, and levels of possible bias varied widely. Twelve of 15 studies that addressed outcomes such as increased awareness found positive associations with those outcomes, with six also reporting null findings. Seven of eight studies that addressed use of services reported positive associations, with two also reporting null findings. The targeted, additional review identified two other studies. Conclusions: Evidence related to community education for family planning purposes is limited and highly variable. As goals of community education are usually limited to shorter-term outcomes, the evidence suggests that a range of approaches may be effective. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Carter, Marion W.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Tregear, Michelle L.] Manila Consulting Grp Inc, Mclean, VA USA. [Moskosky, Susan B.] US DHHS, Off Populat Affairs, Rockville, MD USA. RP Carter, MW (reprint author), CDC, Div STD Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM MCarter1@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 33 TC 4 Z9 4 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S107 EP S115 DI 10.1016/j.amepre.2015.03.030 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800012 PM 26190841 ER PT J AU Gavin, LE Williams, JR Rivera, MI Lachance, CR AF Gavin, Loretta E. Williams, Jessica R. Rivera, Maria I. Lachance, Christina R. TI Programs to Strengthen Parent-Adolescent Cornmunication About Reproductive Health A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; AMERICAN FAMILIES PROGRAM; SEXUAL RISK REDUCTION; DISCUSS SEXUALITY; INTERVENTION; EDUCATION; PREVENTION; BEHAVIORS; IMPACT; COMMUNICATION AB Context: When caring for an adolescent client, providers of contraceptive services must consider whether and how to encourage parent/guardian-child communication about the adolescent's reproductive health. The objective of this systematic review was to summarize the evidence on the effectiveness of programs designed to increase parent-child communication about reproductive health. The review was used to inform national recommendations on quality family planning services. Data analysis occurred from mid-2011 through 2012. Evidence acquisition: Several electronic bibliographic databases were used to identify relevant articles, including Pub Med, CINAHL, PsycINFO, and Pop line, published from January 1985 through February 2011. Evidence synthesis: Sixteen articles met the inclusion criteria: all studies examined the impact on at least one medium- or short-term outcome, and two studies assessed the impact on teen pregnancy. One study examined the impact of a program conducted in a clinic setting; the remainder examined the impact of programs in community settings. All studies showed a positive impact on at least one short-term outcome, and 12 of 16 studies showed an increase in parent-child communication about reproductive health. Four of seven studies found an impact on sexual risk behavior. Conclusions: Most programs increased parent-child communication, and several resulted in reduced sexual risk behavior of adolescents. This suggests that delivering a clinic-based program that effectively helps parents/guardians talk to their adolescent child(ren) about reproductive health, or referring parents/guardians to an evidence-based program in the community, may be beneficial. However, further rigorous research on delivery of these programs in clinical settings is needed. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Gavin, Loretta E.; Rivera, Maria I.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Williams, Jessica R.] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL 33124 USA. [Williams, Jessica R.] MANILA Consulting Grp, Mclean, VA USA. [Gavin, Loretta E.; Lachance, Christina R.] USDHHS, Off Populat Affairs, Rockville, MD 20852 USA. RP Gavin, LE (reprint author), USDHHS, Off Populat Affairs, 1101 Wootton Pkwy,Suite 700, Rockville, MD 20852 USA. EM lorrie.gavin@hhs.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 37 TC 6 Z9 6 U1 4 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S65 EP S72 DI 10.1016/j.amepre.2015.03.022 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800008 PM 26190849 ER PT J AU Gavin, LE Moskosky, SB Barfield, WD AF Gavin, Loretta E. Moskosky, Susan B. Barfield, Wanda D. TI Introduction to the Supplement Development of Federal Recommendations for Family Planning Services SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID ACTING REVERSIBLE CONTRACEPTION; UNITED-STATES; UNINTENDED PREGNANCIES; QUALITY; FAILURE; SAVINGS C1 [Gavin, Loretta E.; Moskosky, Susan B.] Off Populat Affairs, Rockville, MD 20857 USA. [Barfield, Wanda D.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Gavin, LE (reprint author), Off Populat Affairs, 1101 Wootton Pkwy,Suite 700, Rockville, MD 20857 USA. EM lorrie.gavin@hhs.gov NR 44 TC 4 Z9 4 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S1 EP S5 DI 10.1016/j.amepre.2015.03.028 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800001 PM 26190840 ER PT J AU Godfrey, EM Tepper, NK Curtis, KM Moskosky, SB Gavin, LE AF Godfrey, Emily M. Tepper, Naomi K. Curtis, Kathryn M. Moskosky, Susan B. Gavin, Loretta E. TI Developing Federal Clinical Care Recommendations for Women SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article AB The provision of family planning services has important health benefits for the U.S. population. Approximately 25 million women in the U.S. receive contraceptive services annually and 44 million make at least one family planning-related clinical visit each year. These services are provided by private clinicians, as well as publicly funded clinics, including specialty family planning clinics, health departments, Planned Parenthoods, community health centers, and primary care clinics. Recommendations for providing quality family planning services have been published by CDC and the Office of Population Affairs of the DHHS. This paper describes the process used to develop the women's clinical services portion of the new recommendations and the rationale underpinning them. The recommendations define family planning services as contraceptive care, pregnancy testing and counseling, achieving pregnancy, basic infertility care, sexually transmitted disease services, and preconception health. Because many women who seek family planning services have no other source of care, the recommendations also include additional screening services related to women's health, such as cervical cancer screening. These clinical guidelines are aimed at providing the highest-quality care and are designed to establish a national standard for family planning in the U.S. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Godfrey, Emily M.; Tepper, Naomi K.; Curtis, Kathryn M.; Gavin, Loretta E.] CDC, Div Reprod Hlth, Atlanta, GA 30341 USA. [Moskosky, Susan B.] DHHS, Off Populat Affairs, Washington, DC USA. RP Tepper, NK (reprint author), CDC, Div Reprod Hlth, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. EM ntepper@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 13 TC 3 Z9 3 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S6 EP S13 DI 10.1016/j.amepre.2015.02.023 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800002 PM 26190848 ER PT J AU Pazol, K Zapata, LB Tregear, SJ Mautone-Smith, N Gavin, LE AF Pazol, Karen Zapata, Lauren B. Tregear, Stephen J. Mautone-Smith, Nancy Gavin, Loretta E. TI Impact of Contraceptive Education on Contraceptive Knowledge and Decision Making A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; COMPUTER-ASSISTED-INSTRUCTION; RISK REDUCTION; WOMENS KNOWLEDGE; EMERGENCY CONTRACEPTION; INDIVIDUAL MEDICINES; UNINTENDED PREGNANCY; INTRAUTERINE-DEVICES; WRITTEN INFORMATION; CONDOM ACQUISITION AB Context: Educational interventions can help increase knowledge of available contraceptive methods, enabling individuals to make informed decisions and use contraception more effectively. This systematic review evaluated contraceptive education interventions to guide national recommendations on quality family planning services. Evidence acquisition: Three databases (CINAHL, Pub Med, and PsycINFO) were searched from 1985 through 2012 for peer-reviewed articles on educational interventions, with supplemental searches conducted through 2015. Primary outcomes were knowledge, participation in and comfort with decision making, and attitudes toward contraception. Secondary outcomes included contraceptive use behaviors and unintended pregnancy. Evidence synthesis: Database searches in 2011 identified 5,830 articles; 17 met inclusion criteria and were abstracted into evidence tables. Searches in 2012 and 2015 identified four additional studies. Studies used a wide range of tools (decision aids, written materials, audio/videotapes, and interactive games), with and without input from a healthcare provider or educator. Of 15 studies that examined the impact of educational interventions on knowledge, 14 found significant improvement using a range of tools, with and without input from a healthcare provider or educator. Fewer studies evaluated outcomes related to decision making, attitudes toward contraception, contraceptive use behaviors, or unintended pregnancy. Conclusions: Results from this systematic review are consistent with evidence from the broader healthcare field suggesting that a range of educational interventions can increase knowledge. Future studies should assess what aspects of educational interventions are most effective, the extent to which it is necessary to include a healthcare provider or educator, and the extent to which educational interventions can impact behaviors. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Pazol, Karen; Zapata, Lauren B.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Tregear, Stephen J.] Manila Consulting Grp Inc, Mclean, VA USA. [Mautone-Smith, Nancy; Gavin, Loretta E.] Off Populat Affairs, Rockville, MD USA. RP Pazol, K (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS F74, Atlanta, GA 30341 USA. EM kpazol@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 77 TC 12 Z9 12 U1 7 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S46 EP S56 DI 10.1016/j.amepre.2015.03.031 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800006 PM 26190846 ER PT J AU Williams, JR Gavin, LE Carter, MW Glass, E AF Williams, Jessica R. Gavin, Loretta E. Carter, Marion W. Glass, Evelyn TI Client and Provider Perspectives on Quality of Care A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID FAMILY-PLANNING-SERVICES; CONTRACEPTIVE CARE; UNITED-STATES; LOW-INCOME; HEALTH; PREGNANCY; EXPERIENCES; CHAPERONES; ATTITUDES; OFFICE AB Context: A central premise of the literature on healthcare quality is that improving the quality of care will lead to improvements in health outcomes. A systematic review was conducted to better inform quality improvement efforts in the area of family planning. The objective of this systematic review is to update a previous review focused on the quality of family planning services, namely, the impact of quality improvement efforts and client perspectives about what constitutes quality family planning services. In addition, this review includes new literature examining provider perspectives. Evidence acquisition: Multiple databases from January 1985 through January 2015 were searched within the peer-reviewed literature that described the quality of family planning services. The retrieval and inclusion criteria included full-length articles published in English, which described studies occurring in a clinic-based setting to include family planning services. Evidence synthesis: Search strategies identified 16,145 articles, 16 of which met the inclusion criteria. No new intervention studies addressing the impact of quality improvement efforts on family planning outcomes were identified. Sixteen articles provided information relevant to client or provider perspectives about what constitutes quality family planning services. Clients and providers mostly identified the need for services that were accessible, client-centered, and equitable. Themes related to effectiveness, efficiency, and safety were mentioned less frequently. Conclusions: Family planning services that account for both patient and provider perspectives may be more effective. Further research is needed to examine the impact of improved quality on provider practices, client behavior, and health outcomes. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Williams, Jessica R.] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL 33124 USA. [Williams, Jessica R.] MANILA Consulting Grp Inc, Mclean, VA USA. [Gavin, Loretta E.; Carter, Marion W.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Gavin, Loretta E.; Glass, Evelyn] USDHHS, Off Populat Affairs, Washington, DC USA. RP Williams, JR (reprint author), Univ Miami, Sch Nursing & Hlth Studies, POB 248153, Coral Gables, FL 33124 USA. EM j.williams17@miami.edu OI Williams, Jessica/0000-0001-6105-0296 FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA); CDC [2009-N-11195] FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA).; Funding was received from CDC under contract number 2009-N-11195. NR 30 TC 4 Z9 4 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S93 EP S106 DI 10.1016/j.amepre.2015.03.017 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800011 PM 26190852 ER PT J AU Zapata, LB Tregear, SJ Curtis, KM Tiller, M Pazol, K Mautone-Smith, N Gavin, LE AF Zapata, Lauren B. Tregear, Stephen J. Curtis, Kathryn M. Tiller, Marie Pazol, Karen Mautone-Smith, Nancy Gavin, Loretta E. TI Impact of Contraceptive Counseling in Clinical Settings A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE SETTINGS; SERVICES-TASK-FORCE; FAMILY-PLANNING-SERVICES; UNINTENDED PREGNANCY; RHEUMATOID-ARTHRITIS; ORAL-CONTRACEPTIVES; PHYSICAL-ACTIVITY; DECISION-MAKING; UNITED-STATES AB Context: This systematic review evaluated the evidence on the impact of contraceptive counseling provided in clinical settings on reproductive health outcomes to provide information to guide national recommendations on quality family planning services. Evidence acquisition: Multiple databases were searched during 2010-2011 for peer-reviewed articles published in English from January 1985 through February 2011 describing studies that evaluated contraceptive counseling interventions in clinical settings. Studies were excluded if they focused primarily on prevention of HIV or sexually transmitted infections, focused solely on men, or were conducted outside the U.S., Canada, Europe, Australia, or New Zealand. Evidence synthesis: The initial search identified 12,327 articles, of which 22 studies (from 23 articles) met the inclusion criteria. Six studies examined the impact of contraceptive counseling among adolescents, with four finding a significant positive impact on at least one outcome of interest. Sixteen studies examined the impact of counseling among adults or mixed populations (adults and adolescents), with 11 finding a significant positive impact on at least one outcome of interest. Conclusions: Promising components of contraceptive counseling were identified despite the diversity of interventions and inability to compare the relative effectiveness of one approach versus another. The evidence base would be strengthened by improved documentation of counseling procedures; assessment of intervention implementation and fidelity to put study findings into context; and development and inclusion of more RCTs, studies conducted among general samples of women, and studies with sample sizes sufficient to detect important behavioral outcomes at least 12 months post-intervention. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Zapata, Lauren B.; Curtis, Kathryn M.; Pazol, Karen] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Tregear, Stephen J.; Tiller, Marie] Manila Consulting Grp Inc, Mclean, VA USA. [Mautone-Smith, Nancy; Gavin, Loretta E.] USDHHS, Off Populat Affairs, Rockville, MD USA. RP Zapata, LB (reprint author), CDC, 4770 Buford Highway NE,Mailstop F-74, Chamblee, GA 30341 USA. EM lzapata@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 67 TC 10 Z9 10 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S31 EP S45 DI 10.1016/j.amepre.2015.03.023 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800005 PM 26190845 ER PT J AU Zapata, LB Tregear, SJ Tiller, M Pazol, K Mautone-Smith, N Gavin, LE AF Zapata, Lauren B. Tregear, Stephen J. Tiller, Marie Pazol, Karen Mautone-Smith, Nancy Gavin, Loretta E. TI Impact of Reminder Systems in Clinical Settings to Improve Family Planning Outcomes A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; TEXT-MESSAGE REMINDERS; UNITED-STATES; ANTIRETROVIRAL THERAPY; ORAL-CONTRACEPTION; MAIL REMINDER; ADHERENCE; INTERVENTION; MEDICATION; PREGNANCY AB Context: This systematic review evaluated the evidence on the impact of family planning reminder systems interventions intended to remind patients of behaviors to achieve reproductive health goals (e.g., daily text messages reminding oral contraceptive [OC] users to take a pill) to provide information to guide national recommendations on quality family planning services. Evidence acquisition: Multiple databases including PubMed were searched during 2010-2011 for peer-reviewed articles published in English from January 1985 through February 2011 describing studies evaluating reminder systems to improve family planning outcomes. Studies were excluded if they focused primarily on HIV or sexually transmitted infection prevention, focused solely on men, or were conducted outside the U.S., Europe, Australia, or New Zealand. Evidence synthesis: The initial search identified 16,129 articles, five of which met the inclusion criteria. Three studies examined the impact of OC reminder systems; two found a statistically significant positive impact on correct use. Two studies examined the impact of reminder systems among depot medroxyprogesterone acetate (DMPA) users; one found a statistically significant positive impact on correct use. Conclusions: Although mixed support was found for the effectiveness of reminder system interventions on correct use of OCs and DMPA, the highest-quality evidence yielded null findings. The evidence base would be strengthened by the development of additional studies, especially RCTs, which objectively measure outcomes, examine additional contraceptive methods, and have sufficient sample sizes to detect behavioral outcomes at least 12 months post-intervention. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Zapata, Lauren B.; Pazol, Karen] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. [Tregear, Stephen J.; Tiller, Marie] Manila Consulting Grp Inc, Mclean, VA USA. [Mautone-Smith, Nancy; Gavin, Loretta E.] USDHHS, Off Populat Affairs, Rockville, MD USA. RP Zapata, LB (reprint author), CDC, 4770 Buford Highway NE,Mailstop F-74, Chamblee, GA 30341 USA. EM lzapata@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC); Office of Population Affairs (OPA) FX Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC) and the Office of Population Affairs (OPA). NR 29 TC 6 Z9 6 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 SU 1 BP S57 EP S64 DI 10.1016/j.amepre.2015.03.018 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CN2TC UT WOS:000358273800007 PM 26190847 ER PT J AU Weigand, MR Pena-Gonzalez, A Shirey, TB Broeker, RG Ishaq, MK Konstantinidis, KT Raphael, BH AF Weigand, Michael R. Pena-Gonzalez, Angela Shirey, Timothy B. Broeker, Robin G. Ishaq, Maliha K. Konstantinidis, Konstantinos T. Raphael, Brian H. TI Implications of Genome-Based Discrimination between Clostridium botulinum Group I and Clostridium sporogenes Strains for Bacterial Taxonomy SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID SPECIES DEFINITION; NEUROTOXIN GENES; PA 3679; SEQUENCE; DIVERSITY; COMPLEX; SPECIATION; MODEL AB Taxonomic classification of Clostridium botulinum is based on the production of botulinum neurotoxin (BoNT), while closely related, nontoxic organisms are classified as Clostridium sporogenes. However, this taxonomic organization does not accurately mirror phylogenetic relationships between these species. A phylogenetic reconstruction using 2,016 orthologous genes shared among strains of C. botulinum group I and C. sporogenes clearly separated these two species into discrete clades which showed similar to 93% average nucleotide identity (ANI) between them. Clustering of strains based on the presence of variable orthologs revealed 143 C. sporogenes clade-specific genetic signatures, a subset of which were further evaluated for their ability to correctly classify a panel of presumptive C. sporogenes strains by PCR. Genome sequencing of several C. sporogenes strains lacking these signatures confirmed that they clustered with C. botulinum strains in a core genome phylogenetic tree. Our analysis also identified C. botulinum strains that contained C. sporogenes clade-specific signatures and phylogenetically clustered with C. sporogenes strains. The genome sequences of two bont/B2-containing strains belonging to the C. sporogenes clade contained regions with similarity to a bont-bearing plasmid (pCLD), while two different strains belonging to the C. botulinum clade carried bont/B2 on the chromosome. These results indicate that bont/B2 was likely acquired by C. sporogenes strains through horizontal gene transfer. The genome-based classification of these species used to identify candidate genes for the development of rapid assays for molecular identification may be applicable to additional bacterial species that are challenging with respect to their classification. C1 [Weigand, Michael R.; Konstantinidis, Konstantinos T.] Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA. [Pena-Gonzalez, Angela; Konstantinidis, Konstantinos T.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Shirey, Timothy B.; Broeker, Robin G.; Ishaq, Maliha K.; Raphael, Brian H.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA 30333 USA. RP Raphael, BH (reprint author), Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA 30333 USA. EM BRaphael@cdc.gov OI Raphael, Brian/0000-0003-2778-2623; Weigand, Michael/0000-0002-7278-0160 FU Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response; U.S. National Science Foundation [1241046]; Colciencias-Colombian Administrative Department for Science, Technology and Innovation; Oak Ridge Institute for Science and Education FX This work was supported by funds made available from the Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response and in part by the U.S. National Science Foundation under award no. 1241046 (to K.T.K.). A.P.-G. was supported by Colciencias-Colombian Administrative Department for Science, Technology and Innovation through a doctoral fellowship. T.B.S. and M.K.I. were supported by fellowships with the Oak Ridge Institute for Science and Education. NR 50 TC 7 Z9 7 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD AUG PY 2015 VL 81 IS 16 BP 5420 EP 5429 DI 10.1128/AEM.01159-15 PG 10 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA CN2UX UT WOS:000358278600015 PM 26048939 ER PT J AU Stanfill, SB da Silva, ALO Lisko, JG Lawler, TS Kuklenyik, P Tyx, RE Peuchen, EH Richter, P Watson, CH AF Stanfill, Stephen B. Oliveira da Silva, Andre Luiz Lisko, Joseph G. Lawler, Tameka S. Kuklenyik, Peter Tyx, Robert E. Peuchen, Elizabeth H. Richter, Patricia Watson, Clifford H. TI Comprehensive chemical characterization of Rape tobacco products: Nicotine, un-ionized nicotine, tobacco-specific N '-nitrosamines, polycyclic aromatic hydrocarbons, and flavor constituents SO FOOD AND CHEMICAL TOXICOLOGY LA English DT Article DE Smokeless tobacco; Nasal snuff; Rape; Nicotine; Tobacco-specific nitrosamines; Flavors ID SMOKELESS TOBACCO; UNPROTONATED NICOTINE; WOOD ASH; PH; SURVEILLANCE; MOISTURE; CAMPHOR AB Rape, a diverse group of smokeless tobacco products indigenous to South America, is generally used as a nasal snuff and contains substantial amount of plant material with or without tobacco. Previously uncharacterized, rape contains addictive and harmful chemicals that may have public health implications for users. Here we report % moisture, pH, and the levels of total nicotine, un-ionized nicotine, flavor-related compounds, tobacco-specific N-nitrosamines (TSNAs) and polycyclic aromatic hydrocarbons (PAHs) for manufactured and hand-made rape. Most rape products were mildly acidic (pH 5.17-6.23) with total nicotine ranging from 6.32 to 47.6 milligram per gram of sample (mg/g). Calculated un-ionized nicotine ranged from 0.03 to 18.5 mg/g with the highest values associated with hand-made rapes (pH 9.75-10.2), which contain alkaline ashes. In tobacco-containing rapes, minor alkaloid levels and Fourier transform infrared spectra were used to confirm the presence of Nicotiana rustica, a high nicotine tobacco species. There was a wide concentration range of TSNAs and PAHs among the rapes analyzed. Several TSNAs and PAHs identified in the products are known or probable carcinogens according to the International Agency for Research on Cancer. Milligram quantities of some non-tobacco constituents, such as camphor, coumarin, and eugenol, warrant additional evaluation. Published by Elsevier Ltd. C1 [Stanfill, Stephen B.; Lisko, Joseph G.; Lawler, Tameka S.; Kuklenyik, Peter; Tyx, Robert E.; Peuchen, Elizabeth H.; Richter, Patricia; Watson, Clifford H.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Oliveira da Silva, Andre Luiz] Natl Hlth Surveillance Agcy Brazil, Agencia Nacl Vigilancia Sanit ANVISA, Rio De Janeiro, Brazil. RP Stanfill, SB (reprint author), Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA. EM sstanfill@cdc.gov NR 25 TC 2 Z9 2 U1 5 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-6915 EI 1873-6351 J9 FOOD CHEM TOXICOL JI Food Chem. Toxicol. PD AUG PY 2015 VL 82 BP 50 EP 58 DI 10.1016/j.fct.2015.04.016 PG 9 WC Food Science & Technology; Toxicology SC Food Science & Technology; Toxicology GA CN5IO UT WOS:000358463200007 PM 25934468 ER PT J AU Khong, CJ Baggs, J Kleinbaum, D Cochran, R Jernigan, JA AF Khong, Carolyn J. Baggs, James Kleinbaum, David Cochran, Ronda Jernigan, John A. TI The Likelihood of Hospital Readmission Among Patients With Hospital-Onset Central Line-Associated Bloodstream Infections SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CARE-ASSOCIATED INFECTIONS; ELDERLY PATIENTS; PREVENTION; MORTALITY; QUALITY; IMPACT; COST AB OBJECTIVE. To determine whether central line-associated bloodstream infections (CLABSIs) increase the likelihood of readmission. DESIGN. Retrospective matched cohort study for the years 2008-2009. SETTING. Acute care hospitals. PARTICIPANTS. Medicare recipients. CLABSI and readmission status were determined by linking National Healthcare Safety Network surveillance data to the Centers for Medicare and Medicaid Services' Medical Provider and Analysis Review in 8 states. Frequency matching was used on International Classification of Diseases, Ninth Revision, Clinical Modification procedure code category and intensive care unit status. METHODS. We compared the rate of readmission among patients with and without CLABSI during an index hospitalization. Cox proportional hazard analysis was used to assess rate of readmission (the first hospitalization within 30 days after index discharge). Multivariate models included the following covariates: race, sex, length of index hospitalization stay, central line procedure code, Gagne comorbidity score, and individual chronic conditions. RESULTS. Of the 8,097 patients, 2,260 were readmitted within 30 days (27.9%). The rate of first readmission was 7.1 events/person-year for CLABSI patients and 4.3 events/person-year for non-CLABSI patients (P <.001). The final model revealed a small but significant increase in the rate of 30-day readmissions for patients with a CLABSI compared with similar non-CLABSI patients. In the first readmission for CLABSI patients, we also observed an increase in diagnostic categories consistent with CLABSI, including septicemia and complications of a device. CONCLUSIONS. Our analysis found a statistically significant association between CLABSI status and readmission, suggesting that CLABSI may have adverse health impact that extends beyond hospital discharge. C1 [Khong, Carolyn J.; Baggs, James; Kleinbaum, David; Cochran, Ronda; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Kleinbaum, David] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Baggs, J (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A31, Atlanta, GA 30333 USA. EM jbaggs@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 1 Z9 1 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2015 VL 36 IS 8 BP 886 EP 892 DI 10.1017/ice.2015.115 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CN4HS UT WOS:000358391800003 PM 25990620 ER PT J AU See, I Bagchi, S Booth, S Scholz, D Geller, AI Anderson, L Moulton-Meissner, H Finks, JL Kelley, K Gould, CV Patel, PR AF See, Isaac Bagchi, Suparna Booth, Stephanie Scholz, Daniel Geller, Andrew I. Anderson, Lydia Moulton-Meissner, Heather Finks, Jennie L. Kelley, Karen Gould, Carolyn V. Patel, Priti R. TI Outbreak of Clostridium difficile Infections at an Outpatient Hemodialysis Facility-Michigan, 2012-2013 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE AB Investigation of an outbreak of Clostridium difficile infection (CDI) at a hemodialysis facility revealed evidence that limited intra-facility transmission occurred despite adherence to published infection control standards for dialysis clinics. Outpatient dialysis facilities should consider CDI prevention, including environmental disinfection for C. difficile, when formulating their infection control plans. C1 [See, Isaac; Bagchi, Suparna; Geller, Andrew I.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [See, Isaac; Geller, Andrew I.; Anderson, Lydia; Moulton-Meissner, Heather; Gould, Carolyn V.; Patel, Priti R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Bagchi, Suparna] Kansas Dept Hlth, Topeka, KS USA. [Booth, Stephanie; Kelley, Karen] Portage Hlth, Portage Hlth Dialysis, Hancock, MI USA. [Scholz, Daniel] Mayo Clin, Dept Emergency Med, Rochester, MN USA. [Finks, Jennie L.] Michigan Dept Community Hlth, Lansing, MI USA. RP See, I (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE A-16, Atlanta, GA 30333 USA. EM isee@cdc.gov FU Centers for Disease Control and Prevention FX Financial support: This work was supported by the Centers for Disease Control and Prevention. NR 8 TC 2 Z9 2 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2015 VL 36 IS 8 BP 972 EP 974 DI 10.1017/ice.2015.90 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CN4HS UT WOS:000358391800016 PM 25913501 ER PT J AU Henry, KL Thornberry, TP Lee, RD AF Henry, Kimberly L. Thornberry, Terence P. Lee, Rosalyn D. TI The Protective Effects of Intimate Partner Relationships on Depressive Symptomatology Among Adult Parents Maltreated as Children SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Maltreatment; Depression; Protective factors; Intimate partner relationships ID CHILDHOOD SEXUAL-ABUSE; SOCIAL SUPPORT; HEALTH; WOMEN; PSYCHOPATHOLOGY; CONSEQUENCES; MEDIATORS; SYMPTOMS; OUTCOMES; NEGLECT AB Purpose: We examined whether intimate partner relationships in general, and satisfying and stable intimate partner relationships in particular, protect victims of child maltreatment from depressive symptoms during young adulthood. Methods: Prospective, longitudinal data on 485 parents, 99 maltreated during childhood, were used. Longitudinal multilevel models (12 annual interviews, conducted from 1999 to 2010, nested in individuals) were specified to estimate the effects of relationship characteristics on depressive symptomatology by maltreatment status. Results: Relationship characteristics operated as direct protective factors for maltreated and not maltreated individuals. Higher relationship satisfaction and stability were prospectively predictive of less depressive symptomatology. Models of inter and intraindividual variability were also consistent with significant direct protective effects. Between persons, a more satisfying and stable relationship was associated with fewer depressive symptoms. Within person, periods when an individual moved into a relationship and periods of enhanced satisfaction and stability were associated with fewer depressive symptoms. Relationship satisfaction and stability operated as significant buffering protective factors for the effect of maltreatment on depressive symptoms in most models, suggesting that positive intimate partner relationships may reduce the risk that childhood maltreatment poses for adult depressive symptoms. Conclusions: The Centers for Disease Control and Prevention identifies safe, stable, and nurturing relationships as key in preventing maltreatment and its consequences. This study adds to the evidence on the protective role of safe, stable, and nurturing relationships by identifying intimate partner relationship factors that may protect parents who were maltreated during childhood from depressive symptoms. (C) 2015 Society for Adolescent Health and Medicine. All rights reserved. C1 [Henry, Kimberly L.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. [Thornberry, Terence P.] Univ Maryland, Dept Criminol & Criminal Justice, College Pk, MD 20742 USA. [Lee, Rosalyn D.] US Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Henry, KL (reprint author), Colorado State Univ, Dept Psychol, 220 Behav Sci Bldg, Ft Collins, CO 80523 USA. EM kim.henry@colostate.edu FU Centers for Disease Control and Prevention [R01CE001572]; Office of Juvenile Justice and Delinquency Prevention [2006-JW-BX-0074, 86-JN-CX-0007, 96-MU-FX-0014, 2004-MU-FX-0062]; National Institute on Drug Abuse [R01DA020195, R01DA005512]; National Science Foundation [SBR-9123299]; National Institute of Mental Health [R01MH56486, R01MH63386]; National Institute of Child Health and Human Development [P30HD32041]; NSF [SBR-9512290] FX Support for the Rochester Youth Development Study has been provided by the Centers for Disease Control and Prevention (R01CE001572), the Office of Juvenile Justice and Delinquency Prevention (2006-JW-BX-0074, 86-JN-CX-0007, 96-MU-FX-0014, 2004-MU-FX-0062), the National Institute on Drug Abuse (R01DA020195, R01DA005512), the National Science Foundation (SBR-9123299), and the National Institute of Mental Health (R01MH56486, R01MH63386). Work on this project was also aided by grants to the Center for Social and Demographic Analysis at the University at Albany from National Institute of Child Health and Human Development (P30HD32041) and NSF (SBR-9512290). NR 32 TC 2 Z9 2 U1 1 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD AUG PY 2015 VL 57 IS 2 BP 150 EP 156 DI 10.1016/j.jadohealth.2015.02.015 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA CN2OZ UT WOS:000358262900006 PM 25912653 ER PT J AU Merrick, MT Litrownik, AJ Margolis, B Wiley, TRA Everson, MD Dubowitz, H English, D AF Merrick, Melissa T. Litrownik, Alan J. Margolis, Benyamin Wiley, Tisha R. A. Everson, Mark D. Dubowitz, Howard English, Diana TI Sexualized Behaviors Partially Mediate the Link between Maltreatment and Delinquent Behaviors SO JOURNAL OF CHILD AND FAMILY STUDIES LA English DT Article DE Child maltreatment; Sexualized behaviors; Juvenile delinquency; Mediation ID CHILD MALTREATMENT; JUVENILE-DELINQUENCY; ADULT CRIMINALITY; FIT INDEXES; ABUSE; EPIDEMIOLOGY; EXPERIENCES; VIOLENCE; MODELS; IMPACT AB The link between child maltreatment and juvenile delinquency has been well established, yet the underlying mechanisms through which the relationship may be explained are not very well understood. Although sexualized behaviors have been most studied in the context of sexual abuse, increasing evidence suggests that a broader conceptualization is warranted. Therefore, the current study tested sexualized behaviors as a mediator in the relation between child maltreatment of any type and delinquent behaviors using structural equation modeling. This study used a multi-site prospective sample of 804 children who were at high-risk for experiencing maltreatment and part of the Longitudinal Studies of Child Abuse and Neglect consortium. This study found that reported maltreatment was related to delinquency, and sexualized behaviors partially mediated the relationship between child maltreatment and juvenile delinquency. Specifically, children with more maltreatment reports before age 8 had increased sexualized behaviors at age 8, which in turn predicted greater delinquent behaviors at age 12. These results suggest that in addition to maltreatment experiences, early sexualized behaviors (i.e., at age 8) may also be markers for subsequent delinquent behaviors (i.e., at age 12). Researchers and clinicians should work to further clarify the connections among child maltreatment, sexualized behaviors, and delinquency. C1 [Merrick, Melissa T.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. [Litrownik, Alan J.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA. [Margolis, Benyamin] Maternal & Child Hlth Bur, Div Home Visiting & Early Childhood Syst, Hlth Resources & Serv Adm, Rockville, MD USA. [Wiley, Tisha R. A.] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA. [Everson, Mark D.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Dubowitz, Howard] Univ Maryland, Dept Pediat, College Pk, MD 20742 USA. [English, Diana] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. RP Merrick, MT (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. EM kcq7@cdc.gov NR 64 TC 1 Z9 1 U1 3 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1062-1024 EI 1573-2843 J9 J CHILD FAM STUD JI J. Child Fam. Stud. PD AUG PY 2015 VL 24 IS 8 BP 2217 EP 2228 DI 10.1007/s10826-014-0024-3 PG 12 WC Family Studies; Psychology, Developmental; Psychiatry SC Family Studies; Psychology; Psychiatry GA CN1AU UT WOS:000358148300004 ER PT J AU Kondas, AV Olson, VA Li, Y Abel, J Laker, M Rose, L Wilkins, K Turner, J Kline, R Damon, IK AF Kondas, Ashley V. Olson, Victoria A. Li, Yu Abel, Jason Laker, Miriam Rose, Laura Wilkins, Kimberly Turner, Jonathan Kline, Richard Damon, Inger K. TI Variola Virus-Specific Diagnostic Assays: Characterization, Sensitivity, and Specificity (vol 53, pg 1406, 2015) SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Correction C1 [Kondas, Ashley V.; Olson, Victoria A.; Li, Yu; Abel, Jason; Laker, Miriam; Rose, Laura; Wilkins, Kimberly; Turner, Jonathan; Kline, Richard; Damon, Inger K.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Kondas, AV (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. NR 1 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD AUG PY 2015 VL 53 IS 8 BP 2795 EP 2795 DI 10.1128/JCM.01383-15 PG 1 WC Microbiology SC Microbiology GA CN2YV UT WOS:000358290200068 PM 26195639 ER PT J AU Abernathy, E Peairs, RR Chen, MH Icenogle, J Namdari, H AF Abernathy, Emily Peairs, Randall R. Chen, Min-hsin Icenogle, Joseph Namdari, Hassan TI Genomic characterization of a persistent rubella virus from a case of Fuch' uveitis syndrome in a 73 year old man SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Fuchs' uveitis syndrome; Rubella virus; Genomic characterization of rubella virus ID HETEROCHROMIC IRIDOCYCLITIS; UNITED-STATES; MANIFESTATIONS; SURVEILLANCE; PATHOGENESIS; CYCLITIS; DISEASE; PCR AB Background: Many cases of Fuchs' uveitis have been associated with persistent rubella virus infection. A 73-year-old male patient with typical Fuchs' Uveitis Syndrome (FUS) first experienced heterochromia of the left eye at the age fourteen, when rubella was endemic in the US. Objectives: The purposes of this report are to describe the patient's FUS clinical presentations and to characterize the virus detected in the vitreous fluid. Study design: The patient underwent a therapeutic pars plana vitrectomy in May 2013. A real-time RT-PCR assay for rubella virus was performed on the vitreous fluid by Focus Diagnostics. Additional real-time RT-PCR assays for rubella virus detection and RT-PCR assays for generation of templates for sequencing were performed at the Centers for Disease Control and Prevention (CDC). Results: The results from Focus Diagnostics were positive for rubella virus RNA. Real-time RT-PCR assays at CDC were also positive for rubella virus. A rubella virus sequence of 739 nucleotides was determined and phylogenetic analysis showed that the virus was the sole member of a new phylogenetic group when compared to reference virus sequences. Conclusions: While FUS remains a clinical diagnosis, findings in this case support the association between rubella virus and the disease. Phylogenetic analysis provided evidence that this rubella virus was likely a previously undetected genotype which is no longer circulating. Since the patient had rubella prior to 1955, this sequence is from the earliest rubella virus yet characterized. (C) 2015 Elsevier B.V. All rights reserved. C1 [Namdari, Hassan] Clin Micro Immunol Ctr, Clarks Summit, PA 18411 USA. [Peairs, Randall R.] Northeastern Eye Inst, Scranton, PA USA. [Abernathy, Emily; Chen, Min-hsin; Icenogle, Joseph] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Namdari, H (reprint author), Clin Micro Immunol Ctr, 100 Abinton Execut Pk, Clarks Summit, PA 18411 USA. EM efa9@cdc.gov; rpeairs@epix.net; zvp8@cdc.gov; jci1@cdc.gov; hnamdari@clinmicro.com NR 28 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2015 VL 69 BP 104 EP 109 DI 10.1016/j.jcv.2015.06.084 PG 6 WC Virology SC Virology GA CN3IH UT WOS:000358318400024 PM 26209390 ER PT J AU Groome, MJ Moyes, J Cohen, C Walaza, S Tempia, S Pretorius, M Hellferscee, O Chhagan, M Haffejee, S Dawood, H Kahn, K Variava, E Cohen, AL von Gottberg, A Wolter, N Venter, M Madhi, SA AF Groome, Michelle J. Moyes, Jocelyn Cohen, Cheryl Walaza, Sibongile Tempia, Stefano Pretorius, Marthi Hellferscee, Orienka Chhagan, Meera Haffejee, Sumayya Dawood, Halima Kahn, Kathleen Variava, Ebrahim Cohen, Adam L. von Gottberg, Anne Wolter, Nicole Venter, Marietjie Madhi, Shabir A. CA South African Severe Acute Resp Il TI Human metapneumovirus-associated severe acute respiratory illness hospitalisation in HIV-infected and HIV-uninfected South African children and adults SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Human metapneumovirus; HIV; Lower respiratory tract infection ID IMMUNODEFICIENCY-VIRUS TYPE-1; TRACT INFECTIONS; SYNCYTIAL VIRUS; YOUNG-CHILDREN; SEVERE PNEUMONIA; EPIDEMIOLOGY; FEATURES; INFANTS; DISEASE; AGE AB Background: Data on human metapneumovirus (HMPV)-associated severe acute respiratory illness (SARI) are limited in settings with high human immunodeficiency virus (HIV) infection prevalence. Objectives: To describe clinical characteristics and seasonality (all sites), and incidence (Soweto only) of HMPV-associated SARI among children and adults. Study design: Active, prospective, hospital-based, sentinel surveillance for patients hospitalised with SARI was conducted at four sites in South Africa from February 2009-December 2013. Upper respiratory tract samples were tested by multiplex real-time polymerase chain reaction assays for HMPV and other respiratory viruses. Incidence of hospitalisation, stratified by age and HIV-infection status, was calculated for one hospital with population denominators. Results: HMPV was identified in 4.1% of patients enrolled, including 5.6% (593/10503) in children and 1.7% in adults (>= 18 years; 119/6934). The majority of adults (84.0%) had an underlying medical condition, including HIV infection in 87/110 (79.1%). HMPV detection occurred perennially with periods of increased detection, which varied from year to year. The incidence of HMPV-associated hospitalisation in Soweto was highest in infants (653.3 per 100,000 person years; 95% confidence interval (CI) 602.2-707.6). The incidence was higher in HIV-infected persons compared to HIV-uninfected persons in age-groups 5-17 years (RR 6.0; 1.1-20.4), 18-44 years (RR 67.6; 38.0-132.6) and 45-64 years (RR 5.3; 3.4-8.3), while not differing in other age-groups. Conclusions: The burden of HMPV-associated SARI hospitalisation among adults occurred predominantly in HIV-infected persons. Among children, infants were at highest risk, with similar burden of hospitalisation in HIV-infected and HIV-uninfected children. (C) 2015 Elsevier B.V. All rights reserved. C1 [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, ZA-2001 Johannesburg, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, ZA-2001 Johannesburg, South Africa. [Moyes, Jocelyn; Cohen, Cheryl; Walaza, Sibongile; Pretorius, Marthi; Hellferscee, Orienka; von Gottberg, Anne; Wolter, Nicole; Venter, Marietjie; Madhi, Shabir A.] Ctr Resp Dis & Meningitis, Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Moyes, Jocelyn; Walaza, Sibongile] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, ZA-2001 Johannesburg, South Africa. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent South Africa, Influenza Programme, Pretoria, South Africa. [Chhagan, Meera; Haffejee, Sumayya; Dawood, Halima] Univ KwaZulu Natal, Pietermaritzburg Hosp Complex, Pietermaritzburg, South Africa. [Haffejee, Sumayya] Univ KwaZulu Natal, Sch Pathol, Pietermaritzburg, South Africa. [Kahn, Kathleen] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, ZA-2001 Johannesburg, South Africa. [Kahn, Kathleen] Umea Univ, Ctr Global Hlth Res, Umea, Sweden. [Kahn, Kathleen] INDEPTH Network, Accra, Ghana. [Variava, Ebrahim] Klerksdorp Tshepong Hosp, Dept Med, Klerksdorp, South Africa. [Variava, Ebrahim] Univ Witwatersrand, Fac Hlth Sci, Dept Med, ZA-2001 Johannesburg, South Africa. [von Gottberg, Anne; Wolter, Nicole] Univ Witwatersrand, Sch Pathol, Fac Hlth Sci, ZA-2001 Johannesburg, South Africa. RP Groome, MJ (reprint author), Chris Hani Baragwanath Acad Hosp, MRC, Resp & Meningeal Pathogens Res Unit, DST NRF Vaccine Preventable Dis,New Nurses Reside, 11th Floor West Wing,Chris Hani Rd, ZA-2013 Soweto, South Africa. EM groomem@rmpru.co.za RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X FU National Institute for Communicable Diseases of the National Health Laboratory Service; United States Centers for Disease Control and Prevention (CDC), Atlanta; Georgia Preparedness and Response to Avian; Pandemic Influenza in South Africa [U51/IP000155-04] FX This study received funding from the National Institute for Communicable Diseases of the National Health Laboratory Service and was supported in part by funds from the United States Centers for Disease Control and Prevention (CDC), Atlanta, Georgia Preparedness and Response to Avian and Pandemic Influenza in South Africa (Cooperative Agreement Number: U51/IP000155-04). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The funders had no role in study design, implementation, manuscript writing or the decision to submit for publication. The corresponding author had full access to all the data in the study and takes final responsibility for the decision to submit for publication. NR 37 TC 2 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2015 VL 69 BP 125 EP 132 DI 10.1016/j.jcv.2015.06.089 PG 8 WC Virology SC Virology GA CN3IH UT WOS:000358318400028 PM 26209394 ER PT J AU Laiho, JE Oikarinen, S Oikarinen, M Larsson, PG Stone, VM Hober, D Oberste, S Flodstrom-Tullberg, M Isola, J Hyoty, H AF Laiho, Jutta E. Oikarinen, Sami Oikarinen, Maarit Larsson, Par G. Stone, Virginia M. Hober, Didier Oberste, Steven Flodstrom-Tullberg, Malin Isola, Jorma Hyoty, Heikki TI Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Probe design; In situ hybridization; Enterovirus; Type 1 diabetes ID MONOCLONAL-ANTIBODY; COXSACKIEVIRUS B1; CAPSID PROTEIN; HUMAN PANCREAS; ISLET CELLS; TYPE-1; IMMUNOHISTOCHEMISTRY; MYOCARDITIS; LEARN; VP1 AB Background: Enteroviral infections are common, affecting humans across all age groups. RT-PCR is widely used to detect these viruses in clinical samples. However, there is a need for sensitive and specific in situ detection methods for formalin-fixed tissues, allowing for the anatomical localization of the virus and identification of its serotype. Objectives: The aim was to design novel enterovirus probes, assess the impact of probe design for the detection and optimize the new single molecule in situ hybridization technology for the detection of enteroviruses in formalin-fixed paraffin-embedded samples. Study design: Four enterovirus RNA-targeted oligonucleotide RNA probes - two probes for wide range enterovirus detection and two for serotype-targeted detection of Coxsackievirus B1 (CVB1) - were designed and validated for the commercially available QuantiGene View RNA in situ hybridization method. The probe specificities were tested using a panel of cell lines infected with different enterovirus serotypes and CVB infected mouse pancreata. Results: The two widely reactive probe sets recognized 19 and 20 of the 20 enterovirus serotypes tested, as well as 27 and 31 of the 31 CVB1 strains tested. The two CVB1 specific probe sets detected 30 and 14 of the 31 CVB1 strains, with only minor cross-reactivity to other serotypes. Similar results were observed in stained tissues from CVB - infected mice. Conclusions: These novel in-house designed probe sets enable the detection of enteroviruses from formalin-fixed tissue samples. Optimization of probe sequences makes it possible to tailor the assay for the detection of enteroviruses on the serotype or species level. (C) 2015 Elsevier B.V. All rights reserved. C1 [Laiho, Jutta E.; Oikarinen, Sami; Oikarinen, Maarit; Hyoty, Heikki] Univ Tampere, Sch Med, Dept Virol, Tampere 33520, Finland. [Larsson, Par G.; Stone, Virginia M.; Flodstrom-Tullberg, Malin] Karolinska Inst, Dept Med HS, Stockholm, Sweden. [Hober, Didier] Univ Lille 2, CHRU, Lab Virol EA3610, F-59800 Lille, France. [Oberste, Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Isola, Jorma] Inst Biosci & Med Technol, Tampere, Finland. [Hyoty, Heikki] Pirkanmaa Hosp Dist, Fimlab Labs, Tampere, Finland. RP Laiho, JE (reprint author), Univ Tampere, Sch Med, Dept Virol, Biokatu 10,FM-3,5th Floor, Tampere 33520, Finland. EM jutta.e.laiho@staff.uta.fi; sami.oikarinen@uta.fi; maarit.oikarinen@uta.fi; par.larsson@ki.se; virginia.stone@ki.se; didier.hober@chru-lille.fr; soberste@cdc.gov; malin.flodstrom-tullberg@ki.se; jorma.isola@staff.uta.fi; heikki.hyoty@uta.fi RI oikarinen, sami/E-3611-2015; OI Flodstrom Tullberg, Malin/0000-0003-2685-2052 FU JDRF-nPOD; European Commission (Persistent Virus Infection in Diabetes Network [PEVNET] Frame Programme 7) [261441]; Diabetes Research Foundation in Finland; Sigrid Juselius Foundation; Swedish Medical Research Council FX This study was supported by the grants of the JDRF-nPOD, and the European Commission (Persistent Virus Infection in Diabetes Network [PEVNET] Frame Programme 7, Contract No. 261441), Diabetes Research Foundation in Finland, Sigrid Juselius Foundation, and the Swedish Medical Research Council. NR 21 TC 2 Z9 2 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2015 VL 69 BP 165 EP 171 DI 10.1016/j.jcv.2015.06.085 PG 7 WC Virology SC Virology GA CN3IH UT WOS:000358318400034 PM 26209400 ER PT J AU Zhang, YT Moore, DD Nix, WA Oberste, MS Weldon, WC AF Zhang, Yiting Moore, Deborah D. Nix, W. Allan Oberste, M. Steven Weldon, William C. TI Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Enterovirus D68; Intravenous immunoglobulin; Antibody titers ID RESPIRATORY ILLNESS; IMMUNOGLOBULIN PREPARATIONS; ANTIBODIES; PROPHYLAXIS; SEROTYPES; INFECTION; PLASMA; VIRUS AB Background: In 2014, an outbreak of Enterovirus D68 (EV-D68) was recorded as the largest in the US with cases confirmed in 49 states. Intravenous immune globulin (IVIG) has been used to treat enterovirus infections in neonates and is an accepted replacement therapy for immunodeficient patients. Objectives: This study aimed to detect the presence of neutralizing antibodies to EV-D68 viruses from the 2014 outbreak in commercially available IVIG products. Study design: Commercially available lots of IVIG preparations were obtained from five different manufacturers (2-10 preparations per manufacturer) and tested for neutralizing antibodies against the prototype EV-D68 virus and three EV-D68 isolates representing strains circulating during the 2014 outbreak. Results: All lots of IVIG tested were positive for EV-D68 neutralizing antibodies, with high titers ranging from 9.5log(2) to 17.5log(2), and with comparable median titers to all four EV-D68 viruses. Conclusions and discussion: Amino acid sequence differences in the regions of the predicted antigenic sites on the viral capsid may explain some of the differences in neutralization among the different strains. The neutralization titers suggests that the 2014 outbreak EV-D68 viruses share some antigenic sites with the prototype virus and also present some unique antigenic sites distinct from the prototype. However, the commercial IVIG lots tested all contained high levels of neutralizing antibodies against EV-D68. Published by Elsevier B.V. C1 [Zhang, Yiting; Moore, Deborah D.; Nix, W. Allan; Oberste, M. Steven; Weldon, William C.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Weldon, WC (reprint author), 1600 Clifton Rd NE,Mailstop G-17, Atlanta, GA 30333 USA. EM wweldon@cdc.gov OI Oberste, Steve/0000-0002-9170-9845 FU CDC from the Emerging Infections line item FX This work was supported by federal appropriations to CDC from the Emerging Infections line item. NR 18 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2015 VL 69 BP 172 EP 175 DI 10.1016/j.jcv.2015.06.086 PG 4 WC Virology SC Virology GA CN3IH UT WOS:000358318400035 PM 26209401 ER PT J AU Kumar, T Kumar, A Laserson, KF Narain, JP Venkatesh, S Chauhan, LS Averhoff, F Shrivastava, A AF Kumar, T. Kumar, A. Laserson, K. F. Narain, J. P. Venkatesh, S. Chauhan, L. S. Averhoff, F. Shrivastava, A. TI Viral hepatitis in India: Analysis of national disease surveillance program data, 2011-13 SO JOURNAL OF CLINICAL VIROLOGY LA English DT Meeting Abstract CT Viral Hepatitis Summit CY APR 10-12, 2015 CL Shanghai, PEOPLES R CHINA C1 [Kumar, T.; Narain, J. P.] NCDC, India Epidem Intelligence Serv Program, Delhi, India. [Kumar, A.; Shrivastava, A.] NCDC, Div Epidemiol, Delhi, India. [Laserson, K. F.] Ctr Global Hlth CDC India, Div Global Dis Detect, Delhi, India. [Venkatesh, S.] NCDC, Integrated Dis Surveillance Program, Delhi, India. [Chauhan, L. S.] NCDC, Delhi, India. [Averhoff, F.] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2015 VL 69 MA OP0004 BP 248 EP 249 DI 10.1016/j.jcv.2015.06.074 PG 2 WC Virology SC Virology GA CN3IH UT WOS:000358318400112 ER PT J AU Moran-Gilad, J Mendelson, E Burns, CC Bassal, R Gdalevich, M Sofer, D Oberste, MS Shulman, LM Kaliner, E Hindiyeh, M Mor, O Shahar, L Iber, J Yishay, R Manor, J Lev, B Gamzu, R Grotto, I AF Moran-Gilad, Jacob Mendelson, Ella Burns, Cara C. Bassal, Ravit Gdalevich, Michael Sofer, Danit Oberste, M. Steven Shulman, Lester M. Kaliner, Ehud Hindiyeh, Musa Mor, Orna Shahar, Liora Iber, Jane Yishay, Ruth Manor, Joseph Lev, Boaz Gamzu, Ronni Grotto, Itamar TI Field study of fecal excretion as a decision support tool in response to silent reintroduction of wild-type poliovirus 1 into Israel (vol 66, pg 51, 2015) SO JOURNAL OF CLINICAL VIROLOGY LA English DT Correction C1 [Moran-Gilad, Jacob; Kaliner, Ehud; Grotto, Itamar] Minist Hlth, Publ Hlth Serv, Jerusalem, Israel. [Moran-Gilad, Jacob; Grotto, Itamar] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel. [Mendelson, Ella; Sofer, Danit; Shulman, Lester M.; Hindiyeh, Musa; Mor, Orna; Manor, Joseph] Minist Hlth, Cent Virol Lab, Tel Hashomer, Israel. [Mendelson, Ella; Shulman, Lester M.; Gamzu, Ronni] Tel Aviv Univ, Sch Publ Hlth, IL-69978 Tel Aviv, Israel. [Burns, Cara C.; Oberste, M. Steven; Iber, Jane] Ctr Dis Control & Prevent, Viruses Branch, Atlanta, GA USA. [Bassal, Ravit] Minist Hlth, Israel Ctr Dis Control, Tel Hashomer, Israel. [Gdalevich, Michael; Shahar, Liora] Minist Hlth, Southern Dist Hlth Off, Beer Sheva, Israel. [Yishay, Ruth] Minist Hlth, Publ Hlth Serv, Dept Labs, Jerusalem, Israel. [Lev, Boaz; Gamzu, Ronni] Minist Hlth, Jerusalem, Israel. RP Moran-Gilad, J (reprint author), Minist Hlth, Publ Hlth Serv, 39 Yermiyahu St, Jerusalem, Israel. EM giladko@post.bgu.ac.il NR 1 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2015 VL 69 BP 251 EP 251 DI 10.1016/j.jcv.2015.05.016 PG 1 WC Virology SC Virology GA CN3IH UT WOS:000358318400116 ER PT J AU Allen, JA Perrine, CG Scanlon, KS AF Allen, Jessica A. Perrine, Cria G. Scanlon, Kelley S. TI Breastfeeding Supportive Hospital Practices in the US Differ by County Urbanization Level SO JOURNAL OF HUMAN LACTATION LA English DT Article DE breastfeeding; hospital; maternity care; rural; urban ID UNITED-STATES; CARE; DURATION AB Background: Breastfeeding rates are lower among infants living in rural areas of the United States, yet there are limited data on whether hospital breastfeeding support differs between rural and urban areas. Objective: This study aimed to describe whether maternity care practices supportive of breastfeeding vary by level of urbanization. Methods: We linked data from the 2007, 2009, and 2011 Maternity Practices in Infant Nutrition and Care (mPINC) surveys with Rural-Urban Continuum Codes to categorize hospital counties as metropolitan urbanized, nonmetropolitan urbanized, less urbanized, and thinly populated. Results: From 2007 to 2011, the average hospital mPINC score, a composite quality score ranging from 0 to 100, increased from 64 to 71 in metropolitan urbanized counties and from 54 to 65 in thinly populated areas. Scores were lowest in thinly populated counties in 2007 and 2009 and in less urbanized counties in 2011. Examination of 2011 mPINC scores by 7 domains of care revealed that hospitals in less urbanized counties had lower scores than those in metropolitan urbanized counties for feeding of breastfed infants, breastfeeding assistance, staff training, and structural and organizational aspects of care delivery; for 3 of these practices, scores were 10 or more points lowerbreastfeeding assistance, structural and organizational aspects of care, and staff training. In contrast, hospitals in thinly populated areas had higher scores than in metropolitan areas for mother-infant contact and facility discharge care; differences were less than 10 points. Conclusion: Interventions that specifically target rural hospitals may reduce the gap in access to hospital maternity care practices supportive of breastfeeding by population density. C1 [Allen, Jessica A.; Perrine, Cria G.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Allen, JA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop A-27, Atlanta, GA 30341 USA. EM ixm4@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-3344 EI 1552-5732 J9 J HUM LACT JI J. Hum. Lact. PD AUG PY 2015 VL 31 IS 3 BP 440 EP 443 DI 10.1177/0890334415578440 PG 4 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA CM9ZN UT WOS:000358070300018 PM 25800795 ER PT J AU Myles, RL Artstein-McNassar, M Dean, HD Bohannon, B Melville, SK Yeager, R Wheeling, J Rose, CE Zhu, J Dominguez, KL AF Myles, Ranell L. Artstein-McNassar, Melissa Dean, Hazel D. Bohannon, Beverly Melville, Sharon K. Yeager, Richard Wheeling, John Rose, Charles E. Zhu, Julia Dominguez, Kenneth L. TI Perinatal HIV Prevention Outcomes in US-Born Versus Foreign-Born Blacks, PSD Cohort, 1995-2004 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Mother-to-child transmission; HIV/AIDS; Perinatal health; Black women; Foreign-born; US-born; Disaggregation; Country of origin; Birthplace ID AFRICAN-AMERICAN; PREGNANCY OUTCOMES; UNITED-STATES; WOMEN; HEALTH; TRANSMISSION; POPULATIONS; PREVALENCE; DISPARITY AB We examined differences in HIV-infected U.S.-born and foreign-born black mothers who delivered perinatally HIV-exposed and -infected children during 1995-2004 in the Pediatric Spectrum of HIV Disease Project, a longitudinal cohort study. Prevalence ratios were calculated to explain differences in perinatal HIV prevention opportunities comparing U.S.-born to foreign-born and African-born to Caribbean-born black mothers. U.S.-born compared with foreign-born HIV-infected black mothers were significantly more likely to have used cocaine or other non-intravenous illicit drugs, exchanged money or drugs for sex, known their HIV status before giving birth, received intrapartum antiretroviral (ARV) prophylaxis, and delivered a premature infant; and were significantly less likely to have received prenatal care or delivered an HIV-infected infant. African-born compared with Caribbean-born black mothers were more likely to receive intrapartum ARV prophylaxis. These differences by maternal geographical origin have important implications for perinatal HIV transmission prevention, and highlight the validity of disaggregating data by racial/ethnic subgroups. C1 [Myles, Ranell L.; Artstein-McNassar, Melissa; Dean, Hazel D.; Bohannon, Beverly; Rose, Charles E.; Zhu, Julia; Dominguez, Kenneth L.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Artstein-McNassar, Melissa] Washington State Univ, Pullman, WA 99164 USA. [Melville, Sharon K.] Texas Dept State Hlth Serv, Austin, TX USA. [Yeager, Richard] Texas A&M Univ Cent Texas, Killeen, TX USA. [Wheeling, John] Northrop Grumman Inc, Atlanta, GA USA. RP Myles, RL (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop E-07, Atlanta, GA 30333 USA. EM RMyles@cdc.gov FU Centers for Disease Control and Prevention, Atlanta, GA [200-2004-09976]; CDC [U64/CCU303310, U64/CCU206818, U64/CCU114918, U64/CCU603300, U64/CCU903273, U64/CCU203312, U64/CCU901179, U64/CCU410899] FX The PSD project was funded by the Centers for Disease Control and Prevention, Atlanta, GA, contract number 200-2004-09976. This research was supported by CDC cooperative agreements U64/CCU303310, U64/CCU206818, U64/CCU114918, U64/CCU603300, U64/CCU903273, U64/CCU203312, U64/CCU901179, and U64/CCU410899. The authors are grateful to the patients and caregivers who participated in the PSD Consortium and thank the investigators and abstractors at the PSD study sites: Ho-Wen Hsu (University of Massachusetts Medical School, State Laboratory Institute), Barbara Stechenberg (Baystate Medical Center, Springfield), Kenneth McIntosh (Boston Children's Hospital), Stephen Pelton (Boston Medical Center), Katherine Luzuriaga (University of Massachusetts Medical School), H. Cody Meissner (New England Medical Center), Gerard Coste (Cambridge Hospital), Mark Pasternack (Massachusetts General Hospital), Vicki Peters, Kai-Li Liu (New York City Department of Health & Mental Hygiene), Arye Rubinstein (Albert Einstein Hospital), Saroj Bakshi (Bronx Lebanon Hospital), Edward Handelsman (Downstate University Hospital), Elaine Abrams (Harlem Hospital), Cathy Painter (Incarnation Children's Center), Andrew Wiznia (Jacobi Hospital), Ninad Desai (Kings County Medical Center), Nathan Litman (Montifiore Hospital), Joseph Stavola (New York Hospital), Jacob Abadi (North Central Bronx Hospital), Tamara Rakusan, Hans Spiegel, Andrew Bonwit, Robert Parrott (Children's National Medical Center, Washington DC), Sohail Rana (Howard University Hospital), Idith Ortiz, Juan Carlos Orengo (Puerto Rico Departamento de Salud), Eleanor Jiminez (San Juan City Hospital), Irma Febo (University Pediatric Hospital), Wanda Figueroa (Bayamon Regional Hospital), Jose Vazquez Julia (Caguas Regional Hospital), Rosa Delgado (Ponce Regional Hospital), Janet Squires, Theresa Barton (University of Texas -Southwestern, Dallas), Mary E. Paul, I. Celine Hanson, Mark W. Kline (Baylor College of Medicine/Texas Children's Hospital, Houston), Marilyn Doyle (University of Texas Health Science Center -Houston), Janak Patel (University of Texas Medical Branch - Galveston), Sarmistha Hauger (Children's Hospital of Austin - Austin), Terence Doran (University of Texas - San Antonio), Gilberto Handel (Texas Tech Medical Center - El Paso), Toni Frederick, Laurene Mascola (Los Angeles County Health Department), Yvonne Bryson (UCLA School of Medicine), Joseph Church (Children's Hospital of Los Angeles), Audra Deveikis (Memorial Miller Children's Hospital), Margaret Keller (Harbor-UCLA Medical Center), Deborah Lehman (Cedars-Sinai Medical Center), Andrea Kovacs (LAC + USC Maternal Child Clinic), Steve Taylor (Martin Luther King Jr/Drew Medical Center), Victor Wong (Kaiser Permanente Southern California Group), Yvonne Maldonado (Stanford School of Medicine San Francisco), and Catherine Wilfert (Duke University School of Medicine - NC). NR 34 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD AUG PY 2015 VL 17 IS 4 BP 1010 EP 1018 DI 10.1007/s10903-014-0034-7 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN1BD UT WOS:000358149300005 PM 24841594 ER PT J AU Glennon, NB Jabado, O Lo, MK Shaw, ML AF Glennon, Nicole B. Jabado, Omar Lo, Michael K. Shaw, Megan L. TI Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions SO JOURNAL OF VIROLOGY LA English DT Article ID NEWCASTLE-DISEASE-VIRUS; BLACK FLYING FOX; BIG BROWN BATS; TOLL-LIKE RECEPTORS; HENDRA-VIRUS; V-PROTEIN; EXPERIMENTAL-INFECTION; EBOLA-VIRUS; MOLECULAR CHARACTERIZATION; EPTESICUS-SEROTINUS AB Bats are important reservoirs for several viruses, many of which cause lethal infections in humans but have reduced pathogenicity in bats. As the innate immune response is critical for controlling viruses, the nature of this response in bats and how it may differ from that in other mammals are of great interest. Using next-generation transcriptome sequencing (mRNA-seq), we profiled the transcriptional response of Pteropus vampyrus bat kidney (PVK) cells to Newcastle disease virus (NDV), an avian paramyxovirus known to elicit a strong innate immune response in mammalian cells. The Pteropus genus is a known reservoir of Nipah virus (NiV) and Hendra virus (HeV). Analysis of the 200 to 300 regulated genes showed that genes for interferon (IFN) and antiviral pathways are highly upregulated in NDV-infected PVK cells, including genes for beta IFN, RIG-I, MDA5, ISG15, and IRF1. NDV-infected cells also upregulated several genes not previously characterized to be antiviral, such as RND1, SERTAD1, CHAC1, and MORC3. In fact, we show that MORC3 is induced by both IFN and NDV infection in PVK cells but is not induced by either stimulus in human A549 cells. In contrast to NDV infection, HeV and NiV infection of PVK cells failed to induce these innate immune response genes. Likewise, an attenuated response was observed in PVK cells infected with recombinant NDVs expressing the NiV IFN antagonist proteins V and W. This study provides the first global profile of a robust virus-induced innate immune response in bats and indicates that henipavirus IFN antagonist mechanisms are likely active in bat cells. IMPORTANCE Bats are the reservoir host for many highly pathogenic human viruses, including henipaviruses, lyssaviruses, severe acute respiratory syndrome coronavirus, and filoviruses, and many other viruses have also been isolated from bats. Viral infections are reportedly asymptomatic or heavily attenuated in bat populations. Despite their ecological importance to viral maintenance, research into their immune system and mechanisms for viral control has only recently begun. Nipah virus and Hendra virus are two paramyxoviruses associated with high mortality rates in humans and whose reservoir is the Pteropus genus of bats. Greater knowledge of the innate immune response of P. vampyrus bats to viral infection may elucidate how bats serve as a reservoir for so many viruses. C1 [Glennon, Nicole B.; Shaw, Megan L.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. [Glennon, Nicole B.] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA. [Jabado, Omar] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, New York, NY 10029 USA. [Lo, Michael K.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA. RP Shaw, ML (reprint author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. EM megan.shaw@mssm.edu OI Lo, Michael/0000-0002-0409-7896 FU NIH [HHSN272200900032C, R01 AI101308, R21AI102169, T32AI007647] FX This work was supported by in part by NIH grants HHSN272200900032C, R01 AI101308, and R21AI102169 to M.L.S. N.B.G. was supported in part by NIH training grant T32AI007647. NR 101 TC 5 Z9 5 U1 3 U2 26 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD AUG PY 2015 VL 89 IS 15 BP 7550 EP 7566 DI 10.1128/JVI.00302-15 PG 17 WC Virology SC Virology GA CN2UP UT WOS:000358277800010 PM 25972557 ER PT J AU Mir, F Quadri, F Mach, O Ahmed, I Bhatti, Z Khan, A Rehman, NU Durry, E Salama, M Oberste, SM Weldon, WC Sutter, RW Zaidi, AKM AF Mir, Fatima Quadri, Farheen Mach, Ondrej Ahmed, Imran Bhatti, Zaid Khan, Asia Rehman, Najeeb Ur Durry, Elias Salama, Maha Oberste, Steven M. Weldon, William C. Sutter, Roland W. Zaidi, Anita K. M. TI Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial SO LANCET INFECTIOUS DISEASES LA English DT Article ID IMMUNIZATION SCHEDULES; CLINICAL EFFICACY; IMMUNOGENICITY; POLIOMYELITIS; CHILDREN; IMMUNITY; GAMBIA; LIVE; POLIOVACCINE; EPIDEMIC AB Background Supplementary immunisation activities with oral poliovirus vaccines (OPVs) are usually separated by 4 week intervals; however, shorter intervals have been used in security-compromised areas and for rapid outbreak responses. We assessed the immunogenicity of monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than usual intervals in Karachi, Pakistan. Methods This was a multicentre, randomised, controlled, four-arm, open-label, non-inferiority trial done at five primary health-care centres in low-income communities in and around Karachi, Pakistan. Eligible participants were healthy newborn babies with a birthweight of at least 2.5 kg, for whom informed consent was provided by their parent or guardian, and lived less than 30 km from the study clinic. After receiving a birth dose of trivalent OPV, we enrolled and randomly assigned newborn babies (1: 1: 1: 1) to receive two doses of mOPV1 with an interval of 1 week (mOPV1-1 week), 2 weeks (mOPV1-2 weeks), or 4 weeks (mOPV1-4 weeks) between doses, or two doses of bivalent OPV (bOPV) with an interval of 4 weeks between doses (bOPV-4 weeks). We gave the first study dose of OPV at age 6 weeks. We did the randomisation with a centrally generated, computerised allocation sequence with blocks of 16; participants' families and study physicians could not feasibly be masked to the allocations. Trial participants were excluded from local supplementary immunisation activities during the study period. The primary outcome was non-inferiority (within a 20% margin) between groups in seroconversion to type-1 poliovirus. The primary and safety analyses were done in the per-protocol population of infants who received all three doses of vaccine. This trial is registered with ClinicalTrials.gov, number NCT01586572, and is closed to new participants. Findings Between March 1, 2012, and May 31, 2013, we enrolled 1009 newborn babies, and randomly assigned 829 (82%) to treatment. 554 (67%) of the 829 babies were included in the per-protocol analysis. Proportions of seroconversion to type-1 poliovirus were 107/135 (79%, 95% CI 72.4-86.1) with mOPV1-1 week, 108/135 (80%, 73.2-86.8) with mOPV1-2 weeks, 129/148 (87%, 80.9-92.0) with mOPV1-4 weeks, and 107/136 (79%, 71.8-85.6) with bOPV-4 weeks. Non-inferiority was shown between groups and no significant differences were noted. Ten participants died during the trial. Seven of these deaths occurred during the lead-in period before randomisation (two from diarrhoea, five from unknown causes). Three infants died from sepsis after random assignment. No deaths were attributed to the procedures or vaccines. Additionally, we noted no events of vaccine-associated paralysis. Interpretation We identified no significant differences in responses to mOPV1 given with shorter intervals between doses than with the standard 4 week intervals. The short-interval strategy could be particularly beneficial when temporary windows of opportunity for safe access can be granted in areas of conflict-eg, during cease-fire periods. In such situations, we recommend shortening the interval between OPV doses to 7 days. C1 [Mir, Fatima; Quadri, Farheen; Ahmed, Imran; Bhatti, Zaid; Khan, Asia; Rehman, Najeeb Ur; Zaidi, Anita K. M.] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi 74800, Pakistan. [Mach, Ondrej; Salama, Maha; Sutter, Roland W.] WHO, Res Policy & Product Dev, CH-1211 Geneva, Switzerland. [Durry, Elias] WHO, Polio Eradicat Initiat, Karachi, Pakistan. [Oberste, Steven M.; Weldon, William C.] Ctr Dis Control & Prevent, Populat Immun Lab, Polio & Picornavirus Lab Branch, Atlanta, GA USA. RP Zaidi, AKM (reprint author), Aga Khan Univ, Dept Pediat & Child Hlth, Karachi 74800, Pakistan. EM anita.zaidi@aku.edu FU World Health Organization FX World Health Organization. NR 38 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD AUG PY 2015 VL 15 IS 8 BP 889 EP 897 DI 10.1016/S1473-3099(15)00093-6 PG 9 WC Infectious Diseases SC Infectious Diseases GA CN1LW UT WOS:000358182500027 PM 26093979 ER PT J AU Estivariz, CF Anand, A Gary, HE Rahman, M Islam, J Bari, TI Wassilak, SGF Chu, SY Weldon, WC Pallansch, MA Heffellfinger, JD Luby, SP Zaman, K AF Estivariz, Concepcion F. Anand, Abhijeet Gary, Howard E., Jr. Rahman, Mahmudur Islam, Jannatul Bari, Tajul I. Wassilak, Steven G. F. Chu, Susan Y. Weldon, William C. Pallansch, Mark A. Heffellfinger, James D. Luby, Stephen P. Zaman, Khalequ TI Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial SO LANCET INFECTIOUS DISEASES LA English DT Article ID ERADICATION; INFANTS; ROTAVIRUS; WORLDWIDE; DIARRHEA; ENDGAME; BRAZIL AB Background The provision of several doses of monovalent type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3 (bOPV) vaccines through campaigns is essential to stop the circulation of remaining wild polioviruses. Our study aimed to assess the shortening of intervals between campaigns with bOPV and mOPV1 and to assess the immunogenicity of bOPV in routine immunisation schedules. Methods We did an open-label, non-inferiority, five-arm, randomised controlled trial in Bangladesh. We recruited healthy infants aged 6 weeks at 42 immunisation clinics and randomly assigned them (with blocks of 15, three per group) to receive a short three-dose schedule of bOPV (bOPV short) or mOPV1 (mOPV1 short) with the first dose given at age 6 weeks, the second at age 8 weeks, and the third at age 10 weeks; or to a standard three-dose schedule of bOPV (bOPV standard) or mOPV1 (mOPV1 standard) or trivalent OPV (tOPV standard) with the first dose given at age 6 weeks, the second at 10 weeks, and the third at age 14 weeks. The primary outcome was the proportion of infants with antibody seroconversion for type 1, type 2, and type 3 polioviruses. The primary, modified intention-to-treat analysis included all patients who had testable serum samples before and after receiving at least one OPV dose. We used a 10% margin to establish non-inferiority for bOPV groups versus mOPV1 groups in seroconversion for type 1 poliovirus, and for bOPV1 short versus bOPV1 standard for types 1 and 3. This trial is registered at ClinicalTrials.gov, number NCT01633216, and is closed to new participants. Findings Between May 13, 2012, and Jan 21, 2013, we randomly assigned 1000 infants to our study groups. 927 completed all study visits and were included in the primary analysis. Seroconversion for type-1 poliovirus was recorded in 183 (98%, 95% CI 95-100) of 186 infants given bOPV short, 179 (97%, 94-99) of 184 given bOPV standard, 180 (96%, 92-98) of 188 given mOPV short, 178 (99%, 97-100) of 179 given mOPV1 standard, and 175 (92%, 87-96) of 190 given tOPV standard. Seroconversion for type 2 was noted in 16 infants (9%, 5-14) on bOPV short, 29 (16%, 11-22) on bOPV standard, 19 (10%, 7-15) on mOPV short, 33 (18%, 13-25) on mOPV1 standard, and 182 (96%, 92-98) on tOPV standard. Seroconversion for type 3 was noted in 175 infants (94%, 90-97) on bOPV short, 176 (96%, 92-98) on bOPV standard, 18 (10%, 6-15) on mOPV short, 25 (14%, 10-20) on mOPV1 standard, and 167 (88%, 83-92) on tOPV standard. The short schedules for mOPV1 and bOPV elicited a non-inferior antibody response compared with the bOPV standard schedule. 104 adverse events were reported in 100 infants during follow up. 36 of these events needed admission to hospital (32 were pneumonia, two were vomiting or feeding disorders, one was septicaemia, and one was diarrhoea with severe malnutrition). One of the infants admitted to hospital for pneumonia died 5 days after admission. No adverse event was attributed to the vaccines. Interpretation Our trial showed that three doses of mOPV1 or bOPV with a short schedule of 2 week intervals between doses induces an immune response similar to that obtained with the standard schedule of giving doses at 4 week intervals. These findings support the use of these vaccines in campaigns done at short intervals to rapidly increase population immunity against polioviruses to control outbreaks or prevent transmission in high-risk areas. C1 [Estivariz, Concepcion F.; Anand, Abhijeet; Gary, Howard E., Jr.; Wassilak, Steven G. F.; Chu, Susan Y.; Weldon, William C.; Pallansch, Mark A.; Heffellfinger, James D.; Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Islam, Jannatul; Heffellfinger, James D.; Luby, Stephen P.; Zaman, Khalequ] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Bari, Tajul I.] Expanded Programme Immunizat & Surveillance, Dhaka, Bangladesh. RP Estivariz, CF (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. EM cge3@cdc.gov OI Luby, Stephen/0000-0001-5385-899X FU Centers for Disease Control and Prevention; UNICEF FX Centers for Disease Control and Prevention and UNICEF. NR 30 TC 6 Z9 6 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD AUG PY 2015 VL 15 IS 8 BP 898 EP 904 DI 10.1016/S1473-3099(15)00094-8 PG 7 WC Infectious Diseases SC Infectious Diseases GA CN1LW UT WOS:000358182500028 PM 26093980 ER PT J AU Lai, YS Biedermann, P Ekpo, UF Garba, A Mathieu, E Midzi, N Mwinzi, P N'Goran, EK Raso, G Assare, RNK Sacko, M Schur, N Talla, I Tchuente, LAT Toure, S Winkler, MS Utzinger, J Vounatsou, P AF Lai, Ying-Si Biedermann, Patricia Ekpo, Uwem F. Garba, Amadou Mathieu, Els Midzi, Nicholas Mwinzi, Pauline N'Goran, Eliezer K. Raso, Giovanna Assare, Rufin K. Sacko, Moussa Schur, Nadine Talla, Idrissa Tchuente, Louis-Albert Tchuem Toure, Seydou Winkler, Mirko S. Utzinger, Juerg Vounatsou, Penelope TI Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis SO LANCET INFECTIOUS DISEASES LA English DT Review ID SOIL-TRANSMITTED HELMINTHIASIS; NEGLECTED TROPICAL DISEASES; WEST-AFRICA; COTE-DIVOIRE; SIERRA-LEONE; MANSONI; PREVALENCE; PREDICTION; RISK; SCHOOLCHILDREN AB Background Schistosomiasis affects more than 200 million individuals, mostly in sub-Saharan Africa, but empirical estimates of the disease burden in this region are unavailable. We used geostatistical modelling to produce high-resolution risk estimates of infection with Schistosoma spp and of the number of doses of praziquantel treatment needed to prevent morbidity at different administrative levels in 44 countries. Methods We did a systematic review to identify surveys including schistosomiasis prevalence data in sub-Saharan Africa via PubMed, ISI Web of Science, and African Journals Online, from inception to May 2, 2014, with no restriction of language, survey date, or study design. We used Bayesian geostatistical meta-analysis and rigorous variable selection to predict infection risk over a grid of 1 155 818 pixels at 5 x 5 km, on the basis of environmental and socioeconomic predictors and to calculate the number of doses of praziquantel needed for prevention of morbidity. Findings The literature search identified Schistosoma haematobium and Schistosoma mansoni surveys done in, respectively, 9318 and 9140 unique locations. Infection risk decreased from 2000 onwards, yet estimates suggest that 163 million (95% Bayesian credible interval [CrI] 155 million to 172 million; 18.5%, 17.6-19.5) of the sub-Saharan African population was infected in 2012. Mozambique had the highest prevalence of schistosomiasis in school-aged children (52.8%, 95% CrI 48.7-57.8). Low-risk countries (prevalence among school-aged children lower than 10%) included Burundi, Equatorial Guinea, Eritrea, and Rwanda. The numbers of doses of praziquantel needed per year were estimated to be 123 million (95% CrI 121 million to 125 million) for school-aged children and 247 million (239 million to 256 million) for the entire population. Interpretation Our results will inform policy makers about the number of treatments needed at different levels and will guide the spatial targeting of schistosomiasis control interventions. C1 [Lai, Ying-Si; Biedermann, Patricia; Raso, Giovanna; Assare, Rufin K.; Schur, Nadine; Winkler, Mirko S.; Utzinger, Juerg; Vounatsou, Penelope] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland. [Lai, Ying-Si; Biedermann, Patricia; Raso, Giovanna; Assare, Rufin K.; Schur, Nadine; Winkler, Mirko S.; Utzinger, Juerg; Vounatsou, Penelope] Univ Basel, Basel, Switzerland. [Ekpo, Uwem F.] Fed Univ Agr, Dept Biol Sci, Abeokuta, Nigeria. [Garba, Amadou] Reseau Int Schistosomose Environm Amenagement & L, Niamey, Niger. [Mathieu, Els] Natl Ctr Infect Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. [Midzi, Nicholas] Natl Inst Hlth Res, Harare, Zimbabwe. [Mwinzi, Pauline] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [N'Goran, Eliezer K.] Univ Felix Houphouet Boigny, Unite Format & Rech Biosci, Abidjan, Cote Ivoire. [N'Goran, Eliezer K.; Assare, Rufin K.] Ctr Suisse Rech Sci, Abidjan, Cote Ivoire. [Sacko, Moussa] Inst Natl Rech Sante Publ, Bamako, Mali. [Talla, Idrissa] Minist Sante, Direct Lutte Contre Maladie, Dakar, Senegal. [Tchuente, Louis-Albert Tchuem] Univ Yaounde, Lab Parasitol & Ecol, Yaounde, Cameroon. [Tchuente, Louis-Albert Tchuem] Ctr Schistosomiasis & Parasitol, Yaounde, Cameroon. [Toure, Seydou] Minist Sante, Programme Natl Lutte Schistosomiase, Ouagadougou, Burkina Faso. RP Vounatsou, P (reprint author), Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland. EM penelope.vounatsou@unibas.ch FU European Research Council; China Scholarship Council; UBS Optimus Foundation; Swiss National Science Foundation FX European Research Council, China Scholarship Council, UBS Optimus Foundation, and Swiss National Science Foundation. NR 58 TC 24 Z9 25 U1 5 U2 24 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD AUG PY 2015 VL 15 IS 8 BP 927 EP 940 DI 10.1016/S1473-3099(15)00066-3 PG 14 WC Infectious Diseases SC Infectious Diseases GA CN1LW UT WOS:000358182500032 PM 26004859 ER PT J AU Jo, H Schieve, LA Rice, CE Yeargin-Allsopp, M Tian, LH Blumberg, SJ Kogan, MD Boyle, CA AF Jo, Heejoo Schieve, Laura A. Rice, Catherine E. Yeargin-Allsopp, Marshalyn Tian, Lin H. Blumberg, Stephen J. Kogan, Michael D. Boyle, Coleen A. TI Age at Autism Spectrum Disorder (ASD) Diagnosis by Race, Ethnicity, and Primary Household Language Among Children with Special Health Care Needs, United States, 2009-2010 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Autism; Age at diagnosis; Race/ethnicity; Prevalence ID 2007 NATIONAL-SURVEY; YOUNG-CHILDREN; MEDICAL HOME; PREVALENCE; US; IDENTIFICATION; TRENDS; INTERVENTION; SURVEILLANCE; SERVICES AB We examined prevalence of diagnosed autism spectrum disorder (ASD) and age at diagnosis according to child's race/ethnicity and primary household language. From the 2009-2010 National Survey of Children with Special Health Care Needs, we identified 2729 3-17-year-old US children whose parent reported a current ASD diagnosis. We compared ASD prevalence, mean diagnosis age, and percentage with later diagnoses (a parts per thousand yen5 years) across racial/ethnic/primary household language groups: non-Hispanic-white, any language (NHW); non-Hispanic-black, any language (NHB); Hispanic-any-race, English (Hispanic-English); and Hispanic-any-race, other language (Hispanic-Other). We assessed findings by parent-reported ASD severity level and adjusted for family sociodemographics. ASD prevalence estimates were 15.3 (NHW), 10.4 (NHB), 14.1 (Hispanic-English), and 5.2 (Hispanic-Other) per 1000 children. Mean diagnosis age was comparable across racial/ethnic/language groups for 3-4-year-olds. For 5-17-year-olds, diagnosis age varied by race/ethnicity/language and also by ASD severity. In this group, NHW children with mild/moderate ASD had a significantly higher proportion (50.8 %) of later diagnoses than NHB (33.5 %) or Hispanic-Other children (18.0 %). However, NHW children with severe ASD had a comparable or lower (albeit non-significant) proportion (16.4 %) of later diagnoses than NHB (37.8 %), Hispanic-English (30.8 %), and Hispanic-Other children (12.0 %). While NHW children have comparable ASD prevalence and diagnosis age distributions as Hispanic-English children, they have both higher prevalence and proportion of later diagnoses than NHB and Hispanic-Other children. The diagnosis age findings were limited to mild/moderate cases only. Thus, the prevalence disparity might be primarily driven by under-representation (potentially under-identification) of older children with mild/moderate ASD in the two minority groups. C1 [Jo, Heejoo; Schieve, Laura A.; Rice, Catherine E.; Yeargin-Allsopp, Marshalyn; Tian, Lin H.; Boyle, Coleen A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Kogan, Michael D.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. RP Jo, H (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, MS-E86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM heejoojo@usc.edu RI Rice, Catherine/D-6305-2016 FU Intramural CDC HHS [CC999999] NR 41 TC 9 Z9 9 U1 3 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD AUG PY 2015 VL 19 IS 8 BP 1687 EP 1697 DI 10.1007/s10995-015-1683-4 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM9XV UT WOS:000358064600004 PM 25701197 ER PT J AU Wingate, MS Barfield, WD Smith, RA Petrini, J AF Wingate, Martha S. Barfield, Wanda D. Smith, Ruben A. Petrini, Joann TI Perinatal Disparities Between American Indians and Alaska Natives and Other US Populations: Comparative Changes in Fetal and First Day Mortality, 1995-2008 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Fetal death; American Indian and Alaska Natives; Perinatal mortality; Vital statistics ID DISEASE RISK-FACTORS; UNITED-STATES; INFANT-MORTALITY; ETHNIC DISPARITIES; BIRTH CERTIFICATES; DEATH CERTIFICATES; HEALTH; PREGNANCY; AGE; CARE AB To compare fetal and first day outcomes of American Indian and Alaskan Natives (AIAN) with non-AIAN populations. Singleton deliveries to AIAN and non-AIAN populations were selected from live birth-infant death cohort and fetal deaths files from 1995-1998 and 2005-2008. We examined changes over time in maternal characteristics of deliveries and disparities and changes in risks of fetal, first day (< 24 h), and cause-specific deaths. We calculated descriptive statistics, odds ratios and confidence intervals, and ratio of odds ratios (RORs) to indicate changes in disparities. Along with black mothers, AIANs exhibited the highest proportion of risk factors including the highest proportion of diabetes in both time periods (4.6 and 6.5 %). Over time, late fetal death for AIANs decreased 17 % (aOR = 0.83, 95 % CI 0.72-0.97), but we noted a 47 % increased risk over time for Hispanics (aOR = 1.47, 95 % CI 1.40-1.55). Our data indicated no change over time among AIANs for first day death. For AIANs compared to whites, increased risks and disparities persisted for mortality due to congenital anomalies (ROR = 1.28, 95 % CI 1.03-1.60). For blacks compared to AIANs, the increased risks of fetal death (2005-2008: aOR = 0.60, 95 % CI 0.53-0.68) persisted. For Hispanics, lower risks compared to AIANs persisted, but protective effect declined over time. Disparities between AIAN and other groups persist, but there is variability by race/ethnicity in improvement of perinatal outcomes over time. Variability in access to care and pregnancy management should be considered in relation to health equity for fetal and early infant deaths. C1 [Wingate, Martha S.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA. [Barfield, Wanda D.; Smith, Ruben A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Petrini, Joann] Danbury Hosp, Dept Med Educ & Res, Danbury, CT USA. [Petrini, Joann] March Dimes Fdn, Off President, White Plains, NY USA. RP Wingate, MS (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Care Org & Policy, RPHB 3301530 3rd Ave South, Birmingham, AL 35294 USA. EM mslay@uab.edu FU CDC IPA [1003335]; DHHS; HRSA; MCHB [MC00008] FX Dr. Wingate was supported in part by CDC IPA 1003335 and DHHS, HRSA, MCHB Grant MC00008. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention. NR 63 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD AUG PY 2015 VL 19 IS 8 BP 1802 EP 1812 DI 10.1007/s10995-015-1694-1 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM9XV UT WOS:000358064600015 PM 25663653 ER PT J AU Lucke-Wold, BP Smith, KE Nguyen, L Turner, RC Logsdon, AF Jackson, GJ Huber, JD Rosen, CL Miller, DB AF Lucke-Wold, Brandon P. Smith, Kelly E. Linda Nguyen Turner, Ryan C. Logsdon, Aric F. Jackson, Garrett J. Huber, Jason D. Rosen, Charles L. Miller, Diane B. TI Sleep disruption and the sequelae associated with traumatic brain injury SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Sleep disruption; Traumatic brain injury; Neuropsychiatric symptoms; Neurodegeneration; Maintenance insomnia ID UNFOLDED PROTEIN RESPONSE; CHRONIC PRIMARY INSOMNIA; NECROSIS-FACTOR-ALPHA; MINOR HEAD-INJURY; PHASE SYNDROME; PSYCHIATRIC-PATIENTS; BARRIER FUNCTION; MOOD DISORDERS; REM-SLEEP; ONE NIGHT AB Sleep disruption, which includes a loss of sleep as well as poor quality fragmented sleep, frequently follows traumatic brain injury (TBI) impacting a large number of patients each year in the United States. Fragmented and/or disrupted sleep can worsen neuropsychiatric, behavioral, and physical symptoms of TBI. Additionally, sleep disruption impairs recovery and can lead to cognitive decline. The most common sleep disruption following TBI is insomnia, which is difficulty staying asleep. The consequences of disrupted sleep following injury range from deranged metabolomics and blood brain barrier compromise to altered neuroplasticity and degeneration. There are several theories for why sleep is necessary (e.g., glymphatic clearance and metabolic regulation) and these may help explain how sleep disruption contributes to degeneration within the brain. Experimental data indicate disrupted sleep allows hyperphosphorylated tau and amyloid 13 plaques to accumulate. As sleep disruption may act as a cellular stressor, target areas warranting further scientific investigation include the increase in endoplasmic reticulum and oxidative stress following acute periods of sleep deprivation. Potential treatment options for restoring the normal sleep cycle include melatonin derivatives and cognitive behavioral therapy. Published by Elsevier Ltd. C1 [Smith, Kelly E.; Linda Nguyen; Logsdon, Aric F.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA. [Lucke-Wold, Brandon P.; Smith, Kelly E.; Linda Nguyen; Turner, Ryan C.; Logsdon, Aric F.; Huber, Jason D.; Rosen, Charles L.; Miller, Diane B.] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA. [Lucke-Wold, Brandon P.; Turner, Ryan C.; Jackson, Garrett J.; Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA. [Miller, Diane B.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Miller, DB (reprint author), NIOSH, CDC, Morgantown, WV 26505 USA. EM dum6@cdc.gov OI Lucke-Wold, Brandon/0000-0001-6577-4080 FU West Virginia University; American Foundation of Pharmaceutical Education; American Medical Association Foundation; Neurosurgery Research and Education Foundation FX Research Funding and Development Grant West Virginia University. Brandon Lucke-Wold and Aric Logsdon were supported by American Foundation of Pharmaceutical Education Pre-doctoral Fellowships. Brandon Lucke-Wold also was funded by an American Medical Association Foundation Seed-Grant and a Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship. NR 139 TC 4 Z9 4 U1 1 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 EI 1873-7528 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD AUG PY 2015 VL 55 BP 68 EP 77 DI 10.1016/j.neubiorev.2015.04.010 PG 10 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA CN2SA UT WOS:000358271000005 PM 25956251 ER PT J AU Thompson, JL Kuklina, EV Bateman, BT Callaghan, WM James, AH Grotegut, CA AF Thompson, Jennifer L. Kuklina, Elena V. Bateman, Brian T. Callaghan, William M. James, Andra H. Grotegut, Chad A. TI Medical and Obstetric Outcomes Among Pregnant Women With Congenital Heart Disease SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID MATERNAL MORBIDITY; UNITED-STATES; HOSPITALIZATIONS; DELIVERY AB OBJECTIVE: To estimate nationwide trends in the prevalence of maternal congenital heart disease (CHD) and determine whether women with CHD are more likely than women without maternal CHD to have medical and obstetric complications. METHODS: The 2000-2010 Nationwide Inpatient Sample was queried for International Classification of Diseases, 9th Revision, Clinical Modification codes to identify delivery hospitalizations of women with and without CHD. Trends in the prevalence of CHD were determined and then rates of complications were reported for CHD per 10,000 delivery hospitalizations. For Nationwide Inpatient Sample 2008-2010, logistic regression was used to examine associations between CHD and complications. RESULTS: From 2000 to 2010, there was a significant linear increase in the prevalence of CHD from 6.4 to 9.0 per 10,000 delivery hospitalizations (P<.001). Multivariable logistic regression demonstrated that all selected medical complications, including mortality (17.8 compared with 0.7/10,000 deliveries, adjusted odds ratio [OR] 22.10, 95% confidence interval [CI] 13.96-34.97), mechanical ventilation (91.9 compared with 6.9/10,000, adjusted OR 9.94, 95% CI 7.99-12.37), and a composite cardiovascular outcome (614 compared with 34.3/10,000, adjusted OR 10.54, 95% CI 9.55-11.64) were more likely to occur among delivery hospitalizations with maternal CHD than without. Obstetric complications were also common among women with CHD. Delivery hospitalizations with maternal CHD that also included codes for pulmonary circulatory disorders had higher rates of medical complications compared with hospitalizations with maternal CHD without pulmonary circulatory disorders. CONCLUSION: The number of delivery hospitalizations with maternal CHD in the United States is increasing, and although we were not able to determine whether correction of the cardiac lesion affected outcomes, these hospitalizations have a high burden of medical and obstetric complications. C1 [Grotegut, Chad A.] Duke Univ, Div Maternal Fetal Med, Durham, NC 27710 USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp,Div Pharmacoepidemiol & Ph, Dept Anesthesia Crit Care & Pain Management,Dept, Boston, MA 02115 USA. RP Grotegut, CA (reprint author), Duke Univ, Div Maternal Fetal Med, Dept Obstet & Gynecol, DUMC Box 3967, Durham, NC 27710 USA. EM chad.grotegut@duke.edu FU Intramural CDC HHS [CC999999] NR 25 TC 7 Z9 7 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD AUG PY 2015 VL 126 IS 2 BP 346 EP 354 DI 10.1097/AOG.0000000000000973 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CN2WY UT WOS:000358284500003 PM 26241425 ER PT J AU Kourtis, AP Appelgren, K Chevalier, MS McElroy, A AF Kourtis, Athena P. Appelgren, Kristie Chevalier, Michelle S. McElroy, Anita TI Ebola Virus Disease Focus on Children SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Review DE Ebola virus disease; children; infants ID HEMORRHAGIC-FEVER; WEST-AFRICA; CONGO; KIKWIT; OUTBREAK; TRANSMISSION; SURVIVAL; ZAIRE; RISK AB Ebola virus is one of the most deadly pathogens known to infect humans. The current Ebola outbreak in West Africa is unprecedented in magnitude and duration and, as of November 30, 2014, shows no signs of abating. For the first time, cases of Ebola virus disease have been diagnosed in the US, originating from patients who traveled during the incubation period. The outbreak has generated worldwide concern. It is clear that U.S. physicians need to be aware of this disease, know when to consider Ebola and how to care for the patient as well as protect themselves. Children comprise a small percentage of all cases globally, likely because of their lower risk of exposure given social and cultural practices. Limited evidence is available on pediatric disease course and prognosis. In this article, we present an overview of the pathogen, its epidemiology and transmission, clinical and laboratory manifestations, treatment and infection control procedures, with an emphasis on what is known about Ebola virus disease in the pediatric population. C1 [Kourtis, Athena P.; Appelgren, Kristie; Chevalier, Michelle S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [McElroy, Anita] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect, Atlanta, GA 30341 USA. [McElroy, Anita] Emory Univ, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA. RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F74, Atlanta, GA 30341 USA. EM apk3@cdc.gov FU NICHD NIH HHS [K12 HD072245] NR 51 TC 4 Z9 4 U1 3 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD AUG PY 2015 VL 34 IS 8 BP 893 EP 897 DI 10.1097/INF.0000000000000707 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CN4PE UT WOS:000358411500018 PM 25831417 ER PT J AU Auld, AF Alfredo, C Macassa, E Jobarteh, K Shiraishi, RW Rivadeneira, ED Houston, J Spira, TJ Ellerbrock, TV Vaz, P AF Auld, Andrew F. Alfredo, Charity Macassa, Eugenia Jobarteh, Kebba Shiraishi, Ray W. Rivadeneira, Emilia D. Houston, James Spira, Thomas J. Ellerbrock, Tedd V. Vaz, Paula TI Temporal Trends in Patient Characteristics and Outcomes Among Children Enrolled in Mozambique's National Antiretroviral Therapy Program SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pediatric antiretroviral therapy; treatment outcomes; Mozambique ID HIV-INFECTED CHILDREN; SOUTH-AFRICA; FOLLOW-UP; INFANTS; CARE; RETENTION; MORTALITY; TANZANIA; VALUES; ZAMBIA AB Background: During 2004-2009, >12,000 children (<15 years old) initiated antiretroviral therapy (ART) in Mozambique. Nationally representative outcomes and temporal trends in outcomes were investigated. Methods: Rates of death, loss to follow-up (LTFU) and attrition (death or LTFU) were evaluated in a nationally representative sample of 1054 children, who initiated ART during 2004-2009 at 25 facilities randomly selected using probability-proportional-to-size sampling. Results: At ART initiation during 2004-2009, 50% were male; median age was 3.3 years; median CD4% was 13%; median CD4 count was 375 cells/L; median weight-for-age Z score was -2.1. During 2004-2009, median time from HIV diagnosis to care initiation declined from 33 to 0 days (P = 0.001); median time from care to ART declined from 93 to 62 days (P = 0.004); the percentage aged <2 at ART initiation increased from 16% to 48% (P = 0.021); the percentage of patients with prior tuberculosis declined from 50% to 10% (P = 0.009); and the percentage with prior lymphocytic interstitial pneumonia declined from 16% to 1% (P < 0.001). Over 2652 person-years of ART, 183 children became LTFU and 26 died. Twelve-month attrition was 11% overall but increased from 3% to 22% during 2004-2009, mainly because of increases in 12-month LTFU (from 3% to 18%). Conclusion: Declines in the prevalence of markers of advanced HIV disease at ART initiation probably reflect increasing ART access. However, 12-month LTFU increased during program expansion, and this negated any program improvements in outcomes that might have resulted from earlier ART initiation. C1 [Auld, Andrew F.; Shiraishi, Ray W.; Rivadeneira, Emilia D.; Houston, James; Spira, Thomas J.; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Alfredo, Charity; Jobarteh, Kebba] Ctr Dis Control & Prevent, Div Global HIV AIDS, Maputo, Mozambique. [Macassa, Eugenia; Vaz, Paula] Minist Saude, Programa TARV Pediat, Maputo, Mozambique. [Vaz, Paula] Fundacao Ariel Glaser O SIDA Pediat, Maputo, Mozambique. RP Auld, AF (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA. EM aauld@cdc.gov OI Auld, Andrew/0000-0001-5089-9163 FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not imply endorsement by the U.S. Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention. The authors have no conflicts of interest or funding to disclose. NR 42 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD AUG PY 2015 VL 34 IS 8 BP E191 EP E199 DI 10.1097/INF.0000000000000741 PG 9 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CN4PH UT WOS:000358411800002 PM 25955836 ER PT J AU Stone, DM Luo, FJ Lippy, C McIntosh, WL AF Stone, Deborah M. Luo, Feijun Lippy, Caroline McIntosh, Wendy LiKamWa TI The Role of Social Connectedness and Sexual Orientation in the Prevention of Youth Suicide Ideation and Attempts Among Sexually Active Adolescents SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID RISK BEHAVIOR SURVEYS; PROTECTIVE FACTORS; SCHOOL CONNECTEDNESS; BISEXUAL YOUTHS; MENTAL-HEALTH; YOUNG-ADULTS; MINORITY ADOLESCENTS; GAY; VICTIMIZATION; POPULATION AB The impact of types of social connectednessfamily, other adult, and schoolon suicide ideation and attempts among all youth, the relative impact of each type, and effect modification by sexual orientation was assessed. Data were from the 2007-2009 Milwaukee Youth Risk Behavior Surveys. Multivariable logistic regression analyses calculated the risk of suicide ideation and attempts by sexual orientation, types of social connectedness, and their interaction. Among all youth, each type of connectedness modeled singly conferred protective effects for suicide ideation. Family and other adult connectedness protected against suicide attempts. When modeled simultaneously, family connectedness protected against ideation and attempts. Sexual orientation modified the association between other adult connectedness and suicide ideation. Findings suggest that family connectedness confers the most consistent protection among all youth and sexual orientation does not generally modify the association between connectedness and suicidal behavior. C1 [Stone, Deborah M.; Lippy, Caroline; McIntosh, Wendy LiKamWa] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30341 USA. [Luo, Feijun] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat, Atlanta, GA 30341 USA. RP Luo, FJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat, 4770 Buford Highway NE,MS F 62, Atlanta, GA 30341 USA. EM FLuo@cdc.gov NR 71 TC 2 Z9 3 U1 2 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD AUG PY 2015 VL 45 IS 4 BP 415 EP 430 DI 10.1111/sltb.12139 PG 16 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CN2KY UT WOS:000358251100003 PM 25388375 ER PT J AU Macario, E Hannon, SW Baker, R Branche, CM Trahan, C AF Macario, Everly Hannon, Sandra Wills Baker, Robin Branche, Christine M. Trahan, Christina TI Preventing falls in residential construction: Effectiveness of engaging partners for a national social marketing campaign SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE construction falls; small residential; campaign partners; partnership assessment; partnership engagement; social marketing; implementation evaluation ID CARPENTERS; WORKERS AB BackgroundFalls are the leading cause of fatalities in construction. The Safety Pays, Falls Cost campaign aims to prevent falls in residential construction. A critical component of our social marketing approach was to involve 70 partners in reaching target audiences. MethodsWe assessed partner engagement April 2012-August 2013 through: (1) baseline partnership quality interviews (eight partners); (2) pre-/post-partner market readiness in-depth interviews (three partners); (3) a pre-/post- (29/31 partners) online partner engagement survey; and (4) standardized metrics to measure partner activity. ResultsWe found a high level of interest and engagement that increased with the addition of prompting to action through regular communication and new resources from organizers and formation of local partnerships that were able to tailor their activities to their own communities or regions. ConclusionIt is feasible to leverage government-labor-management partnerships that enjoy trust among target audiences to widely disseminate campaign materials and messages. Am. J. Ind. Med. 58:809-823, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Macario, Everly; Hannon, Sandra Wills] Hannon Grp, Publ Hlth Commun, Ft Washington, MD 20744 USA. [Baker, Robin] Univ Calif Berkeley, Ctr Construct Res & Training, Ctr Occupat & Environm Hlth, Berkeley, CA 94720 USA. [Branche, Christine M.] Ctr Dis Control & Prevent, Off Construct Safety & Hlth, NIOSH, Washington, DC USA. [Trahan, Christina] Ctr Construct Res & Training, Silver Spring, MD USA. RP Macario, E (reprint author), Hannon Grp, Publ Hlth Commun, 10002 Edgewater Terrace,Suite 100, Ft Washington, MD 20744 USA. EM emacario@thehannongroup.com FU CPWR-The Center for Construction Research and Training from the National Institute of Occupational Safety and Health (NIOSH) [U60-OH009762] FX The research was made possible by CPWR-The Center for Construction Research and Training through cooperative agreement U60-OH009762 from the National Institute of Occupational Safety and Health (NIOSH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIOSH or CPWR. NR 26 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD AUG PY 2015 VL 58 IS 8 SI SI BP 809 EP 823 DI 10.1002/ajim.22458 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM7RP UT WOS:000357894200002 PM 25916770 ER PT J AU Li, J Zhao, GX Hall, IJ AF Li, Jun Zhao, Guixiang Hall, Ingrid J. TI Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SHARED DECISION-MAKING; SERVICES TASK-FORCE; UNITED-STATES; OLDER; MEN; RECOMMENDATION; GUIDELINES AB Introduction: For many men, the net benefit of prostate cancer screening with prostate-specific antigen (PSA) tests may be small. Many major medical organizations have issued recommendations for prostate cancer screening, stressing the need for shared decision making before ordering a test. The purpose of this study is to better understand associations between discussions about benefits and harms of PSA testing and uptake of the test among men aged >= 40 years. Methods: Associations between pre-screening discussions and PSA testing were examined using self-reported data from the 2012 Behavioral Risk Factor Surveillance System. Unadjusted prevalence of PSA testing was estimated and AORs were calculated using logistic regression in 2014. Results: The multivariate analysis showed that men who had ever discussed advantages of PSA testing only or discussed both advantages and disadvantages were more likely, respectively, to report having had a test within the past year than men who had no discussions (p<0.001). In addition, men who had only discussed the disadvantages of PSA testing with their healthcare providers were more likely (AOR = 2.75, 95% CI = 2.00, 3.79) to report getting tested than men who had no discussions. Conclusions: Discussions of the benefits or harms of PSA testing are positively associated with increased uptake of the test. Given the conflicting recommendations for prostate cancer screening and increasing importance of shared decision making, this study points to the need for understanding how pre-screening discussions are being conducted in clinical practice and the role played by patients' values and preferences in decisions about PSA testing. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Li, Jun; Hall, Ingrid J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Zhao, Guixiang] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. RP Li, J (reprint author), CDC, Div Canc Prevent & Control, 4770 Buford Hwy,Mail Stop F-76, Atlanta, GA 30341 USA. EM ffa2@cdc.gov FU Intramural CDC HHS [CC999999] NR 14 TC 2 Z9 2 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 BP 259 EP 263 DI 10.1016/j.amepre.2015.02.007 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CM8YG UT WOS:000357989000012 PM 25997905 ER PT J AU England, LJ Bunnell, RE Pechacek, TF Tong, VT McAfee, TA AF England, Lucinda J. Bunnell, Rebecca E. Pechacek, Terry F. Tong, Van T. McAfee, Tim A. TI Nicotine and the Developing Human A Neglected Element in the Electronic Cigarette Debate SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; HIGH-SCHOOL-STUDENTS; UNITED-STATES; LUNG-FUNCTION; BRAIN-DEVELOPMENT; ACETYLCHOLINE-RECEPTORS; RHESUS-MONKEYS; SNUFF USE; EXPOSURE; ADOLESCENT AB The elimination of cigarettes and other combusted tobacco products in the U.S. would prevent tens of millions of tobacco-related deaths. It has been suggested that the introduction of less harmful nicotine delivery devices, such as electronic cigarettes or other electronic nicotine delivery systems, will accelerate progress toward ending combustible cigarette use. However, careful consideration of the potential adverse health effects from nicotine itself is often absent from public health debates. Human and animal data support that nicotine exposure during periods of developmental vulnerability (fetal through adolescent stages) has multiple adverse health consequences, including impaired fetal brain and lung development, and altered development of cerebral cortex and hippocampus in adolescents. Measures to protect the health of pregnant women and children are needed and could include (1) strong prohibitions on marketing that increase youth uptake; (2) youth access laws similar to those in effect for other tobacco products; (3) appropriate health warnings for vulnerable populations; (4) packaging to prevent accidental poisonings; (5) protection of non-users from exposure to secondhand electronic cigarette aerosol; (6) pricing that helps minimize youth initiation and use; (7) regulations to reduce product addiction potential and appeal for youth; and (8) the age of legal sale. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [England, Lucinda J.; Bunnell, Rebecca E.; Pechacek, Terry F.; McAfee, Tim A.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Tong, Van T.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. RP England, LJ (reprint author), CDC, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. EM lbe9@cdc.gov FU Pfizer Inc. FX Terry F. Pechacek receives salary support from Pfizer Inc. for "Diffusion of Tobacco Control Fundamentals to Other Large Chinese Cities," an effort to expand tobacco control in major cities in China. No other financial disclosures were reported by the remaining authors of this paper. NR 97 TC 45 Z9 45 U1 7 U2 34 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2015 VL 49 IS 2 BP 286 EP 293 DI 10.1016/j.amepre.2015.01.015 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CM8YG UT WOS:000357989000016 PM 25794473 ER PT J AU Mohr, EL McMullan, LK Lo, MK Spengler, JR Bergeron, E Albarino, CG Shrivastava-Ranjan, P Chiang, CF Nichol, ST Spiropoulou, CF Flint, M AF Mohr, Emma L. McMullan, Laura K. Lo, Michael K. Spengler, Jessica R. Bergeron, Eric Albarino, Cesar G. Shrivastava-Ranjan, Punya Chiang, Cheng-Feng Nichol, Stuart T. Spiropoulou, Christina F. Flint, Mike TI Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses SO ANTIVIRAL RESEARCH LA English DT Article DE Ebola; Lassa; Antiviral; AR-12; BIBX ID NIEMANN-PICK C1; Z-PROTEIN; CELECOXIB; INFECTION; OSU-03012; CELLS; EBOLA; PATHWAY; ENTRY; REPLICATION AB Host cell Idnases are important for the replication of a number of hemorrhagic fever viruses. We tested a panel of kinase inhibitors for their ability to block the replication of multiple hemorrhagic fever viruses. OSU-03012 inhibited the replication of Lassa, Ebola, Marburg and Nipah viruses, whereas BIBX 1382 dihydrochloride inhibited Lassa, Ebola and Marburg viruses. BIBX 1382 blocked both Lassa and Ebola virus glycoprotein-dependent cell entry. These compounds may be used as tools to understand conserved virus-host interactions, and implicate host cell kinases that may be targets for broad spectrum therapeutic intervention. Published by Elsevier B.V. C1 [Mohr, Emma L.; McMullan, Laura K.; Lo, Michael K.; Spengler, Jessica R.; Bergeron, Eric; Albarino, Cesar G.; Shrivastava-Ranjan, Punya; Chiang, Cheng-Feng; Nichol, Stuart T.; Spiropoulou, Christina F.; Flint, Mike] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Mohr, Emma L.] Emory Univ, Dept Pediat, Emory Childrens Ctr, Atlanta, GA 30322 USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS G-14, Atlanta, GA 30333 USA. EM ccs8@cdc.gov OI Lo, Michael/0000-0002-0409-7896; Flint, Michael/0000-0002-5373-787X; Spengler, Jessica R./0000-0002-5383-0513 NR 37 TC 11 Z9 11 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD AUG PY 2015 VL 120 BP 40 EP 47 DI 10.1016/j.antiviral.2015.05.003 PG 8 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA CN0JD UT WOS:000358099000006 PM 25986249 ER PT J AU Peterson, C Xu, LK Florence, C Parks, SE AF Peterson, Cora Xu, Likang Florence, Curtis Parks, Sharyn E. TI Annual Cost of US Hospital Visits for Pediatric Abusive Head Trauma SO CHILD MALTREATMENT LA English DT Article DE child abuse; shaken baby syndrome; costs and cost analysis; economics; hospital ID OPERATIONAL CASE-DEFINITION; CHILD MALTREATMENT; YOUNG-CHILDREN; UNITED-STATES; POPULATION AB We estimated the frequency and direct medical cost from the provider perspective of U.S. hospital visits for pediatric abusive head trauma (AHT). We identified treat-and-release hospital emergency department (ED) visits and admissions for AHT among patients aged 0-4 years in the Nationwide Emergency Department Sample and Nationwide Inpatient Sample (NIS), 2006-2011. We applied cost-to-charge ratios and estimated professional fee ratios from Truven Health MarketScan (R) to estimate per-visit and total population costs of AHT ED visits and admissions. Regression models assessed cost differences associated with selected patient and hospital characteristics. AHT was diagnosed during 6,827 (95% confidence interval [CI] [6,072, 7,582]) ED visits and 12,533 (95% CI [10,395, 14,671]) admissions (28% originating in the same hospital's ED) nationwide over the study period. The average medical cost per ED visit and admission were US$2,612 (error bound: 1,644-3,581) and US$31,901 (error bound: 29,266-34,536), respectively (2012 USD). The average total annual nationwide medical cost of AHT hospital visits was US$69.6 million (error bound: 56.9-82.3 million) over the study period. Factors associated with higher per-visit costs included patient age < 1 year, males, coexisting chronic conditions, discharge to another facility, death, higher household income, public insurance payer, hospital trauma level, and teaching hospitals in urban locations. Study findings emphasize the importance of focused interventions to reduce this type of high-cost child abuse. C1 [Peterson, Cora; Xu, Likang; Florence, Curtis; Parks, Sharyn E.] Ctr Dis Control & Prevent CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Peterson, C (reprint author), CDC Natl Ctr Injury Prevent & Control, Mailstop F-62,4770 Buford Highway, Atlanta, GA 30341 USA. EM cora.peterson@cdc.hhs.gov OI Peterson, Cora/0000-0001-7955-0977 FU Intramural CDC HHS [CC999999] NR 25 TC 2 Z9 2 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5595 EI 1552-6119 J9 CHILD MALTREATMENT JI Child Maltreatment PD AUG PY 2015 VL 20 IS 3 BP 162 EP 169 DI 10.1177/1077559515583549 PG 8 WC Family Studies; Social Work SC Family Studies; Social Work GA CM8DN UT WOS:000357927100002 PM 25911437 ER PT J AU Shlay, JC Rodgers, S Lyons, J Romero, S Vogt, TM McCormick, EV AF Shlay, Judith C. Rodgers, Sarah Lyons, Jean Romero, Scott Vogt, Tara M. McCormick, Emily V. TI Implementing a School-Located Vaccination Program in Denver Public Schools SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE school-located vaccinations; adolescent vaccines; influenza vaccines ID UNIVERSAL INFLUENZA VACCINATION; PRIMARY-CARE PRACTICES; IMMUNIZATION PRACTICES; PROMISING PRACTICES; CHILDREN; HEALTH; ADOLESCENTS; PEDIATRICIANS; DELIVERY; VACCINES AB BACKGROUND: School-located vaccination (SLV) offers an opportunity to deliver vaccines to students, particularly those without a primary care provider. METHODS: This SLV program offered 2 clinics at each of 20 elementary schools (influenza vaccine) and 3 clinics at each of 7 middle/preschool-eighth-grade schools (adolescent platform plus catch-up vaccines) during the 2009-2010 and 2010-2011 school years. Established programmatic processes for immunization delivery in an outreach setting were used. Billing and vaccine inventory management processes were developed. Vaccines from the federal Vaccines for Children program were used for eligible students. Third-party payers were billed for insured students; parents were not billed for services. RESULTS: The proportion of enrolled students who received at least 1 dose of vaccine increased from year 1 to year 2 (elementary: 28% to 31%; middle: 12% to 19%). Issues identified and addressed included program planning with partners, development and implementation of billing processes, development of a solution to adhere to the Family Educational Rights and Privacy Act requirements, development and utilization of an easy-to-comprehend consent form, and implementation of standard work procedures. CONCLUSIONS: This SLV program offered an alternative approach for providing vaccinations to students outside of the primary care setting. To be successful, ongoing partnerships are needed. C1 [Shlay, Judith C.] Univ Colorado Denver, Family Med, Aurora, CO 80045 USA. [Shlay, Judith C.; Rodgers, Sarah] Denver Publ Hlth Dept, Denver Hlth Immunizat & Travel Clin, Denver, CO 80204 USA. [Lyons, Jean] Denver Publ Sch, Dept Nursing & Student Hlth Serv, Div Student Serv, Denver, CO 80203 USA. [Romero, Scott] Denver Publ Sch, Div Student Serv, Hlth Sch Team, Denver, CO 80203 USA. [Vogt, Tara M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [McCormick, Emily V.] Denver Publ Hlth Dept, Denver, CO 80204 USA. RP Shlay, JC (reprint author), Denver Publ Hlth, 605 Bannock St, Denver, CO 80204 USA. EM judith.shlay@dhha.org; Sarah.Rodgers@dhha.org; jean.lyons@dpsk12.org; scott.romero@dpsk12.org; tcv3@cdc.gov; Emily.Mccormick@dhha.org FU Centers for Disease Control and Prevention [U01P000199-01, 1U01IP000196-01] FX This work was funded by a cooperative agreement with the Centers for Disease Control and Prevention, #U01P000199-01 and 1U01IP000196-01. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 34 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD AUG PY 2015 VL 85 IS 8 BP 536 EP 543 DI 10.1111/josh.12281 PG 8 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CM6GS UT WOS:000357786800005 PM 26149309 ER PT J AU Desrosiers, TA Lawson, CC Meyer, RE Stewart, PA Waters, MA Correa, A Olshan, AF AF Desrosiers, Tania A. Lawson, Christina C. Meyer, Robert E. Stewart, Patricia A. Waters, Martha A. Correa, Adolfo Olshan, Andrew F. CA Natl Birth Defects Prevention Stud TI Assessed occupational exposure to chlorinated, aromatic and Stoddard solvents during pregnancy and risk of fetal growth restriction SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID FOR-GESTATIONAL-AGE; BIRTH-DEFECTS PREVENTION; ORGANIC-SOLVENTS; CHEMICAL-SUBSTANCES; PRETERM DELIVERY; UNITED-STATES; OUTCOMES; WEIGHT; TETRACHLOROETHYLENE; TRICHLOROETHYLENE AB Objectives Previous experimental and epidemiological research suggests that maternal exposure to some organic solvents during pregnancy may increase the risk of fetal growth restriction (FGR). We evaluated the association between expert-assessed occupational solvent exposure and risk of small for gestational age (SGA) infants in a population-based sample of women in the National Birth Defects Prevention Study. Methods We analysed data from 2886 mothers and their infants born between 1997 and 2002. Job histories were self-reported. Probability of exposure to six chlorinated, three aromatic and one petroleum solvent was assessed by industrial hygienists. SGA was defined as birthweight<10th centile of birthweight-by-gestational age in a national reference. Logistic regression was used to estimate ORs and 95% CIs to assess the association between SGA and exposure to any solvent(s) or specific solvent classes, adjusting for maternal age and education. Results Approximately 8% of infants were SGA. Exposure prevalence to any solvent was 10% and 8% among mothers of SGA and non-SGA infants, respectively. Among women with >= 50% probability of exposure, we observed elevated but imprecise associations between SGA and exposure to any solvent(s) (1.71; 0.86 to 3.40), chlorinated solvents (1.70; 0.69 to 4.01) and aromatic solvents (1.87; 0.78 to 4.50). Conclusions This is the first population-based study in the USA to investigate the potential association between FGR and assessed maternal occupational exposure to distinct classes of organic solvents during pregnancy. The potential associations observed between SGA and exposure to chlorinated and aromatic solvents are based on small numbers and merit further investigation. C1 [Desrosiers, Tania A.; Olshan, Andrew F.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Lawson, Christina C.; Waters, Martha A.] NIOSH, Cincinnati, OH 45226 USA. [Meyer, Robert E.] State Ctr Hlth Stat, North Carolina Div Publ Hlth, Birth Defects Monitoring Program, Raleigh, NC USA. [Stewart, Patricia A.] Stewart Exposure Assessments LLC, Arlington, VA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. RP Desrosiers, TA (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA. EM ta_desrosiers@unc.edu FU Centres for Disease Control and Prevention; North Carolina Centre for Birth Defects Research and Prevention at the University of North Carolina, Chapel Hill [U50CCU422096, 5U01DD001036]; Centres for Birth Defects Research and Prevention [PA 96043, PA 02081, FOA DD09-001]; National Institute for Occupational Safety and Health [200-2000-08018] FX This study was supported by cooperative agreements with the Centres for Disease Control and Prevention and the North Carolina Centre for Birth Defects Research and Prevention at the University of North Carolina, Chapel Hill (U50CCU422096; 5U01DD001036) as well as with the other Centres for Birth Defects Research and Prevention that participated in the National Birth Defects Prevention Study (PA 96043; PA 02081; FOA DD09-001). The occupational exposure assessment was supported by contract 200-2000-08018 with the National Institute for Occupational Safety and Health. NR 43 TC 0 Z9 0 U1 1 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD AUG PY 2015 VL 72 IS 8 BP 587 EP 593 DI 10.1136/oemed-2015-102835 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM9IB UT WOS:000358020600009 PM 26076683 ER PT J AU Wheeler, MW Shao, K Bailer, AJ AF Wheeler, Matthew W. Shao, Kan Bailer, A. John TI Quantile benchmark dose estimation for continuous endpoints SO ENVIRONMETRICS LA English DT Article DE monotonic exposure-response; heterogeneous variance; quantitative risk assessment; smoothing splines ID REGRESSION QUANTILES; RISK AB Quantitative risk assessment (QRA) characterizes the risk of an adverse health outcome for an organism exposed to a chemical, environmental, physical, or other hazard. Historically, QRAs define risk based upon the increased probability of adverse response because of exposure when compared with the background probability of response in unexposed individuals. For a specified risk level, the exposure-response relationship is inverted to find an exposure (or dose) for minimizing risk; these exposures are often called the benchmark dose (BMD). For continuous endpoints, BMD analyses have employed strong assumptions on the form of the response distribution which may not be met for most toxicology data sets. We propose a reformulation of the BMD for use in QRA for continuous response that is based upon milder assumptions using quantile regression and monotone smoothing splines. This method takes into account the uncertainty in the response distribution as well as uncertainty in the exposure-response relationship. We apply this method to a data example and show through a simulation study that the approach is often superior to current practice. Copyright (c) 2015John Wiley & Sons, Ltd. C1 [Wheeler, Matthew W.] NIOSH, Cincinnati, OH 45226 USA. [Shao, Kan] Indiana Univ, Sch Publ Hlth, Bloomington, IN 47405 USA. [Bailer, A. John] Miami Univ, Dept Stat, Oxford, OH 45056 USA. RP Wheeler, MW (reprint author), NIOSH, Cincinnati, OH 45226 USA. EM mwheeler@cdc.gov OI Shao, Kan/0000-0002-5512-2377 NR 20 TC 1 Z9 1 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1180-4009 EI 1099-095X J9 ENVIRONMETRICS JI Environmetrics PD AUG PY 2015 VL 26 IS 5 BP 363 EP 372 DI 10.1002/env.2342 PG 10 WC Environmental Sciences; Mathematics, Interdisciplinary Applications; Statistics & Probability SC Environmental Sciences & Ecology; Mathematics GA CM2OG UT WOS:000357520200004 ER PT J AU Reyes, HLM Foshee, VA Fortson, BL Valle, LA Breiding, MJ Merrick, MT AF Reyes, H. Luz McNaughton Foshee, Vangie A. Fortson, Beverly L. Valle, Linda A. Breiding, Matthew J. Merrick, Melissa T. TI Longitudinal Mediators of Relations Between Family Violence and Adolescent Dating Aggression Perpetration SO JOURNAL OF MARRIAGE AND FAMILY LA English DT Article DE dating violence; development; intergenerational transmission; intimate partner violence; longitudinal; path analysis ID EMOTION DYSREGULATION; CHILD MALTREATMENT; INTERGENERATIONAL TRANSMISSION; GENDER-DIFFERENCES; DOMESTIC VIOLENCE; MARITAL VIOLENCE; ABUSE; EXPOSURE; BEHAVIOR; STRESS AB Few longitudinal studies have examined the pathways through which family violence leads to dating aggression. In the current study the authors used 3 waves of data obtained from 8th- and 9th-grade adolescents (N=1,965) to examine the hypotheses that the prospective relationship between witnessing family violence and directly experiencing violence and physical dating aggression perpetration is mediated by 3 constructs: (a) normative beliefs about dating aggression (norms), (b) anger dysregulation, and (c) depression. Results from cross-lagged regression models suggest that the relationship between having been hit by an adult and dating aggression is mediated by changes in norms and anger dysregulation, but not depression. No evidence of indirect effects from witnessing family violence to dating aggression was found through any of the proposed mediators. Taken together, the findings suggest that anger dysregulation and normative beliefs are potential targets for dating abuse prevention efforts aimed at youth who have directly experienced violence. C1 [Reyes, H. Luz McNaughton; Foshee, Vangie A.] Univ N Carolina, Dept Hlth Behav, Chapel Hill, NC 29975 USA. [Fortson, Beverly L.; Valle, Linda A.; Breiding, Matthew J.; Merrick, Melissa T.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. RP Reyes, HLM (reprint author), Univ N Carolina, Dept Hlth Behav, CB 7440, Chapel Hill, NC 29975 USA. EM mcnaught@email.unc.edu FU Centers for Disease Control and Prevention (CDC) [U81/CCU409964]; CDC [13IPA130569, 13IPA1303570] FX This study was funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement No. U81/CCU409964 and by an interpersonnel agency agreement between H. Luz McNaughton Reyes and the CDC (13IPA130569) and between Vangie Foshee and the CDC (13IPA1303570). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. There are no conflicts of interest for any of the authors. NR 58 TC 3 Z9 3 U1 5 U2 30 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-2445 EI 1741-3737 J9 J MARRIAGE FAM JI J. Marriage Fam. PD AUG PY 2015 VL 77 IS 4 BP 1016 EP 1030 DI 10.1111/jomf.12200 PG 15 WC Family Studies; Sociology SC Family Studies; Sociology GA CM2CE UT WOS:000357486500014 PM 26719602 ER PT J AU Choi, MJ Morin, CA Scheftel, J Vetter, SM Smith, K Lynfield, R AF Choi, M. J. Morin, C. A. Scheftel, J. Vetter, S. M. Smith, K. Lynfield, R. CA Variant Influenza Invest Team TI Variant Influenza Associated with Live Animal Markets, Minnesota SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Influenza; human influenza A virus; H1N1 subtype ID VIRUS-INFECTION; AGRICULTURAL FAIR; SWINE; TRANSMISSION; WISCONSIN; OUTBREAK; HUMANS; USA AB Variant influenza viruses are swine-origin influenza A viruses that cause illness in humans. Surveillance for variant influenza A viruses, including characterization of exposure settings, is important because of the potential emergence of novel influenza viruses with pandemic potential. In Minnesota, we have documented variant influenza A virus infections associated with swine exposure at live animal markets. C1 [Choi, M. J.; Morin, C. A.; Scheftel, J.; Smith, K.; Lynfield, R.] Minnesota Dept Hlth, St Paul, MN USA. [Choi, M. J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Vetter, S. M.] Minnesota Dept Hlth, Publ Hlth Lab, St Paul, MN USA. RP Choi, MJ (reprint author), 625 Robert St North, St Paul, MN 51555 USA. EM whz2@cdc.gov NR 11 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD AUG PY 2015 VL 62 IS 5 BP 326 EP 330 DI 10.1111/zph.12139 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CM3QS UT WOS:000357598900002 PM 24931441 ER PT J AU Habing, GG Kessler, SE Mollenkopf, DF Wittum, TE Anderson, TC Behravesh, CB Joseph, LA Erdman, MM AF Habing, G. G. Kessler, S. E. Mollenkopf, D. F. Wittum, T. E. Anderson, T. C. Behravesh, C. Barton Joseph, L. A. Erdman, M. M. TI Distribution and Diversity of Salmonella Strains in Shipments of Hatchling Poultry, United States, 2013 SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Salmonella; poultry; zoonoses; disease outbreaks; anti-microbial resistance; chickens ID PULSENET; HATCHERY; ANIMALS; FLOCKS AB Multistate outbreaks of salmonellosis associated with live poultry contact have been occurring with increasing frequency. In 2013, multistate outbreaks of salmonellosis were traced back to exposure to live poultry, some of which were purchased at a national chain of farm stores (Farm store chain Y). This study was conducted at 36 stores of Farm store chain Y and was concurrent with the timing of exposure for the human outbreaks of salmonellosis in 2013. We used environmental swabs of arriving shipment boxes of hatchling poultry and shipment tracking information to examine the distribution, diversity and anti-microbial resistance of non-typhoidal Salmonella (NTS) across farm stores and hatcheries. Isolates recovered from shipment boxes underwent serotyping, anti-microbial resistance (AMR) testing and pulsed-field gel electrophoresis (PFGE). Postal service tracking codes from the shipment boxes were used to determine the hatchery of origin. The PFGE patterns were compared with the PFGE patterns of NTS causing outbreaks of salmonellosis in 2013. A total of 219 hatchling boxes from 36 stores in 13 states were swabbed between 15 March 2013 and 18 April 2013. NTS were recovered from 59 (27%) of 219 hatchling boxes. Recovery was not significantly associated with species of hatchlings, number of birds in the shipment box, or the presence of dead, injured or sick birds. Four of the 23 PFGE patterns and 23 of 50 isolates were indistinguishable from strains causing human outbreaks in 2013. For serotypes associated with human illnesses, PFGE patterns most frequently recovered from shipment boxes were also more frequent causes of human illness. Boxes positive for the same PFGE pattern most frequently originated from the same mail-order hatchery. Only one of 59 isolates was resistant to anti-microbials used to treat Salmonella infections in people. This study provides critical information to address recurrent human outbreaks of salmonellosis associated with mail-order hatchling poultry. C1 [Habing, G. G.; Kessler, S. E.; Mollenkopf, D. F.; Wittum, T. E.] Ohio State Univ, Columbus, OH 43235 USA. [Anderson, T. C.; Behravesh, C. Barton; Joseph, L. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Erdman, M. M.] Natl Vet Serv Lab, Ames, IA 50010 USA. RP Habing, GG (reprint author), Ohio State Univ, A100D Sisson Hall,1920 Coffee Rd, Columbus, OH 43235 USA. EM habing.4@osu.edu FU Intramural CDC HHS [CC999999] NR 16 TC 0 Z9 0 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD AUG PY 2015 VL 62 IS 5 BP 375 EP 380 DI 10.1111/zph.12157 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CM3QS UT WOS:000357598900008 PM 25236179 ER PT J AU Perea, AE Hinckley, AF Mead, PS AF Perea, A. E. Hinckley, A. F. Mead, P. S. TI Tick Bite Prophylaxis: Results From a 2012 Survey of Healthcare Providers SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Lyme disease; tickborne disease; tick bite; antibiotic prophylaxis; DocStyles ID LYME-DISEASE; PREVENTION; DOXYCYCLINE AB In a recent national survey, over 30% of healthcare providers (HCPs) reported prescribing tick bite prophylaxis in the previous year. To clarify provider practices, we surveyed HCPs to determine how frequently and for what reasons they prescribed tick bite prophylaxis. We included four questions regarding tick bite prophylaxis in the DocStyles 2012 survey, a computer-administered questionnaire of 2205 US primary care physicians, paediatricians and nurse practitioners. Responses in 14 states with high Lyme disease incidence (high LDI) were compared with responses from other states (low LDI). Overall, 56.4% of 1485 providers reported prescribing tick bite prophylaxis at least once in the previous year, including 73.9% of HCPs in high LDI and 48.2% in low LDI states. The reasons given were to prevent Lyme disease' (76.9%), patients request it' (40.4%) and to prevent other tickborne diseases' (29.4%). Among HCPs who provided prophylaxis, 45.2% did so despite feeling that it was not indicated. Given a hypothetical scenario involving a patient with an attached tick, 38.1% of HCPs from high LDI states and 15.1% from low LDI states would prescribe a single dose of doxycycline; 19.0% from high LDI states and 27.5% from low LDI states would prescribe a full course of doxycycline. HCPs prescribe tick bite prophylaxis frequently in areas where Lyme disease is rare and for tickborne diseases for which it has not been shown effective. HCPs may be unaware of current tick bite prophylaxis guidelines or find them difficult to implement. More information is needed regarding the efficacy of tick bite prophylaxis for diseases other than Lyme disease. C1 [Perea, A. E.; Hinckley, A. F.; Mead, P. S.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Perea, AE (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM aperea@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 1 Z9 1 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD AUG PY 2015 VL 62 IS 5 BP 388 EP 392 DI 10.1111/zph.12159 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CM3QS UT WOS:000357598900010 PM 25244410 ER PT J AU Sinclair, JR Washburn, F Fox, S Lankau, EW AF Sinclair, J. R. Washburn, F. Fox, S. Lankau, E. W. TI Dogs Entering the United States from Rabies-Endemic Countries, 2011-2012 SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Regulations; importation; zoonotic diseases; rabies; vaccinations; dogs AB International dog imports pose a risk because of the potential movement of disease agents, including the canine rabies virus variant which has been eliminated from the United States since 2007. US regulations require a rabies vaccination certificate for dogs arriving from rabies-endemic countries, but permit the importation of dogs that have not been adequately immunized against rabies, provided that the dogs are confined under conditions that restrict their contact with humans and other animals until they have been immunized. CDC Form 75.37, Notice to Owners and Importers of Dogs', explains the confinement requirements and serves as a binding confinement agreement with the importer. In this evaluation, we describe the characteristics of unimmunized dogs imported into the United States over a 1-year period based upon dog confinement agreements recorded at the Centers for Disease Control and Prevention (CDC) quarantine stations. Confinement agreements were issued for nearly 2800 unimmunized dogs that entered the United States during 1 June 2011-31 May 2012, the majority of which travelled to the United States by air and without any seasonal pattern in import volume. Over 60% of these animals were puppies <3months of age and included a wide variety of breeds. The dogs arrived from 81 countries, with the majority arriving from North America or Europe. Dogs placed on confinement agreements had final destinations in 49 states. California, New York, Texas, Washington and Florida received the largest number of dogs on confinement agreements. These results (which do not reflect human travel or US dog ownership data) suggest that a large portion of unimmunized dogs arrive from rabies-endemic countries for commercial, shelter and rescue purposes. Further evaluation and key stakeholder involvement are needed to assess whether the current dog importation regulations are an adequate compromise between the benefits and risks of dog importation. C1 [Sinclair, J. R.; Washburn, F.] Div Global Migrat & Quarantine, Quarantine & Border Hlth Serv Branch, Natl Ctr Emerging & Zoonot Infect Dis NCEZID, CDC, Atlanta, GA USA. [Washburn, F.] Eagle Med Serv Corp Off, San Antonio, TX USA. [Fox, S.] Affiliated Vet Specialists, Maitland, FL USA. [Lankau, E. W.] LandCow Consulting, Athens, GA USA. [Sinclair, J. R.; Washburn, F.] CDC, NCEZID, Div Global Migrat & Quarantine, Quarantine & Border Hlth Serv Branch, Atlanta, GA 30333 USA. [Washburn, F.] Eagle Med Serv Corp Off, San Antonio, TX USA. [Fox, S.] Affiliated Vet Specialists, Maitland, FL USA. [Lankau, E. W.] LandCow Consulting, Athens, GA USA. RP Sinclair, JR (reprint author), Philadelphia Int Airport, CDC Quarantine Stn Philadelphia, Terminal A West,3rd Floor, Philadelphia, PA 19153 USA. EM bwg5@cdc.gov RI Lankau, Emily/C-8057-2011 OI Lankau, Emily/0000-0002-7094-7780 FU Intramural CDC HHS [CC999999] NR 20 TC 3 Z9 3 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD AUG PY 2015 VL 62 IS 5 BP 393 EP 400 DI 10.1111/zph.12160 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CM3QS UT WOS:000357598900011 PM 25244531 ER PT J AU Dentinger, CM Jacob, K Lee, LV Mendez, HA Chotikanatis, K McDonough, PL Chico, DM De, BK Tiller, RV Traxler, RM Campagnolo, ER Schmitt, D Guerra, MA Slavinski, SA AF Dentinger, C. M. Jacob, K. Lee, L. V. Mendez, H. A. Chotikanatis, K. McDonough, P. L. Chico, D. M. De, B. K. Tiller, R. V. Traxler, R. M. Campagnolo, E. R. Schmitt, D. Guerra, M. A. Slavinski, S. A. TI Human Brucella canis Infection and Subsequent Laboratory Exposures Associated with a Puppy, New York City, 2012 SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Brucella canis; pet dogs; zoonosis; Brucella infection; brucellosis; canine brucellosis; laboratory exposure; pet breeders; personal protection; veterinary treatment ID MELITENSIS; DOGS AB Human Brucella canis infection incidence is unknown. Most identified cases are associated with pet dogs. Laboratory-acquired infections can occur following contact with Brucella spp. We identified a paediatric B.canis case, the source and other exposed persons. A 3-year-old New York City child with fever and dyspnoea was hospitalized for 48h for bronchiolitis. After her admission, blood culture grew B.canis, she was prescribed anti-microbials and recovered. B.canis was also isolated from blood of the child's pet dog; these isolates were genetically similar. The dog originated from an Iowa breeding facility which was quarantined after identification of the dog's infection. Additionally, 31 laboratory workers were exposed and subsequently monitored for symptoms; 15 completed post-exposure prophylaxis. To our knowledge, this is the first report strongly suggesting B.canis zoonotic transmission to a child in the United States, and highlights the need for coordinated control policies to minimize human illness. C1 [Dentinger, C. M.; Lee, L. V.; Slavinski, S. A.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Dentinger, C. M.; Campagnolo, E. R.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, Atlanta, GA USA. [Jacob, K.; Mendez, H. A.; Chotikanatis, K.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [McDonough, P. L.] Cornell Univ, New York State Coll Vet Med, Ithaca, NY USA. [Chico, D. M.] New York State Dept Agr & Markets, Albany, NY USA. [De, B. K.; Tiller, R. V.; Traxler, R. M.; Guerra, M. A.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA USA. [Campagnolo, E. R.] Penn Dept Hlth, Bur Epidemiol, Harrisburg, PA 17108 USA. [Schmitt, D.] Iowa Dept Agr & Land Stewardship, Des Moines, IA USA. RP Dentinger, CM (reprint author), New York City Dept Hlth & Mental Hyg, 2 Gotham Ctr CN 22A 42-09 28th St, Queens, NY 11101 USA. EM cdenting@health.nyc.gov FU Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases Cooperative Agreement [3U50CI000899-02S3]; Public Health Emergency Preparedness (PHEP) from the Centers for Disease Control and Prevention (CDC) [5U90TP000546] FX This journal article was supported by Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases Cooperative Agreement Number 3U50CI000899-02S3 and the Public Health Emergency Preparedness (PHEP) Grant Number 5U90TP000546 from the Centers for Disease Control and Prevention (CDC). NR 33 TC 3 Z9 3 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD AUG PY 2015 VL 62 IS 5 BP 407 EP 414 DI 10.1111/zph.12163 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CM3QS UT WOS:000357598900013 PM 25363807 ER PT J AU Gargano, LM Weiss, P Underwood, NL Seib, K Sales, JM Vogt, TM Rask, K Morfaw, C Murray, DL DiClemente, RJ Hughes, JM AF Gargano, Lisa M. Weiss, Paul Underwood, Natasha L. Seib, Katherine Sales, Jessica M. Vogt, Tara M. Rask, Kimberly Morfaw, Christopher Murray, Dennis L. DiClemente, Ralph J. Hughes, James M. TI School-Located Vaccination Clinics for Adolescents: Correlates of Acceptance Among Parents SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Adolescent; School-located vaccination clinics; Attitudes; Parent ID IMMUNIZATION PROGRAMS; INFLUENZA IMMUNIZATION; RESPONSE RATES; ATTITUDES; CHILDREN; VACCINES; MIDDLE; NONRESPONSE; INTENTION; COVERAGE AB Four vaccines are recommended by The Advisory Committee for Immunization Practices for adolescents: tetanus, diphtheria, acellular pertussis vaccine (Tdap), meningococcal conjugate vaccine (MCV4), human papillomavirus vaccine (HPV), and annual seasonal influenza vaccine. However, coverage among adolescents is suboptimal. School-located vaccination clinics (SLVCs) offer vaccines to students at school, increasing access. This study seeks to determine the relationship between attitudes of parents of middle- and high-school students and acceptance of SLVCs for all four adolescent recommended vaccines. We conducted a telephone and web-based survey among parents of students enrolled in six middle and five high schools in Georgia. Analyses were conducted to examine associations between parental attitudes and willingness to allow their child to be vaccinated at school. Tdap and influenza vaccine had the highest rates of parental SLVC acceptance while HPV vaccine had the lowest. Parents who accepted SLVCs had higher perceived severity of influenza, meningococcal, and HPV illnesses compared to parents who did not accept SLVC. Intention to vaccinate was associated with SLVC acceptance for Tdap [Adjusted OR (AOR) 7.38; 95 % confidence interval (CI) 2.44-22.31], MCV4 (AOR 2.97; 95 % CI 1.67-5.28), and HPV vaccines (AOR 7.61; 95 % CI 3.43-16.89). Social norms were associated with acceptance of SLVCs for influenza vaccine (AOR 1.44; 95 % CI 1.12-1.84). These findings suggest parents of adolescents are generally supportive of SLVCs for recommended adolescent vaccines. Perceived severity of illness and intention to get their adolescent vaccinated were the most consistent correlates of parental SLVC acceptance for all vaccines. Future SLVC planning should focus on perceptions of disease severity and benefits of vaccination. C1 [Gargano, Lisa M.; Weiss, Paul; Underwood, Natasha L.; Seib, Katherine; Sales, Jessica M.; Rask, Kimberly; DiClemente, Ralph J.; Hughes, James M.] Emory Univ, Atlanta, GA 30329 USA. [Vogt, Tara M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Morfaw, Christopher] East Cent Hlth Dist, Augusta, GA USA. [Murray, Dennis L.] Georgia Regents Univ, Augusta, GA USA. RP Gargano, LM (reprint author), Emory Univ, 1462 Clifton Rd Room 446, Atlanta, GA 30329 USA. EM lisa.gargano@gmail.com RI rask, kimberly/M-8001-2016 FU Centers for Disease Control and Prevention [5UO1IP000413]; National Institute of Mental Health, NIH [K01 MH085506] FX We would like to thank Dianne Miller at Emory University, Dr. Ketty M Gonzalez, District Health Director for the East Central Health District, the school district administrators, principals, teachers, and staff of participating schools. We would also like to thank our survey participants. This project is funded by the Centers for Disease Control and Prevention cooperative agreement 5UO1IP000413. Dr. Sales was supported by Grant K01 MH085506 from the National Institute of Mental Health, NIH. NR 33 TC 7 Z9 7 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD AUG PY 2015 VL 40 IS 4 BP 660 EP 669 DI 10.1007/s10900-014-9982-z PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CM0BI UT WOS:000357342800007 PM 25528325 ER PT J AU Li, Y Wang, Y Yan, D Rao, CY AF Li, Y. Wang, Y. Yan, D. Rao, C. Y. TI Self-reported hand hygiene practices, and feasibility and acceptability of alcohol-based hand rubs among village healthcare workers in Inner Mongolia, China SO JOURNAL OF HOSPITAL INFECTION LA English DT Article DE Hand hygiene; Healthcare-associated infection; Village doctors ID GUIDELINE AB Background: Good hand hygiene is critical to reduce the risk of healthcare-associated infections. Limited data are available on hand hygiene practices from rural healthcare systems in China. Aim: To assess the feasibility and acceptability of sanitizing hands with alcohol-based hand rubs (ABHRs) among Chinese village healthcare workers, and to assess their hand hygiene practice. Methods: Five hundred bottles of ABHR were given to village healthcare workers in Inner Mongolia, China. Standardized questionnaires collected information on their work load, availability, and usage of hand hygiene facilities, and knowledge, attitudes, and practices of hand hygiene. Findings: In all, 369 (64.2%) participants completed the questionnaire. Although 84.5% of the ABHR recipients believed that receiving the ABHR improved their hand hygiene practice, 78.8% of recipients would pay no more than US$1.5 out of their own pocket (actual cost US$4). The majority (77.2%) who provided medical care at patients' homes never carried hand rubs with them outside their clinics. In general, self-reported hand hygiene compliance was suboptimal, and the lowest compliance was 'before touching a patient'. Reported top three complaints with using ABHR were skin irritation, splashing, and unpleasant residual. Village doctors with less experience practised less hand hygiene. Conclusion: The overall acceptance of ABHR among the village healthcare workers is high as long as it is provided to them for free/low cost, but their overall hand hygiene practice is suboptimal. Hand hygiene education and training is needed in settings outside of traditional healthcare facilities. Published by Elsevier Ltd on behalf of the Healthcare Infection Society. C1 [Li, Y.; Rao, C. Y.] US Ctr Dis Control & Prevent, Global Dis Detect Program, Beijing, Peoples R China. [Wang, Y.; Yan, D.] Bayan Nur Infect Dis Hosp, Bayan Nur TB Dispensary, Bayan Nur, Inner Mongolia, Peoples R China. [Rao, C. Y.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Atlanta, GA USA. RP Rao, CY (reprint author), US CDC Off, Dongwai Diplomat Off, Suite 601,23 Dongzhimenwai Ave, Beijing 100600, Peoples R China. EM crao@cdc.gov FU CDC [5U2GGH000018] FX This publication was supported by the Cooperative Agreement Number 5U2GGH000018 from the CDC. NR 16 TC 0 Z9 0 U1 1 U2 5 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0195-6701 EI 1532-2939 J9 J HOSP INFECT JI J. Hosp. Infect. PD AUG PY 2015 VL 90 IS 4 BP 338 EP 343 DI 10.1016/j.jhin.2015.04.006 PG 6 WC Infectious Diseases SC Infectious Diseases GA CL3WF UT WOS:000356881600011 PM 25990195 ER PT J AU Guo, CY Tang, YG Qi, ZL Liu, Y Zhao, XR Huo, XP Li, Y Feng, Q Zhao, PH Wang, X Li, Y Wang, HF Hu, J Zhang, XJ AF Guo, Chun-yan Tang, Yi-gui Qi, Zong-li Liu, Yang Zhao, Xiang-rong Huo, Xue-ping Li, Yan Feng, Qing Zhao, Peng-hua Wang, Xin Li, Yuan Wang, Hai-fang Hu, Jun Zhang, Xin-jian TI Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus SO IMMUNOBIOLOGY LA English DT Article DE Influenza virus; H1N1; HA protein; Human tissues, Heterophilic antigen epitopes ID GUILLAIN-BARRE-SYNDROME; ADVERSE EVENTS; VACCINE; IMMUNIZATION; INFECTION; SAFETY AB To characterize the antigenic epitopes of the hemagglutinin (HA) protein of H1N1 influenza virus, a panel consisting of 84 clones of murine monoclonal antibodies (mAbs) were generated using the HA proteins from the 2009 pandemic H1N1 vaccine lysate and the seasonal influenza H1N1(A1) vaccines. Thirty-three (39%) of the 84 mAbs were found to be strain-specific, and 6(7%) of the 84 mAbs were subtype-specific. Twenty (24%) of the 84 mAbs recognized the common HA epitopes shared by 2009 pandemic H1N1, seasonal A1 (H1N1), and A3 (H3N2) influenza viruses. Twenty-five of the 84 clones recognized the common HA epitopes shared by the 2009 pandemic H1N1, seasonal A1 (H1N1) and A3 (H3N2) human influenza viruses, and H5N1 and H9N2 avian influenza viruses. We found that of the 16 (19%) clones of the 84 mAbs panel that were cross-reactive with human respiratory pathogens, 15 were made using the HA of the seasonal A1 (H1N1) virus and 1 was made using the HA of the 2009 pandemic H1N1 influenza virus. Immunohistochemical analysis of the tissue microarray (TMA) showed that 4 of the 84 mAb clones cross-reacted with human tissue (brain and pancreas). Our results indicated that the influenza virus HA antigenic epitopes not only induce type-, subtype-, and strain-specific monoclonal antibodies against influenza A virus but also cross-reactive monoclonal antibodies against human tissues. Further investigations of these cross-reactive (heterophilic) epitopes may significantly improve our understanding of viral antigenic variation, epidemics, pathophysiologic mechanisms, and adverse effects of influenza vaccines. (C) 2015 Elsevier GmbH. All rights reserved. C1 [Guo, Chun-yan; Tang, Yi-gui; Qi, Zong-li; Liu, Yang; Zhao, Xiang-rong; Huo, Xue-ping; Li, Yan; Feng, Qing; Zhao, Peng-hua; Wang, Xin; Li, Yuan; Wang, Hai-fang; Hu, Jun] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 3, Shaanxi Prov Peoples Hosp,Cent Lab,Key Lab Infect, Xian 710068, Peoples R China. [Zhang, Xin-jian] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Hu, J (reprint author), Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 3, Shaanxi Prov Peoples Hosp,Cent Lab,Key Lab Infect, Xian 710068, Peoples R China. EM hjj6562@63.com FU National Science and Technology Major Projects [2014ZX10004002-002-005] FX This research was supported by National Science and Technology Major Projects (No. 2014ZX10004002-002-005). NR 24 TC 0 Z9 0 U1 1 U2 74 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0171-2985 J9 IMMUNOBIOLOGY JI Immunobiology PD AUG PY 2015 VL 220 IS 8 BP 941 EP 946 DI 10.1016/j.imbio.2015.02.002 PG 6 WC Immunology SC Immunology GA CL0PU UT WOS:000356645400001 PM 25708705 ER PT J AU Walker, AT Williams, AJ Gary, HE Pallansch, MA Wassilak, SGF Oberste, MS AF Walker, Allison Taylor Williams, Alford J. Gary, Howard E., Jr. Pallansch, Mark A. Wassilak, Steven G. F. Oberste, M. Steven TI Effect of time at temperature on wild poliovirus titers in stool specimens SO VIROLOGY LA English DT Article DE Polio; Reverse cold chain; Specimen transport; Quality assurance AB Background: The effect of transport temperature on the viability of poliovirus in stool specimens from paralyzed cases has not been tested. Quality assurance of programmatic indicators will be necessary in the final phase of polio eradication. Objective: To estimate the effect of time at elevated temperatures on wild poliovirus titers in stool specimens. Methods: We exposed aliquots of pooled wild poliovirus type 1 specimens to elevated temperatures (27 degrees C, 31 degrees C, and 35 degrees C) for varying time periods up to 14 days. We determined the virus titer of these aliquots and created decay curves at each temperature to estimate the relationship between time at temperature and virus titer. Results: We found significantly different slopes of decay at each temperature. The negative slopes increased as the temperature increased. Conclusions: While poliovirus in stool remains relatively stable at moderately elevated temperature, transport at higher temperatures could impact sample integrity and virus isolation results. Published by Elsevier Inc. C1 [Walker, Allison Taylor; Williams, Alford J.; Gary, Howard E., Jr.; Wassilak, Steven G. F.] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Global Immunizat Div, Dekalb, GA USA. [Pallansch, Mark A.; Oberste, M. Steven] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Walker, AT (reprint author), CDC, Global Immunizat Div, Mailstop A-04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM atwalker@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD AUG PY 2015 VL 482 BP 28 EP 31 DI 10.1016/j.virol.2015.03.005 PG 4 WC Virology SC Virology GA CK7GX UT WOS:000356401900004 PM 25817402 ER PT J AU Courtney-Long, EA Carroll, DD Zhang, QC Stevens, AC Griffin-Blake, S Armour, BS Campbell, VA AF Courtney-Long, Elizabeth A. Carroll, Dianna D. Zhang, Qing C. Stevens, Alissa C. Griffin-Blake, Shannon Armour, Brian S. Campbell, Vincent A. TI Prevalence of Disability and Disability Type Among Adults - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Courtney-Long, Elizabeth A.; Carroll, Dianna D.; Zhang, Qing C.; Stevens, Alissa C.; Griffin-Blake, Shannon; Armour, Brian S.; Campbell, Vincent A.] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Carroll, Dianna D.] CDC, Commissioned Corps, US Publ Hlth Serv, Atlanta, GA 30333 USA. RP Courtney-Long, EA (reprint author), CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM ECourtneyLong@cdc.gov NR 10 TC 11 Z9 11 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 777 EP 783 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100001 PM 26225475 ER PT J AU Reagan-Steiner, S Yankey, D Jeyarajah, J Elam-Evans, LD Singleton, JA Curtis, CR MacNeil, J Markowitz, LE Stokley, S AF Reagan-Steiner, Sarah Yankey, David Jeyarajah, Jenny Elam-Evans, Laurie D. Singleton, James A. Curtis, C. Robinette MacNeil, Jessica Markowitz, Lauri E. Stokley, Shannon TI National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; HPV VACCINATION; RECOMMENDATIONS C1 [Reagan-Steiner, Sarah; Yankey, David; Jeyarajah, Jenny; Elam-Evans, Laurie D.; Singleton, James A.; Curtis, C. Robinette; Stokley, Shannon] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [MacNeil, Jessica] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Markowitz, Lauri E.] CDC, Div Sexually Transmitted Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Reagan-Steiner, S (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM sor1@cdc.gov NR 9 TC 139 Z9 139 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 784 EP 792 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100002 PM 26225476 ER PT J AU Butler, CR O'Connor, MB Lincoln, JM AF Butler, Corey R. O'Connor, Mary B. Lincoln, Jennifer M. TI Aviation-Related Wildland Firefighter Fatalities - United States, 2000-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CLIMATE-CHANGE C1 [Butler, Corey R.] CDC, Natl Inst Occupat Safety & Hlth, Western States Off, Atlanta, GA 30333 USA. [O'Connor, Mary B.; Lincoln, Jennifer M.] CDC, Alaska Pacific Off, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. RP Butler, CR (reprint author), CDC, Natl Inst Occupat Safety & Hlth, Western States Off, Atlanta, GA 30333 USA. EM crbutler@cdc.gov NR 7 TC 2 Z9 2 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 793 EP 796 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100003 PM 26225477 ER PT J AU Syamlal, G Jamal, A Mazurek, JM AF Syamlal, Girija Jamal, Ahmed Mazurek, Jacek M. TI Current Cigarette Smoking Among Workers in Accommodation and Food Services - United States, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID WORKPLACE POLICIES C1 [Syamlal, Girija; Mazurek, Jacek M.] CDC, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. [Jamal, Ahmed] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Syamlal, G (reprint author), CDC, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. EM gsyamlal@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 797 EP 801 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100004 PM 26225478 ER PT J AU McCarty, CL Angelo, K Beer, KD Cibulskas-White, K Quinn, K de Fijter, S Bokanyi, R Germain, ES Baransi, K Barlow, K Shafer, G Hanna, L Spindler, K Walz, E DiOrio, M Jackson, BR Luquez, C Mahon, BE Basler, C Curran, K Matanock, A Walsh, K Slifka, KJ Rao, AK AF McCarty, Carolyn L. Angelo, Kristina Beer, Karlyn D. Cibulskas-White, Katie Quinn, Kim de Fijter, Sietske Bokanyi, Rick Germain, Eric St. Baransi, Karen Barlow, Kevin Shafer, Gwen Hanna, Larry Spindler, Kelly Walz, Elizabeth DiOrio, Mary Jackson, Brendan R. Luquez, Carolina Mahon, Barbara E. Basler, Colin Curran, Kathryn Matanock, Almea Walsh, Kelly Slifka, Kara Jacobs Rao, Agam K. TI Large Outbreak of Botulism Associated with a Church Potluck Meal - Ohio, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [McCarty, Carolyn L.; Cibulskas-White, Katie; Quinn, Kim; de Fijter, Sietske; Bokanyi, Rick; Germain, Eric St.; Baransi, Karen; DiOrio, Mary] CDC, Ohio Dept Hlth, Atlanta, GA 30333 USA. [McCarty, Carolyn L.; Angelo, Kristina; Beer, Karlyn D.; Basler, Colin; Curran, Kathryn; Matanock, Almea; Slifka, Kara Jacobs] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Angelo, Kristina; Beer, Karlyn D.; Jackson, Brendan R.; Luquez, Carolina; Mahon, Barbara E.; Basler, Colin; Curran, Kathryn; Matanock, Almea; Walsh, Kelly; Slifka, Kara Jacobs; Rao, Agam K.] CDC, Div Foodborne Waterborne & Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Barlow, Kevin; Shafer, Gwen; Hanna, Larry; Spindler, Kelly] Fairfield Dept Hlth, Lancaster, OH USA. [Walz, Elizabeth] Fairfield Med Ctr, Lancaster, OH USA. RP McCarty, CL (reprint author), CDC, Ohio Dept Hlth, Atlanta, GA 30333 USA. EM wmw8@cdc.gov NR 3 TC 3 Z9 3 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 802 EP 803 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100005 PM 26225479 ER PT J AU Basler, C Bottichio, L Higa, J Prado, B Wong, M Bosch, S AF Basler, Colin Bottichio, Lyndsay Higa, Jeffrey Prado, Belinda Wong, Michael Bosch, Stacey TI Multistate Outbreak of Human Salmonella Poona Infections Associated with Pet Turtle Exposure - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Basler, Colin] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Basler, Colin; Bottichio, Lyndsay; Bosch, Stacey] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Higa, Jeffrey; Wong, Michael] Calif Dept Publ Hlth, Long Beach, CA USA. [Prado, Belinda] City Long Beach Dept Hlth & Human Serv, Long Beach, CA USA. RP Basler, C (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM cbasler@cdc.gov NR 2 TC 1 Z9 1 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 804 EP 804 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100006 PM 26225480 ER PT J AU Buttery, VW Kenyon, C Grunewald, S Oberste, MS Nix, WA AF Buttery, Vicki W. Kenyon, Cynthia Grunewald, Stacey Oberste, M. Steven Nix, W. Allan TI Atypical Presentations of Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6-Minnesota, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAK; A6 C1 [Buttery, Vicki W.; Kenyon, Cynthia] Univ Minnesota, Minnesota Dept Hlth, Crookston, MN 56716 USA. [Grunewald, Stacey] Univ Minnesota, Crookston, MN USA. [Oberste, M. Steven; Nix, W. Allan] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Buttery, VW (reprint author), Univ Minnesota, Minnesota Dept Hlth, Crookston, MN 56716 USA. EM vicki.buttery@state.mn.us NR 7 TC 2 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 31 PY 2015 VL 64 IS 29 BP 805 EP 805 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TS UT WOS:000359010100007 PM 26225481 ER PT J AU Carias, C Reed, C Kim, IK Foppa, IM Biggerstaff, M Meltzer, MI Finelli, L Swerdlow, DL AF Carias, Cristina Reed, Carrie Kim, Inkyu K. Foppa, Ivo M. Biggerstaff, Matthew Meltzer, Martin I. Finelli, Lyn Swerdlow, David L. TI Net Costs Due to Seasonal Influenza Vaccination - United States, 2005-2009 SO PLOS ONE LA English DT Article ID HEALTHY WORKING ADULTS; PANDEMIC INFLUENZA; CHILDREN; HOSPITALIZATION; IMPACT; AGE; IMMUNIZATION; DISEASE; BURDEN; RISK AB Background Seasonal influenza causes considerable morbidity and mortality across all age groups, and influenza vaccination was recommended in 2010 for all persons aged 6 months and above. We estimated the averted costs due to influenza vaccination, taking into account the seasonal economic burden of the disease. Methods We used recently published values for averted outcomes due to influenza vaccination for influenza seasons 2005-06, 2006-07, 2007-08, and 2008-09, and age cohorts 6 months-4 years, 5-19 years, 20-64 years, and 65 years and above. Costs were calculated according to a payer and societal perspective (in 2009 US$), and took into account medical costs and productivity losses. Results When taking into account direct medical costs (payer perspective), influenza vaccination was cost saving only for the older age group (65 >=) in seasons 2005-06 and 2007-08. Using the same perspective, influenza vaccination resulted in total costs of $US 1.7 billion (95% CI: $US 0.3-4.0 billion) in 2006-07 and $US 1.8 billion (95% CI: $US 0.1-4.1 billion) in 2008-09. When taking into account a societal perspective (and including the averted lost earnings due to premature death) averted deaths in the older age group influenced the results, resulting in cost savings for all ages combined in season 07-08. Discussion Influenza vaccination was cost saving in the older age group (65 >=) when taking into account productivity losses and, in some seasons, when taking into account medical costs only. Averted costs vary significantly per season; however, in seasons where the averted burden of deaths is high in the older age group, averted productivity losses due to premature death tilt overall seasonal results towards savings. Indirect vaccination effects and the possibility of diminished case severity due to influenza vaccination were not considered, thus the averted burden due to influenza vaccine may be even greater than reported. C1 [Carias, Cristina; Swerdlow, David L.] Ctr Dis Control & Prevent, Off Sci & Integrated Programs, Atlanta, GA 30322 USA. [Carias, Cristina] IHRC INC, Atlanta, GA USA. [Reed, Carrie; Kim, Inkyu K.; Foppa, Ivo M.; Biggerstaff, Matthew; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Kim, Inkyu K.; Foppa, Ivo M.] Battelle Mem Inst, Atlanta, GA USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA. RP Carias, C (reprint author), Ctr Dis Control & Prevent, Off Sci & Integrated Programs, Atlanta, GA 30322 USA. EM vnn9@cdc.gov FU IHRC.INC; Battelle Memorial Institute FX IHRC.INC provided support in the form of salaries for authors CC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Battelle Memorial Institute provided support in the form of salaries for authors IKK and IMF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. NR 30 TC 1 Z9 1 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 31 PY 2015 VL 10 IS 7 AR e0132922 DI 10.1371/journal.pone.0132922 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO0JY UT WOS:000358838400022 PM 26230271 ER PT J AU Rehle, T Johnson, L Hallett, T Mahy, M Kim, A Odido, H Onoya, D Jooste, S Shisana, O Puren, A Parekh, B Stover, J AF Rehle, Thomas Johnson, Leigh Hallett, Timothy Mahy, Mary Kim, Andrea Odido, Helen Onoya, Dorina Jooste, Sean Shisana, Olive Puren, Adrian Parekh, Bharat Stover, John TI A Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different Methods SO PLOS ONE LA English DT Article ID PROJECTION PACKAGE; ANTIRETROVIRAL TREATMENT; UNAIDS ESTIMATION; MODEL; INFECTION; INSIGHTS; TRENDS AB Background The interpretation of HIV prevalence trends is increasingly difficult as antiretroviral treatment programs expand. Reliable HIV incidence estimates are critical to monitoring transmission trends and guiding an effective national response to the epidemic. Methods and Findings We used a range of methods to estimate HIV incidence in South Africa: (i) an incidence testing algorithm applying the Limiting-Antigen Avidity Assay (LAg-Avidity EIA) in combination with antiretroviral drug and HIV viral load testing; (ii) a modelling technique based on the synthetic cohort principle; and (iii) two dynamic mathematical models, the EPP/Spectrum model package and the Thembisa model. Overall, the different incidence estimation methods were in broad agreement on HIV incidence estimates among persons aged 15-49 years in 2012. The assay-based method produced slightly higher estimates of incidence, 1.72% (95% CI 1.38 - 2.06), compared with the mathematical models, 1.47%(95% CI 1.23 - 1.72) in Thembisa and 1.52% (95% CI 1.43 - 1.62) in EPP/Spectrum, and slightly lower estimates of incidence compared to the synthetic cohort, 1.9% (95% CI 0.8 - 3.1) over the period from 2008 to 2012. Among youth aged 15-24 years, a declining trend in HIV incidence was estimated by all three mathematical estimation methods. Conclusions The multi-method comparison showed similar levels and trends in HIV incidence and validated the estimates provided by the assay-based incidence testing algorithm. Our results confirm that South Africa is the country with the largest number of new HIV infections in the world, with about 1 000 new infections occurring each day among adults aged 15-49 years in 2012. C1 [Rehle, Thomas; Onoya, Dorina; Jooste, Sean; Shisana, Olive] Human Sci Res Council, Cape Town, South Africa. [Rehle, Thomas; Johnson, Leigh] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa. [Hallett, Timothy] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Mahy, Mary] UNAIDS, Geneva, Switzerland. [Kim, Andrea] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Odido, Helen] UNAIDS, Pretoria, South Africa. [Shisana, Olive] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa. [Puren, Adrian] Natl Inst Communicable Dis, Johannesburg, South Africa. [Stover, John] Futures Inst, Glastonbury, CT USA. RP Rehle, T (reprint author), Human Sci Res Council, Cape Town, South Africa. EM trehle@hsrc.ac.za FU Swiss Agency for Development and Cooperation; United States Centers for Disease Control and Prevention (CDC); President's Emergency Plan for AIDS Relief (PEPFAR) through CDC [5U2GPS000570-05, 3U2GGH00357-02, U2GPS001328]; United Nations Children's Fund; South African National AIDS Council; Bill and Melinda Gates Foundation FX The 2005 survey was commissioned by the Nelson Mandela Foundation, with additional financial support from the Swiss Agency for Development and Cooperation and the United States Centers for Disease Control and Prevention (CDC). The surveys in 2008 and 2012 were mainly funded by the President's Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of Cooperative Agreement Numbers 5U2GPS000570-05, 3U2GGH00357-02 and U2GPS001328, with additional financial support from the United Nations Children's Fund, the South African National AIDS Council, and the Bill and Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 9 Z9 9 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 31 PY 2015 VL 10 IS 7 AR e0133255 DI 10.1371/journal.pone.0133255 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO0JY UT WOS:000358838400030 PM 26230949 ER PT J AU Mallett, CP Beaulieu, E Joly, MH Baras, B Lu, XH Liu, F Levine, MZ Katz, JM Innis, BL Giannini, SL AF Mallett, Corey P. Beaulieu, Edith Joly, Marie-Helene Baras, Benoit Lu, Xiuhua Liu, Feng Levine, Min Z. Katz, Jacqueline M. Innis, Bruce L. Giannini, Sandra L. TI AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes SO VACCINE LA English DT Article DE Avian H7 subtype influenza viruses; H7N1 influenza vaccine; AS03 Adjuvant System; Unprimed mouse immunogenicity model ID INFLUENZA-A VIRUS; BRITISH-COLUMBIA; HUMAN INFECTION; TRANSMISSION; FERRETS; CONJUNCTIVITIS; PATHOGENESIS; PROTECTION; CHALLENGE; OUTBREAK AB Avian H7 is one of several influenza A virus subtypes that have the potential to cause pandemics. Herein we describe preclinical results following administration of an investigational H7N1 inactivated detergent-split virion vaccine adjuvanted with the AS03 Adjuvant System. The adjuvanted H7N1 vaccine was highly immunogenic compared to the non-adjuvanted H7N1 vaccine in unprimed mice with less than 100 ng of hemagglutinin antigen per dose. In addition, compared to the non-adjuvanted vaccine, the AS03-adjuvanted H7N1 vaccine also induced robust HI and VN antibody responses that cross-reacted with other H7 subtypes, including recently emerged H7N9 virus. These H7 data from the preclinical mouse model add to the existing H5 data to suggest that AS03 adjuvant technology may be generally effective for formulating antigen-sparing detergent-split virion vaccines against intrinsically sub-immunogenic avian influenza A virus subtypes. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Mallett, Corey P.; Beaulieu, Edith; Joly, Marie-Helene] GSK Vaccines, Laval, PQ, Canada. [Baras, Benoit; Giannini, Sandra L.] GSK Vaccines, Rixensart, Belgium. [Lu, Xiuhua; Liu, Feng; Levine, Min Z.; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Innis, Bruce L.] GSK Vaccines, King Of Prussia, PA USA. RP Mallett, CP (reprint author), GSK Vaccines, Laval, PQ, Canada. EM corey.p.mallett@gsk.com; edith.r.beaulieu@gsk.com; marie-helene.a.joly@gsk.com; benoit.baras@gsk.com; xal0@cdc.gov; hdy2@cdc.gov; mwl2@cdc.gov; jmk9@cdc.gov; bruce.2.innis@gsk.com; sandra.giannini@gsk.com FU GlaxoSmithKline Biologicals S.A.; US Government FX GlaxoSmithKline Biologicals S.A. funded the mouse immunization study and the cross-reactive antibody studies performed at CDC were funded by the US Government. GlaxoSmithKline Biologicals S.A. and CDC were involved in the discussions related to the experiments and analysis of resulting data described in this publication. GlaxoSmithKline Biologicals S.A. also met all costs associated with the development and publication of this manuscript. NR 27 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 31 PY 2015 VL 33 IS 32 BP 3784 EP 3787 DI 10.1016/j.vaccine.2015.06.053 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN5HN UT WOS:000358460500002 PM 26100923 ER PT J AU Arriola, CS Mercado-Crespo, MC Rivera, B Serrano-Rodriguez, R Macklin, N Rivera, A Graitcer, S Lacen, M Bridges, CB Kennedy, ED AF Arriola, Carmen S. Mercado-Crespo, Melissa C. Rivera, Brenda Serrano-Rodriguez, Ruby Macklin, Nora Rivera, Angel Graitcer, Samuel Lacen, Mayra Bridges, Carolyn B. Kennedy, Erin D. TI Reasons for low influenza vaccination coverage among adults in Puerto Rico, influenza season 2013-2014 SO VACCINE LA English DT Article DE Influenza vaccination; Attitudes; Barriers ID PANDEMIC INFLUENZA; UNITED-STATES; INTERVENTIONS; EMPLOYEES; PHARMACY; VACCINES AB Background: Influenza vaccination is recommended annually for all persons 6 months and older. Reports of increased influenza-related morbidity and mortality during the 2013-2014 influenza season raised concerns about low adult influenza immunization rates in Puerto Rico. In order to inform public health actions to increase vaccination rates, we surveyed adults in Puerto Rico regarding influenza vaccination-related attitudes and barriers. Methods: A random-digit-dialing telephone survey (50% landline: 50% cellphone) regarding influenza vaccination, attitudes, practices and barriers was conducted November 19-25, 2013 among adults in Puerto Rico. Survey results were weighted to reflect sampling design and adjustments for non-response. Results: Among 439 surveyed, 229 completed the survey with a 52% response rate. Respondents' median age was 55 years; 18% reported receiving 2013-2014 influenza vaccination. Among 180 unvaccinated respondents, 38% reported barriers associated with limited access to vaccination, 24% reported they did not want or need influenza vaccination, and 20% reported safety concerns. Vaccinated respondents were more likely to know if they were recommended for influenza vaccination, to report greater perceived risk of influenza illness, and to report being less concerned about influenza vaccine safety (p-value <0.05). Of the 175 respondents who saw a healthcare provider (HCP) since July 1, 2013, 38% reported their HCP recommended influenza vaccination and 17% were offered vaccination. Vaccination rates were higher among adults who received a recommendation and/or offer of influenza vaccination (43% vs. 14%; p-value <0.01). Conclusions: Failure of HCP to recommend and/or offer influenza vaccination and patient attitudes (low perceived risk of influenza virus infection) may have contributed to low vaccination rates during the 2013-2014 season. HCP and public health practitioners should strongly recommend influenza vaccination and provide vaccinations during clinical encounters or refer patients for vaccination. Published by Elsevier Ltd. C1 [Arriola, Carmen S.; Mercado-Crespo, Melissa C.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Arriola, Carmen S.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Mercado-Crespo, Melissa C.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Rivera, Brenda; Serrano-Rodriguez, Ruby; Rivera, Angel] Puerto Rico Dept Hlth, San Juan, PR USA. [Macklin, Nora; Graitcer, Samuel; Lacen, Mayra; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Arriola, CS (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM wus3@cdc.gov RI Emchi, Karma/Q-1952-2016 NR 22 TC 3 Z9 3 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 31 PY 2015 VL 33 IS 32 BP 3829 EP 3835 DI 10.1016/j.vaccine.2015.06.093 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN5HN UT WOS:000358460500008 PM 26144896 ER PT J AU Denniston, MM Klevens, RM Jiles, RB Murphy, TV AF Denniston, Maxine M. Klevens, R. Monina Jiles, Ruth B. Murphy, Trudy V. TI Self-reported hepatitis A vaccination as a predictor of hepatitis A virus antibody protection in US adults: National Health and Nutrition Examination Survey 2007-2012 SO VACCINE LA English DT Article DE Hepatitis A vaccine (HepA); Self-report; Vaccination status; Serological testing; Predictive value; Concordance ID UNITED-STATES; PNEUMOCOCCAL VACCINATION; MEDICAL-RECORD; SURVEILLANCE; PREVENTION; VALIDATION; INFLUENZA; VACCINES; COVERAGE; CHILDREN AB Objectives: To estimate the predictive value of self-reported hepatitis A vaccine (HepA) receipt for the presence of hepatitis A virus (HAV) antibody (anti-HAV) from either past infection or vaccination, as an indicator of HAV protection. Methods: Using 2007-2012 National Health and Nutrition Examination Survey data, we assigned participants to 4 groups based on self-reported HepA receipt and anti-HAV results. We compared characteristics across groups and calculated three measures of agreement between self-report and serologic status (anti-HAV): percentage concordance, and positive (PPV) and negative (NPV) predictive values. Using logistic regression we investigated factors associated with agreement between self-reported vaccination status and serological results. Results: Demographic and other characteristics varied significantly across the 4 groups. Overall agreement between self-reported HepA receipt and serological results was 63.6% (95% confidence interval [Cl] 61.9-65.2); PPV and NPV of self-reported vaccination status for serological result were 47.0% (95% Cl 44.2-49.8) and 69.4% (95% Cl 67.0-71.8), respectively. Mexican American and foreign-born adults had the highest PPVs (71.5% [95% CI 65.9-76.5], and 75.8% [95% Cl 71.4-79.7]) and the lowest NPVs (21.8% [95% CI 18.5-25.4], and 20.0% [95% CI 17.2-23.11), respectively. Young (ages 20-29 years), US-born, and non-Hispanic White adults had the lowest PPVs (37.9% [95% CI 34.5-41.5], 39.1% [95% Cl, 36.0-42.3], and 39.8% [36.1-43.7]), and the highest NPVs (76.9% [95% CI 72.2-81.0,78.5% [95% CI 76.5-80.4)], and 80.6% [95% Cl 78.2-82.8), respectively. Multivariate logistic analyses found age, race/ethnicity, education, place of birth and income to be significantly associated with agreement between self-reported vaccination status and serological results. Conclusions: When assessing hepatitis A protection, self-report of not having received HepA was most likely to identify persons at risk for hepatitis A infection (no anti-HAV) among young, US-born and non-Hispanic White adults, and self-report of HepA receipt was least likely to be reliable among adults with the same characteristics. (C) 2015 Published by Elsevier Ltd. C1 [Denniston, Maxine M.; Klevens, R. Monina; Jiles, Ruth B.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Murphy, Trudy V.] Ctr Dis Control & Prevent, Vaccine Res & Policy, Off Director, Div Viral Hepatitis,Natl Ctr HIV AIDS Viral Hepat, Atlanta, GA 30329 USA. RP Denniston, MM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MailStop G-37, Atlanta, GA 30329 USA. EM mmd1@cdc.gov; rmk2@cdc.gov; rxg0@cdc.gov; nol44m@gmail.com FU Intramural CDC HHS [CC999999] NR 33 TC 1 Z9 1 U1 2 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 31 PY 2015 VL 33 IS 32 BP 3887 EP 3893 DI 10.1016/j.vaccine.2015.06.063 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN5HN UT WOS:000358460500016 PM 26116252 ER PT J AU Paternina-Caicedo, A Parashar, UD Alvis-Guzman, N De Oliveira, LH Castano-Zuluaga, A Cotes-Cantillo, K Gamboa-Garay, O Coronell-Rodriguez, W De la Hoz-Restrepo, F AF Paternina-Caicedo, Angel Parashar, Umesh D. Alvis-Guzman, Nelson De Oliveira, Lucia Helena Castano-Zuluaga, Andres Cotes-Cantillo, Karol Gamboa-Garay, Oscar Coronell-Rodriguez, Wilfrido De la Hoz-Restrepo, Fernando TI Effect of rotavirus vaccine on childhood diarrhea mortality in five Latin American countries SO VACCINE LA English DT Article DE Rotavirus vaccines; Latin America and the Caribbean; Effectiveness; Ecological ID SYSTEMATIC ANALYSIS; GLOBAL BURDEN; EFFICACY; SAFETY AB Background: The aim of this study was to estimate the association between rotavirus vaccine (RV) introduction and reduction of all-cause diarrhea death rates among children in five Latin American countries that introduced RV in 2006. Methods: Diarrhea mortality data was gathered from 2002 until 2009 from the Pan American Health Organization Mortality Database for five "vaccine adopter" countries (Brazil, El Salvador, Mexico, Nicaragua, and Panama) that introduced RV in 2006 and four "control" countries (Argentina, Chile, Costa Rica, and Paraguay) that did not introduce RV by 2009. Time trend analyses were carried out, and effects and 95% confidence intervals (Cl) were estimated. Results: Each of the five vaccine adopter countries, except Panama, showed a significant trend in declining mortality rates during the post-vaccine period from 2006 to 2009, whereas no decline was seen in control countries during these years. Furthermore, trends of reduction of all-cause diarrhea mortality in both children <1 year of age and <5 years of age were greater in the post-vaccination period compared with the pre-vaccine period in all vaccine adopter countries (except for Nicaragua), whereas in control countries, a reverse pattern was seen with greater reduction in the early years from 2002 to 2005 versus 2006-2009. An estimated total of 1777 of annual under-5 deaths were avoided in Brazil, El Salvador, Mexico, and Nicaragua during the post-vaccination period. Conclusion: All vaccine adopter countries, except Panama, showed a significant decrease in all-cause diarrhea-related deaths after RV implementation, even after adjusting for declining trends over time in diarrhea mortality. These data strongly support continuous efforts to increase vaccination coverage of RV vaccines, particularly in countries with high levels of child mortality from diarrhea. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Paternina-Caicedo, Angel; Alvis-Guzman, Nelson; Coronell-Rodriguez, Wilfrido] Univ Cartagena, Cartagena De Indias, Colombia. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [De Oliveira, Lucia Helena] World Hlth Org, Pan Amer Hlth Org, Washington, DC USA. [Cotes-Cantillo, Karol; Gamboa-Garay, Oscar; De la Hoz-Restrepo, Fernando] Univ Nacl Colombia, Bogota, Colombia. [Paternina-Caicedo, Angel; Alvis-Guzman, Nelson] Hosp Infantil Napoleon Franco Pareja, Cartagena, Colombia. [Castano-Zuluaga, Andres] Univ Catolica Norte, IDEAR Dept Econ, Antofagasta, Chile. RP Paternina-Caicedo, A (reprint author), Univ Cartagena, Cartagena De Indias, Colombia. EM angel.paternina@gmail.com RI Paternina-Caicedo, Angel/N-4496-2015 OI Paternina-Caicedo, Angel/0000-0002-6332-5174 FU COLCIENCIAS, a government entity in Colombia [304] FX A partial funding for this research was made by COLCIENCIAS grant no. 304 of 2010, a government entity in Colombia. This funding did not had any influence on the submission or writing of this manuscript. NR 17 TC 7 Z9 7 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 31 PY 2015 VL 33 IS 32 BP 3923 EP 3928 DI 10.1016/j.vaccine.2015.06.058 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN5HN UT WOS:000358460500022 PM 26116247 ER PT J AU Khetsuriani, N Tishkova, F Jabirov, S Wannemuehler, K Kamili, S Pirova, Z Mosina, L Gavrilin, E Ursu, P Drobeniuc, J AF Khetsuriani, Nino Tishkova, Faina Jabirov, Shamsidin Wannemuehler, Kathleen Kamili, Saleem Pirova, Zulfiya Mosina, Liudmila Gavrilin, Eugene Ursu, Pavel Drobeniuc, Jan TI Substantial decline in hepatitis B virus infections following vaccine introduction in Tajikistan SO VACCINE LA English DT Article DE Hepatitis B immunization; Hepatitis B vaccine impact; Hepatitis B virus infections; Prevalence of HBsAg; WHO European Region; Tajikistan ID HEALTH-CARE SETTINGS; DISEASE BURDEN; PREVALENCE; INJECTIONS; SEROEPIDEMIOLOGY; IMMUNIZATION; TRANSMISSION; UZBEKISTAN; COUNTRIES; REGION AB Background: Tajikistan, considered highly endemic area for hepatitis B virus (HBV) in a pre-vaccine era, introduced hepatitis B vaccine in 2002 and reported >= 80% coverage with three doses of hepatitis B vaccine (HepB3) since 2004. However, the impact of vaccine introduction has not been assessed. Methods: We tested residual serum specimens from a 2010 national serosurvey for vaccine-preventable diseases in Tajikistan and assessed the prevalence of HBV infection across groups defined based on the birth cohorts' routine infant hepatitis B vaccination program implementation and HepB3 coverage achieved (>= 80% versus <80%). Serosurvey participants were selected through stratified multi-stage cluster sampling among residents of all regions of Tajikistan aged 1-24 years. All specimens were tested for antibodies against HBV core antigen (anti-HBc) and those found positive were tested for HBV surface antigen (HBsAg). Seroprevalence and 95% confidence intervals were calculated and compared across subgroups using Satterthwaite-adjusted chi-square tests, accounting for the survey design and sampling weights. Results: A total of 2188 samples were tested. Prevalence of HBV infection markers was lowest among cohorts with >= 80% HepB3 coverage (ages, 1-6 years): 2.1% (95% confidence interval, 1.1-4.3%) for antiHBc, 0.4% (0.1-1.3%) for HBsAg, followed by 7.2% (4.1-12.4%) for anti-HBc and 2.1% (0.7-6.1%) for HBsAg among cohorts with <80% HepB3 coverage (ages, 7-8 years), by 12.0% (8.7-16.3%) for anti-HBc and 3.5% (2.2-5.6%) for HBsAg among children's cohorts not targeted for vaccination (ages, 9-14 years), and 28.9% (24.5-33.8%) for anti-HBc and 6.8% (4.5-10.1%) for HBsAg among unvaccinated adult cohorts (ages, 15-24 years). Differences across groups were significant (p <0.001, chi-square) for both markers. Conclusions: The present study demonstrates substantial impact of hepatitis B vaccine introduction on reducing HBV infections in Tajikistan. To achieve further progress in hepatitis B control, Tajikistan should maintain high routine coverage with hepatitis B vaccine, including birth dose. Published by Elsevier Ltd. C1 [Khetsuriani, Nino; Wannemuehler, Kathleen; Kamili, Saleem; Drobeniuc, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tishkova, Faina; Jabirov, Shamsidin] Minist Hlth Tajikistan, Dushanbe, Tajikistan. [Pirova, Zulfiya; Ursu, Pavel] WHO, Country Off, Dushanbe, Tajikistan. [Mosina, Liudmila; Gavrilin, Eugene] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. RP Khetsuriani, N (reprint author), CDC, Ctr Global Hlth, Global Immunizat Div, Immunizat South Caucasus, 9 Asatiani St, Tbilisi, Rep of Georgia. EM nck7@cdc.gov FU CDC; WHO FX Funding for the study was provided by CDC and WHO. NR 38 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 31 PY 2015 VL 33 IS 32 BP 4019 EP 4024 DI 10.1016/j.vaccine.2015.05.092 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN5HN UT WOS:000358460500036 PM 26072015 ER PT J AU Chacon, R Mirza, S Rodriguez, D Paredes, A Guzman, G Moreno, L Then, CJ Jara, J Blanco, N Bonilla, L Clara, WA Minaya, P Palekar, R Azziz-Baumgartner, E AF Chacon, Rafael Mirza, Sara Rodriguez, David Paredes, Antonio Guzman, Giselle Moreno, Lourdes Then, Cecilia J. Jara, Jorge Blanco, Natalia Bonilla, Luis Clara, Wilfrido A. Minaya, Percy Palekar, Rakhee Azziz-Baumgartner, Eduardo TI Demographic and clinical characteristics of deaths associated with influenza A(H1N1) pdm09 in Central America and Dominican Republic 2009-2010 SO BMC PUBLIC HEALTH LA English DT Article DE H1N1 2009; Pandemic influenza deaths; Central america AB Background: The demographic characteristics of pandemic influenza decedents among middle and low-income tropical countries are poorly understood. We explored the demographics of persons who died with influenza A (H1N1)pdm09 infection during 2009-2010, in seven countries in the American tropics. Methods: We used hospital-based surveillance to identify laboratory-confirmed influenza deaths in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Dominican Republic. An influenza death was defined as a person who died within two weeks of a severe acute respiratory infection (SARI) defined as sudden onset of fever > 38 degrees C, cough or sore-throat, and shortness of breath, or difficulty breathing requiring hospitalization, and who tested positive for influenza A (H1N1)pdm09 virus by real time polymerase chain reaction. We abstracted the demographic and clinical characteristics of the deceased from their medical records. Results: During May 2009-June 2010, we identified 183 influenza deaths. Their median age was 32 years (IQR 18-46 years). One-hundred and one (55 %) were female of which 20 (20 %) were pregnant and 7 (7 %) were in postpartum. One-hundred and twelve decedents (61 %) had pre-existing medical conditions, (15 % had obesity, 13 % diabetes, 11 % asthma, 8 % metabolic disorders, 5 % chronic obstructive pulmonary disease, and 10 % neurological disorders). 65 % received oseltamivir but only 5 % received it within 48 h of symptoms onset. Conclusions: The pandemic killed young adults, pregnant women and those with pre-existing medical conditions. Most sought care too late to fully benefit from oseltamivir. We recommend countries review antiviral treatment policies for people at high risk of developing complications. C1 [Chacon, Rafael; Jara, Jorge; Blanco, Natalia; Bonilla, Luis] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Mirza, Sara; Clara, Wilfrido A.; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Rodriguez, David] Minist Hlth, San Salvador, El Salvador. [Paredes, Antonio] Minist Hlth, Guatemala City, Guatemala. [Guzman, Giselle] Social Secur Costa Rica, San Jose, Costa Rica. [Moreno, Lourdes] Minist Hlth, Panama City, Panama. [Then, Cecilia J.] Minist Hlth Dominican Republ, Santo Domingo, Dominican Rep. [Minaya, Percy] Training Epidemiol & Publ Hlth Intervent Network, Guatemala City, Guatemala. [Palekar, Rakhee] Pan Amer Hlth Org, Influenza Grp, Washington, DC USA. RP Chacon, R (reprint author), Univ Valle Guatemala, Ctr Estudios Salud, 18 Av 11-95,Zona 15,Vista Hermosa 3, Guatemala City, Guatemala. EM rchaconf@gmail.com FU U.S. Centers for Disease Control and Prevention [1U01GH000028-03] FX This study was supported by the Cooperative Agreement No. 1U01GH000028-03 from the U.S. Centers for Disease Control and Prevention. None of the coauthors have any conflicts of interest to declare. The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated. NR 0 TC 0 Z9 0 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JUL 31 PY 2015 VL 15 AR 734 DI 10.1186/s12889-015-2064-z PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9DN UT WOS:000358747000003 PM 26227404 ER PT J AU dos Santos, MS Azevedo, J Menezes, APD Cordeiro, SM Escobar, EC Lima, JB Campos, LC Carvalho, MDS Reis, MG Ko, AI Reis, JN AF dos Santos, Milena Soares Azevedo, Jailton Menezes, Ana Paula de Oliveria Cordeiro, Soraia Machado Escobar, Eliane Cunegundes Lima, Josilene Borges Campos, Leila Carvalho Carvalho, Maria da Gloria S. Reis, Mitermayer G. Ko, Albert I. Reis, Joice Neves TI Temporal trends and clonal diversity of penicillin non-susceptible pneumococci from meningitis cases from 1996 to 2012, in Salvador, Brazil SO BMC INFECTIOUS DISEASES LA English DT Article DE Streptococcus pneumoniae; Antibiotic resistance; Genotype; Surveillance ID INVASIVE STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; UNITED-STATES; ANTIMICROBIAL SUSCEPTIBILITY; ADULT PATIENTS; SEROTYPE; RESISTANCE; DISEASE; PREVALENCE; EPIDEMIOLOGY AB Background: Hospital-based surveillance for pneumococcal meningitis has been conducted since January 1996 in the city of Salvador, Brazil. The purpose of this study was to describe the temporal evolution of Penicillin Non-Susceptible Streptococcus pneumoniae (PNSSP) in regards to serotype distributions and clonal diversity recovered from meningitis cases over 17 years. Methods: Broth microdilution was used to identify pneumococcal isolates that were PNSSP (Minimum Inhibitory Concentration > 0.12 mu g/ml). The annual incidence rate of meningitis cases was calculated. Serotyping was defined using multiplex polymerase chain reaction assays and quellung reaction. Genetic diversity of PNSSP isolates was assessed using both pulsed-field gel electrophoresis (PFGE) and Multilocus Sequence Typing (MLST) analyses. Results: A total of 854cerebrospinal fluid (CSF) culture pneumococcal isolates were tested by broth microdilution method and serotyped. A total of 173 (20.3 %) were penicillin non-susceptible (PNSSP) (Minimum Inhibitory concentration >= 0.12 mu g/ml). The annual incidence of meningitis cases declined from 1.65/100,000 population (1996) to 0.2/100,000 population in 2012 and the rate due to PNSSP declined 82 % over the 17-years of surveillance. PNSSP isolates were restricted to 13 serotypes, being the most common ones serotypes14 (45.1 %; 78/173), 23 F (19.1 %; 33/173), 6B (14.4 %; 25/173), 19 F (9.2 %; 16/173) and 19A (5.2 %; 9/173). Among the PNSSP isolates, 94 % had serotypes represented in the 10-valent conjugate vaccine (PCV10). The predominant serotype 14 clonal groups were identified as PFGE group A/multilocus sequence type 66 (ST66) [35.3 % (61/173)] and PFGE group GK/ST156 [4.6 % (8/173)], the latter one associated with high level resistance to penicillin and ceftriaxone. Conclusions: Our results show sustained reductions in pneumococcal meningitis cases in the Metropolitan region of Salvador from 1996 to 2012. This might reflect a beneficial impact of conjugate vaccines. Continued surveillance and further studies need to be conducted to better understanding on PCV10 vaccine impact. C1 [dos Santos, Milena Soares; Azevedo, Jailton; Menezes, Ana Paula de Oliveria; Escobar, Eliane Cunegundes; Campos, Leila Carvalho; Reis, Mitermayer G.; Ko, Albert I.; Reis, Joice Neves] Fundacao Oswaldo Cruz, Minist Saude, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil. [Cordeiro, Soraia Machado; Reis, Joice Neves] Univ Fed Bahia, Dept Anal Clin & Toxicol, Fac Farm, BR-40170115 Salvador, BA, Brazil. [dos Santos, Milena Soares] Univ Fed Bahia, Inst Multidisciplinar Saude, BR-45029094 Vitoria Da Conquista, BA, Brazil. [Menezes, Ana Paula de Oliveria] Univ Estadual Sudoeste Bahia, BR-45206190 Jequie, BA, Brazil. [Lima, Josilene Borges] Univ Fed Bahia, Inst Ciencias Saude, BR-40110902 Salvador, BA, Brazil. [Ko, Albert I.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA. [Carvalho, Maria da Gloria S.] Ctr Dis Control & Prevent, Streptococcus Lab, Atlanta, GA 30333 USA. RP Reis, JN (reprint author), Fundacao Oswaldo Cruz, Minist Saude, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil. EM joice@ufba.br RI Ko, Albert/P-2343-2015; Reis, Joice/H-9227-2013; OI Azevedo, Jailton /0000-0002-0801-8673 FU Brazilian National Research Council [482755/2010-5]; Bahia State Foundation [PP-SUS0001/2009]; PAPES [407551/2012-3]; National Institute of Health [R01 TW007303, D43 TW00919] FX This work was supported by grants from the Brazilian National Research Council (482755/2010-5), the Bahia State Foundation for the support of research (PP-SUS0001/2009), Strategic program to support health research - PAPES (#407551/2012-3), and the National Institute of Health (R01 TW007303,D43 TW00919). NR 36 TC 2 Z9 2 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JUL 30 PY 2015 VL 15 AR 302 DI 10.1186/s12879-015-1049-y PG 10 WC Infectious Diseases SC Infectious Diseases GA CN7UJ UT WOS:000358639200007 PM 26223380 ER PT J AU Jain, S Self, WH Wunderink, RG Fakhran, S Balk, R Bramley, AM Reed, C Grijalva, CG Anderson, EJ Courtney, DM Chappell, JD Qi, C Hart, EM Carroll, F Trabue, C Donnelly, HK Williams, DJ Zhu, Y Arnold, SR Ampofo, K Waterer, GW Levine, M Lindstrom, S Winchell, JM Katz, JM Erdman, D Schneider, E Hicks, LA McCullers, JA Pavia, AT Edwards, KM Finelli, L AF Jain, S. Self, W. H. Wunderink, R. G. Fakhran, S. Balk, R. Bramley, A. M. Reed, C. Grijalva, C. G. Anderson, E. J. Courtney, D. M. Chappell, J. D. Qi, C. Hart, E. M. Carroll, F. Trabue, C. Donnelly, H. K. Williams, D. J. Zhu, Y. Arnold, S. R. Ampofo, K. Waterer, G. W. Levine, M. Lindstrom, S. Winchell, J. M. Katz, J. M. Erdman, D. Schneider, E. Hicks, L. A. McCullers, J. A. Pavia, A. T. Edwards, K. M. Finelli, L. CA CDC EPIC Study Team TI Community-Acquired Pneumonia Requiring Hospitalization among US Adults SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID POLYMERASE-CHAIN-REACTION; PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNIZATION PRACTICES ACIP; ACUTE RESPIRATORY-INFECTION; MYCOPLASMA-PNEUMONIAE; CHLAMYDIA-PNEUMONIAE; ADVISORY-COMMITTEE; REACTION ASSAYS; DIAGNOSIS; VIRUSES AB BACKGROUND Community-acquired pneumonia is a leading infectious cause of hospitalization and death among U.S. adults. Incidence estimates of pneumonia confirmed radio-graphically and with the use of current laboratory diagnostic tests are needed. METHODS We conducted active population-based surveillance for community-acquired pneumonia requiring hospitalization among adults 18 years of age or older in five hospitals in Chicago and Nashville. Patients with recent hospitalization or severe immunosuppression were excluded. Blood, urine, and respiratory specimens were systematically collected for culture, serologic testing, antigen detection, and molecular diagnostic testing. Study radiologists independently reviewed chest radiographs. We calculated population-based incidence rates of community-acquired pneumonia requiring hospitalization according to age and pathogen. RESULTS From January 2010 through June 2012, we enrolled 2488 of 3634 eligible adults (68%). Among 2320 adults with radiographic evidence of pneumonia (93%), the median age of the patients was 57 years (interquartile range, 46 to 71); 498 patients (21%) required intensive care, and 52 (2%) died. Among 2259 patients who had radiographic evidence of pneumonia and specimens available for both bacterial and viral testing, a pathogen was detected in 853 (38%): one or more viruses in 530 (23%), bacteria in 247 (11%), bacterial and viral pathogens in 59 (3%), and a fungal or mycobacterial pathogen in 17 (1%). The most common pathogens were human rhinovirus (in 9% of patients), influenza virus (in 6%), and Streptococcus pneumoniae (in 5%). The annual incidence of pneumonia was 24.8 cases (95% confidence interval, 23.5 to 26.1) per 10,000 adults, with the highest rates among adults 65 to 79 years of age (63.0 cases per 10,000 adults) and those 80 years of age or older (164.3 cases per 10,000 adults). For each pathogen, the incidence increased with age. CONCLUSIONS The incidence of community-acquired pneumonia requiring hospitalization was highest among the oldest adults. Despite current diagnostic tests, no pathogen was detected in the majority of patients. Respiratory viruses were detected more frequently than bacteria. C1 [Jain, S.; Bramley, A. M.; Reed, C.; Levine, M.; Lindstrom, S.; Winchell, J. M.; Katz, J. M.; Erdman, D.; Schneider, E.; Hicks, L. A.; Finelli, L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Self, W. H.; Grijalva, C. G.; Chappell, J. D.; Carroll, F.; Williams, D. J.; Zhu, Y.; Edwards, K. M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Trabue, C.] Univ Tennessee, Hlth Sci Ctr, St Thomas Hlth, Nashville, TN USA. [Arnold, S. R.; McCullers, J. A.] Le Bonheur Childrens Hosp, Memphis, TN USA. [Arnold, S. R.; McCullers, J. A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [McCullers, J. A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Wunderink, R. G.; Anderson, E. J.; Courtney, D. M.; Qi, C.; Hart, E. M.; Donnelly, H. K.; Waterer, G. W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Fakhran, S.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. [Balk, R.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Ampofo, K.; Pavia, A. T.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA. [Waterer, G. W.] Univ Western Australia, Perth, WA 6009, Australia. RP Jain, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM bwc8@cdc.gov OI Wunderink, Richard/0000-0002-8527-4195 FU Influenza Division of the National Center for Immunizations and Respiratory Diseases FX Funded by the Influenza Division of the National Center for Immunizations and Respiratory Diseases. NR 54 TC 128 Z9 145 U1 10 U2 24 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUL 30 PY 2015 VL 373 IS 5 BP 415 EP 427 DI 10.1056/NEJMoa1500245 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CN8BO UT WOS:000358662200005 PM 26172429 ER PT J AU Gregg, EW Albright, A AF Gregg, Edward W. Albright, Ann TI Compelling evidence linking sugary drinks with diabetes SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID SWEETENED BEVERAGE CONSUMPTION; UNITED-STATES; PREVENTION; ADULTS; TRENDS C1 [Gregg, Edward W.; Albright, Ann] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30333 USA. RP Gregg, EW (reprint author), Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30333 USA. EM Edg7@cdc.gov NR 18 TC 0 Z9 0 U1 1 U2 6 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD JUL 29 PY 2015 VL 351 AR h4087 DI 10.1136/bmj.h4087 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CO2UA UT WOS:000359010900017 PM 26224343 ER PT J AU Ackelsberg, J Rakeman, J Hughes, S Petersen, J Mead, P Schriefer, M Kingry, L Hoffmaster, A Gee, JE AF Ackelsberg, Joel Rakeman, Jennifer Hughes, Scott Petersen, Jeannine Mead, Paul Schriefer, Martin Kingry, Luke Hoffmaster, Alex Gee, Jay E. TI Lack of Evidence for Plague or Anthrax on the New York City Subway SO CELL SYSTEMS LA English DT Letter C1 [Ackelsberg, Joel; Rakeman, Jennifer; Hughes, Scott] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Petersen, Jeannine; Mead, Paul; Schriefer, Martin; Kingry, Luke] Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. [Hoffmaster, Alex; Gee, Jay E.] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. RP Ackelsberg, J (reprint author), New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. EM jackelsb@health.nyc.gov OI Kingry, Luke/0000-0002-5724-2575 NR 9 TC 3 Z9 3 U1 0 U2 0 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2405-4712 EI 2405-4720 J9 CELL SYST JI Cell Syst. PD JUL 29 PY 2015 VL 1 IS 1 BP 4 EP 5 DI 10.1016/j.cels.2015.07.008 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA V47AT UT WOS:000209925400003 PM 27135683 ER PT J AU Bruxvoort, K Festo, C Cairns, M Kalolella, A Mayaya, F Kachur, SP Schellenberg, D Goodman, C AF Bruxvoort, Katia Festo, Charles Cairns, Matthew Kalolella, Admirabilis Mayaya, Frank Kachur, S. Patrick Schellenberg, David Goodman, Catherine TI Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device SO PLOS ONE LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; 6-DOSE ARTEMETHER-LUMEFANTRINE; COMBINATION THERAPY; RANDOMIZED-TRIAL; POPULATION PHARMACOKINETICS; SULFADOXINE-PYRIMETHAMINE; ANTIMALARIAL-DRUGS; RURAL TANZANIA; MEDICATION; BENFLUMETOL AB Background Self-report is the most common and feasible method for assessing patient adherence to medication, but can be prone to recall bias and social desirability bias. Most studies assessing adherence to artemisinin-based combination therapies (ACTs) have relied on self-report. In this study, we use a novel customised electronic monitoring device-termed smart blister packs-to examine the validity of self-reported adherence to artemether-lumefantrine (AL) in southern Tanzania. Methods Smart blister packs were designed to look identical to locally available AL blister packs and to record the date and time each tablet was removed from packaging. Patients obtaining AL at randomly selected health facilities and drug stores were followed up at home three days later and interviewed about each dose of AL taken. Blister packs were requested for pill count and extraction of smart blister pack data. Results Data on adherence from both self-report verified by pill count and smart blister packs were available for 696 of 1,204 patients. There was no difference between methods in the proportion of patients assessed to have completed treatment (64% and 67%, respectively). However, the percentage taking the correct number of pills for each dose at the correct times (timely completion) was higher by self-report than smart blister packs (37% vs. 24%; p<0.0001). By smart blister packs, 64% of patients completing treatment did not take the correct number of pills per dose or did not take each dose at the correct time interval. Conclusion Smart blister packs resulted in lower estimates of timely completion of AL and may be less prone to recall and social desirability bias. They may be useful when data on patterns of adherence are desirable to evaluate treatment outcomes. Improved methods of collecting self-reported data are needed to minimise bias and maximise comparability between studies. C1 [Bruxvoort, Katia; Goodman, Catherine] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1, England. [Bruxvoort, Katia; Festo, Charles; Kalolella, Admirabilis; Mayaya, Frank] Ifakara Hlth Inst, Impact Evaluat Themat Grp, Dar Es Salaam, Tanzania. [Cairns, Matthew] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England. [Kachur, S. Patrick] US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Schellenberg, David] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. RP Bruxvoort, K (reprint author), London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1, England. EM katia.bruxvoort@lshtm.ac.uk FU Bill and Melinda Gates Foundation; UK Medical Research Council (MRC); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement FX The study was funded by the Bill and Melinda Gates Foundation, through a grant to the ACT Consortium. MC is supported by a fellowship jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. KB, MC, DS, and CG are members of the LSHTM Malaria Centre. NR 38 TC 2 Z9 2 U1 3 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 27 PY 2015 VL 10 IS 7 AR e0134275 DI 10.1371/journal.pone.0134275 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN7DN UT WOS:000358594300061 PM 26214848 ER PT J AU Lansky, A Johnson, C Oraka, E Sionean, C Joyce, MP DiNenno, E Crepaz, N AF Lansky, Amy Johnson, Christopher Oraka, Emeka Sionean, Catlainn Joyce, M. Patricia DiNenno, Elizabeth Crepaz, Nicole TI Estimating the Number of Heterosexual Persons in the United States to Calculate National Rates of HIV Infection SO PLOS ONE LA English DT Article ID MEN; SEX AB Background This study estimated the proportions and numbers of heterosexuals in the United States (U.S.) to calculate rates of heterosexually acquired human immunodeficiency virus (HIV) infection. Quantifying the burden of disease can inform effective prevention planning and resource allocation. Methods Heterosexuals were defined as males and females who ever had sex with an opposite-sex partner and excluded those with other HIV risks: persons who ever injected drugs and males who ever had sex with another man. We conducted meta-analysis using data from 3 national probability surveys that measured lifetime (ever) sexual activity and injection drug use among persons aged 15 years and older to estimate the proportion of heterosexuals in the United States population. We then applied the proportion of heterosexual persons to census data to produce population size estimates. National HIV infection rates among heterosexuals were calculated using surveillance data (cases attributable to heterosexual contact) in the numerators and the heterosexual population size estimates in the denominators. Results Adult and adolescent heterosexuals comprised an estimated 86.7% (95% confidence interval: 84.1%-89.3%) of the U. S. population. The estimate for males was 84.1% (CI: 81.2%-86.9%) and for females was 89.4% (95% CI: 86.9%-91.8%). The HIV diagnosis rate for 2013 was 5.2 per 100,000 heterosexuals and the rate of persons living with diagnosed HIV infection in 2012was 104 per 100,000 heterosexuals aged 13 years or older. Rates of HIV infection were >20 times as high among black heterosexuals compared to white heterosexuals, indicating considerable disparity. Rates among heterosexual men demonstrated higher disparities than overall population rates for men. Conclusions The best available data must be used to guide decision-making for HIV prevention. HIV rates among heterosexuals in the U.S. are important additions to cost effectiveness and other data used to make critical decisions about resources for prevention of HIV infection. C1 [Lansky, Amy; Johnson, Christopher; Sionean, Catlainn; Joyce, M. Patricia; DiNenno, Elizabeth; Crepaz, Nicole] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Oraka, Emeka] Ctr Dis Control & Prevent, ICF Int, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Lansky, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM ALansky@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 27 PY 2015 VL 10 IS 7 AR e0133543 DI 10.1371/journal.pone.0133543 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN7DN UT WOS:000358594300022 PM 26214309 ER PT J AU Mitruka, K Tsertsvadze, T Butsashvili, M Gamkrelidze, A Sabelashvili, P Adamia, E Chokheli, M Drobeniuc, J Hagan, L Harris, AM Jiqia, T Kasradze, A Ko, S Qerashvili, V Sharvadze, L Tskhomelidze, I Kvaratskhelia, V Morgan, J Ward, JW Averhoff, F AF Mitruka, Kiren Tsertsvadze, Tengiz Butsashvili, Maia Gamkrelidze, Amiran Sabelashvili, Paata Adamia, Ekaterine Chokheli, Mari Drobeniuc, Jan Hagan, Liesl Harris, Aaron M. Jiqia, Tea Kasradze, Ana Ko, Stephen Qerashvili, Vakhtang Sharvadze, Lali Tskhomelidze, Irina Kvaratskhelia, Valeri Morgan, Juliette Ward, John W. Averhoff, Francisco TI Launch of a Nationwide Hepatitis C Elimination Program - Georgia, April 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VIRUS-INFECTION; RISK BEHAVIORS; HIV C1 [Mitruka, Kiren; Drobeniuc, Jan; Harris, Aaron M.; Ward, John W.; Averhoff, Francisco] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Tsertsvadze, Tengiz; Kvaratskhelia, Valeri] Infect Dis AIDS & Clin Immunol Res Ctr, Tbilisi, Rep of Georgia. [Butsashvili, Maia] Neolab, Tbilisi, Rep of Georgia. [Gamkrelidze, Amiran; Kasradze, Ana] Natl Ctr Dis Control & Publ Hlth Georgia, Minist Labor Hlth & Social Affairs Georgia, Tbilisi, Rep of Georgia. [Sabelashvili, Paata] Georgian Harm Reduct Network, Tbilisi, Rep of Georgia. [Adamia, Ekaterine; Tskhomelidze, Irina; Kvaratskhelia, Valeri] Minist Labor Hlth & Social Affairs Georgia, Tbilisi, Rep of Georgia. [Chokheli, Mari] Open Soc Fdn, Tbilisi, Rep of Georgia. [Hagan, Liesl] CDC Fdn, Tbilisi, Rep of Georgia. [Jiqia, Tea] State Regulat Agcy Med Act, Minist Labor Hlth & Social Affairs Georgia, Tbilisi, Rep of Georgia. [Ko, Stephen] Boston Univ, Sch Publ Hlth, Tbilisi, Rep of Georgia. [Sharvadze, Lali] Georgian French Joint Hepatol Clin, Tbilisi, Rep of Georgia. [Morgan, Juliette] South Caucasus CDC Off, Global Dis Detect, Div Global Hlth Protect, Tbilisi, Rep of Georgia. RP Mitruka, K (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM kmitruka@cdc.gov NR 9 TC 7 Z9 7 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 24 PY 2015 VL 64 IS 28 BP 753 EP 757 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9GX UT WOS:000358756400001 PM 26203628 ER PT J AU Kumar, T Shrivastava, A Kumar, A Laserson, KF Narain, JP Venkatesh, S Chauhan, LS Averhoff, F AF Kumar, Tripurari Shrivastava, Aakash Kumar, Anil Laserson, Kayla F. Narain, Jai P. Venkatesh, Srinivasaraghavan Chauhan, Lakhbir S. Averhoff, Francisco TI Viral Hepatitis Surveillance - India, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kumar, Tripurari; Narain, Jai P.] NCDC, India Epidem Intelligence Serv Program, Delhi, India. [Shrivastava, Aakash; Kumar, Anil] NCDC, Div Epidemiol, Delhi, India. [Laserson, Kayla F.] Ctr Global Hlth CDC India, Div Global Dis Detect, Delhi, India. [Venkatesh, Srinivasaraghavan] NCDC, Integrated Dis Surveillance Program, Delhi, India. [Chauhan, Lakhbir S.] NCDC, Off Director, Delhi, India. [Averhoff, Francisco] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Averhoff, F (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM faverhoff@cdc.gov NR 7 TC 4 Z9 4 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 24 PY 2015 VL 64 IS 28 BP 758 EP 762 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9GX UT WOS:000358756400003 PM 26203629 ER PT J AU Kulkarni, PA Duncan, MA Waters, MT Graziano, LT Vaouli, E Cseh, LF Risher, JF Orr, MF Hunte-Ceasar, TC Ellis, EM AF Kulkarni, Prathit A. Duncan, Mary Anne Waters, Michelle T. Graziano, Leah T. Vaouli, Elena Cseh, Larry F. Risher, John F. Orr, Maureen F. Hunte-Ceasar, Tai C. Ellis, Esther M. TI Severe Illness from Methyl Bromide Exposure at a Condominium Resort - US Virgin Islands, March 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kulkarni, Prathit A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Kulkarni, PA (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM pakulkarni@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 24 PY 2015 VL 64 IS 28 BP 763 EP 766 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9GX UT WOS:000358756400004 PM 26203630 ER PT J AU Watkins, LKF Sanchez, GV Albert, AP Roberts, RM Hicks, LA AF Watkins, Louise K. Francois Sanchez, Guillermo V. Albert, Alison P. Roberts, Rebecca M. Hicks, Lauri A. TI Knowledge and Attitudes Regarding Antibiotic Use Among Adult Consumers, Adult Hispanic Consumers, and Health Care Providers - United States, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID EXPECTATIONS; RATES C1 [Watkins, Louise K. Francois] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Watkins, Louise K. Francois; Sanchez, Guillermo V.; Albert, Alison P.; Roberts, Rebecca M.; Hicks, Lauri A.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Watkins, LKF (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM LFrancoisWatkins@cdc.gov NR 10 TC 2 Z9 2 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 24 PY 2015 VL 64 IS 28 BP 767 EP 770 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9GX UT WOS:000358756400005 ER PT J AU Hancock-Allen, JB Barker, L VanDyke, M Holmes, DB AF Hancock-Allen, Jessica B. Barker, Lisa VanDyke, Michael Holmes, Dawn B. TI Death Following Ingestion of an Edible Marijuana Product - Colorado, March 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hancock-Allen, Jessica B.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Hancock-Allen, Jessica B.; Barker, Lisa; VanDyke, Michael] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Holmes, Dawn B.] Denver Off Med Examiner, Denver, CO USA. RP Hancock-Allen, JB (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ydi3@cdc.gov NR 6 TC 8 Z9 8 U1 3 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 24 PY 2015 VL 64 IS 28 BP 771 EP 772 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN9GX UT WOS:000358756400006 PM 26203632 ER PT J AU Gonese, E Mapako, T Dzangare, J Rusakaniko, S Kilmarx, PH Postma, MJ Ngwende, S Mandisarisa, J Nyika, P Mvere, DA Mugurungi, O Tshimanga, M van Hulst, M AF Gonese, Elizabeth Mapako, Tonderai Dzangare, Janet Rusakaniko, Simbarashe Kilmarx, Peter H. Postma, Maarten J. Ngwende, Stella Mandisarisa, John Nyika, Ponesai Mvere, David A. Mugurungi, Owen Tshimanga, Mufuta van Hulst, Marinus TI Within-Gender Changes in HIV Prevalence among Adults between 2005/6 and 2010/11 in Zimbabwe SO PLOS ONE LA English DT Article ID AFRICA; SPREAD; RISK; MEN AB Introduction Zimbabwe has reported significant declines in HIV prevalence between 2005/06 and 2010/ 11 Demography and Health Surveys; a within-gender analysis to identify the magnitude and factors associated with this change, which can be masked, is critical for targeting interventions. Methods We analyzed change in HIV prevalence for 6,947 women and 5,848 men in the 2005/06 survey and 7,313 women and 6,250 men in 201011 surveys using 2005/06 as referent. The data was analyzed taking into consideration the survey design and therefore the svy, mean command in Stata was used in both linear and logistic regression. Results There were similar proportional declines in prevalence at national level for males (15% p=0.011) and females (16%, p=0.008). However, there were variations in decline by provincial setting, demographic variables of age, educational level and some sexual risk behaviours. In logistic regression analysis, statistically significant declines were observed among men in Manicaland, Mashonaland East and Harare (p<0.01) and for women in Manicaland, Mashonaland Central and Harare (p<0.01). Although not statistically significant, numerical increases were observed among men in Matebeleland North, Matebeleland South, Midlands and for both men and women in Bulawayo. Young women in the age range 15-34 experienced a decline in prevalence (p<0.01) while older men 30-44 had a statistically significant decline (p<0.01). Having a secondary and above education, regardless of employment status for both men and women recorded a significant decline. For sexual risk behaviours, currently in union for men and women and not in union for women there was a significant decline in prevalence. Conclusion Zimbabwe has reported a significant decline among both men and women but there are important differentials across provinces, demographic characteristics and sexual risk behaviours that suggest that the epidemic in Zimbabwe is heterogeneous and therefore interventions must be targeted in order to achieve epidemic control. C1 [Gonese, Elizabeth; Kilmarx, Peter H.; Mandisarisa, John] US Ctr Dis Control & Prevent CDC, Harare, Zimbabwe. [Mapako, Tonderai; Mvere, David A.] Natl Blood Serv Zimbabwe, Harare, Zimbabwe. [Mapako, Tonderai; Postma, Maarten J.; van Hulst, Marinus] Univ Groningen, Unit Pharmacoepidemiol & Pharmacoecon PE2, Dept Pharm, Groningen, Netherlands. [Dzangare, Janet; Nyika, Ponesai; Mugurungi, Owen] Minist Hlth & Child Welf, Harare, Zimbabwe. [Rusakaniko, Simbarashe; Tshimanga, Mufuta] Univ Zimbabwe, Dept Community Med, Harare, Zimbabwe. [Kilmarx, Peter H.] CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Ngwende, Stella] Natl Microbiol Reference Lab, Harare, Zimbabwe. [van Hulst, Marinus] Martini Hosp, Dept Clin Pharm & Toxicol, Groningen, Netherlands. RP Gonese, E (reprint author), US Ctr Dis Control & Prevent CDC, Harare, Zimbabwe. EM hol9@cdc.gov OI Kilmarx, Peter/0000-0001-6464-3345 FU United States Agency for International Development (USAID) through the MEASURE DHS project [GPO-C-00-08-00008-00]; Centers for Disease Control and Prevention (CDC); T-REC project - European Union [266194] FX This research is carried out with support provided by the United States Agency for International Development (USAID) through the MEASURE DHS project (#GPO-C-00-08-00008-00) and the Centers for Disease Control and Prevention (CDC) under the President's Emergency Plan for AIDS Relief. T. Mapako was supported by T-REC project funded by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 266194. NR 25 TC 2 Z9 2 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 24 PY 2015 VL 10 IS 7 AR e0129611 DI 10.1371/journal.pone.0129611 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN7NT UT WOS:000358622000005 PM 26208134 ER PT J AU Maama-Maime, LB Mareka, M Ershova, JV Tlali, TE Kao, K Phalatse, M Polansky, L Beres, LK Letsie, M Holtz, TH AF Maama-Maime, Llang B. Mareka, Mathabo Ershova, Julia V. Tlali, Thabong E. Kao, Kekeletso Phalatse, Mamakhetha Polansky, Lauren Beres, Laura K. Letsie, Moselinyane Holtz, Timothy H. TI Antituberculosis Drug Resistance Survey in Lesotho, 2008-2009: Lessons Learned SO PLOS ONE LA English DT Article ID TUBERCULOSIS AB Setting Drug resistance is an increasing threat to tuberculosis (TB) control worldwide. The World Health Organization advises monitoring for drug resistance, with either ongoing surveillance or periodic surveys. Methods The antituberculosis drug resistance survey was conducted in Lesotho in 2008-2009. Basic demographic and TB history information was collected from individuals with positive sputum smear results at 17 diagnostic facilities. Additional sputum sample was sent to the national TB reference laboratory for culture and drug susceptibility testing. Results Among 3441 eligible smear-positive persons, 1121 (32.6%) were not requested to submit sputum for culture. Among 2320 persons submitted sputum, 1164 (50.2%) were not asked for clinical information or did not have valid sputum samples for testing. In addition, 445/ 2320 (19.2%) were excluded from analysis because of other laboratory or data management reasons. Among 984/3441 (28.6%) persons who had data available for analysis, MDR-TB was present in 24/773 (3.1%) of new and 25/195 (12.8%) of retreatment TB cases. Logistical, operational and data management challenges affected survey results. Conclusion MDR-TB is prevalent in Lesotho, but limitations reduced the reliability of our findings. Multiple lessons learned during this survey can be applied to improve the next drug resistance survey in Lesotho and other resource constrained countries may learn how to avoid these bottlenecks. C1 [Maama-Maime, Llang B.] Minist Hlth, Natl TB Programme, Maseru, Lesotho. [Mareka, Mathabo; Tlali, Thabong E.; Kao, Kekeletso; Phalatse, Mamakhetha] Minist Hlth, Lab Serv, Maseru, Lesotho. [Ershova, Julia V.; Polansky, Lauren; Holtz, Timothy H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Beres, Laura K.] Emory Univ, Atlanta, GA 30322 USA. [Letsie, Moselinyane] Minist Hlth, Dis Control, Maseru, Lesotho. RP Ershova, JV (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM jhe3@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 24 PY 2015 VL 10 IS 7 AR e0133808 DI 10.1371/journal.pone.0133808 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN7NT UT WOS:000358622000149 PM 26207630 ER PT J AU Wortham, JM Gray, J Verani, J Contreras, CL Bernart, C Moscoso, F Moir, JC Marroquin, ELR Castellan, R Arvelo, W Lindblade, K McCracken, JP AF Wortham, Jonathan M. Gray, Jennifer Verani, Jennifer Lucia Contreras, Carmen Bernart, Chris Moscoso, Fabiola Carlos Moir, Juan Reyes Marroquin, Emma Lissette Castellan, Rigoberto Arvelo, Wences Lindblade, Kim McCracken, John P. TI Using Standardized Interpretation of Chest Radiographs to Identify Adults with Bacterial Pneumonia-Guatemala, 2007-2012 SO PLOS ONE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; CHILDHOOD PNEUMONIA; GAMBIAN CHILDREN; HERD-IMMUNITY; DIAGNOSIS; ETIOLOGY; DISEASE; ANTIGEN AB Background Bacterial pneumonia is a leading cause of illness and death worldwide, but quantifying its burden is difficult due to insensitive diagnostics. Although World Health Organization (WHO) protocol standardizes pediatric chest radiograph (CXR) interpretation for epidemiologic studies of bacterial pneumonia, its validity in adults is unknown. Methods Patients (age >= 15 years) admitted with respiratory infections to two Guatemalan hospitals between November 2007 and March 2012 had urine and nasopharyngeal/oropharyngeal (NP/OP) swabs collected; blood cultures and CXR were also performed at physician clinical discretion. 'Any bacterial infection' was defined as a positive urine pneumococcal antigen test, isolation of a bacterial pneumonia pathogen from blood culture, or detection of an atypical bacterial pathogen by polymerase chain reaction (PCR) of nasopharyngeal/oropharyngeal (NP/OP) specimens. 'Viral infection' was defined as detection of viral pathogens by PCR of NP/OP specimens. CXRs were interpreted according to the WHO protocol as having 'endpoint consolidation', 'other infiltrate', or 'normal' findings. We examined associations between bacterial and viral infections and endpoint consolidation. Findings Urine antigen and/or blood culture results were available for 721 patients with CXR interpretations; of these, 385 (53%) had endpoint consolidation and 253 (35%) had other infiltrate. Any bacterial infection was detected in 119 (17%) patients, including 106 (89%) pneumococcal infections. Any bacterial infection (Diagnostic Odds Ratio [DOR] = 2.9; 95% confidence Interval (CI): 1.3-7.9) and pneumococcal infection (DOR = 3.4; 95% CI: 1.5-10.0) were associated with 'endpoint consolidation', but not 'other infiltrate' (DOR = 1.7; 95% CI: 0.7-4.9, and 1.7; 95% CI: 0.7-4.9 respectively). Viral infection was not significantly associated with 'endpoint consolidation', 'other infiltrate,' or 'normal' findings. Interpretation 'Endpoint consolidation' was associated with 'any bacterial infection,' specifically pneumococcal infection. Therefore, endpoint consolidation may be a useful surrogate for studies measuring the impact of interventions, such as conjugate vaccines, against bacterial pneumonia. C1 [Wortham, Jonathan M.; Verani, Jennifer; Arvelo, Wences; Lindblade, Kim] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Gray, Jennifer; Lucia Contreras, Carmen; Bernart, Chris; Moscoso, Fabiola; Castellan, Rigoberto; McCracken, John P.] Univ Valle Guatemala, Guatemala City, Guatemala. [Carlos Moir, Juan; Reyes Marroquin, Emma Lissette] Minist Salud Publ & Asistencia Social, Guatemala City, Guatemala. RP Wortham, JM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM vij5@cdc.gov FU U.S Centers for Disease Control and Prevention (CDC) [UO1 GH000028-02] FX This work was supported in part by Cooperative Agreement Number UO1 GH000028-02 from the U.S Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 24 PY 2015 VL 10 IS 7 AR e0133257 DI 10.1371/journal.pone.0133257 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN7NT UT WOS:000358622000072 PM 26207918 ER PT J AU Barcelona, JM Calvert, HG Cance, JD Pitt-Barnes, S Wargo, J Castelli, DM AF Barcelona, Jeanne M. Calvert, Hannah G. Cance, Jessica Duncan Pitt-Barnes, Seraphine Wargo, Jane Castelli, Darla M. TI Implementation Facilitators and Barriers of the Presidential Youth Fitness Program SO RESEARCH QUARTERLY FOR EXERCISE AND SPORT LA English DT Meeting Abstract C1 [Barcelona, Jeanne M.; Calvert, Hannah G.; Cance, Jessica Duncan; Castelli, Darla M.] Univ Texas Austin, Austin, TX 78712 USA. [Pitt-Barnes, Seraphine] Ctr Dis Control & Prevent, Atlanta, GA USA. EM jeannemarita@gmail.com NR 0 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0270-1367 EI 2168-3824 J9 RES Q EXERCISE SPORT JI Res. Q. Exerc. Sport PD JUL 22 PY 2015 VL 86 SU 2 SI SI BP A40 EP A41 PG 2 WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences SC Social Sciences - Other Topics; Psychology; Sport Sciences GA CP2ZD UT WOS:000359745700095 ER PT J AU Calvert, HG Barcelona, JM Cance, JD Pitt-Barnes, S Wargo, J Castelli, DM AF Calvert, Hannah G. Barcelona, Jeanne M. Cance, Jessica Duncan Pitt-Barnes, Seraphine Wargo, Jane Castelli, Darla M. TI Year 1: The Presidential Youth Fitness Program Degree of Implementation SO RESEARCH QUARTERLY FOR EXERCISE AND SPORT LA English DT Meeting Abstract C1 [Calvert, Hannah G.; Barcelona, Jeanne M.; Cance, Jessica Duncan; Castelli, Darla M.] Univ Texas Austin, Austin, TX 78712 USA. [Pitt-Barnes, Seraphine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wargo, Jane] Presidential Youth Fitness Program, Bloomington, IN USA. EM hannah.calvert@utexas.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0270-1367 EI 2168-3824 J9 RES Q EXERCISE SPORT JI Res. Q. Exerc. Sport PD JUL 22 PY 2015 VL 86 SU 2 SI SI BP A64 EP A64 PG 1 WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences SC Social Sciences - Other Topics; Psychology; Sport Sciences GA CP2ZD UT WOS:000359745700149 ER PT J AU Michael, SL Pitt-Barnes, S AF Michael, Shannon L. Pitt-Barnes, Seraphine TI Mediators of Adult Support and Adolescent Physical Activity SO RESEARCH QUARTERLY FOR EXERCISE AND SPORT LA English DT Meeting Abstract C1 [Michael, Shannon L.; Pitt-Barnes, Seraphine] Ctr Dis Control & Prevent, Atlanta, GA USA. EM sot2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0270-1367 EI 2168-3824 J9 RES Q EXERCISE SPORT JI Res. Q. Exerc. Sport PD JUL 22 PY 2015 VL 86 SU 2 SI SI BP A82 EP A83 PG 2 WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences SC Social Sciences - Other Topics; Psychology; Sport Sciences GA CP2ZD UT WOS:000359745700191 ER PT J AU van der Mars, H Dauenhauer, B Stellino, MB Carson, RL Rukavina, P Dolittle, S Kulinna, PH Lorenz, KA Stylianou, M Metzler, MW Hunt, K Marquis, J Trent, M Pitt-Barnes, S McMullen, JM Bulger, SM Elliott, E Jones, E Brusseau, TA Centeio, EE McCaughtry, N Webster, CA Weaver, RG Russ, L Beets, MW Vazou, S McKenzie, TL Barett-Williams, S Lounsbery, MAF AF van der Mars, Hans Dauenhauer, Brian Stellino, Megan Babkes Carson, Russell L. Rukavina, Paul Dolittle, Sarah Kulinna, Pamela H. Lorenz, Kent A. Stylianou, Michalis Metzler, Michael W. Hunt, Kari Marquis, Jenee Trent, Margaret Pitt-Barnes, Seraphine McMullen, Jaimie M. Bulger, Sean M. Elliott, Eloise Jones, Emily Brusseau, Timothy A. Centeio, Erin E. McCaughtry, Nathan Webster, Collin A. Weaver, Robert G. Russ, Laura Beets, Michael W. Vazou, Spyridoula McKenzie, Thomas L. Barett-Williams, Shannon Lounsbery, Monica A. F. TI First Flight of the Fledgling: Advancing Comprehensive School Physical Activity Program Research SO RESEARCH QUARTERLY FOR EXERCISE AND SPORT LA English DT Meeting Abstract C1 [van der Mars, Hans; Dauenhauer, Brian; Stellino, Megan Babkes] Univ No Colorado, Greeley, CO 80639 USA. [Carson, Russell L.; Rukavina, Paul; Dolittle, Sarah] Adelphi Univ, Garden City, NY USA. [Kulinna, Pamela H.; Lorenz, Kent A.; Stylianou, Michalis] Arizona State Univ, Tempe, AZ 85287 USA. [Metzler, Michael W.; Hunt, Kari; Marquis, Jenee; Trent, Margaret] Georgia State Univ, Atlanta, GA 30303 USA. [Pitt-Barnes, Seraphine] Ctr Dis Control & Prevent, Atlanta, GA USA. [McMullen, Jaimie M.] Univ Limerick, Limerick, Ireland. [Bulger, Sean M.; Elliott, Eloise; Jones, Emily] W Virginia Univ, Morgantown, WV 26506 USA. [Brusseau, Timothy A.] Univ Utah, Salt Lake City, UT 84112 USA. [Centeio, Erin E.; McCaughtry, Nathan] Wayne State Univ, Detroit, MI 48202 USA. [Webster, Collin A.; Weaver, Robert G.; Russ, Laura; Beets, Michael W.] Univ S Carolina, Columbia, SC 29208 USA. [Vazou, Spyridoula] Iowa State Univ, Ames, IA USA. [McKenzie, Thomas L.] San Diego State Univ, San Diego, CA 92182 USA. [Barett-Williams, Shannon] Georgia State Coll Educ, Atlanta, GA USA. [Lounsbery, Monica A. F.] Univ Nevada Las Vegas, Las Vegas, NV USA. RI Weaver, Robert/A-3489-2017 OI Weaver, Robert/0000-0001-5889-974X NR 0 TC 0 Z9 0 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0270-1367 EI 2168-3824 J9 RES Q EXERCISE SPORT JI Res. Q. Exerc. Sport PD JUL 22 PY 2015 VL 86 SU 2 SI SI BP A89 EP A90 PG 2 WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences SC Social Sciences - Other Topics; Psychology; Sport Sciences GA CP2ZD UT WOS:000359745700208 ER PT J AU Bowers, JR Kitchel, B Driebe, EM MacCannell, DR Roe, C Lemmer, D de Man, T Rasheed, JK Engelthaler, DM Keim, P Limbago, BM AF Bowers, Jolene R. Kitchel, Brandon Driebe, Elizabeth M. MacCannell, Duncan R. Roe, Chandler Lemmer, Darrin de Man, Tom Rasheed, J. Kamile Engelthaler, David M. Keim, Paul Limbago, Brandi M. TI Genomic Analysis of the Emergence and Rapid Global Dissemination of the Clonal Group 258 Klebsiella pneumoniae Pandemic SO PLOS ONE LA English DT Article ID COMPLETE NUCLEOTIDE-SEQUENCE; STRAIN CAUSING OUTBREAKS; BETA-LACTAMASE; CARBAPENEM RESISTANCE; MULTIDRUG-RESISTANCE; ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; EFFLUX PUMP; MARR FAMILY; 1ST REPORT AB Multidrug-resistant Klebsiella pneumoniae producing the KPC carbapenemase have rapidly spread throughout the world, causing severe healthcare-associated infections with limited antimicrobial treatment options. Dissemination of KPC-producing K. pneumoniae is largely attributed to expansion of a single dominant strain, ST258. In this study, we explore phylogenetic relationships and evolution within ST258 and its clonal group, CG258, using whole genome sequence analysis of 167 isolates from 20 countries collected over 17 years. Our results show a common ST258 ancestor emerged from its diverse parental clonal group around 1995 and likely acquired bla(KPC) prior to dissemination. Over the past two decades, ST258 has remained highly clonal despite diversity in accessory elements and divergence in the capsule polysaccharide synthesis locus. Apart from the large recombination event that gave rise to ST258, few mutations set it apart from its clonal group. However, one mutation occurs in a global transcription regulator. Characterization of outer membrane protein sequences revealed a profile in ST258 that includes a truncated OmpK35 and modified OmpK37. Our work illuminates potential genomic contributors to the pathogenic success of ST258, helps us better understand the global dissemination of this strain, and identifies genetic markers unique to ST258. C1 [Bowers, Jolene R.; Driebe, Elizabeth M.; Roe, Chandler; Lemmer, Darrin; Engelthaler, David M.; Keim, Paul] Translat Genom Res Inst, Flagstaff, AZ 86001 USA. [Kitchel, Brandon; MacCannell, Duncan R.; de Man, Tom; Rasheed, J. Kamile; Limbago, Brandi M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Bowers, JR (reprint author), Translat Genom Res Inst, Flagstaff, AZ 86001 USA. EM jbowers@tgen.org FU National Institutes of Health [R01AI090782] FX This work was supported by award number R01AI090782 from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 77 TC 16 Z9 16 U1 3 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 21 PY 2015 VL 10 IS 7 AR e0133727 DI 10.1371/journal.pone.0133727 PG 24 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN6LZ UT WOS:000358547600137 PM 26196384 ER PT J AU Jones, BE Sauer, B Jones, MM Campo, J Damal, K He, T Ying, J Greene, T Goetz, MB Neuhauser, MM Hicks, LA Samore, MH AF Jones, Barbara Ellen Sauer, Brian Jones, Makoto M. Campo, Jose Damal, Kavitha He, Tao Ying, Jian Greene, Tom Goetz, Matthew Bidwell Neuhauser, Melinda M. Hicks, Lauri A. Samore, Matthew H. TI Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population A Cross-sectional Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID UNITED-STATES; TRACT INFECTIONS; DISEASES SOCIETY; ACUTE BRONCHITIS; AMBULATORY-CARE; ADULTS; AMERICA; TRENDS; RATES AB Background: Despite efforts to reduce antibiotic prescribing for acute respiratory infections (ARIs), information on factors that drive prescribing is limited. Objective: To examine trends in antibiotic prescribing in the Veterans Affairs population over an 8-year period and to identify patient, provider, and setting sources of variation. Design: Retrospective, cross-sectional study. Setting: All emergency departments and primary and urgent care clinics in the Veterans Affairs health system. Participants: All patient visits between 2005 and 2012 with primary diagnoses of ARIs that typically had low proportions of bacterial infection. Patients with infections or comorbid conditions that indicated antibiotic use were excluded. Measurements: Overall antibiotic prescription; macrolide prescription; and patient, provider, and setting characteristics extracted from the electronic health record. Results: The proportion of 1 million visits with ARI diagnoses that resulted in antibiotic prescriptions increased from 67.5% in 2005 to 69.2% in 2012 (P < 0.001). The proportion of macrolide antibiotics prescribed increased from 36.8% to 47.0% (P < 0.001). Antibiotic prescribing was highest for sinusitis (adjusted proportion, 86%) and bronchitis (85%) and varied little according to fever, age, setting, or comorbid conditions. Substantial variation was identified in prescribing at the provider level: The 10% of providers who prescribed the most antibiotics did so during at least 95% of their ARI visits, and the 10% who prescribed the least did so during 40% or fewer of their ARI visits. Limitation: Some clinical data that may have influenced the prescribing decision were missing. Conclusion: Veterans with ARIs commonly receive antibiotics, regardless of patient, provider, or setting characteristics. Macrolide use has increased, and substantial variation was identified in antibiotic prescribing at the provider level. C1 Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. Univ Utah, Salt Lake City, UT 84112 USA. Vet Affairs Kansas City Hlth Care Syst, Kansas City, MO USA. Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. US Dept Vet Affairs, Hines, IL USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Jones, BE (reprint author), George E Wahlen Dept Vet Affairs Med Ctr, Decision Enhancement & Analyt Sci Ctr, 500 Foothill Blvd,Mail Code 182, Salt Lake City, UT 84148 USA. EM barbara.jones@hsc.utah.edu OI Goetz, Matthew/0000-0003-4542-992X FU U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention FX U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention. NR 32 TC 7 Z9 8 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 21 PY 2015 VL 163 IS 2 BP 73 EP + DI 10.7326/M14-1933 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA CN4NS UT WOS:000358407500014 PM 26192562 ER PT J AU Liddell, AM Davey, RT Mehta, AK Varkey, JB Kraft, CS Tseggay, GK Badidi, O Faust, AC Brown, KV Suffredini, AF Barrett, K Wolcott, MJ Marconi, VC Lyon, GM Weinstein, GL Weinmeister, K Sutton, S Hazbun, M Albarino, CG Reed, Z Cannon, D Stroher, U Feldman, M Ribner, BS Lane, HC Fauci, AS Uyeki, TM AF Liddell, Allison M. Davey, Richard T., Jr. Mehta, Aneesh K. Varkey, Jay B. Kraft, Colleen S. Tseggay, Gebre K. Badidi, Oghenetega Faust, Andrew C. Brown, Katia V. Suffredini, Anthony F. Barrett, Kevin Wolcott, Mark J. Marconi, Vincent C. Lyon, G. Marshall, III Weinstein, Gary L. Weinmeister, Kenney Sutton, Shelby Hazbun, Munir Albarino, Cesar G. Reed, Zachary Cannon, Debi Stroeher, Ute Feldman, Mark Ribner, Bruce S. Lane, H. Clifford Fauci, Anthony S. Uyeki, Timothy M. TI Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID WEST-AFRICA; SIERRA-LEONE AB Background: More than 26 000 cases of Ebola virus disease (EVD) have been reported in western Africa, with high mortality. Several patients have been medically evacuated to hospitals in the United States and Europe. Detailed clinical data are limited on the clinical course and management of patients with EVD outside western Africa. Objective: To describe the clinical characteristics and management of a cluster of patients with EVD, including the first cases of Ebola virus (EBOV) infection acquired in the United States. Design: Retrospective clinical case series. Setting: Three U.S. hospitals in September and October 2014. Patients: First imported EVD case identified in the United States and 2 secondary EVD cases acquired in the United States in critical care nurses who cared for the index case patient. Measurements: Clinical recovery, EBOV RNA level, resolution of Ebola viremia, survival with discharge from hospital, or death. Results: The index patient had high EBOV RNA levels, developed respiratory and renal failure requiring critical care support, and died. Both patients with secondary EBOV infection had nonspecific signs and symptoms and developed moderate illness; EBOV RNA levels were moderate, and both patients recovered. Limitation: Both surviving patients received uncontrolled treatment with multiple investigational agents, including convalescent plasma, which limits generalizability of the results. Conclusion: Early diagnosis, prompt initiation of supportive medical care, and moderate clinical illness likely contributed to successful outcomes in both survivors. The inability to determine the potential benefit of investigational therapies and the effect of patient-specific factors that may have contributed to less severe illness highlight the need for controlled clinical studies of these interventions, especially in the setting of a high level of supportive medical care. C1 [Liddell, Allison M.] Texas Hlth Presbyterian Hosp Dallas, Dallas, TX 75231 USA. NIH, Ctr Clin, Bethesda, MD 20892 USA. Emory Univ, Sch Med, Atlanta, GA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. US Army, Med Res Inst Infect Dis, Frederick, MD USA. RP Liddell, AM (reprint author), Texas Hlth Presbyterian Hosp Dallas, 8230 Walnut Hill Lane,Suite 308, Dallas, TX 75231 USA. EM allisonliddell@texashealth.org RI Mehta, Aneesh/B-8054-2012; Marconi, Vincent/N-3210-2014 OI Mehta, Aneesh/0000-0002-6552-9162; Marconi, Vincent/0000-0001-8409-4689 FU National Center for Advancing Translational Sciences of the National Institutes of Health [Atlanta Clinical and Translational Science Institute] [UL1TR000454] FX The authors thank the entire staff of Texas Health Presbyterian Hospital Dallas, particularly Edward Goodman, MD, Beverly Dickson, MD, Otto Javier Marquez-Kerguelen, MD, Sarah S. Way, MD, Mark Till, MD, Glen Owen, MD, Bruce Wall, MD, Elaine Whitaker, MD, David Gonzales, MD, and Sarita Sharma-Louys, MD; Texas Health Resources for its unwavering support; William Dorman and Samantha Tostenson of the U.S. Army Medical Research Institute of Infectious Diseases for technical work on RT-PCR assays; David Henderson, MD, and Tara Palmore, MD, of the National Institutes of Health Clinical Center for their infection control leadership; the nursing and hospital epidemiology staff at the National Institutes of Health Clinical Center for their outstanding patient care; Anne Winkler, MD, of the Emory University Hospital Serious Communicable Diseases Unit for coordinating the convalescent plasma collection and administration; all of the members of the Emory University Hospital Serious Communicable Diseases Unit team for their outstanding contributions to the patient's excellent care (supported by award UL1TR000454 from the National Center for Advancing Translational Sciences of the National Institutes of Health [Atlanta Clinical and Translational Science Institute]); and Tara Sealy, MS, Aridith Gibbons, and Bobbie Rae Erickson, MPH, of the Centers for Disease Control and Prevention for their technical support on the laboratory assays. NR 19 TC 40 Z9 41 U1 2 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 21 PY 2015 VL 163 IS 2 BP 81 EP + DI 10.7326/M15-0530 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA CN4NS UT WOS:000358407500015 PM 25961438 ER PT J AU Liu, YC Posey, DL Cetron, MS Painter, JA AF Liu, Yecai Posey, Drew L. Cetron, Martin S. Painter, John A. TI Tuberculosis Incidence in Immigrants and Refugees Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Liu, Yecai; Posey, Drew L.; Cetron, Martin S.; Painter, John A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Liu, YC (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. NR 4 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 21 PY 2015 VL 163 IS 2 BP 150 EP 151 DI 10.7326/L15-5111-2 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CN4NS UT WOS:000358407500032 PM 26192572 ER PT J AU Steinhardt, LC Onikpo, F Kouame, J Piercefield, E Lama, M Deming, MS Rowe, AK AF Steinhardt, Laura C. Onikpo, Faustin Kouame, Julien Piercefield, Emily Lama, Marcel Deming, Michael S. Rowe, Alexander K. TI Predictors of health worker performance after Integrated Management of Childhood Illness training in Benin: a cohort study SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Health worker performance; Case management; IMCI; Benin; Quality of care; Child health ID MALARIA CASE-MANAGEMENT; CLUSTER RANDOMIZED-TRIAL; UNCOMPLICATED MALARIA; ARTEMETHER-LUMEFANTRINE; MULTICOUNTRY EVALUATION; SICK CHILDREN; FACILITIES; QUALITY; STRATEGY; GUIDELINES AB Background: Correct treatment of potentially life-threatening illnesses (PLTIs) in children under 5 years, such as malaria, pneumonia, and diarrhea, can substantially reduce mortality. The Integrated Management of Childhood Illness (IMCI) strategy has been shown to improve treatment of child illnesses, but multiple studies have shown that gaps in health worker performance remain after training. To better understand factors related to health worker performance, we analyzed 9,330 patient consultations in Benin from 2001-2002, after training one of the first cohorts of 32 health workers in IMCI. Methods: With data abstracted from patient registers specially designed for IMCI-trained health workers, we examined associations between health facility-, health worker-, and patient-level factors and 10 case-management outcomes for PLTIs. Results: Altogether, 63.6 % of children received treatment for all their PLTIs in accordance with IMCI guidelines, and 77.8 % received life-saving treatment (i.e., clinically effective treatment, even if not exactly in accordance with IMCI guidelines). Performance of individual health workers varied greatly, from 15-88 % of patients treated correctly, on average. Multivariate regression analyses identified several factors that might have influenced case-management quality, many outside a manager's direct control. Younger health workers significantly outperformed older ones, and infants received better care than older children. Children with danger signs, those with more complex illnesses, and those with anemia received worse care. Health worker supervision was associated with improved performance for some outcomes. Conclusions: A variety of factors, some outside the direct control of program managers, can influence health worker practices. An understanding of these influences can help inform the development of strategies to improve performance. C1 [Steinhardt, Laura C.; Kouame, Julien; Piercefield, Emily; Rowe, Alexander K.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Onikpo, Faustin] Minist Publ Hlth, Direct Dept Sante Publ Oueme & Plateau, Porto Novo, Benin. [Lama, Marcel] Africare Benin, Porto, Benin. [Deming, Michael S.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Steinhardt, LC (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30329 USA. EM iyp6@cdc.gov NR 49 TC 0 Z9 0 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD JUL 21 PY 2015 VL 15 AR 276 DI 10.1186/s12913-015-0910-4 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CN2TQ UT WOS:000358275200002 PM 26194895 ER PT J AU Fang, J George, MG Hong, YL Loustalot, F AF Fang, Jing George, Mary G. Hong, Yuling Loustalot, Fleetwood TI Use of Aspirin for Prevention of Recurrent Atherosclerotic Cardiovascular Disease Among Adults-20 States and the District of Columbia, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AMERICAN-HEART-ASSOCIATION; SECONDARY PREVENTION; THERAPY; UPDATE C1 [Fang, Jing; George, Mary G.; Hong, Yuling; Loustalot, Fleetwood] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Fang, J (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jfang@cdc.gov NR 10 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 17 PY 2015 VL 64 IS 27 BP 733 EP 737 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN4IT UT WOS:000358394500001 PM 26182190 ER PT J AU Fox, JB Shaw, FE AF Fox, Jared B. Shaw, Frederic E. TI Receipt of Selected Clinical Preventive Services by Adults - United States, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CARE; COVERAGE C1 [Fox, Jared B.] CDC, Off Hlth Syst Collaborat, Off Associate Director Policy, Atlanta, GA 30333 USA. [Shaw, Frederic E.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Fox, JB (reprint author), CDC, Off Hlth Syst Collaborat, Off Associate Director Policy, Atlanta, GA 30333 USA. EM jaredfox@cdc.gov NR 8 TC 5 Z9 5 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 17 PY 2015 VL 64 IS 27 BP 738 EP 742 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN4IT UT WOS:000358394500002 PM 26182191 ER PT J AU Newman, N Jones, C Page, E Ceballos, D Oza, A AF Newman, Nick Jones, Camille Page, Elena Ceballos, Diana Oza, Aalok TI Investigation of Childhood Lead Poisoning from Parental Take-Home Exposure from an Electronic Scrap Recycling Facility - Ohio, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHILDREN C1 [Newman, Nick] NIOSH, Cincinnad Childrens Hosp Pediat Environm Hlth Spe, CDC, Atlanta, GA 30329 USA. [Jones, Camille] NIOSH, City Cincinnati Hlth Dept Childhood Lead Poisonin, CDC, Atlanta, GA 30329 USA. [Page, Elena; Ceballos, Diana; Oza, Aalok] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Atlanta, GA 30329 USA. RP Page, E (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Atlanta, GA 30329 USA. EM epage@cdc.gov FU NCATS NIH HHS [UL1 TR001425, UL1 TR000077] NR 9 TC 4 Z9 4 U1 4 U2 14 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 17 PY 2015 VL 64 IS 27 BP 743 EP 745 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN4IT UT WOS:000358394500003 PM 26182192 ER PT J AU Nielsen, SJ Rhodes, DG Frenk, SM AF Nielsen, Samara Joy Rhodes, Donna G. Frenk, Steven M. TI Percentage of Adults Aged >= 20 Years Who Consumed Dairy on a Given Day, by Amount and Sex - National Health and Nutrition Examination Survey, United States, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Nielsen, Samara Joy] CDC, Natl Hlth & Nutr Examinat Survey Data, Hyattsville, MD USA. CDC, US Dept Hlth & Human Serv, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Nielsen, SJ (reprint author), CDC, Natl Hlth & Nutr Examinat Survey Data, Hyattsville, MD USA. EM snielsen@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 17 PY 2015 VL 64 IS 27 BP 751 EP 751 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN4IT UT WOS:000358394500005 ER PT J AU El Omeiri, N Azziz-Baumgartner, E Clara, W Guzman-Saborio, G Elas, M Mejia, H Molina, IB De Molto, Y Mirza, S Widdowson, MA Ropero-Alvarez, AM AF El Omeiri, Nathalie Azziz-Baumgartner, Eduardo Clara, Wilfrido Guzman-Saborio, Guiselle Elas, Miguel Mejia, Homer Molina, Ida Berenice De Molto, Yadira Mirza, Sara Widdowson, Marc-Alain Ropero-Alvarez, Alba Maria TI Pilot to evaluate the feasibility of measuring seasonal influenza vaccine effectiveness using surveillance platforms in Central-America, 2012 SO BMC PUBLIC HEALTH LA English DT Article DE Adults; Children; Effectiveness; Hospitalization; Influenza; Vaccine ID LABORATORY-CONFIRMED INFLUENZA; HOSPITALIZATIONS; CHILDREN; DESIGNS AB Background: Since 2004, the uptake of seasonal influenza vaccines in Latin America and the Caribbean has markedly increased. However, vaccine effectiveness (VE) is not routinely measured in the region. We assessed the feasibility of using routine surveillance data collected by sentinel hospitals to estimate influenza VE during 2012 against laboratory-confirmed influenza hospitalizations in Costa-Rica, El Salvador, Honduras and Panama. We explored the completeness of variables needed for VE estimation. Methods: We conducted the pilot case-control study at 23 severe acute respiratory infections (SARI) surveillance hospitals. Participant inclusion criteria included children 6 months-11 years and adults >= 60 years targeted for vaccination and hospitalized for SARI during January-December 2012. We abstracted information needed to estimate target group specific VE (i.e., date of illness onset and specimen collection, preexisting medical conditions, 2012 and 2011 vaccination status and date, and pneumococcal vaccination status for children and adults) from SARI case-reports and for children <= 9 years, inquired about the number of annual vaccine doses given. A case was defined as an influenza virus positive by RT-PCR in a person with SARI, while controls were RT-PCR negative. We recruited 3 controls per case from the same age group and month of onset of symptoms. Results: We identified 1,186 SARI case-patients (342 influenza cases; 849 influenza-negative controls), of which 994 (84 %) had all the information on key variables sought. In 893 (75 %) SARI case-patients, the vaccination status field was missing in the SARI case-report forms and had to be completed using national vaccination registers (36 %), vaccination cards (30 %), or other sources (34 %). After applying exclusion criteria for VE analyses, 541 (46 %) SARI case-patients with variables necessary for the group-specific VE analyses were selected (87 cases, 236 controls among children; 64 cases, 154 controls among older adults) and were insufficient to provide precise regional estimates (39 % for children and 25 % for adults of minimum sample size needed). Conclusions: Sentinel surveillance networks in middle income countries, such as some Latin American and Caribbean countries, could provide a simple and timely platform to estimate regional influenza VE annually provided SARI forms collect all necessary information. C1 [El Omeiri, Nathalie] Taskforce Global Hlth Inc, Training Programs Epidemiol & Publ Hlth Intervent, Decatur, GA 30030 USA. [Azziz-Baumgartner, Eduardo; Clara, Wilfrido; Mirza, Sara; Widdowson, Marc-Alain] US Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Guzman-Saborio, Guiselle] Costa Rican Social Secur Fund Caja Costarricense, San Jose, Costa Rica. [Elas, Miguel] Minist Hlth, San Salvador, El Salvador. [Mejia, Homer; Molina, Ida Berenice] Minist Hlth, Tegucigalpa, Honduras. [De Molto, Yadira] Minist Hlth, Panama City, Panama. [Ropero-Alvarez, Alba Maria] Pan Amer Hlth Org, Comprehens Family Immunizat Project, Washington, DC USA. [El Omeiri, Nathalie] Ancon, Pan Amer Hlth Org, Panama City, Panama. RP El Omeiri, N (reprint author), Taskforce Global Hlth Inc, Training Programs Epidemiol & Publ Hlth Intervent, Decatur, GA 30030 USA. EM elomeirin@paho.org FU Centers for Disease Control and Prevention (CDC) through The Pan American Health Organization (PAHO); TEPHINET, a program of the Task Force for Global Health, Inc. FX This work was supported by a grant from the Centers for Disease Control and Prevention (CDC) through The Pan American Health Organization (PAHO) and TEPHINET, a program of the Task Force for Global Health, Inc. NR 30 TC 3 Z9 3 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JUL 17 PY 2015 VL 15 AR 673 DI 10.1186/s12889-015-2001-1 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM8RG UT WOS:000357969100001 PM 26184659 ER PT J AU Toda, K Reef, S Tsuruoka, M Iijima, M Dang, TH Duong, TH Nguyen, VC Nguyen, TH AF Toda, Kohei Reef, Susan Tsuruoka, Miyuki Iijima, Makiko Thanh Huyen Dang Thi Hong Duong Van Cuong Nguyen Tran Hien Nguyen TI Congenital rubella syndrome (CRS) in Vietnam 2011-2012-CRS epidemic after rubella epidemic in 2010-2011 SO VACCINE LA English DT Article DE Congenital rubella syndrome; CRS; CRS surveillance; Rubella; RCV; Routine EPI immunization ID PREGNANCY AB Background: Rubella is endemic in Vietnam with epidemics occurring every 4-5 years. In 2011, Vietnam experienced the large nationwide rubella epidemic. During the rubella epidemic, many infants born with congenital rubella syndrome (CRS) were identified and reported from the neonatal units or cardiology departments of the national hospitals. To understand the burden of CRS, National Expanded Program on Immunization (NEPI) established sentinel CRS surveillance system. Method: Three national paediatric hospitals in Hanoi and Ho Chi Minh City (HCMC) were selected as CRS sentinel surveillance sites. Blood specimens from the infants were collected for rubella specific IgM and ELISA testing was performed at the national measles and rubella laboratory. Results: From January 2011 to December 2012, 424 infants with suspected CRS were identified and reported. Among them 406 (96%) had specimens obtained, 284 (70%) cases were IgM positive including 279 laboratory confirmed CRS and 5 Congenital Rubella Infection (CRI). 13 cases were clinically confirmed and 127 (30%) were discarded. Total 292 infants were confirmed as CRS. Of the 292 infants with CRS, 69% of mothers had a history of "fever and rash" during pregnancy, of which 85% was in the first trimester. The most common clinical defects were congenital heart disease and cataract(s). However, 81.9% of the infants had a combination of major and minor signs and symptoms. Low birth weight in full term infants with confirmed CRS was observed in 114 infants (39%). Conclusions: The newly established CRS sentinel surveillance system documented the significant burden of CRS in Vietnam and provided evidence to the policy makers for the introduction of rubella containing vaccine (RCV) into Vietnam. This report highlights the importance of countries with rubella epidemic to establish CRS surveillance rapidly in order to support the introduction of RCV into the routine Expanded Programme on Immunization (EPI) immunization. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Toda, Kohei; Tsuruoka, Miyuki; Iijima, Makiko] WHO Country Off, Hanoi, Vietnam. [Reef, Susan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thanh Huyen Dang; Thi Hong Duong; Van Cuong Nguyen; Tran Hien Nguyen] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. RP Toda, K (reprint author), WHO Country Off, Hanoi, Vietnam. EM todak@wpro.who.int FU World Health Organization [001] NR 13 TC 2 Z9 2 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 17 PY 2015 VL 33 IS 31 BP 3673 EP 3677 DI 10.1016/j.vaccine.2015.06.035 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN0HZ UT WOS:000358096000011 PM 26087296 ER PT J AU Schiffer, JM Chen, LG Dalton, S Niemuth, NA Sabourin, CL Quinn, CP AF Schiffer, Jarad M. Chen, Ligong Dalton, Shannon Niemuth, Nancy A. Sabourin, Carol L. Quinn, Conrad P. TI Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans SO VACCINE LA English DT Article DE Bacillus anthracis; Anthrax; Anthrax Vaccine Adsorbed; AVA; Biothrax; Correlates of protection; Clinical trial; Non-clinical trial; Animal model ID LETHAL TOXIN NEUTRALIZATION; INTRAMUSCULAR INJECTION; INHALATION ANTHRAX; RHESUS MACAQUES; ANTIGEN; SAFETY; MODEL; IGG; 1ST AB Anthrax Vaccine Adsorbed (AVA, BioThrax(R)) is approved for use in humans as a priming series of 3 intramuscular (i.m.) injections (0, 1, 6 months; 3-IM) with boosters at 12 and 18 months, and annually thereafter for those at continued risk of infection. A reduction in AVA booster frequency would lessen the burden of vaccination, reduce the cumulative frequency of vaccine associated adverse events and potentially expand vaccine coverage by requiring fewer doses per schedule. Because human inhalation anthrax studies are neither feasible nor ethical, AVA efficacy estimates are determined using cross-species bridging of immune correlates of protection (COP) identified in animal models. We have previously reported that the AVA 3-IM priming series provided high levels of protection in non-human primates (NHP) against inhalation anthrax for up to 4 years after the first vaccination. Penalized logistic regressions of those NHP immunological data identified that anti-protective antigen (anti-PA) IgG concentration measured just prior to infectious challenge was the most accurate single COP. In the present analysis, cross-species logistic regression models of this COP were used to predict probability of survival during a 43 month study in humans receiving the current 3-dose priming and 4 boosters (12, 18,30 and 42 months; 7-IM) and reduced schedules with boosters at months 18 and 42 only (5-IM), or at month 42 only (4-IM). All models predicted high survival probabilities for the reduced schedules from 7 to 43 months. The predicted survival probabilities for the reduced schedules were 86.8% (4-IM) and 95.8% (5-IM) at month 42 when antibody levels were lowest. The data indicated that 4-IM and 5-IM are both viable alternatives to the current AVA pre-exposure prophylaxis schedule. Published by Elsevier Ltd. C1 [Schiffer, Jarad M.; Quinn, Conrad P.] Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. [Chen, Ligong; Dalton, Shannon] AREF, Decatur, GA 30033 USA. [Niemuth, Nancy A.; Sabourin, Carol L.] Battelle Mem Inst, Columbus, OH 43210 USA. RP Schiffer, JM (reprint author), MS D01,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM jschiffer@cdc.gov FU Centers for Disease Control and Prevention; DHHS CDC [200-2000-10065] FX This study was funded by the Centers for Disease Control and Prevention. Battelle was funded under DHHS CDC contract number 200-2000-10065. NR 23 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 17 PY 2015 VL 33 IS 31 BP 3709 EP 3716 DI 10.1016/j.vaccine.2015.05.091 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CN0HZ UT WOS:000358096000017 PM 26072016 ER PT J AU Rein, DB Wittenborn, JS Smith, BD Liffmann, DK Ward, JW AF Rein, David B. Wittenborn, John S. Smith, Bryce D. Liffmann, Danielle K. Ward, John W. TI The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis C; cost-effectivenes; pharmacoeconomics; public health; antiviral treatment ID INJECTION-DRUG USERS; GENOTYPE 1 INFECTION; SERVICES TASK-FORCE; UNITED-STATES; LIVER-TRANSPLANTATION; TREATMENT OUTCOMES; SCREENING-PROGRAM; POPULATION; THERAPY; COHORT AB Background. New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. Methods. We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective. Results. Compared to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir (SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR. Conclusions. New treatments are cost-effectiveness per person treated, but pent-up demand for treatment may create challenges for financing. C1 [Rein, David B.; Wittenborn, John S.; Liffmann, Danielle K.] Univ Chicago, NORC, Dept Publ Hlth, Atlanta, GA 30305 USA. [Smith, Bryce D.; Ward, John W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Rein, DB (reprint author), Univ Chicago, NORC, Dept Publ Hlth, 3520 Piedmont Rd NE,Ste 225, Atlanta, GA 30305 USA. EM rein-david@norc.org FU National Foundation for the Centers for Disease Control and Prevention, Inc. MOU [527-11 SC] FX This research was supported by a contract award from the National Foundation for the Centers for Disease Control and Prevention, Inc. MOU # 527-11 SC. Through an award to NORC that did not provide support for this analysis or manuscript, D. B. R., J. S. W., and D. K. L. have received unrestricted research funding related to hepatitis C from Gilead Sciences, Inc. NR 73 TC 42 Z9 42 U1 6 U2 33 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2015 VL 61 IS 2 BP 157 EP 168 DI 10.1093/cid/civ220 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MD UT WOS:000359342500004 PM 25778747 ER PT J AU Campbell, AP Guthrie, KA Englund, JA Farney, RM Minerich, EL Kuypers, J Corey, L Boeckh, M AF Campbell, Angela P. Guthrie, Katherine A. Englund, Janet A. Farney, Robert M. Minerich, Elisa L. Kuypers, Jane Corey, Lawrence Boeckh, Michael TI Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE respiratory virus infection; hematopoietic cell transplant; pneumonia ID TIME RT-PCR; SYNCYTIAL VIRUS; RHINOVIRUS INFECTION; PARAINFLUENZA VIRUS; RECIPIENTS; CHILDREN; GUIDELINES; TRACT; METAPNEUMOVIRUS; CORONAVIRUS AB Background. The management of respiratory virus infections prior to hematopoietic cell transplant (HCT) is difficult. We examined whether respiratory virus detection before HCT influenced the requirement for bronchoscopy, hospitalization, and overall survival following HCT. Methods. Pre-HCT and weekly post-HCT nasal washes were collected through day 100 from patients with and without symptoms. Samples were tested by multiplex polymerase chain reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human metapneumovirus, adenovirus, and human rhinoviruses, corona-viruses, and bocavirus. Results. Of 458 patients, 116 (25%) had respiratory viruses detected pre-HCT. Overall, patients with viruses detected pre-HCT had fewer days alive and out of the hospital and lower survival at day 100 (adjusted hazard ratio [aHR], 2.4; 95% confidence interval [ CI], 1.3-4.5; P = .007) than patients with negative samples; this risk was also present with rhinovirus alone (aHR for mortality, 2.6; 95% CI, 1.2-5.5; P = .01). No difference in bronchoscopy incidence was seen in patients with and without respiratory viruses (aHR, 1.3; 95% CI,.8-2.0; P = .32). In symptomatic patients, those with respiratory viruses detected had increased overall mortality compared with patients without viruses detected (unadjusted HR, 3.5; 95% CI, 1.0-12.1; P = .05); among asymptomatic patients, detection of respiratory viruses was not associated with increased mortality. Conclusions. These data support routine testing for respiratory viruses among symptomatic patients before HCT, and delay of transplant with virus detection when feasible, even for detection of rhinovirus alone. Further study is needed to address whether asymptomatic patients should undergo screening for respiratory virus detection before HCT. C1 [Campbell, Angela P.; Guthrie, Katherine A.; Englund, Janet A.; Farney, Robert M.; Minerich, Elisa L.; Kuypers, Jane; Corey, Lawrence; Boeckh, Michael] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Campbell, Angela P.; Englund, Janet A.; Minerich, Elisa L.] Seattle Childrens Hosp, Seattle, WA USA. [Campbell, Angela P.; Englund, Janet A.; Kuypers, Jane; Corey, Lawrence; Boeckh, Michael] Univ Washington, Seattle, WA 98195 USA. RP Campbell, AP (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS-A32, Atlanta, GA 30329 USA. EM app4@cdc.gov FU National Institutes of Health [K23HL091059, L40AI071572, HL081595, HL93294, CA18029, CA15704]; Seattle Children's Center for Clinical and Translational Research; Clinical and Translational Science Award program [ULI RR025014] FX A. P. C. received funding from the National Institutes of Health (grant numbers K23HL091059 and L40AI071572) and from the Seattle Children's Center for Clinical and Translational Research and the Clinical and Translational Science Award program (grant number ULI RR025014). M. B. received research support from the National Institutes of Health (grant numbers HL081595 and HL93294). The clinical database was supported by funding from the National Institutes of Health (grant numbers CA18029 and CA15704). NR 20 TC 10 Z9 10 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2015 VL 61 IS 2 BP 192 EP 202 DI 10.1093/cid/civ272 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MD UT WOS:000359342500009 PM 25847977 ER PT J AU Pathela, P Braunstein, SL Blank, S Shepard, C Schillinger, JA AF Pathela, Preeti Braunstein, Sarah L. Blank, Susan Shepard, Colin Schillinger, Julia A. TI The High Risk of an HIV Diagnosis Following a Diagnosis of Syphilis: A Population-level Analysis of New York City Men SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE syphilis; HIV incidence ID PREEXPOSURE PROPHYLAXIS; TRANSGENDER WOMEN; SEX; SEROCONVERSION; INFECTION; FLORIDA; TRIAL; ASSAY AB Background. Epidemiologic studies have shown that syphilis is associated with risk for human immunodeficiency virus (HIV) infection. We used population-level syphilis and HIV data to quantify HIV incidence among men following primary or secondary (P&S) syphilis diagnoses and identify the highest-risk subgroups for intensified prevention, such as pre-exposure prophylaxis with antiretroviral medications. Methods. Male cases reported to theNewYorkCityHIV/AIDS and Sexually TransmittedDisease (STD) surveillance registries were matched using a deterministic algorithm. We measured HIV incidence following P&S syphilis diagnosed between 2000 and June 2010 and identified risk factors for HIV infection using Cox proportional hazards models. Results. Of 2805 men with syphilis contributing 11 714 person-years of follow-up, 423 (15.1%) acquired HIV; annual incidence was 3.61%(95% confidence interval [CI], 3.27%, 3.97%). HIV incidence was high among: men who have sex with men (MSM) (5.56%, 95% CI, 5.02%-6.13%); males with secondary compared with primary syphilis (4.10% vs 2.64%, P<.0001); and males diagnosed with another bacterial STD after syphilis (7.89%, 95% CI, 6.62%-9.24%). Conclusions. HIV incidence among men diagnosed with syphilis is high; one in 20 MSM were diagnosed with HIV within a year. Our data have implications for syphilis and HIV screening and may be useful for further targeting HIV-negative populations for pre-exposure prophylaxis. C1 [Pathela, Preeti; Blank, Susan; Schillinger, Julia A.] Bur Sexually Transmitted Dis Control, New York, NY USA. [Braunstein, Sarah L.; Shepard, Colin] Bur HIV AIDS Prevent & Control, New York City Dept Hlth & Mental Hyg, New York, NY USA. [Blank, Susan; Schillinger, Julia A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Pathela, P (reprint author), New York City Dept Hlth & Mental Hyg, Gotham Ctr, 42-09 28th St, Queens, NY 11101 USA. EM ppathela@health.nyc.gov NR 24 TC 11 Z9 11 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2015 VL 61 IS 2 BP 281 EP 287 DI 10.1093/cid/civ289 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MD UT WOS:000359342500022 PM 25870333 ER PT J AU Hoots, BE Finlayson, TJ Wejnert, C Paz-Bailey, G AF Hoots, Brooke E. Finlayson, Teresa J. Wejnert, Cyprian Paz-Bailey, Gabriela CA NHBS Study Grp TI Early Linkage to HIV Care and Antiretroviral Treatment among Men Who Have Sex with Men-20 Cities, United States, 2008 and 2011 SO PLOS ONE LA English DT Article ID WHITE MEN; DISPARITIES; PREVENTION; THERAPY; RISK; INFECTION; BEHAVIORS; SURVEILLANCE; TRANSMISSION; MEDICATION AB Early linkage to care and antiretroviral (ARV) treatment are associated with reduced HIV transmission. Male-to-male sexual contact represents the largest HIV transmission category in the United States; men who have sex with men (MSM) are an important focus of care and treatment efforts. With the release of the National HIV/AIDS Strategy and expanded HIV treatment guidelines, increases in early linkage to care and ARV treatment are expected. We examined differences in prevalence of early linkage to care and ARV treatment among HIV-positive MSM between 2008 and 2011. Data are from the National HIV Behavioral Surveillance System, which monitors behaviors among populations at high risk of HIV infection in 20 U.S. cities with high AIDS burden. MSM were recruited through venue-based, time-space sampling. Prevalence ratios comparing 2011 to 2008 were estimated using linear mixed models. Early linkage was defined as an HIV clinic visit within 3 months of diagnosis. ARV treatment was defined as use at interview. Prevalence of early linkage to care was 79% (187/236) in 2008 and 83% (241/291) in 2011. In multivariable analysis, prevalence of early linkage did not differ significantly between years overall (P = 0.44). Prevalence of ARV treatment was 69% (790/1,142) in 2008 and 79% (1,049/1,336) in 2001. In multivariable analysis, ARV treatment increased overall (P = 0.0003) and among most sub-groups. Black MSM were less likely than white MSM to report ARV treatment (P = 0.01). While early linkage to care did not increase significantly between 2008 and 2011, ARV treatment increased among most sub-groups. Progress is being made in getting MSM on HIV treatment, but more efforts are needed to decrease disparities in ARV coverage. C1 [Hoots, Brooke E.; Finlayson, Teresa J.; Wejnert, Cyprian; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP Hoots, BE (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. EM vie2@cdc.gov NR 24 TC 2 Z9 2 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 15 PY 2015 VL 10 IS 7 AR e0132962 DI 10.1371/journal.pone.0132962 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1RL UT WOS:000358197600190 PM 26176856 ER PT J AU Perelygina, L Adebayo, A Metcalfe, M Icenogle, J AF Perelygina, Ludmila Adebayo, Adebola Metcalfe, Maureen Icenogle, Joseph TI Differences in Establishment of Persistence of Vaccine and Wild Type Rubella Viruses in Fetal Endothelial Cells SO PLOS ONE LA English DT Article ID UNKNOWINGLY PREGNANT-WOMEN; DOUBLE-STRANDED-RNA; NEGATIVE-STRAND; FOLLOW-UP; REPLICATION; INTERFERON; ELIMINATION; ANTIBODIES; AMERICA; MEASLES AB Both wild type (WT) and vaccine rubella virus (RV) can pass through the placenta to infect a human fetus, but only wtRV routinely causes pathology. To investigate possible reasons for this, we compared establishment of persistence of wtRV and RA27/3 vaccine strains in fetal endothelial cells. We showed that yields of RA27/3 and wtRV were similar after the first round of replication, but then only vaccine-infected cultures went through a crisis characterized by partial cell loss and gradual decline of virus titer followed by recovery and establishment of persistent cultures with low levels of RA27/3 secretion. We compared various steps of virus replication, but we were unable to identify changes, which might explain the 2-log difference in RA27/3 and wtRV yields in persistently infected cultures. Whole genome sequencing did not reveal selection of virus variants in either the wtRV or RA27/3 cultures. Quantitative single-cell analysis of RV replication by in situ hybridization detected, on average, 1-4 copies of negative-strand RNA and similar to 50 copies of positive-strand genomic RNA in cells infected with both vaccine and WT viruses. The distinct characteristics of RA27/3 replication were the presence of large amounts of negative-strand RV RNA and RV dsRNA at the beginning of the crisis and the accumulation of high amounts of genomic RNA in a sub-population of infected cells during crisis and persistence. These results suggest that RA27/3 can persist in fetal endothelial cells, but the characteristics of persistence and mechanisms for the establishment and maintenance of persistence are different from wtRV. C1 [Perelygina, Ludmila; Adebayo, Adebola; Metcalfe, Maureen; Icenogle, Joseph] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Icenogle, J (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM jci1@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by core funding from the Centers for Disease Control and Prevention. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 15 PY 2015 VL 10 IS 7 AR e0133267 DI 10.1371/journal.pone.0133267 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1RL UT WOS:000358197600237 PM 26177032 ER PT J AU Zhang, XY Holt, JB Yun, SM Lu, H Greenlund, KJ Croft, JB AF Zhang, Xingyou Holt, James B. Yun, Shumei Lu, Hua Greenlund, Kurt J. Croft, Janet B. TI Validation of Multilevel Regression and Poststratification Methodology for Small Area Estimation of Health Indicators From the Behavioral Risk Factor Surveillance System SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE American Community Survey; Behavioral Risk Factor Surveillance System; external validation; Missouri County-Level Study; multilevel regression and poststratification; small area estimation ID CIGARETTE-SMOKING PREVALENCE; COUNTY-LEVEL PREVALENCE; PRIORITIZING COMMUNITIES; DISEASE PREVALENCE; OBESITY; MODEL; MASSACHUSETTS; INFERENCE; VARIABLES; COVERAGE AB Small area estimation is a statistical technique used to produce reliable estimates for smaller geographic areas than those for which the original surveys were designed. Such small area estimates (SAEs) often lack rigorous external validation. In this study, we validated our multilevel regression and poststratification SAEs from 2011 Behavioral Risk Factor Surveillance System data using direct estimates from 2011 Missouri County-Level Study and American Community Survey data at both the state and county levels. Coefficients for correlation between model-based SAEs and Missouri County-Level Study direct estimates for 115 counties in Missouri were all significantly positive (0.28 for obesity and no health-care coverage, 0.40 for current smoking, 0.51 for diabetes, and 0.69 for chronic obstructive pulmonary disease). Coefficients for correlation between model-based SAEs and American Community Survey direct estimates of no health-care coverage were 0.85 at the county level (811 counties) and 0.95 at the state level. Unweighted and weighted model-based SAEs were compared with direct estimates; unweighted models performed better. External validation results suggest that multilevel regression and poststratification model-based SAEs using single-year Behavioral Risk Factor Surveillance System data are valid and could be used to characterize geographic variations in health indictors at local levels (such as counties) when high-quality local survey data are not available. C1 [Zhang, Xingyou; Holt, James B.; Lu, Hua; Greenlund, Kurt J.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Yun, Shumei] Missouri Dept Hlth & Senior Serv, Off Epidemiol, Jefferson City, MO USA. RP Zhang, XY (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop F78, Atlanta, GA 30341 USA. EM gyx8@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 6 Z9 6 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUL 15 PY 2015 VL 182 IS 2 BP 127 EP 137 DI 10.1093/aje/kwv002 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM9UJ UT WOS:000358054200006 PM 25957312 ER PT J AU Ly, KN Klevens, RM AF Ly, Kathleen N. Klevens, R. Monina TI Trends in Disease and Complications of Hepatitis A Virus Infection in the United States, 1999-2011: A New Concern for Adults SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE hepatitis A virus; hepatitis A hospitalizations; hepatitis A mortality; hepatitis A complications; hepatitis A trends ID VIRAL-HEPATITIS; GREEN ONIONS; OUTBREAK; VACCINATION AB Background. In recent years, few US adults have had exposure and resultant immunity to hepatitis A virus (HAV). Further, persons with liver disease have an increased risk of adverse consequences if they are infected with HAV. Methods. This study used 1999-2011 National Notifiable Diseases Surveillance System and Multiple Cause of Death data to assess trends in the incidence of HAV infection, HAV-related hospitalization, and HAV-related mortality. Results. During 1999-2011, the incidence of HAV infection declined from 6.0 cases/100 000 to 0.4 cases/100 000. Similar declines were seen by sex and age, but persons aged >= 80 years had the highest incidence of HAV infection in 2011 (0.8 cases/100 000). HAV-related hospitalizations increased from 7.3% in 1999 to 24.5% in 2011. The mean age of hospitalized cases increased from 36.0 years in 1999 to 45.1 years in 2011. While HAV-related mortality declined, the mean age at death among decedents with HAV infection increased from 48.0 years in 1999 to 76.2 years in 2011. The median age range of decedents who had HAV infection and a liver-related condition was 51.0 to 68.0 years. Conclusions. Although vaccine-preventable, HAV-related hospitalizations increased greatly, mostly among adults, and liver-related conditions were frequently reported among HAV-infected individuals who died. Public health efforts should focus on the need to assess protection from hepatitis A among adults, including those with liver disease. C1 [Ly, Kathleen N.; Klevens, R. Monina] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Ly, KN (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30333 USA. EM kathleenly@cdc.gov FU CDC FX This work was supported by the CDC. NR 32 TC 11 Z9 11 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2015 VL 212 IS 2 BP 176 EP 182 DI 10.1093/infdis/jiu834 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM6TQ UT WOS:000357823300003 PM 25637352 ER PT J AU Coscolla, M Barry, PM Oeltmann, JE Koshinsky, H Shaw, T Cilnis, M Posey, J Rose, J Weber, T Fofanov, VY Gagneux, S Kato-Maeda, M Metcalfe, JZ AF Coscolla, Mireia Barry, Pennan M. Oeltmann, John E. Koshinsky, Heather Shaw, Tambi Cilnis, Martin Posey, Jamie Rose, Jordan Weber, Terry Fofanov, Viacheslav Y. Gagneux, Sebastien Kato-Maeda, Midori Metcalfe, John Z. TI Genomic Epidemiology of Multidrug-Resistant Mycobacterium tuberculosis During Transcontinental Spread SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Mycobacterium tuberculosis; drug resistance; genomics; epidemiology; EmbR ID DRUG-RESISTANCE; EVOLUTION; TRANSMISSION; STRAINS; LIPOARABINOMANNAN; MUTATIONS; APOPTOSIS; OUTBREAK; FITNESS; AFRICA AB The transcontinental spread of multidrug-resistant (MDR) tuberculosis is poorly characterized in molecular epidemiologic studies. We used genomic sequencing to understand the establishment and dispersion of MDR Mycobacterium tuberculosis within a group of immigrants to the United States. We used a genomic epidemiology approach to study a genotypically matched (by spoligotype, IS6110 restriction fragment length polymorphism, and mycobacterial interspersed repetitive units-variable number of tandem repeat signature) lineage 2/Beijing MDR strain implicated in an outbreak of tuberculosis among refugees in Thailand and consecutive cases within California. All 46 MDR M. tuberculosis genomes from both Thailand and California were highly related, with a median difference of 10 single-nucleotide polymorphisms (SNPs). The Wat Tham Krabok (WTK) strain is a new sequence type distinguished from all known Beijing strains by 55 SNPs and a genomic deletion (Rv1267c) associated with increased fitness. Sequence data revealed a highly prevalent MDR strain that included several closely related but distinct allelic variants within Thailand, rather than the occurrence of a single outbreak. In California, sequencing data supported multiple independent introductions of WTK with subsequent transmission and reactivation within the state, as well as a potential super spreader with a prolonged infectious period. Twenty-seven drug resistance-conferring mutations and 4 putative compensatory mutations were found within WTK strains. Genomic sequencing has substantial epidemiologic value in both low-and high-burden settings in understanding transmission chains of highly prevalent MDR strains. C1 [Coscolla, Mireia; Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Med Parasitol & Infect Biol, Basel, Switzerland. [Coscolla, Mireia; Gagneux, Sebastien] Univ Basel, CH-4003 Basel, Switzerland. [Barry, Pennan M.; Shaw, Tambi; Cilnis, Martin; Weber, Terry] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Richmond, CA USA. [Koshinsky, Heather; Fofanov, Viacheslav Y.] Eureka Genom, Hercules, CA USA. [Rose, Jordan; Kato-Maeda, Midori; Metcalfe, John Z.] Univ Calif San Francisco, San Francisco Gen Hosp, Francis J Curry Int TB Ctr, Div Pulm & Crit Care Med, San Francisco, CA USA. [Oeltmann, John E.; Posey, Jamie] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Metcalfe, JZ (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, 1001 Potrero Ave,Rm 5K1, San Francisco, CA 94110 USA. EM john.metcalfe@ucsf.edu FU National Institutes of Health [K23 AI094251, R01 AI090928]; Robert Wood Johnson Foundation; Swiss National Science Foundation [PP00P3_150750]; European Research Council [309540-EVODRTB] FX This work was supported by the National Institutes of Health (grants K23 AI094251 [to J. Z. M.] and R01 AI090928 [to S. G.]), the Robert Wood Johnson Foundation (Amos Medical Faculty Development Program award to J. Z. M.), the Swiss National Science Foundation (PP00P3_150750 to S. G.), and the European Research Council (309540-EVODRTB to S. G.). NR 41 TC 7 Z9 7 U1 2 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2015 VL 212 IS 2 BP 302 EP 310 DI 10.1093/infdis/jiv025 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM6TQ UT WOS:000357823300016 PM 25601940 ER PT J AU Moore, LV Thompson, FE AF Moore, Latetia V. Thompson, Frances E. TI Adults Meeting Fruit and Vegetable Intake Recommendations - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Moore, Latetia V.] CDC, Div Nutr Phys Act & Obes Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Thompson, Frances E.] NCI, NIH, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Moore, LV (reprint author), CDC, Div Nutr Phys Act & Obes Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM lvmoore@cdc.gov NR 10 TC 17 Z9 17 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 10 PY 2015 VL 64 IS 26 BP 709 EP 713 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN5ET UT WOS:000358453300001 PM 26158351 ER PT J AU Kobayashi, M Beer, KD Bjork, A Chatham-Stephens, K Cherry, CC Arzoaquoi, S Frank, W Kumeh, O Sieka, J Yeiah, A Painter, JE Yoder, JS Flannery, B Mahoney, F Nyenswah, TG AF Kobayashi, Miwako Beer, Karlyn D. Bjork, Adam Chatham-Stephens, Kevin Cherry, Cara C. Arzoaquoi, Sampson Frank, Wilmot Kumeh, Odell Sieka, Joseph Yeiah, Adolphus Painter, Julia E. Yoder, Jonathan S. Flannery, Brendan Mahoney, Frank Nyenswah, Tolbert G. TI Community Knowledge, Attitudes, and Practices Regarding Ebola Virus Disease - Five Counties, Liberia, September-October, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kobayashi, Miwako; Beer, Karlyn D.; Chatham-Stephens, Kevin; Cherry, Cara C.; Painter, Julia E.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Kobayashi, Miwako; Flannery, Brendan] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Beer, Karlyn D.; Painter, Julia E.; Yoder, Jonathan S.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Bjork, Adam] Ctr Global Hlth, Div Global HIV AIDS, Tampa, FL USA. [Chatham-Stephens, Kevin] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Cherry, Cara C.] Off Publ Hlth, Wildlife Hlth Branch, Natl Pk Serv, Biol Resources Div, Ft Collins, CO USA. [Arzoaquoi, Sampson] Bong Cty Hlth Off, Madison, WI USA. [Frank, Wilmot] Sinoe Cty Hlth Off, Greenville, SC USA. [Kumeh, Odell] Maryland Cty Hlth Off, Bethesda, MD USA. [Sieka, Joseph] River Gee Cty Hlth Off, London, England. [Yeiah, Adolphus] Margibi Cty Hlth Off, London, England. [Mahoney, Frank] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Nyenswah, Tolbert G.] Minist Hlth, Liberia, South Africa. RP Kobayashi, M (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM MKobayashi@cdc.gov OI Bjork, Adam/0000-0001-7544-2987 NR 5 TC 7 Z9 7 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 10 PY 2015 VL 64 IS 26 BP 714 EP 718 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN5ET UT WOS:000358453300002 PM 26158352 ER PT J AU Jones, CM Logan, J Gladden, M Bohm, MK AF Jones, Christopher M. Logan, Joseph Gladden, Matthew Bohm, Michele K. TI Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INJECTION-DRUG USE; INCREASES AB Background: Heroin use and overdose deaths have increased significantly in the United States. Assessing trends in heroin use among demographic and particular substance-using groups can inform prevention efforts. Methods: FDA and CDC analyzed data from the National Survey on Drug Use and Health and National Vital Statistics System reported during 2002-2013. Trends in heroin use among demographic and substance using groups were compared for 2002-2004, 2005-2007, 2008-2010, and 2011-2013. A multivariable logistic regression model was used to identify characteristics associated with heroin abuse or dependence. Results: Annual average rates of past-year heroin use increased from 1.6 per 1,000 persons aged >= 12 years in 2002-2004 to 2.6 per 1,000 in 2011-2013. Rates of heroin abuse or dependence were strongly positively correlated with rates of heroin-related overdose deaths over time. For the combined data years 2011-2013, the odds of past-year heroin abuse or dependence were highest among those with past-year cocaine or opioid pain reliever abuse or dependence. Conclusions: Heroin use has increased significantly across most demographic groups. The increase in heroin abuse or dependence parallels the increase in heroin-related overdose deaths. Heroin use is occurring in the context of broader poly-substance use. Implications for Public Health Practice: Further implementation of a comprehensive response that targets the wider range of demographic groups using heroin and addresses the key risk factors for heroin abuse and dependence is needed. Specific response needs include reducing inappropriate prescribing and use of opioids through early identification of persons demonstrating problematic use, stronger prescription drug monitoring programs, and other clinical measures; improving access to, and insurance coverage for, evidence-based substance abuse treatment, including medication-assisted treatment for opioid use disorders; and expanding overdose recognition and response training and access to naloxone to treat opioid pain reliever and heroin overdoses. C1 [Jones, Christopher M.] US FDA, Off Commissioner, Off Publ Hlth Strategy & Anal, Rockville, MD 20857 USA. [Logan, Joseph] CDC, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30333 USA. [Gladden, Matthew; Bohm, Michele K.] CDC, Natl Ctr Injury Prevent & Control, Div Unintent, Atlanta, GA 30333 USA. RP Jones, CM (reprint author), US FDA, Off Commissioner, Off Publ Hlth Strategy & Anal, Rockville, MD 20857 USA. EM Christopher.M.Jones@fda.hhs.gov NR 15 TC 52 Z9 52 U1 4 U2 19 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUL 10 PY 2015 VL 64 IS 26 BP 719 EP 725 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN5ET UT WOS:000358453300003 PM 26158353 ER PT J AU Trecki, J Gerona, RR Schwartz, MD AF Trecki, Jordan Gerona, Roy R. Schwartz, Michael D. TI Synthetic Cannabinoid-Related Illnesses and Deaths SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID STATES C1 [Trecki, Jordan] Drug Enforcement Adm, Off Div Control, Drug & Chem Evaluat Sect, Springfield, VA 22152 USA. [Gerona, Roy R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Schwartz, Michael D.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Trecki, J (reprint author), Drug Enforcement Adm, Off Div Control, Drug & Chem Evaluat Sect, Springfield, VA 22152 USA. NR 5 TC 39 Z9 39 U1 0 U2 11 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUL 9 PY 2015 VL 373 IS 2 BP 103 EP 107 DI 10.1056/NEJMp1505328 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CM3QP UT WOS:000357598600002 PM 26154784 ER PT J AU Bedford, T Riley, S Barr, IG Broor, S Chadha, M Cox, NJ Daniels, RS Gunasekaran, CP Hurt, AC Kelso, A Klimov, A Lewis, NS Li, XY McCauley, JW Odagiri, T Potdar, V Rambaut, A Shu, YL Skepner, E Smith, DJ Suchard, MA Tashiro, M Wang, DY Xu, XY Lemey, P Russell, CA AF Bedford, Trevor Riley, Steven Barr, Ian G. Broor, Shobha Chadha, Mandeep Cox, Nancy J. Daniels, Rodney S. Gunasekaran, C. Palani Hurt, Aeron C. Kelso, Anne Klimov, Alexander Lewis, Nicola S. Li, Xiyan McCauley, John W. Odagiri, Takato Potdar, Varsha Rambaut, Andrew Shu, Yuelong Skepner, Eugene Smith, Derek J. Suchard, Marc A. Tashiro, Masato Wang, Dayan Xu, Xiyan Lemey, Philippe Russell, Colin A. TI Global circulation patterns of seasonal influenza viruses vary with antigenic drift SO NATURE LA English DT Article ID A VIRUS; B VIRUS; SELECTION; DYNAMICS; EPIDEMIOLOGY; NETWORK; SPREAD; STATES; SITES; WAVES AB Understanding the spatiotemporal patterns of emergence and circulation of new human seasonal influenza virus variants is a key scientific and public health challenge. The global circulation patterns of influenza A/H3N2 viruses are well characterized(1-7), but the patterns of A/H1N1 and B viruses have remained largely unexplored. Here we show that the global circulation patterns of A/H1N1 (up to 2009), B/Victoria, and B/Yamagata viruses differ substantially from those of A/H3N2 viruses, on the basis of analyses of 9,604 haemagglutinin sequences of human seasonal influenza viruses from 2000 to 2012. Whereas genetic variants of A/H3N2 viruses did not persist locally between epidemics and were reseeded from East and Southeast Asia, genetic variants of A/H1N1 and B viruses persisted across several seasons and exhibited complex global dynamics with East and Southeast Asia playing a limited role in disseminating new variants. The less frequent global movement of influenza A/H1N1 and B viruses coincided with slower rates of antigenic evolution, lower ages of infection, and smaller, less frequent epidemics compared to A/H3N2 viruses. Detailed epidemic models support differences in age of infection, combined with the less frequent travel of children, as probable drivers of the differences in the patterns of global circulation, suggesting a complex interaction between virus evolution, epidemiology, and human behaviour. C1 [Bedford, Trevor] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA. [Riley, Steven] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, London SW7 2AZ, England. [Riley, Steven; Rambaut, Andrew] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Barr, Ian G.; Hurt, Aeron C.; Kelso, Anne] WHO, Collaborating Ctr Reference & Res Influenza, Melbourne, Vic 3000, Australia. [Broor, Shobha] SGT Med Coll Hosp & Res Inst, Gurgaon 122505, Haryana, India. [Chadha, Mandeep; Potdar, Varsha] Natl Inst Virol, Pune 411001, Maharashtra, India. [Cox, Nancy J.; Klimov, Alexander; Xu, Xiyan] Ctr Dis Control & Prevent, WHO Collaborating Ctr Reference & Res Influenza, Atlanta, GA 30329 USA. [Daniels, Rodney S.; McCauley, John W.] Natl Inst Med Res, MRC, WHO Collaborating Ctr Reference & Res Influenza, London NW7 1AA, England. [Gunasekaran, C. Palani] King Inst Prevent Med & Res, Madras 600032, Tamil Nadu, India. [Hurt, Aeron C.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3010, Australia. [Lewis, Nicola S.; Skepner, Eugene; Smith, Derek J.] Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England. [Li, Xiyan; Shu, Yuelong; Wang, Dayan] China CDC, WHO Collaborating Ctr Reference & Res Influenza, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China. [Odagiri, Takato; Tashiro, Masato] Natl Inst Infect Dis, WHO Collaborating Ctr Reference & Res Influenza, Tokyo 2080011, Japan. [Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland. [Rambaut, Andrew] Univ Edinburgh, Ctr Immunol Infect & Evolut, Edinburgh EH9 3FL, Midlothian, Scotland. [Smith, Derek J.] Erasmus MC, Dept Virosci, NL-3015 Rotterdam, Netherlands. [Suchard, Marc A.] Univ Calif Los Angeles, Dept Biostat, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Lemey, Philippe] KU Leuven Univ Leuven, Rega Inst, Dept Microbiol & Immunol, B-3000 Leuven, Belgium. [Russell, Colin A.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England. RP Russell, CA (reprint author), Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England. EM car44@cam.ac.uk OI Russell, Colin/0000-0002-2113-162X; Barr, Ian/0000-0002-7351-418X; Hurt, Aeron/0000-0003-1826-4314 FU Newton International Fellowship from the Royal Society; National Institutes of Health (NIH) [U54 GM111274]; Medical Research Council (UK) [MR/J008761/1]; Wellcome Trust (UK) [093488/Z/10/Z]; Fogarty International Centre (USA) [R01 TW008246-01]; Department of Homeland Security (USA, RAPIDD program); National Institute of General Medical Sciences (USA) [MIDAS U01 GM110721-01]; National Institute for Health Research (UK, Health Protection Research Unit); Australian Government Department of Health; US Department of Health and Human Services; National Science Foundation DMS [1264153]; NIH [R01 AI 107034]; EU [278433-PREDEMICS]; ERC [260864]; Royal Society; [U117512723] FX We thank National Influenza Centres worldwide for their contributions to influenza virus surveillance. T.B. was supported by a Newton International Fellowship from the Royal Society and through National Institutes of Health (NIH) U54 GM111274. S.R. was supported by Medical Research Council (UK, Project MR/J008761/1), Wellcome Trust (UK, Project 093488/Z/10/Z), Fogarty International Centre (USA, R01 TW008246-01), Department of Homeland Security (USA, RAPIDD program), National Institute of General Medical Sciences (USA, MIDAS U01 GM110721-01) and National Institute for Health Research (UK, Health Protection Research Unit funding). The Melbourne WHO Collaborating Centre for Reference and Research on Influenza was supported by the Australian Government Department of Health and thanks N. Komadina and Y.-M. Deng. The Atlanta WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza was supported by the US Department of Health and Human Services. NIV thanks A.C. Mishra, M. Chawla-Sarkar, A. M. Abraham, D. Biswas, S. Shrikhande, B. AnuKumar, and A. Jain. Influenza surveillance in India was expanded, in part, through US Cooperative Agreements (5U50C1024407 and U51IP000333) and by the Indian Council of Medical Research. M. A. S. was supported through National Science Foundation DMS 1264153 and NIH R01 AI 107034. Work of the WHO Collaborating Centre for Reference and Research on Influenza at the MRC National Institute for Medical Research was supported by U117512723. P.L., A.R. & M.A.S were supported by EU Seventh Framework Programme [FP7/2007-2013] under Grant Agreement no. 278433-PREDEMICS and ERC Grant agreement no. 260864. C.A.R. was supported by a University Research Fellowship from the Royal Society. NR 38 TC 44 Z9 46 U1 7 U2 35 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD JUL 9 PY 2015 VL 523 IS 7559 BP 217 EP U206 DI 10.1038/nature14460 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CM4ZO UT WOS:000357695900036 PM 26053121 ER PT J AU Murray, J Cohen, A Walaza, S Groome, M Madhi, S Variava, E Kahn, K Dawood, H Tempia, S Tshangela, A Venter, M Feikin, D Cohen, C AF Murray, Jillian Cohen, Adam Walaza, Sibongile Groome, Michelle Madhi, Shabir Variava, Ebrahim Kahn, Kathleen Dawood, Halima Tempia, Stefano Tshangela, Akhona Venter, Marietje Feikin, Daniel Cohen, Cheryl TI Determining the Provincial and National Burden of Influenza-Associated Severe Acute Respiratory Illness in South Africa Using a Rapid Assessment Methodology SO PLOS ONE LA English DT Article ID SEASONAL INFLUENZA; TRACT INFECTIONS; SURVEILLANCE; VIRUS; PNEUMONIA; CHILDREN; EPIDEMIOLOGY; PREVALENCE; MORTALITY; TYPE-1 AB Local disease burden data are necessary to set national influenza vaccination policy. In 2010 the population of South Africa was 50 million and the HIV prevalence was 11%. We used a previously developed methodology to determine severe influenza burden in South Africa. Hospitalized severe acute respiratory illness (SARI) incidence was calculated, stratified by HIV status, for four age groups using data from population-based surveillance in one site situated in Gauteng Province for 2009-2011. These rates were adjusted for each of the remaining 8 provinces based on their prevalence of risk factors for pneumonia and healthcare-seeking behavior. We estimated non-hospitalized influenza-associated SARI from healthcare utilization surveys at two sites and used the percent of SARI cases positive for influenza from sentinel surveillance to derive the influenza-associated SARI rate. We applied rates of hospitalized and non-hospitalized influenza-associated SARI to census data to calculate the national number of cases. The percent of SARI cases that tested positive for influenza ranged from 7-17% depending on age group, year, province and HIV status. In 2010, there were an estimated 21,555 total severe influenza cases in HIV-uninfected individuals and 13,876 in HIV-infected individuals. In 2011, there were an estimated 29,892 total severe influenza cases in HIV-uninfected individuals and 17,289 in HIV-infected individuals. The incidence of influenza-associated SARI was highest in children <5 years and was higher in HIV-infected than HIV-uninfected persons in all age groups. Influenza virus was associated with a substantial amount of severe disease, especially in young children and HIV-infected populations in South Africa. C1 [Murray, Jillian; Feikin, Daniel] Johns Hopkins Int Vaccine Access Ctr, Baltimore, MD 21205 USA. [Cohen, Adam; Tempia, Stefano] Ctr Dis Control & Prevent, Pretoria, South Africa. [Cohen, Adam; Venter, Marietje; Feikin, Daniel] Ctr Dis Control & Prevent, Atlanta, GA USA. [Walaza, Sibongile; Madhi, Shabir; Tempia, Stefano; Tshangela, Akhona; Venter, Marietje; Cohen, Cheryl] Natl Inst Communicable Dis, Johannesburg, South Africa. [Groome, Michelle; Madhi, Shabir] MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Madhi, Shabir; Kahn, Kathleen; Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Madhi, Shabir; Kahn, Kathleen; Cohen, Cheryl] Univ Witwatersrand, Sch Pathol, Johannesburg, South Africa. [Variava, Ebrahim] Klerksdorp Tshepong Hosp, Klerksdorp, South Africa. [Kahn, Kathleen; Dawood, Halima] Univ KwaZulu Natal, Durban, South Africa. [Kahn, Kathleen] Umea Univ, Umea, Sweden. [Kahn, Kathleen] INDEPTH Network, Accra, Ghana. [Dawood, Halima] Pietermaritzburg Metropolitan Hosp Complex, Pietermaritzburg, South Africa. [Venter, Marietje] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, ZA-0002 Pretoria, South Africa. RP Murray, J (reprint author), Johns Hopkins Int Vaccine Access Ctr, Baltimore, MD 21205 USA. EM jmurra35@jhu.edu FU Global Health Research Graduate Student Award, Centre for Global Health, Johns Hopkins Bloomberg School of Public Health FX This work was supported by the Global Health Research Graduate Student Award, Centre for Global Health, Johns Hopkins Bloomberg School of Public Health: http://www.hopkinsglobalhealth.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 3 Z9 3 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 8 PY 2015 VL 10 IS 7 AR e0132078 DI 10.1371/journal.pone.0132078 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1EJ UT WOS:000358159700086 PM 26154306 ER PT J AU Reefhuis, J Devine, O Friedman, JM Louik, C Honein, MA AF Reefhuis, Jennita Devine, Owen Friedman, Jan M. Louik, Carol Honein, Margaret A. TI Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID SEROTONIN-REUPTAKE INHIBITORS; PREGNANT-WOMEN; UNITED-STATES; 1ST-TRIMESTER USE; MEDICATION USE; HEART-DEFECTS; RISK; PREVALENCE; POPULATION; METAANALYSIS AB Objective To follow up on previously reported associations between periconceptional use of selective serotonin reuptake inhibitors (SSRIs) and specific birth defects using an expanded dataset from the National Birth Defects Prevention Study. Design Bayesian analysis combining results from independent published analyses with data from a multicenter population based case-control study of birth defects. Setting 10 centers in the United States. Participants 17 952 mothers of infants with birth defects and 9857 mothers of infants without birth defects, identified through birth certificates or birth hospitals, with estimated dates of delivery between 1997 and 2009. Exposures Citalopram, escitalopram, fluoxetine, paroxetine, or sertraline use in the month before through the third month of pregnancy. Posterior odds ratio estimates were adjusted to account for maternal race/ethnicity, education, smoking, and prepregnancy obesity. Main outcome measure 14 birth defects categories that had associations with SSRIs reported in the literature. Results Sertraline was the most commonly reported SSRI, but none of the five previously reported birth defects associations with sertraline was confirmed. For nine previously reported associations between maternal SSRI use and birth defect in infants, findings were consistent with no association. High posterior odds ratios excluding the null value were observed for five birth defects with paroxetine (anencephaly 3.2, 95% credible interval 1.6 to 6.2; atrial septal defects 1.8, 1.1 to 3.0; right ventricular outflow tract obstruction defects 2.4, 1.4 to 3.9; gastroschisis 2.5, 1.2 to 4.8; and omphalocele 3.5, 1.3 to 8.0) and for two defects with fluoxetine (right ventricular outflow tract obstruction defects 2.0, 1.4 to 3.1 and craniosynostosis 1.9, 1.1 to 3.0). Conclusions These data provide reassuring evidence for some SSRIs but suggest that some birth defects occur 2-3.5 times more frequently among the infants of women treated with paroxetine or fluoxetine early in pregnancy. C1 [Reefhuis, Jennita; Devine, Owen; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Louik, Carol] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RP Reefhuis, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. EM JReefhuisNZR5@cdc.gov OI Friedman, Jan/0000-0002-7482-9570 FU US Centers for Disease Control and Prevention FX Data collection was funded by the US Centers for Disease Control and Prevention. NR 32 TC 20 Z9 20 U1 0 U2 11 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD JUL 8 PY 2015 VL 351 AR h3190 DI 10.1136/bmj.h3190 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CM8MP UT WOS:000357955800002 PM 26156519 ER PT J AU Tang, K Guo, YQ Zhang, LX Rowe, LA Roellig, DM Frace, MA Li, N Liu, SY Feng, YY Xiao, LH AF Tang, Kevin Guo, Yaqiong Zhang, Longxian Rowe, Lori A. Roellig, Dawn M. Frace, Michael A. Li, Na Liu, Shiyou Feng, Yaoyu Xiao, Lihua TI Genetic similarities between Cyclospora cayetanensis and cecum-infecting avian Eimeria spp. in apicoplast and mitochondrial genomes SO PARASITES & VECTORS LA English DT Article DE Cyclospora; Genomics; Genome; Apicoplast; Mitochondria; Molecular diagnosis ID MOLECULAR PHYLOGENETIC ANALYSIS; ELECTRON-TRANSPORT CHAIN; PLASMODIUM-FALCIPARUM; PARASITES; APICOMPLEXA; SEQUENCES; SOFTWARE; SUGGESTS; INSIGHTS; COCCIDIA AB Background: Cyclospora cayetanensis is an important cause for diarrhea in children in developing countries and foodborne outbreaks of cyclosporiasis in industrialized nations. To improve understanding of the basic biology of Cyclospora spp. and development of molecular diagnostic tools and therapeutics, we sequenced the complete apicoplast and mitochondrial genomes of C. cayetanensis. Methods: The genome of one Chinese C. cayetanensis isolate was sequenced using Roche 454 and Illumina technologies. The assembled genomes of the apicoplast and mitochondrion were retrieved, annotated, and compared with reference genomes for other apicomplexans to infer genome organizations and phylogenetic relationships. Sequence variations in the mitochondrial genome were identified by comparison of two C. cayetanensis nucleotide sequences from this study and a recent publication. Results: The apicoplast and mitochondrial genomes of C. cayetanensis are 34,155 and 6,229 bp in size and code for 65 and 5 genes, respectively. Comparative genomic analysis showed high similarities between C. cayetanensis and Eimeria tenella in both genomes; they have 85.6 % and 90.4 % nucleotide sequence similarities, respectively, and complete synteny in gene organization. Phylogenetic analysis of the genomic sequences confirmed the genetic similarities between cecum-infecting avian Eimeria spp. and C. cayetanensis. Like in other coccidia, both genomes of C. cayetanensis are transcribed bi-directionally. The apicoplast genome is circular, codes for the complete machinery for protein biosynthesis, and contains two inverted repeats that differ slightly in LSU rRNA gene sequences. In contrast, the mitochondrial genome has a linear concatemer or circular mapping topology. Eight single-nucleotide and one 7-bp multiple-nucleotide variants were detected between the mitochondrial genomes of C. cayetanensis from this and recent studies. Conclusions: The apicoplast and mitochondrial genomes of C. cayetanensis are highly similar to those of cecum-infecting avian Eimeria spp. in both genome organization and sequences. The availability of sequence data beyond rRNA and heat shock protein genes could facilitate studies of C. cayetanensis biology and development of genotyping tools for investigations of cyclosporiasis outbreaks. C1 [Tang, Kevin; Rowe, Lori A.; Frace, Michael A.] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA 30333 USA. [Guo, Yaqiong; Li, Na; Liu, Shiyou; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Guo, Yaqiong; Roellig, Dawn M.; Liu, Shiyou; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Zhang, Longxian] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Yaqiong, Guo/N-4927-2015; Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31425025, 31110103901]; US Centers for Disease Control and Prevention FX This work was supported in part by the National Natural Science Foundation of China (31425025 and 31110103901) and the US Centers for Disease Control and Prevention. NR 37 TC 4 Z9 5 U1 2 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD JUL 8 PY 2015 VL 8 AR 358 DI 10.1186/s13071-015-0966-3 PG 11 WC Parasitology SC Parasitology GA CM1WD UT WOS:000357470300001 PM 26152563 ER PT J AU Solano, CM Okoth, SA Abdallah, JF Pava, Z Dorado, E Incardona, S Huber, CS de Oliveira, AM Bell, D Udhayakumar, V Barnwell, JW AF Murillo Solano, Claribel Okoth, Sheila Akinyi Abdallah, Joseph F. Pava, Zuleima Dorado, Erika Incardona, Sandra Huber, Curtis S. de Oliveira, Alexandre Macedo Bell, David Udhayakumar, Venkatachalam Barnwell, John W. TI Deletion of Plasmodium falciparum Histidine-Rich Protein 2 (pfhrp2) and Histidine-Rich Protein 3 (pfhrp3) Genes in Colombian Parasites SO PLOS ONE LA English DT Article ID RAPID DIAGNOSTIC-TESTS; SULFADOXINE-PYRIMETHAMINE RESISTANCE; MICROSATELLITE MARKERS; AMAZON REGION; MALARIA; POPULATION; ORIGIN; BREAKPOINTS; NETWORK; INVITRO AB A number of studies have analyzed the performance of malaria rapid diagnostic tests (RDTs) in Colombia with discrepancies in performance being attributed to a combination of factors such as parasite levels, interpretation of RDT results and/ or the handling and storage of RDT kits. However, some of the inconsistencies observed with results from Plasmodium falciparum histidine-rich protein 2 (PfHRP2)-based RDTs could also be explained by the deletion of the gene that encodes the protein, pfhrp2, and its structural homolog, pfhrp3, in some parasite isolates. Given that pfhrp2- and pfhrp3-negative P. falciparum isolates have been detected in the neighboring Peruvian and Brazilian Amazon regions, we hypothesized that parasites with deletions of pfhrp2 and pfhrp3 may also be present in Colombia. In this study we tested 100 historical samples collected between 1999 and 2009 from six Departments in Colombia for the presence of pfhrp2, pfhrp3 and their flanking genes. Seven neutral microsatellites were also used to determine the genetic background of these parasites. In total 18 of 100 parasite isolates were found to have deleted pfhrp2, a majority of which (14 of 18) were collected from Amazonas Department, which borders Peru and Brazil. pfhrp3 deletions were found in 52 of the100 samples collected from all regions of the country. pfhrp2 flanking genes PF3D7_0831900 and PF3D7_0831700 were deleted in 22 of 100 and in 1 of 100 samples, respectively. pfhrp3 flanking genes PF3D7_1372100 and PF3D7_1372400 were missing in 55 of 100 and in 57 of 100 samples. Structure analysis of microsatellite data indicated that Colombian samples tested in this study belonged to four clusters and they segregated mostly based on their geographic region. Most of the pfhrp2deleted parasites were assigned to a single cluster and originated from Amazonas Department although a few pfhrp2-negative parasites originated from the other three clusters. The presence of a high proportion of pfhrp2-negative isolates in the Colombian Amazon may have implications for the use of PfHRP2-based RDTs in the region and may explain inconsistencies observed when PfHRP2-based tests and assays are performed. C1 [Murillo Solano, Claribel; Pava, Zuleima; Dorado, Erika] Ctr Int Entrenamiento & Invest Med CIDEIM, Cali, Colombia. [Okoth, Sheila Akinyi; Abdallah, Joseph F.; Huber, Curtis S.; de Oliveira, Alexandre Macedo; Udhayakumar, Venkatachalam; Barnwell, John W.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Okoth, Sheila Akinyi] Atlanta Res & Educ Fdn, Decatur, GA USA. [Incardona, Sandra; Bell, David] Fdn Innovat New Diagnost, CH-1202 Geneva, Switzerland. [Bell, David] Global Good Fund, Intellectual Ventures Lab, Bellevue, WA USA. RP Solano, CM (reprint author), Ctr Int Entrenamiento & Invest Med CIDEIM, Carrera 125 19-225 Av, Cali, Colombia. EM claribel_murillo@cideim.org.co OI Incardona, Sandra/0000-0003-4994-1736 FU Foundation for Innovative New Diagnostics; United States Agency for International Development; Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnologia Francisco Jose de Caldas, Colciencias [512-2010]; CDC based American Society for Microbiology Postdoctoral Fellowship; Atlanta Research and Educational Foundation FX Sample collection and training were supported by Foundation for Innovative New Diagnostics. Genotyping experiments and travel were supported by the Amazon Malaria Initiative, which is funded by the United States Agency for International Development. Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnologia Francisco Jose de Caldas, Colciencias supported CMS (No. 512-2010). CDC based American Society for Microbiology Postdoctoral Fellowship partly supported SAO. Atlanta Research and Educational Foundation partly supported the laboratory work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 5 Z9 5 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 7 PY 2015 VL 10 IS 7 AR e0131576 DI 10.1371/journal.pone.0131576 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1EC UT WOS:000358158900020 ER PT J AU Rees, JC Pierce, CL Schieltz, DM Barr, JR AF Rees, Jon C. Pierce, Carrie L. Schieltz, David M. Barr, John R. TI Simultaneous Identification and Susceptibility Determination to Multiple Antibiotics of Staphylococcus aureus by Bacteriophage Amplification Detection Combined with Mass Spectrometry SO ANALYTICAL CHEMISTRY LA English DT Article ID DESORPTION IONIZATION-TIME; METHICILLIN-RESISTANT; BACILLUS-ANTHRACIS; STATISTICAL-MODEL; ESCHERICHIA-COLI; RAPID DETECTION; INFECTIONS; MECA; PROTEINS; CULTURE AB The continued advance of antibiotic resistance in clinically relevant bacterial strains necessitates the development and refinement of assays that can rapidly and cost-effectively identify bacteria and determine their susceptibility to a panel of antibiotics. A methodology is described herein that exploits the specificity and physiology of the Staphylococci bacteriophage K to identify Staphylococcus aureus (S. aureus) and determine its susceptibility to clindamycin and cefoxitin. The method uses liquid chromatography-mass spectrometry to monitor the replication of bacteriophage after it is used to infect samples thought to contain S. aureus. Amplification of bacteriophage K indicates the sample contains S. aureus, for it is only in the presence of a suitable host that bacteriophage K can amplify. If bacteriophage amplification is detected in samples containing the antibiotics clindamycin or cefoxitin, the sample is deemed to be resistant to these antibiotics, respectively, for bacteriophage can only amplify in a viable host. Thus, with a single work flow, S. aureus can be detected in an unknown sample and susceptibility to clindamycin and cefoxitin can be ascertained. This Article discusses implications for the use of bacteriophage amplification in the clinical laboratory. C1 [Rees, Jon C.; Pierce, Carrie L.; Schieltz, David M.; Barr, John R.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. EM jbarr@cdc.gov NR 45 TC 5 Z9 5 U1 2 U2 20 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD JUL 7 PY 2015 VL 87 IS 13 BP 6769 EP 6777 DI 10.1021/acs.analchem.5b00959 PG 9 WC Chemistry, Analytical SC Chemistry GA CM6ZH UT WOS:000357839700052 PM 26016659 ER PT J AU Toth, DJA Leecaster, M Pettey, WBP Gundlapalli, AV Gao, HJ Rainey, JJ Uzicanin, A Samore, MH AF Toth, Damon J. A. Leecaster, Molly Pettey, Warren B. P. Gundlapalli, Adi V. Gao, Hongjiang Rainey, Jeanette J. Uzicanin, Amra Samore, Matthew H. TI The role of heterogeneity in contact timing and duration in network models of influenza spread in schools SO JOURNAL OF THE ROYAL SOCIETY INTERFACE LA English DT Article DE contact network; epidemiology; influenza; schools; mathematical model ID INFECTIOUS-DISEASE MODEL; DYNAMIC SOCIAL NETWORKS; PANDEMIC INFLUENZA; A H1N1; TRANSMISSION; OUTBREAK; CHILDREN; BEHAVIOR; ADULTS; VIRUS AB Influenza poses a significant health threat to children, and schools may play a critical role in community outbreaks. Mathematical outbreak models require assumptions about contact rates and patterns among students, but the level of temporal granularity required to produce reliable results is unclear. We collected objective contact data from students aged 5-14 at an elementary school and middle school in the state of Utah, USA, and paired those data with a novel, data-based model of influenza transmission in schools. Our simulations produced within-school transmission averages consistent with published estimates. We compared simulated outbreaks over the full resolution dynamic network with simulations on networks with averaged representations of contact timing and duration. For both schools, averaging the timing of contacts over one or two school days caused average outbreak sizes to increase by 1-8%. Averaging both contact timing and pairwise contact durations caused average outbreak sizes to increase by 10% at the middle school and 72% at the elementary school. Averaging contact durations separately across within-class and between-class contacts reduced the increase for the elementary school to 5%. Thus, the effect of ignoring details about contact timing and duration in school contact networks on outbreak size modelling can vary across different schools. C1 [Toth, Damon J. A.; Leecaster, Molly; Pettey, Warren B. P.; Gundlapalli, Adi V.; Samore, Matthew H.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84132 USA. [Toth, Damon J. A.] Univ Utah, Dept Math, Salt Lake City, UT 84132 USA. [Gundlapalli, Adi V.] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA. [Toth, Damon J. A.; Leecaster, Molly; Pettey, Warren B. P.; Gundlapalli, Adi V.; Samore, Matthew H.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84108 USA. [Gundlapalli, Adi V.; Samore, Matthew H.] Univ Utah, Dept Biomed Informat, Salt Lake City, UT 84108 USA. [Gao, Hongjiang; Rainey, Jeanette J.; Uzicanin, Amra] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Toth, DJA (reprint author), Univ Utah, Dept Internal Med, Salt Lake City, UT 84132 USA. EM damon.toth@hsc.utah.edu FU US Centers for Disease Control and Prevention [5U01CK000177] FX This work was supported by the US Centers for Disease Control and Prevention cooperative agreement 5U01CK000177. NR 42 TC 11 Z9 11 U1 0 U2 3 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 1742-5689 EI 1742-5662 J9 J R SOC INTERFACE JI J. R. Soc. Interface PD JUL 6 PY 2015 VL 12 IS 108 AR 20150279 DI 10.1098/rsif.2015.0279 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO0FD UT WOS:000358824600022 PM 26063821 ER PT J AU Woldesenbet, S Jackson, D Lombard, C Dinh, TH Puren, A Sherman, G Ramokolo, V Doherty, T Mogashoa, M Bhardwaj, S Chopra, M Shaffer, N Pillay, Y Goga, A AF Woldesenbet, Selamawit Jackson, Debra Lombard, Carl Dinh, Thu-Ha Puren, Adrian Sherman, Gayle Ramokolo, Vundli Doherty, Tanya Mogashoa, Mary Bhardwaj, Sanjana Chopra, Mickey Shaffer, Nathan Pillay, Yogan Goga, Ameena CA South African PMTCT Evaluation SAP TI Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE) SO PLOS ONE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; IMMUNIZATION CLINICS; HIV; PREGNANCY; WOMEN; SURVEILLANCE; CAPE AB Objectives We examined uptake of prevention of mother-to-child HIV transmission (PMTCT) services, predictors of missed opportunities, and infant HIV transmission attributable to missed opportunities along the PMTCT cascade across South Africa. Methods A cross-sectional survey was conducted among 4-8 week old infants receiving first immunisations in 580 nationally representative public health facilities in 2010. This included maternal interviews and testing infants' dried blood spots for HIV. A weighted analysis was performed to assess uptake of antenatal and perinatal PMTCT services along the PMTCT cascade (namely: maternal HIV testing, CD4 count test/result, and receiving maternal and infant antiretroviral treatment) and predictors of dropout. The population attributable fraction associated with dropouts at each service point are estimated. Results Of 9,803 mothers included, 31.7% were HIV-positive as identified by reactive infant antibody tests. Of these 80.4% received some form of maternal and infant antiretroviral treatment. More than a third (34.9%) of mothers dropped out from one or more steps in the PMTCT service cascade. In a multivariable analysis, the following characteristics were associated with increased dropout from the PMTCT cascade: adolescent (<20 years) mothers, low socioeconomic score, low education level, primiparous mothers, delayed first antenatal visit, homebirth, and non-disclosure of HIV status. Adolescent mothers were twice (adjusted odds ratio: 2.2, 95% confidence interval: 1.5-3.3) as likely to be unaware of their HIV-positive status and had a significantly higher rate (85.2%) of unplanned pregnancies compared to adults aged >= 20 years (55.5%, p = 0.0001). A third (33.8%) of infant HIV infections were attributable to dropout in one or more steps in the cascade. Conclusion A third of transmissions attributable to missed opportunities of PMTCT services can be prevented by optimizing the uptake of PMTCT services. Identified risk factors for low PMTCT service uptake should be addressed through health facility and community-level interventions, including raising awareness, promoting women education, adolescent focused interventions, and strengthening linkages/referral-system between communities and health facilities. C1 [Woldesenbet, Selamawit; Lombard, Carl; Ramokolo, Vundli; Doherty, Tanya] MRC, Hlth Syst Res Unit, Cape Town, South Africa. [Jackson, Debra; Doherty, Tanya; Chopra, Mickey] Univ Western Cape, Sch Publ Hlth, Cape Town, South Africa. [Jackson, Debra; Chopra, Mickey] United Nations Childrens Fund, New York, NY USA. [Dinh, Thu-Ha] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Puren, Adrian; Sherman, Gayle] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Puren, Adrian] Univ Witwatersrand, Fac Hlth Sci, Div Virol & Communicable Dis, Johannesburg, South Africa. [Sherman, Gayle] Univ Witwatersrand, Fac Hlth Sci, Dept Paediat & Child Hlth, Johannesburg, South Africa. [Doherty, Tanya] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Mogashoa, Mary] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Pretoria, South Africa. [Bhardwaj, Sanjana] United Nations Childrens Fund, Pretoria, South Africa. [Shaffer, Nathan] World Hlth Org, Geneva, Switzerland. [Pillay, Yogan] Natl Dept Hlth, Pretoria, South Africa. [Goga, Ameena] Univ Pretoria, Dept Paediat & Child Hlth, ZA-0002 Pretoria, South Africa. [Goga, Ameena] MRC, Hlth Syst Res Unit, Pretoria, South Africa. RP Woldesenbet, S (reprint author), MRC, Hlth Syst Res Unit, Cape Town, South Africa. EM woldeselam@gmail.com FU CDC [1U2GPS001137-02, 1U2GPS001137-03]; United Nations Children's Fund (UNICEF); National Department of Health, South Africa; South Africa National Research Foundation; South African Centre for Epidemiological Modelling and Analysis (SACEMA); African Doctoral Dissertation Research Fellowship; MRC [1U2GPS001137-02, 1U2GPS001137-03] FX This work was supported by the President's Emergency Plan for AIDS Relief under the Cooperative Agreement between CDC and MRC (1U2GPS001137-02 and 1U2GPS001137-03)- A, The United Nations Children's Fund (UNICEF) - A, National Department of Health, South Africa-A, South Africa National Research Foundation-D, South African Centre for Epidemiological Modelling and Analysis (SACEMA) - S, African Doctoral Dissertation Research Fellowship-S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 7 Z9 7 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 6 PY 2015 VL 10 IS 7 AR e0132425 DI 10.1371/journal.pone.0132425 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1DQ UT WOS:000358157600265 PM 26147598 ER PT J AU Hrudey, SE Backer, LC Humpage, AR Krasner, SW Michaud, DS Moore, LE Singer, PC Stanford, BD AF Hrudey, Steve E. Backer, Lorraine C. Humpage, Andrew R. Krasner, Stuart W. Michaud, Dominique S. Moore, Lee E. Singer, Philip C. Stanford, Benjamin D. TI EVALUATING EVIDENCE FOR ASSOCIATION OF HUMAN BLADDER CANCER WITH DRINKING-WATER CHLORINATION DISINFECTION BY-PRODUCTS SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS LA English DT Review ID EPITHELIAL-CELLS; ASSESSING EXPOSURE; WASHINGTON COUNTY; MIXTURES RESEARCH; RISK; TRIHALOMETHANES; SALMONELLA; BROMODICHLOROMETHANE; MUTAGENICITY; OZONATION/POSTCHLORINATION AB Exposure to chlorination disinfection by-products (CxDBPs) is prevalent in populations using chlorination-based methods to disinfect public water supplies. Multifaceted research has been directed for decades to identify, characterize, and understand the toxicology of these compounds, control and minimize their formation, and conduct epidemiologic studies related to exposure. Urinary bladder cancer has been the health risk most consistently associated with CxDBPs in epidemiologic studies. An international workshop was held to (1) discuss the qualitative strengths and limitations that inform the association between bladder cancer and CxDBPs in the context of possible causation, (2) identify knowledge gaps for this topic in relation to chlorine/chloramine-based disinfection practice(s) in the United States, and (3) assess the evidence for informing risk management. Epidemiological evidence linking exposures to CxDBPs in drinking water to human bladder cancer risk provides insight into causality. However, because of imprecise, inaccurate, or incomplete estimation of CxDBPs levels in epidemiologic studies, translation from hazard identification directly to risk management and regulatory policy for CxDBPs can be challenging. Quantitative risk estimates derived from toxicological risk assessment for CxDBPs currently cannot be reconciled with those from epidemiologic studies, notwithstanding the complexities involved, making regulatory interpretation difficult. Evidence presented here has both strengths and limitations that require additional studies to resolve and improve the understanding of exposure response relationships. Replication of epidemiologic findings in independent populations with further elaboration of exposure assessment is needed to strengthen the knowledge base needed to better inform effective regulatory approaches. C1 [Hrudey, Steve E.] Univ Alberta, Fac Med & Dent, Environm & Analyt Toxicol, Edmonton, AB T6G 2G3, Canada. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Humpage, Andrew R.] SA Water, Adelaide, SA, Australia. [Krasner, Stuart W.] Metropolitan Water Dist Southern Calif, Los Angeles, CA USA. [Michaud, Dominique S.] Tufts Univ, Medford, MA 02155 USA. [Singer, Philip C.] Univ N Carolina, Chapel Hill, NC USA. [Stanford, Benjamin D.] Hazen & Sawyer, Raleigh, NC USA. RP Hrudey, SE (reprint author), Univ Alberta, Fac Med & Dent, Environm & Analyt Toxicol, Edmonton, AB T6G 2G3, Canada. EM steve.hrudey@ualberta.ca FU Water Research Foundation [4530]; American Water Works Association; Natural Sciences and Engineering Research Council of Canada FX Funding for this project was provided by the Water Research Foundation, Project 4530, and the American Water Works Association. Open access was funded by a Discovery Grant to SEH from the Natural Sciences and Engineering Research Council of Canada. NR 92 TC 6 Z9 7 U1 8 U2 25 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1093-7404 EI 1521-6950 J9 J TOXICOL ENV HEAL B JI J. Toxicol. Env. Health-Pt b-Crit. Rev. PD JUL 4 PY 2015 VL 18 IS 5 BP 213 EP 241 DI 10.1080/10937404.2015.1067661 PG 29 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CU4XA UT WOS:000363533100001 PM 26309063 ER PT J AU Buser, MC Pohl, HR AF Buser, M. C. Pohl, H. R. TI WINDOWS OF SENSITIVITY TO TOXIC CHEMICALS IN THE DEVELOPMENT OF CLEFT PALATES SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS LA English DT Review ID BUTYL BENZYL PHTHALATE; BOILING COAL LIQUID; OROFACIAL CLEFTS; RETINOIC ACID; C57BL/6N MICE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; TRIBUTYLTIN CHLORIDE; RECEPTOR EXPRESSION; CRITICAL PERIODS; POLYCHLORINATED DIBENZOFURANS AB Cleft lip and cleft palate are among the most common birth defects worldwide. There is a genetic component to the development of these malformations, as well as evidence that environmental exposures and prescription drug use may exacerbate or even produce these manifestations. Thus, it is important to understand the underlying mechanisms and when these exposures affect development of the growing fetus. The purpose of this investigation was to critically review the available literature related to orofacial cleft formation following chemical exposure and identify specific time frames for windows of sensitivity. Further, an aim was to evaluate the potential for predicting effects in humans based on animal studies. Evidence indicates that chemical causes of cleft palate development are due to dose and timing of exposure, susceptibility of the species (i.e., the genetic makeup), and mechanism of action. Several studies demonstrated that dose is a crucial factor; however, some investigators argued that even more important than dose was timing of exposure. Data show that the window of sensitivity to environmental teratogens in the development of cleft palates is quite narrow and follows closely the window of palatogenesis in the fetus of any given species. C1 [Buser, M. C.; Pohl, H. R.] US Dept HHS, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Pohl, HR (reprint author), ATSDR, 1600 Clifton Rd,MS-F57, Atlanta, GA 30333 USA. EM hpohl@cdc.gov NR 120 TC 2 Z9 2 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1093-7404 EI 1521-6950 J9 J TOXICOL ENV HEAL B JI J. Toxicol. Env. Health-Pt b-Crit. Rev. PD JUL 4 PY 2015 VL 18 IS 5 BP 242 EP 257 DI 10.1080/10937404.2015.1068719 PG 16 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CU4XA UT WOS:000363533100002 PM 26503716 ER PT J AU Karon, JM Wiegand, RE van de Wijgert, JH Kilmarx, PH AF Karon, John M. Wiegand, Ryan E. van de Wijgert, Janneke H. Kilmarx, Peter H. TI An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit SO JOURNAL OF BIOPHARMACEUTICAL STATISTICS LA English DT Article DE Mixed models; Quantification limit; Mixture models; Laboratory data ID HIV RNA DATA; CROSSOVER TRIAL; MODELS; THAILAND; SUBJECT; SAFETY; WOMEN AB Laboratory data with a lower quantification limit (censored data) are sometimes analyzed by replacing non-quantifiable values with a single value equal to or less than the quantification limit, yielding possibly biased point estimates and variance estimates that are too small. Motivated by a three-period, three-treatment crossover study of a candidate vaginal microbicide in human immunodeficiency virus (HIV)-infected women, we consider four analysis methods for censored Gaussian data with a single follow-up measurement: nonparametric methods, mixed models, mixture models, and dichotomous measures of a treatment effect. We apply these methods to the crossover study data and use simulation to evaluate the statistical properties of these methods in analyzing the treatment effect in a two-treatment parallel-arm or crossover study with censored Gaussian data. Our simulated data and our mixed and mixture models consider treated follow-up data with the same variance as the baseline data or with an inflated variance. Mixed models have the correct type I error, the best power, the least biased Gaussian parameter treatment-effect estimates, and appropriate confidence interval coverage for these estimates. A crossover study analysis with a period effect can greatly increase the required study sample size. For both designs and both variance assumptions, published sample-size estimation methods do not yield a good estimate of the sample size to obtain the stated power. C1 [Karon, John M.] Apex Syst Inc, Richmond, VA USA. [Wiegand, Ryan E.; Kilmarx, Peter H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [van de Wijgert, Janneke H.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. RP Wiegand, RE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-06, Atlanta, GA 30333 USA. EM rwiegand@cdc.gov OI Kilmarx, Peter/0000-0001-6464-3345 NR 24 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1054-3406 EI 1520-5711 J9 J BIOPHARM STAT JI J. Biopharm. Stat. PD JUL 4 PY 2015 VL 25 IS 4 BP 812 EP 829 DI 10.1080/10543406.2014.920858 PG 18 WC Pharmacology & Pharmacy; Statistics & Probability SC Pharmacology & Pharmacy; Mathematics GA CJ9II UT WOS:000355815400011 PM 24906060 ER PT J AU Ceballos, DM Gong, W Page, E AF Ceballos, Diana M. Gong, Wei Page, Elena TI A Pilot Assessment of Occupational Health Hazards in the US Electronic Scrap Recycling Industry SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE electronic scrap recycling; survey; e-waste; health and safety; electronic waste recycling; e-scrap ID ADULT LEAD-EXPOSURE; MANAGEMENT AB The National Institute for Occupational Safety and Health (NIOSH) surveyed a randomly selected sample of electronic scrap (e-scrap) recycling facilities nationwide to characterize work processes, exposures, and controls. Despite multiple attempts to contact 278 facilities, only 47 responded (17% response rate). Surveyed facilities reported recycling a wide variety of electronics. The most common recycling processes were manual dismantling and sorting. Other processes included shredding, crushing, and automated separation. Many facilities reported that they had health and safety programs in place. However, some facilities reported the use of compressed air for cleaning, a practice that can lead to increased employee dust exposures, and some facilities allowed food and drinks in the production areas, a practice that can lead to ingestion of contaminants. Although our results may not be generalizable to all US e-scrap recycling facilities, they are informative regarding health and safety programs in the industry. We concluded that e-scrap recycling has the potential for a wide variety of occupational exposures particularly because of the frequent use of manual processes. On-site evaluations of e-scrap recyclers are needed to determine if reported work processes, practices, and controls are effective and meet current standards and guidelines. Educating the e-scrap recycling industry about health and safety best practices, specifically related to safe handling of metal dust, would help protect employees. C1 [Ceballos, Diana M.; Gong, Wei; Page, Elena] NIOSH, Hazard Evaluat & Tech Assistance Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Ceballos, DM (reprint author), NIOSH, 1090 Tusculum Ave,MS 11, Cincinnati, OH 45226 USA. EM DCeballos@cdc.gov FU United States Environmental Protection Agency [DW-75-92357701-0]; United States Environmental Protection Agency (CDC/NIOSH IAA) [12-NS12-11]; National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention FX This work was supported by funding from the United States Environmental Protection Agency (Interagency Agreement No: DW-75-92357701-0; CDC/NIOSH IAA No: 12-NS12-11) and the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. NR 23 TC 2 Z9 3 U1 4 U2 19 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUL 3 PY 2015 VL 12 IS 7 BP 482 EP 488 DI 10.1080/15459624.2015.1018516 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CK6EX UT WOS:000356322400003 PM 25738822 ER PT J AU Ashley, K AF Ashley, Kevin TI Analytical Performance Issues Harmonization of NIOSH Sampling and Analytical Methods With Related International Voluntary Consensus Standards SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article C1 [Ashley, Kevin] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Ashley, K (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, 1090 Tusculum Ave,Mail Stop R-7, Cininnati, OH 45226 USA. EM KAshley@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUL 3 PY 2015 VL 12 IS 7 BP D107 EP D115 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CK4MF UT WOS:000356197200001 ER PT J AU Ashley, K AF Ashley, Kevin TI Harmonization of NIOSH Sampling and Analytical Methods With Related International Voluntary Consensus Standards SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article C1 NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Ashley, K (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, 1090 Tusculum Ave,Mail Stop R-7, Cincinnati, OH 45226 USA. EM KAshley@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUL 3 PY 2015 VL 12 IS 7 BP D107 EP D115 DI 10.1080/15459624.2014.995302 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CK4MM UT WOS:000356197900001 ER PT J AU de Graaf, M van Beek, J Vennema, H Podkolzin, AT Hewitt, J Bucardo, F Templeton, K Mans, J Nordgren, J Reuter, G Lynch, M Rasmussen, LD Iritani, N Chan, MC Martella, V Ambert-Balay, K Vinje, J White, PA Koopmans, MP AF de Graaf, M. van Beek, J. Vennema, H. Podkolzin, A. T. Hewitt, J. Bucardo, F. Templeton, K. Mans, J. Nordgren, J. Reuter, G. Lynch, M. Rasmussen, L. D. Iritani, N. Chan, M. C. Martella, V. Ambert-Balay, K. Vinje, J. White, P. A. Koopmans, M. P. TI Emergence of a novel GII.17 norovirus - End of the GII.4 era? SO EUROSURVEILLANCE LA English DT Article ID ACUTE GASTROENTERITIS; UNITED-STATES; SOUTH-AFRICA; WASTE-WATER; OUTBREAKS; INFECTION; CHILDREN; VARIANT; DIVERSITY; STRAINS AB In the winter of 2014/15 a novel GII.P17-GII.17 norovirus strain (GII.17 Kawasaki 2014) emerged, as a major cause of gastroenteritis outbreaks in China and Japan. Since their emergence these novel GII.P17-GII.17 viruses have replaced the previously dominant GII.4 genotype Sydney 2012 variant in some areas in Asia but were only detected in a limited number of cases on other continents. This perspective provides an overview of the available information on GII.17 viruses in order to gain insight in the viral and host characteristics of this norovirus genotype. We further discuss the emergence of this novel GII.P17-GII.17 norovirus in context of current knowledge on the epidemiology of noroviruses. It remains to be seen if the currently dominant norovirus strain GII.4 Sydney 2012 will be replaced in other parts of the world. Nevertheless, the public health community and surveillance systems need to be prepared in case of a potential increase of norovirus activity in the next seasons caused by this novel GII.P17-GII.17 norovirus. C1 [de Graaf, M.; van Beek, J.; Koopmans, M. P.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands. [van Beek, J.; Vennema, H.; Koopmans, M. P.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands. [Podkolzin, A. T.] Minist Publ Hlth Russia, Cent Res Inst Epidemiol, Moscow, Russia. [Hewitt, J.] Inst Environm Sci & Res, Porirua, New Zealand. [Bucardo, F.] Univ Leon, Dept Microbiol, Leon, Nicaragua. [Templeton, K.] Royal Infirm Edinburgh NHS Trust, Dept Med Microbiol, Edinburgh, Midlothian, Scotland. [Mans, J.] Univ Pretoria, Dept Med Virol, Fac Hlth Sci, ZA-0001 Pretoria, South Africa. [Nordgren, J.] Linkoping Univ, Dept Clin & Expt Med, Div Mol Virol, S-58183 Linkoping, Sweden. [Reuter, G.] ANTSZ Reg Inst State Publ Hlth Serv, Natl Reference Lab Gastroenter Viruses, Reg Lab Virol, Pecs, Hungary. [Lynch, M.] Mater Misericordiae Univ Hosp, Dept Microbiol, Dublin, Ireland. [Rasmussen, L. D.] Statens Serum Inst, Microbiol Diagnost & Virol, Virol Surveillance & Res Sect, Copenhagen, Denmark. [Iritani, N.] Osaka City Inst Publ Hlth & Environm Sci, Dept Microbiol, Tennoji Ku, Osaka 543, Japan. [Chan, M. C.] Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China. [Martella, V.] Univ Aldo Moro Bari, Fac Vet Med, Valenzano, Italy. [Ambert-Balay, K.] CHU Dijon, Virol Lab, Natl Reference Ctr Enter Viruses, Dijon, France. [Vinje, J.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [White, P. A.] Univ New S Wales, Fac Sci, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia. RP de Graaf, M (reprint author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands. EM m.degraaf@erasmusmc.nl RI Chan, Martin C.W./B-3588-2009; Reuter, Gabor/I-7412-2013; Martella, Vito/K-3146-2016 OI Chan, Martin C.W./0000-0002-1568-1596; Reuter, Gabor/0000-0002-5857-4934; Martella, Vito/0000-0002-5740-6947 FU EU H2020 grant COMPARE [643476]; Virgo Consortium - Dutch government [FES0908]; Hungarian Scientific Research Fund [OTKA/NKFIH K111615] FX We gratefully acknowledge the submitting laboratories of the sequences from the Noronet database. This work was supported by the EU H2020 grant COMPARE under grant agreement number 643476 and the Virgo Consortium, funded by Dutch government project number FES0908 and the Hungarian Scientific Research Fund (OTKA/NKFIH K111615). The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). NR 51 TC 39 Z9 39 U1 3 U2 18 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD JUL 2 PY 2015 VL 20 IS 26 BP 8 EP 15 AR 21178 PG 8 WC Infectious Diseases SC Infectious Diseases GA CM4OC UT WOS:000357663200002 ER PT J AU Gershon, AA Breuer, J Cohen, JI Cohrs, RJ Gershon, MD Gilden, D Grose, C Hambleton, S Kennedy, PGE Oxman, MN Seward, JF Yamanishi, K AF Gershon, Anne A. Breuer, Judith Cohen, Jeffrey I. Cohrs, Randall J. Gershon, Michael D. Gilden, Don Grose, Charles Hambleton, Sophie Kennedy, Peter G. E. Oxman, Michael N. Seward, Jane F. Yamanishi, Koichi TI Varicella zoster virus infection SO NATURE REVIEWS DISEASE PRIMERS LA English DT Article ID HERPES-SIMPLEX-VIRUS; HUMAN TRIGEMINAL GANGLIA; PLACEBO-CONTROLLED TRIAL; STEM-CELL TRANSPLANTATION; SUBUNIT CANDIDATE VACCINE; POLYMERASE-CHAIN-REACTION; POSTHERPETIC NEURALGIA; UNITED-STATES; HEALTHY-CHILDREN; NERVOUS-SYSTEM AB Infection with varicella zoster virus (VZV) causes varicella (chickenpox), which can be severe in immunocompromised individuals, infants and adults. Primary infection is followed by latency in ganglionic neurons. During this period, no virus particles are produced and no obvious neuronal damage occurs. Reactivation of the virus leads to virus replication, which causes zoster (shingles) in tissues innervated by the involved neurons, inflammation and cell death -a process that can lead to persistent radicular pain (postherpetic neuralgia). The pathogenesis of postherpetic neuralgia is unknown and it is difficult to treat. Furthermore, other zoster complications can develop, including myelitis, cranial nerve palsies, meningitis, stroke (vasculopathy), retinitis, and gastroenterological infections such as ulcers, pancreatitis and hepatitis. VZV is the only human herpesvirus for which highly effective vaccines are available. After varicella or vaccination, both wild-type and vaccine-type VZV establish latency, and long-term immunity to varicella develops. However, immunity does not protect against reactivation. Thus, two vaccines are used: one to prevent varicella and one to prevent zoster. In this Primer we discuss the pathogenesis, diagnosis, treatment, and prevention of VZV infections, with an emphasis on the molecular events that regulate these diseases. For an illustrated summary of this Primer, visit: http://go.nature.com/14xVI1 C1 [Gershon, Anne A.] Columbia Univ Coll Phys & Surg, 630 West 168th St, New York, NY 10032 USA. [Breuer, Judith] UCL, Dept Infect & Immun, London WC1E 6BT, England. [Cohen, Jeffrey I.] NIAID, Med Virol Sect, Infect Dis Lab, NIH, Bethesda, MA USA. [Cohrs, Randall J.; Gilden, Don] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Cohrs, Randall J.; Gilden, Don] Univ Colorado, Sch Med, Dept Microbiol & Immunol, Aurora, CO USA. [Gershon, Michael D.] Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA. [Grose, Charles] Univ Iowa, Childrens Hosp, Div Infect Diseases Virol, Iowa City, IA USA. [Hambleton, Sophie] Newcastle Univ, Sch Med, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England. [Kennedy, Peter G. E.] Univ Glasgow, Inst Neurol Sci, Southern Gen Hosp, Dept Neurol, Glasgow, Lanark, Scotland. [Oxman, Michael N.] Univ Calif San Diego, Sch Med, Vet Affairs San Diego Healthcare Syst, Infect Dis Sect,Med Serv,Div Infect Dis,Dept Med, San Diego, CA 92103 USA. [Seward, Jane F.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, CDC, Atlanta, GA USA. [Yamanishi, Koichi] Osaka Univ, Res Fdn Microbial Dis, Suita, Osaka, Japan. RP Gershon, AA (reprint author), Columbia Univ Coll Phys & Surg, 630 West 168th St, New York, NY 10032 USA. EM aag1@cumc.columbia.edu FU National Institute for Health Research (NIHR) University College London (UCL)/University College London Hospitals NHS Foundation Trust (UCLH) Biomedical Research Centre, UK; National Institute of Allergy and Infectious Diseases, USA; US National Institutes of Health (NIH) [NS082228, AG032958]; NIH [AG032958, AG006127, AI89716, DK 09394]; Sir Jules Thorn Charitable Trust; James R. and Jesse V. Scott Fund for Shingles Research in the Veterans Medical Research Foundation; Wellcome Trust FX J.B. receives funding from the National Institute for Health Research (NIHR) University College London (UCL)/University College London Hospitals NHS Foundation Trust (UCLH) Biomedical Research Centre, UK. J.I.C. is supported by the intramural research program of the National Institute of Allergy and Infectious Diseases, USA. R.J.C. is supported by grants NS082228 and AG032958 from the US National Institutes of Health (NIH). D.G. is supported by grants AG006127 and AG032958 from the NIH. C.G. is supported by grant AI89716 from the NIH. S.H. receives funding from the Sir Jules Thorn Charitable Trust. M.D.G. and A.A.G. receive funding from NIH R01 Grant DK 09394. M.N.O.'s work is partially supported by the James R. and Jesse V. Scott Fund for Shingles Research in the Veterans Medical Research Foundation. P.G.E.K. receives grant funding for research from the Wellcome Trust. NR 211 TC 5 Z9 5 U1 7 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2056-676X J9 NAT REV DIS PRIMERS JI Nat. Rev. Dis. Primers PD JUL 2 PY 2015 VL 1 AR 15016 DI 10.1038/nrdp.2015.16 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA DT2KN UT WOS:000381309300001 PM 27188665 ER PT J AU Shelby, BD Cartagena, D McClee, V Gangadharan, D Weyant, R AF Shelby, Bryan D. Cartagena, Debora McClee, Vondguraus Gangadharan, Denise Weyant, Robbin TI TRANSFER OF SELECT AGENTS AND TOXINS: 2003-2013 SO HEALTH SECURITY LA English DT Article AB The Federal Select Agent Program, which is composed of the Centers for Disease Control and Prevention Division of Select Agents and Toxins and the Animal and Plant Health Inspection Service Agricultural Select Agent Services, regulates entities that possess, use, or transfer biological select agents and toxins in the United States and must preapprove all transfers within or into the US. The requirement to preapprove transfers allows the Federal Select Agent Program to monitor and track shipments to receive alerts of theft, loss, or release during shipment, thereby protecting public health and safety. As part of the program, the Division of Select Agents and Toxins regulates biological select agents and toxins that have been identified by the US government as posing a severe threat to public health and safety. The division analyzed 4,402 transfers that occurred between March 2003 and December 2013 to identify frequently transferred biological select agents and toxins and the types of entities involved in transfers. During the study period, 1 package was lost during shipment and it was determined not to pose a threat to public health. The Federal Bureau of Investigation investigated the loss and concluded that the package was most likely damaged by the commercial carrier and discarded. Further, there were no reports of theft or release associated with biological select agents and toxins shipments. This report represents the first in-depth review of biological select agent and toxin transfers that were approved by the Division of Select Agents and Toxins. C1 [Shelby, Bryan D.; Gangadharan, Denise] Ctr Dis Control & Prevent, Sci, Div Select Agents & Toxins, Atlanta, GA 30333 USA. [Cartagena, Debora; Weyant, Robbin] Ctr Dis Control & Prevent, Div Select Agents & Toxins, Atlanta, GA 30333 USA. [McClee, Vondguraus] Ctr Dis Control & Prevent, Program Serv Branch, Div Select Agents & Toxins, Atlanta, GA 30333 USA. RP Gangadharan, D (reprint author), Ctr Dis Control & Prevent, Sci, Div Select Agents & Toxins, Off Publ Hlth Preparedness & Response, 1600 Clifton Rd,NE MS A-46, Atlanta, GA 30333 USA. EM ghz7@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2326-5094 EI 2326-5108 J9 HEALTH SECUR JI Health Secur. PD JUL-AUG PY 2015 VL 13 IS 4 BP 256 EP 266 DI 10.1089/hs.2015.0009 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD4QR UT WOS:000369908100002 PM 26186667 ER PT J AU Pillai, SK Beekmann, SE Babcock, HM Pavia, AT Koonin, LM Polgreen, PM AF Pillai, Satish K. Beekmann, Susan E. Babcock, Hilary M. Pavia, Andrew T. Koonin, Lisa M. Polgreen, Philip M. TI CLINICIAN BELIEFS AND ATTITUDES REGARDING USE OF RESPIRATORY PROTECTIVE DEVICES AND SURGICAL MASKS FOR INFLUENZA SO HEALTH SECURITY LA English DT Article ID INFECTIOUS-DISEASES SOCIETY; HEALTH-CARE WORKERS; TRIAL; VIRUS AB While influenza transmission is thought to occur primarily by droplet spread, the role of airborne spread remains uncertain. Understanding the beliefs and attitudes of infectious disease physicians regarding influenza transmission and respiratory and barrier protection preferences can provide insights into workplace decisions regarding respiratory protection planning. Physicians participating in the Infectious Diseases Society of America's Emerging Infections Network were queried in November 2013 to determine beliefs and attitudes on influenza transmission. A subset of physicians involved in their facility's respiratory protection decision making were queried about respirator and surgical mask choices under various pandemic scenarios; availability of, and challenges associated with, respirators in their facility; and protective strategies during disposable N95 shortages. The majority of 686 respondents (98%) believed influenza transmission occurs frequently or occasionally via droplets; 44% of respondents believed transmission occurs via small particles frequently (12%) or occasionally (32%). Among the subset of respondents involved in respiratory protection planning at their facility, over 90% preferred surgical masks during provision of non-aerosol-generating patient care for seasonal influenza. However, for the same type of care during an influenza pandemic, two-thirds of respondents opted for disposable N95 filtering facepiece respirators. In settings where filtering facepiece (disposable) N95 respirators were in short supply, preferred conservation strategies included extended use and reuse of disposable N95s. Use of reusable (elastomeric facepiece) respirator types was viewed less favorably. While respondents identified droplets as the primary mode of influenza transmission, during a high-severity pandemic scenario there was increased support for devices that reduced aerosol-based transmission. Use of potentially less familiar respirator types may partially relieve shortages of disposable N95s but also may require significant education efforts so that clinicians are aware of the characteristics of alternative personal protective equipment. C1 [Pillai, Satish K.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA 30329 USA. [Beekmann, Susan E.] Univ Iowa, Carver Coll Med, Infect Dis, Iowa City, IA USA. [Polgreen, Philip M.] Univ Iowa, Dept Infect Dis, Internal Med, Carver Coll Med, Iowa City, IA USA. [Polgreen, Philip M.] Univ Iowa, Coll Publ Hlth, Carver Coll Med, Epidemiol, Iowa City, IA USA. [Babcock, Hilary M.] Washington Univ, Sch Med, Dept Internal Med, Med, St Louis, MO 63110 USA. [Pavia, Andrew T.] Univ Utah, Sch Med, Dept Pediat, Div Pediat Infect Dis, Salt Lake City, UT USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA 30329 USA. RP Pillai, SK (reprint author), Ctr Dis Control & Prevent, NCEZID Div Preparedness & Emerging Infect, 1600 Clifton Rd,MS C18, Atlanta, GA 30329 USA. EM vig8@cdc.gov FU Centers for Disease Control and Prevention [1U50CK000187] FX This publication was supported by Cooperative Agreement Number 1U50CK000187 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. NR 19 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2326-5094 EI 2326-5108 J9 HEALTH SECUR JI Health Secur. PD JUL-AUG PY 2015 VL 13 IS 4 BP 274 EP 280 DI 10.1089/hs.2015.0011 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD4QR UT WOS:000369908100004 PM 26173092 ER PT J AU Rasmussen, SA Jamieson, DJ AF Rasmussen, Sonja A. Jamieson, Denise J. TI What Obstetric Health Care Providers Need to Know About Measles and Pregnancy SO OBSTETRICS AND GYNECOLOGY LA English DT Editorial Material ID MATERNAL VIRUS DISEASES; MUMPS; RUBELLA; HEPATITIS; FETAL; CHICKENPOX; GREENLAND AB From January 1 to April 3, 2015, 159 people from 18 states and the District of Columbia were reported as having measles. Most cases are part of an outbreak linked to a California amusement park. Because measles was eliminated in the United States in 2000, most U.S. clinicians are unfamiliar with the condition. We reviewed information on the current outbreak, measles manifestations, diagnostic methods, treatment, and infection-control recommendations. To identify information on measles and pregnancy, we reviewed reports with 20 or more measles cases during pregnancy that included data on effects on pregnant women or pregnancy outcomes. These reports were identified through MEDLINE from inception through February 2015 using the following strategy: (((pregnan*) AND measles) AND English[Language]) NOT review[Publication Type]. Reference lists also were reviewed to identify additional articles. Pregnant women infected with measles are more likely to be hospitalized, develop pneumonia, and die than nonpregnant women. Adverse pregnancy outcomes, including pregnancy loss, preterm birth, and low birth weight, are associated with maternal measles; however, the risk of congenital defects does not appear to be increased. No antiviral therapy is available; treatment is supportive. Early identification of possible cases is needed so that appropriate infection control can be instituted promptly. The recent measles outbreak highlights the role that obstetric health care providers play in vaccine-preventable illnesses; obstetrician-gynecologists should ensure that patients are up to date on all vaccines, including measles-containing vaccines, and should recommend and ideally offer a measles-containing vaccine to women without evidence of measles immunity before or after pregnancy. C1 Ctr Dis Control & Prevent, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Rasmussen, SA (reprint author), CDC, 1600 Clifton Rd,MS E-33, Atlanta, GA 30333 USA. EM skr9@cdc.gov OI Rasmussen, Sonja/0000-0002-0574-4928 FU Intramural CDC HHS [CC999999] NR 21 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUL PY 2015 VL 126 IS 1 BP 163 EP 170 DI 10.1097/AOG.0000000000000903 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DC2WS UT WOS:000369080100025 PM 25899422 ER PT J AU Stahre, M VanEenwyk, J Siegel, P Njai, R AF Stahre, Mandy VanEenwyk, Juliet Siegel, Paul Njai, Rashid TI Housing Insecurity and the Association With Health Outcomes and Unhealthy Behaviors, Washington State, 2011 SO PREVENTING CHRONIC DISEASE LA English DT Article AB Few studies of associations between housing and health have focused on housing insecurity and health risk behaviors and outcomes. We measured the association between housing insecurity and selected health risk behaviors and outcomes, adjusted for socioeconomic measures, among 8,415 respondents to the 2011 Washington State Behavioral Risk Factor Surveillance System. Housing insecure respondents were about twice as likely as those who were not housing insecure to report poor or fair health status or delay doctor visits because of costs. This analysis supports a call to action among public health practitioners who address disparities to focus on social determinants of health risk behaviors and outcomes. C1 [Stahre, Mandy] Washington State Dept Hlth, Class 2012,POB 47835, Olympia, WA 98504 USA. [VanEenwyk, Juliet] Washington State Dept Hlth, Noninfect Condit Epidemiol, Olympia, WA 98504 USA. [Siegel, Paul; Njai, Rashid] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Stahre, Mandy] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Stahre, M (reprint author), Washington State Dept Hlth, Class 2012,POB 47835, Olympia, WA 98504 USA. EM mandy.stahre@doh.wa.gov FU Epidemic Intelligence Service (EIS) Fellowship FX Work for this article was completed as part of the first author's Epidemic Intelligence Service (EIS) Fellowship requirements. No other financial support was received. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 10 TC 3 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2015 VL 12 AR E109 DI 10.5888/pcd12.140511 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZL UT WOS:000368664100008 PM 26160295 ER PT J AU Steele, CB Rose, JM Townsend, JS Fonseka, J Richardson, LC Chovnick, G AF Steele, C. Brooke Rose, John M. Townsend, Julie S. Fonseka, Jamila Richardson, Lisa C. Chovnick, Gary TI Comprehensive Cancer Control Partners' Use of and Attitudes About Evidence-Based Practices SO PREVENTING CHRONIC DISEASE LA English DT Article ID DISSEMINATION; IMPLEMENTATION; ORGANIZATIONS; TRANSLATION; DIFFUSION; PROGRAMS AB Introduction National Comprehensive Cancer Control Program (NCCCP) awardees are encouraged to work with partners (eg, nonprofit organizations) to develop and implement plans to reduce the cancer burden in their jurisdictions using evidence-based practices (EBPs). However, the extent of EBP use among awardees and their partners is not well understood. Methods From March through July 2012, we conducted a web-based survey of program partners referred by NCCCP program directors who were involved in implementation of cancer control plans. Results Approximately 53% of referred partners (n = 83) completed surveys, 91.6% of whom represented organizations. Most partners reported involvement in helping to identify (80.5%), adapt (81.7%), implement (90.4%), and evaluate (81.9%) EBPs. The factors rated most frequently as very important when selecting EBPs were "consistent with our organization's mission" (89.2%) and "cost-effective" (81.9%). Although most respondents said that their organizations understood the importance of using EBPs (84.3%) and had adequate access to cancer registry data (74.7%), few reported having sufficient financial resources to develop new EBPs (7.9%). The most frequently mentioned benefit of using EBPs was that they are proven to work. Resource limitations and difficulty adapting EBPs for specific populations and settings were challenges. Conclusions Our findings help indicate how NCCCP partners are involved in using EBPs and can guide ongoing efforts to encourage the use of EBPs for cancer control. The challenges of using EBPs that partners identified highlight the need to improve strategies to translate cancer prevention and control research into practice in real-world settings and for diverse populations. C1 [Steele, C. Brooke] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mail Stop F-76,Chamblee Bl, Atlanta, GA 30341 USA. [Rose, John M.; Chovnick, Gary] Battelle Mem Inst, Hlth & Analyt, Arlington, VA USA. [Rose, John M.; Chovnick, Gary] Battelle Mem Inst, Hlth & Analyt, Seattle, WA USA. [Townsend, Julie S.; Fonseka, Jamila; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Steele, CB (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mail Stop F-76,Chamblee Bl, Atlanta, GA 30341 USA. EM BSteele1@cdc.gov FU Centers for Disease Control and Prevention [200-2008-27956-0015] FX This study was supported by contract 200-2008-27956-0015 from the Centers for Disease Control and Prevention. The authors report no conflicts of interest. NR 27 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2015 VL 12 AR E113 DI 10.5888/pcd12.150095 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZL UT WOS:000368664100012 PM 26182148 ER PT J AU Vickerman, KA Zhang, L Malarcher, A Mowery, P Nash, C AF Vickerman, Katrina A. Zhang, Lei Malarcher, Ann Mowery, Paul Nash, Chelsea TI Cessation Outcomes Among Quitline Callers in Three States During a National Tobacco Education Campaign SO PREVENTING CHRONIC DISEASE LA English DT Article ID SMOKING-CESSATION; ANTISMOKING ADS; MEDIA CAMPAIGN; INTERVENTIONS; SMOKERS; LEVEL AB Introduction Antismoking mass media campaigns, such as the Centers for Disease Control and Prevention's Tips from Former Smokers (Tips) campaign, increase the number of tobacco users calling tobacco quitlines. Few studies have investigated long-term tobacco use cessation for callers during antismoking media campaigns. Studies have suggested that callers during campaigns may be less committed to quitting and have lower quit rates. This study examines tobacco user cessation outcomes 7 months after quitline enrollment during the 2012 Tips campaign (March 19 through June 10, 2012). Methods We analyzed data for 715 tobacco users who enrolled in the Nebraska, North Carolina, or Texas state quitline multiple-call programs during the 2012 Tips campaign and responded to a 7-month postenrollment survey (38.5% survey response rate). We used multivariable logistic regression analyses to determine whether 7-day and 30-day point prevalence abstinence rates 7 months after enrollment were related to level of exposure to the campaign. Results In multivariable models, only lower nicotine dependence and higher call completion were associated with higher odds of 7-day and 30-day abstinence 7 months after enrollment. Tips campaign exposure was not associated with abstinence. Conclusion Once enrolled in quitline counseling, quitline callers achieved similar outcomes regardless of Tips campaign exposure levels. While the campaign did not appear to directly affect odds of tobacco abstinence through quitlines, antismoking mass media campaigns such as Tips are valuable in increasing tobacco users' exposure to quitlines and thus increasing their likelihood of making a quit attempt and eventually achieving tobacco abstinence. C1 [Vickerman, Katrina A.] Alere Wellbeing, Res Training & Evaluat Serv, 999 Third Ave,Ste 2000, Seattle, WA 98104 USA. [Zhang, Lei; Malarcher, Ann] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Mowery, Paul] Biostatistics Inc, Atlanta, GA USA. [Nash, Chelsea] Alere Wellbeing, Seattle, WA 98104 USA. RP Vickerman, KA (reprint author), Alere Wellbeing, Res Training & Evaluat Serv, 999 Third Ave,Ste 2000, Seattle, WA 98104 USA. EM Katrina.Vickerman@alere.com FU Centers for Disease Control and Prevention FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This research was funded by the Centers for Disease Control and Prevention. The Nebraska, North Carolina, and Texas state quitlines funded the collection of the 7-month survey data analyzed in this study as part of their quitline program evaluation plan. The authors thank Tim McAfee, MD, and Susan Zbikowski, PhD, for their review and feedback on this manuscript and for input on the study design. The authors also thank Audrey Snow and Oliver Lundt for their help extracting data for this project. We also acknowledge the 3 state quitlines that participated in the study. NR 29 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2015 VL 12 AR E110 DI 10.5888/pcd12.150024 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZL UT WOS:000368664100009 PM 26182145 ER PT J AU Weir, HK Thompson, TD Soman, A Moller, B Leadbetter, S White, MC AF Weir, Hannah K. Thompson, Trevor D. Soman, Ashwini Moller, Bjorn Leadbetter, Steven White, Mary C. TI Meeting the Healthy People 2020 Objectives to Reduce Cancer Mortality SO PREVENTING CHRONIC DISEASE LA English DT Article ID NORDIC COUNTRIES; THYROID-CANCER; NATION; FUTURE; CARE; PROJECTIONS; PREDICTION; BURDEN; TRENDS; IMPACT AB Introduction Healthy People 2020 (HP2020) calls for a 10% to 15% reduction in death rates from 2007 to 2020 for selected cancers. Trends in death rates can be used to predict progress toward meeting HP2020 targets. Methods We used mortality data from 1975 through 2009 and population estimates and projections to predict deaths for all cancers and the top 23 cancers among men and women by race. We apportioned changes in deaths from population risk and population growth and aging. Results From 1975 to 2009, the number of cancer deaths increased among white and black Americans primarily because of an aging white population and a growing black population. Overall, age-standardized cancer death rates (risk) declined in all groups. From 2007 to 2020, rates are predicted to continue to decrease while counts of deaths are predicted to increase among men (15%) and stabilize among women (increase <10%). Declining death rates are predicted to meet HP2020 targets for cancers of the female breast, lung and bronchus, cervix and uterus, colon and rectum, oral cavity and pharynx, and prostate, but not for melanoma. Conclusion Cancer deaths among women overall are predicted to increase by less than 10%, because of, in part, declines in breast, cervical, and colorectal cancer deaths among white women. Increased efforts to promote cancer prevention and improve survival are needed to counter the impact of a growing and aging population on the cancer burden and to meet melanoma target death rates. C1 [Weir, Hannah K.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy,Mailstop F76, Atlanta, GA 30341 USA. [Thompson, Trevor D.; Leadbetter, Steven; White, Mary C.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Soman, Ashwini] Northrop Grumman Corp, Atlanta, GA USA. [Moller, Bjorn] Canc Registry Norway, Oslo, Norway. RP Weir, HK (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy,Mailstop F76, Atlanta, GA 30341 USA. EM hbw4@cdc.gov NR 30 TC 7 Z9 7 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2015 VL 12 AR E104 DI 10.5888/pcd12.140482 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZL UT WOS:000368664100003 PM 26133647 ER PT J AU Andrews, CD Heneine, W AF Andrews, Chasity D. Heneine, Walid TI Cabotegravir long-acting for HIV-1 prevention SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE cabotegravir; GSK1265744; GSK744; long-acting injectable; nonhuman primate; preexposure prophylaxis ID HUMAN-IMMUNODEFICIENCY-VIRUS; VAGINAL SHIV CHALLENGE; TENOFOVIR DISOPROXIL FUMARATE; PREEXPOSURE PROPHYLAXIS; INTRAVAGINAL RING; PROTECTS MACAQUES; RHESUS MACAQUES; CCR5 INHIBITOR; GENITAL-TRACT; TRANSMISSION AB Purpose of reviewPreexposure prophylaxis (PrEP) with daily Truvada has demonstrated clinical efficacy against HIV-1 acquisition that correlates with high adherence. Long-acting antiretroviral drugs offer an alternative to daily regimens and may improve PrEP adherence. This review summarizes the preclinical nonhuman primate studies for evaluating the efficacy of cabotegravir long-acting as PrEP and the ongoing phase 2a studies assessing safety, tolerability, and acceptability of cabotegravir long-acting.Recent findingsCabotegravir is an HIV-1 integrase strand transfer inhibitor with intrinsic properties that permit its formulation as a long-acting injectable suspension. In clinical evaluation, cabotegravir long-acting has a half-life that permits infrequent dosing, possibly once every 3 months. In validated macaque models, cabotegravir long-acting demonstrated high protection against both rectal and vaginal transmission at clinically achievable drug concentrations.SummaryPrEP, after approval of Truvada, continues to evolve to address adherence limitations of daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits quarterly dosing and demonstrated high efficacy in macaque models supporting dose selection and clinical development. Clinical studies have confirmed dose selection in phase 2a trials with cabotegravir long-acting to ultimately lead to phase 2b/3 PrEP efficacy trials. C1 [Andrews, Chasity D.] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA. [Heneine, Walid] Ctr Dis Control & Prevent, Lab Branch, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Atlanta, GA USA. RP Andrews, CD (reprint author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA. EM candrews@adarc.org FU NIH [R0-AI100724] FX This work was partially supported by NIH grants R0-AI100724. NR 47 TC 8 Z9 8 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD JUL PY 2015 VL 10 IS 4 BP 258 EP 263 DI 10.1097/COH.0000000000000161 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CY4DC UT WOS:000366357800008 PM 26049951 ER PT J AU Schnall, R Mosley, JP Iribarren, SJ Bakken, S Carballo-Dieguez, A Brown, W AF Schnall, Rebecca Mosley, Jocelyn Patterson Iribarren, Sarah J. Bakken, Suzanne Carballo-Dieguez, Alex Brown, William, III TI Comparison of a User-Centered Design, Self-Management App to Existing mHealth Apps for Persons Living With HIV SO JMIR MHEALTH AND UHEALTH LA English DT Article DE mHealth; HIV; mobile apps; user-centered design ID HUMAN-IMMUNODEFICIENCY-VIRUS; MOBILE PHONE APPLICATIONS; HEALTH-CARE; PATIENT EDUCATION; CHRONIC DISEASE; INFORMATION; INTERVENTIONS; INFECTION; SUPPORT; ADOLESCENTS AB Background: There is preliminary evidence that mobile health (mHealth) apps are feasible, attractive, and an effective platform for the creation of self-management tools for persons living with HIV (PLWH). As a foundation for the current study, we conducted formative research using focus groups, participatory design sessions, and usability evaluation methods to inform the development of a health management app for PLWH. The formative research resulted in identification of the following functional requirements of a mHealth app for self-management: (1) communication between providers and peers, (2) medication reminders, (3) medication log, (4) lab reports, (5) pharmacy information, (6) nutrition and fitness, (7) resources (eg, social services, substance use, video testimonials), (8) settings, and (9) search function. Objective: The purpose of this study was to conduct an ecological review of the existing apps for PLWH and to compare the functionality of existing apps with the app specifications identified in our formative work. Methods: We searched two mobile app stores (Google Play and iTunes) and found a total of 5606 apps. We reviewed the apps, narrowed our search terms, and found a total of 112 apps. Of these, we excluded 97 (86.6%) apps that were either not in English (10/112, 8.9%), not HIV focused (32/112, 28.9%), or focused only on HIV prevention (2/112, 7.8%); targeted health care providers (26/112, 23.2%); provided information only on conference schedules and events (7/112, 6.3%), fundraisers (7/112, 6.3%), specific clinics (7/112, 6.3%), international or narrow local resources (3/112, 2.7%); or were identified in the first search but were no longer on the market at the next review (4/112, 3.6%). The 15 apps meeting inclusion criteria were then evaluated for inclusion of the nine functionalities identified in our earlier work. Results: Of the 15 apps that we included in our final review, none had all of the functionalities that were identified in our formative work. The apps that we identified included the following functionalities: communication with providers and/or peers (4/15, 27%), medication reminders (6/15, 40%), medication logs (7/15, 47%), lab reports (5/15, 33%), pharmacy information (4/15, 27%), resources (7/15, 47%), settings (11/15, 73%), and search function (6/15, 40%). No apps included nutrition or fitness information. Conclusions: Currently, there are only a small number of apps that have been designed for PLWH to manage their health. Of the apps that are currently available, none have all of the desired functionalities identified by PLWH and experts in our formative research. Findings from this work elucidate the need to develop and evaluate mobile apps that meet PLWH's desired functional specifications. C1 [Schnall, Rebecca; Iribarren, Sarah J.; Bakken, Suzanne] Columbia Univ, Sch Nursing, New York, NY 10032 USA. [Mosley, Jocelyn Patterson] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Bakken, Suzanne; Brown, William, III] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA. [Carballo-Dieguez, Alex; Brown, William, III] New York State Psychiat Inst & Hosp, HIV Ctr, Div Gender Sexual & Hlth, New York, NY 10032 USA. [Carballo-Dieguez, Alex; Brown, William, III] Columbia Univ, New York, NY 10032 USA. RP Schnall, R (reprint author), Columbia Univ, Sch Nursing, 617 West 168th St, New York, NY 10032 USA. EM rb897@columbia.edu OI Iribarren, Sarah/0000-0003-2980-0717 FU NINR NIH HHS [T32 NR014205]; NLM NIH HHS [T15 LM007079] NR 60 TC 3 Z9 3 U1 3 U2 10 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 2291-5222 J9 JMIR MHEALTH UHEALTH JI JMIR mHealth uHealth PD JUL-SEP PY 2015 VL 3 IS 3 AR e91 DI 10.2196/mhealth.4882 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CW2GP UT WOS:000364809700008 PM 26385783 ER PT J AU Thoma, M AF Thoma, Marie TI Measuring Infertility: Searching for Consensus SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID CURRENT-DURATION APPROACH; UNITED-STATES; PREVALENCE; DEFINITION; PREGNANCY; PARTNERS; TIME C1 [Thoma, Marie] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, Hyattsville, MD 20782 USA. RP Thoma, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, Reprod Stat Branch, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM MThoma@cdc.gov NR 22 TC 0 Z9 0 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JUL 1 PY 2015 VL 24 IS 7 BP 541 EP 543 DI 10.1089/jwh.2015.5399 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CU9WH UT WOS:000363896900001 PM 26172995 ER PT J AU Warner, L Jamieson, DJ Barfield, WD AF Warner, Lee Jamieson, Denise J. Barfield, Wanda D. TI CDC Releases a National Public Health Action Plan for the Detection, Prevention, and Management of Infertility SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID FERTILITY TREATMENTS; MULTIPLE BIRTHS C1 [Warner, Lee; Jamieson, Denise J.; Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Warner, L (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway Northeast,Mailstop F-74, Atlanta, GA 30341 USA. EM dlw7@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JUL 1 PY 2015 VL 24 IS 7 BP 548 EP 549 DI 10.1089/jwh.2015.5355 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CU9WH UT WOS:000363896900004 PM 26133516 ER PT J AU Crawford, S Fussman, C Bailey, M Bernson, D Jamieson, DJ Murray-Jordan, M Kissin, DM AF Crawford, Sara Fussman, Chris Bailey, Marie Bernson, Dana Jamieson, Denise J. Murray-Jordan, Melissa Kissin, Dmitry M. TI Estimates of Lifetime Infertility from Three States: The Behavioral Risk Factor Surveillance System SO JOURNAL OF WOMENS HEALTH LA English DT Article ID ASSISTED REPRODUCTIVE TECHNOLOGY; UNITED-STATES; OUTCOMES; PREGNANCIES; IMPACT; CARE AB Background: Knowledge of state-specific infertility is limited. The objectives of this study were to explore state-specific estimates of lifetime prevalence of having ever experienced infertility, sought treatment for infertility, types of treatments sought, and treatment outcomes. Methods: Male and female adult residents aged 18-50 years from three states involved in the States Monitoring Assisted Reproductive Technology Collaborative (Florida, Massachusetts, and Michigan) were asked state-added infertility questions as part of the 2012 Behavioral Risk Factor Surveillance System, a state-based, health-related telephone survey. Analysis involved estimation of lifetime prevalence of infertility. Results: The estimated lifetime prevalence of infertility among 1,285 adults in Florida, 1,302 in Massachusetts, and 3,360 in Michigan was 9.7%, 6.0%, and 4.2%, respectively. Among 736 adults in Florida, 1,246 in Massachusetts, and 2,742 in Michigan that have ever tried to get pregnant, the lifetime infertility prevalence was 25.3% in Florida, 9.9% in Massachusetts, and 5.8% in Michigan. Among those with a history of infertility, over half sought treatment (60.7% in Florida, 70.6% in Massachusetts, and 51.6% in Michigan), the most common being non-assisted reproductive technology fertility treatments (61.3% in Florida, 66.0% in Massachusetts, and 75.9% in Michigan). Conclusion: State-specific estimates of lifetime infertility prevalence in Florida, Massachusetts, and Michigan varied. Variations across states are difficult to interpret, as they likely reflect both true differences in prevalence and differences in data collection questionnaires. State-specific estimates are needed for the prevention, detection, and management of infertility, but estimates should be based on a common set of questions appropriate for these goals. C1 [Crawford, Sara; Jamieson, Denise J.; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Fussman, Chris] Michigan Dept Community Hlth, Lansing, MI USA. [Bailey, Marie; Murray-Jordan, Melissa] Florida Dept Hlth, Tallahassee, FL USA. [Bernson, Dana] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Crawford, S (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F74, Atlanta, GA 30341 USA. EM sgv0@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 2 Z9 2 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JUL 1 PY 2015 VL 24 IS 7 BP 578 EP 586 DI 10.1089/jwh.2014.5102 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CU9WH UT WOS:000363896900009 PM 26172998 ER PT J AU Xu, FJ Leidner, AJ Tong, X Holmberg, SD AF Xu, Fujie Leidner, Andrew J. Tong, Xin Holmberg, Scott D. TI Estimating the Number of Patients Infected With Chronic HCV in the United States Who Meet Highest or High-Priority Treatment Criteria SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID C VIRUS-INFECTION; CHRONIC HEPATITIS COHORT; VIRAL-HEPATITIS; CARE; MORTALITY; FIBROSIS; HEALTH AB We estimated the number of people infected with HCV in the United States who would qualify for immediate treatment according to the 2014 guidance. We based fibrosis stage on biopsy results, when available, or on FIB-4 scores. We used laboratory tests and International Classification of Diseases, Ninth Revision, Clinical Modification codes to determine if patients had any qualifying comorbidities. Of the 2.7 million people with HCV infection, we assumed that 1.35 million (50%) had been diagnosed. We estimated 457 000 met the highest and 356 000 the high-priority criteria for treatment, indicating that as many as 813 000 people could be treated immediately with new therapies. These estimates can inform planning efforts to address clinical capacity constraints and treatment costs. C1 [Xu, Fujie; Leidner, Andrew J.; Tong, Xin; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Xu, FJ (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,Mailstop G-37, Atlanta, GA 30333 USA. EM fax1@cdc.gov NR 20 TC 3 Z9 3 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2015 VL 105 IS 7 BP 1285 EP 1289 DI 10.2105/AJPH.2015.302652 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6FX UT WOS:000362909400007 PM 25973816 ER PT J AU Chibucos, MC Etienne, KA Orvis, J Lee, HK Daugherty, S Lockhart, SR Ibrahim, AS Bruno, VM AF Chibucos, Marcus C. Etienne, Kizee A. Orvis, Joshua Lee, Hongkyu Daugherty, Sean Lockhart, Shawn R. Ibrahim, Ashraf S. Bruno, Vincent M. TI The genome sequence of four isolates from the family Lichtheimiaceae SO PATHOGENS AND DISEASE LA English DT Article DE Lichtheimia; Mucorales; mucormycosis; Rhizopus; fungal phylogeny; fungal genomics ID CUTANEOUS MUCORMYCOSIS; GENE PREDICTION; ALIGNMENT; ZYGOMYCOSIS; PHYLOGENIES; ORTHOLOGS; PROGRAM; PATIENT; RAMOSA; RNA AB This study reports the release of draft genome sequences of two isolates of Lichtheimia corymbifera and two isolates of L. ramosa. Phylogenetic analyses indicate that the two L. corymbifera strains (CDC-B2541 and 008-049) are closely related to the previously sequenced L. corymbifera isolate (FSU 9682) while our two L. ramosa strains CDC-B5399 and CDC-B5792 cluster apart from them. These genome sequences will further the understanding of intraspecies and interspecies genetic variation within the Mucoraceae family of pathogenic fungi. C1 [Chibucos, Marcus C.; Orvis, Joshua; Daugherty, Sean; Bruno, Vincent M.] Univ Maryland, Sch Med, Inst Genomes Sci, Baltimore, MD 21201 USA. [Chibucos, Marcus C.; Bruno, Vincent M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. [Etienne, Kizee A.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Lee, Hongkyu; Ibrahim, Ashraf S.] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Inst Harbor, Div Infect Dis, Torrance, CA 90502 USA. [Ibrahim, Ashraf S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bruno, VM (reprint author), Univ Maryland, Sch Med, Inst Genomes Sci, 801 W Baltimore St, Baltimore, MD 21201 USA. EM vbruno@umaryland.edu OI Chibucos, Marcus/0000-0001-9586-0780 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900009C]; [U19AI110820]; [R01 AI063503] FX This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900009C. VMB and ASI were supported by U19AI110820. ASI was also supported by R01 AI063503. The findings and conclusions of this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 34 TC 1 Z9 1 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2049-632X J9 PATHOG DIS JI Pathog. Dis. PD JUL PY 2015 VL 73 IS 5 AR ftv024 DI 10.1093/femspd/ftv024 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT1QB UT WOS:000362573900007 ER PT J AU Leuraud, K Richardson, DB Cardis, E Daniels, RD Gillies, M O'Hagan, JA Hamra, GB Haylock, R Laurier, D Moissonnier, M Schubauer-Berigan, MK Thierry-Chef, I Kesminiene, A AF Leuraud, Klervi Richardson, David B. Cardis, Elisabeth Daniels, Robert D. Gillies, Michael O'Hagan, Jacqueline A. Hamra, Ghassan B. Haylock, Richard Laurier, Dominique Moissonnier, Monika Schubauer-Berigan, Mary K. Thierry-Chef, Isabelle Kesminiene, Ausrele TI Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study SO LANCET HAEMATOLOGY LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; ATOMIC-BOMB SURVIVORS; NUCLEAR INDUSTRY; RETROSPECTIVE COHORT; CANCER-RISKS; MORTALITY; EXPOSURE; 15-COUNTRY; US AB Background There is much uncertainty about the risks of leukaemia and lymphoma after repeated or protracted low-dose radiation exposure typical of occupational, environmental, and diagnostic medical settings. We quantified associations between protracted low-dose radiation exposures and leukaemia, lymphoma, and multiple myeloma mortality among radiation-monitored adults employed in France, the UK, and the USA. Methods We assembled a cohort of 308 297 radiation-monitored workers employed for at least 1 year by the Atomic Energy Commission, AREVA Nuclear Cycle, or the National Electricity Company in France, the Departments of Energy and Defence in the USA, and nuclear industry employers included in the National Registry for Radiation Workers in the UK. The cohort was followed up for a total of 8 . 22 million person-years. We ascertained deaths caused by leukaemia, lymphoma, and multiple myeloma. We used Poisson regression to quantify associations between estimated red bone marrow absorbed dose and leukaemia and lymphoma mortality. Findings Doses were accrued at very low rates (mean 1.1 mGy per year, SD 2.6). The excess relative risk of leukaemia mortality (excluding chronic lymphocytic leukaemia) was 2.96 per Gy (90% CI 1.17-5.21; lagged 2 years), most notably because of an association between radiation dose and mortality from chronic myeloid leukaemia (excess relative risk per Gy 10.45, 90% CI 4.48-19.65). Interpretation This study provides strong evidence of positive associations between protracted low-dose radiation exposure and leukaemia. C1 [Leuraud, Klervi; Laurier, Dominique] Inst Radioprotect & Surete Nucl, Fontenay Aux Roses, France. [Richardson, David B.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Cardis, Elisabeth] Ctr Res Environm Epidemiol, Barcelona, Spain. [Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain. [Cardis, Elisabeth] CIBER Epidemiol & Salud Publ, Madrid, Spain. [Daniels, Robert D.; Schubauer-Berigan, Mary K.] NIOSH, Cincinnati, OH 45226 USA. [Gillies, Michael; O'Hagan, Jacqueline A.; Haylock, Richard] Publ Hlth England Ctr Radiat Chem & Environm Haza, Chilton, England. [Hamra, Ghassan B.] Drexel Univ, Sch Publ Hlth, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USA. [Moissonnier, Monika; Thierry-Chef, Isabelle; Kesminiene, Ausrele] Int Agcy Res Canc, F-69372 Lyon, France. RP Leuraud, K (reprint author), IRSN PRP HOM SRBE, Radiobiol & Epidemiol Dept, Radiat Protect Div, Inst Radiol Protect & Nucl Safety, BP 17, Fontenay Aux Roses, France. EM klervi.leuraud@irsn.fr RI Cardis, Elisabeth/C-3904-2017 FU Centers for Disease Control and Prevention [5R03 0H010056-02]; Ministry of Health, Labour and Welfare of Japan [2012-02-21-01]; AREVA; Electricite de France; National Institute for Occupational Safety and Health; US Department of Energy; US Department of Health and Human Service; US Department of Energy through University of North Carolina from the National Institute for Occupational Safety and Health [R03 OH-010056] FX This work was partly funded by the Centers for Disease Control and Prevention (5R03 0H010056-02) and the Ministry of Health, Labour and Welfare of Japan (GA No 2012-02-21-01). The construction of the French cohort was realised by the Institut de Radioprotection et de Surete Nucleaire, with partial funding from AREVA and Electricite de France. The Institut de Radioprotection et de Surete Nucleaire thanks all people from the French Atomic Energy Commission, AREVA, and Electricite de France who cooperated in the elaboration of the French cohort. For the US contribution, funding was provided by the National Institute for Occupational Safety and Health, by the US Department of Energy through an agreement with the US Department of Health and Human Services, and through a grant received by the University of North Carolina from the National Institute for Occupational Safety and Health (R03 OH-010056). The construction of the UK cohort was undertaken by Public Health England who operate the UK's National Registry for Radiation Workers. Public Health England thank all of the organisations and individuals participating in the National Registry for Radiation Workers for their cooperation, and the National Registry for Radiation Workers steering group for their continued support. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 37 TC 49 Z9 53 U1 1 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2352-3026 J9 LANCET HAEMATOL JI Lancet Haematol. PD JUL PY 2015 VL 2 IS 7 BP E276 EP E281 DI 10.1016/S2352-3026(15)00094-0 PG 6 WC Hematology SC Hematology GA CS4VG UT WOS:000362073500006 PM 26436129 ER EF